
XIENCE Alpine™
Everolimus Eluting Coronary Stent Systems
Instructions for Use



Table of Contents

- 1.0 PRODUCT DESCRIPTION
 - 1.1 Device Component Description
 - 1.2 Drug Component Description
 - 1.2.1 Everolimus
 - 1.2.2. Inactive Ingredients – Non-erodible Polymer
 - 1.2.3 Product Matrix and Everolimus Content
- 2.0 INDICATIONS
- 3.0 CONTRAINDICATIONS
- 4.0 WARNINGS
- 5.0 PRECAUTIONS
 - 5.1 General Precautions
 - 5.2 Pre- and Post-Procedure Antiplatelet Regimen
 - 5.3 Multiple Stent Use
 - 5.4 Brachytherapy
 - 5.5 Use in Conjunction with Other Procedures
 - 5.6 Use in Special Populations
 - 5.6.1 Pregnancy
 - 5.6.2 Lactation
 - 5.6.3 Gender
 - 5.6.4 Ethnicity
 - 5.6.5 Pediatric Use
 - 5.6.6 Geriatric Use
 - 5.7 Lesion / Vessel Characteristics
 - 5.8 Drug Interactions
 - 5.9 Immune Suppression Potential
 - 5.10 Lipid Elevation Potential
 - 5.11 Magnetic Resonance Imaging (MRI)
 - 5.12 Stent Handling
 - 5.13 Stent Placement
 - 5.13.1 Stent Preparation
 - 5.13.2 Stent Implantation
 - 5.14 Stent System Removal
 - 5.15 Post-Procedure
- 6.0 DRUG INFORMATION
 - 6.1 Mechanism of Action
 - 6.2 Pharmacokinetics
 - 6.3 Interactions with Drugs or Other Substances
 - 6.4 Carcinogenicity, Genotoxicity, and Reproductive Toxicity
 - 6.5 Pregnancy

-
- 6.6 Lactation
 - 7.0 OVERVIEW OF CLINICAL EXPERIENCE
 - 8.0 ADVERSE EVENTS
 - 8.1 Observed Adverse Events
 - 8.2 Stent Thrombosis Definitions
 - 8.3 Potential Adverse Events
 - 9.0 SPIRIT FAMILY OF CLINICAL TRIALS
 - 9.1 SPIRIT PRIME Clinical Trial
 - 9.2 SPIRIT III Pivotal Clinical Trial
 - 9.2.1 SPIRIT III Randomized Clinical Trial (RCT)
 - 9.2.2 Dual Vessel Treatment in SPIRIT III
 - 9.2.3 SPIRIT III US 4.0 mm Arm
 - 9.3 SPIRIT IV Clinical Trial
 - 9.3.1 SPIRIT IV Randomized Clinical Trial
 - 9.3.2 Multiple Vessel Treatment in SPIRIT IV
 - 9.4 SPIRIT Small Vessel Registry
 - 9.5 Pooled Analysis of the SPIRIT II-III-IV Clinical Trials
 - 9.6 Gender-Based Analysis of the SPIRIT Family of Clinical Trials
 - 9.6.1 Background
 - 9.6.2 Gender-Based Analysis of the SPIRIT PRIME Clinical Trial
 - 9.6.3 Gender-Based Analysis in the SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Clinical Trials
 - 9.7 XIENCE V USA Post-Approval Study
 - 9.7.1 Analysis of Patients with 4.0 mm Stent
 - 9.7.2 Analysis of Patients Treated with Direct Stenting
 - 9.7.3 Pre-specified XIENCE V USA Subgroup Analysis
 - 9.8 EXPERT CTO Clinical Trial
 - 9.8.1 Gender-Based Analysis of the EXPERT CTO Clinical Trial
 - 9.9 Analysis of Diabetic Patients
 - 9.9.1 Analysis of Diabetic Subjects in SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Trials
 - 9.9.2 Bayesian Analysis of Diabetic Patients Treated with XIENCE Stents
 - 10.0 INDIVIDUALIZATION OF TREATMENT
 - 11.0 PATIENT COUNSELING AND PATIENT INFORMATION
 - 12.0 HOW SUPPLIED
 - 13.0 OPERATOR'S INSTRUCTIONS
 - 13.1 Inspection Prior to Use
 - 13.2 Materials Required
 - 13.3 Preparation
 - 13.3.1 Packaging Removal
 - 13.3.2 Guide Wire Lumen Flush
 - 13.3.3 Delivery System Preparation
 - 13.4 Delivery Procedure
 - 13.5 Deployment Procedure

13.6 Removal Procedure
13.7 Post-Deployment Dilatation of Stent Segments

14.0 *IN VITRO* COMPLIANCE INFORMATION

15.0 REUSE PRECAUTION STATEMENT

16.0 PATENTS AND TRADEMARKS

**THE COMPONENTS OF THE XIENCE ALPINE STENT SYSTEM
ARE STERILE.**

1.0 PRODUCT DESCRIPTION

The XIENCE Alpine Everolimus Eluting Coronary Stent System is comprised of two main components: the drug-coated stent and the balloon expandable delivery system. The XIENCE Alpine Stent System uses the identical stent and stent contacting balloon materials, and the identical drug coating formulation and drug dose density (100 ug/cm²) as the XIENCE PRIME[®] Everolimus Eluting Coronary Stent System. The XIENCE Alpine Stent System is available in two delivery system configurations: Rapid Exchange (RX) and Over-the-Wire (OTW).

The XIENCE Alpine family of stent systems includes:

| Product | Stent Diameter (mm) | Stent Length (mm) | Reference Vessel Diameter (RVD mm) | Lesion Length (mm) |
|----------------|--------------------------------------|-------------------------------|---|---------------------------|
| XIENCE Alpine | 2.25, 2.5, 2.75, 3.0, 3.25, 3.5, 4.0 | 8, 12, 15, 18, 23, 28, 33, 38 | ≥ 2.5 and ≤ 4.25 | ≤ 32 |

Hereafter, the XIENCE Alpine family of stent systems is referred to as the XIENCE Alpine stent or XIENCE Alpine stent system. The XIENCE Alpine stent systems are device / drug combination products consisting of a drug-coated stent and a balloon expandable delivery system. The stent is coated with a formulation containing everolimus, the active ingredient, embedded in a non-erodible polymer, which is identical to the FDA approved XIENCE Xpedition[®], XIENCE V[®] and XIENCE PRIME Everolimus Eluting Coronary Stent System.

1.1 Device Component Description

The device component consists of a medical grade L-605 cobalt chromium (CoCr) drug-coated stent mounted onto the XIENCE Alpine stent delivery system. The device component characteristics are summarized in Table 1.1-1.

Table 1.1-1: XIENCE Alpine Stent System Product Description

| XIENCE Alpine Stent System | | |
|---|--|---|
| Available Stent Lengths (mm) | 8, 12, 15, 18, 23, 28, 33, 38 | |
| Available Stent Diameters (mm) | 2.25, 2.5, 2.75, 3.0, 3.25, 3.5, 4.0 | |
| Stent Material | A medical grade L-605 cobalt chromium CoCr alloy identical to the material used in the XIENCE V, XIENCE PRIME, and XIENCE Xpedition stent | |
| Drug Component | A conformal coating of a non-erodible polymer loaded with 100 µg/cm ² of everolimus with a maximum nominal drug content of 232 µg on the large stent (4.0 x 38 mm) | |
| Delivery System Working Length | 145 cm | |
| Delivery System Design | RX: Single access port to inflation lumen; guide wire exit notch is located 25.5 cm from tip; designed for guide wires ≤ 0.014". OTW: Sidearm adaptor provides access to balloon inflation / deflation lumen and guide wire lumen; designed for guide wires ≤ 0.014". | |
| Stent Delivery System Balloon | A compliant, tapered balloon, with two radiopaque markers located on the catheter shaft to indicate balloon positioning and expanded stent length | |
| Balloon Inflation Pressure | Rated Burst Pressure (RBP): 18 atm (1824 kPa) | |
| | Stent Diameter (mm) | <i>In vitro</i> Stent Nominal Pressure (atm) |
| | 2.25 | 10 |
| | 2.5 | 10 |
| | 2.75 | 10 |
| | 3.0 | 10 |
| | 3.25 | 10 |
| | 3.5 | 10 |
| 4.0 | 10 | |
| Minimum Guiding Catheter Inner Diameter | 2.25 – 3.5 mm Stent Diameters 5 F (0.056" / 1.42 mm ID) | 4.0 Stent Diameter, 8 – 33 mm lengths 5 F (0.056" / 1.42 mm ID) 4.0 Stent Diameter, 38 mm length 6 F (0.066" / 1.68 mm ID) |
| Catheter Shaft Outer Diameter | Distal: 0.034" (0.86 mm) Proximal (RX): 0.029" (0.74 mm) Proximal (OTW): 0.045" (1.14 mm) | |

1.2.3 Product Matrix and Everolimus Content

Table 1.2.3-1: XIENCE Alpine Stent System Product Matrix and Everolimus Content

| Model Number (RX) | Model Number (OTW) | Nominal Expanded Stent Diameter (mm) | Nominal Unexpanded Stent Length (mm) | Nominal Everolimus Content (µg) |
|-------------------|--------------------|--------------------------------------|--------------------------------------|---------------------------------|
| 1125225-08 | 1145225-08 | 2.25 | 8 | 40 |
| 1125250-08 | 1145250-08 | 2.5 | | 40 |
| 1125275-08 | 1145275-08 | 2.75 | | 40 |
| 1125300-08 | 1145300-08 | 3.0 | | 40 |
| 1125325-08 | 1145325-08 | 3.25 | | 40 |
| 1125350-08 | 1145350-08 | 3.5 | | 50 |
| 1125400-08 | 1145400-08 | 4.0 | 50 | |
| 1120225-12 | 1145225-12 | 2.25 | 12 | 60 |
| 1125250-12 | 1145250-12 | 2.5 | | 60 |
| 1125275-12 | 1145275-12 | 2.75 | | 60 |
| 1125300-12 | 1145300-12 | 3.0 | | 60 |
| 1125325-12 | 1145325-12 | 3.25 | | 60 |
| 1125350-12 | 1145350-12 | 3.5 | | 75 |
| 1125400-12 | 1145400-12 | 4.0 | 75 | |
| 1120225-15 | 1145225-15 | 2.25 | 15 | 74 |
| 1125250-15 | 1145250-15 | 2.5 | | 74 |
| 1125275-15 | 1145275-15 | 2.75 | | 74 |
| 1125300-15 | 1145300-15 | 3.0 | | 74 |
| 1125325-15 | 1145325-15 | 3.25 | | 74 |
| 1125350-15 | 1145350-15 | 3.5 | | 91 |
| 1125400-15 | 1145400-15 | 4.0 | 91 | |
| 1120225-18 | 1145225-18 | 2.25 | 18 | 88 |
| 1125250-18 | 1145250-18 | 2.5 | | 88 |
| 1125275-18 | 1145275-18 | 2.75 | | 88 |
| 1125300-18 | 1145300-18 | 3.0 | | 88 |
| 1125325-18 | 1145325-18 | 3.25 | | 88 |
| 1125350-18 | 1145350-18 | 3.5 | | 116 |
| 1125400-18 | 1145400-18 | 4.0 | 116 | |
| 1120225-23 | 1145225-23 | 2.25 | 23 | 109 |
| 1125250-23 | 1145250-23 | 2.5 | | 109 |
| 1125275-23 | 1145275-23 | 2.75 | | 109 |
| 1125300-23 | 1145300-23 | 3.0 | | 109 |
| 1125325-23 | 1145325-23 | 3.25 | | 109 |
| 1125350-23 | 1145350-23 | 3.5 | | 141 |
| 1125400-23 | 1145400-23 | 4.0 | 141 | |
| 1120225-28 | 1145225-28 | 2.25 | 28 | 137 |
| 1125250-28 | 1145250-28 | 2.5 | | 137 |
| 1125275-28 | 1145275-28 | 2.75 | | 137 |
| 1125300-28 | 1145300-28 | 3.0 | | 137 |
| 1125325-28 | 1145325-28 | 3.25 | | 137 |
| 1125350-28 | 1145350-28 | 3.5 | | 174 |
| 1125400-28 | 1145400-28 | 4.0 | 174 | |
| 1125250-33 | 1145250-33 | 2.5 | 33 | 157 |
| 1125275-33 | 1145275-33 | 2.75 | | 157 |
| 1125300-33 | 1145300-33 | 3.0 | | 157 |
| 1125325-33 | 1145325-33 | 3.25 | | 157 |
| 1125350-33 | 1145350-33 | 3.5 | | 199 |
| 1125400-33 | 1145400-33 | 4.0 | | 199 |
| 1125250-38 | 1145250-38 | 2.5 | 38 | 185 |
| 1125275-38 | 1145275-38 | 2.75 | | 185 |
| 1125300-38 | 1145300-38 | 3.0 | | 185 |
| 1125325-38 | 1145325-38 | 3.25 | | 185 |
| 1125350-38 | 1145350-38 | 3.5 | | 232 |
| 1125400-38 | 1145400-38 | 4.0 | | 232 |

2.0 INDICATIONS

The XIENCE Alpine stent system is indicated for improving coronary artery luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease due to *de novo* native coronary artery lesions (length \leq 32 mm) with reference vessel diameters of \geq 2.25 mm to \leq 4.25 mm. In addition, the XIENCE Alpine stent system is indicated for treating *de novo* chronic total coronary occlusions.

3.0 CONTRAINDICATIONS

The XIENCE Alpine stent system is contraindicated for use in patients:

- Who cannot receive antiplatelet and / or anticoagulant therapy (see section 5.2 – *Precautions, Pre- and Post-Procedure Antiplatelet Regimen* for more information)
- With lesions that prevent complete angioplasty balloon inflation or proper placement of the stent or stent delivery system
- With hypersensitivity or contraindication to everolimus or structurally related compounds, cobalt, chromium, nickel, tungsten, acrylic, and fluoropolymers

4.0 WARNINGS

- Ensure that the inner package sterile barrier has not been opened or damaged prior to use.
- Judicious patient selection is necessary, because the use of this device carries the associated risk of stent thrombosis, vascular complications, and / or bleeding events.
- This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy (see section 5.2 for important information regarding antiplatelet therapy).

5.0 PRECAUTIONS

5.1 General Precautions

- Stent implantation should only be performed by physicians who have received appropriate training.
- Stent placement should be performed at hospitals where emergency coronary artery bypass graft surgery is accessible.
- Subsequent restenosis may require repeat dilatation of the arterial segment containing the stent. Long-term outcomes following repeat dilatation of the stent is presently unknown.
- Risks and benefits should be considered in patients with severe contrast agent allergies.
- Care should be taken to control the guiding catheter tip during stent delivery, deployment, and balloon withdrawal. Before withdrawing the stent delivery system, visually confirm complete balloon deflation by fluoroscopy to avoid guiding catheter movement into the vessel and subsequent arterial damage.
- Stent thrombosis is a low-frequency event that is frequently associated with myocardial infarction (MI) or death. Data from the SPIRIT family of clinical trials have been prospectively evaluated and adjudicated using both the protocol definition of stent thrombosis and the definition developed by the Academic Research Consortium (ARC),

and demonstrate specific patterns of stent thrombosis that vary depending on the definition used (see section 8.2 – *Adverse Events, Stent Thrombosis Definitions* and section 9.5 – *Pooled Analysis of the SPIRIT II-III-IV Clinical Trials* for more information).

- When DES are used outside the specified Indications for Use, patient outcomes may differ from the results observed in the SPIRIT family of clinical trials.
- Compared to use within the specified Indications for Use, the use of DES in patients and lesions outside of the labeled indications, including more tortuous anatomy, may have an increased risk of adverse events, including stent thrombosis, stent embolization, MI, or death.
- Orally administered everolimus combined with cyclosporine is associated with increased serum cholesterol and triglyceride levels.

5.2 Pre- and Post-Procedure Antiplatelet Regimen

- In the SPIRIT PRIME clinical trial, clopidogrel bisulfate or ticlopidine hydrochloride was administered pre-procedure and for a minimum of 12 months post-procedure (75 mg per day). Aspirin was administered pre-procedure and continued through 5 years (a minimum of 80 mg per day) to reduce thrombosis risk. At 1 year, dual antiplatelet therapy compliance in the Core Size Registry was 92.8% (360/388) and in the Long Lesion Registry was 89.0% (89/100). Upon subject completion of the study, physicians recommended that the subject remain on the aspirin regimen indefinitely.
- The optimal duration of dual antiplatelet therapy, specifically clopidogrel, is unknown and DES thrombosis may still occur despite continued therapy. Data from several studies on sirolimus-eluting or paclitaxel-eluting stents suggest that a longer duration of clopidogrel than was recommended post-procedurally in DES pivotal trials may be beneficial. Current guidelines recommend that patients receive aspirin indefinitely and P2Y₁₂ inhibitor therapy for at least 12 months, if subjects are not at high risk of bleeding (ref: ACCF/AHA/SCAI PCI Practice Guidelines¹).
- It is very important that the patient comply with the post-procedural antiplatelet therapy recommendations. Early discontinuation of prescribed antiplatelet medication could result in a higher risk of thrombosis, MI, or death. Prior to percutaneous coronary intervention (PCI), if the patient is required to undergo a surgical or dental procedure that might require early discontinuation of antiplatelet therapy, the interventionalist and patient should carefully consider whether a DES and its associated recommended antiplatelet therapy is the appropriate PCI treatment of choice. Following PCI, should a surgical or dental procedure be recommended, requiring suspension of antiplatelet therapy, the risks and benefits of the procedure should be weighed against the possible risks associated with early discontinuation of antiplatelet therapy. Patients who require early discontinuation of antiplatelet therapy (e.g., secondary to active bleeding) should be monitored carefully for cardiac events. At the discretion of the patient's treating physicians, the antiplatelet therapy should be restarted as soon as possible.

¹ Levine et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation*, 2011; 124: e574-651

5.3 Multiple Stent Use

The XIENCE Alpine Stent System is the newest member of the XIENCE Family of Stents. The XIENCE Alpine Stent System is based on the predicate XIENCE Xpedition, XIENCE PRIME and XIENCE V Stent Systems. Therefore, the extensive body of XIENCE PRIME and XIENCE V clinical data is supportive of the performance of the XIENCE Alpine Stent System.

A patient's exposure to drug and polymer is proportional to the number and total length of implanted stents. In the SPIRIT PRIME study, total stent length per subject was limited to 76 mm with treatment allowed for up to two lesions each in a different epicardial vessel using XIENCE PRIME and XIENCE PRIME LL. Use of more than two XIENCE PRIME stents to treat lesions longer than 32 mm has not been evaluated and may increase patient complication risks. Studies evaluating the effects of higher drug doses have not been conducted.

In the SPIRIT II, SPIRIT III, and SPIRIT IV clinical trials, lesions > 22 mm in length and ≤ 28 mm in length were treated with planned overlapping XIENCE V stents in the XIENCE V arm, or a single 32 mm TAXUS stent or planned overlapping TAXUS stents in the TAXUS arm.

In the SPIRIT IV clinical trial, there were 239 patients in the planned overlapping XIENCE V stent subgroup, 55 patients in the single 32 mm TAXUS stent subgroup, and 99 patients in the planned overlapping TAXUS subgroup (with 6 patients in the TAXUS arm receiving both single 32 mm and overlapping TAXUS stents). At two years, the target lesion failure (TLF) rate was 11.9% in the planned overlapping XIENCE V stent subgroup, 11.3% in the single 32 mm TAXUS stent subgroup, and 12.9% in the planned overlapping TAXUS stent subgroup.

In the pooled SPIRIT II, SPIRIT III, and SPIRIT IV analysis, there was a total of 317 patients in the planned overlapping XIENCE V stent subgroup, 86 patients in the single 32 mm TAXUS stent subgroup, and 113 patients in the planned overlapping TAXUS stent subgroup. At two years, the TLF rate was 11.7% in the planned overlapping XIENCE V stent subgroup, 12.2% in the single 32 mm TAXUS stent subgroup, and 12.1% in the planned overlapping TAXUS stent subgroup. At two years, the all cause mortality rate was 3.2% in the planned overlapping XIENCE V stent subgroup, 4.9% in the single 32 mm TAXUS stent subgroup, and 1.9% in the planned overlapping TAXUS stent subgroup. The cardiac death rate was 1.0% in the planned overlapping XIENCE V stent subgroup, 1.2% in the single 32 mm TAXUS stent subgroup, and 0.9% in the planned overlapping TAXUS stent subgroup. At two years, the rate of target vessel MI was 3.2% in the planned overlapping XIENCE V stent subgroup, 7.3% in the single 32 mm TAXUS stent subgroup, and 3.7% in the planned overlapping TAXUS stent subgroup. The Academic Research Consortium (ARC)-defined definite plus probable stent thrombosis rate at two years was 0.7% in the planned overlapping XIENCE V stent subgroup, 1.3% in the single 32 mm TAXUS stent subgroup, and 1.9% in the planned overlapping TAXUS stent subgroup.

In XIENCE V USA, there was no angiographic restriction for patient enrollment. Stent implantation was done per site's standard care. There were 8040 patients with a total of 11,137 lesions treated during the index procedure. The mean lesion length was 15.8 mm, with 29% of those ≥ 20 mm in length based on visual estimation. Approximately 40.8% of patients had 2 or more stents implanted during the index procedure with a total of 12,873 XIENCE V stents implanted. The mean stent length was 29.2 mm per patient and 21.2 mm per lesion. Stent overlaps occurred in 14.5% of the lesions treated during the index procedure.

In XIENCE V USA, the clinical results of patients with single lesion treated and lesion length ≥ 20 mm (N = 1388) are summarized in section 9.7.3. In this pre-specified subgroup of patients

with long lesions, the mean lesion length was 28 mm with a total XIENCE V stent length of 34.3 mm per patient. At 1 year, the composite of cardiac death or target vessel MI rate (defined by ARC) was 6.8%, the ARC definite and probable ST rate was 0.79%, the ARC defined device-oriented endpoint (composite of cardiac death, target vessel MI [per ARC] and all TLR) was 9.3%.

In XIENCE V USA, there were 1301 (16.7%) patients with 1577 lesions (14.5%) where stent overlapping during the index procedure was reported, including situations where an implanted XIENCE V stent overlaps with a previously implanted stent prior to the index procedure. At 1 year, the composite of cardiac death or target vessel MI rate (defined by ARC) was 9.8%, the ARC definite and probable ST rate was 1.40%, TLF (composite of cardiac death, target vessel MI [per ARC] and clinically indicated TLR) was 13.1%.

Effects of multiple stenting using XIENCE Alpine stents combined with other drug-eluting stents are unknown. When multiple drug-eluting stents are required, use only XIENCE stents with the identical Co-Cr stent material and drug coating (e.g., XIENCE V, XIENCE nano[®], XIENCE PRIME, XIENCE Xpedition, or XIENCE Alpine) in order to avoid potential interactions with other drug-eluting or coated stents.

In addition, only stents composed of similar materials should be implanted in consecutive stent- to-stent contact, to avoid corrosion potential between unrelated materials.

5.4 Brachytherapy

XIENCE Alpine stent safety and effectiveness have not been evaluated in patients with prior target lesion or in-stent restenosis-related brachytherapy.

5.5 Use in Conjunction with Other Procedures

The safety and effectiveness of using mechanical atherectomy devices (directional atherectomy catheters, rotational atherectomy catheters) or laser angioplasty catheters in conjunction with XIENCE Alpine stent implantation have not been established.

5.6 Use in Special Populations

5.6.1 Pregnancy

Pregnancy Category C: see section 6.5 – *Drug Information, Pregnancy*. The XIENCE Alpine stent has not been tested in pregnant women or in men intending to father children. Effects on the developing fetus have not been studied. Effective contraception should be initiated before implanting a XIENCE Alpine stent and continued for one year after implantation. While there is no contraindication, the risks and reproductive effects are unknown at this time.

5.6.2 Lactation

See section 6.6 – *Drug Information, Lactation*. A decision should be made whether to discontinue nursing prior to stent implantation, considering the importance of the stent to the mother.

5.6.3 Gender

A gender analysis was not pre-specified in the SPIRIT PRIME clinical study. However, post-hoc analyses were conducted to evaluate gender-specific outcomes associated with the XIENCE PRIME stents in the SPIRIT PRIME trials, and the XIENCE V stent in the pooled data from the SPIRIT II, SPIRIT III, and SPIRIT IV trials (see section 9.6). Additional gender specific data associated with the EXPERT CTO trial can be found in Section 9.8.

5.6.4 Ethnicity

Insufficient subject numbers prevent ethnicity-related analyses of the XIENCE family of stents safety and effectiveness. Table 5.6.4-1 provides an overview of all non-Caucasians enrolled in the SPIRIT Trials.

Table 5.6.4-1: Non-Caucasians in the SPIRIT and XIENCE V USA Trials

| | Non-Caucasian Population |
|---------------------|---------------------------------|
| SPIRIT III | 8.8% (88/1001) |
| SPIRIT IV | 6.4% (236/3687) |
| SPIRIT Small Vessel | 9.9% (14/142) |
| SPIRIT PRIME CSR | 7.7% (29/375) |
| SPIRIT PRIME LLR | 8.3% (8/96) |
| XIENCE V USA | 12.3% (990/8027) |

5.6.5 Pediatric Use

The safety and effectiveness of the XIENCE Alpine stent in pediatric subjects have not been established.

5.6.6 Geriatric Use

The XIENCE PRIME clinical trial did not have an upper age limit. Among the 401 patients in the SPIRIT PRIME Core Size Registry, 167 were older than age 65 and 234 were age 65 or younger. Among the 104 patients in the SPIRIT PRIME Long Lesion Registry, 48 patients were older than age 65 and 56 were age 65 or younger. A post-hoc analysis showed no clinically significant differences in clinical endpoints between patients older than age 65 compared to those age 65 years or younger.

5.7 Lesion / Vessel Characteristics

Safety and effectiveness of the XIENCE Alpine stent have not been established for subject populations with the following clinical settings:

- Unresolved vessel thrombus at the lesion site
- Coronary artery reference vessel diameters < 2.25 mm or > 4.25 mm
- Lesion lengths > 32 mm
- Lesions located in saphenous vein grafts

-
- Lesions located in unprotected left main coronary artery, ostial lesions, and lesions located at a bifurcation
 - Previously stented lesions
 - Diffuse disease or poor flow (TIMI < 1) distal to the identified lesions
 - Excessive tortuosity proximal to or within the lesion
 - Recent acute myocardial infarction (AMI) or evidence of thrombus in the target vessel
 - Multivessel disease
 - In-stent restenosis

In the all-inclusive, real-world XIENCE V USA post-approval study, several pre-specified subgroup analyses (including the above-mentioned AMI, multivessel disease and in-stent restenosis) were conducted. Please see section 9.7.3 for the clinical outcomes of XIENCE V in those clinical settings.

5.8 Drug Interactions

See section 6.3 – *Drug Information, Interactions with Drugs or Other Substances*. Several drugs are known to affect everolimus metabolism, and other drug interactions may also occur. Everolimus is known to be a substrate for both cytochrome P4503A4 (CYP3A4) and P-glycoprotein (PgP). Everolimus absorption and subsequent elimination may be influenced by drugs that affect these pathways. Everolimus has also been shown to reduce the clearance of some prescription medications when administered orally along with cyclosporine (CsA). Formal drug interaction studies have not been performed with the XIENCE Alpine stent because of limited systemic exposure to everolimus eluted from XIENCE Alpine (see section 6.2 – *Drug Information, Pharmacokinetics*). Therefore, due consideration should be given to the potential for both systemic and local drug interactions in the vessel wall, when deciding to place the XIENCE Alpine stent in a patient taking a drug with known interaction with everolimus, or when deciding to initiate therapy with such a drug in a patient who has recently received a XIENCE Alpine stent.

5.9 Immune Suppression Potential

Everolimus, the XIENCE Alpine stent active ingredient, is an immunosuppressive agent. Immune suppression was not observed in the SPIRIT family of clinical trials. However, for patients who receive several XIENCE Alpine stents simultaneously, it may be possible for everolimus systemic concentrations to approach immunosuppressive levels temporarily, especially in patients who also have hepatic insufficiency or who are taking drugs that inhibit CYP3A4 or P-glycoprotein. Therefore, consideration should be given to patients taking other immunosuppressive agents or who are at risk for immune suppression.

5.10 Lipid Elevation Potential

Oral everolimus use in renal transplant and advanced renal cell carcinoma patients was associated with increased serum cholesterol and triglycerides, which in some cases required treatment. The effect was seen with both low and high dose prolonged oral therapy in a dose related manner. When used according to the indications for use, exposure to systemic everolimus concentrations from the XIENCE Alpine stent is expected to be significantly lower than concentration exposure usually obtained in transplant patients. Increased serum cholesterol and triglycerides were not observed in the SPIRIT family of clinical trials.

5.11 Magnetic Resonance Imaging (MRI)

Nonclinical testing has demonstrated that the XIENCE Alpine stent, in single and in overlapped configurations up to 71 mm in length, is MR Conditional. It can be scanned safely under the following conditions:

- Static magnetic field of 1.5 or 3 Tesla
- Spatial gradient field of 2500 Gauss/cm or less
- Maximum whole-body-averaged specific absorption rate (SAR) of 2.0 W/kg (normal operating mode) for up to 15 minutes of scanning for each sequence

The XIENCE Alpine stent should not migrate in this MRI environment. Nonclinical testing at field strengths greater than 3 Tesla has not been performed to evaluate stent migration or heating. MRI at 1.5 or 3 Tesla may be performed immediately following the implantation of the XIENCE Alpine stent.

Stent heating was derived by using the measured nonclinical, *in vitro* temperature rises in a GE Excite 3 Tesla scanner and in a GE 1.5 Tesla coil in combination with the local specific absorption rates (SARs) in a digitized human heart model. The maximum whole body averaged SAR was determined by validated calculation. At overlapped lengths of up to 71 mm, the XIENCE Alpine stent produced a nonclinical maximum local temperature rise of 3.3°C at a maximum whole body averaged SAR of 2.0 W/kg (normal operating mode) for 15 minutes. These calculations do not take into consideration the cooling effects of blood flow.

The effects of MRI on overlapped stents greater than 71 mm in length or stents with fractured struts are unknown.

As demonstrated in nonclinical testing, an image artifact can be present when scanning the XIENCE Alpine stent. MR image quality may be compromised if the area of interest is in the exact same area, or relatively close to, the position of the XIENCE Alpine stent. Therefore, it may be necessary to optimize the MR imaging parameters for the presence of XIENCE Alpine stent.

It is suggested that patients register the conditions under which the implant can safely be scanned with the MedicAlert Foundation (www.medicalert.org) or an equivalent organization.

5.12 Stent Handling

- **Each stent is for single use only.** Do not resterilize or reuse this device. Note the “Use by” (expiration) date on the product label.
- **The foil pouch is not a sterile barrier.** The inner header bag (pouch) within the foil pouch is the sterile barrier. **Only the contents of the inner pouch should be considered sterile.** The outside surface of the inner pouch is NOT sterile.
- **Do not remove the stent from the delivery system.** Removal may damage the stent and / or lead to stent embolization. These components are intended to perform together as a system.
- The delivery system should not be used in conjunction with other stents.
- Special care must be taken not to handle or disrupt the stent on the balloon, particularly during delivery system removal from packaging, placement over the guide wire and advancement through the rotating hemostatic valve adapter and guiding catheter hub.

-
- **Do not manipulate, touch, or handle the stent** with your fingers, which may cause coating damage, contamination, or stent dislodgement from the delivery balloon.
 - Use only the appropriate balloon inflation media (see section 13.3.3 – *Operator's Instructions, Delivery System Preparation*). Do not use air or any gaseous medium to inflate the balloon as this may cause uneven expansion and difficulty in stent deployment.

5.13 Stent Placement

5.13.1 Stent Preparation

- **Do not prepare or pre-inflate the delivery system prior to stent deployment other than as directed.** Use the balloon purging technique described in section 13.3.3 – *Operator's Instructions, Delivery System Preparation*.
- **While introducing the delivery system into the vessel, do not induce negative pressure on the delivery system.** This may cause dislodgement of the stent from the balloon.
- Use guiding catheters which have lumen sizes that are suitable to accommodate the stent delivery system (see section 1.1 – *Product Description, Device Component Description*).

5.13.2 Stent Implantation

- The decision to pre-dilate the lesion with an appropriate sized balloon should be carefully based on patient and lesion characteristics. The XIENCE V USA Clinical Trial demonstrated that in a real-world setting, direct stenting with XIENCE V stents in single-lesion treated patients who did not have a staged procedure was non-inferior to stenting utilizing pre-dilation. In this analysis, there was, as expected, some degree of selection bias with lesions undergoing direct-stenting displaying lower complexity than lesions undergoing pre-dilation. However, adjustment for baseline differences in lesion characteristics did not change the finding of non-inferiority of direct stenting to pre-dilation. Please see Section 9.7.2 for the detailed clinical results from XIENCE V USA post-approval study.
- Do not expand the stent if it is not properly positioned in the vessel (see section 5.14 – *Precautions, Stent System Removal*).
- Implanting a stent may lead to vessel dissection and acute closure requiring additional intervention (CABG, further dilatation, placement of additional stents, or other).
- Although the safety and effectiveness of treating more than one lesion per coronary artery with XIENCE Alpine stents have not been established, if this is performed, place the stent in the distal lesion before the proximal lesion in order to minimize dislodgement risk incurred by traversing through deployed stents.
- Stent placement may compromise side branch patency.
- **Do not exceed Rated Burst Pressure (RBP) as indicated on product label.** See Table 14-1: XIENCE Alpine Stent Compliance. Balloon pressures should be monitored during inflation. Applying pressures higher than specified on the product label may result in a ruptured balloon with possible arterial damage and dissection. The stent inner diameter should approximate 1.1 times the reference diameter of the vessel.

-
- An unexpanded stent may be retracted into the guiding catheter one time only. An unexpanded stent should not be reintroduced into the artery once it has been pulled back into the guiding catheter. Subsequent movement in and out through the distal end of the guiding catheter should not be performed, as the stent may be damaged when retracting the undeployed stent back into the guiding catheter.
 - Should **resistance** be felt **at any time** during coronary stent system withdrawal, please follow the steps provided in section 5.14 – *Precautions, Stent System Removal*.
 - Stent retrieval methods (i.e., using additional wires, snares, and / or forceps) may result in additional trauma to the coronary vasculature and / or the vascular access site. Complications may include bleeding, hematoma, or pseudoaneurysm.
 - Although the stent delivery system balloon is strong enough to expand the stent without rupture, a circumferential balloon tear distal to the stent and prior to complete stent expansion could cause the balloon to become tethered to the stent, requiring surgical removal. In case of balloon rupture, it should be withdrawn and if necessary, a new dilatation catheter exchanged over the guide wire to complete the expansion of the stent.
 - Ensure the stented area covers the entire lesion / dissection site and that no gaps exist between stents.
 - Do not torque the catheter more than one (1) full turn.

5.14 Stent System Removal

Stent delivery system removal prior to stent deployment:

If removal of a stent system is required prior to deployment, ensure that the guiding catheter is coaxially positioned relative to the stent delivery system, and cautiously withdraw the stent delivery system into the guiding catheter. Should unusual resistance be felt at any time when withdrawing the stent towards the guiding catheter, the stent delivery system and the guiding catheter should be removed as a single unit. This should be done under direct visualization with fluoroscopy.

Withdrawal of the stent delivery catheter from the deployed stent:

1. Deflate the balloon by pulling negative on the inflation device. Larger and longer balloons will take more time (up to 30 seconds) to deflate than smaller and shorter balloons. Confirm balloon deflation under fluoroscopy and wait 10 – 15 seconds longer.
2. Position the inflation device to “negative” or “neutral” pressure.
3. Stabilize guiding catheter position just outside coronary ostium and anchor in place. Maintain guide wire placement across stent segment.
4. Gently remove the stent delivery system with slow and steady pressure.
5. Tighten the rotating hemostatic valve.

If during withdrawal of the catheter resistance is encountered, use the following steps to improve balloon rewrap.

- Re-inflate the balloon up to nominal pressure.

-
- Repeat steps 1 through 5 above.

Failure to follow these steps and / or applying excessive force to the delivery system can potentially result in loss of or damage to the stent and / or delivery system components.

If it is necessary to retain guide wire position for subsequent artery / lesion access, leave the guide wire in place and remove all other system components.

Stent retrieval methods (i.e., additional wires, snares, and / or forceps) may result in additional trauma to the coronary vasculature and / or the vascular access site. Complications may include, but are not limited to, bleeding, hematoma, or pseudoaneurysm.

5.15 Post-Procedure

- When **crossing a newly deployed stent** with an intravascular ultrasound (IVUS) catheter, a coronary guide wire, a balloon catheter or delivery system, exercise care to avoid disrupting the stent placement, apposition, geometry, and / or coating.
- Antiplatelet therapy should be administered post-procedure (see section 5.2 – *Precautions, Pre- and Post-Procedure Antiplatelet Regimen*). Patients who require early discontinuation of antiplatelet therapy (e.g., secondary to active bleeding) should be monitored carefully for cardiac events. At the discretion of the patient's treating physician, the antiplatelet therapy should be restarted as soon as possible.
- If the patient requires imaging, see section 5.11 – *Precautions, Magnetic Resonance Imaging (MRI)*.

6.0 DRUG INFORMATION

6.1 Mechanism of Action

The mechanism by which the XIENCE Alpine stent inhibits neointimal growth as seen in pre-clinical and clinical studies has not been established. At the cellular level, everolimus inhibits growth factor-stimulated cell proliferation. At the molecular level, everolimus forms a complex with the cytoplasmic protein FKBP-12 (FK 506 Binding Protein). This complex binds to and interferes with FKBP-12 Rapamycin Associated Protein (FRAP), also known as mammalian target of rapamycin (mTOR), leading to inhibition of cell metabolism, growth, and proliferation by arresting the cell cycle at the late G1 stage.

6.2 Pharmacokinetics

Pharmacokinetic studies have not been performed using the XIENCE Alpine stent, but were conducted on the similar XIENCE V stent. The XIENCE Alpine stent is similar to XIENCE V with regards to the stent design, identical stent coating technology (dosing and drug to polymer ratio), and similar delivery system materials. Given these similarities, the findings from the XIENCE V pharmacokinetic studies, as described below, are applicable to the XIENCE Alpine stent. Everolimus pharmacokinetics, when eluted from the XIENCE V stent post-implantation, has been evaluated in three different substudies in three different geographies. The SPIRIT III clinical trial design includes a pharmacokinetic substudy in the U.S. randomized arm and a pharmacokinetic substudy in the Japanese nonrandomized arm. The third PK substudy was conducted as part of the SPIRIT II clinical trial at sites in Europe, India, and New Zealand.

Whole blood everolimus PK parameters determined from subjects receiving the XIENCE V stent are provided in Table 6.2-1.

Table 6.2-1: Whole Blood Everolimus Pharmacokinetic Parameters in Patients Following XIENCE V Stent Implantation

| SPIRIT III RCT and 4.0 Arm | | | | | | | |
|---|-----------|------------------------|--------------------------|-----------------------------------|---|---|-----------------------|
| | Dose (µg) | t _{max} (h) | C _{max} (ng/mL) | t _{1/2} (h) ^a | AUC _{0-t} ^a (ng.h/mL) | AUC _{0-∞} ^a (ng.h/mL) | CL (L/h) ^a |
| | | median (range) | mean ± SD | mean ± SD | mean ± SD | mean ± SD | mean ± SD |
| 2.5 – 3.0 x 18 mm (n = 3 ^b) | 88 µg | 0.050 (0.50 – 1.88) | 0.3867 ± 0.09866 | | 5.31 ± 4.114 | | |
| 3.5 – 4.0 x 28 mm (n = 6 ^c) | 181 µg | 0.50 (0.07 – 1.00) | 1.175 ± 0.6817 | 79.08 ± 57.24 | 23.73 ± 13.63 | 44.00 ± 28.67 | 5.130 ± 2.114 |
| SPIRIT III Japanese Arm | | | | | | | |
| | Dose (µg) | t _{max} (h) | C _{max} (ng/mL) | t _{1/2} (h) ^a | AUC _{0-t} (ng.h/mL) | AUC _{0-∞} ^a (ng.h/mL) | CL (L/h) |
| | | median (range) | mean ± SD | mean ± SD | mean ± SD | mean ± SD | mean ± SD |
| 2.5 – 3.0 x 18 mm (n = 6) | 88 µg | 1.00 (0.50 – 1.02) | 0.5017 ± 0.1398 | 45.22 ± 35.08 | 5.049 ± 2.138 | 12.98 ± 7.078 | 9.286 ± 6.069 |
| 3.5 – 4.0 x 18 mm (n = 4 ^b) | 113 µg | 0.51 (0.50 – 0.53) | 0.6500 ± 0.08756 | 53.57 ± 19.34 | 11.02 ± 4.002 | 19.97 ± 7.890 | 6.471 ± 2.807 |
| SPIRIT II Clinical Trial | | | | | | | |
| | Dose (µg) | t _{max} (h) | C _{max} (ng/mL) | t _{1/2} (h) ^a | AUC _{last} (ng.h/mL) | AUC _{0-∞} ^a (ng.h/mL) | CL (L/h) ^a |
| | | median (range) | mean ± SD | mean ± SD | mean ± SD | mean ± SD | mean ± SD |
| 2.5 – 3.0 x 18 mm (n = 13) | 88 µg | 0.50 (0.13 – 2.17) | 0.4369 ± 0.1507 | 54.08 ± 35.78 | 8.255 ± 5.863 | 19.60 ± 15.30 | 8.066 ± 6.443 |
| 3.5 – 4.0 x 18 mm (n = 4 ^c) | 113 µg | 0.50 (0.50 – 0.50) | 0.5850 ± 0.2630 | 47.60 ± 62.13 | 42.54 ± 58.83 | 22.79 ± 31.47 | 16.96 ± 13.07 |
| 3.5 – 4.0 x 28 mm (n = 4) | 181 µg | 0.46 (0.17 – 1.00) | 0.7925 ± 0.1406 | 103.4 ± 64.17 | 28.07 ± 13.18 | 52.71 ± 27.40 | 5.332 ± 5.048 |

^a Accurate determination not possible due to rapid disappearance of everolimus from the blood

^b n = 5 for t_{1/2} and CL

^c n = 3 for t_{1/2} and CL

t_{max} (h) = time to maximum concentration

C_{max} = maximum observed blood concentration

t_{1/2} (h) = terminal phase half-life

AUC_{0-t} or AUC_{last} = the area beneath the blood concentration versus time curve: time zero to the final quantifiable concentration

AUC_(0-∞) = the area beneath the blood concentration versus time curve: time zero to the extrapolated infinite time

CL = total blood clearance

In all subjects, the maximum time to everolimus disappearance was 168 hours; however, 1 subject in the SPIRIT II clinical trial had detectable levels at 30 days. In all 3 studies, the C_{max} value never reached the minimum therapeutic value of 3.0 ng/mL necessary for effective systemic administration to prevent organ rejection in patients taking Certican[®]. The PK parameters representing elimination, t_{1/2}, AUC_{0-t}, AUC_{last}, AUC_∞, and CL, could also not be determined accurately due to rapid everolimus disappearance from blood. These types of results have been seen with other drug-eluting stents.

Everolimus disappearance from circulation following XIENCE V stent implantation should further limit systemic exposure and adverse events associated with long-term systemic administration at therapeutic levels. Despite limited systemic exposure to everolimus, local arterial delivery has been demonstrated in pre-clinical studies. The same results are expected for XIENCE Alpine due to the similarities with XIENCE V stated above.

6.3 Interactions with Drugs or Other Substances

Everolimus is extensively metabolized by the cytochrome P4503A4 (CYP3A4) in the liver and to some extent in the intestinal wall, and is a substrate for the countertransporter P-glycoprotein (PgP). Therefore, absorption and subsequent elimination of everolimus may be influenced by drugs that also affect CYP3A4 and PgP pathways. Everolimus has also been shown to reduce the clearance of some prescription medications when it was administered orally along with cyclosporine (CsA). Formal drug interaction studies have not been performed with the XIENCE Alpine or XIENCE V stents because of limited systemic exposure to everolimus eluted from XIENCE V (see section 6.2 – *Drug Information, Pharmacokinetics*). However, consideration should be given to the potential for both systemic and local drug interactions in the vessel wall when deciding to place the XIENCE Alpine stent in a subject taking a drug with known interaction with everolimus.

Everolimus, when prescribed as an oral medication, may interact with the drugs / foods² listed below. Medications that are strong inhibitors of CYP3A4 or PgP might reduce everolimus metabolism *in vivo*. Hence, co-administration of strong inhibitors of CYP3A4 or PgP may increase the blood concentrations of everolimus. Medications that are strong inducers of CYP3A4 or PgP might increase everolimus metabolism *in vivo* resulting in decreased blood concentrations of everolimus.

- CYP3A4 / PgP inhibitors
 - Antifungal agents (e.g., fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole)
 - Macrolide antibiotics (e.g., erythromycin, clarithromycin, telithromycin)
 - Calcium channel blockers (e.g., verapamil, nifedipine, diltiazem)
 - Protease inhibitors (e.g., ritonavir, atazanavir, saquinavir, darunavir, indinavir, nelfinavir, amprenavir, fosamprenavir)
 - Other (e.g., cyclosporine, nefazodone, cisapride, metoclopramide, bromocriptine, cimetidine, danazol, sildenafil, terfenadine, astemizole, grapefruit / grapefruit juice, digoxin)

- CYP3A4 / PgP inducers
 - Antibiotics (e.g., rifampin, rifabutin, ciprofloxacin, ofloxacin)
 - Anticonvulsants (e.g., carbamazepine, phenobarbital, phenytoin)
 - Non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, nevirapine)
 - Glucocorticoids (e.g., dexamethasone, prednisone, prednisolone)
 - HMGCoA reductase inhibitors (simvastatin, lovastatin)
 - Other (e.g., St. John's Wort)

Everolimus is approved in the United States under the name of Zortress[®] for the prophylaxis of organ rejection in adult kidney transplant recipients at low-moderate immunologic risk, at the dose of 1.5 mg/day when taken by mouth. Outside the United States, Zortress is sold under the brand name Certican in more than 70 countries. Everolimus is also approved in the United States under the name of Afinitor[®] for the treatment of patients with advanced renal cell carcinoma (cancer) after failure of treatment with sunitinib or sorafenib, at doses of 5 to 20 mg/day when taken by mouth. The amount of drug that circulates in the bloodstream

² Zortress Prescribing Information from Drugs@FDA, label approved on April 20, 2010.

following implantation of a XIENCE Alpine stent is several folds lower than that obtained with oral doses (1.5 mg to 20 mg/day).

6.4 Carcinogenicity, Genotoxicity, and Reproductive Toxicity

The carcinogenicity, genotoxicity, and reproductive toxicity of the XIENCE Alpine stent have not been evaluated; however, long-term carcinogenicity and teratology studies were performed with the similar XIENCE V stent. The test results from the XIENCE V stent, as described below, are applicable to the XIENCE Alpine, due to similar stent design, delivery system materials, and identical stent coating technology.

A 26-week carcinogenicity study was conducted to evaluate the carcinogenic potential of XIENCE V stents following subcutaneous implantation in transgenic mice. During the course of the study, there were no abnormal clinical observations that suggested a carcinogenic effect of the test group (XIENCE V stent). The test group did not demonstrate an increased incidence of neoplastic lesions when compared to the negative control group. However, the positive control and the experimental positive control groups demonstrated notable increases in the incidence of neoplastic lesions compared to either the test or the negative control group. Based on the results of this study, the XIENCE V stent does not appear to be carcinogenic when implanted in transgenic mice for 26 weeks.

Genotoxicity studies were conducted on the XIENCE V stent in mammalian cells and bacteria. These studies included gene mutations in bacteria (Ames Test), gene mutations in mammalian cells (chromosomal aberration), test for clastogenicity in mammalian cells, and mammalian erythrocyte micronucleus test. Based on the results of these studies, the XIENCE V stent is not genotoxic.

In addition, a reproductive toxicity (teratology) study was conducted in female Sprague-Dawley rats. The XIENCE V stent did not affect the fertility or reproductive capability of female Sprague-Dawley rats. There was no statistical difference between the test article (XIENCE V stent) and the control system in terms of any of the evaluated parameters. The test article had no effect on litter size and caused no increase of *in utero* mortality. Additionally, the XIENCE V stent did not cause any reproductive toxicity in the offspring in this study.

6.5 Pregnancy

Pregnancy Category C: There are no adequate everolimus or XIENCE Alpine stent-related studies in pregnant women. Effects of a similar stent, XIENCE V, on prenatal and postnatal rat development were no different than the controls (see section 6.4 – *Drug Information, Carcinogenicity, Genotoxicity, and Reproductive Toxicity*). When administered at oral doses of 0.1 mg/kg or above, everolimus showed effects on prenatal and postnatal rat development limited to slight body weight changes and fetal survival without any specific toxic potential.³ Effective contraception should be initiated before implanting a XIENCE Alpine stent and continued for one year post-implantation. The XIENCE Alpine stent should be used in pregnant women only if potential benefits outweigh potential risks.

The safety of the XIENCE Alpine stent has not been evaluated in males intending to father children.

³ Certican Investigator's Brochure

6.6 Lactation

It is unknown whether everolimus is distributed in human milk. Also, everolimus pharmacokinetic and safety profiles have not been determined in infants. Consequently, mothers should be advised of potential serious adverse reactions to everolimus in nursing infants. Prior to XIENCE Alpine stent implantation, decisions should be made regarding whether to discontinue nursing or conduct an alternate percutaneous coronary intervention procedure.

7.0 OVERVIEW OF CLINICAL EXPERIENCE

SPIRIT PRIME is a prospective, open-label, multicenter, nonrandomized clinical trial using the core size XIENCE PRIME and XIENCE PRIME LL stent system. Approximately 500 subjects at up to 75 sites were to be enrolled in the Core Size Registry or Long Lesion Registry. Each subject was to receive treatment in up to two *de novo* native coronary lesions, each in a different epicardial vessel. The Core Size Registry was to enroll approximately 400 subjects in which all were to be treated with core size XIENCE PRIME (stent diameters 2.25, 2.5, 3.0, 3.5 or 4.0 mm with stent lengths 8, 18, or 28⁴ mm). The Long Lesion Registry was to enroll approximately 100 subjects in which all were to be treated with at least one XIENCE PRIME LL (stent diameters 2.5, 3.0, 3.5 or 4.0 mm with stent lengths 33 or 38 mm). Treatment of a second target lesion with a core size XIENCE PRIME was recommended. The primary endpoint was target lesion failure (TLF) at 1 year. Secondary endpoints included clinical outcomes at 30 and 180 days and annually from 1 to 3 years. Final follow-up through 3 year is presented here. The SPIRIT PRIME clinical trial is Abbott Vascular's pivotal US trial evaluating XIENCE PRIME.

The XIENCE PRIME stent is similar to the FDA approved XIENCE V stent system. XIENCE V EECSS has been studied extensively in four clinical trials, SPIRIT FIRST, SPIRIT II, SPIRIT III, and SPIRIT IV. Initial clinical safety and performance of the XIENCE V EECSS stent was demonstrated in the SPIRIT FIRST clinical trial in which the XIENCE V EECSS was compared to the VISION bare metal stent. The SPIRIT II clinical trial was a continuation in the assessment of the safety and performance of the XIENCE V EECSS versus the TAXUS[®] Express[®] stent. The SPIRIT III clinical trial was a pivotal clinical trial to demonstrate the safety and effectiveness of the XIENCE V EECSS. SPIRIT IV further evaluated the safety and effectiveness of XIENCE V in a large population of complex subjects. The SPIRIT family of trials evaluating the XIENCE V EECSS is ongoing, inclusive of Investigational Device Exemption (IDE) and post-marketing trials. For more information on the XIENCE V EECSS, refer to the XIENCE V EECSS Instructions for Use (IFU).

Principal XIENCE V safety and effectiveness information is derived from the SPIRIT III clinical trial and confirmed by the SPIRIT IV clinical trial. These studies evaluated the performance of XIENCE V in subjects with symptomatic ischemic disease due to *de novo* lesions in native coronary arteries. Major study characteristics for SPIRIT III and SPIRIT IV are summarized below and listed in Table 7-1.

SPIRIT III, a pivotal clinical trial, was designed to demonstrate the non-inferiority of the XIENCE V stent to the TAXUS Express stent (TAXUS stent) and was conducted in the United States (US) and Japan. The SPIRIT III RCT was a prospective, randomized (2:1; XIENCE V:TAXUS), active-controlled, single-blinded, multicenter, clinical trial in the US designed to evaluate the safety and efficacy of the XIENCE V stent in the treatment of up to two

⁴ The 28 mm length stent was studied in the XIENCE PRIME Core Size Registry. The results of the Core Size Registry are presented in Tables 9.1-2 to 9.1-3.

de novo lesions ≤ 28 mm in length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 3.75 mm. The RCT study was designed to enroll 1,002 subjects at up to 80 sites in the US. The primary endpoint in the RCT was in-segment late loss at 240 days, and the co-primary endpoint was ischemia-driven target vessel failure (TVF, defined as the composite of cardiac death, MI, or ischemia-driven TVR) at 270 days. Other secondary endpoints included clinical outcomes of all the subjects (30, 180, 270 days and annually from 1 to 5 years), as well as angiographic results and intravascular ultrasound (IVUS) results at 240 days. Five-year results are available, completing follow-up for SPIRIT III RCT.

The SPIRIT IV trial was a prospective, randomized, active-controlled, single-blinded, multicenter evaluation of the XIENCE V stent compared to the TAXUS Express Stent⁵ (TAXUS stent) in the treatment of up to three *de novo* lesions ≤ 28 mm in length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 4.25 mm. The SPIRIT IV trial was randomized 2:1 (XIENCE V:TAXUS) and designed to enroll 3,690 subjects at up to 80 sites in the US. Subjects were stratified by diabetes mellitus (diabetic vs. non-diabetic) and lesion characteristics (complex vs. noncomplex). Complex lesion characteristics included triple vessels treatment, or dual lesions per vessel treatment, or lesions involving RCA-aorto-ostial locations, or bifurcation lesions. The primary endpoint was target lesion failure (TLF) at 1 year. The major secondary endpoints were ID-TLR at 1 year and the composite of cardiac death or target vessel MI at 1 year. Formal non-inferiority and superiority testing were planned for the primary and the two major secondary endpoints by following a fixed sequence. Secondary endpoints included clinical outcomes at 30, 180, 270 days and annually from 1 to 3 years. Three-year results are available, completing follow-up for the SPIRIT IV trial.

The SPIRIT Small Vessel (SV) Registry was a prospective, single-arm, open-label, US multicenter registry study using 2.25 mm diameter XIENCE V EECSS. The trial enrolled a total of 150 subjects, of which 69 subjects were included in an angiographic follow-up cohort, at 33 sites. The SPIRIT SV trial allowed for target and non-target lesion treatment. The target lesion was identified as that lesion intended to be treated by the 2.25 mm XIENCE V EECSS and the non-target lesion was identified as that lesion intended to be treated by the commercial XIENCE V EECSS. The SPIRIT SV trial allowed for single target lesion or two lesion treatment (two target lesions or one target and one non-target lesion) in separate epicardial vessels. The primary endpoint was target lesion failure (TLF, defined as the composite of cardiac death, target vessel myocardial infarction and clinically indicated target lesion revascularization) at 1 year. Three-year results are available, completing follow-up for SPIRIT SV.

The XIENCE V USA study was a prospective, multicenter, FDA mandated post-approval study to evaluate the continued safety and effectiveness of the XIENCE V EECSS in “real-world” settings after commercialization in the US, and also to support the FDA dual antiplatelet therapy (DAPT) initiative. A total of 8,040 patients were consecutively enrolled from 191 sites in the US in two enrollment stages (5,042 patients from the first stage and 2,998 patients from the second stage). There were three cohorts in this study: (1) phase I cohort (from index procedure to 1 year), consisting of all enrolled patients from both enrollment stages; (2) long-term follow-up cohort (from 1 year to 4 years), consisting of patients from the first enrollment stage who were not transferred to HCRI-DAPT study and remained in the study beyond 1 year; (3) AV-DAPT cohort (from 1 year to 33 months), consisting of patients from the second enrollment stage who were eligible and randomized to the AV-DAPT study. Patients were considered enrolled upon signing the Institutional Review Board (IRB)-approved informed consent form (ICF) and upon completion of the index procedure utilizing only XIENCE V EECSS was (were) implanted during the index procedure. There were no angiographic inclusion and exclusion criteria for this study. For the phase I and the long-term follow-up cohorts, the primary endpoint was the annual rate of

⁵ In the TAXUS stent arm, there was 1 subject who received 1 TAXUS® Liberté® Stent.

ARC-defined stent thrombosis (definite and probable), and the co-primary endpoint was the annual composite rate of cardiac death or any MI. The study design of the AV-DAPT cohort follows the HCRI-DAPT study (IDE#G080186). Final clinical follow-up through 4 years is available for all the enrolled patients (long-term follow-up cohort).

Table 7-1 summarizes the clinical trial designs for the SPIRIT family of trials. Table 7-2 summarizes the clinical trial design for the XIENCE V USA post-approval study.

Table 7-1: SPIRIT Family Clinical Trial Designs

| | SPIRIT PRIME Clinical Trial | | SPIRIT III Clinical Trial | | SPIRIT IV Clinical Trial | SPIRIT Small Vessel Registry |
|--|---|---|---|---|---|---|
| | Core Size Registry | Long Lesion Registry | RCT (Pivotal) | 4.0 Arm (Registry) | | |
| Study Type / Design | <ul style="list-style-type: none"> • Multicenter • Single-arm • Open-label | <ul style="list-style-type: none"> • Multicenter • Single-arm • Open-label | <ul style="list-style-type: none"> • Multicenter • Randomized • Single-blinded • Active-control | <ul style="list-style-type: none"> • Multicenter • Single-arm • Open-label | <ul style="list-style-type: none"> • Multicenter • Randomized • Single-blinded • Active-Control | <ul style="list-style-type: none"> • Multicenter • Nonrandomized • Open-label • Non-blinded • Single-arm |
| Number of Subjects Enrolled | Total: 400 | Total: 100 | Total: 1,002 XIENCE V: 668 TAXUS Express Control: 334 | Total: 80 | Total: 3,690 XIENCE V: 2,460 TAXUS Express Control: 1,230 | Total : 150 No Control |
| Treatment | Up to two <i>de novo</i> lesions in different epicardial vessels | Up to two <i>de novo</i> lesions in different epicardial vessels | Up to two <i>de novo</i> lesions in different epicardial vessels | Up to two <i>de novo</i> lesions in different epicardial vessels | Up to three <i>de novo</i> lesions, maximum of two lesions per epicardial vessel | Up to two <i>de novo</i> lesions in different epicardial vessels |
| Lesion Size | RVD: $\geq 2.25 \leq 4.25$ mm Length: ≤ 22 mm | XIENCE PRIME CS: RVD: $\geq 2.25 \leq 4.25$ mm Length: ≤ 22 mm XIENCE PRIME LL: RVD: $\geq 2.5 \leq 4.25$ mm Length: > 22 mm and ≤ 32 mm | RVD: $\geq 2.5 \leq 3.75$ mm Length: ≤ 28 mm | RVD: $> 3.75 \leq 4.25$ mm Length: ≤ 28 mm | RVD: $\geq 2.5 \leq 4.25^{\$}$ mm Length: ≤ 28 mm | RVD: $\geq 2.25 < 2.50$ mm Length: ≤ 28 mm |
| Stent Sizes (XIENCE PRIME / XIENCE V) | XIENCE PRIME Diameter: 2.25, 2.5, 3.0, 3.5, 4.0 mm Length: 8, 18, 28*** mm | XIENCE PRIME LL Diameter: 2.5, 3.0, 3.5, 4.0 mm Length: 33, 38 mm | XIENCE V Diameter: 2.5, 3.0, 3.5 mm Length: 8, 18, 28 mm | XIENCE V Diameter: 4.0 mm Length: 8, 18, 28 mm | XIENCE V Diameter: 2.5, 3.0, 3.5, 4.0 [§] mm Length: 8, 18, 28 mm | XIENCE V Diameter: 2.25 mm Length: 8, 18, 28 mm |
| Post-Procedure Antiplatelet Therapy | Clopidogrel 12 months minimum (or ticlopidine per site standard), aspirin 3 years | Clopidogrel 12 months minimum (or ticlopidine per site standard), aspirin 3 years | Clopidogrel 6 months minimum (or ticlopidine per site standard), aspirin 5 years | Clopidogrel 6 months minimum (or ticlopidine per site standard), aspirin 5 years | Clopidogrel 12 months minimum (or ticlopidine per site standard), # aspirin 3 years | Clopidogrel 12 months minimum (or ticlopidine per site standard), aspirin indefinitely |

| | SPIRIT PRIME Clinical Trial | | SPIRIT III Clinical Trial | | SPIRIT IV Clinical Trial | SPIRIT Small Vessel Registry |
|---|---|---|---|--------------------------------------|---|--|
| | Core Size Registry | Long Lesion Registry | RCT (Pivotal) | 4.0 Arm (Registry) | | |
| Primary Endpoint •Primary Analysis •Major Secondary Analysis 1 •Major Secondary Analysis 2 | TLF (Target lesion failure) at 1 year •TLF (per ARC) at 1 year compared to PG* of 9.2% •TLF (per protocol) at 1 year compared to PG* of 9.2% •TLF (per ARC) at 1 year compared to PG* of 15.3% | TLF (Target Lesion failure) at 1 year •TLF (per ARC) at 1 year compared to PG* of 19.2% •TLF (per protocol) at 1 year compared to PG* of 19.2% •TLF (per ARC) at 1 year compared to PG* of 26% | In-segment late loss at 240 days | In-segment late loss at 240 days | TLF (Target Lesion failure) at 1 year | Clinically indicated target lesion failure at 1 year (composite of cardiac death, target vessel MI and clinically indicated TLR) |
| Co-Primary Endpoint | None | None | TVF (Target vessel Failure) at 270 days | None | None | None |
| Major Secondary Endpoint | None | None | None | None | <ul style="list-style-type: none"> Ischemia-driven Target Lesion Revascularization (ID-TLR) at 1 year Composite endpoint of cardiac death or target vessel MI at 1 year | None |
| Clinical Follow-up | 30, 180 days, 1 to 3 years | 30, 180 days, 1 to 3 years | 30, 180, 240, 270 days, 1 to 5 years | 30, 180, 240, 270 days, 1 to 5 years | 30, 180, 270 days, 1 to 3 years | 30, 240 days, 1 to 3 years |
| Status | 1, 2, and 3 years reported | 1, 2, and 3 years reported | 1, 2, 3, 4, and 5 years reported | 1, 2, 3, 4, and 5 years reported | 1, 2 and 3 years reported | 1, 2, and 3 years reported |

* Performance Goal (PG)

** In the TAXUS arm, there was 1 patient who received 1 TAXUS® Liberté® stent.

*** The 28 mm length stent was studied in the Core Size Registry. The results of the Core Size Registry are presented in Tables 9.1-2 to 9.1-3.

§ RVD ≥ 2.5 mm to ≤ 3.75 mm and stent sizes up to 3.5 mm until 4.0 mm TAXUS is commercially available.

All subjects receiving a study stent were to be maintained on 75 mg of clopidogrel bisulfate daily for a minimum of 6 months, and per the American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI) guidelines it was strongly recommended that subjects should be treated with clopidogrel bisulfate up to 12 months if they are not at high risk for bleeding.

Table 7-2: XIENCE V USA Post-Approval Study Design

| | XIENCE V USA Phase I Cohort | XIENCE V USA Long-Term Follow-up Cohort | XIENCE V USA AV-DAPT Cohort |
|--|--|--|---|
| Study Type / Design | <ul style="list-style-type: none"> • Multicenter • Prospective | <ul style="list-style-type: none"> • Multicenter • Prospective | <ul style="list-style-type: none"> • Multicenter • Randomized • Double-blinded • Placebo Control |
| Number of Subjects Enrolled | Total: 8040 | Total: 4663 | Total: 868 |
| Treatment | Only XIENCE V EECSS implanted during the index procedure; otherwise per site standard care | Only XIENCE V EECSS implanted during the index procedure; otherwise per site standard care | Only XIENCE V EECSS implanted during the index procedure; otherwise per site standard care. At 1 year, patients were randomized to receive either thienopyridine or placebo treatment for additional 18 months along with aspirin |
| Lesion Size | No angiographic restrictions | No angiographic restrictions | No angiographic restrictions |
| Stent Sizes (XIENCE V) | Diameter: 2.5, 2.75, 3.0, 3.5, 4.0 mm Length: 8, 12, 15, 18, 23, 28 mm | Diameter: 2.5, 2.75, 3.0, 3.5, 4.0 mm Length: 8, 12, 15, 18, 23, 28 mm | Diameter: 2.5, 2.75, 3.0, 3.5, 4.0 mm Length: 8, 12, 15, 18, 23, 28 mm |
| Post-Procedure Antiplatelet Therapy | Per site standard | Per site standard | Patients were randomized to receive either thienopyridine or placebo treatment between 12 and 30 months. Thienopyridine or placebo will be discontinued between 30 and 33 months. Aspirin is required through 33 months. |
| Primary Endpoint | ARC definite and probable stent thrombosis up to 1 year | ARC definite and probable stent thrombosis from year 1 to 4 | MACE (composite of all death, MI and stroke) 12 – 33 months |
| Co-Primary Endpoint | Composite rate of cardiac death or any MI at 1 year | Composite rate of cardiac death or any MI from year 1 to 4 | ARC definite and probable ST 12 – 33 months |
| Major Safety Endpoint | None | None | Major bleeding (GUSTO severe and moderate bleeding combined) 12 – 33 months |
| Major Secondary Endpoint | None | None | None |
| Clinical Follow-up | 14, 30, 180 days, and 1 year | 2, 3, and 4 years | 15, 24, 30, and 33 months |
| Angiographic Follow-up | None | None | None |
| IVUS Follow-up | None | None | None |
| PK Study | None | None | None |
| Status | 1 year reported | 2, 3, and years reported | 15, 24, 30, and 33 months reported |

8.0 ADVERSE EVENTS

8.1 Observed Adverse Events

Principal adverse event information is derived from the SPIRIT PRIME Core Size Registry, SPIRIT IV, SPIRIT III, and SPIRIT SV clinical trials and is shown in Table 8.1-1. Principal adverse events from the XIENCE V USA clinical trial are presented in Table 8.1-2. See also section 8.3 – *Adverse Events, Potential Adverse Events*. See section 9.0 – *SPIRIT Family of Clinical Trials* for more complete study design descriptions and results.

Note: Information on adverse events for subjects in the SPIRIT PRIME Long Lesion Registry is in Table 9.1-4.

**Table 8.1-1: SPIRIT Family:
Principal Adverse Events from Post-Procedure to Latest Follow-up**

| | SPIRIT PRIME | SPIRIT IV | | SPIRIT III (RCT) | | | SPIRIT SV |
|-----------------------------------|---|---------------------|------------------|--------------------|-----------------|------------------------------|----------------------------|
| | Core Size Registry ^s (N = 401) | XIENCE V (N = 2458) | TAXUS (N = 1229) | XIENCE V (N = 669) | TAXUS (N = 333) | XIENCE V 4.0 mm Arm (N = 73) | 2.25 mm XIENCE V (N = 144) |
| In -Hospital Adverse Events | | | | | | | |
| TLF | 2.0% (8/401) | 1.4% (35/2451) | 1.9% (23/1224) | 0.9% (6/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| MACE | 2.0% (8/401) | 1.4% (35/2451) | 1.9% (23/1224) | 0.9% (6/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| TVF | NA | 1.5% (36/2451) | 2.0% (24/1224) | 0.9% (6/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| All Death | 0.0% (0/401) | 0.0% (0/2451) | 0.0% (0/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.0% (0/143) |
| Cardiac Death | 0.0% (0/401) | 0.0% (0/2451) | 0.0% (0/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.0% (0/143) |
| Non-Cardiac Death | 0.0% (0/401) | 0.0% (0/2451) | 0.0% (0/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.0% (0/143) |
| MI | 1.7% (7/401) | 1.4% (35/2451) | 1.8% (22/1224) | 0.7% (5/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| QMI | 0.2% (1/401) | 0.1% (3/2451) | 0.2% (2/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.7% (1/143) |
| NQMI | 1.5% (6/401) | 1.3% (32/2451) | 1.6% (20/1224) | 0.7% (5/669) | 1.8% (6/330) | 4.1% (3/73) | 0.7% (1/143) |
| Cardiac Death or MI | 1.7% (7/401) | 1.4% (35/2451) | 1.8% (22/1224) | 0.7% (5/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| Ischemia-Driven Revascularization | 0.5% (2/401) | 0.4% (9/2451) | 0.5% (6/1224) | 0.1% (1/669) | 0.0% (0/330) | 0.0% (0/73) | 0.7% (1/143) |
| Ischemia -- Driven TLR | 0.2% (1/401) | 0.3% (8/2451) | 0.4% (5/1224) | 0.1% (1/669) | 0.0% (0/330) | 0.0% (0/73) | 0.0% (0/143) |
| Ischemia -- Driven TVR, Non TL | 0.2% (1/401) | 0.1% (3/2451) | 0.2% (2/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.7% (1/143) |
| Stent Thrombosis (Per Protocol) | 0.5% (2/401) | 0.1% (3/2451) | 0.4% (5/1224) | 0.1% (1/669) | 0.0% (0/330) | 1.4% (1/73) | 0.0% (0/143) |
| 30-Day TLF | 2.2% (9/401) | 1.6% (38/2451) | 2.7% (33/1222) | 1.2% (8/667) | 2.1% (7/330) | 4.1% (3/73) | 2.1% (3/140) |
| 6-Month TLF ¹ | 3.8% (15/399) | 2.5% (62/2435) | 5.1% (62/1208) | 2.3% (15/663) | 4.3% (14/326) | 6.8% (5/73) | NA |
| 9-Month TLF ² | NA | 3.4% (83/2419) | 6.1% (73/1201) | 4.1% (27/657) | 7.8% (25/321) | 6.8% (5/73) | 7.2% (10/139) |
| 30-Day TVF | NA | 1.9% (46/2451) | 2.9% (36/1222) | 1.5% (10/667) | 2.7% (9/330) | 4.1% (3/73) | 2.9% (4/140) |
| 6-Month TVF | NA | 3.4% (82/2435) | 6.0% (73/1208) | 3.8% (25/663) | 4.9% (16/326) | 6.8% (5/73) | NA |
| 9-Month ⁵ TVF | NA | 4.6% (111/2419) | 7.1% (85/1201) | 7.2% (47/657) | 9.0% (29/321) | 6.8% (5/73) | 9.4% (13/139) |

| | SPRIT PRIME | SPRIT IV | | SPRIT III (RCT) | | | SPRIT SV |
|---|---|---------------------|------------------|--------------------|-----------------|------------------------------|----------------------------|
| | Core Size Registry ^s (N = 401) | XIENCE V (N = 2458) | TAXUS (N = 1229) | XIENCE V (N = 669) | TAXUS (N = 333) | XIENCE V 4.0 mm Arm (N = 73) | 2.25 mm XIENCE V (N = 144) |
| 1-Year Subject Counts of Adverse Events | | | | | | | |
| TLF ³ | 4.5% (18/399) | 4.0% (97/2416) | 6.8% (81/1195) | 5.2% (34/653) | 9.7% (31/320) | 6.8% (5/73) | 8.1% (11/136) |
| TVF | NA | 5.5% (134/2416) | 7.7% (92/1195) | 8.6% (56/653) | 11.3% (36/320) | 6.8% (5/73) | 11.0% (15/136) |
| All Death | 0.8% (3/399) | 1.0% (25/2416) | 1.3% (15/1195) | 1.2% (8/655) | 1.2% (4/321) | 1.4% (1/73) | 1.5% (2/136) |
| Cardiac Death | 0.3% (1/399) | 0.4% (10/2416) | 0.4% (5/1195) | 0.8% (5/655) | 0.9% (3/321) | 1.4% (1/73) | 1.5% (2/136) |
| Non-Cardiac Death | 0.5% (2/399) | 0.6% (15/2416) | 0.8% (10/1195) | 0.5% (3/655) | 0.3% (1/321) | 0.0% (0/73) | 0.0% (0/136) |
| All MI | 1.8% (7/399) | 1.9% (45/2416) | 3.1% (37/1195) | 2.8% (18/653) | 4.1% (13/320) | 4.1% (3/73) | 1.5% (2/136) |
| QMI | 0.3% (1/399) | 0.1% (3/2416) | 0.4% (5/1195) | 0.3% (2/653) | 0.3% (1/320) | 0.0% (0/73) | 0.7% (1/136) |
| NQMI | 1.5% (6/399) | 1.7% (42/2416) | 2.8% (33/1195) | 2.5% (16/653) | 3.8% (12/320) | 4.1% (3/73) | 0.7% (1/136) |
| Target Vessel MI | 1.8% (7/399) | 1.8% (44/2416) | 2.9% (35/1195) | NA | NA | NA | 1.5% (2/136) |
| Cardiac Death or all MI | 2.0% (8/399) | 2.2% (54/2416) | 3.3% (39/1195) | 3.4% (22/653) | 4.7% (15/320) | 5.5% (4/73) | 2.9% (4/136) |
| ID* TVR | 4.5% (18/399) | 3.9% (94/2416) | 5.9% (70/1195) | 6.1% (40/653) | 7.5% (24/320) | 2.7% (2/73) | 8.8% (12/136) |
| ID* TLR | 2.5% (10/399) | 2.5% (61/2416) | 4.6% (55/1195) | 3.4% (22/653) | 5.6% (18/320) | 2.7% (2/73) | 5.1% (7/136) |
| ID* Non-TLR TVR | 2.8% (11/399) | 2.3% (56/2416) | 3.1% (37/1195) | 3.1% (20/653) | 4.4% (14/320) | 0.0% (0/73) | 5.9% (8/136) |
| Protocol Defined Stent Thrombosis ⁴ | 0.5% (2/399) | 0.17% (4/2389) | 0.85% (10/1181) | 0.8% (5/647) | 0.6% (2/317) | 1.4% (1/72) | 2.2% (3/136) |
| ARC Definite+Probable Stent Thrombosis ⁴ | 0.5% (2/399) | 0.29% (7/2391) | 1.10% (13/1181) | 1.1% (7/652) | 0.6% (2/319) | 0.0% (0/72) | 1.5% (2/136) |
| ARC Definite Stent Thrombosis ⁴ | 0.5% (2/399) | 0.25% (6/2391) | 0.85% (10/1181) | 0.8% (5/652) | 0.0% (0/319) | 0.0% (0/72) | 0.7% (1/138) |
| 2-Year Subject Counts of Adverse Events | | | | | | | |
| TLF ³ | 6.4% (25/392) | 7.0% (167/2388) | 10.0% (119/1190) | 7.1% (45/637) | 12.8% (39/305) | 8.6% (6/70) | 8.3% (11/133) |
| TVF | NA | 9.6% (230/2388) | 11.8% (140/1190) | 11.3% (72/637) | 16.4% (50/305) | 10.0% (7/70) | 12.0% (16/133) |
| All Death | 2.0% (8/392) | 2.1% (51/2388) | 2.7% (32/1190) | 2.0% (13/642) | 2.6% (8/309) | 6.9% (5/72) | 1.5% (2/133) |
| Cardiac Death | 0.5% (2/392) | 0.9% (22/2388) | 1.3% (15/1190) | 1.1% (7/642) | 1.3% (4/309) | 2.8% (2/72) | 1.5% (2/133) |

| | SPiRiT PRIME | SPiRiT IV | | SPiRiT III (RCT) | | | SPiRiT SV |
|---|---|---------------------|------------------|--------------------|-----------------|------------------------------|----------------------------|
| | Core Size Registry ^s (N = 401) | XIENCE V (N = 2458) | TAXUS (N = 1229) | XIENCE V (N = 669) | TAXUS (N = 333) | XIENCE V 4.0 mm Arm (N = 73) | 2.25 mm XIENCE V (N = 144) |
| Vascular Death | 0.5% (2/392) | NA | NA | NA | NA | NA | NA |
| Non-Cardiac Death | 1.0% (4/392) | 1.2% (29/2388) | 1.4% (17/1190) | 0.9% (6/642) | 1.3% (4/309) | 4.2% (3/72) | 0.0% (0/133) |
| All MI | 2.0% (8/392) | 2.6% (61/2388) | 3.9% (47/1190) | 3.3% (21/637) | 5.9% (18/305) | 4.3% (3/70) | 1.5% (2/133) |
| QMI | 0.5% (2/392) | 0.1% (3/2388) | 0.8% (9/1190) | 0.5% (3/637) | 0.7% (2/305) | 0.0% (0/70) | 0.8% (1/133) |
| NQMI | 1.5% (6/392) | 2.4% (58/2388) | 3.4% (40/1190) | 2.8% (18/637) | 5.2% (16/305) | 4.3% (3/70) | 0.8% (1/133) |
| Target Vessel MI | 1.8% (7/392) | 2.3% (56/2388) | 3.5% (42/1190) | NA | NA | NA | 1.5% (2/133) |
| Cardiac Death or all MI | 2.6% (10/392) | 3.4% (82/2388) | 4.6% (55/1190) | 4.1% (26/637) | 6.9% (21/305) | 7.1% (5/70) | 3.0% (4/133) |
| ID* TVR | 6.9% (27/392) | 7.0% (168/2388) | 8.9% (106/1190) | 8.8% (56/637) | 11.1% (34/305) | 4.3% (3/70) | 9.8% (13/133) |
| ID* TLR | 4.1% (16/392) | 4.4% (106/2388) | 6.9% (82/1190) | 4.6% (29/637) | 7.5% (23/305) | 2.9% (2/70) | 5.3% (7/133) |
| ID* Non-TLR TVR | 4.3% (17/392) | 3.9% (94/2388) | 4.3% (51/1190) | 4.9% (31/637) | 6.6% (20/305) | 1.4% (1/70) | 6.8% (9/133) |
| 3-Year Subject Counts of Adverse Events | | | | | | | |
| TLF ³ | 8.5% (33/390) | 9.5% (223/2348) | 11.9% (138/1158) | 8.9% (56/629) | 15.1% (46/305) | 8.8% (6/68) | 12.1% (16/132) |
| TVF | NA | 13.3% (312/2348) | 14.5% (168/1158) | 14.3% (90/629) | 20.0% (61/305) | 11.8% (8/68) | 16.7% (22/132) |
| All Death | 3.1% (12/390) | 3.4% (81/2348) | 5.2% (60/1158) | 2.8% (18/636) | 4.5% (14/312) | 8.5% (6/71) | 3.8% (5/132) |
| Cardiac Death | 0.8% (3/390) | 1.4% (34/2348) | 1.9% (22/1158) | 1.6% (10/636) | 1.9% (6/312) | 2.8% (2/71) | 3.8% (5/132) |
| Vascular Death | 0.5% (2/390) | NA | NA | NA | NA | NA | NA |
| Non-Cardiac Death | 1.8% (7/390) | 2.0% (47/2348) | 3.3% (38/1158) | 1.3% (8/636) | 2.6% (8/312) | 5.6% (4/71) | 0.0% (0/132) |
| All MI | 3.1% (12/390) | 3.1% (73/2348) | 4.7% (55/1158) | 3.8% (24/629) | 6.6% (20/305) | 4.4% (3/68) | 1.5% (2/132) |
| QMI | 1.0% (4/390) | 0.3% (6/2348) | 0.9% (11/1158) | 0.5% (3/629) | 0.7% (2/305) | 0.0% (0/68) | 0.8% (1/132) |
| NQMI | 2.6% (10/390) | 2.9% (67/2348) | 4.0% (46/1158) | 3.3% (21/629) | 5.9% (18/305) | 4.4% (3/68) | 0.8% (1/132) |
| Target Vessel MI | 2.6% (10/390) | 2.8% (65/2348) | 4.1% (48/1158) | NA | NA | NA | 1.5% (2/132) |
| Cardiac Death or all MI | 3.8% (15/390) | 4.5% (105/2348) | 6.0% (70/1158) | 5.1% (32/629) | 8.2% (25/305) | 7.4% (5/68) | 5.3% (7/132) |

| | SPiRiT PRIME | SPiRiT IV | | SPiRiT III (RCT) | | | SPiRiT SV | |
|---|---|---------------------|------------------|--------------------|-----------------|------------------------------|----------------------------|--|
| | Core Size Registry ^s (N = 401) | XIENCE V (N = 2458) | TAXUS (N = 1229) | XIENCE V (N = 669) | TAXUS (N = 333) | XIENCE V 4.0 mm Arm (N = 73) | 2.25 mm XIENCE V (N = 144) | |
| ID* TVR | 9.5% (37/390) | 10.1% (238/2348) | 10.6% (123/1158) | 11.1% (70/629) | 14.8% (45/305) | 5.9% (4/68) | 12.1% (16/132) | |
| ID* TLR | 5.4% (21/390) | 6.3% (148/2348) | 7.9% (92/1158) | 5.7% (36/629) | 9.2% (28/305) | 2.9% (2/68) | 6.8% (9/132) | |
| ID* Non-TLR TVR | 5.9% (23/390) | 5.6% (132/2348) | 5.4% (63/1158) | 6.7% (42/629) | 8.9% (27/305) | 2.9% (2/68) | 8.3% (11/132) | |
| 4-Year Subject Counts of Adverse Events | | | | | | | | |
| TLF ³ | NA | NA | NA | 11.9% (73/615) | 17.2% (52/302) | 8.8% (6/68) | NA | |
| TVF | NA | NA | NA | 18.5% (114/615) | 22.5% (68/302) | 11.8% (8/68) | NA | |
| All Death | NA | NA | NA | 4.9% (31/628) | 6.1% (19/311) | 8.5% (6/71) | NA | |
| Cardiac Death | NA | NA | NA | 2.5% (16/628) | 2.6% (8/311) | 2.8% (2/71) | NA | |
| Non-Cardiac Death | NA | NA | NA | 2.4% (15/628) | 3.5% (11/311) | 5.6% (4/71) | NA | |
| All MI | NA | NA | NA | 4.4% (27/615) | 6.6% (20/302) | 4.4% (3/68) | NA | |
| QMI | NA | NA | NA | 1.0% (6/615) | 0.7% (2/302) | 0.0% (0/68) | NA | |
| NQMI | NA | NA | NA | 3.4% (21/615) | 6.0% (18/302) | 4.4% (3/68) | NA | |
| Target Vessel MI | NA | NA | NA | NA | NA | NA | NA | |
| Cardiac Death or all MI | NA | NA | NA | 6.5% (40/615) | 8.9% (27/302) | 7.4% (5/68) | NA | |
| ID* TVR | NA | NA | NA | 14.3% (88/615) | 16.6% (50/302) | 5.9% (4/68) | NA | |
| ID* TLR | NA | NA | NA | 8.0% (49/615) | 10.6% (32/302) | 4.4% (3/68) | NA | |
| ID* Non-TLR TVR | NA | NA | NA | 7.8% (48/615) | 9.6% (29/302) | 2.9% (2/68) | NA | |
| 5-Year Subject Counts of Adverse Events | | | | | | | | |
| 5-Year TLF ³ | NA | NA | NA | 13.4% (81/605) | 20.6% (59/286) | 10.4% (7/67) | NA | |
| TVF | NA | NA | NA | 20.3% (123/605) | 26.6% (76/286) | 11.9% (8/67) | NA | |
| All Death | NA | NA | NA | 6.0% (37/621) | 10.3% (31/300) | 8.6% (6/70) | NA | |
| Cardiac Death | NA | NA | NA | 2.7% (17/621) | 4.3% (13/300) | 2.9% (2/70) | NA | |

| | SPIRIT PRIME | SPIRIT IV | | SPIRIT III (RCT) | | | SPIRIT SV |
|-------------------------|---|---------------------|------------------|--------------------|-----------------|------------------------------|----------------------------|
| | Core Size Registry [§] (N = 401) | XIENCE V (N = 2458) | TAXUS (N = 1229) | XIENCE V (N = 669) | TAXUS (N = 333) | XIENCE V 4.0 mm Arm (N = 73) | 2.25 mm XIENCE V (N = 144) |
| Non-Cardiac Death | NA | NA | NA | 3.2% (20/621) | 6.0% (18/300) | 5.7% (4/70) | NA |
| All MI | NA | NA | NA | 4.6% (28/605) | 7.0% (20/286) | 4.5% (3/67) | NA |
| QMI | NA | NA | NA | 1.0% (6/605) | 0.7% (2/286) | 0.0% (0/67) | NA |
| NQMI | NA | NA | NA | 3.8% (23/605) | 6.3% (18/286) | 4.5% (3/67) | NA |
| Target Vessel MI | NA | NA | NA | NA | NA | NA | NA |
| Cardiac Death or all MI | NA | NA | NA | 7.1% (43/605) | 11.2% (32/286) | 7.5% (5/67) | NA |
| ID* TVR | NA | NA | NA | 15.7% (95/605) | 19.9% (57/286) | 6.0% (4/67) | NA |
| ID* TLR | NA | NA | NA | 8.9% (54/605) | 12.9% (37/286) | 4.5% (3/67) | NA |
| ID* Non-TLR TVR | NA | NA | NA | 8.8% (53/605) | 11.9% (34/286) | 3.0% (2/67) | NA |

Notes:

- Population for SPIRIT PRIME Core Size Registry consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8-hour post-index procedure and hospital discharge. SPIRIT III and IV based on intent-to-treat population (all subjects randomized, regardless of the treatment they actually received).
- In-hospital is defined as hospitalization less than or equal to 7-day post-index procedure.
- All counts presented in this table are subject counts. Subjects are counted only once for each event for each time period.
- This table includes revascularizations on any target vessel(s) / lesion(s) for subjects with two or more target vessels / lesions treated.
- One subject in the SPIRIT III, TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- TLF includes cardiac death, target vessel MI (per protocol definition) and ischemia-driven TLR. For SPIRIT III 4.0 mm arm, MACE (cardiac death, all MI [per protocol definition] and ischemia-driven TLR) is reported, as TLF was not an endpoint.
- SPIRIT SV based on full analysis set (FAS) population.
- For SPIRIT III, cardiac death is defined as the number of patients experiencing cardiac death through the follow-up time point / (the number of patients experiencing cardiac death through the follow-up time point + the number of patients followed through the follow-up time point without cardiac death + the number of patients terminated prior to the follow-up time point who did not experience cardiac death but experienced non-cardiac death, MI, ID or non-ID TLR, or ID or non-ID TVR).
- Deaths were adjudicated in SPIRIT PRIME as cardiac, vascular, and non-cardiovascular. SPIRIT III, IV, and SV adjudicated deaths as cardiac or non-cardiac.

¹ SPIRIT III and SPIRIT IV include 14-day window. SPIRIT PRIME includes 28-day window.

² SPIRIT III and SPIRIT IV includes 14-day window.

³ SPIRIT III, SPIRIT IV, and SPIRIT PRIME include 28-day window.

⁴ See section 8.2 – Adverse Events, Stent Thrombosis Definitions.

⁵ SPIRIT SV 8-month data are presented, as follow-up was not required at 9 months

[§] For Long Lesion Registry data, see Table 9.1-4.

* For SPIRIT PRIME, it is captured as clinically-indicated (CI)

**Table 8.1-2: XIENCE V USA Post-Approval Study
Principal Adverse Events from Post-Procedure to 4 Years**

| | XIENCE V USA | | | | |
|--|------------------------|--------------------|--------------------|--------------------|------------------------|
| | XIENCE V (N = 8040) | | | | XIENCE V (N = 5020) |
| | In-Hospital | 30 Days | 6 Months | 1 Year | 4 Years |
| TLF | 2.7% (214/8001) | 3.5% (275/7963) | 6.2% (490/7854) | 9.4% (707/7522) | 19.3% (875/4530) |
| All Death | 0.02% (2/8001) | 0.4% (28/7963) | 1.4% (108/7854) | 2.6% (194/7522) | 10.9% (494/4530) |
| Cardiac Death | 0.01% (1/8001) | 0.3% (25/7963) | 0.9% (69/7854) | 1.4% (108/7522) | 5.4% (244/4530) |
| Vascular Death | 0.0% (0/8001) | 0.01% (1/7963) | 0.1% (6/7854) | 0.2% (12/7522) | 0.7% (32/4530) |
| Non-Cardiovascular Death | 0.01% (1/8001) | 0.03% (2/7963) | 0.4% (33/7854) | 1.0% (74/7522) | 4.8% (218/4530) |
| MI | 2.7% (216/8001) | 3.3% (266/7963) | 4.7% (372/7854) | 6.3% (475/7522) | 11.3% (511/4530) |
| QMI | 0.2% (18/8001) | 0.3% (25/7963) | 0.4% (30/7854) | 0.5% (39/7522) | 1.5% (68/4530) |
| NQMI | 2.5% (198/8001) | 3.0% (241/7963) | 4.4% (346/7854) | 5.9% (442/7522) | 10.1% (457/4530) |
| Cardiac Death or MI | 2.7% (216/8001) | 3.6% (286/7963) | 5.4% (422/7854) | 7.2% (545/7522) | 14.9% (676/4530) |
| Clinically- Indicated Revascularization | 0.2% (17/8001) | 1.0% (81/7963) | 4.5% (352/7854) | 8.1% (607/7522) | 19.9% (901/4530) |
| Clinically- Indicated TLR | 0.2% (13/8001) | 0.4% (30/7963) | 2.2% (173/7854) | 4.4% (330/7522) | 10.4% (473/4530) |
| Clinically- Indicated TVR, Non TL | 0.02% (2/8001) | 0.2% (15/7963) | 1.0% (82/7854) | 2.1% (161/7522) | 6.1% (277/4530) |
| Stent Thrombosis (ARC Definite and Probable) | 0.11% (9/8000) | 0.40% (32/7951) | 0.58% (45/7790) | 0.81% (60/7380) | 1.56% (64/4093) |
| Stent Thrombosis (ARC Definite) | 0.11% (9/8000) | 0.23% (18/7951) | 0.35% (27/7790) | 0.54% (40/7380) | 1.05% (43/4093) |

Notes:

- In-hospital is defined as hospitalization less than or equal to 7-day post-index procedure.
- 30-day window is through 37 days (7-day window).
- 6-month window is through 194 days (14-day window).
- 1-year window is through 407 days (42-day window) or randomization date if occurred within 407 days for the second enrollment phase.
- 4-year window is through 1502 days (42-day window).
- All counts presented in this table are subject counts. Subjects are counted only once for each event for each time period.
- ARC MI definition was used for MI and MI related endpoints.
- TLF includes cardiac death, target vessel MI and clinically indicated TLR.

8.2 Stent Thrombosis Definitions

Protocol-defined stent thrombosis (ST) was categorized as acute (< 1 day), subacute (1 – 30 days) and late (> 30 days) and was defined as any of the following⁶:

- Clinical presentation of acute coronary syndrome with angiographic evidence of stent thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)
- In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)⁷ in the distribution of the target lesion within 30 days

All stent thrombosis events were also classified using the ST definitions proposed by the Academic Research Consortium (ARC)⁸. This was performed by an independent event committee blinded to the treatment group of the individual subject. The committee categorized each incident of ST by timing and level of probability (definite, probable, possible), and relation to the original index procedure (primary, secondary after revascularization). These categories are defined as follows:

Timing:

- Early ST: 0 to 30 days post-stent implantation
- Late ST: 31 days to 1 year post-stent implantation
- Very late ST: > 1 year post-stent implantation

Level of probability:

- Definite ST – considered to have occurred by either angiographic or pathologic confirmation
- Probable ST – considered to have occurred after intracoronary stenting in the following cases:
 1. Any unexplained death within the first 30 days
 2. Irrespective of the time after the index procedure, any MI which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause
- Possible ST – considered to have occurred with any unexplained death following 30 days after the intracoronary stenting until the end of trial follow-up⁹

8.3 Potential Adverse Events

Adverse events (in alphabetical order) which may be associated with percutaneous coronary and treatment procedures including coronary stent use in native coronary arteries include, but are not limited to:

- Abrupt closure
- Access site, pain, hematoma, or hemorrhage
- Acute myocardial infarction

⁶ For SPIRIT FIRST Stent Thrombosis is defined as total occlusion by angiography at the stent site with abrupt onset of symptoms, elevated biochemical markers, and ECG changes consistent with MI.

⁷ Non-specific ST/T changes, and cardiac enzyme elevations do not suffice.

⁸ Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. *Circ* 2007;115:2344-51.

⁹ All data within these Instructions for Use are presented as definite+probable only.

-
- Allergic reaction or hypersensitivity to contrast agent or cobalt, chromium, nickel, tungsten, acrylic and fluoropolymers; and drug reactions to antiplatelet drugs or contrast agent
 - Aneurysm
 - Arterial perforation and injury to the coronary artery
 - Arterial rupture
 - Arteriovenous fistula
 - Arrhythmias, atrial and ventricular
 - Bleeding complications, which may require transfusion
 - Cardiac tamponade
 - Coronary artery spasm
 - Coronary or stent embolism
 - Coronary or stent thrombosis
 - Death
 - Dissection of the coronary artery
 - Distal emboli (air, tissue or thrombotic)
 - Emergent or non-emergent surgery
 - Fever
 - Hypotension and / or hypertension
 - Infection and pain at insertion site
 - Injury to the coronary artery
 - Ischemia (myocardial)
 - Myocardial infarction (MI)
 - Nausea and vomiting
 - Palpitations
 - Peripheral ischemia (due to vascular injury)
 - Pseudoaneurysm
 - Renal failure
 - Restenosis of the stented segment of the artery
 - Shock / pulmonary edema
 - Stroke / cerebrovascular accident (CVA)
 - Total occlusion of coronary artery
 - Unstable or stable angina pectoris
 - Vascular complications including at the entry site which may require vessel repair
 - Vessel dissection

Zortress, the oral formulation of everolimus developed by Novartis Pharmaceuticals Corporation, has been evaluated in clinical trials and is approved in the United States for the prevention of organ rejection in adult kidney transplant recipients at the dose of 1.5 mg/day.

Outside the US, Zortress is sold under the brand name Certican in more than 70 countries. Everolimus is also approved in the United States under the name of Afinitor for patients with advanced renal cell carcinoma (cancer), after failure of treatment with sunitinib or sorafenib, at doses of 5 to 20 mg/day when taken by mouth. The following list includes the known risks of everolimus at the oral doses listed above:

- Abdominal pain (including upper abdominal pain)
- Anemia
- Angioedema

-
- Anorexia
 - Asthenia
 - Constipation
 - Cough
 - Delayed wound healing / fluid accumulation
 - Diarrhea
 - Dyslipidemia (including hyperlipidemia and hypercholesterolemia)
 - Dysgeusia
 - Dyspepsia
 - Dyspnea
 - Dysuria
 - Dry skin
 - Edema (peripheral)
 - Epistaxis
 - Fatigue
 - Headache
 - Hematuria
 - Hyperglycemia (may include new onset of diabetes)
 - Hyperkalemia
 - Hyperlipidemia
 - Hypertension
 - Hypokalemia
 - Hypomagnesemia
 - Hypophosphatemia
 - Increased serum creatinine
 - Infections and serious infections: bacterial, viral, fungal, and protozoal infections (may include herpes virus infection, polyoma virus infection which may be associated with BK virus associated nephropathy, and / or other opportunistic infections)
 - Insomnia
 - Interaction with strong inhibitors and inducers of CYP3A4 or PgP
 - Leukopenia
 - Lymphoma and other malignancies (including skin cancer)
 - Male infertility (azospermia and / or oligospermia)
 - Mucosal inflammation (including oral ulceration and oral mucositis)
 - Nausea
 - Neutropenia
 - Non-infectious pneumonitis
 - Pain: extremity, incision site and procedural, back, chest, musculoskeletal
 - Proteinuria
 - Pruritus
 - Pyrexia
 - Rash
 - Stomatitis
 - Thrombocytopenia
 - Thrombotic microangiopathy (TMA) / Thrombotic thrombocytopenic purpura (TTP) / Hemolytic uremic syndrome (HUS)
 - Tremor
 - Upper respiratory tract infection

-
- Urinary tract infection
 - Vomiting

Live vaccines should be avoided and close contact with those that have had live vaccines should be avoided. Fetal harm can occur when administered to a pregnant woman. There may be other potential adverse events that are unforeseen at this time.

9.0 SPIRIT FAMILY OF CLINICAL TRIALS

The SPIRIT PRIME clinical trial was conducted to demonstrate the safety and effectiveness of the XIENCE PRIME family of stent systems. Given the substantial similarities between the XIENCE PRIME and XIENCE V stent systems, clinical trials previously conducted on the XIENCE V stent are also relevant and included below.

9.1 SPIRIT PRIME Clinical Trial

The SPIRIT PRIME clinical trial was designed to demonstrate the safety and effectiveness of the XIENCE PRIME family of stent systems. This global trial consists of two separate arms, the Core Size Registry and the Long Lesion Registry. One-year results are presented here.

Primary Objective: The objective of the SPIRIT PRIME clinical trial is to evaluate the safety and effectiveness of the XIENCE PRIME family of stent systems in improving coronary luminal diameter in subjects with symptomatic heart disease due to a maximum of two *de novo* native coronary artery lesions, each in a different epicardial vessel.

Design: The SPIRIT PRIME clinical trial is a prospective, nonrandomized, open-label, multicenter study consisting of two separate arms, the Core Size Registry (stent diameters 2.25, 2.5, 3.0, 3.5, 4.0 mm with stent lengths 8, 18, and 28¹⁰ mm) and the Long Lesion Registry (stent diameters 2.5, 3.0, 3.5, 4.0 mm with stent lengths 33 and 38 mm) in approximately 500 subjects at up to 75 global sites. For clinical trial design purposes, the 28 mm length stent is included in the Core Size Registry because the historical data on XIENCE V used to develop the comparative performance goal includes stent lengths up to 28 mm. The Long Lesion Registry only includes subjects with at least one 33 and 38 mm length stents as there were limited data on these stent lengths from which to develop a comparative performance goal.

Each subject was to receive treatment in up to two *de novo* native coronary lesions, each lesion in a different epicardial vessel. Subjects in the Core Size Registry were allowed to have: one target lesion treated with the core size XIENCE PRIME stent system (stent diameters 2.25 – 4.0 mm with stent lengths 8, 18, 28 mm) or two target lesions in separate epicardial vessels, treated with two core size XIENCE PRIME stent systems (stent diameters 2.25 – 4.0 mm with stent lengths 8, 18, 28 mm).

Subjects in the Long Lesion Registry were allowed to have: one target lesion treated with the XIENCE PRIME stent system (stent diameters 2.5 – 4.0 mm with stent lengths 33 or 38 mm) or two target lesions in separate epicardial vessels, treated with two XIENCE PRIME stent systems (stent diameters 2.5 – 4.0 mm with stent lengths 33 or 38 mm) or one XIENCE PRIME stent system (stent diameters 2.5 – 4.0 mm with stent lengths 33 or 38 mm) and one

¹⁰ The 28 mm length stent was studied in the XIENCE PRIME Core Size Registry. The results of the Core Size Registry are presented in Tables 9.1-2 to 9.1-3.

XIENCE PRIME stent system (stent diameters 2.25 – 4.0 mm with stent lengths 8, 18, 28 mm). All subjects in the Long Lesion Registry were required to be treated with at least one XIENCE PRIME stent of 33 or 38 mm in length. For both the Core Size Registry and Long Lesion Registry, planned overlap was not allowed; however, overlap was allowed in case of bailout stenting.

The primary endpoint is target lesion failure (TLF) at one year, a composite endpoint of cardiac death, target vessel myocardial infarction (TV-MI), and clinically indicated target lesion revascularization (CI-TLR). The primary endpoint rates of TLF at 1 year (per protocol and per ARC definitions) were compared to a set of pre-specified performance goals (PGs) for both Core Size Registry and Long Lesion Registry as shown below.

The PG for the Core Size Registry was developed utilizing historical data from the SPIRIT III trial, while the PG for the Long Lesion Registry was developed based on a regression analysis conducted on the historical data from the pooled SPIRIT II and III trials. Although the SPIRIT PRIME trial defined TLF based on the ARC definition of MI, the historical SPIRIT II and III trials used to develop the initial PG were based on the per protocol definition of MI. In order to provide a comparison of outcomes using the same definitions for both the treatment arms and PGs, two subsequent analyses, with PGs developed using the same definitions (per protocol and per ARC), were developed and are presented in rows 2 and 3 of the table below.

Table 9.1-1: Analyses of the Primary Endpoint

| TLF Primary Endpoint | Core Size Registry* Performance Goal | Long Lesion Registry** Performance Goal |
|---|---|--|
| TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 9.2% ¹ | 19.2% ¹ |
| TLF Cardiac Death, <i>Protocol-Defined TV-MI</i> , CI-TLR | 9.2% ¹ | 19.2% ¹ |
| TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 15.3% ² | 26.0% ² |

¹ Performance goal developed based on per protocol-defined MI.

² Performance goal developed based on per ARC-defined MI.

* The Core Size Registry includes 2.25 – 4.0 mm stent diameters, 8, 18, 28 mm lengths.

** The Long Lesion Registry includes 2.5 – 4.0 mm stent diameters, 33 and 38 mm stent lengths.

Demographics: In the Core Size Registry, the mean age was 62.70 ± 10.23 years, 70.3% (282/401) were male, 29.7% (119/401) were female and 92.3% (346/375) were white. The average body mass index (BMI) was 30.86 ± 5.83 kg/m² and 50.3% (192/382) of subjects were obese, with a BMI ≥ 30. Regarding medical risk factors in the Core Size Registry, 19.2% (77/401) were tobacco users, 76.6% (307/401) were hypertensive requiring medication, and 80.3% (322/401) were hypercholesterolemic requiring medication. There were 11.1% (44/397) of subjects having had a prior cardiac intervention on the target vessel and 23.0% (91/395) had a prior MI. In addition, there were 45.6% (183/401) of subjects with stable angina and 24.9% (100/401) of subjects with unstable angina. Furthermore, the Core Size Registry consisted of 34.9% (140/401) diabetics, 29.9% (120/401) diabetics requiring medication and 3.5% (14/401) diabetics requiring diet and exercise only.

In the Long Lesion Registry, the mean age was 63.46 ± 9.44 years, 62.5% (65/104) were male, 37.5% (39/104) were female and 91.7% (88/96) were white. The average body mass index (BMI) was 30.67 ± 5.84 kg/m², and 49.5% (50/101) of subjects were obese, with a BMI ≥ 30 . Regarding medical risk factors in the Long Lesion Registry, 26.9% (28/104) were tobacco users, 75.0% (78/104) were hypertensive requiring medication, and 80.8% (84/104) were hypercholesterolemic requiring medication. There were 11.8% (12/102) of subjects having had a prior cardiac intervention on the target vessel and 22.5% (23/102) had a prior MI. In addition, there were 49.0% (51/104) of subjects with stable angina and 23.1% (24/104) of subjects with unstable angina. Furthermore, the Long Lesion Registry consisted of 35.6% (37/104) diabetics, 31.7% (33/104) diabetics requiring medication and 1.9% (2/104) diabetics requiring diet and exercise only.

Results: The results are presented in Table 9.1-2 to Table 9.1-4. These analyses are based on the Full Analysis Set (FAS). The FAS population is defined as subjects who have received at least one of the following: the core size XIENCE PRIME stent system (stent diameters 2.25 – 4.0 mm with stent lengths 8, 18, 28 mm) or the XIENCE PRIME LL stent system (stent diameters 2.5 – 4.0 mm with stent lengths 33 or 38 mm), including bailout. SPIRIT PRIME Core Size and Long Lesion Registries met all pre-specified PGs with statistical significance. The observed TLF rate at one year was 4.5% (18/399) (per protocol-defined MI) and 6.5% (26/399) (per ARC-defined MI) in the Core Size Registry, and 7.7% (8/104) (per protocol-defined MI) and 12.5% (13/104) (per ARC-defined MI) in the Long Lesion Registry. At the three-year follow-up visit, the follow-up rate for the CSR was 377 (94.0%) and 99 (95.2%) for the LLR. At 3 years, the observed TLF rate was 8.5% (33/390) (per protocol-defined MI) and 10.8% (42/390) (per ARC-defined MI) in the Core Size Registry, and 9.6% (10/104) (per protocol-defined MI) and 14.4% (15/104) (per ARC-defined MI) in the Long Lesion Registry.

Table 9.1-2: SPIRIT PRIME Primary Endpoint Results

| Core Size Registry* | XIENCE PRIME (N = 401) | Performance Goal | p-value¹ |
|---|-----------------------------------|-----------------------------|----------------------------|
| 1 Year TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 6.5% (26/399) | 9.2% [§] | 0.0338 |
| 1 Year TLF Cardiac Death, <i>Protocol-Defined TV-MI</i> , CI-TLR | 4.5% (18/399) | 9.2% [§] | 0.0003 |
| 1 Year TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 6.5% (26/399) | 15.3% [#] | < 0.0001 |
| Long Lesion Registry** | XIENCE PRIME (N = 104) | Performance Goal | p-value¹ |
| 1 Year TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 12.5% (13/104) | 19.2% [§] | 0.0484 |
| 1 Year TLF Cardiac Death, <i>Protocol-Defined TV-MI</i> , CI-TLR | 7.7% (8/104) | 19.2% [§] | 0.0009 |
| 1 Year TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 12.5% (13/104) | 26.0% [#] | 0.0006 |

Notes:

- N is the total number of subjects.
- Population for SPIRIT PRIME consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8-hour post-index procedure and hospital discharge.
- TLF includes cardiac death, target vessel MI and clinically indicated TLR.
- Time frame includes follow-up window (365 + 28 days).

¹ One-sided p-value against pre-specified performed goals, to be compared at a 0.05 significance level.

[§] Performance Goal developed based on per protocol-defined MI.

[#] Performance Goal developed based on per ARC-defined MI.

* The Core Size Registry includes 2.25 – 4.0 mm stent diameters, 8, 18, 28 mm lengths.

** The Long Lesion Registry includes 2.5 – 4.0 mm stent diameters, 33 and 38 mm stent lengths.

Table 9.1-3: SPIRIT PRIME Core Size Registry Clinical Results*

| | Outcomes at 3 Years Core Size Registry* (N = 401) |
|---|--|
| Composite Effectiveness and Safety | |
| TLF (per protocol) | 8.5% (33/390) |
| TLF (per ARC) | 10.8% (42/390) |
| Effectiveness | |
| CI-TLR | 5.4% (21/390) |
| CI-TLR, CABG | 1.0% (4/390) |
| CI-TLR, PCI | 4.6% (18/390) |
| CI-TVR | 9.5% (37/390) |
| Safety | |
| All Death | 3.1% (12/390) |
| Cardiac Death | 0.8% (3/390) |
| Vascular Death | 0.5% (2/390) |
| Non-Cardiac Death | 1.8% (7/390) |
| Target Vessel MI (per protocol) | 2.6% (10/390) |
| Target Vessel QMI (per protocol) | 0.3% (1/390) |
| Target Vessel NQMI (per protocol) | 2.3% (9/390) |
| All MI (per protocol) | 3.1% (12/390) |
| QMI (per protocol) | 1.0% (4/390) |
| NQMI (per protocol) | 2.6% (10/390) |
| Target Vessel MI (per ARC) | 6.2% (24/390) |
| Target Vessel QMI (per ARC) | 0.3% (1/390) |
| Target Vessel NQMI (per ARC) | 5.9% (23/390) |
| All MI (per ARC) | 7.9% (31/390) |
| QMI (per ARC) | 1.0% (4/390) |
| NQMI (per ARC) | 7.4% (29/390) |
| Cardiac Death or All protocol MI | 3.8% (15/390) |
| Cardiac Death or All ARC MI | 8.7% (34/390) |
| ARC Definite+Probable Stent Thrombosis | |
| Cumulative through 3 years | 0.8% (3/380) |
| Acute/ / Subacute (0 – 30 days) | 0.5% (2/401) |
| Late (31 days – 1 year) | 0.0% (0/399) |
| Very Late (1 – 3 years) | 0.3% (1/379) |

Notes:

- TLF is defined as a hierarchical composite of cardiac death, Target Vessel MI, and clinically indicated TLR.
- Population for SPIRIT PRIME Core Size Registry consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8-hour post-index procedure and hospital discharge.
- ARC: Academic Research Consortium

* The Core Size Registry includes 2.25 – 4.0 mm stent diameters, 8, 18, 28 mm lengths.

Table 9.1-4: SPIRIT PRIME Long Lesion Registry Clinical Results

| | Outcomes at 3 Years Long Lesion Registry* (N = 104) |
|---|--|
| Composite Effectiveness and Safety | |
| TLF (per protocol) | 9.6% (10/104) |
| TLF (per ARC) | 14.4% (15/104) |
| Effectiveness | |
| CI-TLR | 4.8% (5/104) |
| CI-TLR, CABG | 1.0% (1/104) |
| CI-TLR, PCI | 4.8% (5/104) |
| CI-TVR | 7.7% (8/104) |
| Safety | |
| All Death | 2.9% (3/104) |
| Cardiac Death | 0.0% (0/104) |
| Vascular Death | 0.0% (0/104) |
| Non-Cardiac Death | 2.9% (3/104) |
| Target Vessel MI (per protocol) | 4.8% (5/104) |
| Target Vessel QMI (per protocol) | 1.9% (2/104) |
| Target Vessel NQMI (per protocol) | 2.9% (3/104) |
| All MI (per protocol) | 5.8% (6/104) |
| QMI (per protocol) | 2.9% (3/104) |
| NQMI (per protocol) | 3.8% (4/104) |
| Target Vessel MI (per ARC) | 10.6% (11/104) |
| Target Vessel QMI (per ARC) | 1.9% (2/104) |
| Target Vessel NQMI (per ARC) | 8.7% (9/104) |
| All MI (per ARC) | 11.5% (12/104) |
| QMI (per ARC) | 2.9% (3/104) |
| NQMI (per ARC) | 9.6% (10/104) |
| Cardiac Death or All protocol MI | 5.8% (6/104) |
| Cardiac Death or All ARC MI | 11.5% (12/104) |
| ARC Definite+Probable Stent Thrombosis | |
| Cumulative through 3 years | 0.0% (0/99) |
| Acute/ / Subacute (0 – 30 days) | 0.0% (0/104) |
| Late (31 days – 1 year) | 0.0% (0/104) |
| Very Late (1–3 years) | 0.0% (0/99) |

Notes:

- TLF is defined as a hierarchical composite of cardiac death, Target Vessel MI, and clinically indicated TLR.
- Population for SPIRIT PRIME Core Size Registry consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8-hour post-index procedure and hospital discharge.
- ARC: Academic Research Consortium

* The Long Lesion Registry includes 2.5 – 4.0 mm stent diameters, 33 and 38 mm stent lengths.

Study Strengths and Limitations: The SPIRIT PRIME study was a prospective, open-label, multicenter study with two separate arms. All event adjudications were performed by an independent Clinical Event Committee (CEC) with 100% site-reported adjudicable events being source-verified. The study provides important information on the clinical outcomes in patients with long lesions and demonstrates the safety and effectiveness of both the core size and

33 mm and 38 mm XIENCE PRIME stents. The study is limited by being a small study with no head-to-head comparison with other DES platforms. In addition, due to the small population size, subgroup analysis can at best be considered exploratory.

9.2 SPIRIT III Pivotal Clinical Trial

SPIRIT III, a pivotal clinical trial, was designed to demonstrate the non-inferiority of the XIENCE V stent to the TAXUS Express Stent (TAXUS stent) and was conducted in the United States (US) and Japan. The SPIRIT III clinical trial consists of a US randomized clinical trial (RCT), a nonrandomized 4.0 mm diameter stent arm in the US, and a nonrandomized arm in Japan, which included a pharmacokinetic substudy. Enrollment is complete in the RCT, the 4.0 mm diameter stent arm, and the Japan arm.

The SPIRIT III clinical trial included a pharmacokinetic substudy in a subject subset derived from the RCT¹¹ and Japan nonrandomized arm (see section 6.2 – *Drug Information, Pharmacokinetics*). Eleven sites in the US and 9 sites in Japan participated in this substudy and have enrolled 34 subjects (17 subjects in the US and 17 subjects in Japan). Venous blood was drawn at regular intervals for pharmacokinetics analysis of total blood everolimus level at pre-determined sites.

9.2.1 SPIRIT III Randomized Clinical Trial (RCT)

Primary Objective: The objective of the SPIRIT III RCT was to demonstrate the non-inferiority in in-segment late loss at 240 days and target vessel failure at 270 days of the XIENCE V stent compared to the TAXUS stent in the treatment of up to two *de novo* lesions ≤ 28 mm in length in native coronary arteries with a reference vessel diameter (RVD) ≥ 2.5 mm to ≤ 3.75 mm.

Design: The SPIRIT III RCT was a prospective, 2:1 (XIENCE V:TAXUS) randomized, active-controlled, single-blinded, parallel, multicenter, non-inferiority evaluation of the XIENCE V stent compared to the TAXUS stent in the treatment of up to two *de novo* lesions ≤ 28 mm in length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 3.75 mm. Given the available XIENCE V stent lengths of 8, 18 and 28 mm for this trial, in the XIENCE V arm, treatment of a target lesion > 22 mm and ≤ 28 mm in length was accomplished by planned overlap of either two 18 mm stents or a 28 mm and an 8 mm stent (see section 5.3 – *Precautions, Multiple Stent Use*). In the TAXUS arm, overlap was only permitted for bailout or to ensure adequate lesion coverage. The RCT was designed to enroll 1,002 subjects at up to 80 sites in the United States.

If non-inferiority of the primary endpoint of in-segment late loss was demonstrated, it was pre-specified that testing for superiority could be conducted.

All subjects had clinical follow-up at 30, 180, and 270 days and annually from 1 to 5 years. A pre-specified subgroup of 564 subjects had angiographic follow-up at 240 days. Of these 564, 240 subjects had IVUS at baseline and 240 days. Subjects that received a bailout stent also had IVUS at baseline and angiographic and IVUS follow-up at 240 days.

¹¹ Includes one subject from the 4.0 mm nonrandomized arm.

Following the index procedure, all subjects were to be maintained on clopidogrel bisulfate daily for a minimum of 6 months and aspirin daily to be taken throughout the length of the trial (5 years).

Demographics: The mean age was 63.2 years for the XIENCE V arm and 62.8 for the TAXUS arm. The XIENCE V arm had 70.1% (469/669) males and the TAXUS arm had 65.7% (218/332) males. The XIENCE V arm had 32.3% (215/666) of subjects with prior cardiac interventions and the TAXUS arm had 29.5% (98/332). The XIENCE V arm had 29.6% (198/669) of subjects with a history of diabetes and the TAXUS arm had 27.9% (92/330). The XIENCE V arm had 15.4% (103/669) of subjects with a lesion treated in two vessels and TAXUS had 15.4% (51/332). The XIENCE V arm had 8.1% (54/669) of subjects with planned stent overlap. The XIENCE V arm had 8.6% (57/666) of subjects with a history of prior CABG while the TAXUS arm had 3.6% (12/332) ($p = 0.0033$). The XIENCE V arm had 18.7% (123/657) of subjects with a history of unstable angina while the TAXUS arm had 25.1% (82/327) ($p = 0.0243$). The remaining subject baseline clinical features were well-matched between the XIENCE V arm and the TAXUS arm.

Results: The results are presented in Table 9.2.1-1: SPIRIT III RCT Primary Endpoint Results, Table 9.2.1-2: SPIRIT III RCT Clinical Results, Table 9.2.1-3: SPIRIT III 8-Month Angiographic and IVUS Results, Figure 9.2.1-1: SPIRIT III: Kaplan Meier Time-to-Event Curve for Target Vessel Failure through 5 Years and Table 9.2.1-4: SPIRIT III RCT ARC-Defined Definite+Probable Stent Thrombosis through 5 Years. These analyses are based on the intent-to-treat population.

The co-primary endpoint of in-segment late loss at 240 days was met with measurements of 0.14 ± 0.41 mm (301) for the XIENCE V arm and 0.28 ± 0.48 mm (134) for the TAXUS arm ($p < 0.0001$ for non-inferiority). In a pre-specified analysis, the XIENCE V stent was shown to be superior to the TAXUS stent with respect to in-segment late loss at 240 days ($p = 0.0037$).

The co-primary endpoint of ischemia-driven TVF through 284 days was met with rates of 7.6% (50/660) for the XIENCE V arm and 9.7% (31/320) for the TAXUS arm ($p < 0.0001$ for non-inferiority).

Table 9.2.1-1: SPIRIT III RCT Primary Endpoint Results

| Measurements | XIENCE V (N = 669) (M = 376) | TAXUS (N = 333) (M = 188) | Difference [95% CI] | Non- Inferiority p-value | Superiority p-value |
|--|------------------------------------|---------------------------------|--|--------------------------------|------------------------|
| 8-Month¹ Late Loss, In-Segment (mm) | 0.14 ± 0.41 (301) | 0.28 ± 0.48 (134) | -0.14 [-0.23, -0.05] ² | < 0.0001 ³ | 0.0037 ⁴ |
| 9-Month⁵ Target Vessel Failure⁶ | 7.2% (47/657) | 9.0% (29/321) | -1.88% [-5.58%, 1.82%] ² | < 0.0001 ⁷ | Not Pre-specified |

Notes:

- N is the total number of subjects; M is the total number of analysis lesions for the angiographic group.
- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- Analysis results include 9-month events identified at the 9-month follow-up.
- ¹ 8-month time frame includes follow-up window (240 + 28 days).
- ² By normal approximation.
- ³ One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 0.195 mm, to be compared at a 0.025 significance level.
- ⁴ Two-sided p-value by superiority test using two-sample T-test, to be compared at a 0.05 significance level.
- ⁵ 9-month time frame includes follow-up window (270 + 14 days).
- ⁶ TVF is defined as hierarchical composite of cardiac death, MI, ischemia-driven TLR and ischemia-driven non-TLR TVR.
- ⁷ One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 5.5%, to be compared at a 0.05 significance level.

Table 9.2.1-2: SPIRIT III RCT Clinical Results

| | Outcomes at 9 Months | | | Outcomes at 5 Years (latest available follow-up) | | |
|--------------------------------------|-----------------------|--------------------|-------------------------------------|---|--------------------|-------------------------------------|
| | XIENCE V (N = 669) | TAXUS (N = 333) | Difference [95% CI] ¹ | XIENCE V (N = 669) | TAXUS (N = 333) | Difference [95% CI] ¹ |
| Composite Efficacy and Safety | | | | | | |
| TVF ² | 7.2% (47/657) | 9.0% (29/321) | -2.11% [-5.93%, 1.71%] | 20.3% (123/605) | 26.6% (76/286) | -6.24% [-12.28%, -0.20%] |
| MACE ³ | 4.6% (30/657) | 8.1% (26/321) | -3.75% [-7.26%, -0.24%] | 14.4% (87/605) | 22.0% (63/286) | -7.65% [-13.21%, -2.09%] |
| Efficacy | | | | | | |
| Ischemia-Driven TLR | 2.6% (17/657) | 5.0% (16/321) | -2.40% [-5.07%, 0.28%] | 8.9% (54/605) | 12.9% (37/286) | -4.01% [-8.52%, 0.49%] |
| TLR, CABG | 0.2% (1/657) | 0.0% (0/321) | 0.15% [Assump. not met] | 1.0% (6/605) | 1.0% (3/286) | -0.06% [Assump. not met] |
| TLR, PCI | 2.4% (16/657) | 5.0% (16/321) | -2.55% [-5.21%, 0.11%] | 8.3% (50/605) | 11.9% (34/286) | -3.62% [-7.97%, 0.72%] |
| Ischemia-Driven TVR, Non TL | 3.0% (20/657) | 4.0% (13/321) | -1.01% [-3.53%, 1.52%] | 8.8% (53/605) | 11.9% (34/286) | -3.13% [-7.50%, 1.25%] |
| Non-TLR TVR, CABG | 0.5% (3/657) | 0.6% (2/321) | -0.17% [Assump. not met] | 1.8% (11/605) | 2.4% (7/286) | -0.63% [-2.71%, 1.45%] |
| Non-TLR TVR, PCI | 2.6% (17/657) | 3.4% (11/321) | -0.84% [-3.17%, 1.49%] | 6.9% (42/605) | 9.8% (28/286) | -2.85% [-6.84%, 1.15%] |
| Safety | | | | | | |
| All Death | 0.9% (6/658) | 0.9% (3/322) | -0.02% [Assump. not met] | 6.0% (37/621) | 10.3% (31/300) | -4.38% [-8.29%, -0.46%] |
| Cardiac Death | 0.5% (3/658) | 0.6% (2/322) | -0.17% [Assump. not met] | 2.7% (17/621) | 4.3% (13/300) | -1.60% [-4.23%, 1.04%] |
| Non-Cardiac Death | 0.5% (3/658) | 0.3% (1/322) | 0.15% [Assump. not met] | 3.2% (20/621) | 6.0% (18/300) | -2.78% [-5.80%, 0.25%] |
| MI | 2.0% (13/657) | 2.5% (8/321) | -0.51% [-2.52%, 1.50%] | 4.6% (28/605) | 7.0% (20/286) | -2.36% [-5.76%, 1.03%] |
| QMI | 0.2% (1/657) | 0.0% (0/321) | 0.15% [Assump. not met] | 1.0% (6/605) | 0.7% (2/286) | 0.29% [Assump. not met] |
| NQMI | 1.8% (12/657) | 2.5% (8/321) | -0.67% [-2.65%, 1.32%] | 3.8% (23/605) | 6.3% (18/286) | -2.49% [-5.69%, 0.71%] |
| Cardiac Death or MI | 2.4% (16/657) | 3.1% (10/321) | -0.68% [-2.92%, 1.56%] | 7.1% (43/605) | 11.2% (32/286) | -4.08% [-8.27%, 0.11%] |
| Stent Thrombosis – Protocol Defined | 0.5% (3/654) | 0.0% (0/320) | 0.46% [Assump. not met] | 1.7% (10/583) | 2.2% (6/269) | -0.52% [-2.57%, 1.54%] |
| Acute (< 1 day) | 0.0% (0/669) | 0.0% (0/330) | 0.00% [Assump. not met] | 0.1% (1/669) | 0.0% (0/330) | 0.15% [Assump. not met] |
| Subacute (1 – 30 days) | 0.3% (2/667) | 0.0% (0/330) | 0.30% [Assump. not met] | 0.3% (2/667) | 0.0% (0/330) | 0.30% [Assump. not met] |
| Late (> 30 days) | 0.2% (1/653) | 0.0% (0/320) | 0.15% [Assump. not met] | 1.2% (7/582) | 2.2% (6/269) | -1.03% [-3.00%, 0.95%] |
| Stent Thrombosis – ARC Definite | 0.8% (5/652) | 0.0% (0/319) | 0.77% [Assump. not met] | 1.2% (7/582) | 0.7% (2/268) | 0.46% [Assump. not met] |

Notes:

- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 9-month and 5-year time frames include follow-up window (270 +14 days and 1825 + 28 days, respectively).
- “Assump. not met” means that the assumption of normal approximation was not met due to small sample size or frequency of events.
- Cardiac death is defined as the number of patients experiencing cardiac death through the follow-up time point / (the number of patients experiencing cardiac death through the follow-up time point + the number of patients followed through the follow-up time point without cardiac death + the number of patients terminated prior to the follow-up time point who did not experience cardiac death but experienced non-cardiac death, MI, ID or non-ID TLR, or ID or non-ID TVR).

¹ Confidence Interval was calculated using the normal approximation, not adjusted for multiplicity, and is meant for descriptive purposes only.

² TVF is defined as a hierarchical composite of cardiac death, MI, ischemic-driven TLR and ischemic-driven non-TLR TVR.

³ MACE is defined as a hierarchical composite of cardiac death, MI, ischemic-driven TLR.

Table 9.2.1-3: SPIRIT III 8-Month Angiographic and IVUS Results


| | XIENCE V (N = 376) (M_{ANGIO} = 427) (M_{IVUS} = 181) | TAXUS (N = 188) (M_{ANGIO} = 220) (M_{IVUS} = 93) | Difference [95% CI]¹ |
|--------------------------------------|--|--|--|
| Angiographic Results | | | |
| In-Stent MLD | | | |
| Post-Procedure | 2.71 ± 0.43 (425) | 2.74 ± 0.40 (220) | -0.03 [-0.10, 0.04] |
| 8 Months | 2.56 ± 0.53 (343) | 2.45 ± 0.65 (158) | 0.11 [-0.01, 0.23] |
| In-Segment MLD | | | |
| Post-Procedure | 2.35 ± 0.44 (426) | 2.36 ± 0.45 (220) | -0.01 [-0.08, 0.06] |
| 8 Months | 2.22 ± 0.53 (344) | 2.12 ± 0.60 (158) | 0.10 [-0.01, 0.21] |
| In-Stent %DS | | | |
| Post-Procedure | 0.32 ± 8.86 (424) | -0.78 ± 10.65 (220) | 1.10 [-0.55, 2.74] |
| 8 Months | 5.92 ± 16.40 (343) | 10.30 ± 21.43 (158) | -4.38 [-8.16, -0.60] |
| In-Segment %DS | | | |
| Post-Procedure | 13.89 ± 8.04 (425) | 13.92 ± 7.20 (220) | -0.03 [-1.26, 1.19] |
| 8 Months | 18.77 ± 14.43 (344) | 22.82 ± 16.35 (158) | -4.05 [-7.03, -1.06] |
| Late Loss | | | |
| In-Stent | 0.16 ± 0.41 (342) | 0.30 ± 0.53 (158) | -0.15 [-0.24, -0.05] |
| In-Segment | 0.14 ± 0.39 (343) | 0.26 ± 0.46 (158) | -0.13 [-0.21, -0.04] |
| Binary Restenosis | | | |
| In-Stent | 2.3% (8/343) | 5.7% (9/158) | -3.36% [-7.32%, 0.59%] |
| In-Segment | 4.7% (16/344) | 8.9% (14/158) | -4.21% [-9.17%, 0.75%] |
| IVUS Results | | | |
| Neointimal Volume (mm ³) | 10.13 ± 11.46 (101) | 20.87 ± 13.51 (41) | -10.74 [-20.92, -0.56] |
| % Volume Obstruction | 6.91 ± 6.35 (98) | 11.21 ± 9.86 (39) | -4.30 [-7.72, -0.88] |
| Incomplete Apposition | | | |
| Post-Procedure | 34.4% (31/90) | 25.6% (11/43) | 8.86% [-7.46%, 25.19%] |
| 8 Months | 25.6% (23/90) | 16.3% (7/43) | 9.28% [-4.97%, 23.52%] |
| Persistent | 24.4% (22/90) | 14.0% (6/43) | 10.49% [-3.15%, 24.13%] |
| Late Acquired | 1.1% (1/90) | 2.3% (1/43) | -1.21% [Assump. not met] |

Notes:

- N is the total number of subjects; MANGIO is the total number of lesions in the protocol required angiographic cohort and MIVUS is the total number of lesions in the protocol required IVUS cohort.
- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 8-month time frame includes follow-up window (240 + 28 days).
- "Assump. not met" means that the assumption of normal approximation was not met due to small sample size or frequency of events.

¹ Confidence Interval was calculated using the normal approximation, not adjusted for multiplicity, and is meant for descriptive purposes only.

Figure 9.2.1-1: SPIRIT III: Kaplan Meier Time-to-Event Curve for Target Vessel Failure through 5 Years



| TVF | Event Free | Event Rate | p-value ¹ |
|----------|------------|------------|----------------------|
| XIENCE V | 80.7% | 19.3% | 0.0549 |
| TAXUS | 75.5% | 24.5% | |

Note:

- Time frame includes follow-up window (1825 + 28 days).
- ¹p-value based on log rank and not adjusted for multiple comparisons

Table 9.2.1-4: SPIRIT III RCT ARC-Defined Definite+Probable Stent Thrombosis through 5 Years

| | XIENCE V (N = 669) | TAXUS (N = 333) | Difference [95% CI] ¹ |
|---|-----------------------|--------------------|-------------------------------------|
| ARC Definite+Probable Stent Thrombosis (0 days – 5 years) | 1.5% (9/582) | 1.9% (5/268) | -0.32% [-2.22%, 1.59%] |
| Acute (< 1 day) | 0.1% (1/669) | 0.0% (0/330) | 0.15% [Assump. not met] |
| Subacute (1 – 30 days) | 0.3% (2/667) | 0.0% (0/330) | 0.30% [Assump. not met] |
| Late (31 days – 1 year) | 0.5% (3/649) | 0.6% (2/317) | -0.17% [Assump. not met] |
| Very Late (> 1 years) | 0.5% (3/580) | 1.1% (3/267) | -0.61% [Assump. not met] |

Notes:

- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- Time frame includes follow-up window (1825 + 28 days).
- "Assump. not met" means that assumption of the normal approximation was not met due to small sample size or frequency of events.

¹ Confidence Interval was calculated using the normal approximation, not adjusted for multiplicity, and is meant for descriptive purposes only.

9.2.2 Dual Vessel Treatment in SPIRIT III

Subjects requiring treatment in more than one vessel comprise a subgroup that is at increased risk for cardiovascular events compared with single vessel disease patients. Subjects requiring both single and dual vessel treatment were included in the SPIRIT III trial; however, there were no pre-specified hypotheses for these patient subgroups.

Table 9.2.2-1 shows the clinical outcomes through 9 months and 5 years in single vessel and dual vessel treated subjects from a post-hoc analysis of SPIRIT III. The number of vessels treated was one of the stratification factors used in the randomization to assure a balance between the XIENCE V and TAXUS treatment arms.

Table 9.2.2-1: Clinical Results in Single and Dual Vessel Treatment through 5 Years (SPIRIT III RCT)

| | 9 Months | | | | 5 Years | | | |
|-----------------------------|----------------------------------|-------------------------------|--------------------------------|----------------------------|----------------------------------|-------------------------------|--------------------------------|----------------------------|
| | Single Vessel XIENCE V (N = 566) | Single Vessel TAXUS (N = 281) | Dual Vessel XIENCE V (N = 103) | Dual Vessel TAXUS (N = 51) | Single Vessel XIENCE V (N = 566) | Single Vessel TAXUS (N = 281) | Dual Vessel XIENCE V (N = 103) | Dual Vessel TAXUS (N = 51) |
| TVF | 6.3% (35/556) | 7.0% (19/271) | 11.9% (12/101) | 20.0% (10/50) | 18.0% (92/510) | 22.9% (55/240) | 32.6% (31/95) | 45.7% (21/46) |
| Ischemia-Driven TLR | 2.3% (13/556) | 4.1% (11/271) | 4.0% (4/101) | 10.0% (5/50) | 8.4% (43/510) | 11.3% (27/240) | 11.6% (11/95) | 21.7% (10/46) |
| Ischemia-Driven TVR, Non TL | 2.7% (15/556) | 2.2% (6/271) | 5.0% (5/101) | 14.0% (7/50) | 6.7% (34/510) | 8.8% (21/240) | 20.0% (19/95) | 28.3% (13/46) |
| All Death | 1.1% (6/557) | 0.4% (1/271) | 0.0% (0/101) | 3.9% (2/51) | 6.1% (32/523) | 9.9% (25/252) | 5.1% (5/98) | 12.5% (6/48) |
| Cardiac Death | 0.5% (3/557) | 0.4% (1/271) | 0.0% (0/101) | 2.0% (1/51) | 2.9% (15/523) | 4.0% (10/252) | 2.0% (2/98) | 6.3% (3/48) |
| Non-Cardiac Death | 0.5% (3/557) | 0.0% (0/271) | 0.0% (0/101) | 2.0% (1/51) | 3.3% (17/523) | 6.0% (15/252) | 3.1% (3/98) | 6.3% (3/48) |
| MI | 1.6% (9/556) | 1.5% (4/271) | 4.0% (4/101) | 8.0% (4/50) | 3.7% (19/510) | 4.6% (11/240) | 9.5% (9/95) | 19.6% (9/46) |
| Cardiac Death or MI | 2.2% (12/556) | 1.8% (5/271) | 4.0% (4/101) | 10.0% (5/50) | 6.5% (33/510) | 8.8% (21/240) | 10.5% (10/95) | 23.9% (11/46) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.4% (2/553) | 0.0% (0/271) | 1.0% (1/101) | 0.0% (0/49) | 1.2% (6/490) | 1.8% (4/226) | 4.3% (4/93) | 4.7% (2/43) |
| ARC Definite+Probable | 0.7% (4/554) | 0.0% (0/271) | 2.0% (2/101) | 0.0% (0/49) | 0.8% (4/488) | 1.3% (3/225) | 5.3% (5/94) | 4.7% (2/43) |
| ARC Definite | 0.4% (2/554) | 0.0% (0/271) | 2.0% (2/101) | 0.0% (0/49) | 0.6% (3/488) | 0.4% (1/225) | 4.3% (4/94) | 2.3% (1/43) |

Note:

- Cardiac death is defined as the number of patients experiencing cardiac death through the follow-up time point / (the number of patients experiencing cardiac death through the follow-up time point + the number of patients followed through the follow-up time point without cardiac death + the number of patients terminated prior to the follow-up time point who did not experience cardiac death but experienced non-cardiac death, MI, ID or non-ID TLR, or ID or non-ID TVR).

9.2.3 SPIRIT III US 4.0 mm Arm

Primary Objective: The objective of the SPIRIT III 4.0 mm arm was to demonstrate the non-inferiority in in-segment late loss at 240 days of the XIENCE V 4.0 mm stent in the treatment of de novo lesions with RVD 3.75 to 4.25 mm, compared to the TAXUS arm from the SPIRIT III RCT.

Design: The SPIRIT III 4.0 mm study was a prospective, single-arm, multicenter clinical trial in the United States evaluating the 4.0 mm diameter XIENCE V stent in *de novo* native coronary artery lesions ≤ 28 mm in length with a RVD > 3.75 mm to ≤ 4.25 mm. Seventy-three (73) subjects were enrolled in the SPIRIT III 4.0 mm study arm. For early demonstration of efficacy (in-segment late loss at 240 days), an interim analysis was performed after 69 of the enrolled subjects had completed their scheduled follow-up and after unblinding of the SPIRIT III RCT.

All subjects had clinical follow-up at 30, 180, 240, and 270 days, and annually from 1 to 5 years. In addition, all subjects had angiographic follow-up at 240 days. IVUS was performed for subjects who received a bailout stent at baseline and 240 days.

Following the index procedure, all subjects were to be maintained on clopidogrel bisulfate daily for a minimum of 6 months and aspirin daily to be taken throughout the length of the trial (5 years).

Demographics: The mean age in the SPIRIT III 4.0 arm was 61.9 years with 72.5% (50/69) male, 21.7% (15/69) had prior cardiac interventions, and 30.4% (21/69) had a history of diabetes.

Results: The results are presented in Table 9.2.3-1: SPIRIT III 4.0 mm Primary Endpoint Result, Table 9.2.3-2: SPIRIT III 4.0 mm Clinical Results, Table 9.2.3-3: SPIRIT III 4.0 mm 8-month Angiographic Results, and Table 9.2.3-4: SPIRIT III 4.0 mm ARC-Defined Stent Thrombosis through 5 years. These analyses were performed on the intent-to-treat population. Although SPIRIT III allowed treatment of two separate epicardial vessels, all subjects in the SPIRIT III 4.0 arm had only one vessel treated. The 5-year follow-up rate for the SPIRIT III 4.0 mm arm was 87.7% (64/73).

The primary endpoint of in-segment late loss at 240 days was met with measurements of 0.17 ± 0.38 mm (49 analysis lesions) for the XIENCE V 4.0 mm arm and 0.28 ± 0.48 mm (134 analysis lesions) for the TAXUS arm from the SPIRIT III RCT ($p < 0.0001$ for non-inferiority).

Table 9.2.3-1: SPIRIT III 4.0 mm Primary Endpoint Result

| Measurements | XIENCE V (M = 69) | TAXUS (M = 188) | Difference [95% CI] | Non- Inferiority p-value |
|---|----------------------|-----------------------|---------------------------------------|--------------------------------|
| 8-Month Late Loss, In-Segment (mm) | 0.17 ± 0.38 (49) | 0.28 ± 0.48 (134) | -0.11 [-0.24, 0.03] ¹ | < 0.0001 ² |

Notes:

- M is the total number of analysis lesions.
- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- Time frame includes follow-up window (240 + 28 days).

¹ By normal approximation.

² One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 0.195 mm, to be compared at a 0.038 significance level.

Table 9.2.3-2: SPIRIT III 4.0 mm Clinical Results

| | Outcomes at 9 Months XIENCE V (N = 73) | Outcomes at 5 Years (Final Follow-up) XIENCE V (N = 73) | Outcomes at 5 Years (Final Follow-up) TAXUS RCT (N = 333) |
|--------------------------------------|--|--|--|
| Composite Efficacy and Safety | | | |
| TVF ¹ | 6.8% (5/73) | 11.9% (8/67) | 26.6% (76/286) |
| MACE ² | 6.8% (5/73) | 10.4% (7/67) | 22.0% (63/286) |
| Efficacy | | | |
| Ischemia-Driven TLR | 2.7% (2/73) | 4.5% (3/67) | 12.9% (37/286) |
| TLR, CABG | 0.0% (0/73) | 0.0% (0/67) | 1.0% (3/286) |
| TLR, PCI | 2.7% (2/73) | 4.5% (3/67) | 11.9% (34/286) |
| Ischemia-Driven TVR, Non TL | 0.0% (0/73) | 3.0% (2/67) | 11.9% (34/286) |
| Non-TLR TVR, CABG | 0.0% (0/73) | 0.0% (0/67) | 2.4% (7/286) |
| Non-TLR TVR, PCI | 0.0% (0/73) | 3.0% (2/67) | 9.8% (28/286) |
| Safety | | | |
| All Death | 1.4% (1/73) | 8.6% (6/70) | 10.3% (31/300) |
| Cardiac Death | 1.4% (1/73) | 2.9% (2/70) | 4.3% (13/300) |
| Non-Cardiac Death | 0.0% (0/73) | 5.7% (4/70) | 6.0% (18/300) |
| MI | 4.1% (3/73) | 4.5% (3/67) | 7.0% (20/286) |
| QMI | 0.0% (0/73) | 0.0% (0/67) | 0.7% (2/286) |
| NQMI | 4.1% (3/73) | 4.5% (3/67) | 6.3% (18/286) |
| Cardiac Death or MI | 5.5% (4/73) | 7.5% (5/67) | 11.2% (32/286) |
| Stent Thrombosis – Protocol Defined | 1.4% (1/72) | 3.1% (2/65) | 2.2% (6/269) |
| Acute (≤ 1 day) | 1.4% (1/73) | 1.4% (1/73) | 0.0% (0/330) |
| Subacute (>1 – 30 days) | 0.0% (0/73) | 0.0% (0/73) | 0.0% (0/330) |
| Late (> 30 days) | 0.0% (0/72) | 1.5% (1/65) | 2.2% (6/269) |
| Stent Thrombosis – ARC Definite | 0.0% (0/72) | 0.0% (0/64) | 0.8% (2/268) |

Notes:

- 9-month and 5-year time frames include follow-up window (270 +14 days and 1825 + 28 days, respectively).
- Cardiac death is defined as the number of patients experiencing cardiac death through the follow-up time point / (the number of patients experiencing cardiac death through the follow-up time point + the number of patients followed through the follow-up time point without cardiac death + the number of patients terminated prior to the follow-up time point who did not experience cardiac death but experienced non-cardiac death, MI, ID or non-ID TLR, or ID or non-ID TVR).

¹ TVF is defined as a hierarchical composite of cardiac death, MI, ischemic-driven TLR and ischemic-driven non-TLR TVR.

² MACE is defined as a hierarchical composite of cardiac death, MI, ischemic-driven TLR.

Table 9.2.3-3: SPIRIT III 4.0 mm 8-Month Angiographic Results

| | XIENCE V (N = 69) (M = 69) |
|-----------------------------|---|
| Angiographic Results | |
| In-Stent MLD | |
| Post-Procedure | 3.46 ± 0.38 (69) |
| 8 Months | 3.36 ± 0.46 (49) |
| In-Segment MLD | |
| Post-Procedure | 3.07 ± 0.43 (69) |
| 8 Months | 2.91 ± 0.51 (49) |
| In-Stent %DS | |
| Post-Procedure | 2.12 ± 10.27 (69) |
| 8 Months | 4.78 ± 13.20 (49) |
| In-Segment %DS | |
| Post-Procedure | 13.42 ± 8.08 (69) |
| 8 Months | 17.92 ± 10.83 (49) |
| Late Loss | |
| In-Stent | 0.12 ± 0.34 (49) |
| In-Segment | 0.17 ± 0.38 (49) |
| Binary Restenosis | |
| In-Stent | 0.0% (0/49) |
| In-Segment | 2.0% (1/49) |

Notes:

- N is the total number of subjects; M is the total number of lesions at baseline.
- 8-month time frame includes follow-up window (240 + 28 days).

Table 9.2.3-4: SPIRIT III 4.0 mm ARC-Defined Stent Thrombosis through 5 Years

| | XIENCE V (N = 73) |
|--|------------------------------|
| ARC Definite+Probable Stent Thrombosis (0 days – 5 years) | 0.0% (0/64) |
| Acute (≤ 1 day) | 0.0% (0/73) |
| Subacute (>1 – 30 days) | 0.0% (0/73) |
| Late (31 days – 1 year) | 0.0% (0/72) |
| Very Late (>1 year) | 0.0% (0/64) |
| ARC Definite Stent Thrombosis (0 days – 5 years) | 0.0% (0/64) |

Note:

- Time frame includes follow-up window (1825 + 28 days).

9.3 SPIRIT IV Clinical Trial

The SPIRIT IV clinical study was designed to confirm the safety and efficacy of the XIENCE V stent when compared to the TAXUS Express stent¹² (TAXUS stent). This randomized controlled trial (RCT) was conducted in the United States (US).

9.3.1 SPIRIT IV Randomized Clinical Trial

Primary Objective: The objective of the SPIRIT IV clinical trial was to determine the safety and effectiveness of the XIENCE V stent for the treatment of subjects with up to three *de novo* coronary artery lesions (maximum of two lesions per epicardial vessel).

Design: The SPIRIT IV clinical trial was a prospective, 2:1 randomized (XIENCE V:TAXUS), active-controlled, single-blinded, multicenter evaluation of the XIENCE V stent compared to the TAXUS stent in the treatment of up to three *de novo* lesions ≤ 28 mm in length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 4.25 mm. Subjects were stratified by diabetes mellitus (diabetic vs. non-diabetic) and lesion characteristics (complex vs. non-complex). Complex lesion characteristics included triple vessel treatment, or dual lesions per vessel treatment, or lesions involving RCA-aorto-ostial locations, or bifurcations lesions. The SPIRIT IV clinical trial was designed to enroll 3,690 subjects at up to 80 sites in the US.

The primary endpoint was target lesion failure (TLF) at 1 year. The major secondary endpoints were ischemia-driven TLR at 1 year and the composite of cardiac death or target vessel MI at 1 year. Formal non-inferiority and superiority testing were planned for the primary and the two major secondary endpoints. To control the familywise Type I error rate, all non-inferiority and superiority hypotheses were tested following a fixed sequence.

The XIENCE V stents used in the SPIRIT IV trial included stents 2.5, 3.0, and 3.5 mm in diameter, and 8, 18 and 28 mm in length. In the XIENCE V arm, treatment of target lesions > 22 mm and ≤ 28 mm in length was accomplished by overlapping either two 18 mm stents or a 28 mm and an 8 mm stent (see section 5.3 – *Precautions, Multiple Stent Use*). In the TAXUS arm, the treatment strategy for lesions > 22 mm and ≤ 28 mm was recommended to be in accordance to the TAXUS Directions for Use (DFU) at the time of enrollment; these lesions were treated with single 32 mm TAXUS stent or planned overlapping TAXUS stents.

Subjects were evaluated at 30, 180, and 270 days following the index procedure. Follow-up has been performed through 3 years, completing the trial.

According to the guidelines from the American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI), following the index procedure, all subjects were to be maintained on 75 mg clopidogrel bisulfate daily for 12 months if subjects were not at high risk for bleeding and ≥ 80 mg of aspirin daily throughout the length of the trial (3 years).

Demographics: The mean age was 63.3 years for both the XIENCE V arm and the TAXUS arm. The XIENCE V arm had 67.7% (1665/2458) males and the TAXUS arm had 67.8% (833/1229) males. The XIENCE V arm had 31.5% (772/2450) of subjects with prior cardiac

¹² Of the 1,229 subjects enrolled in the TAXUS arm, 1 subject received one TAXUS Liberté stent.

interventions and the TAXUS arm had 30.7% (376/1224). The XIENCE V arm had 32.0% (786/2455) of subjects with a history of diabetes and the TAXUS arm had 32.5% (399/1228). The XIENCE V arm had 24.8% (609/2458) of subjects with two or more lesions treated and TAXUS had 25.3% (311/1229). The XIENCE V arm had 9.7% (239/2458) of subjects with planned stent overlap. The TAXUS arm had 8.1% (99/1229)¹³ of subjects with planned stent overlap and 4.5% (55/1229) of subjects treated with single 32 mm TAXUS stent only. The XIENCE V arm had 27.7% (669/2416) of subjects with a history of unstable angina while the TAXUS arm had 28.9% (347/1202). The remaining subject baseline clinical features were well-matched between the XIENCE V arm and the TAXUS arm.

Results: The results are presented in Table 9.3.1-1: SPIRIT IV Primary and Major Secondary Endpoint Results, Table 9.3.1-2: SPIRIT IV Clinical Results through 3 Years, Figure 9.3.1-1: SPIRIT IV: Kaplan Meier Time-to-Event Curve for TLF through 3 Years, Figure 9.3.1-2: SPIRIT IV: Kaplan Meier Time-to-Event Curve for ID-TLR through 3 Years, and Figure 9.3.1-3: SPIRIT IV: Kaplan Meier Time-to-Event Curve for Cardiac Death or Target Vessel MI through 3 Years. These analyses are based on the intent-to-treat population. At the three-year visit, the follow-up rate for the XIENCE V arm was 91.8% (2257) and 89.1% (1095) for the TAXUS arm.

Primary Endpoint Analysis (Table 9.3.1-1): The primary endpoint was met with TLF rates at 1 year of 4.0% (97/2416) for the XIENCE V arm and 6.8% (81/1195) for the TAXUS arm ($p < 0.0001$ for non-inferiority). In a pre-specified analysis, the XIENCE V stent was shown to be superior to the TAXUS stent in terms of the primary endpoint of TLF at 1 year ($p_{\text{Sup}} = 0.0004$).

Major Secondary Endpoint Analysis (Table 9.3.1-1): The major secondary endpoint of ID-TLR was shown to be statistically non-inferior for the XIENCE V stent compared to the TAXUS stent. The ID-TLR rate through 1 year was 2.3% (56/2416) for the XIENCE V arm and 4.6% (55/1195) for the TAXUS arm ($p < 0.0001$ for non-inferiority). The XIENCE V arm also showed non-inferiority to the TAXUS arm in terms of the composite endpoint of cardiac death or target vessel MI with rates of 2.2% (53/2416) for the XIENCE V arm and 3.2% (38/1195) for the TAXUS arm ($p < 0.0001$ for non-inferiority).

In a pre-specified analysis, the XIENCE V stent was shown to be superior to the TAXUS stent in terms of ID-TLR at 1 year ($p_{\text{Sup}} = 0.0003$). The rate of composite of cardiac death or target vessel MI was numerically lower in patients treated with the XIENCE V EECSS compared to the TAXUS PECSS ($p_{\text{Sup}} = 0.09$).

¹³ Includes 6 patients who received planned overlapping TAXUS stents as well as single 32 mm TAXUS stent in two different lesions.

Table 9.3.1-1: SPIRIT IV Primary and Major Secondary Endpoint Results

| Primary Endpoint | XIENCE V (N = 2458) | TAXUS (N = 1229) | Difference [Upper 1-Sided 97.5% CL] | Non-Inferiority p-value | Superiority p-value |
|---|------------------------|---------------------|--|----------------------------|------------------------|
| 1 Year TLF | 4.0% (97/2416) | 6.8% (81/1195) | -2.76% [-1.14%] ¹ | < 0.0001 ² | 0.0004 ³ |
| Major Secondary Endpoints | XIENCE V (N = 2458) | TAXUS (N = 1229) | Difference [Upper 1-Sided 95% CL] | Non-Inferiority p-value | Superiority p-value |
| 1 Year ID-TLR | 2.3% (56/2416) | 4.6% (55/1195) | -2.28% [-1.17%] ¹ | < 0.0001 ⁴ | 0.0003 ³ |
| 1 Year Cardiac Death or Target Vessel MI | 2.2% (53/2416) | 3.2% (38/1195) | -0.99% [-0.02%] ¹ | < 0.0001 ⁴ | 0.09 ³ |

Notes:

- N is the total number of subjects.
- TLF includes cardiac death, target vessel MI (per protocol definition) and ischemia-driven TLR.
- Time frame includes follow-up window (365 + 28 days).

¹ By normal approximation.

² One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 3.1%, to be compared at a 0.025 significance level.

³ Two-sided p-value by superiority test using Fisher's exact test, to be compared at a 0.05 significance level.

⁴ One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 2.1%, to be compared at a 0.05 significance level.


Table 9.3.1-2: SPIRIT IV Clinical Results through 3 Years

| | Outcomes at 1 Year | | | Outcomes at 3 Years (final follow-up) | | |
|--|------------------------|---------------------|-------------------------------------|--|---------------------|-------------------------------------|
| | XIENCE V (N = 2458) | TAXUS (N = 1229) | Difference [95% CI] ¹ | XIENCE V (N = 2458) | TAXUS (N = 1229) | Difference [95% CI] ¹ |
| Composite Efficacy and Safety | | | | | | |
| TLF | 4.0% (97/2416) | 6.8% (81/1195) | -2.76% [-4.39%, -1.14%] | 9.5% (223/2348) | 11.9% (138/1158) | -2.42% [-4.63%, -0.21%] |
| TVF | 5.5% (134/2416) | 7.7% (92/1195) | -2.15% [-3.92%, -0.39%] | 13.3% (312/2348) | 14.5% (168/1158) | -1.22% [-3.67%, 1.23%] |
| Efficacy | | | | | | |
| Ischemia-Driven TLR | 2.3% (56/2416) | 4.6% (55/1195) | -2.28% [-3.62%, -0.95%] | 6.3% (148/2348) | 7.9% (92/1158) | -1.64% [-3.48%, 0.20%] |
| TLR, CABG | 0.4% (9/2416) | 0.4% (5/1195) | -0.05% [-0.49%, 0.39%] | 0.8% (18/2348) | 0.9% (10/1158) | -0.10% [-0.74%, 0.54%] |
| TLR, PCI | 2.0% (48/2416) | 4.3% (51/1195) | -2.28% [-3.56%, -1.01%] | 5.7% (134/2348) | 7.5% (87/1158) | -1.81% [-3.59%, -0.02%] |
| Ischemia-Driven TVR | 3.8% (93/2416) | 5.7% (68/1195) | -1.84% [-3.36%, -0.32%] | 10.1% (238/2348) | 10.6% (123/1158) | -0.49% [-2.64%, 1.67%] |
| Safety | | | | | | |
| All Death | 1.0% (25/2416) | 1.3% (15/1195) | -0.22% [-0.97%, 0.53%] | 3.4% (81/2348) | 5.2% (60/1158) | -1.73% [-3.21%, -0.26%] |
| Cardiac Death | 0.4% (10/2416) | 0.4% (5/1195) | -0.00% [-0.45%, 0.44%] | 1.4% (34/2348) | 1.9% (22/1158) | -0.45% [-1.37%, 0.47%] |
| Non-Cardiac Death | 0.6% (15/2416) | 0.8% (10/1195) | -0.22% [-0.82%, 0.39%] | 2.0% (47/2348) | 3.3% (38/1158) | -1.28% [-2.45%, -0.11%] |
| Target Vessel MI | 1.8% (44/2416) | 2.9% (35/1195) | -1.11% [-2.20%, -0.01%] | 2.8% (65/2348) | 4.1% (48/1158) | -1.38% [-2.70%, -0.05%] |
| Cardiac Death or Target Vessel MI | 2.2% (53/2416) | 3.2% (38/1195) | -0.99% [-2.14%, 0.17%] | 4.1% (97/2348) | 5.5% (64/1158) | -1.40% [-2.94%, 0.15%] |
| All MI | 1.9% (45/2416) | 3.1% (37/1195) | -1.23% [-2.35%, -0.11%] | 3.1% (73/2348) | 4.7% (55/1158) | -1.64% [-3.05%, -0.23%] |
| QMI | 0.1% (3/2416) | 0.4% (5/1195) | -0.29% [Assump. not met] | 0.3% (6/2348) | 0.9% (11/1158) | -0.69% [-1.29%, -0.10%] |
| NQMI | 1.7% (42/2416) | 2.8% (33/1195) | -1.02% [-2.09%, 0.04%] | 2.9% (67/2348) | 4.0% (46/1158) | -1.12% [-2.43%, 0.19%] |
| Cardiac Death or MI | 2.2% (54/2416) | 3.3% (39/1195) | -1.03% [-2.20%, 0.14%] | 4.5% (105/2348) | 6.0% (70/1158) | -1.57% [-3.18%, 0.03%] |
| Protocol -Defined Stent Thrombosis (Cumulative) | 0.17% (4/2389) | 0.85% (10/1181) | -0.68% [Assump. not met] | 0.79% (18/2266) | 1.99% (22/1104) | -1.20% [-2.10%, -0.30%] |
| Acute / Subacute (0 – 30 days) | 0.12% (3/2451) | 0.57% (7/1221) | -0.45% [Assump. not met] | 0.12% (3/2451) | 0.57% (7/1221) | -0.45% [Assump. not met] |
| Late (> 30 days) | 0.04% (1/2389) | 0.34% (4/1181) | -0.30% [Assump. not met] | 0.62% (14/2265) | 1.45% (16/1103) | -0.83% [-1.61%, -0.06%] |
| ARC Definite+Probable Stent Thrombosis (Cumulative) | 0.29% (7/2391) | 1.10% (13/1181) | -0.81% [-1.44%, -0.17%] | 0.62% (14/2263) | 1.73% (19/1098) | -1.11% [-1.95%, -0.28%] |
| Early (0 – 30 days) | 0.16% (4/2451) | 0.74% (9/1221) | -0.57% [Assump. not met] | 0.16% (4/2451) | 0.74% (9/1221) | -0.57% [Assump. not met] |
| Late (31 days – 1 year) | 0.13% (3/2391) | 0.42% (5/1181) | -0.30% [Assump. not met] | 0.13% (3/2385) | 0.42% (5/1183) | -0.30% [Assump. not met] |
| Very late (> 1 year) | - | - | - | 0.31% (7/2260) | 0.55% (6/1095) | -0.24% [-0.73%, 0.26%] |
| ARC -Definite Stent Thrombosis (Cumulative) | 0.25% (6/2391) | 0.85% (10/1181) | -0.60% [-1.16%, -0.04%] | 0.49% (11/2263) | 1.28% (14/1098) | -0.79% [-1.51%, -0.07%] |

Notes:

- 1-year and 3-year time frames include follow-up window (365 ± 28 days and 1095 ± 28 days, respectively).
 - TLF is defined as a hierarchical composite of cardiac death, target vessel MI (per protocol definition), and ischemic-driven TLR.
 - TVF is defined as a hierarchical composite of cardiac death, all MI (per protocol definition), ischemic-driven TLR and ischemic-driven non-TLR TVR.
- ¹ Confidence Interval was calculated using the normal approximation, not adjusted for multiplicity and is meant for descriptive purposes only.

Figure 9.3.1-1: SPIRIT IV: Kaplan Meier Time-to-Event Curve for TLF through 3 Years




| TLF | Event Free | Event Rate | p-value ¹ |
|----------|------------|------------|----------------------|
| XIENCE V | 90.8% | 9.2% | 0.0221 |
| TAXUS | 88.3% | 11.7% | |

Note:

- Time frame includes follow-up window (1095 + 28 days).

¹p-value based on log rank and not adjusted for multiple comparisons

Figure 9.3.1-2: SPIRIT IV: Kaplan Meier Time-to-Event Curve for ID-TLR through 3 Years




| ID-TLR | Event Free | Event Rate | p-value ¹ |
|----------|------------|------------|----------------------|
| XIENCE V | 93.8% | 6.2% | 0.0577 |
| TAXUS | 92.2% | 7.8% | |

Note:

- Time frame includes follow-up window (1095 + 28 days).

¹p-value based on log rank and not adjusted for multiple comparisons

Figure 9.3.1-3: SPIRIT IV: Kaplan Meier Time-to-Event Curve for Cardiac Death or Target Vessel MI through 3 Years



| Cardiac Death or TV-MI | Event Free | Event Rate | p-value ¹ |
|------------------------|------------|------------|----------------------|
| XIENCE V | 96.0% | 4.0% | 0.0670 |
| TAXUS | 94.6% | 5.4% | |

Note:

- Time frame includes follow-up window (1095 + 28 days).
- ¹p-value based on log rank and not adjusted for multiple comparisons

9.3.2 Multiple Vessel Treatment in SPIRIT IV

Subjects requiring treatment in more than one vessel comprise a subgroup that is at increased risk for cardiovascular events compared with single vessel disease patients. The SPIRIT IV trial allowed for up to 3 vessels to be treated. In the XIENCE V arm, 389 subjects received dual vessel treatment while 19 subjects received triple vessel treatment. In the TAXUS arm, 218 subjects received dual vessel treatment while 5 subjects received triple vessel treatment. There were no pre-specified hypotheses for patients in the single vessel treatment and multiple vessel treatment subgroups.

Table 9.3.2-1 shows the clinical outcomes through 3 years in single- and multiple-vessel treated subjects from a post-hoc analysis of SPIRIT IV.

Table 9.3.2-1: Clinical Results in Single and Multiple Vessel Treatment through 3 Years (SPIRIT IV)

| | Outcomes at 1 Year | | | | Outcomes at 3 Years (final follow-up) | | | |
|-----------------------------------|---|--------------------------------------|--|---------------------------------------|--|--------------------------------------|--|---------------------------------------|
| | Single Vessel XIENCE V (N = 2050) | Single Vessel TAXUS (N = 1006) | Multiple Vessel XIENCE V (N = 408) | Multiple Vessel TAXUS (N = 223) | Single Vessel XIENCE V (N = 2050) | Single Vessel TAXUS (N = 1006) | Multiple Vessel XIENCE V (N = 408) | Multiple Vessel TAXUS (N = 223) |
| TLF | 3.8% (76/2014) | 6.0% (59/983) | 5.2% (21/402) | 10.4% (22/212) | 8.3% (163/1959) | 11.0% (105/952) | 15.4% (60/389) | 16.0% (33/206) |
| Ischemia-Driven TLR | 2.1% (42/2014) | 4.0% (39/983) | 3.5% (14/402) | 7.5% (16/212) | 5.3% (104/1959) | 7.0% (67/952) | 11.3% (44/389) | 12.1% (25/206) |
| Ischemia-Driven TVR, Non TL | 1.9% (38/2014) | 2.0% (20/983) | 4.0% (16/402) | 4.2% (9/212) | 4.6% (91/1959) | 5.0% (48/952) | 10.5% (41/389) | 7.3% (15/206) |
| All Death | 0.9% (18/2014) | 1.3% (13/983) | 1.7% (7/402) | 0.9% (2/212) | 3.1% (60/1959) | 5.6% (53/952) | 5.4% (21/389) | 3.4% (7/206) |
| Cardiac Death | 0.3% (6/2014) | 0.4% (4/983) | 1.0% (4/402) | 0.5% (1/212) | 1.2% (24/1959) | 2.0% (19/952) | 2.6% (10/389) | 1.5% (3/206) |
| Non-Cardiac Death | 0.6% (12/2014) | 0.9% (9/983) | 0.7% (3/402) | 0.5% (1/212) | 1.8% (36/1959) | 3.6% (34/952) | 2.8% (11/389) | 1.9% (4/206) |
| Target Vessel MI | 1.8% (37/2014) | 2.3% (23/983) | 1.7% (7/402) | 5.7% (12/212) | 2.7% (53/1959) | 3.7% (35/952) | 3.1% (12/389) | 6.3% (13/206) |
| Cardiac Death or Target Vessel MI | 2.1% (43/2014) | 2.6% (26/983) | 2.5% (10/402) | 5.7% (12/212) | 3.9% (77/1959) | 5.3% (50/952) | 5.1% (20/389) | 6.8% (14/206) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.15% (3/1996) | 0.51% (5/971) | 0.25% (1/393) | 2.38% (5/210) | 0.79% (15/1900) | 1.88% (17/903) | 0.82% (3/366) | 2.49% (5/201) |
| ARC Definite+Probable | 0.20% (4/1996) | 0.72% (7/971) | 0.76% (3/395) | 2.86% (6/210) | 0.47% (9/1895) | 1.45% (13/897) | 1.36% (5/368) | 2.99% (6/201) |
| ARC Definite | 0.20% (4/1990) | 0.51% (5/972) | 0.51% (2/395) | 2.37% (5/211) | 0.47% (9/1895) | 1.00% (9/897) | 0.54% (2/368) | 2.49% (5/201) |

Notes:

- 1-year and 3-year time frames include follow-up window (365 + 28 days and 1095 ± 28 days, respectively)
- Multiple vessel subgroup included subjects having two or more vessels treated.
- There were 24 triple vessel treated subjects in SPIRIT IV; Of those, 19 were XIENCE V subjects and 5 were TAXUS subjects.

Study Strengths and Limitations: The SPIRIT IV trial was a prospective, randomized, active-controlled, single-blinded, multicenter evaluation of the XIENCE V stent compared to the TAXUS Express Stent and was designed to enroll 3,690 subjects in the US. With a large sample size and high data quality, the study provides important safety and effectiveness information on clinical outcomes in a more complex population than those in SPIRIT III. In spite of the large population and less restrictive enrollment criteria however, subgroup analyses from SPIRIT IV are considered exploratory.

9.4 SPIRIT Small Vessel Registry

Objective: The objective of the SPIRIT SV Registry trial was to evaluate the safety and effectiveness of the 2.25 mm XIENCE V EECSS in improving coronary luminal diameter in subjects with ischemic heart disease due to a maximum of two *de novo* native coronary artery lesions in small vessels, each in a different epicardial vessel.

Design: The SPIRIT SV trial enrolled a total of 150 subjects at 33 sites. Additionally, there was an angiographic cohort of 69 subjects who received the 2.25 mm XIENCE V EECSS. Subjects enrolled in the SPIRIT SV trial were allowed to have: 1) one target lesion (treated with one 2.25 mm XIENCE V EECSS), 2) two target lesions (treated with two 2.25 mm XIENCE V EECSS) in separate epicardial vessels, or 3) one target lesion (treated with one 2.25 mm XIENCE V EECSS) and one non-target lesion (treated with commercial sizes of XIENCE V EECSS) in separate epicardial vessels. Planned overlap was allowed for both the target and non-target lesions only with commercial sizes of XIENCE V EECSS. Bailout was allowed with a commercial XIENCE V or 2.25 mm XIENCE V EECSS. The protocol-required RVD for the target lesion was ≥ 2.25 mm to < 2.50 mm and the lesion length was ≤ 28 mm. The 2.25 mm XIENCE V EECSS was available in stent lengths of 8, 18 and 28 mm. The non-target lesion could be treated by the commercial XIENCE V EECSS with a RVD of ≥ 2.5 mm to ≤ 4.25 mm. The commercial XIENCE V EECSS was available in stent diameters of 2.5, 2.75, 3.0, 3.5, 4.0 mm and stent lengths of 8, 12, 15, 18, 23, 28 mm. The primary endpoint was target lesion failure (TLF, defined as the composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularization) at 1 year.

Demographics: For the subjects treated with the 2.25 mm XIENCE V EECSS, the mean age was 63 ± 11 years, and the majority of the population was male (61.8%, 89/144). In subjects treated with the 2.25 mm XIENCE V EECSS, 22.9% (32/140) were tobacco users, 81.9% (118/144) were hypertensive requiring medication, 86.5% (122/141) had hypercholesterolemia requiring medication, and 39.2% (56/143) were diabetic. Additionally, 68.8% (99/144) of the subjects had stable angina and 27.1% (39/144) had unstable angina. In subjects treated with the 2.25 mm XIENCE V EECSS, 72.2% (104/144) underwent single vessel treatment, and 27.8% (40/144) underwent dual vessel treatment.

Results: The results are presented in Table 9.4-1 (Primary Endpoint Results), Table 9.4-2 (Clinical Results), Table 9.4-3 (Stent Thrombosis Results), Table 9.4-4 (Angiographic Results) and Figure 9.4-1 (Time-to-Event Curve for TLF). These analyses are based on the full analysis set (FAS) population (defined as subjects that received the 2.25 mm XIENCE V EECSS). The primary analysis of the primary endpoint was analyzed in the FAS population. The 1-year TLF rate was 8.1% with an upper limit of the one-sided 95% confidence interval of 13.03%, which met the pre-specified performance goal of 20.4% ($p < 0.0001$). The 3-year follow-up rate for the SPIRIT Small Vessel Registry was 88.2% (127/144).

Table 9.4-1: SPIRIT SV Primary Endpoint Result

| Primary Endpoint | 2.25 mm XIENCE V (N = 144) | Upper 1-Sided 95% CL | p-value ¹ |
|------------------|-------------------------------|-------------------------|----------------------|
| 1-year TLF | 8.1% (11/136) | 13.03% | < 0.0001 |

Notes:

- N is the total number of subjects.
- TLF includes cardiac death, target vessel MI (per protocol definition) and clinically indicated TLR.
- Time frame includes follow-up window (365 ± 28 days).

¹ One-sided p-value by testing against the performance goal of 20.4% using exact test at 0.05 significance level.

Table 9.4-2: SPIRIT SV Clinical Endpoint Results through 3 Years

| 2.25 mm XIENCE V Arm | Per Protocol Definition | |
|--|---------------------------|---|
| Acute Success (post index procedure) | ITT* (N = 149) | |
| Clinical Device Success | 95.21% (139/146) | |
| Clinical Procedure Success | 97.93% (142/145) | |
| Clinical Outcomes | At 1 Year | At 3 Years (final follow-up) |
| Component Endpoints | FAS (N = 144) | FAS (N = 144) |
| All Death | 1.5% (2/136) | 3.8% (5/132) |
| Cardiac Death | 1.5% (2/136) | 3.8% (5/132) |
| Non-Cardiac Death | 0.0% (0/136) | 0.0% (0/132) |
| Target Vessel MI | 1.5% (2/136) | 1.5% (2/132) |
| Non Target Vessel MI | 0.0% (0/136) | 0.0% (0/132) |
| Clinically Indicated TLR (CI-TLR) | 5.1% (7/136) | 6.8% (9/132) |
| Clinically Indicated TVR (CI-TVR) | 8.8% (12/136) | 12.1% (16/132) |
| All TLR | 6.6% (9/136) | 8.3% (11/132) |
| All TVR | 10.3% (14/136) | 13.6% (18/132) |
| All Revascularization | 14.7% (20/136) | 23.5% (31/132) |
| Composite Endpoints | | |
| Cardiac Death or MI | 2.9% (4/136) | 5.3% (7/132) |
| Cardiac Death or All MI or CI-TLR | 8.1% (11/136) | 12.1% (16/132) |
| All Death or All MI or All Revascularization | 16.9% (23/136) | 26.5% (35/132) |
| TLF | 8.1% (11/136) | 12.1% (16/132) |

Notes:

- N is the total number of subjects; L is the number of lesions.
- Per protocol MI definition was used for Target Vessel MI, Non Target Vessel MI, and all composite endpoints. MI per protocol definition is: Q-wave MI: Development of new, pathological Q waves on the ECG, and Non Q-wave MI: Elevation of CK levels to ≥ two times the upper limit of normal with elevated CK-MB in the absence of new pathological Q waves.
- 1-year and 3-year time frames include follow-up window (365 ± 28 days and 1095 ± 28 days, respectively).
- Non Target Vessel MI includes MI not attributed to the treated vessel.
- All Revascularization includes TVR and non-TVR, and non-treated vessel revascularization.
- FAS (full analysis set) is defined as subjects that received the 2.25 mm XIENCE V EECSS in the SPIRIT SV trial.
- Clinical Device Success: The successful delivery and deployment of the first study stent intended to be implanted at the intended target lesion (or in an overlapping stent setting, a successful delivery and deployment of the intended first and second investigational stents) and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (or by visual estimation if QCA unavailable). Bailout lesions were included as device success only if the above criteria for clinical device success were met for the bailout stent.
- Clinical Procedure Success: The achievement of a final in-stent diameter stenosis (DS) of < 50% (by QCA) using the assigned device and with any adjunctive devices, without the occurrence of cardiac death, target vessel MI (per protocol definition), or repeat coronary revascularization of the target lesion during the hospital stay (up to 7 days if a subject still is in the hospital). If QCA %DS was not available, procedure success data were considered missing.

* The ITT population provides the most accurate estimate of successful 2.25 mm XIENCE V stent implantation because it includes all subjects, regardless of whether the attempted implantation of 2.25 mm XIENCE V stent was successful.

Table 9.4-3: SPIRIT SV Stent Thrombosis Results through 3 Years

| Stent Thrombosis | FAS (N = 144) | | |
|--|-------------------------|--|-------------------------------|
| | Per Protocol Definition | Per ARC Definition (Definite+Probable) | Per ARC Definition (Definite) |
| Acute (≤ 1 day) | 0.0% (0/144) | 0.0% (0/144) | 0.0% (0/144) |
| Subacute ($> 1 - 30$ days) | 0.7% (1/142) | 0.7% (1/142) | 0.0% (0/142) |
| Acute / Subacute (0 – 30 days) | 0.7% (1/142) | 0.7% (1/142) | 0.0% (0/142) |
| Late (Protocol: > 30 days; ARC: 31 – 393 days) | 2.3% (3/129) | 0.7% (1/137) | 0.7% (1/137) |
| Very Late (ARC only) (394 – 1123 days) | - | 0.0% (0/128) | 0.0% (0/128) |
| Overall (0 – 1123 days) | 3.1% (4/130) | 1.5% (2/130) | 0.8% (1/130) |

Table 9.4-4: SPIRIT SV 240-Day Angiographic Results (Angiographic Cohort¹)

| XIENCE V 2.25 mm Arm | FAS (N = 69) (L = 69) |
|-------------------------|-----------------------------|
| 240-day Late Loss | |
| In-Stent | 0.20 \pm 0.40 (52) |
| In-Segment | 0.16 \pm 0.41 (52) |
| Proximal | 0.21 \pm 0.35 (34) |
| Distal | 0.00 \pm 0.28 (45) |
| 240-day %DS | |
| In-Stent | 12.86 \pm 19.58 (52) |
| In-Segment | 20.85 \pm 22.53 (52) |
| Proximal | 14.31 \pm 13.16 (37) |
| Distal | 10.40 \pm 8.45 (46) |
| 240-day ABR | |
| In-Stent | 3.8% (2/52) |
| In-Segment | 9.6% (5/52) |
| Proximal | 2.7% (1/37) |
| Distal | 0.0% (0/46) |


Notes:

N is the total number of subjects. L is the total number of lesions.

240-day angiographic data is available for 52 subjects.

¹ Per protocol defined qualifying angiogram with follow-up window extended to 268 days.

Figure 9.4-1: SPIRIT SV: Kaplan Meier Time-to-Event Curve for TLF through 3 Years



| TLF | Event Free | Event Rate |
|----------------------|------------|------------|
| XIENCE V 2.25 mm Arm | 88.4% | 11.6% |

Note:

- Time frame includes follow-up window (1095 + 28 days).

Study Strengths and Limitations: The SPIRIT SV study was a prospective, open-label, multicenter registry. All event adjudications were performed by an independent Clinical Event Committee (CEC) with 100% site-reported adjudicable events being source-verified. The study provides important information on clinical outcomes and demonstrates the safety and effectiveness of the 2.25 mm XIENCE V stent in patients with small vessels. The study is limited by being a small registry with no head-to-head comparison with other DES platforms. In addition, due to the small population size, subgroup analysis can at best be considered exploratory.

9.5 Pooled Analysis of the SPIRIT II-III-IV Clinical Trials

A subject-level pooled analysis of three randomized, single-blinded, controlled trials was conducted to provide an assessment of safety outcomes with increased precision and to better estimate the incidence of low frequency events in specific subgroups. Definitive proof of the presence or absence of any differences between such subgroups requires prospectively powered assessment in dedicated clinical trials.

Data from the SPIRIT II, SPIRIT III randomized control trial (RCT) arm, and SPIRIT IV clinical trials were pooled to compare the XIENCE V stent to the TAXUS stent in 4989 subjects (with 6233 lesions) through 3 years (1123 days) of follow-up. Although SPIRIT IV permitted the enrollment of somewhat more complex patients, the three studies have subjects with generally similar baseline and angiographic characteristics and share key elements of study design, allowing pooling of the data for the purposes of these safety analyses.

Table 9.5-1: Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Clinical Results through 3 Years

| Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV | 1 Year | | 3 Years | |
|---|---|---|---|---|
| | XIENCE V (N = 3350) [95% CI] ¹ | TAXUS (N = 1639) ² [95% CI] ¹ | XIENCE V (N = 3350) [95% CI] ¹ | TAXUS (N = 1639) ² [95% CI] ¹ |
| TLF | 4.3% (143/3295) [3.67%, 5.09%] | 7.5% (119/1592) [6.23%, 8.88%] | 9.3% (295/3184) [8.28%, 10.33%] | 12.7% (196/1541) [11.10%, 14.49%] |
| Ischemia-Driven TLR | 2.7% (88/3295) [2.15%, 3.28%] | 4.9% (78/1592) [3.89%, 6.08%] | 6.1% (195/3184) [5.32%, 7.01%] | 8.3% (128/1541) [6.98%, 9.80%] |
| TLR, CABG | 0.3% (11/3295) [0.17%, 0.60%] | 0.3% (5/1592) [0.10%, 0.73%] | 0.7% (23/3184) [0.46%, 1.08%] | 0.8% (13/1541) [0.45%, 1.44%] |
| TLR, PCI | 2.4% (78/3295) [1.88%, 2.95%] | 4.6% (74/1592) [3.67%, 5.80%] | 5.6% (178/3184) [4.82%, 6.45%] | 7.8% (120/1541) [6.50%, 9.24%] |
| Ischemia-Driven TVR | 4.3% (143/3295) [3.67%, 5.09%] | 6.3% (100/1592) [5.14%, 7.59%] | 10.2% (326/3184) [9.21%, 11.34%] | 11.5% (177/1541) [9.94%, 13.18%] |
| All Death | 1.1% (36/3295) [0.77%, 1.51%] | 1.4% (22/1592) [0.87%, 2.08%] | 3.4% (109/3184) [2.82%, 4.11%] | 5.3% (81/1541) [4.20%, 6.49%] |
| Cardiac Death | 0.5% (15/3295) [0.26%, 0.75%] | 0.6% (9/1592) [0.26%, 1.07%] | 1.4% (45/3184) [1.03%, 1.89%] | 2.0% (31/1541) [1.37%, 2.84%] |
| Non-Cardiac Death | 0.6% (21/3295) [0.39%, 0.97%] | 0.8% (13/1592) [0.44%, 1.39%] | 2.0% (64/3184) [1.55%, 2.56%] | 3.2% (50/1541) [2.42%, 4.26%] |
| Target Vessel MI | 1.8% (60/3295) [1.39%, 2.34%] | 3.1% (49/1592) [2.29%, 4.05%] | 2.9% (91/3184) [2.31%, 3.50%] | 4.4% (68/1541) [3.44%, 5.56%] |
| Cardiac Death or Target Vessel MI | 2.2% (73/3295) [1.74%, 2.78%] | 3.4% (54/1592) [2.56%, 4.40%] | 4.1% (132/3184) [3.48%, 4.90%] | 5.8% (90/1541) [4.72%, 7.13%] |
| All MI | 2.0% (65/3295) [1.53%, 2.51%] | 3.3% (53/1592) [2.50%, 4.33%] | 3.3% (106/3184) [2.73%, 4.01%] | 5.2% (80/1541) [4.14%, 6.42%] |
| QMI | 0.2% (5/3295) [0.05%, 0.35%] | 0.4% (6/1592) [0.14%, 0.82%] | 0.3% (11/3184) [0.17%, 0.62%] | 0.8% (13/1541) [0.45%, 1.44%] |
| NQMI | 1.8% (60/3295) [1.39%, 2.34%] | 3.0% (48/1592) [2.23%, 3.98%] | 3.0% (95/3184) [2.42%, 3.64%] | 4.5% (69/1541) [3.50%, 5.63%] |
| Cardiac Death or All MI | 2.4% (78/3295) [1.88%, 2.95%] | 3.6% (57/1592) [2.72%, 4.61%] | 4.6% (147/3184) [3.91%, 5.40%] | 6.6% (101/1541) [5.37%, 7.91%] |
| Protocol-Defined Stent Thrombosis (Cumulative) | 0.3% (10/3258) [0.15%, 0.56%] | 0.8% (13/1574) [0.44%, 1.41%] | 0.9% (28/3071) [0.61%, 1.32%] | 2.0% (30/1471) [1.38%, 2.90%] |
| Acute / Subacute (0 – 30 days) | 0.2% (6/3341) [0.07%, 0.39%] | 0.4% (7/1628) [0.17%, 0.88%] | 0.2% (7/3341) [0.08%, 0.43%] | 0.4% (7/1628) [0.17%, 0.88%] |
| Late (> 30 days) | 0.1% (4/3257) [0.03%, 0.31%] | 0.4% (7/1574) [0.18%, 0.91%] | 0.7% (21/3069) [0.42%, 1.04%] | 1.6% (24/1470) [1.05%, 2.42%] |
| ARC Definite+Probable Stent Thrombosis (Cumulative) | 0.4% (13/3261) [0.21%, 0.68%] | 1.0% (16/1574) [0.58%, 1.65%] | 0.8% (24/3069) [0.50%, 1.16%] | 1.8% (26/1463) [1.16%, 2.59%] |
| Acute / Subacute (0 – 30 days) | 0.2% (7/3341) [0.08%, 0.43%] | 0.6% (10/1628) [0.29%, 1.13%] | 0.2% (7/3341) [0.08%, 0.43%] | 0.6% (10/1628) [0.29%, 1.13%] |
| Late (31 days – 1 year) | 0.2% (6/3260) [0.07%, 0.40%] | 0.5% (8/1574) [0.22%, 1.00%] | 0.2% (6/3254) [0.07%, 0.40%] | 0.5% (8/1577) [0.22%, 1.00%] |
| Very late (> 1 year) | - | - | 0.4% (11/3064) [0.18%, 0.64%] | 0.7% (10/1458) [0.33%, 1.26%] |
| ARC-Definite Stent Thrombosis (Cumulative) | 0.3% (11/3261) [0.17%, 0.60%] | 0.8% (12/1574) [0.39%, 1.33%] | 0.6% (18/3069) [0.35%, 0.93%] | 1.2% (18/1463) [0.73%, 1.94%] |
| Bleeding Complications | 3.1% (102/3261) [2.56%, 3.78%] | 3.3% (52/1573) [2.48%, 4.31%] | 5.8% (180/3086) [5.03%, 6.72%] | 6.6% (97/1474) [5.37%, 7.97%] |


Notes:

- 1-year and 3-year time frames include follow-up window (365 + 28 days and 1095 ± 28 days, respectively).

¹ By Clopper-Pearson Exact Confidence Interval

² In the pooled TAXUS stent arm, there were 18 subjects who received at least one TAXUS Liberté stent.

Figure 9.5-1: Kaplan Meier Time-to-Event Curves through 3 Years (Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV)



Note: p-value based on log rank and not adjusted for multiple comparisons

9.6 Gender-Based Analysis of the SPIRIT Family of Clinical Trials

9.6.1 Background

Cardiovascular disease is the leading cause of death for both women and men in the US and coronary artery disease is a major cause of morbidity and mortality in women. It is estimated that the prevalence of coronary artery disease in the United States is 9.1% (9,200,000) in males and 7.0% (8,400,000) in females for adults at least 20 years old according to the American Heart Association 2010 Update.¹⁴ However, it is estimated that only 36% of annual PCIs are performed in women.¹⁵ In PCI clinical trials, women represent only 25 – 35% of the enrolled populations, and there are relatively little gender-specific data. The disproportionate enrollment distribution in these trials may be partly attributable to gender differences in symptoms and pathophysiology,¹⁶ which may lead to under-diagnosis and under-referral of female patients with CAD. Women tend to have worse clinical outcomes compared to men, most likely due to their higher baseline risk profile and more complex angiographic characteristics.^{17, 18, 19}

9.6.2 Gender-Based Analysis of the SPIRIT PRIME Clinical Trial

Abbott Vascular performed a post-hoc evaluation of the SPIRIT PRIME clinical trial for possible sex-based differences in baseline characteristics and clinical outcomes, as well as for any interaction between treatment and sex / gender. The SPIRIT PRIME trial was not designed or powered to study safety or effectiveness differences between sexes, so these analyses are considered exploratory without definitive conclusions.

In the Core Size Registry, 119/401 (29.7%) subjects were female and 282/401 (70.3%) were male. In the Long Lesion Registry, 39/104 (37.5%) subjects were female and 65/104 (62.5%) were male. In comparison, the prevalence of coronary artery disease (CAD) is estimated at 9.2 million in males and 8.4 million in females for adults age 20 and older in the United States (i.e., the CAD population is estimated to be 52.2% males and 47.7% females). The disproportionate enrollment distribution in this trial may be partly attributable to gender differences in symptoms and pathophysiology, which may lead to under-diagnosis and under-referral of female patients with CAD. The gender proportions enrolled in this trial are similar to other drug-eluting stent trials.^{20, 21}

¹⁴ Lloyd-Jones D, Adams R, Carnethon M, De Simone G, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. *Circulation* 2010; 121:e46-215.

¹⁵ Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2009; 119(3):e21-181.

¹⁶ Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: Gender Differences in Traditional and Novel Risk Factors, Symptom Evaluation, and Gender-Optimized Diagnostic Strategies. *J Am Coll Cardiol* 2006 47: S4-20.

¹⁷ Mahoney EM, Jurkowitz CT, Chu H, Becker ER, Culler S, Kosinski AS, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. *Jama* 2002; 288(15):1851-8.

¹⁸ Akhter N, Milford-Beland S, Roe MT, Piana RN, Kao J, Shroff A. Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). *Am Heart J* 2009; 157(1):141-8.

¹⁹ Vaina S, Voudris V, Morice M-C, de Bruyne B, Colombo A, Macaya C, Richardt, G, Fajadet, J et al. Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularization in patients with multivessel coronary artery disease: Insights from ARTS I and ARTS II. *EuroInterv*. 2009; 4(4):492-501.

²⁰ Lansky AJ, Costa RA, Mooney M, et al. Gender-Based Outcomes After Paclitaxel-Eluting Stent Implantation in Patients With Coronary Artery Disease. *J Am Coll Cardiol* 2005 45: 1180-5.

Table 9.6.2-1 presents the baseline demographics, risk factors, and angiographic characteristics by gender for subjects in the Core Size Registry. As is consistent with previous literature, female patients at baseline were numerically older and had a higher BMI. Additionally, more females than males had hypertension requiring medication and diabetes mellitus. Table 9.6.2-2 presents the baseline demographics, risk factors, and angiographic characteristics by gender for subjects in the Long Lesion Registry.

Table 9.6.2-1: Demographics, Risk Factors, and Baseline Angiographic Characteristics for SPIRIT PRIME Core Size Registry Subjects*

| Subject / Lesion Characteristics | Male (N = 282) (M = 315) | Female (N = 119) (M = 132) | Total (N = 401) (M = 447) | p-value |
|--|--------------------------------|----------------------------------|---------------------------------|---------------------|
| Baseline Demographics, Mean ± SD (n) | | | | |
| Age (year) | 61.63 ± 10.37 (282) | 65.23 ± 9.47 (119) | 62.70 ± 10.23 (401) | 0.0009 ¹ |
| Baseline Risk Factors, % (No./total) | | | | |
| All Diabetes | 31.9% (90/282) | 42.0% (50/119) | 34.9% (140/401) | 0.0663 ² |
| Diabetes Treated with Insulin | 7.4% (21/282) | 14.3% (17/119) | 9.5% (38/401) | 0.0400 ² |
| Current Tobacco Use | 19.1% (54/282) | 19.3% (23/119) | 19.2% (77/401) | 1.0000 ² |
| Hypertension Requiring Medication | 73.4% (207/282) | 84.0% (100/119) | 76.6% (307/401) | 0.0278 ² |
| Hypercholesterolemia Requiring Medication | 80.9% (228/282) | 79.0% (94/119) | 80.3% (322/401) | 0.6815 ² |
| Stable Angina | 44.0% (124/282) | 49.6% (59/119) | 45.6% (183/401) | 0.3244 ² |
| Unstable Angina | 25.2% (71/282) | 24.4% (29/119) | 24.9% (100/401) | 0.9001 ² |
| Prior MI | 25.0% (69/276) | 18.5% (22/119) | 23.0% (91/395) | 0.1927 ² |
| Target Vessel, % (No./total) | | | | |
| LAD | 44.1% (139/315) | 46.2% (61/132) | 44.7% (200/447) | 0.7545 ² |
| Circumflex or Ramus | 23.8% (75/315) | 25.8% (34/132) | 24.4% (109/447) | 0.7174 ² |
| RCA | 31.7% (100/315) | 28.0% (37/132) | 30.6% (137/447) | 0.5001 ² |
| LMCA | 0.0% (0/315) | 0.0% (0/132) | 0.0% (0/447) | NA |
| Pre-Procedure QCA Analysis, Mean ± SD (m) | | | | |
| Lesion Length (mm) | 13.91 ± 5.10 (315) | 13.06 ± 4.75 (132) | 13.66 ± 5.01 (447) | 0.0940 ¹ |
| Pre-Procedure RVD (mm) | 2.76 ± 0.48 (315) | 2.63 ± 0.45 (132) | 2.72 ± 0.48 (447) | 0.0067 ¹ |
| Pre-Procedure MLD (mm) | 0.82 ± 0.40 (315) | 0.81 ± 0.26 (132) | 0.81 ± 0.36 (447) | 0.7352 ¹ |
| Pre-Procedure Percent Diameter Stenosis (%DS) | 70.01 ± 12.87 (315) | 68.58 ± 8.53 (132) | 69.59 ± 11.76 (447) | 0.1676 ¹ |

*Subjects with Cardiac Enzyme Data in Window

¹ From T-test

² From Fisher's exact test

Note: All p-values displayed are two-tailed and not from formal hypothesis testing and are displayed for descriptive purposes only.

Note: N is the total number of subjects.

Note: M is the total number of target lesions.

²¹ Solinas E, Nikolsky E, Lansky AJ, et al. Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation. J Am Coll Cardiol 2007;50:2111–6

Note: This table contains only subjects with post-index procedure cardiac enzyme data in window (between 8 hours post-index procedure and hospital discharge).

Table 9.6.2-2: Demographics, Risk Factors, and Baseline Angiographic Characteristics for SPIRIT PRIME Long Lesion Registry Subjects*

| Subject / Lesion Characteristics | Male (N = 65) (M = 80) | Female (N = 39) (M = 44) | Total (N = 104) (M = 124) | p-value |
|--|------------------------------|--------------------------------|---------------------------------|---------------------|
| Baseline Demographics, Mean ± SD (n) | | | | |
| Age (year) | 63.64 ± 9.97 (65) | 63.15 ± 8.60 (39) | 63.46 ± 9.44 (104) | 0.7927 ¹ |
| Baseline Risk Factors, % (No./total) | | | | |
| All Diabetes | 32.3% (21/65) | 41.0% (16/39) | 35.6% (37/104) | 0.4027 ² |
| Diabetes Treated with Insulin | 9.2% (6/65) | 10.3% (4/39) | 9.6% (10/104) | 1.0000 ² |
| Current Tobacco Use | 26.2% (17/65) | 28.2% (11/39) | 26.9% (28/104) | 0.8232 ² |
| Hypertension Requiring Medication | 76.9% (50/65) | 71.8% (28/39) | 75.0% (78/104) | 0.6418 ² |
| Hypercholesterolemia Requiring Medication | 81.5% (53/65) | 79.5% (31/39) | 80.8% (84/104) | 0.8023 ² |
| Stable Angina | 43.1% (28/65) | 59.0% (23/39) | 49.0% (51/104) | 0.1563 ² |
| Unstable Angina | 27.7% (18/65) | 15.4% (6/39) | 23.1% (24/104) | 0.2289 ² |
| Prior MI | 25.0% (16/64) | 18.4% (7/38) | 22.5% (23/102) | 0.4753 ² |
| Target Vessel, % (No./total) | | | | |
| LAD | 41.3% (33/80) | 40.9% (18/44) | 41.1% (51/124) | 1.0000 ² |
| Circumflex or Ramus | 27.5% (22/80) | 18.2% (8/44) | 24.2% (30/124) | 0.2803 ² |
| RCA | 31.3% (25/80) | 40.9% (18/44) | 34.7% (43/124) | 0.3261 ² |
| LMCA | 0.0% (0/80) | 0.0% (0/44) | 0.0% (0/124) | NA |
| Pre-Procedure QCA Analysis, Mean ± SD (m) | | | | |
| Lesion Length (mm) | 26.62 ± 7.89 (80) | 25.17 ± 6.83 (44) | 26.10 ± 7.53 (124) | 0.2872 ¹ |
| Pre-Procedure RVD (mm) | 2.80 ± 0.46 (80) | 2.66 ± 0.40 (44) | 2.75 ± 0.44 (124) | 0.0864 ¹ |
| Pre-Procedure MLD (mm) | 0.75 ± 0.28 (80) | 0.79 ± 0.31 (44) | 0.77 ± 0.29 (124) | 0.5067 ¹ |
| Pre-Procedure Percent Diameter Stenosis (%DS) | 72.05 ± 8.74 (80) | 68.76 ± 9.60 (44) | 70.88 ± 9.15 (124) | 0.0632 ¹ |

*Subjects with Cardiac Enzyme Data in Window

¹ From T-test

² From Fisher's exact test

Note: All p-values displayed are two-tailed and not from formal hypothesis testing and are displayed for descriptive purposes only.

Note: N is the total number of subjects.

Note: M is the total number of target lesions.

Note: This table contains only subjects with post-index procedure cardiac enzyme data in window (between 8 hours post-index procedure and hospital discharge).

A post-hoc analysis was conducted on the composite primary safety and effectiveness endpoint of TLF, per protocol and per ARC, to assess for heterogeneity of treatment effect across sex / gender (using Fisher's Exact Test). Table 9.6.2-3 and Table 9.6.2-4 present the 3-year clinical results for the Core Size Registry and Long Lesion Registry, respectively. Due to the modest sample size (Core Size Registry 282 males vs. 119 females and Long Lesion Registry 65 males vs. 39 females), these analyses and interpretation are limited.

Table 9.6.2-3: Clinical Results for All Female and All Male Subgroups in the SPIRIT PRIME Core Size Registry through 3 Years*

| SPIRIT PRIME | Male (N = 282) | Female (N = 119) | Total (N = 401) | p-value ¹ |
|--|-------------------|---------------------|--------------------|----------------------|
| All Death | 4.0% (11/274) | 0.9% (1/116) | 3.1% (12/390) | 0.1192 |
| Cardiac Death | 1.1% (3/274) | 0.0% (0/116) | 0.8% (3/390) | 0.5578 |
| Non-Cardiac Death | 2.6% (7/274) | 0.0% (0/116) | 1.8% (7/390) | 0.1091 |
| Target Vessel MI per Protocol | 2.9% (8/274) | 1.7% (2/116) | 2.6% (10/390) | 0.7297 |
| Cardiac Death or Target Vessel MI per Protocol | 4.0% (11/274) | 1.7% (2/116) | 3.3% (13/390) | 0.3599 |
| Target Vessel MI per ARC | 5.5% (15/274) | 7.8% (9/116) | 6.2% (24/390) | 0.4891 |
| Cardiac Death or Target Vessel MI per ARC | 6.6% (18/274) | 7.8% (9/116) | 6.9% (27/390) | 0.6666 |
| Major Bleeding Complication | 4.5% (12/265) | 1.7% (2/115) | 3.7% (14/380) | 0.2439 |
| Stent Thrombosis | | | | |
| Protocol defined | 1.5% (4/263) | 0.0% (0/115) | 1.1% (4/378) | 0.3185 |
| ARC definite + probable | 1.1% (3/265) | 0.0% (0/115) | 0.8% (3/380) | 0.5566 |
| TLF | | | | |
| per Protocol | 9.1% (25/274) | 6.9% (8/116) | 8.5% (33/390) | 0.5540 |
| per ARC | 10.2% (28/274) | 12.1% (14/116) | 10.8% (42/390) | 0.5948 |
| Ischemia-Driven TLR | 5.5% (15/274) | 5.2% (6/116) | 5.4% (21/390) | 1.0000 |
| Ischemia-Driven TVR, non TL | 5.8% (16/274) | 6.0% (7/116) | 5.9% (23/390) | 1.0000 |

*Subjects with Cardiac Enzyme Data in Window

¹ From Fisher's exact test

Note: All p-values displayed are two-tailed and not from formal hypothesis testing and are displayed for descriptive purposes only.

Note: Subjects are only counted once for each type of event in each time period.

Note: N is the total number of subjects.

Note: This table contains only subjects with post-index procedure cardiac enzyme data in window (between 8 hours post-index procedure and hospital discharge).

Table 9.6.2-4: Clinical Results for All Female and All Male Subgroups in the SPIRIT PRIME Long Lesion Registry through 3 Years^{1*}

| SPIRIT PRIME | Male (N = 65) | Female (N = 39) | Total (N = 104) | p-value ¹ |
|--|------------------|--------------------|--------------------|----------------------|
| All Death | 3.1% (2/65) | 2.6% (1/39) | 2.9% (3/104) | 1.0000 |
| Cardiac Death | 0.0% (0/65) | 0.0% (0/39) | 0.0% (0/104) | NA |
| Non-Cardiac Death | 3.1% (2/65) | 2.6% (1/39) | 2.9% (3/104) | 1.0000 |
| Target Vessel MI per Protocol | 4.6% (3/65) | 5.1% (2/39) | 4.8% (5/104) | 1.0000 |
| Cardiac Death or Target Vessel MI per Protocol | 4.6% (3/65) | 5.1% (2/39) | 4.8% (5/104) | 1.0000 |
| Target Vessel MI per ARC | 13.8% (9/65) | 5.1% (2/39) | 10.6% (11/104) | 0.2024 |
| Cardiac Death or Target Vessel MI per ARC | 13.8% (9/65) | 5.1% (2/39) | 10.6% (11/104) | 0.2024 |
| Major Bleeding Complication | 3.2% (2/62) | 2.7% (1/37) | 3.0% (3/99) | 1.0000 |
| Stent Thrombosis | | | | |
| Protocol defined | 0.0% (0/62) | 0.0% (0/37) | 0.0% (0/99) | NA |
| ARC definite + probable | 0.0% (0/62) | 0.0% (0/37) | 0.0% (0/99) | NA |
| TLF | | | | |
| per Protocol | 10.8% (7/65) | 7.7% (3/39) | 9.6% (10/104) | 0.7397 |
| per ARC | 18.5% (12/65) | 7.7% (3/39) | 14.4% (15/104) | 0.1585 |
| Ischemia-Driven TLR | 6.2% (4/65) | 2.6% (1/39) | 4.8% (5/104) | 0.6480 |
| Ischemia-Driven TVR, non TL | 7.7% (5/65) | 2.6% (1/39) | 5.8% (6/104) | 0.4063 |

*Subjects with Cardiac Enzyme Data in Window

¹ From Fisher's exact test

Note: All p-values displayed are two-tailed and not from formal hypothesis testing and are displayed for descriptive purposes only.

Note: Subjects are only counted once for each type of event in each time period.

Note: N is the total number of subjects.

Note: This table contains only subjects with post-index procedure cardiac enzyme data in window (between 8 hours post-index procedure and hospital discharge).

9.6.3 Gender-Based Analysis in the SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Clinical Trials

To evaluate gender-specific clinical outcomes with the XIENCE V stent, Abbott Vascular conducted a pooled analysis of SPIRIT II, SPIRIT III RCT, and SPIRIT IV. The pooled SPIRIT trial data were assessed for differences between males and females in baseline characteristics and study outcomes, as well as for any interaction between treatment and gender. Results suggest that the general conclusions of safety and effectiveness of the XIENCE V stent can be generalized for males and females.

In the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV intent-to-treat population, 1584 subjects were female (32%) and 3404 subjects were male (68%). The gender proportions enrolled in this trial are similar to other drug-eluting stent trials.^{22, 23}

Of the 1584 female subjects in the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV population, 1058 were XIENCE V subjects and 526 were TAXUS subjects.

Table 9.6.3-1 describes the demographics, risk factors, and baseline angiographic characteristics of all female and all male subgroups of the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV population.

Table 9.6.3-1: Demographics, Risk Factors, and Baseline Angiographic Characteristics for the All-Female and All-Male Subgroups (Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Population)

| Subject Characteristics | All Females (N = 1584; 32%) (M = 1901) | All Males (N = 3404; 68%) (M = 4332) | p-value ¹ |
|--|--|--|----------------------|
| Baseline Demographics, Mean ± SD (n) | | | |
| Age (year) | 65.7 ± 10.5 (1584) | 62.0 ± 10.2 (3404) | < 0.0001 |
| Baseline Risk Factors, % (No./total) | | | |
| All Diabetes | 35.9% (569/1583) | 28.7% (975/3398) | < 0.0001 |
| Diabetes Treated with Insulin | 12.1% (192/1583) | 6.5% (222/3398) | < 0.0001 |
| Current Tobacco Use | 21.7% (337/1550) | 23.2% (772/3321) | 0.2555 |
| Hypertension Requiring Medication | 80.7% (1278/1584) | 73.9% (2511/3398) | < 0.0001 |
| Hypercholesterolemia Requiring Medication | 73.2% (1143/1562) | 75.9% (2537/3341) | 0.0399 |
| Stable Angina | 57.2% (889/1554) | 57.7% (1933/3348) | 0.7327 |
| Unstable Angina | 29.1% (452/1554) | 25.5% (854/3348) | 0.0092 |
| Prior MI | 15.8% (245/1551) | 23.6% (783/3316) | < 0.0001 |
| Target Vessel, % (No./total) | | | |
| LAD | 43.1% (820/1901) | 39.6% (1712/4327) | 0.0085 |
| Circumflex or Ramus | 21.9% (416/1901) | 26.8% (1159/4327) | < 0.0001 |
| RCA | 35.0% (665/1901) | 33.6% (1454/4327) | 0.2959 |
| LMCA | 0.0% (0/1901) | 0.0% (2/4327) | 1.0000 |
| Pre-Procedure QCA Analysis, Mean ± SD (m) | | | |
| Lesion Length (mm) | 14.22 ± 6.25 (1888) | 14.79 ± 6.51 (4293) | 0.0012 |
| Pre-Procedure RVD (mm) | 2.66 ± 0.44 (1894) | 2.79 ± 0.48 (4303) | < 0.0001 |
| Pre-Procedure MLD (mm) | 0.79 ± 0.38 (1899) | 0.78 ± 0.40 (4310) | 0.2207 |
| Pre-Procedure Percent Diameter Stenosis (%DS) | 69.92 ± 12.84 (1899) | 71.58 ± 13.05 (4310) | < 0.0001 |

N is the total number of subjects; M is the total number of lesions analyzed.

¹ p-values are displayed for descriptive purposes only.

²² Lansky AJ, Costa RA, Mooney M, et al. Gender-Based Outcomes After Paclitaxel-Eluting Stent Implantation in Patients With Coronary Artery Disease. *J Am Coll Cardiol* 2005 45: 1180-5.

²³ Solinas E, Nikolsky E, Lansky AJ, et al. Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation. *J Am Coll Cardiol* 2007;50:2111-6

Table 9.6.3-1 shows that females in the SPIRIT family of trials were older and had higher rates of diabetes, hypertension, and unstable angina compared with males. The generally higher clinical risk profile in females is consistent with gender differences in baseline demographics reported from other PCI studies.^{24, 25, 26, 27, 28, 29, 30}

Table 9.6.3-2 presents key clinical outcomes through 3 years in female and male subjects from the SPIRIT IV trial and the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV population. In post-hoc analyses of the pooled SPIRIT II, SPIRIT III RCT and SPIRIT IV population, rates of death, target vessel MI and stent thrombosis through 3 years were comparable between females and males. At 3 years, post-hoc analyses of the SPIRIT IV trial suggest that females treated with XIENCE V stents (despite generally increased clinical risk factors at baseline) had numerically similar adverse event rates compared to males treated with XIENCE V stents. Comparisons of study outcomes in patients receiving the XIENCE V stent versus the TAXUS stent were consistent within each gender subgroup. Based on the interaction p-value calculated from Wald Chi-square statistics of logistic regression analysis, no significant treatment-by-gender interaction effect was observed at a 0.15 significance level. These analyses suggest that the conclusions regarding safety and effectiveness of the XIENCE V stent are generalizable to both males and females. However, it should be noted that there were no pre-specified hypotheses for the use of the XIENCE V stent in females.

²⁴ Correa-De-Araujo R. Serious gaps: how lack of sex/gender- based research impairs health. *J Womens Health (Larchmt)* 2006; 15(10):1116-22.

²⁵ Abbott JD, Vlachos HA, Selzer F, Sharaf BL, Holper E, Glaser R et al. Gender-based outcomes in percutaneous coronary intervention with drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry). *Am J Cardiol* 2007; 99(5):626-31.

²⁶ Akhter N, Milford-Beland S, Roe MT, Piana RN, Kao J, Shroff A. Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). *Am Heart J* 2009; 157(1):141-8.

²⁷ Vaina S, Voudris V, Morice M-C, de Bruyne B, Colombo A, Macaya C, Richardt, G, Fajadet, J et al. Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularization in patients with multivessel coronary artery disease: Insights from ARTS I and ARTS II. *EuroInterv.* 2009; 4(4):492-501.

²⁸ Blomkalns AI, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. *J Am Coll Cardiol* 2005; 45(6):832-7.

²⁹ Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, et al. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigations to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation* 2005; 111(13):1611-8.

³⁰ Lansky AJ, Costa RA, Mooney M, Midei MG, Lui HK, Strickland W, et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. *J Am Coll Cardiol* 2005; 45 (8):1180-5.

Table 9.6.3-2: Clinical Results in XIENCE V Females, XIENCE V Males and All Subjects through 3 Years (SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Population)

| Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV | 1 Year | | | | 3 Years | | | |
|---|--------------------|------------------|---------------------|------------------|--------------------|------------------|---------------------|------------------|
| | XIENCE V | | All Subjects | | XIENCE V | | All Subjects | |
| | Females (N = 1058) | Males (N = 2292) | XIENCE V (N = 3350) | TAXUS (N = 1639) | Females (N = 1057) | Males (N = 2293) | XIENCE V (N = 3350) | TAXUS (N = 1639) |
| All Death | 1.2% (12/1038) | 1.1% (24/2257) | 1.1% (36/3295) | 1.4% (22/1592) | 3.0% (30/993) | 3.6% (79/2191) | 3.4% (109/3184) | 5.3% (81/1541) |
| Cardiac Death | 0.5% (5/1038) | 0.4% (10/2257) | 0.5% (15/3295) | 0.6% (9/1592) | 1.2% (12/993) | 1.5% (33/2191) | 1.4% (45/3184) | 2.0% (31/1541) |
| Non-Cardiac Death | 0.7% (7/1038) | 0.6% (14/2257) | 0.6% (21/3295) | 0.8% (13/1592) | 1.8% (18/993) | 2.1% (46/2191) | 2.0% (64/3184) | 3.2% (50/1541) |
| Target Vessel MI | 1.9% (20/1038) | 1.8% (40/2257) | 1.8% (60/3295) | 3.1% (49/1592) | 2.7% (27/993) | 2.9% (64/2191) | 2.9% (91/3184) | 4.4% (68/1541) |
| Cardiac Death or Target Vessel MI | 2.4% (25/1038) | 2.1% (48/2257) | 2.2% (73/3295) | 3.4% (54/1592) | 3.9% (39/993) | 4.2% (93/2191) | 4.1% (132/3184) | 5.8% (90/1541) |
| Bleeding Complication | 4.5% (46/1029) | 2.5% (56/2232) | 3.1% (102/3261) | 3.3% (52/1573) | 8.3% (80/967) | 4.7% (100/2119) | 5.8% (180/3086) | 6.6% (97/1474) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.4% (4/1028) | 0.3% (6/2230) | 0.3% (10/3258) | 0.8% (13/1574) | 0.7% (7/963) | 1.0% (21/2108) | 0.9% (28/3071) | 2.0% (30/1471) |
| ARC Definite+Probable | 0.4% (4/1028) | 0.4% (9/2233) | 0.4% (13/3261) | 1.0% (16/1574) | 0.5% (5/961) | 0.9% (19/2108) | 0.8% (24/3069) | 1.8% (26/1463) |
| ARC Definite | 0.4% (4/1026) | 0.3% (7/2229) | 0.3% (11/3255) | 0.8% (12/1577) | 0.4% (4/961) | 0.7% (14/2108) | 0.6% (18/3069) | 1.2% (18/1463) |
| TLF | 4.0% (31/777) | 4.0% (66/1639) | 4.0% (97/2416) | 6.8% (81/1195) | 9.3% (69/745) | 9.6% (154/1603) | 9.5% (223/2348) | 11.9% (138/1158) |
| Ischemia-Driven TLR | 2.2% (17/777) | 2.4% (39/1639) | 2.3% (56/2416) | 4.6% (55/1195) | 5.8% (43/745) | 6.6% (105/1603) | 6.3% (148/2348) | 7.9% (92/1158) |
| Ischemia-Driven TVR, Non TL | 2.7% (21/777) | 2.0% (33/1639) | 2.2% (54/2416) | 2.4% (29/1195) | 5.6% (42/745) | 5.6% (90/1603) | 5.6% (132/2348) | 5.4% (63/1158) |

Notes:

- One subject in SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 1-year and 3-year time frames include follow-up window (365 ± 28 days and 1095 ± 28 days, respectively).
- TLF is defined as a hierarchical composite of cardiac death, Target Vessel MI (per protocol definition), and ischemia-driven TLR.

9.7 XIENCE V USA Post-Approval Study

Objective: The objectives of the XIENCE V USA post-approval study were: (1) to evaluate the continued safety and effectiveness of the XIENCE V EECSS during commercial use in real-world settings; (2) to support the Food and Drug Administration's (FDA) dual antiplatelet therapy (DAPT) initiative.

Design: The XIENCE V USA study was a prospective, multicenter, FDA-mandated post-approval study with 3 cohorts: phase I (from index procedure to 1 year), long-term follow-up cohort of phase II (from 1 year to 4 years), and AV-DAPT cohort of phase II (from 1 year to 33 months). Patients were considered as enrolled upon signing the Institutional Review Board (IRB)-approved informed consent form (ICF) and only XIENCE V EECSS was (were) implanted during the index procedure. There were no angiographic inclusion and exclusion criteria for this study. A total of 8,040 patients were consecutively enrolled from 191 sites in U.S. from two enrollment phases (5,042 patients from the first enrollment phase and 2,998 patients from the second enrollment phase). Phase I cohort consisted of all the 8,040 enrolled patients. Clinical follow-up occurred at 14, 30, 180 days, and 1 year. The long-term follow-up cohort of phase II consisted of 4,663 patients from the first enrollment phase who were not transferred to the HCRI- DAPT study (IDE#G080186) and remained in the study beyond 1 year. Clinical follow-up occurred at 2, 3, and years. For phase I and the long-term follow-up cohort, the primary endpoint was the annual rate of ARC-defined stent thrombosis (definite and probable), and the co-primary endpoint was the annual composite rate of cardiac death or any MI. For phase I, the primary hypothesis for the co-primary endpoint of cardiac death or MI from 0-1 year is based on a comparison of the near on-label patients from the second enrollment stage of XIENCE V USA who had cardiac markers drawn between 12 – 24 hours post procedure to the population of SPIRIT III and SPIRIT III-like patients in SPIRIT IV treated with XIENCE V (with a non-inferiority margin of 3%). For the long-term follow-up cohort, the four yearly annual rates of ARC-defined definite and probable stent thrombosis will be simultaneously evaluated against a performance goal of 1.5%. The AV-DAPT cohort of phase II consisted of 868 patients from the second enrollment phase who were eligible and got randomized at 12 months post-index procedure to either DAPT or placebo for an additional 18 months thienopyridine treatment (from 12 to 30 months). Clinical follow-up and endpoints for the AV-DAPT cohort are the same as the HCRI-DAPT study (IDE#G080186). All clinical endpoint events were adjudicated by an independent CEC.

Results: Phase I of the study has been completed in the entire population. A total of 8,040 patients with 11,137 lesions were treated with a total of 12,873 XIENCE V stents during the index procedure. There were 39% near on-label patients and 61% non near on-label patients. The non near on-label cohort includes patients with any of the following: baseline lesion length > 28 mm, reference vessel diameter < 2.5 mm or > 4.25 mm, restenosis, chronic total occlusion, graft lesion, bifurcation with side branch \geq 2 mm, ostial, left main, more than 2 lesions stented in the same vessel, more than 2 vessels treated, acute MI, renal insufficiency, ejection fraction < 30%, or staged procedure. Patients who do not meet the above criteria are classified as the "near on-label" cohort. Baseline characteristics (Table 9.7-1) and key endpoint results through 4 years were summarized below (Table 9.7-2 and Table 9.7-3). The 4-year follow-up rate for the XIENCE V USA clinical trial was 87.7% (4,405/5,020).

The 1-year primary endpoint of ARC definite and probable ST rate was 0.81%. The 1-year co-primary endpoint of the composite cardiac death or MI rate was 7.2%. The primary analysis for the co-primary endpoint was summarized in Table 9.7-2. The difference in cardiac death or MI rate between XIENCE V USA and SPIRIT study was 0.01% with the 95% upper confidence limit being 1.74%, which was less than the quasi non-inferiority margin of 3% ($P_{NI} = 0.0022$).

Table 9.7-1: XIENCE V USA Baseline Characteristics

| Analysis population: 8040 patients, 11,137 lesions, 12,873 stents | | | |
|---|----------------------|-------------------------------|---------------------|
| Patient Demographics | | Procedural Characteristics | |
| Male | 69.6% (5599/8040) | Vessels Treated | |
| Age (year) | 64.58 ± 10.82 (8040) | 1 | 86.3% (6564/7609) |
| All Diabetes Mellitus | 35.8% (2856/7969) | 2 | 13.1% (998/7609) |
| Oral Hypoglycemics Treated | 23.6% (1879/7969) | ≥ 3 | 0.6% (47/7609) |
| Insulin Treated | 12.3% (979/7969) | Target Vessels | |
| Multivessel Disease | 39.8% (3202/8040) | RCA | 32.8% (3656/11136) |
| Prior MI | 29.7% (2212/7440) | LAD | 37.5% (4173/11136) |
| Prior PCI | 39.1% (3065/7836) | LCX | 23.5% (2617/11136) |
| Prior CABG | 16.4% (1289/7836) | LMCA | 1.6% (182/11136) |
| Unstable Angina | 28.7% (2188/7612) | Graft | 4.6% (508/11136) |
| AMI | 14.7% (1054/7146) | Lesions Treated | |
| Renal Insufficiency | 10.5% (840/8015) | 1 | 70.0% (5627/8040) |
| Lesion Characteristics | | 2 | 23.2% (1868/8040) |
| Reference Vessel Diameter (mm) | 3.02 ± 0.53 (10707) | ≥ 3 | 6.8% (545/8040) |
| Lesion Length (mm) | 15.8 ± 9.4 (10642) | Stenting | |
| Lesion Type | | Direct stenting (per lesion) | 36.8% (4096/11126) |
| A | 17.7% (1643/9273) | Stents implanted per patient | 1.6 ± 0.9 (8040) |
| B1 | 32.4% (3002/9273) | Patients with > 1 stent | 40.8% (3280/8040) |
| B2 | 25.8% (2390/9273) | Stent length per patient (mm) | 29.2 ± 19.1 (8039) |
| C | 24.1% (2238/9273) | Stent length per lesion (mm) | 21.2 ± 11.3 (11093) |
| Restenosis Lesion | 8.7% (972/11134) | | |
| Bifurcation Lesion | 9.7% (1084/11120) | | |
| Ostial Lesion | 11.2% (1176/10456) | | |
| Patient Categorization | | | |
| Near On-label | 39.0% (3132/8040) | | |
| Non Near On-label ¹ | 61.0% (4908/8040) | | |
| Lesion length > 28 mm | 12.5% (613/4908) | > 2 lesions in same vessel | 4.6% (227/4908) |
| Reference vessel diameter < 2.5 mm | 5.3% (258/4908) | > 2 vessels treated | 1.0% (47/4908) |
| Reference vessel diameter > 4.25 mm | 2.0% (97/4908) | AMI | 21.5% (1054/4908) |
| Chronic total occlusion | 3.7% (184/4908) | Renal insufficiency | 17.1% (840/4908) |
| Graft lesion | 8.8% (431/4908) | LVEF < 30% | 4.1% (200/4908) |
| Bifurcation with side branch ≥ 2 mm | 15.2% (746/4908) | With staged procedure | 8.9% (439/4908) |
| Ostial lesion | 22.5% (1103/4908) | | |
| Left main | 3.6% (179/4908) | | |
| Restenosis lesion | 17.3% (847/4908) | | |

Note: Numbers presented here are % (n/N) or mean ± SD.

¹ A patient can be counted in more than 1 category of the non near on-label criteria.

Table 9.7-2: XIENCE V USA Primary Analysis of the 1-Year Co-Primary Endpoint

| | XIENCE V USA (N = 997) | SPIRIT III and IV (N = 2720) | Difference (Upper One-Sided 95% CI) | Non-inferiority p-value |
|-----------------------------|---------------------------|---------------------------------|---|----------------------------|
| 1 Year Cardiac Death and MI | 6.2% (55/881) | 6.2% (166/2663) | 0.01% (1.74%) | 0.0022 |

Notes:

- N is the total number of patients.
- The 1-year window is through 407 days (or randomization date if occurred within 407 days for the second enrollment phase) for XIENCE V USA, and 393 days for SPIRIT III and IV.
- The XIENCE V USA arm includes near on-label patients from the second enrollment phase who had cardiac enzyme collected between 12 and 24 hours post-index procedure.
- The SPIRIT study arm includes XIENCE V patients in SPIRIT III and SPIRIT III-like XIENCE V patients in SPIRIT IV.
- One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 3% at 0.05 significance level.

Table 9.7-3: XIENCE V USA Clinical Outcomes at 1 and 4 Years

| | XIENCE V USA Overall Population at 1 Year (N = 8040) | XIENCE V USA Long-Term Follow-up Cohort at 4 Years (N = 5020) |
|--|--|--|
| COMPOSITE EFFICACY & SAFETY | | |
| TLF (WHO MI Definition) | 6.9% (514/7491) | 16.5% (747/4518) |
| TLF (ARC) | 9.4% (707/7522) | 19.3% (875/4530) |
| EFFICACY (Non-Hierarchical Subject Counts) | | |
| Clinically- indicated TLR | 4.4% (330/7522) | 10.4% (473/4530) |
| Clinically-indicated TLR, CABG | 0.8% (57/7522) | 2.0% (91/4530) |
| Clinically-indicated TLR, PCI | 4.0% (301/7522) | 8.9% (402/4530) |
| Clinically- indicated TVR, nonTLR | 2.1% (161/7522) | 6.1% (277/4530) |
| SAFETY (Non-Hierarchical Subject Counts) | | |
| All Death | 2.6% (194/7522) | 10.9% (494/4530) |
| Cardiac Death | 1.4% (108/7522) | 5.4% (244/4530) |
| Vascular Death | 0.2% (12/7522) | 0.7% (32/4530) |
| Non-Cardiovascular Death | 1.0% (74/7522) | 4.8% (218/4530) |
| Target Vessel MI (WHO) | 1.9% (140/7491) | 3.5% (157/4518) |
| Target Vessel MI (ARC) | 5.5% (415/7522) | 8.7% (396/4530) |
| All MI (WHO) | 2.2% (162/7491) | 4.8% (215/4518) |
| QMI | 0.5% (39/7491) | 1.5% (68/4518) |
| NQMI | 1.7% (126/7491) | 3.4% (152/4518) |
| All MI (ARC) | 6.3% (475/7522) | 11.3% (511/4530) |
| QMI | 0.5% (39/7522) | 1.5% (68/4530) |
| NQMI | 5.9% (442/7522) | 10.1% (457/4530) |
| COMPOSITE SAFETY | | |
| Cardiac Death or Target Vessel MI (WHO) | 3.1% (231/7491) | 8.0% (361/4518) |
| Cardiac Death or Target Vessel MI (ARC) | 6.5% (491/7522) | 12.6% (571/4530) |
| Cardiac Death or MI (WHO) | 3.3% (250/7491) | 9.1% (412/4518) |
| Cardiac Death or MI (ARC) | 7.2% (545/7522) | 14.9% (676/4530) |
| STENT THROMBOSIS (ARC-Defined Definite/ / Probable) | | |
| Cumulative through 1 year | 0.81% (60/7380) | - |
| Acute/ / Subacute (0 – 30 days) | 0.40% (32/7951) | - |
| Late (31 – 365 days) | 0.37% (27/7364) | - |
| Very Late (366 – 1502 days) | - | 0.55% (22/4032) |

| | XIENCE V USA Overall Population at 1 Year (N = 8040) | XIENCE V USA Long-Term Follow-up Cohort at 4 Years (N = 5020) |
|--|--|--|
| Cumulative through 4 years | - | 1.56% (64/4093) |
| STENT THROMBOSIS (ARC-Defined Definite) | | |
| Cumulative through 1 year | 0.54% (40/7380) | - |
| Acute/ / Subacute (0 – 30 days) | 0.23% (18/7951) | - |
| Late (31 – 365 days) | 0.29% (21/7364) | - |
| Very Late (366 – 1502 days) | - | 0.42% (17/4032) |
| Cumulative through 4 years | - | 1.05% (43/4093) |

Notes:

- N is the total number of patients.
- The 1-year window is through 407 days (or randomization date if occurred within 407 days for the second enrollment phase of XIENCE V USA). The 4-year window is through 1502 days.)
- Per ARC definition was used for MI and MI related endpoints.
- TLF is defined as hierarchical composite of cardiac death, target vessel MI (per ARC definition), and clinically indicated TLR.

Study Strengths and Limitations: The XIENCE V USA study was a prospective, open-label, multicenter, post-approval study. All event adjudications were performed by an independent event committee with 100% site-reported adjudicable events being source-verified. With a large sample size and high data quality, the study provides important information on the clinical outcomes in a real-world population beyond those from selected patients in randomized pre-approval studies. However, the study is limited by being observational in nature, and therefore a head-to-head comparison with other DES platforms was not possible. In addition, the monitoring level is less rigorous than a randomized pivotal trial. However, the consistent results between XIENCE V USA near on-label population and the XIENCE V arm in SPIRIT III and IV trials suggests that the quality measures taken in XIENCE V USA study as described above produced high quality data. Therefore, this study affords a reliable benchmark for understanding the safety of XIENCE V EECSS in the context of real-world clinical practice.

9.7.1 Analysis of Patients with 4.0 mm Stent

There were 186 near on-label patients with at least one XIENCE V 4.0 mm stent implanted during the index procedure. A pre-specified descriptive comparison of 1-year TLR is summarized in Table 9.7.1-1.

Table 9.7.1-1: XIENCE V USA Patients with 4.0 mm Stent

| | XIENCE V USA (N = 186) | SPIRIT III and IV (N = 74) |
|------------|---------------------------|-------------------------------|
| 1-Year TLR | 3.4% (6/177) | 2.7% (2/74) |

Notes:

- N is the total number of patients.
- The 1-year window is through 407 days (or randomization date if occurred within 407 days for the second enrollment phase) for XIENCE V USA, and 393 days for SPIRIT III and IV.
- The XIENCE V USA arm includes near on-label patients who had at least a 4.0 mm XIENCE V stent implanted during the index procedure.
- The SPIRIT study arm includes XIENCE V patients in SPIRIT III 4.0 mm registry and SPIRIT III-like XIENCE V patients in SPIRIT IV who were treated with at least a 4.0 mm XIENCE V stent.

9.7.2 Analysis of Patients Treated with Direct Stenting

There were two pre-specified hypothesis tests on direct stenting. The results of both tests were summarized in Table 9.7.2-1. One-year TLF rate of XIENCE V USA patients who had a single lesion treated with direct stenting in real-world settings was non-inferior to the event rate of SPIRIT III-like XIENCE V patients in SPIRIT IV who had a single lesion treated with pre-dilatation ($P_{NI} = 0.0119$). In XIENCE V USA, one-year TLF rate in patients who had a single lesion treated with direct stenting was non-inferior to the event rate of those who had a single lesion treated with pre-dilatation ($P_{NI} < 0.0001$).

In these two analyses, there was, as expected, some degree of selection bias with lesions undergoing direct-stenting displaying lower complexity than lesions undergoing pre-dilatation. For hypothesis 1, there were more patients who had prior cardiac intervention and history of MI in XIENCE V USA direct stenting group, but there were more B2/C lesions and more multiple stents implanted in the SPIRIT IV pre-dilatation group. The propensity score approach was utilized to address this selection bias. A logistic regression was fit to obtain the propensity score for direct stenting, which was defined as the probability of having direct stenting given specific values for the following variables: age, sex, current smoker, diabetes treated, hypertension requiring medication, lipid disorder requiring medication, prior CABG, prior PCI, CCS III or IV stable angina, prior MI, prior brachytherapy, multivessel disease, LAD, heavy calcification, baseline DS%, TIMI, lesion length ≥ 22 mm, B2/C lesion, and multiple stents per lesion. Then patients were divided into 5 strata with approximately equal size based on the rank of their propensity scores. A stratified non-inferiority test was finally performed. For hypothesis 2, the XIENCE V USA direct stenting group had less B2/C lesion, less bifurcations, and fewer patients with multiple stents implanted than the predilatation group. For hypothesis 2, the propensity analysis method was the same as hypothesis 1, except that some additional variables were added such as AMI, renal insufficiency, LVEF $< 30\%$, left main, graft, restenotic lesion, bifurcation, ostial lesion, and history of stroke, which were not included in the propensity model of hypothesis 1 because these patients were either excluded in SPIRIT IV or data were not collected in SPIRIT IV. The propensity analysis results for both hypothesis 1 and hypothesis 2 indicated that adjustment for baseline differences in lesion characteristics did not change the findings of non-inferiority of direct stenting to pre-dilatation in either analysis (Table 9.7.2-1).

Table 9.7.2-1: XIENCE V USA Direct Stenting Results

| Analysis 1 | XIENCE V USA Direct Stenting (N = 506) | SPIRIT IV Pre-dilatation (N = 1726) | Difference (Upper One-Sided 95% CI) | Non-inferiority p-value |
|---|--|---|--|--------------------------------|
| 1-Year TLF | 7.7% (34/440) | 7.4% (124/1687) | 0.38% (3.01%) | 0.0119 |
| 1-Year TLF (Propensity Score Analysis) | 7.7% (34/440) | 7.4% (124/1687) | -0.09% (2.70%) | 0.0079 |
| Hierarchical TLF Components | | | | |
| Cardiac Death | 0.7% (3/440) | 0.4% (6/1687) | NA | NA |
| Target Vessel MI | 4.5% (20/440) | 5.7% (97/1687) | NA | NA |
| Clinically indicated TLR | 2.5% (11/440) | 1.2% (21/1687) | NA | NA |
| 1-Year Stent Thrombosis (ARC definite / probable) | 0.23% (1/430) | 0.18% (3/1675) | NA | NA |
| 1-Year Stent Thrombosis (ARC definite) | 0.23% (1/430) | 0.18% (3/1675) | NA | NA |
| Analysis 2 | XIENCE V USA Direct Stenting (N = 1947) | XIENCE V USA Pre-dilatation (N = 3405) | Difference (Upper One-Sided 95% CI) | Non-inferiority p-value |
| 1-Year TLF | 6.8% (124/1817) | 7.9% (252/3182) | -1.10% (0.23%) | < 0.0001 |
| 1-Year TLF (Propensity Score Analysis) | 6.8% (124/1817) | 7.9% (252/3182) | -0.60% (0.75%) | 0.0008 |
| Hierarchical TLF Components | | | | |
| Cardiac Death | 1.3% (24/1817) | 1.3% (40/3182) | NA | NA |
| Target Vessel MI | 3.3% (60/1817) | 4.5% (142/3182) | NA | NA |
| Clinically indicated TLR | 2.2% (40/1817) | 2.2% (70/3182) | NA | NA |
| 1-Year Stent Thrombosis (ARC definite / probable) | 0.56% (10/1786) | 0.51% (16/3118) | NA | NA |
| 1-Year Stent Thrombosis (ARC definite) | 0.28% (5/1786) | 0.35% (11/3118) | NA | NA |

Notes:

- N is the total number of patients.
- The 1-year window is through 407 days (or randomization date if occurred within 407 days for the second enrollment phase) for XIENCE V USA, and 393 days for SPIRIT IV study.
- In Analysis 1, the XIENCE V USA direct stenting arm included patients from the second enrollment phases who had cardiac enzyme collected between 12 and 24 hours post procedure and only 1 lesion treated during index procedure and the lesion was treated with direct stenting. Patients with staged procedure (s) were excluded. The SPIRIT IV pre-dilatation arm included SPIRIT III-like XIENCE V patients in SPIRIT IV who had only 1 lesion treated. All SPIRIT IV patients were considered to have pre-dilatation done for lesions treated during index procedure per protocol requirement. One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 4% at 0.05 significance level.
- In Analysis 2, the XIENCE V USA direct stenting arm included all patients who had only 1 lesion treated and the lesion was treated with direct stenting from both enrollment phases of XIENCE V USA. The XIENCE V USA pre-dilatation arm included all patients who had only 1 lesion treated and the lesion was treated with pre-dilatation from both enrollment phases of XIENCE V USA. Patients with staged procedure(s) were excluded. One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 2% at 0.05 significance level.
- TLF included cardiac death, target vessel MI (per ARC definition) and clinically indicated TLR. In SPIRIT IV, ischemic-driven TLR was used rather than clinically indicated. The two definitions are similar but differ in regards to clinically indicated TLR requiring that there is ≥ 50% diameter stenosis and the presence of clinical symptoms. Ischemic-driven TLR does not always require angiographic evidence of ≥ 50% diameter stenosis; revascularization due to a positive functional ischemia study alone qualifies as ischemic-driven.

9.7.3 Pre-specified XIENCE V USA Subgroup Analysis

Elderly (age \geq 65 years), female, insulin-treated diabetic, acute MI (STEMI and NSTEMI combined) patients and patients with multivessel disease and two vessels stented are at increased risk for cardiovascular morbidity and mortality. In addition, patients with complex lesion characteristics, such as long lesions (\geq 20 mm), bifurcation lesions, ostial lesions and in-stent restenotic lesion are also associated with worse clinical outcomes. In XIENCE V USA, the above-mentioned subgroups were pre-specified for descriptive analysis to assess the safety and effectiveness of those high-risk patients. There were no pre-specified hypotheses for those subgroups.

The pre-specified XIENCE V USA subgroup 4-year clinical outcomes were summarized in Table 9.7.3-1.

| Table 9.7.3-1: XIENCE V USA Subgroup Clinical Outcomes through 4 Years | XV USA Overall (N = 5020) | Near on-label (N = 1871) | Age ≥ 65 (N = 2495) | Female (N = 1564) | Insulin-Treated Diabetics (N = 593) | Acute MI (STEMI/ NSTEMI) (N = 667) | Multivessel Disease (N = 2050) | Two Vessels Treated (N = 620) | Long Lesions (≥ 20mm) (N = 860) | Bifurcation Lesions (N = 261) | Ostial Lesions (N = 366) | ISR (N = 257) |
|---|---------------------------------|--------------------------------|------------------------|----------------------|---|---|--------------------------------------|-------------------------------------|--|-------------------------------------|--------------------------------|-------------------|
| COMPOSITE EFFICACY AND SAFETY | | | | | | | | | | | | |
| ARC-Defined Device Oriented Endpoint | 19.7% (893/4530) | 13.4% (228/1704) | 20.3% (475/2339) | 21.7% (305/1406) | 37.3% (198/531) | 22.2% (129/581) | 25.1% (471/1875) | 26.2% (148/565) | 18.3% (142/776) | 12.6% (28/222) | 23.9% (77/322) | 27.6% (64/232) |
| TLF | 19.3% (875/4530) | 13.0% (222/1704) | 20.0% (468/2339) | 21.1% (297/1406) | 37.1% (197/531) | 21.9% (127/581) | 24.7% (463/1875) | 25.3% (143/565) | 18.2% (141/776) | 12.2% (27/222) | 23.9% (77/322) | 27.2% (63/232) |
| SAFETY | | | | | | | | | | | | |
| Cardiac Death or Target Vessel MI | 12.6% (571/4530) | 8.3% (142/1704) | 14.5% (338/2339) | 14.0% (197/1406) | 26.9% (143/531) | 15.8% (92/581) | 15.8% (296/1875) | 16.5% (93/565) | 12.1% (94/776) | 6.8% (15/222) | 14.6% (47/322) | 14.7% (34/232) |
| Cardiac Death or MI | 14.9% (676/4530) | 10.3% (176/1704) | 16.2% (380/2339) | 16.1% (227/1406) | 30.1% (160/531) | 20.1% (117/581) | 18.6% (348/1875) | 18.2% (103/565) | 14.3% (111/776) | 8.1% (18/222) | 18.0% (58/322) | 17.7% (41/232) |
| All Death | 10.9% (494/4530) | 7.8% (133/1704) | 15.0% (352/2339) | 11.7% (164/1406) | 22.0% (117/531) | 14.1% (82/581) | 12.3% (230/1875) | 11.5% (65/565) | 12.0% (93/776) | 6.3% (14/222) | 13.7% (44/322) | 9.9% (23/232) |
| Cardiac Death | 5.4% (244/4530) | 3.3% (57/1704) | 6.7% (157/2339) | 5.4% (76/1406) | 14.1% (75/531) | 6.7% (39/581) | 6.6% (123/1875) | 6.4% (36/565) | 5.0% (39/776) | 1.8% (4/222) | 6.2% (20/322) | 4.7% (11/232) |
| All MI | 11.3% (511/4530) | 8.0% (137/1704) | 11.6% (272/2339) | 12.5% (176/1406) | 20.9% (111/531) | 15.3% (89/581) | 14.3% (268/1875) | 14.3% (81/565) | 10.8% (84/776) | 6.3% (14/222) | 13.0% (42/322) | 15.1% (35/232) |
| QMI | 1.5% (68/4530) | 1.1% (18/1704) | 1.1% (26/2339) | 1.5% (21/1406) | 2.3% (12/531) | 3.6% (21/581) | 1.8% (34/1875) | 2.5% (14/565) | 1.4% (11/776) | 0.5% (1/222) | 0.6% (2/322) | 0.9% (2/232) |
| NQMI | 10.1% (457/4530) | 7.1% (121/1704) | 10.7% (251/2339) | 11.2% (158/1406) | 19.0% (101/531) | 12.7% (74/581) | 12.9% (242/1875) | 12.6% (71/565) | 9.8% (76/776) | 5.9% (13/222) | 12.4% (40/322) | 14.7% (34/232) |
| Target Vessel MI | 8.7% (396/4530) | 5.9% (101/1704) | 9.5% (222/2339) | 10.2% (143/1406) | 17.3% (92/531) | 10.7% (62/581) | 11.3% (212/1875) | 12.4% (70/565) | 8.2% (64/776) | 5.0% (11/222) | 9.6% (31/322) | 11.6% (27/232) |
| Efficacy | | | | | | | | | | | | |
| TLR | 10.9% (495/4530) | 7.1% (121/1704) | 9.5% (222/2339) | 11.9% (167/1406) | 20.0% (106/531) | 11.2% (65/581) | 14.5% (271/1875) | 15.6% (88/565) | 10.1% (78/776) | 7.2% (16/222) | 13.7% (44/322) | 20.3% (47/232) |
| Stent Thrombosis | | | | | | | | | | | | |
| ARC Definite / Probable | 1.56% (64/4093) | 0.70% (11/1577) | 1.60% (33/2058) | 1.53% (19/1244) | 3.39% (15/443) | 2.57% (13/506) | 2.27% (38/1674) | 2.34% (12/513) | 1.45% (10/688) | 0.98% (2/205) | 1.04% (3/288) | 2.86% (6/210) |
| ARC Definite | 1.05% (43/4093) | 0.25% (4/1577) | 0.92% (19/2058) | 1.05% (13/1244) | 2.03% (9/443) | 2.17% (11/506) | 1.43% (24/1674) | 1.17% (6/513) | 1.02% (7/688) | 0.98% (2/205) | 0.69% (2/288) | 2.38% (5/210) |

Notes:

- N is the total number of patients
- The 4-year window is through 1502 days
- Per ARC definition was used for MI and MI-related endpoints.

-
- ARC-defined device oriented endpoint is defined as hierarchical composite of cardiac death, target vessel MI (per ARC definition), and TLR.
 - TLF included cardiac death, target vessel MI (per ARC definition) and clinically indicated TLR. Near on-label patients are those who are not defined as non near on-label. The non near on-label cohort includes patients with any of the following: baseline lesion length >28 mm, reference vessel diameter < 2.5 mm or > 4.25 mm, restenosis, chronic total occlusion, graft lesion, bifurcation with side branch ≥ 2 mm, ostial, left main, more than 2 lesions stented in the same vessel, more than 2 vessels treated, acute MI, renal insufficiency, ejection fraction < 30%, or staged procedure. For long lesion (≥ 20 mm), bifurcation, ostial and ISR subgroups, only patients with single-lesion treated during the index procedure and without any staged procedures were included in the analysis

9.8 EXPERT CTO Clinical Trial

The EXPERT CTO clinical trial was designed to demonstrate the safety and effectiveness of the XIENCE family of stent systems in the treatment of chronic total occlusions (CTO). The trial, conducted in the United States, consists of a single arm, and one-year results are presented here.

Primary Objective: The objective of the EXPERT CTO clinical trial is to evaluate the safety and effectiveness of the XIENCE family of stent systems in improving coronary luminal diameter in subjects with symptomatic heart disease due to CTO.

Design: The EXPERT CTO clinical trial is a prospective, nonrandomized, open-label, multicenter single-arm study evaluating stent diameters of 2.25 – 4.0 mm with stent lengths 8 – 38 mm in 222 subjects at 20 sites in the United States. Each subject was to receive treatment of one *de novo* native coronary CTO lesion. However, treatment of non-CTO lesions distal to the target lesion (non-target lesions in the target vessel) which was not identified on the pre-procedural angiogram prior to CTO recanalization but were identified only after successful CTO recanalization, was allowed using XIENCE stents. Treatment of one lesion in a non-target vessel was also allowed during the index procedure.

The primary endpoint is major adverse cardiac events (MACE) at one year, a composite endpoint of death, myocardial infarction (MI), and clinically driven target lesion revascularization (TLR). The primary endpoint rate of MACE at 1 year was compared to a pre-specified performance goal (PG). The PG of 24.4% for the EXPERT CTO trial was developed utilizing historical clinical trial data. First, the average 1-year MACE rate per ARC MI definition was weighted by sample size and adjusted for MI definition if necessary. The adjustment was derived from Abbott Vascular historical trials to account for difference in the primary endpoint between ARC and protocol MI definitions. The weighted average event rate after the above adjustment was 14.4%. The final performance goal was set at 24.4% after adding a delta of 10% to account for variability and uncertainty. Analyses of the primary endpoint were conducted on both the intent-to-treat (ITT) population and per protocol (PP) population.

Demographics: The mean age was 61.65 ± 10.43 years, 81.1% (180/222) were male, 18.9% (42/222) were female and 80.2% (178/222) were white. Regarding medical risk factors, 26.0% (54/208) were tobacco users, 91.9% (203/221) were hypertensive, and 96.8% (215/222) were dyslipidemic. There were 43.4% (96/221) of subjects who had a prior percutaneous cardiac intervention, 29.0% (61/210) who had a prior MI, and 9.9% (22/222) who had prior coronary artery bypass graft surgery. Furthermore, the population consisted of 40.1% (89/222) diabetics, of which 68.5% (61/89) were diabetics requiring oral medication, 30.3% (27/89) were diabetics requiring insulin, and 28.1% (25/89) were diabetics controlled by diet.

Results: The primary endpoint results are presented in Table 9.8-1. These analyses are based on the ITT and PP populations. The ITT population is defined as all enrolled patients for whom recanalization and pre-dilatation of the target lesion are completed and the study stent(s) (XIENCE V and / or XIENCE PRIME) is inserted into the coronary guiding catheter. The PP population is defined as all ITT patients for the stent-related analysis in whom at least one study stent is implanted with both procedure success and available follow-up data but without major protocol deviations due to inappropriate enrollment.

The observed MACE rate at one year was 18.5% (39/211) in the ITT population and 8.2% (15/183) in the PP population. Both the ITT and PP populations met the primary endpoint with MACE rates significantly lower than the pre-specified PG (24.4%) ($p = 0.0248$ and $p < 0.0001$, respectively).

Secondary endpoints are presented in Table 9.8-2.

Table 9.8-1: EXPERT CTO Primary Endpoint Results

| Primary Endpoint Analysis | MACE | Upper One-Sided 95% CL ⁴ | Performance Goal | p-value ⁴ |
|---|----------------|-------------------------------------|------------------|----------------------|
| ITT Set ¹ (N = 222) Exact Rate ³ | 18.5% (39/211) | 23.4% | 24.4% | 0.0248 |
| PP Set ² (N = 183) Exact Rate ³ | 8.2% (15/183) | 12.3% | 24.4% | < 0.0001 |

¹ ITT subjects include all subjects who met the study entry criteria, signed the written informed consent, were enrolled in the trial, and whose target lesion was successfully crossed and predilated.

² The per-protocol population is defined as all ITT subjects in whom at least one study stent was implanted, met procedure success, had available follow-up data (i.e., a MACE event within 360 days or follow up of at least 330 days), and did not have major protocol deviations due to inappropriate enrollment.

³ The numerator includes subjects who have MACE events before or on day 360, and the denominator includes subjects who had had available follow-up data (i.e., a MACE event within 360 days or follow up of at least 330 days).

⁴ p-value and upper one-sided 95% CI were calculated using exact binomial method.

Table 9.8-2: EXPERT CTO Clinical Results

| | Outcomes at 1 Year ITT (N = 222) |
|--|---|
| Composite Effectiveness and Safety | |
| TLF (per ARC) | 15.8% (33/209) |
| TLF (per protocol) | 9.1% (19/209) |
| Effectiveness | |
| Clinically driven TLR | 6.3% (13/207) |
| Clinically driven TLR, CABG | 0.5% (1/206) |
| Clinically driven TLR, PCI | 5.8% (12/207) |
| Clinically driven TVR | 7.2% (15/207) |
| Safety | |
| All Death | 1.9% (4/210) |
| Cardiac Death | 1.0% (2/208) |
| Non-Cardiac Death | 1.0% (2/208) |
| Target Vessel MI (per ARC) | 12.0% (25/209) |
| Target Vessel QMI (per ARC) | 1.0% (2/208) |
| Target Vessel NQMI (per ARC) | 11.1% (23/207) |
| All MI (per ARC) | 13.9% (29/209) |
| QMI (per ARC) | 1.0% (2/208) |
| NQMI (per ARC) | 13.0% (27/207) |
| Target Vessel MI (per protocol) | 3.4% (7/208) |
| Target Vessel QMI (per protocol) | 1.0% (2/208) |
| Target Vessel NQMI (per protocol) | 2.4% (5/206) |
| All MI (per protocol) | 3.4% (7/208) |
| QMI (per protocol) | 1.0% (2/208) |
| NQMI (per protocol) | 2.4% (5/206) |
| ARC Definite+Probable Stent Thrombosis | |
| Cumulative through 1 year | 1.4% (3/207) |
| Acute (0 – 1 day) | 0.0% (0/222) |
| Subacute (2 – 30 days) | 0.9% (2/218) |
| Late (31 days – 1 year) | 0.5% (1/206) |
| ARC Definite Stent Thrombosis (cumulative) | 1.0% (2/207) |

Notes:

- TLF is defined as a hierarchical composite of cardiac death, Target Vessel MI, and clinically driven TLR.
- ARC: Academic Research Consortium

Study Strengths and Limitations: The EXPERT CTO study was a prospective, open-label, multicenter study. All event adjudications were performed by an independent Clinical Event Committee (CEC) with 100% site-reported adjudicable events being source-verified. This study provides important information on clinical outcomes in patients with chronic total occlusions treated with the XIENCE family of stents. The study is limited by being a small study with no head-to-head comparison with other DES platforms. In addition, due to the small population size, subgroup analysis can at best be considered exploratory.

9.8.1 Gender-Based Analysis of the EXPERT CTO Clinical Trial

Abbott Vascular performed a post hoc evaluation of the EXPERT CTO clinical trial for possible sex-based differences in baseline characteristics and clinical outcomes, as well as for any interaction between treatment and sex/gender. The EXPERT CTO trial was not designed or powered to study safety or effectiveness differences between sexes, so these analyses are considered exploratory without definitive conclusions.

In the EXPERT CTO study, 81.1% (180/222) were male and 18.9% (42/222) were female. In comparison, the prevalence of coronary artery disease (CAD) is estimated at 9.2 million in males and 8.4 million in females for adults age 20 and older the United States (i.e., the CAD population is estimated to be 52.2% males and 47.7% females). The disproportionate enrollment distribution in this trial may be partly attributable to gender differences in symptoms and pathophysiology, which may lead to under-diagnosis and under-referral of female patients with CAD. The gender proportions enrolled in this trial are similar to other CTO drug-eluting stent trials.^{31,32,33}

Table 9.8.1-1 presents the baseline demographics, risk factors, and angiographic characteristics by gender for subjects in the EXPERT CTO trial. As is consistent with previous literature, female patients at baseline were numerically older. More females than males were diabetic.

³¹Kandzari DE, Rao SV, Moses JW, et al. Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial. *J Am Coll Cardiol Intv* 2009;2:97-106.

³²Valenti R, Vergara R, Migliorini A, et al. Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. *J Am Coll Cardiol* 2013;61:545-550.

³³Wohrle J, Rottbauer W, Imhof A. Everolimus-eluting stents for treatment of chronic total coronary occlusions. *Clin Res in Cardiol* 2011;101:23-28

Table 9.8.1-1: Demographics, Risk Factors, and Baseline Angiographic Characteristics for EXPERT CTO

| Subject / Lesion Characteristics | Male (N = 180) (L = 180) | Female (N = 42) (L = 42) | Difference [95% CI] | p-value |
|--|--------------------------------|--------------------------------|------------------------|---------|
| Baseline Demographics, Mean ± SD (n) | | | | |
| Age (year) | 61.08±10.46 (180) | 64.12±10.09 (42) | -3.04[-6.45,0.37] | 0.089 |
| Baseline Risk Factors, % (No./total) | | | | |
| All Diabetes | 38.3% (69/180) | 47.6% (20/42) | -9.3%[-26.0%,7.4%] | 0.297 |
| Diabetes Treated with Insulin | 29.0% (20/69) | 35.0% (7/20) | -6.0%[-29.5%,17.5%] | 0.593 |
| Current Tobacco Use | 28.9% (48/166) | 14.3% (6/42) | 14.6%[2.0%,27.3%] | 0.222 |
| Hypertension | 91.6% (164/179) | 92.9% (39/42) | -1.2%[-10.0%,7.5%] | 1.000 |
| Dyslipidemia | 96.1% (173/180) | 100.0% (42/42) | -3.9%[-6.7%,-1.1%] | 0.352 |
| Congestive Heart Failure | 13.3% (24/180) | 7.1% (3/42) | 6.2%[-3.0%,15.4%] | 0.430 |
| Prior PCI | 44.1% (79/179) | 40.5% (17/42) | 3.7%[-12.9%,20.2%] | 0.731 |
| Prior MI | 30.0% (51/170) | 25.0% (10/40) | 5.0%[-10.1%,20.1%] | 0.569 |
| Target Vessel, % (No./total) | | | | |
| LAD | 30.6% (55/180) | 33.3% (14/42) | -2.8%[-18.5%,13.0%] | 0.715 |
| Circumflex or Ramus | 17.8% (32/180) | 7.1% (3/42) | 10.6%[1.1%,20.2%] | 0.103 |
| RCA | 51.7% (93/180) | 59.5% (25/42) | -7.9%[-24.4%,8.7%] | 0.394 |
| LMCA | 0.0% (0/180) | 0.0% (0/42) | 0.0%[0.0%,0.0%] | -- |
| Pre-Procedure QCA Analysis, Mean ± SD (m) | | | | |
| Lesion Length (mm) | 35.92±19.20 (180) | 36.68±15.19 (42) | -0.76[-6.14,4.62] | 0.811 |
| Pre-Procedure RVD (mm) | 2.69±0.43 (180) | 2.52±0.43 (42) | 0.17[0.02,0.31] | 0.022 |
| Pre-Procedure MLD (mm) | 0.01±0.06 (180) | 0.00±0.00 (42) | 0.01[0.00,0.02] | 0.026 |
| Pre-Procedure Percent Diameter Stenosis (%DS) | 99.62±2.36 (180) | 100.00±0.00 (42) | -0.38[-0.72,-0.04] | 0.032 |

A post hoc analysis was conducted on the composite primary safety and effectiveness endpoint of MACE, per ARC and per protocol, to assess for heterogeneity of treatment effect across sex / gender (Table 9.8.1-2). Due to the modest sample size (180 males vs. 42 females), these analyses and interpretation are limited.

Table 9.8.1-2: Clinical Results for All Female and All Male Subgroups in the EXPERT CTO Study through 1 Year

| EXPERT CTO | Male (N = 180) | Female (N = 42) | Difference [95% CI] | p-value |
|-------------------------------|-------------------|--------------------|------------------------|---------|
| All Death | 1.2% (2/171) | 5.1% (2/39) | -4.0%[-11.1%,3.1%] | 0.158 |
| Cardiac Death | 0.6% (1/170) | 2.6% (1/38) | -2.0%[-7.3%,3.2%] | 0.333 |
| Non-Cardiac Death | 0.6% (1/170) | 2.6% (1/38) | -2.0%[-7.3%,3.2%] | 0.333 |
| Target Vessel MI per ARC | 11.1% (19/171) | 15.8% (6/38) | -4.7%[-17.2%,7.8%] | 0.413 |
| Target Vessel MI per Protocol | 3.5% (6/171) | 2.7% (1/37) | 0.8%[-5.1%,6.7%] | 1.000 |
| Clinically-Driven TLR | 6.5% (11/170) | 5.4% (2/37) | 1.1%[-7.1%,9.2%] | 1.000 |
| Clinically-Driven TVR, non TL | 1.2% (2/169) | 0.0% (0/37) | 1.2%[-0.4%,2.8%] | 1.000 |
| Stent Thrombosis | | | | |
| ARC definite + probable | 1.2% (2/170) | 2.7% (1/37) | -1.5%[-7.0%,3.9%] | 0.448 |
| MACE | | | | |
| per ARC MI definition | 16.9% (29/172) | 25.6% (10/39) | -8.8%[-23.6%,6.0%] | 0.252 |
| per Protocol MI definition | 9.3% (16/172) | 12.8% (5/39) | -3.5%[-14.9%,7.8%] | 0.553 |

9.9 Analysis of Diabetic Patients

9.9.1 *Analysis of Diabetic Subjects in SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Trials*

Diabetic subjects comprise an important subject subgroup that is at increased risk for cardiovascular morbidity and mortality. Although diabetic subjects were included in the SPIRIT family of trials, there were no pre-specified hypotheses for the use of the XIENCE V stent in diabetic individuals.

Tables 9.9.1-1 and 9.9.1-2 show the clinical outcomes through 3 years in subjects from a post-hoc analysis of the SPIRIT IV and the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV population. History of diabetes was one of the stratification factors used in randomization to assure a balance between the XIENCE V and TAXUS treatment arms for each individual trial. In XIENCE V patients, there were numerically higher event rates in diabetics compared with non-diabetics. Given the potential for confounding variables, no conclusions can be drawn from these post-hoc analyses.

**Table 9.9.1-1: Clinical Results in Diabetics and Non-Diabetics through 3 Years
(SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT and SPIRIT IV Population)**

| SPIRIT IV | 1 Year | | | | 3 Years | | | |
|--|------------------------|---------------------|------------------------|--------------------|------------------------|---------------------|------------------------|--------------------|
| | Non-Diabetics | | All Diabetics | | Non-Diabetics | | All Diabetics | |
| | XIENCE V (N = 1669) | TAXUS (N = 829) | XIENCE V (N = 786) | TAXUS (N = 399) | XIENCE V (N = 1669) | TAXUS (N = 829) | XIENCE V (N = 786) | TAXUS (N = 399) |
| TLF | 3.1% (52/1652) | 6.7% (55/815) | 5.9% (45/761) | 6.9% (26/379) | 8.2% (132/1610) | 11.4% (90/790) | 12.4% (91/735) | 13.1% (48/367) |
| Ischemia-Driven TLR | 1.8% (29/1652) | 4.5% (37/815) | 3.5% (27/761) | 4.7% (18/379) | 5.7% (91/1610) | 8.1% (64/790) | 7.8% (57/735) | 7.6% (28/367) |
| Ischemia-Driven TVR, Non-TL | 1.5% (24/1652) | 2.2% (18/815) | 3.9% (30/761) | 2.9% (11/379) | 4.8% (77/1610) | 4.9% (39/790) | 7.5% (55/735) | 6.5% (24/367) |
| Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV | Non-Diabetics | | All Diabetics | | Non-Diabetics | | All Diabetics | |
| | XIENCE V (N = 2312) | TAXUS (N = 1125) | XIENCE V (N = 1035) | TAXUS (N = 509) | XIENCE V (N = 2312) | TAXUS (N = 1125) | XIENCE V (N = 1035) | TAXUS (N = 509) |
| | TLF | 3.2% (74/2284) | 8.0% (89/1106) | 6.8% (69/1008) | 6.2% (30/482) | 8.0% (177/2211) | 12.7% (137/1075) | 12.2% (118/970) |
| Ischemia-Driven TLR | 2.0% (45/2284) | 5.3% (59/1106) | 4.3% (43/1008) | 3.9% (19/482) | 5.7% (125/2211) | 8.7% (94/1075) | 7.2% (70/970) | 7.4% (34/462) |
| Ischemia-Driven TVR, Non-TL | 1.9% (43/2284) | 3.5% (39/1106) | 3.8% (38/1008) | 2.9% (14/482) | 5.2% (114/2211) | 5.6% (60/1075) | 6.9% (67/970) | 7.1% (33/462) |
| All Death | 0.8% (19/2284) | 1.7% (19/1106) | 1.7% (17/1008) | 0.6% (3/482) | 2.5% (56/2211) | 5.5% (59/1075) | 5.5% (53/970) | 4.8% (22/462) |
| Cardiac Death | 0.2% (5/2284) | 0.7% (8/1106) | 1.0% (10/1008) | 0.2% (1/482) | 0.8% (18/2211) | 1.7% (18/1075) | 2.8% (27/970) | 2.8% (13/462) |
| Non-Cardiac Death | 0.6% (14/2284) | 1.0% (11/1106) | 0.7% (7/1008) | 0.4% (2/482) | 1.7% (38/2211) | 3.8% (41/1075) | 2.7% (26/970) | 1.9% (9/462) |
| Target Vessel MI | 1.3% (30/2284) | 3.0% (33/1106) | 3.0% (30/1008) | 3.3% (16/482) | 2.1% (47/2211) | 4.1% (44/1075) | 4.5% (44/970) | 5.2% (24/462) |
| Cardiac Death or Target Vessel MI | 1.5% (35/2284) | 3.3% (37/1106) | 3.8% (38/1008) | 3.5% (17/482) | 2.9% (65/2211) | 5.3% (57/1075) | 6.9% (67/970) | 7.1% (33/462) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.1% (3/2265) | 0.7% (8/1091) | 0.7% (7/990) | 1.0% (5/479) | 0.5% (11/2150) | 1.6% (16/1018) | 1.9% (17/918) | 3.1% (14/449) |
| ARC Definite+Probable | 0.1% (3/2265) | 0.9% (10/1091) | 1.0% (10/993) | 1.3% (6/479) | 0.4% (8/2148) | 1.7% (17/1017) | 1.7% (16/918) | 2.0% (9/442) |
| ARC Definite | 0.1% (3/2265) | 0.5% (6/1091) | 0.8% (8/993) | 1.3% (6/479) | 0.3% (7/2148) | 1.1% (11/1017) | 1.2% (11/918) | 1.6% (7/442) |

Notes:

- One subject in SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 1-year and 3-year time frames include follow-up window (365 + 28 days and 1095 + 28 days, respectively).

**Table 9.9.1-2: Clinical Results in Diabetics through 3 Years
(SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and
SPIRIT IV Population – XIENCE V Subjects)**

| SPIRIT IV | 1 Year | | | | 3 Years | | | |
|--|-------------------------------------|-------------------------------------|--|--|-------------------------------------|-------------------------------------|--|--|
| | Non-Diabetics (N = 1669) | All Diabetics (N = 786) | Insulin-Dependent Diabetics (N = 209) | Non-Insulin-Dependent Diabetics (N = 577) | Non-Diabetics (N = 1669) | All Diabetics (N = 786) | Insulin-Dependent Diabetics (N = 209) | Non-Insulin-Dependent Diabetics (N = 577) |
| TLF | 3.1% (52/1652) | 5.9% (45/761) | 7.0% (14/199) | 5.5% (31/562) | 8.2% (132/1610) | 12.4% (91/735) | 17.3% (33/191) | 10.7% (58/544) |
| Ischemia-Driven TLR | 1.8% (29/1652) | 3.5% (27/761) | 5.0% (10/199) | 3.0% (17/562) | 5.7% (91/1610) | 7.8% (57/735) | 13.1% (25/191) | 5.9% (32/544) |
| Ischemia-Driven TVR, Non TL | 1.5% (24/1652) | 3.9% (30/761) | 6.5% (13/199) | 3.0% (17/562) | 4.8% (77/1610) | 7.5% (55/735) | 11.0% (21/191) | 6.3% (34/544) |
| Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV | Non-Diabetics (N = 2312) | All Diabetics (N = 1035) | Insulin-Dependent Diabetics (N = 272) | Non-Insulin-Dependent Diabetics (N = 763) | Non-Diabetics (N = 2312) | All Diabetics (N = 1035) | Insulin-Dependent Diabetics (N = 272) | Non-Insulin-Dependent Diabetics (N = 763) |
| TLF | 3.2% (74/2284) | 6.8% (69/1008) | 8.8% (23/262) | 6.2% (46/746) | 8.0% (177/2211) | 12.2% (118/970) | 16.3% (41/252) | 10.7% (77/718) |
| Ischemia-Driven TLR | 2.0% (45/2284) | 4.3% (43/1008) | 6.1% (16/262) | 3.6% (27/746) | 5.7% (125/2211) | 7.2% (70/970) | 11.9% (30/252) | 5.6% (40/718) |
| Ischemia-Driven TVR, Non TL | 1.9% (43/2284) | 3.8% (38/1008) | 5.3% (14/262) | 3.2% (24/746) | 5.2% (114/2211) | 6.9% (67/970) | 8.7% (22/252) | 6.3% (45/718) |
| All Death | 0.8% (19/2284) | 1.7% (17/1008) | 2.3% (6/262) | 1.5% (11/746) | 2.5% (56/2211) | 5.5% (53/970) | 6.0% (15/252) | 5.3% (38/718) |
| Cardiac Death | 0.2% (5/2284) | 1.0% (10/1008) | 1.1% (3/262) | 0.9% (7/746) | 0.8% (18/2211) | 2.8% (27/970) | 3.2% (8/252) | 2.6% (19/718) |
| Non-Cardiac Death | 0.6% (14/2284) | 0.7% (7/1008) | 1.1% (3/262) | 0.5% (4/746) | 1.7% (38/2211) | 2.7% (26/970) | 2.8% (7/252) | 2.6% (19/718) |
| Target Vessel MI | 1.3% (30/2284) | 3.0% (30/1008) | 4.6% (12/262) | 2.4% (18/746) | 2.1% (47/2211) | 4.5% (44/970) | 6.0% (15/252) | 4.0% (29/718) |
| Cardiac Death or Target Vessel MI | 1.5% (35/2284) | 3.8% (38/1008) | 5.0% (13/262) | 3.4% (25/746) | 2.9% (65/2211) | 6.9% (67/970) | 7.9% (20/252) | 6.5% (47/718) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.1% (3/2265) | 0.7% (7/990) | 0.8% (2/256) | 0.7% (5/734) | 0.5% (11/2150) | 1.9% (17/918) | 2.5% (6/238) | 1.6% (11/680) |
| ARC Definite+Probable | 0.1% (3/2265) | 1.0% (10/993) | 1.2% (3/257) | 1.0% (7/736) | 0.4% (8/2148) | 1.7% (16/918) | 2.1% (5/237) | 1.6% (11/681) |
| ARC Definite | 0.1% (3/2265) | 0.8% (8/993) | 0.8% (2/257) | 0.8% (6/736) | 0.3% (7/2148) | 1.2% (11/918) | 1.3% (3/237) | 1.2% (8/681) |

Notes:

- One subject in SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 1-year and 3-year time frames include follow-up window (365 ± 28 days and 1095 ± 28 days, respectively)

9.9.2 Bayesian Analysis of Diabetic Patients Treated with XIENCE Stents

A Statistical Analysis Plan (SAP) was developed with a pre-specified hypothesis to evaluate the safety and effectiveness of the XIENCE Family of Everolimus-Eluting Coronary Stent Systems (XIENCE stent, including XIENCE V, XIENCE PRIME, XIENCE Xpedition and XIENCE Alpine stents) to treat *de novo* native coronary artery lesions in diabetic patients with coronary artery disease. This section provides an overview of the SAP and the results supporting the use of the XIENCE stent in patients with diabetes mellitus (DM).

Primary Objective: To evaluate the safety and effectiveness of the XIENCE stent for the treatment of *de novo* lesions in native coronary arteries in diabetic patients.

Population: The analysis population consists of diabetic patients from the following trial/registry databases:

- SPIRIT IV
- SPIRIT PRIME (including Core Size Registry and Long Lesion Registry)
- XIENCE V USA First Enrollment Phase
- XIENCE V USA Second Enrollment Phase
- External databases: Cleveland Clinic and Wake Forest Baptist Medical Center databases

A total of 1239 patients were included in the DM analysis. The contributions of patients from each trial/registry database were: SPIRIT IV (N=451); SPIRIT PRIME (N=121); XIENCE V USA First Enrollment Phase (N=185); XIENCE V USA Second Enrollment Phase (N=192); and the pooled external databases from Cleveland Clinic and Wake Forest (N=290).

Design: A Bayesian hierarchical modeling approach was utilized to analyze the primary endpoint of Target Vessel Failure (TVF) at 12 months, defined as a composite of cardiac death, target-vessel myocardial infarction (TVMI), and ischemia driven target vessel revascularization (ID-TVR), which was tested against a pre-specified performance goal of 14.8% (expected rate 8.6% plus a delta of 6.2%).

Results from the six data sources were used in the analysis. Data from the four historical Abbott Vascular (AV) sponsored trial databases (SPIRIT IV, SPIRIT PRIME, XIENCE V USA first enrollment phase, and XIENCE V USA second enrollment phase) were considered as prior information. The two external XIENCE databases (Cleveland Clinic and Wake Forest) were pooled as current data and served as the basis for statistical inference.

Patients were included in the analysis if they have diabetes mellitus (based on medical history) and had at least one XIENCE stent implanted for the treatment of up to two *de novo* lesions (each located in a different epicardial vessel) < 32 mm in length in native coronary arteries with an RVD between 2.25 and 4.25 mm. The other clinical and lesion criteria of the diabetic analysis population are consistent with the enrollment criteria of the SPIRIT III US Pivotal Clinical Trial.

Demographics and Lesion Characteristics: The mean age of the diabetic population was 63 years from the pooled historical AV trials (SPIRIT IV, SPIRIT PRIME, XIENCE V USA first enrollment phase and second enrollment phase) and 65 years from the pooled two external databases (Wake Forest and Cleveland Clinic). There were 62.8% males from the pooled AV trials and 64.1% from the pooled external databases. Insulin treated diabetic patients comprised of 25.9% and 35.5% of the overall diabetic analysis population from the pooled AV trials and

pooled external databases, respectively. A total of 26.6% of patients presented with unstable angina from the pooled AV trials and 57.6% from the pooled external databases. There were 23.8% and 35.9% patients who had prior MI, 34.2% and 44.8% who had prior PCI, and 10.5% and 24.5% who had prior CABG from the pooled AV trials and pooled external databases, respectively. The mean lesion length was 13.5 mm for the pooled AV trials, and 16.3 mm for the pooled external databases. There were 12.0% type C lesions in the pooled AV trials and 25.5% in the pooled external databases. There were 2.6% (32/1239) patients treated with 33 or 38 mm stents in this pooled dataset (2.5% from the pooled AV trials, and 2.8% from the pooled external databases). Compared to the pooled AV trials, patient and lesion characteristics in the two external databases were generally more complex, likely due to their non-trial real-world settings.

Primary Endpoint Results: The primary endpoint of TVF rate at 1-year was evaluated in diabetic patients from the six trial/registry databases using a Bayesian statistical model. The posterior mean of 1-year TVF rate was 8.04%. The posterior probability of a 1-year TVF rate < 14.8% (performance goal) is > 0.999 (Table 9.9.2-1), which exceeds the pre-specified success criteria (> 0.975). Therefore, the XIENCE stent met the pre-specified success criteria for the primary endpoint of 1-year TVF.

Table 9.9.2-1: The XIENCE Diabetic Bayesian Analysis Primary Endpoint

| Primary Endpoint | TVF Rate [95% Central Posterior Interval] * | Bayesian Posterior Probability (TVF < 14.8%) |
|------------------|--|---|
| 1-year TVF | 8.04% [5.23%, 11.52%] | > 0.999 |

* The posterior mean is the Bayesian posterior average; the 95% central posterior interval is the symmetric 95% Bayesian credible interval, similar to the 95% confidence interval.

Notes:

- The 1-year window is through 393 days (365 + 28 days).
- TVF is defined as hierarchical composite of cardiac death, target vessel MI, and ischemia-driven TVR. For the primary composite endpoint of TVF, an adjustment factor of 0.826 was applied to one of the external databases to calculate the TVF rate based on the composite rate of all death/all MI/all TVR as the specifics of these events were not available from that database.

1-Year Clinical Outcomes: The 1-year clinical outcomes of the XIENCE diabetic population from each of the AV trials (SPIRIT IV, SPIRIT PRIME and XIENCE V USA) and the pooled two external databases are presented in Table 9.9.2-2.

Table 9.9.2-2: One- Year Clinical Outcomes of the XIENCE Diabetic Population

| | SPIRIT IV (N=451) | SPIRIT PRIME (N=121) | XV USA 5K (N=185) | XV USA 3K (N=192) | Pooled External (N=290) |
|-----------------------|------------------------------|---------------------------------|------------------------------|------------------------------|------------------------------------|
| TVF | 7.9% (34/433) | 11.8% (14/119) | 7.3% (13/178) | 3.6% (6/169) | 8.0% (21/261) |
| TLF | 5.5% (24/433) | 5.9% (7/119) | 6.7% (12/178) | 2.4% (4/169) | 2.4% (3/126) |
| Cardiac death or TVMI | 3.0% (13/433) | 2.5% (3/119) | 3.4% (6/178) | 0.6% (1/169) | 0.8% (1/126) |
| ID-TVR | 5.5% (24/433) | 9.2% (11/119) | 5.1% (9/178) | 3.0% (5/169) | 6.3% (8/126) |
| ID-TLR | 3.2% (14/433) | 3.4% (4/119) | 3.9% (7/178) | 1.8% (3/169) | 2.4% (3/126) |
| Death | 1.4% (6/433) | 0.0% (0/119) | 2.2% (4/178) | 1.2% (2/169) | 3.1% (8/261) |
| Cardiac death | 0.9% (4/433) | 0.0% (0/119) | 1.1% (2/178) | 0.6% (1/169) | 0.0% (0/126) |
| TVMI | 2.3% (10/433) | 2.5% (3/119) | 2.2% (4/178) | 0.0% (0/169) | 0.8% (1/126) |
| ST (ARC def/prob) | 0.9% (4/431) | 0.0% (0/119) | 0.0% (0/175) | 0.6% (1/169) | 0.8% (2/261) |

Notes:

- Numbers presented in this table are % (n/N).
- The 1-year window is through 393 days (365 + 28 days).
- XV USA 5K refers to the first enrollment phase of 5,000 patients in the XIENCE V USA study; XV USA 3K refers to the second enrollment phase of 3,000 patients in the XIENCE V USA study; pooled external refers to the pooled analysis of the two external databases (Cleveland Clinic and Wake Forest).
- TVF is defined as hierarchical composite of cardiac death, target vessel MI, and ischemia-driven TVR; TLF is defined as hierarchical composite of cardiac death, target vessel MI, and ischemia-driven TLR. ID-TLR= ischemia driven target lesion revascularization; ID-TVR=ischemia driven target vessel revascularization; TVMI=target vessel myocardial infarction; ST (ARC def/prob) = definite or probable stent thrombosis defined per the ARC definition.
- MI from the historical AV trials was defined per protocol and was categorized as Q-wave (development of new, pathological Q waves on the ECG) or non-Q-wave (elevation of CK levels to greater than two times the upper limit of normal and elevated CK-MB in the absence of new pathological Q waves). For the two external databases, MI was defined based on Universal MI definition per the National Cardiovascular Data Registry (NCDR) requirement.
- For the primary composite endpoint of TVF, an adjustment factor of 0.826 was applied to one of the two external databases in order to calculate the TVF rate based on the composite rate of all death/all MI/all TVR, as the specifics of these events were not available from that database.
- For other endpoints (TLF, cardiac death or TVMI, ID-TLR, ID-TVR, cardiac death and TVMI), only one of the external databases was included in the analysis, as the specific event information was not available in the other external database.

10.0 INDIVIDUALIZATION OF TREATMENT

The risks and benefits should be considered for each patient before using the XIENCE Alpine stent. Patient selection factors to be assessed should include a judgment regarding risk of long-term antiplatelet therapy. Stenting is generally avoided in those patients at heightened risk of bleeding (e.g., patients with recently active gastritis or peptic ulcer disease) in which anticoagulation therapy would be contraindicated.

Antiplatelet drugs should be used in combination with the XIENCE Alpine stent. Physicians should use information from the SPIRIT clinical trials, coupled with current drug eluting stent (DES) literature and the specific needs of individual patients to determine the specific antiplatelet / anticoagulation regimen to be used for their patients in general practice. See also section 5.2 – *Precautions, Pre- and Post-Procedure Antiplatelet Regimen*, section 5.6 – *Precautions, Use in Special Populations*, and section 5.7 – *Precautions, Lesion / Vessel Characteristics*.

Premorbid conditions that increase the risk of poor initial results or the risks of emergency referral for bypass surgery (diabetes mellitus, renal failure, and severe obesity) should be reviewed.

11.0 PATIENT COUNSELING AND PATIENT INFORMATION

Physicians should consider the following in counseling patients about this product:

- Discuss the risks associated with stent placement
- Discuss the risks associated with an everolimus eluting stent
- Discuss the risks of early discontinuation of the antiplatelet therapy
- Discuss the risks of late stent thrombosis with DES use in higher risk patient subgroups
- Discuss the risk / benefit issues for this particular patient
- Discuss alternation to current lifestyle immediately following the procedure and over the long term

The following patient materials are provided for this product:

- A Patient Information Guide, including information on coronary artery disease, the implant procedure and the XIENCE Alpine stent system (provided to physician, online at http://www.abbotvascular.com/docs/coronary_intervention/xience/ePG_XIENCE.pdf, or by calling customer service 1-800-227-9902)
- A Stent Implant Card, including both patient information and stent implant information (provided in package).

12.0 HOW SUPPLIED

Sterile – This device is sterilized with ethylene oxide gas, and is non-pyrogenic. It is intended for single use only. Do not resterilize. Do not use if the package is opened or damaged.

Contents – One (1) XIENCE Alpine stent system; one (1) flushing tool (for the XIENCE Alpine RX stent system); one (1) stent implant card

Storage – Store in a dry, dark, cool place. Protect from light. Do not remove from carton until ready for use. Store at 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F).

13.0 OPERATOR'S INSTRUCTIONS

13.1 Inspection Prior to Use

- Carefully inspect the sterile package before opening and check for damage to the sterile barrier. Do not use if the integrity of the sterile package has been compromised.
- Do not use after the "Use by" date.
- Tear open the foil pouch and remove the inner pouch.
Note: The outside of the inner pouch is NOT sterile. Open the inner pouch and pass or drop the product into the sterile field using an aseptic technique.
- Prior to using the XIENCE Alpine stent system, carefully remove the system from the package and inspect for bends, kinks, and other damage. Verify that the stent does not extend beyond the radiopaque balloon markers. Do not use if any defects are noted. However, **do not manipulate, touch, or handle the stent** with your fingers, which may cause coating damage, contamination, or stent dislodgement from the delivery balloon.

Note: At any time during use of the XIENCE Alpine RX stent system, if the stainless steel proximal shaft has been bent or kinked, do not continue to use the catheter.

13.2 Materials Required

- Appropriate guiding catheter(s). See Table 1.1-1: XIENCE Alpine Stent System Product Description
- 2 – 3 syringes (10 – 20 ml)
- 1,000 u/500 ml heparinized normal saline (HepNS)
- 0.014" (0.36 mm) x 175 cm (minimum length) guide wire
- Rotating hemostatic valve with appropriate minimum inner diameter (0.096" [2.44 mm])
- Contrast diluted 1:1 with heparinized normal saline
- Inflation device
- Pre-deployment dilatation catheter
- Three-way stopcock
- Torque device
- Guide wire introducer
- Appropriate arterial sheath
- Appropriate anticoagulation and antiplatelet drugs

13.3 Preparation

13.3.1 Packaging Removal

Note: The foil pouch is not a sterile barrier. The inner header bag (pouch) within the foil pouch is the sterile barrier. Only the contents of the inner pouch should be considered sterile. The outside surface of the inner pouch is NOT sterile.

1. Carefully remove the delivery system from its protective tubing for preparation of the delivery system. When using a Rapid Exchange (RX) system, do not bend or kink the hypotube during removal.
2. Remove the product mandrel and protective stent sheath by grasping the catheter just proximal to the stent (at the proximal balloon bond site), and with the other hand, grasp the stent protector and gently remove distally. If unusual resistance is felt during product mandrel and stent sheath removal, do not use this product and replace with another. Follow product returns procedure for the unused device.

13.3.2 Guide Wire Lumen Flush

1. Over the Wire (OTW) only: Flush the guide wire lumen with HepNS until fluid exits the distal end of the delivery system.
2. Rapid Exchange (RX) only: Flush the guide wire lumen with HepNS using the flushing tool supplied with the product. Insert the flushing tool into the tip of the catheter and flush until fluid exits the guide wire exit notch.

Note: Avoid manipulation of the stent while flushing the guide wire lumen, as this may disrupt the placement of the stent on the balloon.

13.3.3 Delivery System Preparation

1. Prepare an inflation device / syringe with diluted contrast medium.
2. Attach an inflation device / syringe to the stopcock; attach it to the inflation port of the product. Do not bend the product hypotube, when connecting to the inflation device / syringe.
3. With the tip down, orient the delivery system vertically.
4. Open the stopcock to delivery system; pull negative for 30 seconds; release to neutral for contrast fill.
5. Close the stopcock to the delivery system; purge the inflation device / syringe of all air.
6. Repeat steps 3 through 5 until all air is expelled. If bubbles persist, do not use the product.
7. If a syringe was used, attach a prepared inflation device to stopcock.
8. Open the stopcock to the delivery system.
9. Leave on neutral.

Note: While introducing the delivery system into the vessel, do not induce negative pressure on the delivery system. This may cause dislodgement of the stent from the balloon.

Note: If air is seen in the shaft, repeat section 13.3.3 – *Operator’s Instructions, Delivery System Preparation*, steps 3 through 5, to prevent uneven stent expansion.

13.4 Delivery Procedure

1. Prepare the vascular access site according to standard practice.
2. The decision to pre-dilate the lesion with an appropriate sized balloon should be based on patient and lesion characteristics. **If pre-dilatation is performed**, limit the longitudinal length of pre-dilatation by the PTCA balloon to avoid creating a region of vessel injury that is outside the boundaries of the XIENCE Alpine stent.
3. For long lesions, size the stent to the diameter of the most distal portion of the vessel.

Note: If choosing between two stent diameters for tight lesions, choose the smaller diameter stent and inflate. See section 14.0 – *In vitro Compliance Information*.

4. Maintain neutral pressure on the inflation device attached to the delivery system. Open the rotating hemostatic valve as wide as possible.
5. Backload the delivery system onto the proximal portion of the guide wire, while maintaining guide wire position across the target lesion.
6. Carefully advance the delivery system into the guiding catheter and over the guide wire to the target lesion. When using a Rapid Exchange (RX) system, be sure to keep the hypotube straight. Ensure guiding catheter stability before advancing the stent system into the coronary artery.

Note: If unusual resistance is felt before the stent exits the guiding catheter, do not force passage. Resistance may indicate a problem and the use of excessive force may result in stent damage or dislodgement. Maintain guide wire placement across the lesion and remove the delivery system and guiding catheter as a single unit.

7. Advance the delivery system over the guide wire to the target lesion under direct fluoroscopic visualization. Utilize the radiopaque balloon markers to position the stent across the lesion. Perform angiography to confirm stent position. If the position of the stent is not optimal, it should be carefully repositioned or removed (see section 5.14 – *Precautions, Stent System Removal*). The balloon markers indicate both the stent edges and the balloon shoulders. Expansion of the stent should not be undertaken if the stent is not properly positioned in the target lesion.

Note: If removal of a stent system is required prior to deployment, ensure that the guiding catheter is coaxially positioned relative to the stent delivery system, and cautiously withdraw the stent delivery system into the guiding catheter. Should unusual resistance be felt at any time when withdrawing the stent towards the guiding catheter, the stent delivery system and the guiding catheter should be removed as a single unit. This should be done under direct visualization with fluoroscopy.

8. Tighten the rotating hemostatic valve. The stent is now ready to be deployed.

13.5 Deployment Procedure

CAUTION: Refer to Table 14-1: XIENCE Alpine Stent Compliance, for *in vitro* stent inner diameter, nominal pressure, and RBP.

1. Prior to deployment, reconfirm the correct position of the stent relative to the target lesion using the radiopaque balloon markers.
2. Deploy the stent slowly by pressurizing the delivery system in 2 atm increments, every 5 seconds, until stent is completely expanded. Fully expand the stent by inflating to nominal pressure at a minimum. Accepted practice generally targets an initial deployment pressure that would achieve a stent inner diameter ratio of about 1.1 times the reference vessel diameter (see Table 14-1: XIENCE Alpine Stent Compliance).
3. For long lesions, size the stent to the diameter of the most distal portion of the vessel and expand stent to nominal pressure at minimum. Maintain pressure for 30 seconds. If necessary, the delivery system can be repressurized or further pressurized to assure complete apposition of the stent to the artery wall.
4. Maintain pressure for 30 seconds for full expansion of the stent. Fluoroscopic visualization during stent expansion should be used in order to properly judge the optimum stent diameter as compared to the proximal and distal native coronary artery diameters (reference vessel diameters). Optimal stent expansion and proper apposition requires that the stent be in full contact with the arterial wall.

Note: See section 13.6 – *Removal Procedure* for instruction on withdrawal of stent delivery system.

5. If necessary, the delivery system can be repressurized or further pressurized to assure complete apposition of the stent to the artery wall.

Note: Do not exceed the labeled rated burst pressure (RBP) of 18 atm (1824 kPa).

6. Fully cover the entire lesion and balloon-treated area (including dissections) with the XIENCE Alpine stent, allowing for adequate stent coverage into healthy tissue proximal and distal to the lesion.
7. Deflate the balloon by pulling negative on the inflation device for 30 seconds. Confirm complete balloon deflation before attempting to move the delivery system. If unusual resistance is felt during stent delivery system withdrawal, pay particular attention to guiding catheter position.

Note: See section 13.6 – *Removal Procedure* for instruction on withdrawal of stent delivery system.

8. Confirm stent position and deployment using standard angiographic techniques. For optimal results, the entire stenosed arterial segment should be covered by the stent. Fluoroscopic visualization during stent expansion should be used in order to properly judge the optimum expanded stent diameter as compared to the proximal and distal coronary artery diameter(s). Optimal expansion requires that the stent be in full contact with the artery wall. Stent wall contact should be verified through routine angiography or intravascular ultrasound (IVUS).
9. If the deployed stent size is still inadequate with respect to reference vessel diameter, a larger balloon may be used to further expand the stent. If the initial

angiographic appearance is suboptimal, the stent may be further expanded using a low profile, high pressure, noncompliant balloon dilatation catheter. If this is required, the stented segment should be carefully recrossed with a prolapsed guide wire to avoid disrupting the stent geometry. Deployed stents should not be left underdilated.

CAUTION: Do not dilate the stent beyond the following limits.

| <u>Nominal Stent Diameter</u> | <u>Dilatation Limit</u> |
|-------------------------------|-------------------------|
| 2.25 mm and 2.5 mm | 3.25 mm |
| 2.75 mm, 3.0 mm, and 3.25 mm | 3.75 mm |
| 3.5 mm and 4.0 mm | 4.5 mm |

10. If more than one XIENCE Alpine stent is needed to cover the lesion and balloon-treated area, it is suggested that, to avoid the potential for gap restenosis, the stents be adequately overlapped. To ensure that there are no gaps between stents, the balloon marker bands of the second XIENCE Alpine stent should be positioned inside the deployed stent prior to expansion.
11. Reconfirm stent position and angiographic results. Repeat inflations until optimal stent deployment is achieved.

13.6 Removal Procedure

Withdrawal of the stent delivery catheter from the deployed stent:

1. Deflate the balloon by pulling negative on the inflation device. Larger and longer balloons will take more time (up to 30 seconds) to deflate than smaller and shorter balloons. Confirm balloon deflation under fluoroscopy and wait 10 – 15 seconds longer.
2. Position inflation device on “negative” or “neutral” pressure.
3. Stabilize guiding catheter position just outside coronary ostium and anchor in place. Maintain guide wire placement across stent segment.
4. Gently remove the stent delivery system with slow and steady pressure.
5. Tighten the rotating hemostatic valve.

If during withdrawal of the stent delivery catheter resistance is encountered, use the following steps to improve balloon rewrap:

- Re-inflate the balloon up to nominal pressure.
- Repeat steps 1 through 5 above.

Post-stent delivery system withdrawal – Stent deployment confirmation

1. Confirm stent position and deployment using standard angiographic techniques. For optimal results, the entire stenosed arterial segment should be covered by the stent. Fluoroscopic visualization during stent expansion should be used in order to properly judge the optimum expanded stent diameter as compared to the proximal and distal coronary artery diameter(s). **Optimal expansion requires**

that the stent be in full contact with the artery wall. Stent wall contact should be verified through routine angiography or intravascular ultrasound (IVUS).

2. If more than one XIENCE Alpine stent is needed to cover the lesion and balloon treated area, it is suggested that, to avoid the potential for gap restenosis, the stents be adequately overlapped.
3. To ensure that there are no gaps between stents, the balloon marker bands of the second XIENCE Alpine stent should be positioned inside the deployed stent prior to expansion.
4. Reconfirm stent position and angiographic results to assess stented area. Repeat inflations until optimal stent deployment is achieved. If post-dilatation is necessary, ensure that the final stent diameter matches the reference vessel diameter. **Assure that the stent wall is in contact with the artery wall.**

13.7 Post-Deployment Dilatation of Stent Segments

1. All efforts should be taken to assure that the stent is not underdilated.
2. If the deployed stent size is still inadequate with respect to the vessel diameter, or if full contact with the vessel wall is not achieved, a larger balloon may be used to expand the stent further. The stent may be further expanded using a low profile, high pressure, and noncompliant balloon catheter. If this is required, the stented segment should be recrossed carefully with a prolapsed guide wire to avoid dislodging the stent. The balloon should be centered within the stent and should not extend outside of the stented region.

CAUTION: Do not dilate the stent beyond the following limits.

| <u>Nominal Stent Diameter</u> | <u>Dilatation Limit</u> |
|-------------------------------|-------------------------|
| 2.25 mm and 2.5 mm | 3.25 mm |
| 2.75 mm, 3.0 mm, and 3.25 mm | 3.75 mm |
| 3.5 mm and 4.0 mm | 4.5 mm |

14.0 IN VITRO COMPLIANCE INFORMATION

**Table 14-1: XIENCE Alpine Stent Compliance
(Nominal Pressure for Each Diameter Indicated by Bold Font)**

| Pressure | | Stent ID (mm) by System Diameter | | | | | | |
|-----------|------|----------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|
| atm | kPa | 2.25 mm | 2.5 mm | 2.75 mm | 3.0 mm | 3.25 mm | 3.5 mm | 4.0 mm |
| 8 | 811 | 2.14 | 2.41 | 2.71 | 2.91 | 3.10 | 3.37 | 3.85 |
| 9 | 912 | 2.19 | 2.46 | 2.77 | 2.97 | 3.16 | 3.43 | 3.92 |
| 10 | 1013 | 2.23 | 2.51 | 2.81 | 3.03 | 3.22 | 3.49 | 3.99 |
| 11 | 1115 | 2.27 | 2.55 | 2.87 | 3.08 | 3.28 | 3.55 | 4.05 |
| 12 | 1216 | 2.30 | 2.59 | 2.90 | 3.12 | 3.33 | 3.60 | 4.11 |
| 13 | 1317 | 2.34 | 2.62 | 2.94 | 3.15 | 3.37 | 3.65 | 4.15 |
| 14 | 1419 | 2.37 | 2.66 | 2.97 | 3.19 | 3.41 | 3.69 | 4.20 |
| 15 | 1520 | 2.39 | 2.68 | 3.00 | 3.21 | 3.44 | 3.72 | 4.24 |
| 16 | 1621 | 2.42 | 2.71 | 3.02 | 3.24 | 3.47 | 3.75 | 4.27 |
| 17 | 1723 | 2.44 | 2.73 | 3.04 | 3.26 | 3.50 | 3.78 | 4.30 |
| 18 (RBP)* | 1824 | 2.46 | 2.74 | 3.07 | 3.28 | 3.52 | 3.81 | 4.33 |
| 19 | 1925 | 2.48 | 2.76 | 3.09 | 3.30 | 3.54 | 3.83 | 4.35 |
| 20 | 2027 | 2.49 | 2.77 | 3.11 | 3.32 | 3.56 | 3.85 | 4.38 |

Note: These nominal data are based on *in vitro* testing at 37°C and do not take into account lesion resistance.

Ensure full deployment of the stent (see section 13.5 – *Operator's Instructions, Deployment Procedure*) and confirm the stent sizing angiographically.

*Do not exceed the rated burst pressure (RBP).

15.0 REUSE PRECAUTION STATEMENT

Do not use if sterile barrier is damaged. If damage is found, call your Abbott Vascular representative.

For single patient use only. Do not reuse, reprocess, or resterilize.

16.0 PATENTS AND TRADEMARKS

This product and / or its use may be covered by one or more of the following United States Patents: 6,179,810; 6,384,046; 6,629,994; 6,656,220; 6,746,423; 6,887,219; 6,887,510; 6,890,318; 6,929,657; 6,939,373; 6,957,152; 7,549,975; 7,662,130; 7,828,766; 7,833,193; 7,906,066; 7,947,207; 8,043,553; 8,052,638; 8,075,583; 8,173,062; 8,221,112; 8,221,444; 8,308,711; 8,382,738; 8,388,575; 8,388,602; 8,394,055; 8,444,608; 8,444,802; 8,535,596; 8,540,927; 8,613,722. Other U.S. patents pending. Other patents issued and pending outside of the U.S.

XIENCE Alpine is a trademark of the Abbott Group of Companies.

XIENCE PRIME, XIENCE Xpedition, XIENCE V, and XIENCE nano are registered trademarks of the Abbott Group of Companies.

TAXUS, TAXUS Express, and TAXUS Liberté are registered trademarks of Boston Scientific Corporation or its affiliates.

Zortress, Certican, and Afinitor are registered trademarks of Novartis Pharmaceuticals, Inc.



















Abbott Vascular

3200 Lakeside Drive
Santa Clara, CA 95054 USA

CUSTOMER SERVICE

TEL: (800) 227-9902
FAX: (800) 601-8874
Outside USA TEL: (951) 914-4669
Outside USA FAX: (951) 914-2531

Graphical Symbols for Medical Device Labeling

| | | | |
|---|---|--|--|
|  Manufacturer |  Catalogue number |  French size |  Date of manufacture |
|  Do not resterilize |  Sterilized using ethylene oxide |  Consult instructions for use |  Inner diameter |
|  Use by |  Batch code |  Do not reuse |  Flushing tool |
|  Non-pyrogenic |  Contents (numeral represents quantity of units inside) |  Guiding catheter |  MR conditional |

©2014 Abbott

**XIENCE PRIME[®] and XIENCE PRIME LL
Everolimus Eluting Coronary Stent Systems
Instructions for Use**



Table of Contents

- 1.0 PRODUCT DESCRIPTION
 - 1.1 Device Component Description
 - 1.2 Drug Component Description
 - 1.2.1 Everolimus
 - 1.2.2 Inactive Ingredients – Non-erodible Polymer
 - 1.2.3 Product Matrix and Everolimus Content
- 2.0 INDICATIONS
- 3.0 CONTRAINDICATIONS
- 4.0 WARNINGS
- 5.0 PRECAUTIONS
 - 5.1 General Precautions
 - 5.2 Pre- and Post-Procedure Antiplatelet Regimen
 - 5.3 Multiple Stent Use
 - 5.4 Brachytherapy
 - 5.5 Use in Conjunction with Other Procedures
 - 5.6 Use in Special Populations
 - 5.6.1 Pregnancy
 - 5.6.2 Lactation
 - 5.6.3 Gender
 - 5.6.4 Ethnicity
 - 5.6.5 Pediatric Use
 - 5.6.6 Geriatric Use
 - 5.7 Lesion / Vessel Characteristics
 - 5.8 Drug Interactions
 - 5.9 Immune Suppression Potential
 - 5.10 Lipid Elevation Potential
 - 5.11 Magnetic Resonance Imaging (MRI)
 - 5.12 Stent Handling
 - 5.13 Stent Placement
 - 5.13.1 Stent Preparation
 - 5.13.2 Stent Implantation
 - 5.14 Stent System Removal
 - 5.15 Post-Procedure

-
- 6.0 DRUG INFORMATION
 - 6.1 Mechanism of Action
 - 6.2 Pharmacokinetics
 - 6.3 Interactions with Drugs or Other Substances
 - 6.4 Carcinogenicity, Genotoxicity, and Reproductive Toxicity
 - 6.5 Pregnancy
 - 6.6 Lactation
 - 7.0 OVERVIEW OF CLINICAL EXPERIENCE
 - 8.0 ADVERSE EVENTS
 - 8.1 Observed Adverse Events
 - 8.2 Stent Thrombosis Definitions
 - 8.3 Potential Adverse Events
 - 9.0 SPIRIT FAMILY OF CLINICAL TRIALS
 - 9.1 SPIRIT PRIME Clinical Trial
 - 9.2 SPIRIT III Pivotal Clinical Trial
 - 9.2.1 SPIRIT III Randomized Clinical Trial (RCT)
 - 9.2.2 Dual Vessel Treatment in SPIRIT III
 - 9.2.3 SPIRIT III US 4.0 mm Arm
 - 9.3 SPIRIT IV Clinical Trial
 - 9.3.1 SPIRIT IV Randomized Clinical Trial
 - 9.3.2 Multiple Vessel Treatment in SPIRIT IV
 - 9.4 SPIRIT Small Vessel Registry
 - 9.5 Pooled Analysis of the SPIRIT II-III-IV Clinical Trials
 - 9.6 Gender-Based Analysis of the SPIRIT Family of Clinical Trials
 - 9.6.1 Background
 - 9.6.2 Gender-Based Analysis of the SPIRIT PRIME Clinical Trial
 - 9.6.3 Gender-Based Analysis in the SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Clinical Trials
 - 9.7 XIENCE V USA Post Approval Study
 - 9.7.1 Analysis of Patients with 4.0 mm Stent
 - 9.7.2 Analysis of Patients Treated with Direct Stenting
 - 9.7.3 Pre-specified XIENCE V USA Subgroup Analysis
 - 9.8 EXPERT CTO Clinical Trial
 - 9.8.1 Gender-Based Analysis of the EXPERT CTO Clinical Trial
 - 9.9 Analysis of Diabetic Patients
 - 9.9.1 Analysis of Diabetic Subjects in SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Trials
 - 9.9.2 Bayesian Analysis of Diabetic Patients treated with XIENCE Stents
 - 10.0 INDIVIDUALIZATION OF TREATMENT
 - 11.0 PATIENT COUNSELING AND PATIENT INFORMATION
 - 12.0 HOW SUPPLIED
 - 13.0 OPERATOR'S INSTRUCTIONS
 - 13.1 Inspection Prior to Use
 - 13.2 Materials Required

-
- 13.3 Preparation
 - 13.3.1 Packaging Removal
 - 13.3.2 Guide Wire Lumen Flush
 - 13.3.3 Delivery System Preparation
 - 13.4 Delivery Procedure
 - 13.5 Deployment Procedure
 - 13.6 Removal Procedure
 - 13.7 Post-Deployment Dilatation of Stent Segments
-
- 14.0 *IN VITRO* COMPLIANCE INFORMATION
 - 15.0 REUSE PRECAUTION STATEMENT
 - 16.0 PATENTS AND TRADEMARKS

THE COMPONENTS OF THE XIENCE PRIME STENT SYSTEM ARE STERILE.

1.0 PRODUCT DESCRIPTION

The XIENCE PRIME family of stent systems includes:

- The XIENCE PRIME Everolimus Eluting Coronary Stent System (stent diameters 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm, stent lengths 8, 12, 15, 18, 23 mm)
- XIENCE PRIME LL Everolimus Eluting Coronary Stent System (stent diameters 2.25¹, 2.5, 2.75, 3.0, 3.5, 4.0 mm, stent lengths 28, 33, 38 mm) Everolimus Eluting Coronary Stent Systems

Hereafter the XIENCE PRIME family of stent systems is referred to as the XIENCE PRIME stent or XIENCE PRIME stent system. The XIENCE PRIME stent systems are device / drug combination products consisting of a drug-coated stent and a balloon expandable delivery system. The stent is coated with a formulation containing everolimus, the active ingredient, embedded in a non-erodible polymer, which is identical to the FDA approved XIENCE V[®] Everolimus Eluting Coronary Stent System (XIENCE V EECSS).

¹ The 2.25 mm stent diameter for XIENCE PRIME LL is only available in the 28 mm stent length.

1.1 Device Component Description

The device component consists of a medical grade L-605 cobalt chromium (CoCr) drug-coated stent mounted onto the XIENCE PRIME stent delivery system. The device component characteristics are summarized in Table 1-1.

Table 1-1: XIENCE PRIME Stent System Product Description

| | XIENCE PRIME Stent System | | | | | | | | | | | | | | | |
|---------------------------------|---|----------------------------------|---------------------|--|------|---|-----|---|------|---|-----|----|-----|----|-----|----|
| | XIENCE PRIME | XIENCE PRIME LL | | | | | | | | | | | | | | |
| Available Stent Lengths (mm) | 8, 12, 15, 18, 23 | 28*, 33, 38 | | | | | | | | | | | | | | |
| Available Stent Diameters (mm) | 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 | 2.25**, 2.5, 2.75, 3.0, 3.5, 4.0 | | | | | | | | | | | | | | |
| Stent Material | A medical grade L-605 cobalt chromium CoCr alloy identical to the material used in the XIENCE V stent | | | | | | | | | | | | | | | |
| Drug Component | A conformal coating of a non-erodible polymer loaded with 100 µg/cm ² of everolimus with a maximum nominal drug content of 232 µg on the large stent (4.0 x 38 mm) | | | | | | | | | | | | | | | |
| Delivery System Working Length | 143 cm | | | | | | | | | | | | | | | |
| Delivery System Design | Single access port to inflation lumen; guide wire exit notch is located 25.5 cm from tip; designed for guide wires ≤ 0.014". | | | | | | | | | | | | | | | |
| Stent Delivery System Balloon | A compliant, tapered balloon, with two radiopaque markers located on the catheter shaft to indicate balloon positioning and expanded stent length | | | | | | | | | | | | | | | |
| Balloon Inflation Pressure | Rated Burst Pressure (RBP): 18 atm (1824 kPa) <table border="1" data-bbox="597 1115 1284 1325"> <thead> <tr> <th>Stent Diameter (mm)</th> <th><i>In vitro</i> Stent Nominal Pressure (atm)</th> </tr> </thead> <tbody> <tr> <td>2.25</td> <td>8</td> </tr> <tr> <td>2.5</td> <td>8</td> </tr> <tr> <td>2.75</td> <td>8</td> </tr> <tr> <td>3.0</td> <td>10</td> </tr> <tr> <td>3.5</td> <td>10</td> </tr> <tr> <td>4.0</td> <td>10</td> </tr> </tbody> </table> | | Stent Diameter (mm) | <i>In vitro</i> Stent Nominal Pressure (atm) | 2.25 | 8 | 2.5 | 8 | 2.75 | 8 | 3.0 | 10 | 3.5 | 10 | 4.0 | 10 |
| Stent Diameter (mm) | <i>In vitro</i> Stent Nominal Pressure (atm) | | | | | | | | | | | | | | | |
| 2.25 | 8 | | | | | | | | | | | | | | | |
| 2.5 | 8 | | | | | | | | | | | | | | | |
| 2.75 | 8 | | | | | | | | | | | | | | | |
| 3.0 | 10 | | | | | | | | | | | | | | | |
| 3.5 | 10 | | | | | | | | | | | | | | | |
| 4.0 | 10 | | | | | | | | | | | | | | | |
| Guiding Catheter Inner Diameter | ≥ 5 F (0.056") | | | | | | | | | | | | | | | |
| Catheter Shaft Outer Diameter | Distal: 0.034" (0.86 mm) Proximal: 0.031" (0.79 mm) | | | | | | | | | | | | | | | |


* The 28 mm length stent was studied in the XIENCE PRIME Core Size Registry. The results of the Core Size Registry are presented in Tables 9.1-2 to 9.1-3.

**The 2.25 mm diameter stent for XIENCE PRIME LL is only available in the 28 mm stent length.

1.2.2 Inactive Ingredients – Non-erodible Polymer

The XIENCE PRIME stent contains inactive ingredients, including poly n-butyl methacrylate (PBMA), a polymer that adheres to the stent and drug coating, and PVDF-HFP, which is comprised of vinylidene fluoride and hexafluoropropylene monomers as the drug matrix layer containing everolimus. PBMA is a homopolymer with a molecular weight (Mw) of 264,000 to 376,000 dalton. PVDF-HFP is a non-erodible semicrystalline random copolymer with a molecular weight (Mw) of 254,000 to 293,000 dalton. The drug matrix copolymer is mixed with everolimus (83%/17% w/w polymer/everolimus ratio) and applied to the entire PBMA-coated stent surface. The drug load is 100 µg/cm² for all product sizes. No topcoat layer is used. The polymer chemical structures are shown in Figure 1.2.2-1 below.

Figure 1.2.2-1: Non-erodible Polymer Chemical Structures



1.2.3 Product Matrix and Everolimus Content

Table 1.2.3-1: XIENCE PRIME Stent System Product Matrix and Everolimus Content

| Model Number (RX) | Nominal Expanded Stent Diameter (mm) | Nominal Unexpanded Stent Length (mm) | Nominal Everolimus Content (µg) |
|-------------------|--------------------------------------|--------------------------------------|---------------------------------|
| 1011730 - 08 | 2.25 | 8 | 40 |
| 1011731 - 08 | 2.5 | | 40 |
| 1011732 - 08 | 2.75 | | 40 |
| 1011733 - 08 | 3.0 | | 40 |
| 1011734 - 08 | 3.5 | | 50 |
| 1011735 - 08 | 4.0 | | 50 |
| 1011730 - 12 | 2.25 | 12 | 60 |
| 1011731 - 12 | 2.5 | | 60 |
| 1011732 - 12 | 2.75 | | 60 |
| 1011733 - 12 | 3.0 | | 60 |
| 1011734 - 12 | 3.5 | | 75 |
| 1011735 - 12 | 4.0 | | 75 |
| 1011730 - 15 | 2.25 | 15 | 74 |
| 1011731 - 15 | 2.5 | | 74 |
| 1011732 - 15 | 2.75 | | 74 |
| 1011733 - 15 | 3.0 | | 74 |
| 1011734 - 15 | 3.5 | | 91 |
| 1011735 - 15 | 4.0 | | 91 |
| 1011730 - 18 | 2.25 | 18 | 88 |
| 1011731 - 18 | 2.5 | | 88 |
| 1011732 - 18 | 2.75 | | 88 |
| 1011733 - 18 | 3.0 | | 88 |
| 1011734 - 18 | 3.5 | | 116 |
| 1011735 - 18 | 4.0 | | 116 |
| 1011730 - 23 | 2.25 | 23 | 109 |
| 1011731 - 23 | 2.5 | | 109 |
| 1011732 - 23 | 2.75 | | 109 |
| 1011733 - 23 | 3.0 | | 109 |
| 1011734 - 23 | 3.5 | | 141 |
| 1011735 - 23 | 4.0 | | 141 |
| 1011730 - 28 | 2.25 | 28 | 137 |
| 1011731 - 28 | 2.5 | | 137 |
| 1011732 - 28 | 2.75 | | 137 |
| 1011733 - 28 | 3.0 | | 137 |
| 1011734 - 28 | 3.5 | | 174 |
| 1011735 - 28 | 4.0 | | 174 |
| 1011731 - 33 | 2.5 | 33 | 157 |
| 1011732 - 33 | 2.75 | | 157 |
| 1011733 - 33 | 3.0 | | 157 |
| 1011734 - 33 | 3.5 | | 199 |
| 1011735 - 33 | 4.0 | | 199 |
| 1011731 - 38 | 2.5 | 38 | 185 |
| 1011732 - 38 | 2.75 | | 185 |
| 1011733 - 38 | 3.0 | | 185 |
| 1011734 - 38 | 3.5 | | 232 |
| 1011735 - 38 | 4.0 | | 232 |

2.0 INDICATIONS

The XIENCE PRIME stent system is indicated for improving coronary artery luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease due to *de novo* native coronary artery lesions (length \leq 32 mm) with reference vessel diameters of \geq 2.25 mm to \leq 4.25 mm. Additionally, the XIENCE PRIME stent system is indicated for treating *de novo* chronic total coronary occlusions.

3.0 CONTRAINDICATIONS

The XIENCE PRIME stent system is contraindicated for use in patients:

- Who cannot receive antiplatelet and / or anticoagulant therapy (see section 5.2 – *Precautions, Pre- and Post-Procedure Antiplatelet Regimen* for more information)
- With lesions that prevent complete angioplasty balloon inflation or proper placement of the stent or stent delivery system
- With hypersensitivity or contraindication to everolimus or structurally-related compounds, cobalt, chromium, nickel, tungsten, acrylic, and fluoropolymers

4.0 WARNINGS

- Ensure that the inner package sterile barrier has not been opened or damaged prior to use.
- Judicious patient selection is necessary, because the use of this device carries the associated risk of stent thrombosis, vascular complications, and / or bleeding events.
- This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy (see section 5.2 for important information regarding antiplatelet therapy).

5.0 PRECAUTIONS

5.1 General Precautions

- Stent implantation should only be performed by physicians who have received appropriate training.
- Stent placement should be performed at hospitals where emergency coronary artery bypass graft surgery is accessible.
- Subsequent restenosis may require repeat dilatation of the arterial segment containing the stent. Long-term outcomes following repeat dilatation of the stent is presently unknown.
- Risks and benefits should be considered in patients with severe contrast agent allergies.
- Care should be taken to control the guiding catheter tip during stent delivery, deployment, and balloon withdrawal. Before withdrawing the stent delivery system, visually confirm complete balloon deflation by fluoroscopy to avoid guiding catheter movement into the vessel and subsequent arterial damage.
- Stent thrombosis is a low-frequency event that is frequently associated with myocardial infarction (MI) or death. Data from the SPIRIT family of clinical trials have been prospectively evaluated and adjudicated using both the protocol definition of stent thrombosis and the definition developed by the Academic Research Consortium (ARC),

and demonstrate specific patterns of stent thrombosis that vary depending on the definition used (see section 8.2 – *Adverse Events, Stent Thrombosis Definitions* and section 9.4 – *Spirit Family of Clinical Trials, Pooled SPIRIT II-III-IV Clinical Trials* for more information).

- When DES are used outside the specified Indications for Use, patient outcomes may differ from the results observed in the SPIRIT family of clinical trials.
- Compared to use within the specified Indications for Use, the use of DES in patients and lesions outside of the labeled indications, including more tortuous anatomy, may have an increased risk of adverse events, including stent thrombosis, stent embolization, MI, or death.
- Orally administered everolimus combined with cyclosporine is associated with increased serum cholesterol and triglyceride levels.

5.2 Pre- and Post-Procedure Antiplatelet Regimen

- In the SPIRIT PRIME clinical trial, clopidogrel bisulfate or ticlopidine hydrochloride was administered pre-procedure and for a minimum of 12 months post-procedure (75 mg per day). Aspirin was administered pre-procedure and continued through 5 years (a minimum of 80 mg per day) to reduce thrombosis risk. At 1 year, dual antiplatelet therapy compliance in the Core Size Registry was 92.8% (360/388) and in the Long Lesion Registry was 89.0% (89/100). Upon subject completion of the study, physicians recommended that the subject remain on the aspirin regimen indefinitely).
- The optimal duration of dual antiplatelet therapy, specifically clopidogrel, is unknown and DES thrombosis may still occur despite continued therapy. Data from several studies on sirolimus-eluting or paclitaxel-eluting stents suggest that a longer duration of clopidogrel than was recommended post-procedurally in DES pivotal trials may be beneficial. Current guidelines recommend that patients receive aspirin indefinitely and P2Y₁₂ inhibitor therapy for at least 12 months, if subjects are not at high risk of bleeding (ref: ACCF/AHA/SCAI PCI Practice Guidelines²).
- It is very important that the patient comply with the post-procedural antiplatelet therapy recommendations. Early discontinuation of prescribed antiplatelet medication could result in a higher risk of thrombosis, MI, or death. Prior to percutaneous coronary intervention (PCI), if the patient is required to undergo a surgical or dental procedure that might require early discontinuation of antiplatelet therapy, the interventionalist and patient should carefully consider whether a DES and its associated recommended antiplatelet therapy is the appropriate PCI treatment of choice. Following PCI, should a surgical or dental procedure be recommended, requiring suspension of antiplatelet therapy, the risks and benefits of the procedure should be weighed against the possible risks associated with early discontinuation of antiplatelet therapy. Patients who require early discontinuation of antiplatelet therapy (e.g., secondary to active bleeding) should be monitored carefully for cardiac events. At the discretion of the patient's treating physicians, the antiplatelet therapy should be restarted as soon as possible.

² Levine et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation*, 2011; 124: e574-651

5.3 Multiple Stent Use

A patient's exposure to drug and polymer is proportional to the number and total length of implanted stents. In the SPIRIT PRIME study; total stent length per subject was limited to 76 mm with treatment allowed for up to two lesions each in a different epicardial vessel using XIENCE PRIME and XIENCE PRIME LL. Use of more than two XIENCE PRIME stents to treat lesions longer than 32 mm has not been evaluated and may increase patient complication risks. Studies evaluating the effects of higher drug doses have not been conducted.

In the SPIRIT II, SPIRIT III, and SPIRIT IV clinical trials, lesions > 22 mm in length and ≤ 28 mm in length were treated with planned overlapping XIENCE V stents in the XIENCE V arm, or a single 32 mm TAXUS stent or planned overlapping TAXUS stents in the TAXUS arm.

In the SPIRIT IV clinical trial, there were 239 patients in the planned overlapping XIENCE V stent subgroup, 55 patients in the single 32 mm TAXUS stent subgroup, and 99 patients in the planned overlapping TAXUS subgroup (with 6 patients in the TAXUS arm receiving both single 32 mm and overlapping TAXUS stents). At two years, the target lesion failure (TLF) rate was 11.9% in the planned overlapping XIENCE V stent subgroup, 11.3% in the single 32 mm TAXUS stent subgroup, and 12.9% in the planned overlapping TAXUS stent subgroup.

In the pooled SPIRIT II, SPIRIT III, and SPIRIT IV analysis, there were a total of 317 patients in the planned overlapping XIENCE V stent subgroup, 86 patients in the single 32 mm TAXUS stent subgroup, and 113 patients in the planned overlapping TAXUS stent subgroup. At two years, the TLF rate was 11.7% in the planned overlapping XIENCE V stent subgroup, 12.2% in the single 32 mm TAXUS stent subgroup, and 12.1% in the planned overlapping TAXUS stent subgroup. At two years, the all-cause mortality rate was 3.2% in the planned overlapping XIENCE V stent subgroup, 4.9% in the single 32 mm TAXUS stent subgroup, and 1.9% in the planned overlapping TAXUS stent subgroup. The cardiac death rate was 1.0% in the planned overlapping XIENCE V stent subgroup, 1.2% in the single 32 mm TAXUS stent subgroup, and 0.9% in the planned overlapping TAXUS stent subgroup. At two years, the rate of target vessel MI was 3.2% in the planned overlapping XIENCE V stent subgroup, 7.3% in the single 32 mm TAXUS stent subgroup, and 3.7% in the planned overlapping TAXUS stent subgroup. The Academic Research Consortium (ARC)-defined definite plus probable stent thrombosis rate at two years was 0.7% in the planned overlapping XIENCE V stent subgroup, 1.3% in the single 32 mm TAXUS stent subgroup, and 1.9% in the planned overlapping TAXUS stent subgroup.

In XIENCE V USA, there was no angiographic restriction for patient enrollment. Stent implantation was done per site's standard care. There were 8040 patients with a total of 20 mm (N = 1388) are summarized in Section 9.7.3. In this pre-specified subgroup of patients with long lesions, the mean lesion length was 28 mm with a total XIENCE V stent length of 34.3 mm per patient. At 1 year, the composite of cardiac death or target vessel MI rate (defined by ARC) was 6.8%, the ARC definite and probable ST rate was 0.79%, the ARC defined device-oriented endpoint (composite of cardiac death, target vessel MI [per ARC] and all TLR) was 9.3%.

In XIENCE V USA, there were 1301 (16.7%) patients with 1577 lesions (14.5%) where stent overlapping during the index procedure was reported, including situations where an implanted XIENCE V stent overlaps with a previous implanted stent prior to the index procedure. At 1 year, the composite of cardiac death or target vessel MI rate (defined by ARC) was 9.8%, the ARC definite and probable ST rate was 1.40%, TLF (composite of cardiac death, target vessel MI [per ARC] and clinically indicated TLR) was 13.1%.

Effects of multiple stenting using XIENCE PRIME stents combined with other drug-eluting stents are unknown. When multiple drug-eluting stents are required, use only XIENCE stents with the identical Co-Cr stent material and drug coating (e.g., XIENCE V, XIENCE nano® or XIENCE PRIME) in order to avoid potential interactions with other drug-eluting or coated stents.

In addition, only stents composed of similar materials should be implanted in consecutive stent- to-stent contact, to avoid corrosion potential between unrelated materials.

5.4 Brachytherapy

XIENCE PRIME stent safety and effectiveness have not been evaluated in patients with prior target lesion or in-stent restenosis-related brachytherapy.

5.5 Use in Conjunction with Other Procedures

The safety and effectiveness of using mechanical atherectomy devices (directional atherectomy catheters, rotational atherectomy catheters) or laser angioplasty catheters in conjunction with XIENCE PRIME stent implantation have not been established.

5.6 Use in Special Populations

5.6.1 Pregnancy

Pregnancy Category C, see section 6.5 – *Drug Information, Pregnancy*. The XIENCE PRIME stent has not been tested in pregnant women or in men intending to father children. Effects on the developing fetus have not been studied. Effective contraception should be initiated before implanting a XIENCE PRIME stent and continued for one year after implantation. While there is no contraindication, the risks and reproductive effects are unknown at this time.

5.6.2 Lactation

See section 6.6 – *Drug Information, Lactation*. A decision should be made whether to discontinue nursing prior to stent implantation, considering the importance of the stent to the mother.

5.6.3 Gender

A gender analysis was not pre-specified in the SPIRIT PRIME clinical study. However, post-hoc analyses were conducted to evaluate gender-specific outcomes associated with the XIENCE PRIME stents in the SPIRIT PRIME trials, and the XIENCE V stent in the pooled data from the SPIRIT II, SPIRIT III, and SPIRIT IV trials (see Section 9.6). Additional gender specific data associated with the EXPERT CTO trial can be found in Section 9.8.

5.6.4 Ethnicity

Insufficient subject numbers prevent ethnicity-related analyses of the XIENCE family of stents safety and effectiveness. **Table 5.6.4-1** provides an overview of all Non-Caucasians enrolled in the SPIRIT Trials.

Table 5.6.4-1: Non-Caucasians in the SPIRIT and XIENCE V USA Trials

| | Non-Caucasian Population |
|---------------------|--------------------------|
| SPIRIT III | 8.8% (88/1001) |
| SPIRIT IV | 6.4% (236/3687) |
| SPIRIT Small Vessel | 9.9% (14/142) |
| SPIRIT PRIME CSR | 7.7% (29/375) |
| SPIRIT PRIME LLR | 8.3% (8/96) |
| XIENCE V USA | 12.3% (990/8027) |

5.6.5 Pediatric Use

The safety and effectiveness of the XIENCE PRIME stent in pediatric subjects have not been established.

5.6.6 Geriatric Use

The XIENCE PRIME clinical trial did not have an upper age limit. Among the 401 patients in the SPIRIT PRIME Core Size Registry, 167 were older than age 65 and 234 were age 65 or younger. Among the 104 patients in the SPIRIT PRIME Long Lesion Registry, 48 patients were older than age 65 and 56 were age 65 or younger. A post hoc analysis showed no clinically significant differences in clinical endpoints between patients older than age 65 compared to those age 65 years or younger.

5.7 Lesion / Vessel Characteristics

Safety and effectiveness of the XIENCE PRIME stent have not been established for subject populations with the following clinical settings:

- Unresolved vessel thrombus at the lesion site
- Coronary artery reference vessel diameters < 2.25 mm or > 4.25 mm
- Lesion lengths > 32 mm
- Lesions located in saphenous vein grafts
- Lesions located in unprotected left main coronary artery, ostial lesions, and lesions located at a bifurcation
- Previously stented lesions
- Diffuse disease or poor flow (TIMI < 1) distal to the identified lesions
- Excessive tortuosity proximal to or within the lesion
- Recent acute myocardial infarction (AMI) or evidence of thrombus in the target vessel
- Multivessel disease
- In-stent restenosis

In the all-inclusive, real-world XIENCE V USA post-approval study, several pre-specified subgroup analysis (including the above-mentioned AMI, multivessel disease and in-stent restenosis) were conducted. Please see section 9.7.3 for the clinical outcomes of XIENCE V in those clinical settings.

5.8 Drug Interactions

See section 6.3 – *Drug Information, Interactions with Drugs or Other Substances*.

Several drugs are known to affect everolimus metabolism, and other drug interactions may also occur. Everolimus is known to be a substrate for both cytochrome P4503A4 (CYP3A4) and P-glycoprotein (PgP). Everolimus absorption and subsequent elimination may be influenced by drugs that affect these pathways. Everolimus has also been shown to reduce the clearance of some prescription medications when administered orally along with cyclosporine (CsA). Formal drug interaction studies have not been performed with the XIENCE PRIME stent because of limited systemic exposure to everolimus eluted from XIENCE PRIME (see section 6.2 – *Drug Information, Pharmacokinetics*). Therefore, due consideration should be given to the potential for both systemic and local drug interactions in the vessel wall, when deciding to place the XIENCE PRIME stent in a patient taking a drug with known interaction with everolimus, or when deciding to initiate therapy with such a drug in a patient who has recently received a XIENCE PRIME stent.

5.9 Immune Suppression Potential

Everolimus, the XIENCE PRIME stent active ingredient, is an immunosuppressive agent. Immune suppression was not observed in the SPIRIT family of clinical trials. However, for patients who receive several XIENCE PRIME stents simultaneously, it may be possible for everolimus systemic concentrations to approach immunosuppressive levels temporarily, especially in patients who also have hepatic insufficiency or who are taking drugs that inhibit CYP3A4 or P-glycoprotein. Therefore, consideration should be given to patients taking other immunosuppressive agents or who are at risk for immune suppression.

5.10 Lipid Elevation Potential

Oral everolimus use in renal transplant and advanced renal cell carcinoma patients was associated with increased serum cholesterol and triglycerides, which in some cases required treatment. The effect was seen with both low and high dose prolonged oral therapy in a dose related manner. When used according to the indications for use, exposure to systemic everolimus concentrations from the XIENCE PRIME stent is expected to be significantly lower than concentration exposure usually obtained in transplant patients. Increased serum cholesterol and triglycerides were not observed in the SPIRIT family of clinical trials.

5.11 Magnetic Resonance Imaging (MRI)

Nonclinical testing has demonstrated that the XIENCE PRIME stent, in single and in overlapped configurations up to 71 mm in length, is MR Conditional. It can be scanned safely under the following conditions:

- Static magnetic field of 1.5 or 3 Tesla
- Spatial gradient field of 2500 Gauss/cm or less
- Maximum whole-body-averaged specific absorption rate (SAR) of 2.0 W/kg (normal operating mode) for up to 15 minutes of scanning for each sequence

The XIENCE PRIME stent should not migrate in this MRI environment. Nonclinical testing at field strengths greater than 3 Tesla has not been performed to evaluate stent migration or

heating. MRI at 1.5 or 3 Tesla may be performed immediately following the implantation of the XIENCE PRIME stent.

Stent heating was derived by using the measured nonclinical, *in vitro* temperature rises in a GE Excite 3 Tesla scanner and in a GE 1.5 Tesla coil in combination with the local specific absorption rates (SARs) in a digitized human heart model. The maximum whole body averaged SAR was determined by validated calculation. At overlapped lengths of up to 71 mm, the XIENCE PRIME stent produced a nonclinical maximum local temperature rise of 3.3°C at a maximum whole body averaged SAR of 2.0 W/kg (normal operating mode) for 15 minutes. These calculations do not take into consideration the cooling effects of blood flow.

The effects of MRI on overlapped stents greater than 71 mm in length or stents with fractured struts are unknown.

As demonstrated in nonclinical testing, an image artifact can be present when scanning the XIENCE PRIME stent. MR image quality may be compromised if the area of interest is in the exact same area, or relatively close to, the position of the XIENCE PRIME stent. Therefore, it may be necessary to optimize the MR imaging parameters for the presence of XIENCE PRIME stent.

It is suggested that patients register the conditions under which the implant can safely be scanned with the MedicAlert Foundation (www.medicalert.org) or an equivalent organization.

5.12 Stent Handling

- **Each stent is for single use only.** Do not resterilize or reuse this device. Note the “Use by” (expiration) date on the product label.
- **The foil pouch is not a sterile barrier.** The inner header bag (pouch) within the foil pouch is the sterile barrier. **Only the contents of the inner pouch should be considered sterile.** The outside surface of the inner pouch is NOT sterile.
- **Do not remove the stent from the delivery system.** Removal may damage the stent and/or lead to stent embolization. These components are intended to perform together as a system.
- The delivery system should not be used in conjunction with other stents.
- Special care must be taken not to handle or disrupt the stent on the balloon, particularly during delivery system removal from packaging, placement over the guide wire and advancement through the rotating hemostatic valve adapter and guiding catheter hub.
- **Do not manipulate, touch, or handle the stent** with your fingers, which may cause coating damage, contamination, or stent dislodgement from the delivery balloon.
- Use only the appropriate balloon inflation media (see section 13.3.3 – *Operator’s Instructions, Delivery System Preparation*). Do not use air or any gaseous medium to inflate the balloon as this may cause uneven expansion and difficulty in stent deployment.

5.13 Stent Placement

5.13.1 Stent Preparation

- **Do not prepare or pre-inflate the delivery system prior to stent deployment other than as directed.** Use the balloon purging technique described in section 13.3.3 – *Operator's Instructions, Delivery System Preparation*.
- **While introducing the delivery system into the vessel, do not induce negative pressure on the delivery system.** This may cause dislodgement of the stent from the balloon.
- Use guiding catheters which have lumen sizes that are suitable to accommodate the stent delivery system (see section 1.1 – *Product Description, Device Component Description*).

5.13.2 Stent Implantation

- The decision to pre-dilate the lesion with an appropriate sized balloon should be carefully based on patient and lesion characteristics. The XIENCE V USA Clinical Trial demonstrated that in a real-world setting, direct stenting with XIENCE V stents in single-lesion treated patients who did not have a staged procedure was non-inferior to stenting utilizing pre-dilation. In this analysis there was, as expected, some degree of selection bias with lesions undergoing direct-stenting displaying lower complexity than lesions undergoing pre-dilation. However, adjustment for baseline differences in lesion characteristics did not change the finding of non-inferiority of direct stenting to pre-dilation. Please see Section 9.7.2 for the detailed clinical results from XIENCE V USA post-approval study.
- Do not expand the stent if it is not properly positioned in the vessel (see section 5.14 – *Precautions, Stent System Removal*).
- Implanting a stent may lead to vessel dissection and acute closure requiring additional intervention (CABG, further dilatation, placement of additional stents, or other).
- Although the safety and effectiveness of treating more than one lesion per coronary artery with XIENCE PRIME stents have not been established, if this is performed, place the stent in the distal lesion before the proximal lesion in order to minimize dislodgement risk incurred by traversing through deployed stents.
- Stent placement may compromise side branch patency.
- **Do not exceed Rated Burst Pressure (RBP) as indicated on product label.** See Table 14-1: XIENCE PRIME Stent Compliance. Balloon pressures should be monitored during inflation. Applying pressures higher than specified on the product label may result in a ruptured balloon with possible arterial damage and dissection. The stent inner diameter should approximate 1.1 times the reference diameter of the vessel.
- An unexpanded stent may be retracted into the guiding catheter one time only. An unexpanded stent should not be reintroduced into the artery once it has been pulled back into the guiding catheter. Subsequent movement in and out through the distal end of the guiding catheter should not be performed, as the stent may be damaged when retracting the undeployed stent back into the guiding catheter.
- Should **resistance** be felt **at any time** during coronary stent system withdrawal, please follow the steps provided in section 5.14 – *Precautions, Stent System Removal*.

-
- Stent retrieval methods (i.e., using additional wires, snares, and/or forceps) may result in additional trauma to the coronary vasculature and/or the vascular access site. Complications may include bleeding, hematoma, or pseudoaneurysm.
 - Although the stent delivery system balloon is strong enough to expand the stent without rupture, a circumferential balloon tear distal to the stent and prior to complete stent expansion, could cause the balloon to become tethered to the stent, requiring surgical removal. In case of balloon rupture, it should be withdrawn and, if necessary, a new dilatation catheter exchanged over the guide wire to complete the expansion of the stent.
 - Ensure the stented area covers the entire lesion/dissection site and that no gaps exist between stents.
 - Do not torque the catheter more than one (1) full turn.

5.14 Stent System Removal

Stent delivery system removal prior to stent deployment:

If removal of a stent system is required prior to deployment, ensure that the guiding catheter is coaxially positioned relative to the stent delivery system, and cautiously withdraw the stent delivery system into the guiding catheter. Should unusual resistance be felt at any time when withdrawing the stent towards the guiding catheter, the stent delivery system and the guiding catheter should be removed as a single unit. This should be done under direct visualization with fluoroscopy.

Withdrawal of the stent delivery catheter from the deployed stent:

1. Deflate the balloon by pulling negative on the inflation device. Larger and longer balloons will take more time (up to 30 seconds) to deflate than smaller and shorter balloons. Confirm balloon deflation under fluoroscopy and wait 10 – 15 seconds longer.
2. Position the inflation device to “negative” or “neutral” pressure.
3. Stabilize guiding catheter position just outside coronary ostium and anchor in place. Maintain guide wire placement across stent segment.
4. Gently remove the stent delivery system with slow and steady pressure.
5. Tighten the rotating hemostatic valve.

If during withdrawal of the catheter resistance is encountered use the following steps to improve balloon rewrap.

- Re-inflate the balloon up to nominal pressure.
- Repeat steps 1 through 5 above.

Failure to follow these steps and / or applying excessive force to the delivery system can potentially result in loss of or damage to the stent and / or delivery system components.

If it is necessary to retain guide wire position for subsequent artery / lesion access, leave the guide wire in place and remove all other system components.

Stent retrieval methods (i.e., additional wires, snares, and / or forceps) may result in additional trauma to the coronary vasculature and / or the vascular access site. Complications may include, but are not limited to, bleeding, hematoma, or pseudoaneurysm.

5.15 Post-Procedure

- When **crossing a newly deployed stent** with an intravascular ultrasound (IVUS) catheter, a coronary guide wire, a balloon catheter or delivery system, exercise care to avoid disrupting the stent placement, apposition, geometry, and/or coating.
- Antiplatelet therapy should be administered post-procedure (see section 5.2 – *Precautions, Pre- and Post-Procedure Antiplatelet Regimen*). Patients who require early discontinuation of antiplatelet therapy (e.g., secondary to active bleeding) should be monitored carefully for cardiac events. At the discretion of the patient's treating physician, the antiplatelet therapy should be restarted as soon as possible.
- If the patient requires imaging, see section 5.11 – *Precautions, Magnetic Resonance Imaging (MRI)*.

6.0 DRUG INFORMATION

6.1 Mechanism of Action

The mechanism by which the XIENCE PRIME stent inhibits neointimal growth as seen in pre-clinical and clinical studies has not been established. At the cellular level, everolimus inhibits growth factor-stimulated cell proliferation. At the molecular level, everolimus forms a complex with the cytoplasmic protein FKBP-12 (FK 506 Binding Protein). This complex binds to and interferes with FKBP-12 Rapamycin Associated Protein (FRAP), also known as mammalian target of rapamycin (mTOR), leading to inhibition of cell metabolism, growth, and proliferation by arresting the cell cycle at the late G1 stage.

6.2 Pharmacokinetics

Pharmacokinetic studies have not been performed using the XIENCE PRIME stent, but were conducted on the similar XIENCE V stent. The XIENCE PRIME stent is similar to XIENCE V with regards to the stent design, identical stent coating technology (dosing and drug to polymer ratio), and similar delivery system materials. Given these similarities, the findings from the XIENCE V pharmacokinetic studies, as described below, are applicable to the XIENCE PRIME stent. Everolimus pharmacokinetics when eluted from the XIENCE V stent post-implantation has been evaluated in three different substudies in three different geographies. The SPIRIT III clinical trial design includes a pharmacokinetic substudy in the US randomized arm and a pharmacokinetic substudy in the Japanese nonrandomized arm. The third PK substudy was conducted as part of the SPIRIT II clinical trial at sites in Europe, India, and New Zealand. Whole blood everolimus PK parameters determined from subjects receiving the XIENCE V stent are provided in Table 6.2-1.

Table 6.2-1: Whole Blood Everolimus Pharmacokinetic Parameters in Patients Following XIENCE V Stent Implantation

| SPIRIT III RCT and 4.0 Arm | | | | | | | |
|---------------------------------------|-----------|----------------------|--------------------------|-----------------------------------|---|---|-----------------------|
| | Dose (µg) | t _{max} (h) | C _{max} (ng/mL) | t _{1/2} (h) ^a | AUC _{0-t} ^a (ng.h/mL) | AUC _{0-∞} ^a (ng.h/mL) | CL (L/h) ^a |
| | | median (range) | mean ± SD | mean ± SD | mean ± SD | mean ± SD | mean ± SD |
| 2.5-3.0 x 18 mm (n = 3 ^b) | 88 µg | 0.050 (0.50-1.88) | 0.3867 ± 0.09866 | | 5.31 ± 4.114 | | |
| 3.5-4.0 x 28 mm (n = 6 ^c) | 181 µg | 0.50 (0.07-1.00) | 1.175 ± 0.6817 | 79.08 ± 57.24 | 23.73 ± 13.63 | 44.00 ± 28.67 | 5.130 ± 2.114 |
| SPIRIT III Japanese Arm | | | | | | | |
| | Dose (µg) | t _{max} (h) | C _{max} (ng/mL) | t _{1/2} (h) ^a | AUC _{0-t} (ng.h/mL) | AUC _{0-∞} ^a (ng.h/mL) | CL (L/h) |
| | | median (range) | mean ± SD | mean ± SD | mean ± SD | mean ± SD | mean ± SD |
| 2.5-3.0 x 18 mm (n = 6) | 88 µg | 1.00 (0.50-1.02) | 0.5017 ± 0.1398 | 45.22 ± 35.08 | 5.049 ± 2.138 | 12.98 ± 7.078 | 9.286 ± 6.069 |
| 3.5-4.0 x 18 mm (n = 4 ^b) | 113 µg | 0.51 (0.50-0.53) | 0.6500 ± 0.08756 | 53.57 ± 19.34 | 11.02 ± 4.002 | 19.97 ± 7.890 | 6.471 ± 2.807 |
| SPIRIT II Clinical Trial | | | | | | | |
| | Dose (µg) | t _{max} (h) | C _{max} (ng/mL) | t _{1/2} (h) ^a | AUC _{last} (ng.h/mL) | AUC _{0-∞} ^a (ng.h/mL) | CL (L/h) ^a |
| | | median (range) | mean ± SD | mean ± SD | mean ± SD | mean ± SD | mean ± SD |
| 2.5-3.0 x 18 mm (n = 13) | 88 µg | 0.50 (0.13-2.17) | 0.4369 ± 0.1507 | 54.08 ± 35.78 | 8.255 ± 5.863 | 19.60 ± 15.30 | 8.066 ± 6.443 |
| 3.5-4.0 x 18 mm (n = 4 ^c) | 113 µg | 0.50 (0.50-0.50) | 0.5850 ± 0.2630 | 47.60 ± 62.13 | 42.54 ± 58.83 | 22.79 ± 31.47 | 16.96 ± 13.07 |
| 3.5-4.0 x 28 mm (n = 4) | 181 µg | 0.46 (0.17-1.00) | 0.7925 ± 0.1406 | 103.4 ± 64.17 | 28.07 ± 13.18 | 52.71 ± 27.40 | 5.332 ± 5.048 |

^a Accurate determination not possible due to rapid disappearance of everolimus from the blood

^b n = 5 for t_{1/2} and CL

^c n = 3 for t_{1/2} and CL

t_{max} (h) = time to maximum concentration

C_{max} = maximum observed blood concentration

t_{1/2} (h) = terminal phase half-life

AUC_{0-t} or AUC_{last} = the area beneath the blood concentration versus time curve: time zero to the final quantifiable concentration

AUC_{0-∞} = the area beneath the blood concentration versus time curve: time zero to the extrapolated infinite time

CL = total blood clearance

In all subjects, the maximum time to everolimus disappearance was 168 hours; however, 1 subject in the SPIRIT II clinical trial had detectable levels at 30 days. In all 3 studies, the C_{max} value never reached the minimum therapeutic value of 3.0 ng/mL necessary for effective systemic administration to prevent organ rejection in patients taking Certican[®]. The PK parameters representing elimination, t_{1/2}, AUC_{0-t}, AUC_{last}, AUC_∞, and CL, could also not be determined accurately due to rapid everolimus disappearance from blood. These types of results have been seen with other drug-eluting stents.

Everolimus disappearance from circulation following XIENCE V stent implantation should further limit systemic exposure and adverse events associated with long-term systemic administration at therapeutic levels. Despite limited systemic exposure to everolimus, local arterial delivery has been demonstrated in pre-clinical studies. The same results are expected for XIENCE PRIME due to the similarities with XIENCE V stated above.

6.3 Interactions with Drugs or Other Substances

Everolimus is extensively metabolized by the cytochrome P4503A4 (CYP3A4) in the liver and to some extent in the intestinal wall, and is a substrate for the countertransporter P-glycoprotein (PgP). Therefore, absorption and subsequent elimination of everolimus may be influenced by drugs that also affect CYP3A4 and PgP pathways. Everolimus has also been shown to reduce

the clearance of some prescription medications when it was administered orally along with cyclosporine (CsA). Formal drug interaction studies have not been performed with the XIENCE PRIME or XIENCE V stents because of limited systemic exposure to everolimus eluted from XIENCE V (see section 6.2 – *Drug Information, Pharmacokinetics*). However, consideration should be given to the potential for both systemic and local drug interactions in the vessel wall when deciding to place the XIENCE PRIME stent in a subject taking a drug with known interaction with everolimus.

Everolimus, when prescribed as an oral medication, may interact with the drugs/foods³ listed below. Medications that are strong inhibitors of CYP3A4 or PgP might reduce everolimus metabolism *in vivo*. Hence, co-administration of strong inhibitors of CYP3A4 or PgP may increase the blood concentrations of everolimus. Medications that are strong inducers of CYP3A4 or PgP might increase everolimus metabolism *in vivo* resulting in decreased blood concentrations of everolimus.

- CYP3A4/PgP inhibitors
 - Antifungal agents (e.g., fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole)
 - Macrolide antibiotics (e.g., erythromycin, clarithromycin, telithromycin)
 - Calcium channel blockers (e.g., verapamil, nifedipine, diltiazem)
 - Protease inhibitors (e.g., ritonavir, atazanavir, saquinavir, darunavir, indinavir, nelfinavir, amprenavir, fosamprenavir)
 - Other (e.g., cyclosporine, nefazodone, cisapride, metoclopramide, bromocriptine, cimetidine, danazol, sildenafil, terfenadine, astemizole, grapefruit/grapefruit juice, digoxin)
- CYP3A4/PgP inducers
 - Antibiotics (e.g., rifampin, rifabutin, ciprofloxacin, ofloxacin)
 - Anticonvulsants (e.g., carbamazepine, phenobarbital, phenytoin)
 - Non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, nevirapine)
 - Glucocorticoids (e.g., dexamethasone, prednisone, prednisolone)
 - HMGCoA reductase inhibitors (simvastatin, lovastatin)
 - Other (e.g., St. John's Wort)

Everolimus is approved in the United States under the name of Zortress[®] for the prophylaxis of organ rejection in adult kidney transplant recipients at low-moderate immunologic risk, at the dose of 1.5 mg/day when taken by mouth. Outside the United States, Zortress is sold under the brand name Certican in more than 70 countries. Everolimus is also approved in the United States under the name of Afinitor[®] for the treatment of patients with advanced renal cell carcinoma (cancer) after failure of treatment with sunitinib or sorafenib, at doses of 5 to 20 mg/day when taken by mouth. The amount of drug that circulates in the bloodstream following implantation of a XIENCE PRIME stent is several folds lower than that obtained with oral doses (1.5 mg to 20 mg/day).

³ Zortress Prescribing Information from Drugs@FDA, label approved on April 20, 2010.

6.4 Carcinogenicity, Genotoxicity, and Reproductive Toxicity

The carcinogenicity, genotoxicity, and reproductive toxicity of the XIENCE PRIME stent have not been evaluated; however, long term carcinogenicity and teratology studies were performed with the similar XIENCE V stent. The test results from the XIENCE V stent, as described below, are applicable to the XIENCE PRIME, due to similar stent design, delivery system materials, and identical stent coating technology.

A 26-week carcinogenicity study was conducted to evaluate the carcinogenic potential of XIENCE V stents following subcutaneous implantation in transgenic mice. During the course of the study, there were no abnormal clinical observations that suggested a carcinogenic effect of the test group (XIENCE V stent). The test group did not demonstrate an increased incidence of neoplastic lesions when compared to the negative control group. However, the positive control and the experimental positive control groups demonstrated notable increases in the incidence of neoplastic lesions compared to either the test or the negative control group. Based on the results of this study, the XIENCE V stent does not appear to be carcinogenic when implanted in transgenic mice for 26 weeks.

Genotoxicity studies were conducted on the XIENCE V stent in mammalian cells and bacteria. These studies included gene mutations in bacteria (Ames Test), gene mutations in mammalian cells (chromosomal aberration), test for clastogenicity in mammalian cells, and mammalian erythrocyte micronucleus test. Based on the results of these studies, the XIENCE V stent is not genotoxic.

In addition, a reproductive toxicity (teratology) study was conducted in female Sprague-Dawley rats. The XIENCE V stent did not affect the fertility or reproductive capability of female Sprague-Dawley rats. There was no statistical difference between the test article (XIENCE V stent) and the control system in terms of any of the evaluated parameters. The test article had no effect on litter size and caused no increase of *in utero* mortality. Additionally, the XIENCE V stent did not cause any reproductive toxicity in the offspring in this study.

6.5 Pregnancy

Pregnancy Category C: There are no adequate everolimus or XIENCE PRIME stent related studies in pregnant women. Effects of a similar stent, XIENCE V, on prenatal and postnatal rat development were no different than the controls (see section 6.4 – *Drug Information, Carcinogenicity, Genotoxicity, and Reproductive Toxicity*). When administered at oral doses of 0.1 mg/kg or above, everolimus showed effects on prenatal and postnatal rat development limited to slight body weight changes and fetal survival without any specific toxic potential.⁴ Effective contraception should be initiated before implanting a XIENCE PRIME stent and continued for one year post-implantation. The XIENCE PRIME stent should be used in pregnant women only if potential benefits outweigh potential risks.

The safety of the XIENCE PRIME stent has not been evaluated in males intending to father children.

⁴ Certican Investigator's Brochure

6.6 Lactation

It is unknown whether everolimus is distributed in human milk. Also, everolimus pharmacokinetic and safety profiles have not been determined in infants. Consequently, mothers should be advised of potential serious adverse reactions to everolimus in nursing infants. Prior to XIENCE PRIME stent implantation, decisions should be made regarding whether to discontinue nursing or conduct an alternate percutaneous coronary intervention procedure.

7.0 OVERVIEW OF CLINICAL EXPERIENCE

SPIRIT PRIME is a prospective, open-label, multicenter nonrandomized clinical trial using the core size XIENCE PRIME and XIENCE PRIME LL stent system. Approximately 500 subjects at up to 75 sites were to be enrolled in the Core Size Registry or Long Lesion Registry. Each subject was to receive treatment in up to two *de novo* native coronary lesions, each in a different epicardial vessel. The Core Size Registry was to enroll approximately 400 subjects in which all were to be treated with core size XIENCE PRIME (stent diameters 2.25, 2.5, 3.0, 3.5 or 4.0 mm with stent lengths 8, 18, or 28⁵ mm). The Long Lesion Registry was to enroll approximately 100 subjects in which all were to be treated with at least one XIENCE PRIME LL (stent diameters 2.5, 3.0, 3.5 or 4.0 mm with stent lengths 33 or 38 mm). Treatment of a second target lesion with a core size XIENCE PRIME was recommended. The primary endpoint was target lesion failure (TLF) at 1 year. Secondary endpoints included clinical outcomes at 30 and 180 days and annually from 1 to 3 years. Final follow-up through 3 years is presented here. The SPIRIT PRIME clinical trial is Abbott Vascular's pivotal US trial evaluating XIENCE PRIME.

The XIENCE PRIME stent is similar to the FDA approved XIENCE V stent system. XIENCE V EECSS has been studied extensively in four clinical trials, SPIRIT FIRST, SPIRIT II, SPIRIT III, and SPIRIT IV. Initial clinical safety and performance of the XIENCE V EECSS stent was demonstrated in the SPIRIT FIRST clinical trial in which the XIENCE V EECSS was compared to the VISION bare metal stent. The SPIRIT II clinical trial was a continuation in the assessment of the safety and performance of the XIENCE V EECSS versus the TAXUS[®] Express[®] stent. The SPIRIT III clinical trial was a pivotal clinical trial to demonstrate the safety and effectiveness of the XIENCE V EECSS. SPIRIT IV further evaluated the safety and effectiveness of XIENCE V in a large population of complex subjects. The SPIRIT family of trials evaluating the XIENCE V EECSS is ongoing, inclusive of Investigational Device Exemption (IDE) and post-marketing trials. For more information on the XIENCE V EECSS, refer to the XIENCE V EECSS Instructions for Use (IFU).

Principal XIENCE V safety and effectiveness information is derived from the SPIRIT III clinical trial and confirmed by the SPIRIT IV clinical trial. These studies evaluated the performance of XIENCE V in subjects with symptomatic ischemic disease due to *de novo* lesions in native coronary arteries. Major study characteristics for SPIRIT III and SPIRIT IV are summarized below and listed in Table 7-1.

SPIRIT III, a pivotal clinical trial, was designed to demonstrate the non-inferiority of the XIENCE V stent to the TAXUS Express stent (TAXUS stent) and was conducted in the United States (US) and Japan. The SPIRIT III RCT was a prospective, randomized (2:1; XIENCE V:TAXUS), active-controlled, single-blinded, multicenter, clinical trial in the US designed to evaluate the safety and efficacy of the XIENCE V stent in the treatment of up to two *de novo* lesions ≤ 28 mm in length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 3.75 mm.

⁵ The 28 mm length stent was studied in the XIENCE PRIME Core Size Registry. The results of the Core Size Registry are presented in Tables 9.1-2 to 9.1-3.

The RCT study was designed to enroll 1,002 subjects at up to 80 sites in the US. The primary endpoint in the RCT was in-segment late loss at 240 days, and the co-primary endpoint was ischemia-driven target vessel failure (TVF, defined as the composite of cardiac death, MI, or ischemia-driven TVR) at 270 days. Other secondary endpoints included clinical outcomes of all the subjects (30, 180, 270 days and annually from 1 to 5 years), as well as angiographic results and intravascular ultrasound (IVUS) results at 240 days. Five year results are available, completing follow-up for SPIRIT III RCT.

The SPIRIT IV trial was a prospective, randomized, active-controlled, single-blinded, multicenter evaluation of the XIENCE V stent compared to the TAXUS Express Stent⁶ (TAXUS stent) in the treatment of up to three *de novo* lesions ≤ 28 mm in length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 4.25 mm. The SPIRIT IV trial was randomized 2:1 (XIENCE V:TAXUS) and designed to enroll 3,690 subjects at up to 80 sites in the US. Subjects were stratified by diabetes mellitus (diabetic vs. non-diabetic) and lesion characteristics (complex vs. noncomplex). Complex lesion characteristics included triple vessels treatment, or dual lesions per vessel treatment, or lesions involving RCA-aorto-ostial locations, or bifurcation lesions. The primary endpoint was target lesion failure (TLF) at 1 year. The major secondary endpoints were ID-TLR at 1 year and the composite of cardiac death or target vessel MI at 1 year. Formal non-inferiority and superiority testing were planned for the primary and the two major secondary endpoints by following a fixed sequence. Secondary endpoints included clinical outcomes at 30, 180, 270 days and annually from 1 to 3 years. Three-year results are available, completing follow-up for the SPIRIT IV trial.

The SPIRIT Small Vessel (SV) Registry was a prospective, single-arm, open-label, US multicenter registry study using 2.25 mm diameter XIENCE V EECSS. The trial enrolled a total of 150 subjects, of which 69 subjects were included in an angiographic follow-up cohort, at 33 sites. The SPIRIT SV trial allowed for target and non-target lesion treatment. The target lesion was identified as that lesion intended to be treated by the 2.25 mm XIENCE V EECSS and the non-target lesion was identified as that lesion intended to be treated by the commercial XIENCE V EECSS. The SPIRIT SV trial allowed for single target lesion or two lesion treatment (two target lesions or one target and one non-target lesion) in separate epicardial vessels. The primary endpoint was target lesion failure (TLF, defined as the composite of cardiac death, target vessel myocardial infarction and clinically indicated target lesion revascularization) at 1 year. Three-year results are available, completing follow-up for SPIRIT SV.

The XIENCE V USA study was a prospective, multicenter, FDA mandated post-approval study to evaluate the continued safety and effectiveness of the XIENCE V EECSS in “real-world” settings after commercialization in US, and also to support the FDA dual antiplatelet therapy (DAPT) initiative. A total of 8,040 patients were consecutively enrolled from 191 sites in US in two enrollment stages (5,042 patients from the first stage and 2,998 patients from the second stage). There were three cohorts in this study: (1) phase I cohort (from index procedure to 1 year), consisting of all enrolled patients from both enrollment stages; (2) long-term follow-up cohort (from 1 year to 4 years), consisting of patients from the first enrollment stage who were not transferred to HCRI-DAPT study and remained in the study beyond 1 year; (3) AV-DAPT cohort (from 1 year to 33 months), consisting of patients from the second enrollment stage who were eligible and randomized to the AV-DAPT study. Patients were considered enrolled upon signing the Institutional Review Board (IRB)-approved informed consent form (ICF) and upon completion of the index procedure utilizing only XIENCE V EECSS was (were) implanted during the index procedure. There were no angiographic inclusion and exclusion criteria for this study. For the phase I and the long-term follow-up cohorts, the primary endpoint was the annual rate of ARC-defined stent thrombosis (definite and probable), and the co-primary endpoint was the annual composite rate of cardiac death or any MI. The study design of the AV-DAPT cohort

⁶ In the TAXUS stent arm, there was 1 subject who received 1 TAXUS[®] Liberté[®] Stent.

follows the HCRI-DAPT study (IDE#G080186). Final clinical follow-up through 4 years is available for all the enrolled patients (long-term follow-up cohort).

Table 7-1 summarizes the clinical trial designs for the SPIRIT family of trials. Table 7-2 summarizes the clinical trial design for the XIENCE V USA post-approval study.

Table 7-1: SPIRIT Family Clinical Trial Designs

| | SPIRIT PRIME Clinical Trial | | SPIRIT III Clinical Trial | | SPIRIT IV Clinical Trial | SPIRIT Small Vessel Registry |
|---|---|---|---|---|---|--|
| | Core Size Registry | Long Lesion Registry | RCT (Pivotal) | 4.0 Arm (Registry) | | |
| Study Type/Design | <ul style="list-style-type: none"> • Multicenter • Single-arm • Open-label | <ul style="list-style-type: none"> • Multicenter • Single-arm • Open-label | <ul style="list-style-type: none"> • Multicenter • Randomized • Single-blinded • Active-Control | <ul style="list-style-type: none"> • Multicenter • Single-arm • Open-label | <ul style="list-style-type: none"> • Multicenter • Randomized • Single-blinded • Active-Control | <ul style="list-style-type: none"> • Multicenter • Non-randomized • Open-label • Non-blinded • Single-arm |
| Number of Subjects Enrolled | Total: 400 | Total: 100 | Total: 1,002 XIENCE V: 668 TAXUS Express Control: 334 | Total: 80 | Total: 3,690 XIENCE V: 2,460 TAXUS Express Control: 1,230 ^{**} | Total : 150 No Control |
| Treatment | Up to two <i>de novo</i> lesions in different epicardial vessels | Up to two <i>de novo</i> lesions in different epicardial vessels | Up to two <i>de novo</i> lesions in different epicardial vessels | Up to two <i>de novo</i> lesions in different epicardial vessels | Up to three <i>de novo</i> lesions, maximum of two lesions per epicardial vessel | Up to two <i>de novo</i> lesions in different epicardial vessels |
| Lesion Size | RVD: $\geq 2.25 \leq 4.25$ mm Length: ≤ 22 mm | XIENCE PRIME CS: RVD: $\geq 2.25 \leq 4.25$ mm Length: ≤ 22 mm XIENCE PRIME LL: RVD: $\geq 2.5 \leq 4.25$ mm Length: > 22 mm and ≤ 32 mm | RVD: $\geq 2.5 \leq 3.75$ mm Length: ≤ 28 mm | RVD: $> 3.75 \leq 4.25$ mm Length: ≤ 28 mm | RVD: $\geq 2.5 \leq 4.25^{\S}$ mm Length: ≤ 28 mm | RVD: $\geq 2.25 < 2.50$ mm Length: ≤ 28 mm |
| Stent Sizes (XIENCE PRIME/ XIENCE V) | XIENCE PRIME Diameter: 2.25, 2.5, 3.0, 3.5, 4.0 mm Length: 8, 18, 28 ^{***} mm | XIENCE PRIME LL Diameter: 2.5, 3.0, 3.5, 4.0 mm Length: 33, 38 mm | XIENCE V Diameter: 2.5, 3.0, 3.5 mm Length: 8, 18, 28 mm | XIENCE V Diameter: 4.0 mm Length: 8, 18, 28 mm | XIENCE V Diameter: 2.5, 3.0, 3.5, 4.0 ^{\\$} mm Length: 8, 18, 28 mm | XIENCE V Diameter: 2.25 mm Length: 8, 18, 28 mm |
| Post-Procedure Antiplatelet Therapy | Clopidogrel 12 months minimum (or ticlopidine per site standard), aspirin 3 years | Clopidogrel 12 months minimum (or ticlopidine per site standard), aspirin 3 years | Clopidogrel 6 months minimum (or ticlopidine per site standard), aspirin 5 years | Clopidogrel 6 months minimum (or ticlopidine per site standard), aspirin 5 years | Clopidogrel 12 months minimum (or ticlopidine per site standard), [#] aspirin 3 years | Clopidogrel 12 months minimum (or ticlopidine per site standard), aspirin indefinitely |

| | SPIRIT PRIME Clinical Trial | | SPIRIT III Clinical Trial | | SPIRIT IV Clinical Trial | SPIRIT Small Vessel Registry |
|---|---|---|---|--------------------------------------|---|--|
| | Core Size Registry | Long Lesion Registry | RCT (Pivotal) | 4.0 Arm (Registry) | | |
| Primary Endpoint •Primary Analysis •Major Secondary Analysis 1 •Major Secondary Analysis 2 | TLF (Target lesion failure) at 1 year •TLF (per ARC) at 1 year compared to PG* of 9.2% •TLF (per protocol) at 1 year compared to PG* of 9.2% •TLF (per ARC) at 1 year compared to PG* of 15.3% | TLF (Target Lesion failure) at 1 year •TLF (per ARC) at 1 year compared to PG* of 19.2% •TLF (per protocol) at 1 year compared to PG* of 19.2% •TLF (per ARC) at 1 year compared to PG* of 26% | In-segment late loss at 240 days | In-segment late loss at 240 days | TLF (Target Lesion failure) at 1 year | Clinically indicated target lesion failure at 1 year (composite of cardiac death, target vessel MI and clinically indicated TLR) |
| Co-Primary Endpoint | None | None | TVF (Target vessel Failure) at 270 days | None | None | None |
| Major Secondary Endpoint | None | None | None | None | • Ischemia-driven Target Lesion Revascularization (ID-TLR) at 1 year • Composite endpoint of cardiac death or target vessel MI at 1-year | None |
| Clinical Follow-up | 30, 180 days, 1 to 3 years | 30, 180 days, 1 to 3 years | 30, 180, 240, 270 days, 1 to 5 years | 30, 180, 240, 270 days, 1 to 5 years | 30, 180, 270 days, 1 to 3 years | 30 days, 240 days, 1 to 3 years |
| Status | One, 2, and 3 years reported | One, 2, and 3 years reported | One, 2, 3, 4, and 5 years reported | One, 2, 3, 4, and 5 years reported | One, 2, and 3 years reported | One, 2, and 3 years reported |

* Performance Goal (PG)

** In the TAXUS arm, there was 1 patient who received 1 TAXUS® Liberté® stent.

*** The 28 mm length stent was studied in the Core Size Registry. The results of the Core Size Registry are presented in Tables 9.1-2 to 9.1-3.

§ RVD ≥ 2.5 mm to ≤ 3.75 mm and stent sizes up to 3.5 mm until 4.0 mm TAXUS is commercially available

All subjects receiving a study stent were to be maintained on 75 mg of clopidogrel bisulfate daily for a minimum of 6 months, and per the American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI) guidelines it was strongly recommended that subjects should be treated with clopidogrel bisulfate up to 12 months if they are not at high risk for bleeding.

Table 7-2: XIENCE V USA Post-Approval Study Design

| | XIENCE V USA Phase I Cohort | XIENCE V USA Long-Term Follow-up Cohort | XIENCE V USA AV-DAPT Cohort |
|--|--|--|---|
| Study Type/Design | <ul style="list-style-type: none"> • Multicenter • Prospective | <ul style="list-style-type: none"> • Multicenter • Prospective | <ul style="list-style-type: none"> • Multicenter • Randomized • Double-blinded • Placebo Control |
| Number of Subjects Enrolled | Total: 8040 | Total: 4663 | Total: 868 |
| Treatment | Only XIENCE V EECSS implanted during the index procedure; otherwise per site standard care | Only XIENCE V EECSS implanted during the index procedure; otherwise per site standard care | Only XIENCE V EECSS implanted during the index procedure; otherwise per site standard care. At 1 year, patients were randomized to receive either thienopyridine or placebo treatment for additional 18 months along with aspirin |
| Lesion Size | No angiographic restrictions | No angiographic restrictions | No angiographic restrictions |
| Stent Sizes (XIENCE V) | Diameter: 2.5, 2.75, 3.0, 3.5, 4.0 mm Length: 8, 12, 15, 18, 23, 28 mm | Diameter: 2.5, 2.75, 3.0, 3.5, 4.0 mm Length: 8, 12, 15, 18, 23, 28 mm | Diameter: 2.5, 2.75, 3.0, 3.5, 4.0 mm Length: 8, 12, 15, 18, 23, 28 mm |
| Post-Procedure Antiplatelet Therapy | Per site standard | Per site standard | Patients were randomized to receive either thienopyridine or placebo treatment between 12 and 30 months. Thienopyridine or placebo will be discontinued between 30 and 33 months. Aspirin is required through 33 months. |
| Primary Endpoint | ARC definite and probable stent thrombosis up to 1 year | ARC definite and probable stent thrombosis from year 1 to 4 | MACE (composite of all death, MI and stroke) 12-33 months |
| Co-Primary Endpoint | Composite rate of cardiac death or any MI at 1 year | Composite rate of cardiac death or any MI from year 1 to 4 | ARC definite and probable ST 12-33 months |
| Major Safety Endpoint | None | None | Major bleeding (GUSTO severe and moderate bleeding combined) 12-33 months |
| Major Secondary Endpoint | None | None | None |
| Clinical Follow-up | 14, 30, 180 days, and 1 year | 2, 3, and 4 years | 15, 24, 30, and 33 months |
| Angiographic Follow-up | None | None | None |
| IVUS Follow-up | None | None | None |
| PK Study | None | None | None |
| Status | 1 year reported | Two, 3, and 4 years reported | 15, 24, 30, and 33 months reported |

8.0 ADVERSE EVENTS

8.1 Observed Adverse Events

Principal adverse event information is derived from the SPIRIT PRIME Core Size Registry, SPIRIT IV, SPIRIT III, and SPIRIT SV clinical trials and is shown in Table 8.1-1. Principal adverse events from the XIENCE V USA clinical trial are presented in Table 8.1-2. See also section 8.3 – *Adverse Events, Potential Adverse Events*. See section 9.0 – *SPIRIT Family of Clinical Trials* for more complete study design descriptions and results.

Note: Information on adverse events for subjects in the SPIRIT PRIME Long Lesion Registry is in Table 9.1-4.

**Table 8.1-1: SPIRIT Family:
Principal Adverse Events from Post-Procedure to Latest Follow-up**

| | SPIRIT PRIME | SPIRIT IV | | SPIRIT III (RCT) | | | SPIRIT SV |
|---|---|---------------------|------------------|--------------------|-----------------|------------------------------|----------------------------|
| | Core Size Registry ^s (N = 401) | XIENCE V (N = 2458) | TAXUS (N = 1229) | XIENCE V (N = 669) | TAXUS (N = 333) | XIENCE V 4.0 mm Arm (N = 73) | 2.25 mm XIENCE V (N = 144) |
| In Hospital Adverse Events | | | | | | | |
| TLF | 2.0% (8/401) | 1.4% (35/2451) | 1.9% (23/1224) | 0.9% (6/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| MACE | 2.0% (8/401) | 1.4% (35/2451) | 1.9% (23/1224) | 0.9% (6/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| TVF | NA | 1.5% (36/2451) | 2.0% (24/1224) | 0.9% (6/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| All Death | 0.0% (0/401) | 0.0% (0/2451) | 0.0% (0/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.0% (0/143) |
| Cardiac Death | 0.0% (0/401) | 0.0% (0/2451) | 0.0% (0/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.0% (0/143) |
| Non-Cardiac Death | 0.0% (0/401) | 0.0% (0/2451) | 0.0% (0/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.0% (0/143) |
| MI | 1.7% (7/401) | 1.4% (35/2451) | 1.8% (22/1224) | 0.7% (5/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| QMI | 0.2% (1/401) | 0.1% (3/2451) | 0.2% (2/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.7% (1/143) |
| NQMI | 1.5% (6/401) | 1.3% (32/2451) | 1.6% (20/1224) | 0.7% (5/669) | 1.8% (6/330) | 4.1% (3/73) | 0.7% (1/143) |
| Cardiac Death or MI | 1.7% (7/401) | 1.4% (35/2451) | 1.8% (22/1224) | 0.7% (5/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| Ischemia-Driven Revascularization | 0.5% (2/401) | 0.4% (9/2451) | 0.5% (6/1224) | 0.1% (1/669) | 0.0% (0/330) | 0.0% (0/73) | 0.7% (1/143) |
| Ischemia – Driven TLR | 0.2% (1/401) | 0.3% (8/2451) | 0.4% (5/1224) | 0.1% (1/669) | 0.0% (0/330) | 0.0% (0/73) | 0.0% (0/143) |
| Ischemia – Driven TVR, Non TL | 0.2% (1/401) | 0.1% (3/2451) | 0.2% (2/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.7% (1/143) |
| Stent Thrombosis (Per Protocol) | 0.5% (2/401) | 0.1% (3/2451) | 0.4% (5/1224) | 0.1% (1/669) | 0.0% (0/330) | 1.4% (1/73) | 0.0% (0/143) |
| 30-Day TLF | 2.2% (9/401) | 1.6% (38/2451) | 2.7% (33/1222) | 1.2% (8/667) | 2.1% (7/330) | 4.1% (3/73) | 2.1% (3/140) |
| 6-Month TLF ¹ | 3.8% (15/399) | 2.5% (62/2435) | 5.1% (62/1208) | 2.3% (15/663) | 4.3% (14/326) | 6.8% (5/73) | NA |
| 9-Month TLF ² | NA | 3.4% (83/2419) | 6.1% (73/1201) | 4.1% (27/657) | 7.8% (25/321) | 6.8% (5/73) | 7.2% (10/139) |
| 30-Day TVF | NA | 1.9% (46/2451) | 2.9% (36/1222) | 1.5% (10/667) | 2.7% (9/330) | 4.1% (3/73) | 2.9% (4/140) |
| 6-Month TVF | NA | 3.4% (82/2435) | 6.0% (73/1208) | 3.8% (25/663) | 4.9% (16/326) | 6.8% (5/73) | NA |
| 9-Month ⁵ TVF | NA | 4.6% (111/2419) | 7.1% (85/1201) | 7.2% (47/657) | 9.0% (29/321) | 6.8% (5/73) | 9.4% (13/139) |
| 1-Year Subject Counts of Adverse Events | | | | | | | |
| TLF ³ | 4.5% (18/399) | 4.0% (97/2416) | 6.8% (81/1195) | 5.2% (34/653) | 9.7% (31/320) | 6.8% (5/73) | 8.1% (11/136) |
| TVF | NA | 5.5% (134/2416) | 7.7% (92/1195) | 8.6% (56/653) | 11.3% (36/320) | 6.8% (5/73) | 11.0% (15/136) |
| All Death | 0.8% (3/399) | 1.0% (25/2416) | 1.3% (15/1195) | 1.2% (8/655) | 1.2% (4/321) | 1.4% (1/73) | 1.5% (2/136) |

| | SPiRiT PRIME | SPiRiT IV | | SPiRiT III (RCT) | | | SPiRiT SV |
|---|---|---------------------|------------------|--------------------|-----------------|------------------------------|----------------------------|
| | Core Size Registry ^s (N = 401) | XIENCE V (N = 2458) | TAXUS (N = 1229) | XIENCE V (N = 669) | TAXUS (N = 333) | XIENCE V 4.0 mm Arm (N = 73) | 2.25 mm XIENCE V (N = 144) |
| Cardiac Death | 0.3% (1/399) | 0.4% (10/2416) | 0.4% (5/1195) | 0.8% (5/655) | 0.9% (3/321) | 1.4% (1/73) | 1.5% (2/136) |
| Non-Cardiac Death | 0.5% (2/399) | 0.6% (15/2416) | 0.8% (10/1195) | 0.5% (3/655) | 0.3% (1/321) | 0.0% (0/73) | 0.0% (0/136) |
| All MI | 1.8% (7/399) | 1.9% (45/2416) | 3.1% (37/1195) | 2.8% (18/653) | 4.1% (13/320) | 4.1% (3/73) | 1.5% (2/136) |
| QMI | 0.3% (1/399) | 0.1% (3/2416) | 0.4% (5/1195) | 0.3% (2/653) | 0.3% (1/320) | 0.0% (0/73) | 0.7% (1/136) |
| NQMI | 1.5% (6/399) | 1.7% (42/2416) | 2.8% (33/1195) | 2.5% (16/653) | 3.8% (12/320) | 4.1% (3/73) | 0.7% (1/136) |
| Target Vessel MI | 1.8% (7/399) | 1.8% (44/2416) | 2.9% (35/1195) | NA | NA | NA | 1.5% (2/136) |
| Cardiac Death or all MI | 2.0% (8/399) | 2.2% (54/2416) | 3.3% (39/1195) | 3.4% (22/653) | 4.7% (15/320) | 5.5% (4/73) | 2.9% (4/136) |
| ID* TVR | 4.5% (18/399) | 3.9% (94/2416) | 5.9% (70/1195) | 6.1% (40/653) | 7.5% (24/320) | 2.7% (2/73) | 8.8% (12/136) |
| ID* TLR | 2.5% (10/399) | 2.5% (61/2416) | 4.6% (55/1195) | 3.4% (22/653) | 5.6% (18/320) | 2.7% (2/73) | 5.1% (7/136) |
| ID* Non-TLR TVR | 2.8% (11/399) | 2.3% (56/2416) | 3.1% (37/1195) | 3.1% (20/653) | 4.4% (14/320) | 0.0% (0/73) | 5.9% (8/136) |
| Protocol Defined Stent Thrombosis ⁴ | 0.5% (2/399) | 0.17% (4/2389) | 0.85% (10/1181) | 0.8% (5/647) | 0.6% (2/317) | 1.4% (1/72) | 2.2% (3/136) |
| ARC Definite+Probable Stent Thrombosis ⁴ | 0.5% (2/399) | 0.29% (7/2391) | 1.10% (13/1181) | 1.1% (7/652) | 0.6% (2/319) | 0.0% (0/72) | 1.5% (2/136) |
| ARC Definite Stent Thrombosis ⁴ | 0.5% (2/399) | 0.25% (6/2391) | 0.85% (10/1181) | 0.8% (5/652) | 0.0% (0/319) | 0.0% (0/72) | 0.7% (1/138) |
| 2-Year Subject Counts of Adverse Events | | | | | | | |
| TLF ³ | 6.4% (25/392) | 7.0% (167/2388) | 10.0% (119/1190) | 7.1% (45/637) | 12.8% (39/305) | 8.6% (6/70) | 8.3% (11/133) |
| TVF | NA | 9.6% (230/2388) | 11.8% (140/1190) | 11.3% (72/637) | 16.4% (50/305) | 10.0% (7/70) | 12.0% (16/133) |
| All Death | 2.0% (8/392) | 2.1% (51/2388) | 2.7% (32/1190) | 2.0% (13/642) | 2.6% (8/309) | 6.9% (5/72) | 1.5% (2/133) |
| Cardiac Death | 0.5% (2/392) | 0.9% (22/2388) | 1.3% (15/1190) | 1.1% (7/642) | 1.3% (4/309) | 2.8% (2/72) | 1.5% (2/133) |
| Vascular Death | 0.5% (2/392) | NA | NA | NA | NA | NA | NA |
| Non-Cardiac Death | 1.0% (4/392) | 1.2% (29/2388) | 1.4% (17/1190) | 0.9% (6/642) | 1.3% (4/309) | 4.2% (3/72) | 0.0% (0/133) |
| All MI | 2.0% (8/392) | 2.6% (61/2388) | 3.9% (47/1190) | 3.3% (21/637) | 5.9% (18/305) | 4.3% (3/70) | 1.5% (2/133) |
| QMI | 0.5% (2/392) | 0.1% (3/2388) | 0.8% (9/1190) | 0.5% (3/637) | 0.7% (2/305) | 0.0% (0/70) | 0.8% (1/133) |
| NQMI | 1.5% (6/392) | 2.4% (58/2388) | 3.4% (40/1190) | 2.8% (18/637) | 5.2% (16/305) | 4.3% (3/70) | 0.8% (1/133) |
| Target Vessel MI | 1.8% (7/392) | 2.3% (56/2388) | 3.5% (42/1190) | NA | NA | NA | 1.5% (2/133) |
| Cardiac Death or all MI | 2.6% (10/392) | 3.4% (82/2388) | 4.6% (55/1190) | 4.1% (26/637) | 6.9% (21/305) | 7.1% (5/70) | 3.0% (4/133) |
| ID* TVR | 6.9% (27/392) | 7.0% (168/2388) | 8.9% (106/1190) | 8.8% (56/637) | 11.1% (34/305) | 4.3% (3/70) | 9.8% (13/133) |

| | SPiRiT PRIME | SPiRiT IV | | SPiRiT III (RCT) | | | SPiRiT SV |
|---|---|---------------------|------------------|--------------------|-----------------|------------------------------|----------------------------|
| | Core Size Registry ^s (N = 401) | XIENCE V (N = 2458) | TAXUS (N = 1229) | XIENCE V (N = 669) | TAXUS (N = 333) | XIENCE V 4.0 mm Arm (N = 73) | 2.25 mm XIENCE V (N = 144) |
| ID* TLR | 4.1% (16/392) | 4.4% (106/2388) | 6.9% (82/1190) | 4.6% (29/637) | 7.5% (23/305) | 2.9% (2/70) | 5.3% (7/133) |
| ID* Non-TLR TVR | 4.3% (17/392) | 3.9% (94/2388) | 4.3% (51/1190) | 4.9% (31/637) | 6.6% (20/305) | 1.4% (1/70) | 6.8% (9/133) |
| 3-Year Subject Counts of Adverse Events | | | | | | | |
| TLF ³ | 8.5% (33/390) | 9.5% (223/2348) | 11.9% (138/1158) | 8.9% (56/629) | 15.1% (46/305) | 8.8% (6/68) | 12.1% (16/132) |
| TVF | NA | 13.3% (312/2348) | 14.5% (168/1158) | 14.3% (90/629) | 20.0% (61/305) | 11.8% (8/68) | 16.7% (22/132) |
| All Death | 3.1% (12/390) | 3.4% (81/2348) | 5.2% (60/1158) | 2.8% (18/636) | 4.5% (14/312) | 8.5% (6/71) | 3.8% (5/132) |
| Cardiac Death | 0.8% (3/390) | 1.4% (34/2348) | 1.9% (22/1158) | 1.6% (10/636) | 1.9% (6/312) | 2.8% (2/71) | 3.8% (5/132) |
| Vascular Death | 0.5% (2/390) | NA | NA | NA | NA | NA | NA |
| Non-Cardiac Death | 1.8% (7/390) | 2.0% (47/2348) | 3.3% (38/1158) | 1.3% (8/636) | 2.6% (8/312) | 5.6% (4/71) | 0.0% (0/132) |
| All MI | 3.1% (12/390) | 3.1% (73/2348) | 4.7% (55/1158) | 3.8% (24/629) | 6.6% (20/305) | 4.4% (3/68) | 1.5% (2/132) |
| QMI | 1.0% (4/390) | 0.3% (6/2348) | 0.9% (11/1158) | 0.5% (3/629) | 0.7% (2/305) | 0.0% (0/68) | 0.8% (1/132) |
| NQMI | 2.6% (10/390) | 2.9% (67/2348) | 4.0% (46/1158) | 3.3% (21/629) | 5.9% (18/305) | 4.4% (3/68) | 0.8% (1/132) |
| Target Vessel MI | 2.6% (10/390) | 2.8% (65/2348) | 4.1% (48/1158) | NA | NA | NA | 1.5% (2/132) |
| Cardiac Death or all MI | 3.8% (15/390) | 4.5% (105/2348) | 6.0% (70/1158) | 5.1% (32/629) | 8.2% (25/305) | 7.4% (5/68) | 5.3% (7/132) |
| ID* TVR | 9.5% (37/390) | 10.1% (238/2348) | 10.6% (123/1158) | 11.1% (70/629) | 14.8% (45/305) | 5.9% (4/68) | 12.1% (16/132) |
| ID* TLR | 5.4% (21/390) | 6.3% (148/2348) | 7.9% (92/1158) | 5.7% (36/629) | 9.2% (28/305) | 2.9% (2/68) | 6.8% (9/132) |
| ID* Non-TLR TVR | 5.9% (23/390) | 5.6% (132/2348) | 5.4% (63/1158) | 6.7% (42/629) | 8.9% (27/305) | 2.9% (2/68) | 8.3% (11/132) |
| 4-Year Subject Counts of Adverse Events | | | | | | | |
| TLF ³ | NA | NA | NA | 11.9% (73/615) | 17.2% (52/302) | 8.8% (6/68) | NA |
| TVF | NA | NA | NA | 18.5% (114/615) | 22.5% (68/302) | 11.8% (8/68) | NA |
| All Death | NA | NA | NA | 4.9% (31/628) | 6.1% (19/311) | 8.5% (6/71) | NA |
| Cardiac Death | NA | NA | NA | 2.5% (16/628) | 2.6% (8/311) | 2.8% (2/71) | NA |
| Non-Cardiac Death | NA | NA | NA | 2.4% (15/628) | 3.5% (11/311) | 5.6% (4/71) | NA |
| All MI | NA | NA | NA | 4.4% (27/615) | 6.6% (20/302) | 4.4% (3/68) | NA |
| QMI | NA | NA | NA | 1.0% (6/615) | 0.7% (2/302) | 0.0% (0/68) | NA |
| NQMI | NA | NA | NA | 3.4% (21/615) | 6.0% (18/302) | 4.4% (3/68) | NA |

| | SPIRIT PRIME | SPIRIT IV | | SPIRIT III (RCT) | | | SPIRIT SV |
|---|---|---------------------|------------------|--------------------|-----------------|------------------------------|----------------------------|
| | Core Size Registry ^s (N = 401) | XIENCE V (N = 2458) | TAXUS (N = 1229) | XIENCE V (N = 669) | TAXUS (N = 333) | XIENCE V 4.0 mm Arm (N = 73) | 2.25 mm XIENCE V (N = 144) |
| Target Vessel MI | NA | NA | NA | NA | NA | NA | NA |
| Cardiac Death or all MI | NA | NA | NA | 6.5% (40/615) | 8.9% (27/302) | 7.4% (5/68) | NA |
| ID* TVR | NA | NA | NA | 14.3% (88/615) | 16.6% (50/302) | 5.9% (4/68) | NA |
| ID* TLR | NA | NA | NA | 8.0% (49/615) | 10.6% (32/302) | 4.4% (3/68) | NA |
| ID* Non-TLR TVR | NA | NA | NA | 7.8% (48/615) | 9.6% (29/302) | 2.9% (2/68) | NA |
| 5-Year Subject Counts of Adverse Events | | | | | | | |
| 5-Year TLF ³ | NA | NA | NA | 13.4% (81/605) | 20.6% (59/286) | 10.4% (7/67) | NA |
| TVF | NA | NA | NA | 20.3% (123/605) | 26.6% (76/286) | 11.9% (8/67) | NA |
| All Death | NA | NA | NA | 6.0% (37/621) | 10.3% (31/300) | 8.6% (6/70) | NA |
| Cardiac Death | NA | NA | NA | 2.7% (17/621) | 4.3% (13/300) | 2.9% (2/70) | NA |
| Non-Cardiac Death | NA | NA | NA | 3.2% (20/621) | 6.0% (18/300) | 5.7% (4/70) | NA |
| All MI | NA | NA | NA | 4.6% (28/605) | 7.0% (20/286) | 4.5% (3/67) | NA |
| QMI | NA | NA | NA | 1.0% (6/605) | 0.7% (2/286) | 0.0% (0/67) | NA |
| NQMI | NA | NA | NA | 3.8% (23/605) | 6.3% (18/286) | 4.5% (3/67) | NA |
| Target Vessel MI | NA | NA | NA | NA | NA | NA | NA |
| Cardiac Death or all MI | NA | NA | NA | 7.1% (43/605) | 11.2% (32/286) | 7.5% (5/67) | NA |
| ID* TVR | NA | NA | NA | 15.7% (95/605) | 19.9% (57/286) | 6.0% (4/67) | NA |
| ID* TLR | NA | NA | NA | 8.9% (54/605) | 12.9% (37/286) | 4.5% (3/67) | NA |
| ID* Non-TLR TVR | NA | NA | NA | 8.8% (53/605) | 11.9% (34/286) | 3.0% (2/67) | NA |

Notes:

- Population for SPIRIT PRIME Core Size Registry consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8-hour post-index procedure and hospital discharge. SPIRIT III and IV based on intent-to-treat population (all subjects randomized, regardless of the treatment they actually received).
- In-hospital is defined as hospitalization less than or equal to 7-day post-index procedure.
- All counts presented in this table are subject counts. Subjects are counted only once for each event for each time period.
- This table includes revascularizations on any target vessel(s) / lesion(s) for subjects with two or more target vessels / lesions treated.
- One subject in the SPIRIT III, TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
 - TLF includes cardiac death, target vessel MI (per protocol definition) and ischemia-driven TLR. For SPIRIT III 4.0 mm arm, MACE (cardiac death, all MI [per protocol definition] and ischemia-driven TLR) is reported, as TLF was not an endpoint.
- SPIRIT SV based on full analysis set (FAS) population.
- For SPIRIT III, cardiac death is defined as the number of patients experiencing cardiac death through the follow-up time point / (the number of patients experiencing cardiac death through the follow-up time point + the number of patients followed through the follow-up time point without cardiac death + the number of patients terminated prior to the follow-up time point who did not experience cardiac death but experienced non-cardiac death, MI, ID or non-ID TLR, or ID or non-ID TVR).

– Deaths were adjudicated in SPIRIT PRIME as cardiac, vascular, and non-cardiovascular. SPIRIT III, IV, and SV adjudicated deaths as cardiac or non-cardiac.

¹ SPIRIT III and SPIRIT IV include 14-day window. SPIRIT PRIME includes 28-day window.

² SPIRIT III and SPIRIT IV includes 14-day window.

³ SPIRIT III, SPIRIT IV, and SPIRIT PRIME include 28-day window.

⁴ See section 8.2 – *Adverse Events, Stent Thrombosis Definitions*.

⁵ SPIRIT SV 8-month data are presented, as follow-up was not required at 9 months

[§] For Long Lesion Registry data, see Table 9.1-4.

* For SPIRIT PRIME, it is captured as clinically indicated (CI).

**Table 8.1-2: XIENCE V USA Post-Approval Study
Principal Adverse Events from Post-Procedure to 4 Years**

| | XIENCE V USA | | | | |
|--|------------------------|--------------------|--------------------|--------------------|------------------------|
| | XIENCE V (N = 8040) | | | | XIENCE V (N = 5020) |
| | In-Hospital | 30 Days | 6 Months | 1 Year | 4 Years |
| TLF | 2.7% (214/8001) | 3.5% (275/7963) | 6.2% (490/7854) | 9.4% (707/7522) | 19.3% (875/4530) |
| All Death | 0.02% (2/8001) | 0.4% (28/7963) | 1.4% (108/7854) | 2.6% (194/7522) | 10.9% (494/4530) |
| Cardiac Death | 0.01% (1/8001) | 0.3% (25/7963) | 0.9% (69/7854) | 1.4% (108/7522) | 5.4% (244/4530) |
| Vascular Death | 0.0% (0/8001) | 0.01% (1/7963) | 0.1% (6/7854) | 0.2% (12/7522) | 0.7% (32/4530) |
| Non-Cardiovascular Death | 0.01% (1/8001) | 0.03% (2/7963) | 0.4% (33/7854) | 1.0% (74/7522) | 4.8% (218/4530) |
| MI | 2.7% (216/8001) | 3.3% (266/7963) | 4.7% (372/7854) | 6.3% (475/7522) | 11.3% (511/4530) |
| QMI | 0.2% (18/8001) | 0.3% (25/7963) | 0.4% (30/7854) | 0.5% (39/7522) | 1.5% (68/4530) |
| NQMI | 2.5% (198/8001) | 3.0% (241/7963) | 4.4% (346/7854) | 5.9% (442/7522) | 10.1% (457/4530) |
| Cardiac Death or MI | 2.7% (216/8001) | 3.6% (286/7963) | 5.4% (422/7854) | 7.2% (545/7522) | 14.9% (676/4530) |
| Clinically Indicated Revascularization | 0.2% (17/8001) | 1.0% (81/7963) | 4.5% (352/7854) | 8.1% (607/7522) | 19.9% (901/4530) |
| Clinically Indicated TLR | 0.2% (13/8001) | 0.4% (30/7963) | 2.2% (173/7854) | 4.4% (330/7522) | 10.4% (473/4530) |
| Clinically Indicated TVR, Non TL | 0.02% (2/8001) | 0.2% (15/7963) | 1.0% (82/7854) | 2.1% (161/7522) | 6.1% (277/4530) |
| Stent Thrombosis (ARC Definite and Probable) | 0.11% (9/8000) | 0.40% (32/7951) | 0.58% (45/7790) | 0.81% (60/7380) | 1.56% (64/4093) |
| Stent Thrombosis (ARC Definite) | 0.11% (9/8000) | 0.23% (18/7951) | 0.35% (27/7790) | 0.54% (40/7380) | 1.05% (43/4093) |

Notes:

- In-hospital is defined as hospitalization less than or equal to 7 days post-index procedure
- 30-day window is through 37 days (7-day window)
- 6-month window is through 194 days (14-day window)
- 1-year window is through 407 days (42-day window) or randomization date if occurred within 407 days for the second enrollment phase. 4-year window is through 1502 days (42-day window).
- All counts presented in this table are subject counts. Subjects are counted only once for each event for each time period.
- ARC MI definition was used for MI and MI related endpoints.
- TLF includes cardiac death, target vessel MI and clinically indicated TLR.

8.2 Stent Thrombosis Definitions

Protocol defined stent thrombosis (ST) was categorized as acute (< 1 day), subacute (1 – 30 days) and late (> 30 days) and was defined as any of the following⁷:

- Clinical presentation of acute coronary syndrome with angiographic evidence of stent thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)
- In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)⁸ in the distribution of the target lesion within 30 days

All stent thrombosis events were also classified using the ST definitions proposed by the Academic Research Consortium (ARC)⁹. This was performed by an independent event committee blinded to the treatment group of the individual subject. The committee categorized each incident of ST by timing and level of probability (definite, probable, possible), and relation to the original index procedure (primary, secondary after revascularization). These categories are defined as follows:

Timing:

- Early ST: 0 to 30 days post stent implantation
- Late ST: 31 days to 1 year post stent implantation
- Very late ST: > 1 year post stent implantation

Level of probability:

- Definite ST – considered to have occurred by either angiographic or pathologic confirmation
- Probable ST – considered to have occurred after intracoronary stenting in the following cases:
 1. Any unexplained death within the first 30 days
 2. Irrespective of the time after the index procedure, any MI which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause
- Possible ST – considered to have occurred with any unexplained death following 30 days after the intracoronary stenting until the end of trial follow-up¹⁰

8.3 Potential Adverse Events

Adverse events (in alphabetical order) which may be associated with percutaneous coronary and treatment procedures including coronary stent use in native coronary arteries include, but are not limited to:

- Abrupt closure
- Access site, hematoma, or hemorrhage
- Acute myocardial infarction

⁷ For SPIRIT FIRST Stent Thrombosis is defined as total occlusion by angiography at the stent site with abrupt onset of symptoms, elevated biochemical markers, and ECG changes consistent with MI.

⁸ Non-specific ST/T changes, and cardiac enzyme elevations do not suffice.

⁹ Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. *Circ* 2007;115:2344-51.

¹⁰ All data within these Instructions for Use are presented as definite+probable only.

-
- Allergic reaction or hypersensitivity to contrast agent or cobalt, chromium, nickel, tungsten, acrylic and fluoropolymers; and drug reactions to antiplatelet drugs or contrast agent
 - Aneurysm
 - Arterial perforation and injury to the coronary artery
 - Arterial rupture
 - Arteriovenous fistula
 - Arrhythmias, atrial and ventricular
 - Bleeding complications, which may require transfusion
 - Cardiac tamponade
 - Coronary artery spasm
 - Coronary or stent embolism
 - Coronary or stent thrombosis
 - Death
 - Dissection of the coronary artery
 - Distal emboli (air, tissue or thrombotic)
 - Emergent or non-emergent surgery
 - Fever
 - Hypotension and/or hypertension
 - Infection and pain at insertion site
 - Injury to the coronary artery
 - Ischemia (myocardial)
 - Myocardial infarction (MI)
 - Nausea and vomiting
 - Palpitations
 - Peripheral ischemia (due to vascular injury)
 - Pseudoaneurysm
 - Renal failure
 - Restenosis of the stented segment of the artery
 - Shock / pulmonary edema
 - Stroke / cerebrovascular accident (CVA)
 - Total occlusion of coronary artery
 - Unstable or stable angina pectoris
 - Vascular complications including at the entry site which may require vessel repair
 - Vessel dissection

Zortress the oral formulation of everolimus developed by Novartis Pharmaceuticals Corporation, has been evaluated in clinical trials and is approved in the United States for the prevention of organ rejection in adult kidney transplant recipients at the dose of 1.5 mg/day.

Outside the U.S., Zortress is sold under the brand name, Certican, in more than 70 countries. Everolimus is also approved in the United States under the name of Afinitor for patients with advanced renal cell carcinoma (cancer), after failure of treatment with sunitinib or sorafenib, at doses of 5 to 20 mg/day when taken by mouth. The following list includes the known risks of everolimus at the oral doses listed above:

- Abdominal pain (including upper abdominal pain)
- Anemia
- Angioedema

-
- Anorexia
 - Asthenia
 - Constipation
 - Cough
 - Delayed wound healing / fluid accumulation
 - Diarrhea
 - Dyslipidemia (including hyperlipidemia and hypercholesterolemia)
 - Dysgeusia
 - Dyspepsia
 - Dyspnea
 - Dysuria
 - Dry skin
 - Edema (peripheral)
 - Epistaxis
 - Fatigue
 - Headache
 - Hematuria
 - Hyperglycemia (may include new onset of diabetes)
 - Hyperkalemia
 - Hyperlipidemia
 - Hypertension
 - Hypokalemia
 - Hypomagnesemia
 - Hypophosphatemia
 - Increased serum creatinine
 - Infections and serious infections: bacterial, viral, fungal, and protozoal infections (may include herpes virus infection, polyoma virus infection which may be associated with BK virus associated nephropathy, and / or other opportunistic infections)
 - Insomnia
 - Interaction with strong inhibitors and inducers of CYP3A4 or PgP
 - Leukopenia
 - Lymphoma and other malignancies (including skin cancer)
 - Male infertility (azospermia and / or oligospermia)
 - Mucosal inflammation (including oral ulceration and oral mucositis)
 - Nausea
 - Neutropenia
 - Non-infectious pneumonitis
 - Pain: extremity, incision site and procedural, back, chest, musculoskeletal
 - Proteinuria
 - Pruritus
 - Pyrexia
 - Rash
 - Stomatitis
 - Thrombocytopenia
 - Thrombotic microangiopathy (TMA) / Thrombotic thrombocytopenic purpura (TTP) / Hemolytic uremic syndrome (HUS)
 - Tremor
 - Upper respiratory tract infection

-
- Urinary tract infection
 - Vomiting

Live vaccines should be avoided and close contact with those that have had live vaccines should be avoided. Fetal harm can occur when administered to a pregnant woman. There may be other potential adverse events that are unforeseen at this time.

9.0 SPIRIT FAMILY OF CLINICAL TRIALS

The SPIRIT PRIME clinical trial was conducted to demonstrate the safety and effectiveness of the XIENCE PRIME family of stent systems. Given the substantial similarities between the XIENCE PRIME and XIENCE V stent systems, clinical trials previously conducted on the XIENCE V stent are also relevant and included below.

9.1 SPIRIT PRIME Clinical Trial

The SPIRIT PRIME clinical trial was designed to demonstrate the safety and effectiveness of the XIENCE PRIME family of stent systems. This global trial consists of two separate arms, the Core Size Registry and the Long Lesion Registry. One-year results are presented here.

Primary Objective: The objective of the SPIRIT PRIME clinical trial is to evaluate the safety and effectiveness of the XIENCE PRIME family of stent systems in improving coronary luminal diameter in subjects with symptomatic heart disease due to a maximum of two *de novo* native coronary artery lesions, each in a different epicardial vessel.

Design: The SPIRIT PRIME clinical trial is a prospective, nonrandomized, open-label, multicenter study consisting of two separate arms, the Core Size Registry (stent diameters 2.25, 2.5, 3.0, 3.5, 4.0 mm with stent lengths 8, 18, and 28¹¹ mm) and the Long Lesion Registry (stent diameters, 2.5, 3.0, 3.5, 4.0 mm with stent lengths 33 and 38 mm) in approximately 500 subjects at up to 75 global sites. For clinical trial design purposes, the 28 mm length stent is included in the Core Size Registry because the historical data on XIENCE V used to develop the comparative performance goal includes stent lengths up to 28 mm. The Long Lesion Registry only includes subjects with at least one 33 and 38 mm length stents as there were limited data on these stent lengths from which to develop a comparative performance goal.

Each subject was to receive treatment in up to two *de novo* native coronary lesions, each lesion in a different epicardial vessel. Subjects in the Core Size Registry were allowed to have: one target lesion treated with the core size XIENCE PRIME stent systems (stent diameters 2.25 – 4.0 mm with stent lengths 8, 18, 28 mm) or two target lesions in separate epicardial vessels, treated with two core size XIENCE PRIME stent systems (stent diameters 2.25 – 4.0 mm with stent lengths 8, 18, 28 mm).

Subjects in the Long Lesion Registry were allowed to have: one target lesion treated with the XIENCE PRIME stent system (stent diameters 2.5 – 4.0 mm with stent lengths 33 or 38 mm) or two target lesions in separate epicardial vessels, treated with two XIENCE PRIME stent system (stent diameters 2.5 – 4.0 mm with stent lengths 33 or 38 mm) or one XIENCE PRIME stent system (stent diameters 2.5 – 4.0 mm with stent lengths 33 or 38 mm) and one XIENCE PRIME stent system (stent diameters 2.25 – 4.0 mm with stent lengths 8, 18, 28 mm). All subjects in the

¹¹ The 28 mm length stent was studied in the XIENCE PRIME Core Size Registry. The results of the Core Size Registry are presented in Tables 9.1-2 to 9.1-3.

Long Lesion Registry were required to be treated with at least one XIENCE PRIME stent of 33 or 38 mm in length. For both the Core Size Registry and Long Lesion Registry, planned overlap was not allowed, however overlap was allowed in case of bailout stenting.

The primary endpoint is target lesion failure (TLF) at one year, a composite endpoint of cardiac death, target vessel myocardial infarction (TV-MI), and clinically indicated target lesion revascularization (CI-TLR). The primary endpoint rates of TLF at 1 year (per protocol and per ARC definitions) were compared to a set of pre-specified performance goals (PGs) for both Core Size Registry and Long Lesion Registry as shown below.

The PG for the Core Size Registry was developed utilizing historical data from the SPIRIT III trial, while the PG for the Long Lesion Registry was developed based on a regression analysis conducted on the historical data from the pooled SPIRIT II and III trials. Although the SPIRIT PRIME trial defined TLF based on the ARC definition of MI, the historical SPIRIT II and III trials used to develop the initial PG were based on the per protocol definition of MI. In order to provide a comparison of outcomes using the same definitions for both the treatment arms and PGs, two subsequent analyses, with PGs developed using the same definitions (per protocol and per ARC), were developed and are presented in rows 2 and 3 of the table below.

Table 9.1-1: Analyses of the Primary Endpoint

| TLF Primary Endpoint | Core Size Registry* Performance Goal | Long Lesion Registry** Performance Goal |
|--|---|--|
| TLF Cardiac Death, <i>ARC-Defined TV-MI,</i> CI-TLR | 9.2% ¹ | 19.2% ¹ |
| TLF Cardiac Death, <i>Protocol-Defined TV-MI,</i> CI-TLR | 9.2% ¹ | 19.2% ¹ |
| TLF Cardiac Death, <i>ARC-Defined TV-MI,</i> CI-TLR | 15.3% ² | 26.0% ² |

¹ Performance goal developed based on per protocol-defined MI.

² Performance goal developed based on per ARC-defined MI.

* The Core Size Registry includes 2.25 – 4.0 mm stent diameters, 8, 18, 28 mm lengths

** The Long Lesion Registry includes 2.5 – 4.0 mm stent diameters, 33 and 38 mm stent lengths

Demographics: In the Core Size Registry, the mean age was 62.70 ± 10.23 years, 70.3% (282/401) were male, 29.7% (119/401) were female and 92.3% (346/375) were white. The average body mass index (BMI) was 30.86 ± 5.83 kg/m² and 50.3% (192/382) of subjects were obese, with a BMI ≥ 30. Regarding medical risk factors in the Core Size Registry, 19.2% (77/401) were tobacco users, 76.6% (307/401) were hypertensive requiring medication, and 80.3% (322/401) were hypercholesterolemic requiring medication. There were 11.1% (44/397) of subjects having had a prior cardiac intervention on the target vessel and 23.0% (91/395) had a prior MI. In addition, there were 45.6% (183/401) of subjects with stable angina and 24.9% (100/401) of subjects with unstable angina. Furthermore, the Core Size Registry consisted of 34.9% (140/401) diabetics, 29.9% (120/401) diabetics requiring medication and 3.5% (14/401) diabetics requiring diet and exercise only.

In the Long Lesion Registry, the mean age was 63.46 ± 9.44 years, 62.5% (65/104) were male, 37.5% (39/104) were female and 91.7% (88/96) were white. The average body mass index (BMI) was 30.67 ± 5.84 kg/m², and 49.5% (50/101) of subjects were obese, with a BMI ≥ 30 . Regarding medical risk factors in the Long Lesion Registry, 26.9% (28/104) were tobacco users, 75.0% (78/104) were hypertensive requiring medication, and 80.8% (84/104) were hypercholesterolemic requiring medication. There were 11.8% (12/102) of subjects having had a prior cardiac intervention on the target vessel and 22.5% (23/102) had a prior MI. In addition, there were 49.0% (51/104) of subjects with stable angina and 23.1% (24/104) of subjects with unstable angina. Furthermore, the Long Lesion Registry consisted of 35.6% (37/104) diabetics, 31.7% (33/104) diabetics requiring medication and 1.9% (2/104) diabetics requiring diet and exercise only.

Results: The results are presented in Table 9.1-2 to Table 9.1-4. These analyses are based on the Full Analysis Set (FAS). The FAS population is defined as subjects who have received at least one of the following: the core size XIENCE PRIME stent system (stent diameters 2.25 – 4.0 mm with stent lengths 8, 18, 28 mm) or the XIENCE PRIME LL stent system (stent diameters 2.5 – 4.0 mm with stent lengths 33 or 38 mm), including bailout. SPIRIT PRIME Core Size and Long Lesion Registries met all pre-specified PGs with statistical significance. The observed TLF rate at one year was 4.5% (18/399) (per protocol-defined MI) and 6.5% (26/399) (per ARC-defined MI) in the Core Size Registry, and 7.7% (8/104) (per protocol-defined MI) and 12.5% (13/104) (per ARC-defined MI) in the Long Lesion Registry. At the three-year follow-up visit, the follow-up rate for the CSR was 377 (94.0%) and 99 (95.2%) for the LLR. At 3 years, the observed TLF rate was 8.5% (33/390) (per protocol-defined MI) and 10.8% (42/390) (per ARC-defined MI) in the Core Size Registry, and 9.6% (10/104) (per protocol-defined MI) and 14.4% (15/104) (per ARC-defined MI) in the Long Lesion Registry.

Table 9.1-2: SPIRIT PRIME Primary Endpoint Results

| Core Size Registry* | XIENCE PRIME (N = 401) | Performance Goal | p-value¹ |
|---|-----------------------------------|-----------------------------|----------------------------|
| 1 Year TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 6.5% (26/399) | 9.2% [§] | 0.0338 |
| 1 Year TLF Cardiac Death, <i>Protocol-Defined TV-MI</i> , CI-TLR | 4.5% (18/399) | 9.2% [§] | 0.0003 |
| 1 Year TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 6.5% (26/399) | 15.3% [#] | < 0.0001 |
| Long Lesion Registry** | XIENCE PRIME (N = 104) | Performance Goal | p-value¹ |
| 1 Year TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 12.5% (13/104) | 19.2% [§] | 0.0484 |
| 1 Year TLF Cardiac Death, <i>Protocol-Defined TV-MI</i> , CI-TLR | 7.7% (8/104) | 19.2% [§] | 0.0009 |
| 1 Year TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 12.5% (13/104) | 26.0% [#] | 0.0006 |

Notes:

- N is the total number of subjects.
- Population for SPIRIT PRIME consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8-hour post-index procedure and hospital discharge.
- TLF includes cardiac death, target vessel MI and clinically indicated TLR.
- Time frame includes follow-up window (365 + 28 days).

¹ One-sided p-value against pre-specified performed goals, to be compared at a 0.05 significance level.

[§] Performance Goal developed based on per protocol-defined MI.

[#] Performance Goal developed based on per ARC-defined MI.

* The Core Size Registry includes 2.25 – 4.0 mm stent diameters, 8, 18, 28 mm lengths

** The Long Lesion Registry includes 2.5 – 4.0 mm stent diameters, 33 and 38 mm stent lengths.

Table 9.1-3: SPIRIT PRIME Core Size Registry Clinical Results*

| | Outcomes at 3 Years Core Size Registry* (N = 401) |
|---|--|
| Composite Effectiveness and Safety | |
| TLF (per protocol) | 8.5% (33/390) |
| TLF (per ARC) | 10.8% (42/390) |
| Effectiveness | |
| CI-TLR | 5.4% (21/390) |
| CI-TLR, CABG | 1.0% (4/390) |
| CI-TLR, PCI | 4.6% (18/390) |
| CI-TVR | 9.5% (37/390) |
| Safety | |
| All Death | 3.1% (12/390) |
| Cardiac Death | 0.8% (3/390) |
| Vascular Death | 0.5% (2/390) |
| Non-Cardiovascular Death | 1.8% (7/390) |
| Target Vessel MI (per protocol) | 2.6% (10/390) |
| Target Vessel QMI (per protocol) | 0.3% (1/390) |
| Target Vessel NQMI (per protocol) | 2.3% (9/390) |
| All MI (per protocol) | 3.1% (12/390) |
| QMI (per protocol) | 1.0% (4/390) |
| NQMI (per protocol) | 2.6% (10/390) |
| Target Vessel MI (per ARC) | 6.2% (24/390) |
| Target Vessel QMI (per ARC) | 0.3% (1/390) |
| Target Vessel NQMI (per ARC) | 5.9% (23/390) |
| All MI (per ARC) | 7.9% (31/390) |
| QMI (per ARC) | 1.0% (4/390) |
| NQMI (per ARC) | 7.4% (29/390) |
| Cardiac Death or All protocol MI | 3.8% (15/390) |
| Cardiac Death or All ARC MI | 8.7% (34/390) |
| ARC Definite+Probable Stent Thrombosis | |
| Cumulative through 3 years | 0.8% (3/380) |
| Acute/Subacute (0 – 30 days) | 0.5% (2/401) |
| Late (31 days – 1 year) | 0.0% (0/399) |
| Very Late (1 year-3 years) | 0.3% (1/379) |

Notes:

- TLF is defined as a hierarchical composite of cardiac death, Target Vessel MI, and clinically indicated TLR.
- Population for SPIRIT PRIME Core Size Registry consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8-hour post-index procedure and hospital discharge.
- ARC: Academic Research Consortium

* The Core Size Registry includes 2.25 – 4.0 mm stent diameters, 8, 18, 28 mm lengths

Table 9.1-4: SPIRIT PRIME Long Lesion Registry Clinical Results

| | Outcomes at 3 Years Long Lesion Registry* (N = 104) |
|---|--|
| Composite Effectiveness and Safety | |
| TLF (per protocol) | 9.6% (10/104) |
| TLF (per ARC) | 14.4% (15/104) |
| Effectiveness | |
| CI-TLR | 4.8% (5/104) |
| CI-TLR, CABG | 1.0% (1/104) |
| CI-TLR, PCI | 4.8% (5/104) |
| CI-TVR | 7.7% (8/104) |
| Safety | |
| All Death | 2.9% (3/104) |
| Cardiac Death | 0.0% (0/104) |
| Vascular Death | 0.0% (0/104) |
| Non-Cardiovascular Death | 2.9% (3/104) |
| Target Vessel MI (per protocol) | 4.8% (5/104) |
| Target Vessel QMI (per protocol) | 1.9% (2/104) |
| Target Vessel NQMI (per protocol) | 2.9% (3/104) |
| All MI (per protocol) | 5.8% (6/104) |
| QMI (per protocol) | 2.9% (3/104) |
| NQMI (per protocol) | 3.8% (4/104) |
| Target Vessel MI (per ARC) | 10.6% (11/104) |
| Target Vessel QMI (per ARC) | 1.9% (2/104) |
| Target Vessel NQMI (per ARC) | 8.7% (9/104) |
| All MI (per ARC) | 11.5% (12/104) |
| QMI (per ARC) | 2.9% (3/104) |
| NQMI (per ARC) | 9.6% (10/104) |
| Cardiac Death or All protocol MI | 5.8% (6/104) |
| Cardiac Death or All ARC MI | 11.5% (12/104) |
| ARC Definite+Probable Stent Thrombosis | |
| Cumulative through 3 years | 0.0% (0/99) |
| Acute/Subacute (0 – 30 days) | 0.0% (0/104) |
| Late (31 days – 1 year) | 0.0% (0/104) |
| Very Late (1-3 years) | 0.0% (0/99) |

Notes:

- TLF is defined as a hierarchical composite of cardiac death, Target Vessel MI, and clinically indicated TLR.
- Population for SPIRIT PRIME Core Size Registry consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8-hour post-index procedure and hospital discharge.
- ARC: Academic Research Consortium

* The Long Lesion Registry includes 2.5 – 4.0 mm stent diameters, 33 and 38 mm stent lengths

Study Strengths and Limitations: The SPIRIT PRIME study was a prospective, open-label, multicenter study with two separate arms. All event adjudications were performed by an independent Clinical Event Committee (CEC) with 100% site-reported adjudicable events being source-verified. The study provides important information on the clinical outcomes in patients with long lesions and demonstrates the safety and effectiveness of both the core size and

33 mm and 38 mm XIENCE PRIME stents. The study is limited by being a small study with no head-to-head comparison with other DES platforms. In addition, due to the small population size, subgroup analysis can at best be considered exploratory.

9.2 SPIRIT III Pivotal Clinical Trial

SPIRIT III, a pivotal clinical trial, was designed to demonstrate the non-inferiority of the XIENCE V stent to the TAXUS Express Stent (TAXUS stent) and was conducted in the United States (US) and Japan. The SPIRIT III clinical trial consists of a US randomized clinical trial (RCT), a nonrandomized 4.0 mm diameter stent arm in the US, and a nonrandomized arm in Japan, which included a pharmacokinetic substudy. Enrollment is complete in the RCT, the 4.0 mm diameter stent arm, and the Japan arm.

The SPIRIT III clinical trial included a pharmacokinetic substudy in a subject subset derived from the RCT¹² and Japan nonrandomized arm (see section 6.2 – *Drug Information, Pharmacokinetics*). Eleven sites in the US and 9 sites in Japan participated in this substudy and have enrolled 34 subjects (17 subjects in the US and 17 subjects in Japan). Venous blood was drawn at regular intervals for pharmacokinetics analysis of total blood everolimus level at pre-determined sites.

9.2.1 SPIRIT III Randomized Clinical Trial (RCT)

Primary Objective: The objective of the SPIRIT III RCT was to demonstrate the non-inferiority in in-segment late loss at 240 days and target vessel failure at 270 days of the XIENCE V stent compared to the TAXUS stent in the treatment of up to two *de novo* lesions ≤ 28 mm in length in native coronary arteries with a reference vessel diameter (RVD) ≥ 2.5 mm to ≤ 3.75 mm.

Design: The SPIRIT III RCT was a prospective, 2:1 (XIENCE V:TAXUS) randomized, active-controlled, single-blinded, parallel, multicenter non-inferiority evaluation of the XIENCE V stent compared to the TAXUS stent in the treatment of up to two *de novo* lesions ≤ 28 mm in length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 3.75 mm. Given the available XIENCE V stent lengths of 8, 18 and 28 mm for this trial, in the XIENCE V arm, treatment of a target lesion > 22 mm and ≤ 28 mm in length was accomplished by planned overlap of either two 18 mm stents or a 28 mm and an 8 mm stent (see section 5.3 – *Precautions, Multiple Stent Use*). In the TAXUS arm, overlap was only permitted for bailout or to ensure adequate lesion coverage. The RCT was designed to enroll 1,002 subjects at up to 80 sites in the United States.

If non-inferiority of the primary endpoint of in-segment late loss was demonstrated, it was pre-specified that testing for superiority could be conducted.

All subjects had clinical follow-up at 30, 180, and 270 days and annually from 1 to 5 years. A pre-specified subgroup of 564 subjects had angiographic follow-up at 240 days. Of these 564, 240 subjects had IVUS at baseline and 240 days. Subjects that received a bailout stent also had IVUS at baseline and angiographic and IVUS follow-up at 240 days.

Following the index procedure, all subjects were to be maintained on clopidogrel bisulfate daily for a minimum of 6 months and aspirin daily to be taken throughout the length of the trial (5 years).

¹² Includes one subject from the 4.0 mm nonrandomized arm.

Demographics: The mean age was 63.2 years for the XIENCE V arm and 62.8 for the TAXUS arm. The XIENCE V arm had 70.1% (469/669) males and the TAXUS arm had 65.7% (218/332) males. The XIENCE V arm had 32.3% (215/666) of subjects with prior cardiac interventions and the TAXUS arm had 29.5% (98/332). The XIENCE V arm had 29.6% (198/669) of subjects with a history of diabetes and the TAXUS arm had 27.9% (92/330). The XIENCE V arm had 15.4% (103/669) of subjects with a lesion treated in two vessels and TAXUS had 15.4% (51/332). The XIENCE V arm had 8.1% (54/669) of subjects with planned stent overlap. The XIENCE V arm had 8.6% (57/666) of subjects with a history of prior CABG while the TAXUS arm had 3.6% (12/332) ($p = 0.0033$). The XIENCE V arm had 18.7% (123/657) of subjects with a history of unstable angina while the TAXUS arm had 25.1% (82/327) ($p = 0.0243$). The remaining subject baseline clinical features were well-matched between the XIENCE V arm and the TAXUS arm.

Results: The results are presented in Table 9.2.1-1: SPIRIT III RCT Primary Endpoint Results, Table 9.2.1-2: SPIRIT III RCT Clinical Results, Table 9.2.1-3: SPIRIT III 8-Month Angiographic and IVUS Results, Figure 9.2.1-1: SPIRIT III: Kaplan Meier Time-to-Event Curve for Target Vessel Failure through 5 Years and Table 9.2.1-4: SPIRIT III RCT ARC-Defined Definite+Probable Stent Thrombosis through 5 Years. These analyses are based on the intent-to-treat population.

The co-primary endpoint of in-segment late loss at 240 days was met with measurements of 0.14 ± 0.41 mm (301) for the XIENCE V arm and 0.28 ± 0.48 mm (134) for the TAXUS arm ($p < 0.0001$ for non-inferiority). In a pre-specified analysis, the XIENCE V stent was shown to be superior to the TAXUS stent with respect to in-segment late loss at 240 days ($p = 0.0037$).

The co-primary endpoint of ischemia-driven TVF through 284 days was met with rates of 7.6% (50/660) for the XIENCE V arm and 9.7% (31/320) for the TAXUS arm ($p < 0.0001$ for non-inferiority).

Table 9.2.1-1: SPIRIT III RCT Primary Endpoint Results

| Measurements | XIENCE V (N = 669) (M = 376) | TAXUS (N = 333) (M = 188) | Difference [95% CI] | Non- Inferiority p-value | Superiority p-value |
|--|------------------------------------|---------------------------------|--|--------------------------------|------------------------|
| 8-Month¹ Late Loss, In-Segment (mm) | 0.14 ± 0.41 (301) | 0.28 ± 0.48 (134) | -0.14 [-0.23, -0.05] ² | < 0.0001 ³ | 0.0037 ⁴ |
| 9-Month⁵ Target Vessel Failure⁶ | 7.2% (47/657) | 9.0% (29/321) | -1.88% [-5.58%, 1.82%] ² | < 0.0001 ⁷ | Not Pre-specified |

Notes:

- N is the total number of subjects; M is the total number of analysis lesions for the angiographic group.
- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- Analysis results include 9-month events identified at the 9-month follow-up.
- ¹ 8-month time frame includes follow-up window (240 + 28 days).
- ² By normal approximation.
- ³ One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 0.195 mm, to be compared at a 0.025 significance level.
- ⁴ Two-sided p-value by superiority test using two-sample T-test, to be compared at a 0.05 significance level.
- ⁵ 9-month time frame includes follow-up window (270 + 14 days).
- ⁶ TVF is defined as hierarchical composite of cardiac death, MI, ischemia-driven TLR and ischemia-driven non-TLR TVR.
- ⁷ One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 5.5%, to be compared at a 0.05 significance level.

Table 9.2.1-2: SPIRIT III RCT Clinical Results

| | Outcomes at 9 Months | | | Outcomes at 5 Years (latest available follow-up) | | |
|--------------------------------------|-----------------------|--------------------|-------------------------------------|---|--------------------|-------------------------------------|
| | XIENCE V (N = 669) | TAXUS (N = 333) | Difference [95% CI] ¹ | XIENCE V (N = 669) | TAXUS (N = 333) | Difference [95% CI] ¹ |
| Composite Efficacy and Safety | | | | | | |
| TVF ² | 7.2% (47/657) | 9.0% (29/321) | -2.11% [-5.93%, 1.71%] | 20.3% (123/605) | 26.6% (76/286) | -6.24% [-12.28%, -0.20%] |
| MACE ³ | 4.6% (30/657) | 8.1% (26/321) | -3.75% [-7.26%, -0.24%] | 14.4% (87/605) | 22.0% (63/286) | -7.65% [-13.21%, -2.09%] |
| Efficacy | | | | | | |
| Ischemia-Driven TLR | 2.6% (17/657) | 5.0% (16/321) | -2.40% [-5.07%, 0.28%] | 8.9% (54/605) | 12.9% (37/286) | -4.01% [-8.52%, 0.49%] |
| TLR, CABG | 0.2% (1/657) | 0.0% (0/321) | 0.15% [Assump. not met] | 1.0% (6/605) | 1.0% (3/286) | -0.06% [Assump. not met] |
| TLR, PCI | 2.4% (16/657) | 5.0% (16/321) | -2.55% [-5.21%, 0.11%] | 8.3% (50/605) | 11.9% (34/286) | -3.62% [-7.97%, 0.72%] |
| Ischemia-Driven TVR, Non TL | 3.0% (20/657) | 4.0% (13/321) | -1.01% [-3.53%, 1.52%] | 8.8% (53/605) | 11.9% (34/286) | -3.13% [-7.50%, 1.25%] |
| Non-TLR TVR, CABG | 0.5% (3/657) | 0.6% (2/321) | -0.17% [Assump. not met] | 1.8% (11/605) | 2.4% (7/286) | -0.63% [-2.71%, 1.45%] |
| Non-TLR TVR, PCI | 2.6% (17/657) | 3.4% (11/321) | -0.84% [-3.17%, 1.49%] | 6.9% (42/605) | 9.8% (28/286) | -2.85% [-6.84%, 1.15%] |
| Safety | | | | | | |
| All Death | 0.9% (6/658) | 0.9% (3/322) | -0.02% [Assump. not met] | 6.0% (37/621) | 10.3% (31/300) | -4.38% [-8.29%, -0.46%] |
| Cardiac Death | 0.5% (3/658) | 0.6% (2/322) | -0.17% [Assump. not met] | 2.7% (17/621) | 4.3% (13/300) | -1.60% [-4.23%, 1.04%] |
| Non-Cardiac Death | 0.5% (3/658) | 0.3% (1/322) | 0.15% [Assump. not met] | 3.2% (20/621) | 6.0% (18/300) | -2.78% [-5.80%, 0.25%] |
| MI | 2.0% (13/657) | 2.5% (8/321) | -0.51% [-2.52%, 1.50%] | 4.6% (28/605) | 7.0% (20/286) | -2.36% [-5.76%, 1.03%] |
| QMI | 0.2% (1/657) | 0.0% (0/321) | 0.15% [Assump. not met] | 1.0% (6/605) | 0.7% (2/286) | 0.29% [Assump. not met] |
| NQMI | 1.8% (12/657) | 2.5% (8/321) | -0.67% [-2.65%, 1.32%] | 3.8% (23/605) | 6.3% (18/286) | -2.49% [-5.69%, 0.71%] |
| Cardiac Death or MI | 2.4% (16/657) | 3.1% (10/321) | -0.68% [-2.92%, 1.56%] | 7.1% (43/605) | 11.2% (32/286) | -4.08% [-8.27%, 0.11%] |
| Stent Thrombosis – Protocol Defined | 0.5% (3/654) | 0.0% (0/320) | 0.46% [Assump. not met] | 1.7% (10/583) | 2.2% (6/269) | -0.52% [-2.57%, 1.54%] |
| Acute (< 1 day) | 0.0% (0/669) | 0.0% (0/330) | 0.00% [Assump. not met] | 0.1% (1/669) | 0.0% (0/330) | 0.15% [Assump. not met] |
| Subacute (1 – 30 days) | 0.3% (2/667) | 0.0% (0/330) | 0.30% [Assump. not met] | 0.3% (2/667) | 0.0% (0/330) | 0.30% [Assump. not met] |
| Late (> 30 days) | 0.2% (1/653) | 0.0% (0/320) | 0.15% [Assump. not met] | 1.2% (7/582) | 2.2% (6/269) | -1.03% [-3.00%, 0.95%] |
| Stent Thrombosis – ARC Definite | 0.8% (5/652) | 0.0% (0/319) | 0.77% [Assump. not met] | 1.2% (7/582) | 0.7% (2/268) | 0.46% [Assump. not met] |

Notes:

- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 9-month and 5-year time frames include follow-up window (270 +14 days and 1825 + 28 days, respectively).
- “Assump. not met” means that the assumption of normal approximation was not met due to small sample size or frequency of events.
- Cardiac death is defined as the number of patients experiencing cardiac death through the follow-up time point / (the number of patients experiencing cardiac death through the follow-up time point + the number of patients followed through the follow-up time point without cardiac death + the number of patients terminated prior to the follow-up time point who did not experience cardiac death but experienced non-cardiac death, MI, ID or non-ID TLR, or ID or non-ID TVR).

¹ Confidence Interval was calculated using the normal approximation, not adjusted for multiplicity, and is meant for descriptive purposes only.

² TVF is defined as a hierarchical composite of cardiac death, MI, ischemic-driven TLR and ischemic-driven non-TLR TVR.

³ MACE is defined as a hierarchical composite of cardiac death, MI, ischemic-driven TLR.

Table 9.2.1-3: SPIRIT III 8-Month Angiographic and IVUS Results


| | XIENCE V (N = 376) (M _{ANGIO} = 427) (M _{IVUS} = 181) | TAXUS (N = 188) (M _{ANGIO} = 220) (M _{IVUS} = 93) | Difference [95% CI] ¹ |
|--------------------------------------|--|--|-------------------------------------|
| Angiographic Results | | | |
| In-Stent MLD | | | |
| Post-Procedure | 2.71 ± 0.43 (425) | 2.74 ± 0.40 (220) | -0.03 [-0.10, 0.04] |
| 8 Months | 2.56 ± 0.53 (343) | 2.45 ± 0.65 (158) | 0.11 [-0.01, 0.23] |
| In-Segment MLD | | | |
| Post-Procedure | 2.35 ± 0.44 (426) | 2.36 ± 0.45 (220) | -0.01 [-0.08, 0.06] |
| 8 Months | 2.22 ± 0.53 (344) | 2.12 ± 0.60 (158) | 0.10 [-0.01, 0.21] |
| In-Stent %DS | | | |
| Post-Procedure | 0.32 ± 8.86 (424) | -0.78 ± 10.65 (220) | 1.10 [-0.55, 2.74] |
| 8 Months | 5.92 ± 16.40 (343) | 10.30 ± 21.43 (158) | -4.38 [-8.16, -0.60] |
| In-Segment %DS | | | |
| Post-Procedure | 13.89 ± 8.04 (425) | 13.92 ± 7.20 (220) | -0.03 [-1.26, 1.19] |
| 8 Months | 18.77 ± 14.43 (344) | 22.82 ± 16.35 (158) | -4.05 [-7.03, -1.06] |
| Late Loss | | | |
| In-Stent | 0.16 ± 0.41 (342) | 0.30 ± 0.53 (158) | -0.15 [-0.24, -0.05] |
| In-Segment | 0.14 ± 0.39 (343) | 0.26 ± 0.46 (158) | -0.13 [-0.21, -0.04] |
| Binary Restenosis | | | |
| In-Stent | 2.3% (8/343) | 5.7% (9/158) | -3.36% [-7.32%, 0.59%] |
| In-Segment | 4.7% (16/344) | 8.9% (14/158) | -4.21% [-9.17%, 0.75%] |
| IVUS Results | | | |
| Neointimal Volume (mm ³) | 10.13 ± 11.46 (101) | 20.87 ± 13.51 (41) | -10.74 [-20.92, -0.56] |
| % Volume Obstruction | 6.91 ± 6.35 (98) | 11.21 ± 9.86 (39) | -4.30 [-7.72, -0.88] |
| Incomplete Apposition | | | |
| Post-Procedure | 34.4% (31/90) | 25.6% (11/43) | 8.86% [-7.46%, 25.19%] |
| 8 Months | 25.6% (23/90) | 16.3% (7/43) | 9.28% [-4.97%, 23.52%] |
| Persistent | 24.4% (22/90) | 14.0% (6/43) | 10.49% [-3.15%, 24.13%] |
| Late Acquired | 1.1% (1/90) | 2.3% (1/43) | -1.21% [Assump. not met] |

Notes:

- N is the total number of subjects; M_{ANGIO} is the total number of lesions in the protocol required angiographic cohort and M_{IVUS} is the total number of lesions in the protocol required IVUS cohort.
- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 8-month time frame includes follow-up window (240 + 28 days).
- "Assump. not met" means that the assumption of normal approximation was not met due to small sample size or frequency of events.

¹ Confidence Interval was calculated using the normal approximation, not adjusted for multiplicity, and is meant for descriptive purposes only.

Figure 9.2.1-1: SPIRIT III: Kaplan Meier Time-to-Event Curve for Target Vessel Failure through 5 Years



| TVF | Event Free | Event Rate | p-value [†] |
|----------|------------|------------|----------------------|
| XIENCE V | 80.7% | 19.3% | 0.0549 |
| TAXUS | 75.5% | 24.5% | |

Note:

- Time frame includes follow-up window (1825 + 28 days).
- [†]p-value based on log rank and not adjusted for multiple comparisons

Table 9.2.1-4: SPIRIT III RCT ARC-Defined Definite+Probable Stent Thrombosis through 5 Years

| | XIENCE V (N = 669) | TAXUS (N = 333) | Difference [95% CI]¹ |
|---|-------------------------------|----------------------------|--|
| ARC Definite+Probable Stent Thrombosis (0 days – 5 years) | 1.5% (9/582) | 1.9% (5/268) | -0.32% [-2.22%, 1.59%] |
| Acute (< 1 day) | 0.1% (1/669) | 0.0% (0/330) | 0.15% [Assump. not met] |
| Subacute (1 – 30 days) | 0.3% (2/667) | 0.0% (0/330) | 0.30% [Assump. not met] |
| Late (31 days – 1 year) | 0.5% (3/649) | 0.6% (2/317) | -0.17% [Assump. not met] |
| Very Late (> 1 years) | 0.5% (3/580) | 1.1% (3/267) | -0.61% [Assump. not met] |

Notes:

- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- Time frame includes follow-up window (1825 + 28 days).
- “Assump. not met” means that assumption of the normal approximation was not met due to small sample size or frequency of events.

¹ Confidence Interval was calculated using the normal approximation, not adjusted for multiplicity, and is meant for descriptive purposes only.

9.2.2 Dual Vessel Treatment in SPIRIT III

Subjects requiring treatment in more than one vessel comprise a subgroup that is at increased risk for cardiovascular events compared with single vessel disease patients. Subjects requiring both single and dual vessel treatment were included in the SPIRIT III trial; however there were no pre-specified hypotheses for these patient subgroups.

Table 9.2.2-1 shows the clinical outcomes through 9 months and 5 years in single vessel and dual vessel treated subjects from a post-hoc analysis of SPIRIT III. The number of vessels treated was one of the stratification factors used in the randomization to assure a balance between the XIENCE V and TAXUS treatment arms.

Table 9.2.2-1: Clinical Results in Single and Dual Vessel Treatment through 5 Years (SPIRIT III RCT)

| | 9 Months | | | | 5 Years | | | |
|-----------------------------|----------------------------------|-------------------------------|--------------------------------|----------------------------|----------------------------------|-------------------------------|--------------------------------|----------------------------|
| | Single Vessel XIENCE V (N = 566) | Single Vessel TAXUS (N = 281) | Dual Vessel XIENCE V (N = 103) | Dual Vessel TAXUS (N = 51) | Single Vessel XIENCE V (N = 566) | Single Vessel TAXUS (N = 281) | Dual Vessel XIENCE V (N = 103) | Dual Vessel TAXUS (N = 51) |
| TVF | 6.3% (35/556) | 7.0% (19/271) | 11.9% (12/101) | 20.0% (10/50) | 18.0% (92/510) | 22.9% (55/240) | 32.6% (31/95) | 45.7% (21/46) |
| Ischemia-Driven TLR | 2.3% (13/556) | 4.1% (11/271) | 4.0% (4/101) | 10.0% (5/50) | 8.4% (43/510) | 11.3% (27/240) | 11.6% (11/95) | 21.7% (10/46) |
| Ischemia-Driven TVR, Non TL | 2.7% (15/556) | 2.2% (6/271) | 5.0% (5/101) | 14.0% (7/50) | 6.7% (34/510) | 8.8% (21/240) | 20.0% (19/95) | 28.3% (13/46) |
| All Death | 1.1% (6/557) | 0.4% (1/271) | 0.0% (0/101) | 3.9% (2/51) | 6.1% (32/523) | 9.9% (25/252) | 5.1% (5/98) | 12.5% (6/48) |
| Cardiac Death | 0.5% (3/557) | 0.4% (1/271) | 0.0% (0/101) | 2.0% (1/51) | 2.9% (15/523) | 4.0% (10/252) | 2.0% (2/98) | 6.3% (3/48) |
| Non-Cardiac Death | 0.5% (3/557) | 0.0% (0/271) | 0.0% (0/101) | 2.0% (1/51) | 3.3% (17/523) | 6.0% (15/252) | 3.1% (3/98) | 6.3% (3/48) |
| MI | 1.6% (9/556) | 1.5% (4/271) | 4.0% (4/101) | 8.0% (4/50) | 3.7% (19/510) | 4.6% (11/240) | 9.5% (9/95) | 19.6% (9/46) |
| Cardiac Death or MI | 2.2% (12/556) | 1.8% (5/271) | 4.0% (4/101) | 10.0% (5/50) | 6.5% (33/510) | 8.8% (21/240) | 10.5% (10/95) | 23.9% (11/46) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.4% (2/553) | 0.0% (0/271) | 1.0% (1/101) | 0.0% (0/49) | 1.2% (6/490) | 1.8% (4/226) | 4.3% (4/93) | 4.7% (2/43) |
| ARC Definite+Probable | 0.7% (4/554) | 0.0% (0/271) | 2.0% (2/101) | 0.0% (0/49) | 0.8% (4/488) | 1.3% (3/225) | 5.3% (5/94) | 4.7% (2/43) |
| ARC Definite | 0.4% (2/554) | 0.0% (0/271) | 2.0% (2/101) | 0.0% (0/49) | 0.6% (3/488) | 0.4% (1/225) | 4.3% (4/94) | 2.3% (1/43) |

Note:

- Cardiac death is defined as the number of patients experiencing cardiac death through the follow-up time point / (the number of patients experiencing cardiac death through the follow-up time point + the number of patients followed through the follow-up time point without cardiac death + the number of patients terminated prior to the follow-up time point who did not experience cardiac death but experienced non-cardiac death, MI, ID or non-ID TLR, or ID or non-ID TVR).

9.2.3 SPIRIT III US 4.0 mm Arm

Primary Objective: The objective of the SPIRIT III 4.0 mm arm was to demonstrate the non-inferiority in in-segment late loss at 240 days of the XIENCE V 4.0 mm stent in the treatment of *de novo* lesions with RVD 3.75 to 4.25 mm, compared to the TAXUS arm from the SPIRIT III RCT.

Design: The SPIRIT III 4.0 mm study was a prospective, single-arm, multicenter clinical trial in the United States evaluating the 4.0 mm diameter XIENCE V stent in *de novo* native coronary artery lesions ≤ 28 mm in length with a RVD > 3.75 mm to ≤ 4.25 mm. Seventy-three (73) subjects were enrolled in the SPIRIT III 4.0 mm study arm. For early demonstration of efficacy (in-segment late loss at 240 days), an interim analysis was performed after 69 of the enrolled subjects had completed their scheduled follow-up and after unblinding of the SPIRIT III RCT.

All subjects had clinical follow-up at 30, 180, 240, and 270 days, and annually from 1 to 5 years. In addition, all subjects had angiographic follow-up at 240 days. IVUS was performed for subjects who received a bailout stent at baseline and 240 days.

Following the index procedure, all subjects were to be maintained on clopidogrel bisulfate daily for a minimum of 6 months and aspirin daily to be taken throughout the length of the trial (5 years).

Demographics: The mean age in the SPIRIT III 4.0 arm was 61.9 years with 72.5% (50/69) male, 21.7% (15/69) had prior cardiac interventions, and 30.4% (21/69) had a history of diabetes.

Results: The results are presented in Table 9.2.3-1: SPIRIT III 4.0 mm Primary Endpoint Result, Table 9.2.3-2: SPIRIT III 4.0 mm Clinical Results, Table 9.2.3-3: SPIRIT III 4.0 mm 8-Month Angiographic Results, and Table 9.2.3-4: SPIRIT III 4.0 mm ARC-Defined Stent Thrombosis through 5 years. These analyses were performed on the intent-to-treat population. Although SPIRIT III allowed treatment of two separate epicardial vessels, all subjects in the SPIRIT III 4.0 arm had only one vessel treated. The 5-year follow-up rate for the SPIRIT III 4.0 mm arm was 87.7% (64/73).

The primary endpoint of in-segment late loss at 240 days was met with measurements of 0.17 ± 0.38 mm (49 analysis lesions) for the XIENCE V 4.0 mm arm and 0.28 ± 0.48 mm (134 analysis lesions) for the TAXUS arm from the SPIRIT III RCT ($p < 0.0001$ for non-inferiority).

Table 9.2.3-1: SPIRIT III 4.0 mm Primary Endpoint Result

| Measurements | XIENCE V (M = 69) | TAXUS (M = 188) | Difference [95% CI] | Non- Inferiority p-value |
|---|----------------------|-----------------------|---------------------------------------|--------------------------------|
| 8-Month Late Loss, In-Segment (mm) | 0.17 ± 0.38 (49) | 0.28 ± 0.48 (134) | -0.11 [-0.24, 0.03] ¹ | < 0.0001 ² |

Notes:

- M is the total number of analysis lesions.
- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- Time frame includes follow-up window (240 + 28 days).

¹ By normal approximation.

² One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 0.195 mm, to be compared at a 0.038 significance level.

Table 9.2.3-2: SPIRIT III 4.0 mm Clinical Results

| | Outcomes at 9 Months XIENCE V (N = 73) | Outcomes at 5 Years (Final Follow-up) XIENCE V (N = 73) | Outcomes at 5 Years (Final Follow-up) TAXUS RCT (N = 333) |
|--------------------------------------|--|--|--|
| Composite Efficacy and Safety | | | |
| TVF ¹ | 6.8% (5/73) | 11.9% (8/67) | 26.6% (76/286) |
| MACE ² | 6.8% (5/73) | 10.4% (7/67) | 22.0% (63/286) |
| Efficacy | | | |
| Ischemia-Driven TLR | 2.7% (2/73) | 4.5% (3/67) | 12.9% (37/286) |
| TLR, CABG | 0.0% (0/73) | 0.0% (0/67) | 1.0% (3/286) |
| TLR, PCI | 2.7% (2/73) | 4.5% (3/67) | 11.9% (34/286) |
| Ischemia-Driven TVR, Non TL | 0.0% (0/73) | 3.0% (2/67) | 11.9% (34/286) |
| Non-TLR TVR, CABG | 0.0% (0/73) | 0.0% (0/67) | 2.4% (7/286) |
| Non-TLR TVR, PCI | 0.0% (0/73) | 3.0% (2/67) | 9.8% (28/286) |
| Safety | | | |
| All Death | 1.4% (1/73) | 8.6% (6/70) | 10.3% (31/300) |
| Cardiac Death | 1.4% (1/73) | 2.9% (2/70) | 4.3% (13/300) |
| Non-Cardiac Death | 0.0% (0/73) | 5.7% (4/70) | 6.0% (18/300) |
| MI | 4.1% (3/73) | 4.5% (3/67) | 7.0% (20/286) |
| QMI | 0.0% (0/73) | 0.0% (0/67) | 0.7% (2/286) |
| NQMI | 4.1% (3/73) | 4.5% (3/67) | 6.3% (18/286) |
| Cardiac Death or MI | 5.5% (4/73) | 7.5% (5/67) | 11.2% (32/286) |
| Stent Thrombosis – Protocol Defined | 1.4% (1/72) | 3.1% (2/65) | 2.2% (6/269) |
| Acute (≤ 1 day) | 1.4% (1/73) | 1.4% (1/73) | 0.0% (0/330) |
| Subacute (>1 – 30 days) | 0.0% (0/73) | 0.0% (0/73) | 0.0% (0/330) |
| Late (> 30 days) | 0.0% (0/72) | 1.5% (1/65) | 2.2% (6/269) |
| Stent Thrombosis – ARC Definite | 0.0% (0/72) | 0.0% (0/64) | 0.8% (2/268) |

Notes:

- 9-month and 5-year time frames include follow-up window (270 +14 days and 1825 + 28 days, respectively).
- Cardiac death is defined as the number of patients experiencing cardiac death through the follow-up time point / (the number of patients experiencing cardiac death through the follow-up time point + the number of patients followed through the follow-up time point without cardiac death + the number of patients terminated prior to the follow-up time point who did not experience cardiac death but experienced non-cardiac death, MI, ID or non-ID TLR, or ID or non-ID TVR).

¹ TVF is defined as a hierarchical composite of cardiac death, MI, ischemic-driven TLR and ischemic-driven non-TLR TVR.

² MACE is defined as a hierarchical composite of cardiac death, MI, ischemic-driven TLR.

Table 9.2.3-3: SPIRIT III 4.0 mm 8-Month Angiographic Results

| | XIENCE V (N = 69) (M = 69) |
|-----------------------------|----------------------------------|
| Angiographic Results | |
| In-Stent MLD | |
| Post-Procedure | 3.46 ± 0.38 (69) |
| 8 Months | 3.36 ± 0.46 (49) |
| In-Segment MLD | |
| Post-Procedure | 3.07 ± 0.43 (69) |
| 8 Months | 2.91 ± 0.51 (49) |
| In-Stent %DS | |
| Post-Procedure | 2.12 ± 10.27 (69) |
| 8 Months | 4.78 ± 13.20 (49) |
| In-Segment %DS | |
| Post-Procedure | 13.42 ± 8.08 (69) |
| 8 Months | 17.92 ± 10.83 (49) |
| Late Loss | |
| In-Stent | 0.12 ± 0.34 (49) |
| In-Segment | 0.17 ± 0.38 (49) |
| Binary Restenosis | |
| In-Stent | 0.0% (0/49) |
| In-Segment | 2.0% (1/49) |

Notes:

- N is the total number of subjects; M is the total number of lesions at baseline.
- 8-month time frame includes follow-up window (240 + 28 days).

Table 9.2.3-4: SPIRIT III 4.0 mm ARC-Defined Stent Thrombosis through 5 Years

| | XIENCE V (N = 73) |
|--|----------------------|
| ARC Definite+Probable Stent Thrombosis (0 days – 5 years) | 0.0% (0/64) |
| Acute (≤ 1 day) | 0.0% (0/73) |
| Subacute (>1 – 30 days) | 0.0% (0/73) |
| Late (31 days – 1 year) | 0.0% (0/72) |
| Very Late (>1 years) | 0.0% (0/64) |
| ARC Definite Stent Thrombosis (0 days – 5 years) | 0.0% (0/64) |

Note:

- Time frame includes follow-up window (1825 + 28 days).

9.3 SPIRIT IV Clinical Trial

The SPIRIT IV clinical study was designed to confirm the safety and efficacy of the XIENCE V stent when compared to the TAXUS Express stent¹³ (TAXUS stent). This randomized controlled trial (RCT) was conducted in the United States (US).

9.3.1 SPIRIT IV Randomized Clinical Trial

Primary Objective: The objective of the SPIRIT IV clinical trial was to determine the safety and effectiveness of the XIENCE V stent for the treatment of subjects with up to three *de novo* coronary artery lesions (maximum of two lesions per epicardial vessel).

Design: The SPIRIT IV clinical trial was a prospective, 2:1 randomized (XIENCE V:TAXUS), active-controlled, single-blinded, multicenter evaluation of the XIENCE V stent compared to the TAXUS stent in the treatment of up to three *de novo* lesions ≤ 28 mm in length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 4.25 mm. Subjects were stratified by diabetes mellitus (diabetic vs. non-diabetic) and lesion characteristics (complex vs. non-complex). Complex lesion characteristics included triple vessel treatment, or dual lesions per vessel treatment, or lesions involving RCA-aorto-ostial locations, or bifurcations lesions. The SPIRIT IV clinical trial was designed to enroll 3,690 subjects at up to 80 sites in the US.

The primary endpoint was target lesion failure (TLF) at 1 year. The major secondary endpoints were ischemia-driven TLR at 1 year and the composite of cardiac death or target vessel MI at 1 year. Formal non-inferiority and superiority testing were planned for the primary and the two major secondary endpoints. To control the familywise Type I error rate, all non-inferiority and superiority hypotheses were tested following a fixed sequence.

The XIENCE V stents used in the SPIRIT IV trial included stents 2.5, 3.0, and 3.5 mm in diameter, and 8, 18 and 28 mm in length. In the XIENCE V arm, treatment of target lesions > 22 mm and ≤ 28 mm in length was accomplished by overlapping either two 18 mm stents or a 28 mm and an 8 mm stent (see section 5.3 – *Precautions, Multiple Stent Use*). In the TAXUS arm, the treatment strategy for lesions > 22 mm and ≤ 28 mm was recommended to be in accordance to the TAXUS Directions for Use (DFU) at the time of enrollment; these lesions were treated with single 32 mm TAXUS stent or planned overlapping TAXUS stents.

Subjects were evaluated at 30, 180, and 270 days following the index procedure. Follow-up has been performed through 3 years, completing the trial.

According to the guidelines from the American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI), following the index procedure, all subjects were to be maintained on 75 mg clopidogrel bisulfate daily for 12 months if subjects were not at high risk for bleeding and ≥ 80 mg of aspirin daily throughout the length of the trial (3 years).

Demographics: The mean age was 63.3 years for both the XIENCE V arm and the TAXUS arm. The XIENCE V arm had 67.7% (1665/2458) males and the TAXUS arm had 67.8% (833/1229) males. The XIENCE V arm had 31.5% (772/2450) of subjects with prior cardiac interventions and the TAXUS arm had 30.7% (376/1224). The XIENCE V arm had 32.0% (786/2455) of subjects with a history of diabetes and the TAXUS arm had 32.5% (399/1228).

¹³ Of the 1,229 subjects enrolled in the TAXUS arm, 1 subject received one TAXUS Liberté stent.

The XIENCE V arm had 24.8% (609/2458) of subjects with two or more lesions treated and TAXUS had 25.3% (311/1229). The XIENCE V arm had 9.7% (239/2458) of subjects with planned stent overlap. The TAXUS arm had 8.1% (99/1229)¹⁴ of subjects with planned stent overlap and 4.5% (55/1229) of subjects treated with single 32 mm TAXUS stent only. The XIENCE V arm had 27.7% (669/2416) of subjects with a history of unstable angina while the TAXUS arm had 28.9% (347/1202). The remaining subject baseline clinical features were well-matched between the XIENCE V arm and the TAXUS arm.

Results: The results are presented in Table 9.3.1-1: SPIRIT IV Primary and Major Secondary Endpoint Results, Table 9.3.1-2: SPIRIT IV Clinical Results through 3 Years, Figure 9.3.1-1: SPIRIT IV: Kaplan Meier Time-to-Event Curve for TLF through 3 Years, Figure 9.3.1-2: SPIRIT IV: Kaplan Meier Time-to-Event Curve for ID-TLR through 3 Years, and Figure 9.3.1-3: SPIRIT IV: Kaplan Meier Time-to-Event Curve for Cardiac Death or Target Vessel MI through 3 Years. These analyses are based on the intent-to-treat population. At the three-year visit, the follow-up rate for the XIENCE V arm was 91.8% (2257) and 89.1% (1095) for the TAXUS arm.

Primary Endpoint Analysis (Table 9.3.1-1): The primary endpoint was met with TLF rates at 1 year of 4.0% (97/2416) for the XIENCE V arm and 6.8% (81/1195) for the TAXUS arm ($p < 0.0001$ for non-inferiority). In a pre-specified analysis, the XIENCE V stent was shown to be superior to the TAXUS stent in terms of the primary endpoint of TLF at 1 year ($p_{\text{Sup}} = 0.0004$).

Major Secondary Endpoint Analysis (Table 9.3.1-1): The major secondary endpoint of ID-TLR was shown to be statistically non-inferior for the XIENCE V stent compared to the TAXUS stent. The ID-TLR rate through 1 year was 2.3% (56/2416) for the XIENCE V arm and 4.6% (55/1195) for the TAXUS arm ($p < 0.0001$ for non-inferiority). The XIENCE V arm also showed non-inferiority to the TAXUS arm in terms of the composite endpoint of cardiac death or target vessel MI with rates of 2.2% (53/2416) for the XIENCE V arm and 3.2% (38/1195) for the TAXUS arm ($p < 0.0001$ for non-inferiority).

In a pre-specified analysis, the XIENCE V stent was shown to be superior to the TAXUS stent in terms of ID-TLR at 1 year ($p_{\text{Sup}} = 0.0003$). The rate of composite of cardiac death or target vessel MI was numerically lower in patients treated with the XIENCE V EECSS compared to the TAXUS PECSS ($p_{\text{Sup}} = 0.09$).

¹⁴ Includes 6 patients who received planned overlapping TAXUS stents as well as single 32 mm TAXUS stent in two different lesions.

Table 9.3.1-1: SPIRIT IV Primary and Major Secondary Endpoint Results

| Primary Endpoint | XIENCE V (N = 2458) | TAXUS (N = 1229) | Difference [Upper 1-Sided 97.5% CL] | Non-Inferiority p-value | Superiority p-value |
|---|------------------------|---------------------|--|----------------------------|------------------------|
| 1 Year TLF | 4.0% (97/2416) | 6.8% (81/1195) | -2.76% [-1.14%] ¹ | < 0.0001 ² | 0.0004 ³ |
| Major Secondary Endpoints | XIENCE V (N = 2458) | TAXUS (N = 1229) | Difference [Upper 1-Sided 95% CL] | Non-Inferiority p-value | Superiority p-value |
| 1 Year ID-TLR | 2.3% (56/2416) | 4.6% (55/1195) | -2.28% [-1.17%] ¹ | < 0.0001 ⁴ | 0.0003 ³ |
| 1 Year Cardiac Death or Target Vessel MI | 2.2% (53/2416) | 3.2% (38/1195) | -0.99% [-0.02%] ¹ | < 0.0001 ⁴ | 0.09 ³ |

Notes:

- N is the total number of subjects.
- TLF includes cardiac death, target vessel MI (per protocol definition) and ischemia-driven TLR.
- Time frame includes follow-up window (365 + 28 days).

¹ By normal approximation.

² One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 3.1%, to be compared at a 0.025 significance level.

³ Two-sided p-value by superiority test using Fisher's exact test, to be compared at a 0.05 significance level.

⁴ One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 2.1%, to be compared at a 0.05 significance level.


Table 9.3.1-2: SPIRIT IV Clinical Results through 3 Years

| | Outcomes at 1 Year | | | Outcomes at 3 Years (final follow-up) | | |
|--|------------------------|---------------------|-------------------------------------|--|---------------------|-------------------------------------|
| | XIENCE V (N = 2458) | TAXUS (N = 1229) | Difference [95% CI] ¹ | XIENCE V (N = 2458) | TAXUS (N = 1229) | Difference [95% CI] ¹ |
| Composite Efficacy and Safety | | | | | | |
| TLF | 4.0% (97/2416) | 6.8% (81/1195) | -2.76% [-4.39%, -1.14%] | 9.5% (223/2348) | 11.9% (138/1158) | -2.42% [-4.63%, -0.21%] |
| TVF | 5.5% (134/2416) | 7.7% (92/1195) | -2.15% [-3.92%, -0.39%] | 13.3% (312/2348) | 14.5% (168/1158) | -1.22% [-3.67%, 1.23%] |
| Efficacy | | | | | | |
| Ischemia-Driven TLR | 2.3% (56/2416) | 4.6% (55/1195) | -2.28% [-3.62%, -0.95%] | 6.3% (148/2348) | 7.9% (92/1158) | -1.64% [-3.48%, 0.20%] |
| TLR, CABG | 0.4% (9/2416) | 0.4% (5/1195) | -0.05% [-0.49%, 0.39%] | 0.8% (18/2348) | 0.9% (10/1158) | -0.10% [-0.74%, 0.54%] |
| TLR, PCI | 2.0% (48/2416) | 4.3% (51/1195) | -2.28% [-3.56%, -1.01%] | 5.7% (134/2348) | 7.5% (87/1158) | -1.81% [-3.59%, -0.02%] |
| Ischemia-Driven TVR | 3.8% (93/2416) | 5.7% (68/1195) | -1.84% [-3.36%, -0.32%] | 10.1% (238/2348) | 10.6% (123/1158) | -0.49% [-2.64%, 1.67%] |
| Safety | | | | | | |
| All Death | 1.0% (25/2416) | 1.3% (15/1195) | -0.22% [-0.97%, 0.53%] | 3.4% (81/2348) | 5.2% (60/1158) | -1.73% [-3.21%, -0.26%] |
| Cardiac Death | 0.4% (10/2416) | 0.4% (5/1195) | -0.00% [-0.45%, 0.44%] | 1.4% (34/2348) | 1.9% (22/1158) | -0.45% [-1.37%, 0.47%] |
| Non-Cardiac Death | 0.6% (15/2416) | 0.8% (10/1195) | -0.22% [-0.82%, 0.39%] | 2.0% (47/2348) | 3.3% (38/1158) | -1.28% [-2.45%, -0.11%] |
| Target Vessel MI | 1.8% (44/2416) | 2.9% (35/1195) | -1.11% [-2.20%, -0.01%] | 2.8% (65/2348) | 4.1% (48/1158) | -1.38% [-2.70%, -0.05%] |
| Cardiac Death or Target Vessel MI | 2.2% (53/2416) | 3.2% (38/1195) | -0.99% [-2.14%, 0.17%] | 4.1% (97/2348) | 5.5% (64/1158) | -1.40% [-2.94%, 0.15%] |
| All MI | 1.9% (45/2416) | 3.1% (37/1195) | -1.23% [-2.35%, -0.11%] | 3.1% (73/2348) | 4.7% (55/1158) | -1.64% [-3.05%, -0.23%] |
| QMI | 0.1% (3/2416) | 0.4% (5/1195) | -0.29% [Assump. not met] | 0.3% (6/2348) | 0.9% (11/1158) | -0.69% [-1.29%, -0.10%] |
| NQMI | 1.7% (42/2416) | 2.8% (33/1195) | -1.02% [-2.09%, 0.04%] | 2.9% (67/2348) | 4.0% (46/1158) | -1.12% [-2.43%, 0.19%] |
| Cardiac Death or MI | 2.2% (54/2416) | 3.3% (39/1195) | -1.03% [-2.20%, 0.14%] | 4.5% (105/2348) | 6.0% (70/1158) | -1.57% [-3.18%, 0.03%] |
| Protocol Defined Stent Thrombosis (Cumulative) | 0.17% (4/2389) | 0.85% (10/1181) | -0.68% [Assump. not met] | 0.79% (18/2266) | 1.99% (22/1104) | -1.20% [-2.10%, -0.30%] |
| Acute/Subacute (0 – 30 days) | 0.12% (3/2451) | 0.57% (7/1221) | -0.45% [Assump. not met] | 0.12% (3/2451) | 0.57% (7/1221) | -0.45% [Assump. not met] |
| Late (> 30 days) | 0.04% (1/2389) | 0.34% (4/1181) | -0.30% [Assump. not met] | 0.62% (14/2265) | 1.45% (16/1103) | -0.83% [-1.61%, -0.06%] |
| ARC Definite+Probable Stent Thrombosis (Cumulative) | 0.29% (7/2391) | 1.10% (13/1181) | -0.81% [-1.44%, -0.17%] | 0.62% (14/2263) | 1.73% (19/1098) | -1.11% [-1.95%, -0.28%] |
| Early (0 – 30 days) | 0.16% (4/2451) | 0.74% (9/1221) | -0.57% [Assump. not met] | 0.16% (4/2451) | 0.74% (9/1221) | -0.57% [Assump. not met] |
| Late (31 days – 1 year) | 0.13% (3/2391) | 0.42% (5/1181) | -0.30% [Assump. not met] | 0.13% (3/2385) | 0.42% (5/1183) | -0.30% [Assump. not met] |
| Very late (> 1 year) | - | - | - | 0.31% (7/2260) | 0.55% (6/1095) | -0.24% [-0.73%, 0.26%] |
| ARC Definite Stent Thrombosis (Cumulative) | 0.25% (6/2391) | 0.85% (10/1181) | -0.60% [-1.16%, -0.04%] | 0.49% (11/2263) | 1.28% (14/1098) | -0.79% [-1.51%, -0.07%] |

Notes:

- 1-year and 3-year time frames include follow-up window (365 ± 28 days and 1095 ± 28 days, respectively).
 - TLF is defined as a hierarchical composite of cardiac death, target vessel MI (per protocol definition), and ischemic-driven TLR.
 - TVF is defined as a hierarchical composite of cardiac death, all MI (per protocol definition), ischemic-driven TLR and ischemic-driven non-TLR TVR.
- ¹ Confidence Interval was calculated using the normal approximation, not adjusted for multiplicity and is meant for descriptive purposes only.

Figure 9.3.1-1: SPIRIT IV: Kaplan Meier Time-to-Event Curve for TLF through 3 Years




| TLF | Event Free | Event Rate | p-value ¹ |
|----------|------------|------------|----------------------|
| XIENCE V | 90.8% | 9.2% | 0.0221 |
| TAXUS | 88.3% | 11.7% | |

Note:

- Time frame includes follow-up window (1095 + 28 days).
¹p-value based on log rank and not adjusted for multiple comparisons

Figure 9.3.1-2: SPIRIT IV: Kaplan Meier Time-to-Event Curve for ID-TLR through 3 Years




| ID-TLR | Event Free | Event Rate | p-value ¹ |
|----------|------------|------------|----------------------|
| XIENCE V | 93.8% | 6.2% | 0.0577 |
| TAXUS | 92.2% | 7.8% | |

Note:

- Time frame includes follow-up window (1095 + 28 days).

¹p-value based on log rank and not adjusted for multiple comparisons

Figure 9.3.1-3: SPIRIT IV: Kaplan Meier Time-to-Event Curve for Cardiac Death or Target Vessel MI through 3 Years



| Cardiac Death or TV-MI | Event Free | Event Rate | p-value ¹ |
|------------------------|------------|------------|----------------------|
| XIENCE V | 96.0% | 4.0% | 0.0670 |
| TAXUS | 94.6% | 5.4% | |

Note:

- Time frame includes follow-up window (1095 + 28 days).
- ¹p-value based on log rank and not adjusted for multiple comparisons

9.3.2 Multiple Vessel Treatment in SPIRIT IV

Subjects requiring treatment in more than one vessel comprise a subgroup that is at increased risk for cardiovascular events compared with single vessel disease patients. The SPIRIT IV trial allowed for up to 3 vessels to be treated. In the XIENCE V arm, 389 subjects received dual vessel treatment while 19 subjects received triple vessel treatment. In the TAXUS arm, 218 subjects received dual vessel treatment while 5 subjects received triple vessel treatment. There were no pre-specified hypotheses for patients in the single vessel treatment and multiple vessel treatment subgroups.

Table 9.3.2-1 shows the clinical outcomes through 3 years in single- and multiple-vessel treated subjects from a post-hoc analysis of SPIRIT IV.

Table 9.3.2-1: Clinical Results in Single and Multiple Vessel Treatment through 3 Years (SPIRIT IV)

| | Outcomes at 1 Year | | | | Outcomes at 3 Years (final follow-up) | | | |
|--------------------------------------|---|--------------------------------------|--|---------------------------------------|--|--------------------------------------|--|---------------------------------------|
| | Single Vessel XIENCE V (N = 2050) | Single Vessel TAXUS (N = 1006) | Multiple Vessel XIENCE V (N = 408) | Multiple Vessel TAXUS (N = 223) | Single Vessel XIENCE V (N = 2050) | Single Vessel TAXUS (N = 1006) | Multiple Vessel XIENCE V (N = 408) | Multiple Vessel TAXUS (N = 223) |
| TLF | 3.8% (76/2014) | 6.0% (59/983) | 5.2% (21/402) | 10.4% (22/212) | 8.3% (163/1959) | 11.0% (105/952) | 15.4% (60/389) | 16.0% (33/206) |
| Ischemia-Driven TLR | 2.1% (42/2014) | 4.0% (39/983) | 3.5% (14/402) | 7.5% (16/212) | 5.3% (104/1959) | 7.0% (67/952) | 11.3% (44/389) | 12.1% (25/206) |
| Ischemia-Driven TVR, Non TL | 1.9% (38/2014) | 2.0% (20/983) | 4.0% (16/402) | 4.2% (9/212) | 4.6% (91/1959) | 5.0% (48/952) | 10.5% (41/389) | 7.3% (15/206) |
| All Death | 0.9% (18/2014) | 1.3% (13/983) | 1.7% (7/402) | 0.9% (2/212) | 3.1% (60/1959) | 5.6% (53/952) | 5.4% (21/389) | 3.4% (7/206) |
| Cardiac Death | 0.3% (6/2014) | 0.4% (4/983) | 1.0% (4/402) | 0.5% (1/212) | 1.2% (24/1959) | 2.0% (19/952) | 2.6% (10/389) | 1.5% (3/206) |
| Non-Cardiac Death | 0.6% (12/2014) | 0.9% (9/983) | 0.7% (3/402) | 0.5% (1/212) | 1.8% (36/1959) | 3.6% (34/952) | 2.8% (11/389) | 1.9% (4/206) |
| Target Vessel MI | 1.8% (37/2014) | 2.3% (23/983) | 1.7% (7/402) | 5.7% (12/212) | 2.7% (53/1959) | 3.7% (35/952) | 3.1% (12/389) | 6.3% (13/206) |
| Cardiac Death or Target Vessel MI | 2.1% (43/2014) | 2.6% (26/983) | 2.5% (10/402) | 5.7% (12/212) | 3.9% (77/1959) | 5.3% (50/952) | 5.1% (20/389) | 6.8% (14/206) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.15% (3/1996) | 0.51% (5/971) | 0.25% (1/393) | 2.38% (5/210) | 0.79% (15/1900) | 1.88% (17/903) | 0.82% (3/366) | 2.49% (5/201) |
| ARC Definite+Probable | 0.20% (4/1996) | 0.72% (7/971) | 0.76% (3/395) | 2.86% (6/210) | 0.47% (9/1895) | 1.45% (13/897) | 1.36% (5/368) | 2.99% (6/201) |
| ARC Definite | 0.20% (4/1990) | 0.51% (5/972) | 0.51% (2/395) | 2.37% (5/211) | 0.47% (9/1895) | 1.00% (9/897) | 0.54% (2/368) | 2.49% (5/201) |

Notes:

- 1-year and 3-year time frames include follow-up window (365 ± 28 days and 1095 ± 28 days, respectively)
- Multiple vessel subgroup included subjects having two or more vessels treated.
- There were 24 triple vessel treated subjects in SPIRIT IV; Of those, 19 were XIENCE V subjects and 5 were TAXUS subjects.

Study Strengths and Limitations: The SPIRIT IV trial was a prospective, randomized, active-controlled, single-blinded, multicenter evaluation of the XIENCE V stent compared to the TAXUS Express Stent and was designed to enroll 3,690 subjects in the US. With a large sample size and high data quality, the study provides important safety and effectiveness information on clinical outcomes in a more complex population than those in SPIRIT III. In spite of the large population and less restrictive enrollment criteria however, subgroup analyses from SPIRIT IV are considered exploratory.

9.4 SPIRIT Small Vessel Registry

Objective: The objective of the SPIRIT SV Registry trial was to evaluate the safety and effectiveness of the 2.25 mm XIENCE V EECSS in improving coronary luminal diameter in subjects with ischemic heart disease due to a maximum of two *de novo* native coronary artery lesions in small vessels, each in a different epicardial vessel.

Design: The SPIRIT SV trial enrolled a total of 150 subjects at 33 sites. Additionally, there was an angiographic cohort of 69 subjects who received the 2.25 mm XIENCE V EECSS. Subjects enrolled in the SPIRIT SV trial were allowed to have: 1) one target lesion (treated with one 2.25 mm XIENCE V EECSS), 2) two target lesions (treated with two 2.25 mm XIENCE V EECSS) in separate epicardial vessels, or 3) one target lesion (treated with one 2.25 mm XIENCE V EECSS) and one non-target lesion (treated with commercial sizes of XIENCE V EECSS) in separate epicardial vessels. Planned overlap was allowed for both the target and non-target lesions only with commercial sizes of XIENCE V EECSS. Bailout was allowed with a commercial XIENCE V or 2.25 mm XIENCE V EECSS. The protocol-required RVD for the target lesion was ≥ 2.25 mm to < 2.50 mm and the lesion length was ≤ 28 mm. The 2.25 mm XIENCE V EECSS was available in stent lengths of 8, 18 and 28 mm. The non-target lesion could be treated by the commercial XIENCE V EECSS with a RVD of ≥ 2.5 mm to ≤ 4.25 mm. The commercial XIENCE V EECSS was available in stent diameters of 2.5, 2.75, 3.0, 3.5, 4.0 mm and stent lengths of 8, 12, 15, 18, 23, 28 mm. The primary endpoint was target lesion failure (TLF, defined as the composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularization) at 1 year.

Demographics: For the subjects treated with the 2.25 mm XIENCE V EECSS, the mean age was 63 ± 11 years, and the majority of the population was male (61.8%, 89/144). In subjects treated with the 2.25 mm XIENCE V EECSS, 22.9% (32/140) were tobacco users, 81.9% (118/144) were hypertensive requiring medication, 86.5% (122/141) had hypercholesterolemia requiring medication, and 39.2% (56/143) were diabetic. Additionally, 68.8% (99/144) of the subjects had stable angina and 27.1% (39/144) had unstable angina. In subjects treated with the 2.25 mm XIENCE V EECSS, 72.2% (104/144) underwent single vessel treatment, and 27.8% (40/144) underwent dual vessel treatment.

Results: The results are presented in Table 9.4-1 (Primary Endpoint Results), Table 9.4-2 (Clinical Results), Table 9.4-3 (Stent Thrombosis Results), Table 9.4-4 (Angiographic Results) and Figure 9.4-1 (Time-to-Event Curve for TLF). These analyses are based on the full analysis set (FAS) population (defined as subjects that received the 2.25 mm XIENCE V EECSS). The primary analysis of the primary endpoint was analyzed in the FAS population. The 1-year TLF rate was 8.1% with an upper limit of the one-sided 95% confidence interval of 13.03%, which met the pre-specified performance goal of 20.4% ($p < 0.0001$). The 3-year follow-up rate for the SPIRIT Small Vessel Registry was 88.2% (127/144).

Table 9.4-1: SPIRIT SV Primary Endpoint Result

| Primary Endpoint | 2.25 mm XIENCE V (N = 144) | Upper 1-Sided 95% CL | p-value ¹ |
|------------------|-------------------------------|-------------------------|----------------------|
| 1-year TLF | 8.1% (11/136) | 13.03% | < 0.0001 |

Notes:

- N is the total number of subjects.
- TLF includes cardiac death, target vessel MI (per protocol definition) and clinical-indicated TLR.
- Time frame includes follow-up window (365 ± 28 days).

¹ One-sided p-value by testing against the performance goal of 20.4% using exact test at 0.05 significance level.

Table 9.4-2: SPIRIT SV Clinical Endpoint Results through 3 Years

| 2.25 mm XIENCE V Arm | Per Protocol Definition | |
|--|-------------------------|-------------------------------------|
| Acute Success (post index procedure) | ITT* (N = 149) | |
| Clinical Device Success | 95.21% (139/146) | |
| Clinical Procedure Success | 97.93% (142/145) | |
| Clinical Outcomes | At 1 Year | At 3 Years (final follow-up) |
| Component Endpoints | FAS (N = 144) | FAS (N = 144) |
| All Death | 1.5% (2/136) | 3.8% (5/132) |
| Cardiac Death | 1.5% (2/136) | 3.8% (5/132) |
| Non-Cardiac Death | 0.0% (0/136) | 0.0% (0/132) |
| Target Vessel MI | 1.5% (2/136) | 1.5% (2/132) |
| Non Target Vessel MI | 0.0% (0/136) | 0.0% (0/132) |
| Clinically -Indicated TLR (CI-TLR) | 5.1% (7/136) | 6.8% (9/132) |
| Clinically -Indicated TVR (CI-TVR) | 8.8% (12/136) | 12.1% (16/132) |
| All TLR | 6.6% (9/136) | 8.3% (11/132) |
| All TVR | 10.3% (14/136) | 13.6% (18/132) |
| All Revascularization | 14.7% (20/136) | 23.5% (31/132) |
| Composite Endpoints | | |
| Cardiac Death or MI | 2.9% (4/136) | 5.3% (7/132) |
| Cardiac Death or All MI or CI-TLR | 8.1% (11/136) | 12.1% (16/132) |
| All Death or All MI or All Revascularization | 16.9% (23/136) | 26.5% (35/132) |
| TLF | 8.1% (11/136) | 12.1% (16/132) |

Notes:

- N is the total number of subjects; L is the number of lesions.
- Per protocol MI definition was used for Target Vessel MI, Non Target Vessel MI, and all composite endpoints. MI per protocol definition is: Q-wave MI: Development of new, pathological Q waves on the ECG, and Non Q-wave MI: Elevation of CK levels to \geq two times the upper limit of normal with elevated CK-MB in the absence of new pathological Q waves.
- 1-year and 3-year time frames include follow-up window (365 ± 28 days and 1095 ± 28 days, respectively).
- Non Target Vessel MI includes MI not attributed to the treated vessel.
- All Revascularization includes TVR and non-TVR, and non-treated vessel revascularization.
- FAS (full analysis set) is defined as subjects that received the 2.25 mm XIENCE V EECSS in the SPIRIT SV trial.
- Clinical Device Success: The successful delivery and deployment of the first study stent intended to be implanted at the intended target lesion (or in an overlapping stent setting, a successful delivery and deployment of the intended first and second investigational stents) and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (or by visual estimation if QCA unavailable). Bailout lesions were included as device success only if the above criteria for clinical device success were met for the bailout stent.
- Clinical Procedure Success: The achievement of a final in-stent diameter stenosis (DS) of $< 50\%$ (by QCA) using the assigned device and with any adjunctive devices, without the occurrence of cardiac death, target vessel MI (per protocol definition), or repeat coronary revascularization of the target lesion during the hospital stay (up to 7 days if a subject still is in the hospital). If QCA %DS was not available, procedure success data were considered missing.
- The ITT population provides the most accurate estimate of successful 2.25 mm XIENCE V stent implantation because it includes all subjects, regardless of whether the attempted implantation of 2.25 mm XIENCE V stent was successful.

Table 9.4-3: SPIRIT SV Stent Thrombosis Results through 3 Years

| Stent Thrombosis | FAS (N = 144) | | |
|--|-------------------------|--|-------------------------------|
| | Per Protocol Definition | Per ARC Definition (Definite+Probable) | Per ARC Definition (Definite) |
| Acute (\leq 1 day) | 0.0% (0/144) | 0.0% (0/144) | 0.0% (0/144) |
| Subacute ($>$ 1 – 30 days) | 0.7% (1/142) | 0.7% (1/142) | 0.0% (0/142) |
| Acute/Subacute (0 – 30 days) | 0.7% (1/142) | 0.7% (1/142) | 0.0% (0/142) |
| Late (Protocol: $>$ 30 days; ARC: 31 – 393 days) | 2.3% (3/129) | 0.7% (1/137) | 0.7% (1/137) |
| Very Late (ARC only) (394 – 1123 days) | - | 0.0% (0/128) | 0.0% (0/128) |
| Overall (0 – 1123 days) | 3.1% (4/130) | 1.5% (2/130) | 0.8% (1/130) |

Table 9.4-4: SPIRIT SV 240-Day Angiographic Results (Angiographic Cohort¹)

| XIENCE V 2.25 mm Arm | FAS (N = 69) (L = 69) |
|-------------------------|-----------------------------|
| 240-day Late Loss | |
| In-Stent | 0.20 \pm 0.40 (52) |
| In-Segment | 0.16 \pm 0.41 (52) |
| Proximal | 0.21 \pm 0.35 (34) |
| Distal | 0.00 \pm 0.28 (45) |
| 240-day %DS | |
| In-Stent | 12.86 \pm 19.58 (52) |
| In-Segment | 20.85 \pm 22.53 (52) |
| Proximal | 14.31 \pm 13.16 (37) |
| Distal | 10.40 \pm 8.45 (46) |
| 240-day ABR | |
| In-Stent | 3.8% (2/52) |
| In-Segment | 9.6% (5/52) |
| Proximal | 2.7% (1/37) |
| Distal | 0.0% (0/46) |


Notes:

N is the total number of subjects. L is the total number of lesions.

240-day angiographic data is available for 52 subjects.

¹ Per protocol defined qualifying angiogram with follow-up window extended to 268 days.

Figure 9.4-1: SPIRIT SV: Kaplan Meier Time-to-Event Curve for TLF through 3 Years



| TLF | Event Free | Event Rate |
|----------------------|------------|------------|
| XIENCE V 2.25 mm Arm | 88.4% | 11.6% |

Note:

- Time frame includes follow-up window (1095 + 28 days).

Study Strengths and Limitations: The SPIRIT SV study was a prospective, open-label, multicenter registry. All event adjudications were performed by an independent Clinical Event Committee (CEC) with 100% site-reported adjudicable events being source-verified. The study provides important information on clinical outcomes and demonstrates the safety and effectiveness of the 2.25 mm XIENCE V stent in patients with small vessels. The study is limited by being a small registry with no head-to-head comparison with other DES platforms. In addition, due to the small population size, subgroup analysis can at best be considered exploratory.

9.5 Pooled Analysis of the SPIRIT II-III-IV Clinical Trials

A subject-level pooled analysis of three randomized, single-blinded, controlled trials was conducted to provide an assessment of safety outcomes with increased precision and to better estimate the incidence of low frequency events in specific subgroups. Definitive proof of the presence or absence of any differences between such subgroups requires prospectively powered assessment in dedicated clinical trials.

Data from the SPIRIT II, SPIRIT III randomized control trial (RCT) arm, and SPIRIT IV clinical trials were pooled to compare the XIENCE V stent to the TAXUS stent in 4989 subjects (with 6233 lesions) through 3 years (1123 days) of follow-up. Although SPIRIT IV permitted the enrollment of somewhat more complex patients, the three studies have subjects with generally similar baseline and angiographic characteristics and share key elements of study design, allowing pooling of the data for the purposes of these safety analyses.

Table 9.5-1: Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Clinical Results through 3 Years

| Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV | 1 Year | | 3 Years | |
|---|---|---|---|---|
| | XIENCE V (N = 3350) [95% CI] ¹ | TAXUS (N = 1639) ² [95% CI] ¹ | XIENCE V (N = 3350) [95% CI] ¹ | TAXUS (N = 1639) ² [95% CI] ¹ |
| TLF | 4.3% (143/3295) [3.67%, 5.09%] | 7.5% (119/1592) [6.23%, 8.88%] | 9.3% (295/3184) [8.28%, 10.33%] | 12.7% (196/1541) [11.10%, 14.49%] |
| Ischemia-Driven TLR | 2.7% (88/3295) [2.15%, 3.28%] | 4.9% (78/1592) [3.89%, 6.08%] | 6.1% (195/3184) [5.32%, 7.01%] | 8.3% (128/1541) [6.98%, 9.80%] |
| TLR, CABG | 0.3% (11/3295) [0.17%, 0.60%] | 0.3% (5/1592) [0.10%, 0.73%] | 0.7% (23/3184) [0.46%, 1.08%] | 0.8% (13/1541) [0.45%, 1.44%] |
| TLR, PCI | 2.4% (78/3295) [1.88%, 2.95%] | 4.6% (74/1592) [3.67%, 5.80%] | 5.6% (178/3184) [4.82%, 6.45%] | 7.8% (120/1541) [6.50%, 9.24%] |
| Ischemia-Driven TVR | 4.3% (143/3295) [3.67%, 5.09%] | 6.3% (100/1592) [5.14%, 7.59%] | 10.2% (326/3184) [9.21%, 11.34%] | 11.5% (177/1541) [9.94%, 13.18%] |
| All Death | 1.1% (36/3295) [0.77%, 1.51%] | 1.4% (22/1592) [0.87%, 2.08%] | 3.4% (109/3184) [2.82%, 4.11%] | 5.3% (81/1541) [4.20%, 6.49%] |
| Cardiac Death | 0.5% (15/3295) [0.26%, 0.75%] | 0.6% (9/1592) [0.26%, 1.07%] | 1.4% (45/3184) [1.03%, 1.89%] | 2.0% (31/1541) [1.37%, 2.84%] |
| Non-Cardiac Death | 0.6% (21/3295) [0.39%, 0.97%] | 0.8% (13/1592) [0.44%, 1.39%] | 2.0% (64/3184) [1.55%, 2.56%] | 3.2% (50/1541) [2.42%, 4.26%] |
| Target Vessel MI | 1.8% (60/3295) [1.39%, 2.34%] | 3.1% (49/1592) [2.29%, 4.05%] | 2.9% (91/3184) [2.31%, 3.50%] | 4.4% (68/1541) [3.44%, 5.56%] |
| Cardiac Death or Target Vessel MI | 2.2% (73/3295) [1.74%, 2.78%] | 3.4% (54/1592) [2.56%, 4.40%] | 4.1% (132/3184) [3.48%, 4.90%] | 5.8% (90/1541) [4.72%, 7.13%] |
| All MI | 2.0% (65/3295) [1.53%, 2.51%] | 3.3% (53/1592) [2.50%, 4.33%] | 3.3% (106/3184) [2.73%, 4.01%] | 5.2% (80/1541) [4.14%, 6.42%] |
| QMI | 0.2% (5/3295) [0.05%, 0.35%] | 0.4% (6/1592) [0.14%, 0.82%] | 0.3% (11/3184) [0.17%, 0.62%] | 0.8% (13/1541) [0.45%, 1.44%] |
| NQMI | 1.8% (60/3295) [1.39%, 2.34%] | 3.0% (48/1592) [2.23%, 3.98%] | 3.0% (95/3184) [2.42%, 3.64%] | 4.5% (69/1541) [3.50%, 5.63%] |
| Cardiac Death or All MI | 2.4% (78/3295) [1.88%, 2.95%] | 3.6% (57/1592) [2.72%, 4.61%] | 4.6% (147/3184) [3.91%, 5.40%] | 6.6% (101/1541) [5.37%, 7.91%] |
| Protocol Defined Stent Thrombosis (Cumulative) | 0.3% (10/3258) [0.15%, 0.56%] | 0.8% (13/1574) [0.44%, 1.41%] | 0.9% (28/3071) [0.61%, 1.32%] | 2.0% (30/1471) [1.38%, 2.90%] |
| Acute/Subacute (0 – 30 days) | 0.2% (6/3341) [0.07%, 0.39%] | 0.4% (7/1628) [0.17%, 0.88%] | 0.2% (7/3341) [0.08%, 0.43%] | 0.4% (7/1628) [0.17%, 0.88%] |
| Late (> 30 days) | 0.1% (4/3257) [0.03%, 0.31%] | 0.4% (7/1574) [0.18%, 0.91%] | 0.7% (21/3069) [0.42%, 1.04%] | 1.6% (24/1470) [1.05%, 2.42%] |
| ARC Definite+Probable Stent Thrombosis (Cumulative) | 0.4% (13/3261) [0.21%, 0.68%] | 1.0% (16/1574) [0.58%, 1.65%] | 0.8% (24/3069) [0.50%, 1.16%] | 1.8% (26/1463) [1.16%, 2.59%] |
| Acute/Subacute (0 – 30 days) | 0.2% (7/3341) [0.08%, 0.43%] | 0.6% (10/1628) [0.29%, 1.13%] | 0.2% (7/3341) [0.08%, 0.43%] | 0.6% (10/1628) [0.29%, 1.13%] |
| Late (31 days – 1 year) | 0.2% (6/3260) [0.07%, 0.40%] | 0.5% (8/1574) [0.22%, 1.00%] | 0.2% (6/3254) [0.07%, 0.40%] | 0.5% (8/1577) [0.22%, 1.00%] |
| Very late (> 1 year) | - | - | 0.4% (11/3064) [0.18%, 0.64%] | 0.7% (10/1458) [0.33%, 1.26%] |
| ARC Definite Stent Thrombosis (Cumulative) | 0.3% (11/3261) [0.17%, 0.60%] | 0.8% (12/1574) [0.39%, 1.33%] | 0.6% (18/3069) [0.35%, 0.93%] | 1.2% (18/1463) [0.73%, 1.94%] |
| Bleeding Complications | 3.1% (102/3261) [2.56%, 3.78%] | 3.3% (52/1573) [2.48%, 4.31%] | 5.8% (180/3086) [5.03%, 6.72%] | 6.6% (97/1474) [5.37%, 7.97%] |


Notes:

• 1-year and 3-year time frames include follow-up window (365 + 28 days and 1095 ± 28 days, respectively)

¹ By Clopper-Pearson Exact Confidence Interval

² In the pooled TAXUS stent arm, there were 18 subjects who received at least one TAXUS Liberté stent.

Figure 9.5-1: Kaplan Meier Time-to-Event Curves through 3 Years (Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV)



Note: p-value based on log rank and not adjusted for multiple comparisons

9.6 Gender-Based Analysis of the SPIRIT Family of Clinical Trials

9.6.1 Background

Cardiovascular disease is the leading cause of death for both women and men in the U.S. and coronary artery disease is a major cause of morbidity and mortality in women. It is estimated that the prevalence of coronary artery disease in the United States is 9.1% (9,200,000) in males and 7.0% (8,400,000) in females for adults at least 20 years old according to the American Heart Association 2010 Update.¹⁵ However, it is estimated that only 36% of annual PCIs are performed in women.¹⁶ In PCI clinical trials, women represent only 25 – 35% of the enrolled populations, and there are relatively little gender-specific data. The disproportionate enrollment distribution in these trials may be partly attributable to gender differences in symptoms and pathophysiology,¹⁷ which may lead to under-diagnosis and under-referral of female patients with CAD. Women tend to have worse clinical outcomes compared to men, most likely due to their higher baseline risk profile and more complex angiographic characteristics.^{18, 19, 20}

9.6.2 Gender-Based Analysis of the SPIRIT PRIME Clinical Trial

Abbott Vascular performed a post hoc evaluation of the SPIRIT PRIME clinical trial for possible sex-based differences in baseline characteristics and clinical outcomes, as well as for any interaction between treatment and sex / gender. The SPIRIT PRIME trial was not designed or powered to study safety or effectiveness differences between sexes, so these analyses are considered exploratory without definitive conclusions.

In the Core Size Registry, 119/401 (29.7%) subjects were female and 282/401 (70.3%) were male. In the Long Lesion Registry, 39/104 (37.5%) subjects were female and 65/104 (62.5%) were male. In comparison, the prevalence of coronary artery disease (CAD) is estimated at 9.2 million in males and 8.4 million in females for adults age 20 and older the United States (i.e., the CAD population is estimated to be 52.2% males and 47.7% females). The disproportionate enrollment distribution in this trial may be partly attributable to gender differences in symptoms and pathophysiology, which may lead to under-diagnosis and under-referral of female patients with CAD. The gender proportions enrolled in this trial are similar to other drug-eluting stent trials.^{21, 22}

¹⁵ Lloyd-Jones D, Adams R, Carnethon M, De Simone G, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. *Circulation* 2010; 121:e46-215.

¹⁶ Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2009; 119(3):e21-181.

¹⁷ Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: Gender Differences in Traditional and Novel Risk Factors, Symptom Evaluation, and Gender-Optimized Diagnostic Strategies. *J Am Coll Cardiol* 2006 47: S4-20.

¹⁸ Mahoney EM, Jurkowitz CT, Chu H, Becker ER, Culler S, Kosinski AS, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. *Jama* 2002; 288(15):1851-8.

¹⁹ Akhter N, Milford-Beland S, Roe MT, Piana RN, Kao J, Shroff A. Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). *Am Heart J* 2009; 157(1):141-8.

²⁰ Vaina S, Voudris V, Morice M-C, de Bruyne B, Colombo A, Macaya C, Richardt, G, Fajadet, J et al. Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularization in patients with multivessel coronary artery disease: Insights from ARTS I and ARTS II. *EuroInterv*. 2009; 4(4):492-501.

²¹ Lansky AJ, Costa RA, Mooney M, et al. Gender-Based Outcomes After Paclitaxel-Eluting Stent Implantation in Patients With Coronary Artery Disease. *J Am Coll Cardiol* 2005 45: 1180-5.

Table 9.6.2-1 presents the baseline demographics, risk factors, and angiographic characteristics by gender for subjects in the Core Size Registry. As is consistent with previous literature, female patients at baseline were numerically older and had a higher BMI. Additionally, more females than males had hypertension requiring medication and diabetes mellitus. Table 9.6.2-2 presents the baseline demographics, risk factors, and angiographic characteristics by gender for subjects in the Long Lesion Registry

Table 9.6.2-1: Demographics, Risk Factors, and Baseline Angiographic Characteristics for SPIRIT PRIME Core Size Registry Subjects*

| Subject / Lesion Characteristics | Male (N = 282) (M = 315) | Female (N = 119) (M = 132) | Total (N = 401) (M = 447) | p-value |
|--|--------------------------------|----------------------------------|---------------------------------|---------------------|
| Baseline Demographics, Mean ± SD (n) | | | | |
| Age (year) | 61.63 ± 10.37 (282) | 65.23 ± 9.47 (119) | 62.70 ± 10.23 (401) | 0.0009 ¹ |
| Baseline Risk Factors, % (No./total) | | | | |
| All Diabetes | 31.9% (90/282) | 42.0% (50/119) | 34.9% (140/401) | 0.0663 ² |
| Diabetes Treated with Insulin | 7.4% (21/282) | 14.3% (17/119) | 9.5% (38/401) | 0.0400 ² |
| Current Tobacco Use | 19.1% (54/282) | 19.3% (23/119) | 19.2% (77/401) | 1.0000 ² |
| Hypertension Requiring Medication | 73.4% (207/282) | 84.0% (100/119) | 76.6% (307/401) | 0.0278 ² |
| Hypercholesterolemia Requiring Medication | 80.9% (228/282) | 79.0% (94/119) | 80.3% (322/401) | 0.6815 ² |
| Stable Angina | 44.0% (124/282) | 49.6% (59/119) | 45.6% (183/401) | 0.3244 ² |
| Unstable Angina | 25.2% (71/282) | 24.4% (29/119) | 24.9% (100/401) | 0.9001 ² |
| Prior MI | 25.0% (69/276) | 18.5% (22/119) | 23.0% (91/395) | 0.1927 ² |
| Target Vessel, % (No./total) | | | | |
| LAD | 44.1% (139/315) | 46.2% (61/132) | 44.7% (200/447) | 0.7545 ² |
| Circumflex or Ramus | 23.8% (75/315) | 25.8% (34/132) | 24.4% (109/447) | 0.7174 ² |
| RCA | 31.7% (100/315) | 28.0% (37/132) | 30.6% (137/447) | 0.5001 ² |
| LMCA | 0.0% (0/315) | 0.0% (0/132) | 0.0% (0/447) | NA |
| Pre-Procedure QCA Analysis, Mean ± SD (m) | | | | |
| Lesion Length (mm) | 13.91 ± 5.10 (315) | 13.06 ± 4.75 (132) | 13.66 ± 5.01 (447) | 0.0940 ¹ |
| Pre-Procedure RVD (mm) | 2.76 ± 0.48 (315) | 2.63 ± 0.45 (132) | 2.72 ± 0.48 (447) | 0.0067 ¹ |
| Pre-Procedure MLD (mm) | 0.82 ± 0.40 (315) | 0.81 ± 0.26 (132) | 0.81 ± 0.36 (447) | 0.7352 ¹ |
| Pre-Procedure Percent Diameter Stenosis (%DS) | 70.01 ± 12.87 (315) | 68.58 ± 8.53 (132) | 69.59 ± 11.76 (447) | 0.1676 ¹ |

*Subjects with Cardiac Enzyme Data in Window

¹ From T-test.

² From Fisher's exact test.

Note: All p-values displayed are two-tailed and not from formal hypothesis testing and are displayed for descriptive purposes only.

Note: N is the total number of subjects.

Note: M is the total number of target lesions.

²² Solinas E, Nikolsky E, Lansky AJ, et al. Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation. J Am Coll Cardiol 2007;50:2111-6

Note: This table contains only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge).

Table 9.6.2-2: Demographics, Risk Factors, and Baseline Angiographic Characteristics for SPIRIT PRIME Long Lesion Registry Subjects*

| Subject / Lesion Characteristics | Male (N = 65) (M = 80) | Female (N = 39) (M = 44) | Total (N = 104) (M = 124) | p-value |
|--|------------------------------|--------------------------------|---------------------------------|---------------------|
| Baseline Demographics, Mean ± SD (n) | | | | |
| Age (year) | 63.64 ± 9.97 (65) | 63.15 ± 8.60 (39) | 63.46 ± 9.44 (104) | 0.7927 ¹ |
| Baseline Risk Factors, % (No./total) | | | | |
| All Diabetes | 32.3% (21/65) | 41.0% (16/39) | 35.6% (37/104) | 0.4027 ² |
| Diabetes Treated with Insulin | 9.2% (6/65) | 10.3% (4/39) | 9.6% (10/104) | 1.0000 ² |
| Current Tobacco Use | 26.2% (17/65) | 28.2% (11/39) | 26.9% (28/104) | 0.8232 ² |
| Hypertension Requiring Medication | 76.9% (50/65) | 71.8% (28/39) | 75.0% (78/104) | 0.6418 ² |
| Hypercholesterolemia Requiring Medication | 81.5% (53/65) | 79.5% (31/39) | 80.8% (84/104) | 0.8023 ² |
| Stable Angina | 43.1% (28/65) | 59.0% (23/39) | 49.0% (51/104) | 0.1563 ² |
| Unstable Angina | 27.7% (18/65) | 15.4% (6/39) | 23.1% (24/104) | 0.2289 ² |
| Prior MI | 25.0% (16/64) | 18.4% (7/38) | 22.5% (23/102) | 0.4753 ² |
| Target Vessel, % (No./total) | | | | |
| LAD | 41.3% (33/80) | 40.9% (18/44) | 41.1% (51/124) | 1.0000 ² |
| Circumflex or Ramus | 27.5% (22/80) | 18.2% (8/44) | 24.2% (30/124) | 0.2803 ² |
| RCA | 31.3% (25/80) | 40.9% (18/44) | 34.7% (43/124) | 0.3261 ² |
| LMCA | 0.0% (0/80) | 0.0% (0/44) | 0.0% (0/124) | NA |
| Pre-Procedure QCA Analysis, Mean ± SD (m) | | | | |
| Lesion Length (mm) | 26.62 ± 7.89 (80) | 25.17 ± 6.83 (44) | 26.10 ± 7.53 (124) | 0.2872 ¹ |
| Pre-Procedure RVD (mm) | 2.80 ± 0.46 (80) | 2.66 ± 0.40 (44) | 2.75 ± 0.44 (124) | 0.0864 ¹ |
| Pre-Procedure MLD (mm) | 0.75 ± 0.28 (80) | 0.79 ± 0.31 (44) | 0.77 ± 0.29 (124) | 0.5067 ¹ |
| Pre-Procedure Percent Diameter Stenosis (%DS) | 72.05 ± 8.74 (80) | 68.76 ± 9.60 (44) | 70.88 ± 9.15 (124) | 0.0632 ¹ |

*Subjects with Cardiac Enzyme Data in Window

¹ From T-test.

² From Fisher's exact test.

Note: All p-values displayed are two-tailed and not from formal hypothesis testing and are displayed for descriptive purposes only.

Note: N is the total number of subjects.

Note: M is the total number of target lesions.

Note: This table contains only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge).

A post hoc analysis was conducted on the composite primary safety and effectiveness endpoint of TLF, per protocol and per ARC, to assess for heterogeneity of treatment effect across sex / gender (using Fisher's Exact Test). Table 9.6.2-3 and Table 9.6.2-4 present the 3-year clinical results for the Core Size Registry and Long Lesion Registry, respectively. Due to the modest sample size (Core Size Registry 282 males vs. 119 females and Long Lesion Registry 65 males vs. 39 females), these analyses and interpretation are limited.

Table 9.6.2-3: Clinical Results for All Female and All Male Subgroups in the SPIRIT PRIME Core Size Registry through 3 Years*

| SPIRIT PRIME | Male (N = 282) | Female (N = 119) | Total (N = 401) | p-value ¹ |
|--|-------------------|---------------------|--------------------|----------------------|
| All Death | 4.0% (11/274) | 0.9% (1/116) | 3.1% (12/390) | 0.1192 |
| Cardiac Death | 1.1% (3/274) | 0.0% (0/116) | 0.8% (3/390) | 0.5578 |
| Non-Cardiac Death | 2.6% (7/274) | 0.0% (0/116) | 1.8% (7/390) | 0.1091 |
| Target Vessel MI per Protocol | 2.9% (8/274) | 1.7% (2/116) | 2.6% (10/390) | 0.7297 |
| Cardiac Death or Target Vessel MI per Protocol | 4.0% (11/274) | 1.7% (2/116) | 3.3% (13/390) | 0.3599 |
| Target Vessel MI per ARC | 5.5% (15/274) | 7.8% (9/116) | 6.2% (24/390) | 0.4891 |
| Cardiac Death or Target Vessel MI per ARC | 6.6% (18/274) | 7.8% (9/116) | 6.9% (27/390) | 0.6666 |
| Major Bleeding Complication | 4.5% (12/265) | 1.7% (2/115) | 3.7% (14/380) | 0.2439 |
| Stent Thrombosis | | | | |
| Protocol defined | 1.5% (4/263) | 0.0% (0/115) | 1.1% (4/378) | 0.3185 |
| ARC definite + probable | 1.1% (3/265) | 0.0% (0/115) | 0.8% (3/380) | 0.5566 |
| TLF | | | | |
| per Protocol | 9.1% (25/274) | 6.9% (8/116) | 8.5% (33/390) | 0.5540 |
| per ARC | 10.2% (28/274) | 12.1% (14/116) | 10.8% (42/390) | 0.5948 |
| Ischemia-Driven TLR | 5.5% (15/274) | 5.2% (6/116) | 5.4% (21/390) | 1.0000 |
| Ischemia-Driven TVR, non TL | 5.8% (16/274) | 6.0% (7/116) | 5.9% (23/390) | 1.0000 |

*Subjects with Cardiac Enzyme Data in Window

¹ From Fisher's exact test.

Note: All p-values displayed are two-tailed and not from formal hypothesis testing and are displayed for descriptive purposes only.

Note: Subjects are only counted once for each type of event in each time period.

Note: N is the total number of subjects.

Note: This table contains only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge).

Table 9.6.2-4: Clinical Results for All Female and All Male Subgroups in the SPIRIT PRIME Long Lesion Registry through 3 Years*

| SPIRIT PRIME | Male (N = 65) | Female (N = 39) | Total (N = 104) | p-value ¹ |
|--|------------------|--------------------|--------------------|----------------------|
| All Death | 3.1% (2/65) | 2.6% (1/39) | 2.9% (3/104) | 1.0000 |
| Cardiac Death | 0.0% (0/65) | 0.0% (0/39) | 0.0% (0/104) | NA |
| Non-Cardiac Death | 3.1% (2/65) | 2.6% (1/39) | 2.9% (3/104) | 1.0000 |
| Target Vessel MI per Protocol | 4.6% (3/65) | 5.1% (2/39) | 4.8% (5/104) | 1.0000 |
| Cardiac Death or Target Vessel MI per Protocol | 4.6% (3/65) | 5.1% (2/39) | 4.8% (5/104) | 1.0000 |
| Target Vessel MI per ARC | 13.8% (9/65) | 5.1% (2/39) | 10.6% (11/104) | 0.2024 |
| Cardiac Death or Target Vessel MI per ARC | 13.8% (9/65) | 5.1% (2/39) | 10.6% (11/104) | 0.2024 |
| Major Bleeding Complication | 3.2% (2/62) | 2.7% (1/37) | 3.0% (3/99) | 1.0000 |
| Stent Thrombosis | | | | |
| Protocol defined | 0.0% (0/62) | 0.0% (0/37) | 0.0% (0/99) | NA |
| ARC definite + probable | 0.0% (0/62) | 0.0% (0/37) | 0.0% (0/99) | NA |
| TLF | | | | |
| per Protocol | 10.8% (7/65) | 7.7% (3/39) | 9.6% (10/104) | 0.7397 |
| per ARC | 18.5% (12/65) | 7.7% (3/39) | 14.4% (15/104) | 0.1585 |
| Ischemia-Driven TLR | 6.2% (4/65) | 2.6% (1/39) | 4.8% (5/104) | 0.6480 |
| Ischemia-Driven TVR, non TL | 7.7% (5/65) | 2.6% (1/39) | 5.8% (6/104) | 0.4063 |

*Subjects with Cardiac Enzyme Data in Window

¹ From Fisher's exact test.

Note: All p-values displayed are two-tailed and not from formal hypothesis testing and are displayed for descriptive purposes only.

Note: Subjects are only counted once for each type of event in each time period.

Note: N is the total number of subjects.

Note: This table contains only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge).

9.6.3 Gender-Based Analysis in the SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Clinical Trials

To evaluate gender-specific clinical outcomes with the XIENCE V stent, Abbott Vascular conducted a pooled analysis of SPIRIT II, SPIRIT III RCT, and SPIRIT IV. The pooled SPIRIT trial data were assessed for differences between males and females in baseline characteristics and study outcomes, as well as for any interaction between treatment and gender. Results suggest that the general conclusions of safety and effectiveness of the XIENCE V stent can be generalized for males and females.

In the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV intent-to-treat population, 1584 subjects were female (32%) and 3404 subjects were male (68%). The gender proportions enrolled in this trial are similar to other drug-eluting stent trials.^{23, 24}

Of the 1584 female subjects in the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV population, 1058 were XIENCE V subjects and 526 were TAXUS subjects.

Table 9.6.3-1 describes the demographics, risk factors, and baseline angiographic characteristics of all female and all male subgroups of the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV population.

Table 9.6.3-1: Demographics, Risk Factors, and Baseline Angiographic Characteristics for the All-Female and All-Male Subgroups (Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Population)

| Subject Characteristics | All Females (N = 1584; 32%) (M = 1901) | All Males (N = 3404; 68%) (M = 4332) | p-value ¹ |
|--|--|--|----------------------|
| Baseline Demographics, Mean ± SD (n) | | | |
| Age (year) | 65.7 ± 10.5 (1584) | 62.0 ± 10.2 (3404) | < 0.0001 |
| Baseline Risk Factors, % (No./total) | | | |
| All Diabetes | 35.9% (569/1583) | 28.7% (975/3398) | < 0.0001 |
| Diabetes Treated with Insulin | 12.1% (192/1583) | 6.5% (222/3398) | < 0.0001 |
| Current Tobacco Use | 21.7% (337/1550) | 23.2% (772/3321) | 0.2555 |
| Hypertension Requiring Medication | 80.7% (1278/1584) | 73.9% (2511/3398) | < 0.0001 |
| Hypercholesterolemia Requiring Medication | 73.2% (1143/1562) | 75.9% (2537/3341) | 0.0399 |
| Stable Angina | 57.2% (889/1554) | 57.7% (1933/3348) | 0.7327 |
| Unstable Angina | 29.1% (452/1554) | 25.5% (854/3348) | 0.0092 |
| Prior MI | 15.8% (245/1551) | 23.6% (783/3316) | < 0.0001 |
| Target Vessel, % (No./total) | | | |
| LAD | 43.1% (820/1901) | 39.6% (1712/4327) | 0.0085 |
| Circumflex or Ramus | 21.9% (416/1901) | 26.8% (1159/4327) | < 0.0001 |
| RCA | 35.0% (665/1901) | 33.6% (1454/4327) | 0.2959 |
| LMCA | 0.0% (0/1901) | 0.0% (2/4327) | 1.0000 |
| Pre-Procedure QCA Analysis, Mean ± SD (m) | | | |
| Lesion Length (mm) | 14.22 ± 6.25 (1888) | 14.79 ± 6.51 (4293) | 0.0012 |
| Pre-Procedure RVD (mm) | 2.66 ± 0.44 (1894) | 2.79 ± 0.48 (4303) | < 0.0001 |
| Pre-Procedure MLD (mm) | 0.79 ± 0.38 (1899) | 0.78 ± 0.40 (4310) | 0.2207 |
| Pre-Procedure Percent Diameter Stenosis (%DS) | 69.92 ± 12.84 (1899) | 71.58 ± 13.05 (4310) | < 0.0001 |

N is the total number of subjects; M is the total number of lesions analyzed.

¹ p-values are displayed for descriptive purposes only.

²³ Lansky AJ, Costa RA, Mooney M, et al. Gender-Based Outcomes After Paclitaxel-Eluting Stent Implantation in Patients With Coronary Artery Disease. *J Am Coll Cardiol* 2005 45: 1180-5.

²⁴ Solinas E, Nikolsky E, Lansky AJ, et al. Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation. *J Am Coll Cardiol* 2007;50:2111-6

Table 9.6.3-1 shows that females in the SPIRIT family of trials were older and had higher rates of diabetes, hypertension, and unstable angina compared with males. The generally higher clinical risk profile in females is consistent with gender differences in baseline demographics reported from other PCI studies.^{25, 26, 27, 28, 29, 30, 31}

Table 9.6.3-2 presents key clinical outcomes through 3 years in female and male subjects from the SPIRIT IV trial and the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV population. In post-hoc analyses of the pooled SPIRIT II, SPIRIT III RCT and SPIRIT IV population, rates of death, target vessel MI and stent thrombosis through 3 years were comparable between females and males. At 3 years, post-hoc analyses of the SPIRIT IV trial suggest that females treated with XIENCE V stents (despite generally increased clinical risk factors at baseline) had numerically similar adverse event rates compared to males treated with XIENCE V stents. Comparisons of study outcomes in patients receiving the XIENCE V stent versus the TAXUS stent were consistent within each gender subgroup. Based on the interaction p-value calculated from Wald Chi-square statistics of logistic regression analysis, no significant treatment-by-gender interaction effect was observed at a 0.15 significance level. These analyses suggest that the conclusions regarding safety and effectiveness of the XIENCE V stent are generalizable to both males and females. However, it should be noted that there were no pre-specified hypotheses for the use of the XIENCE V stent in females.

²⁵ Correa-De-Araujo R. Serious gaps: how lack of sex/gender- based research impairs health. *J Womens Health (Larchmt)* 2006; 15(10):1116-22.

²⁶ Abbott JD, Vlachos HA, Selzer F, Sharaf BL, Holper E, Glaser R et al. Gender-based outcomes in percutaneous coronary intervention with drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry). *Am J Cardiol* 2007; 99(5):626-31.

²⁷ Akhter N, Milford-Beland S, Roe MT, Piana RN, Kao J, Shroff A. Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). *Am Heart J* 2009; 157(1):141-8.

²⁸ Vaina S, Voudris V, Morice M-C, de Bruyne B, Colombo A, Macaya C, Richardt, G, Fajadet, J et al. Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularization in patients with multivessel coronary artery disease: Insights from ARTS I and ARTS II. *EuroInterv.* 2009; 4(4):492-501.

²⁹ Blomkalns AI, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. *J Am Coll Cardiol* 2005; 45(6):832-7.

³⁰ Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, et al. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigations to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation* 2005; 111(13):1611-8.

³¹ Lansky AJ, Costa RA, Mooney M, Midei MG, Lui HK, Strickland W, et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. *J Am Coll Cardiol* 2005; 45 (8):1180-5.

Table 9.6.3-2: Clinical Results in XIENCE V Females, XIENCE V Males and All Subjects through 3 Years (SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Population)

| Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV | 1 Year | | | | 3 Years | | | |
|---|--------------------|------------------|---------------------|------------------|--------------------|------------------|---------------------|------------------|
| | XIENCE V | | All Subjects | | XIENCE V | | All Subjects | |
| | Females (N = 1058) | Males (N = 2292) | XIENCE V (N = 3350) | TAXUS (N = 1639) | Females (N = 1057) | Males (N = 2293) | XIENCE V (N = 3350) | TAXUS (N = 1639) |
| All Death | 1.2% (12/1038) | 1.1% (24/2257) | 1.1% (36/3295) | 1.4% (22/1592) | 3.0% (30/993) | 3.6% (79/2191) | 3.4% (109/3184) | 5.3% (81/1541) |
| Cardiac Death | 0.5% (5/1038) | 0.4% (10/2257) | 0.5% (15/3295) | 0.6% (9/1592) | 1.2% (12/993) | 1.5% (33/2191) | 1.4% (45/3184) | 2.0% (31/1541) |
| Non-Cardiac Death | 0.7% (7/1038) | 0.6% (14/2257) | 0.6% (21/3295) | 0.8% (13/1592) | 1.8% (18/993) | 2.1% (46/2191) | 2.0% (64/3184) | 3.2% (50/1541) |
| Target Vessel MI | 1.9% (20/1038) | 1.8% (40/2257) | 1.8% (60/3295) | 3.1% (49/1592) | 2.7% (27/993) | 2.9% (64/2191) | 2.9% (91/3184) | 4.4% (68/1541) |
| Cardiac Death or Target Vessel MI | 2.4% (25/1038) | 2.1% (48/2257) | 2.2% (73/3295) | 3.4% (54/1592) | 3.9% (39/993) | 4.2% (93/2191) | 4.1% (132/3184) | 5.8% (90/1541) |
| Bleeding Complication | 4.5% (46/1029) | 2.5% (56/2232) | 3.1% (102/3261) | 3.3% (52/1573) | 8.3% (80/967) | 4.7% (100/2119) | 5.8% (180/3086) | 6.6% (97/1474) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.4% (4/1028) | 0.3% (6/2230) | 0.3% (10/3258) | 0.8% (13/1574) | 0.7% (7/963) | 1.0% (21/2108) | 0.9% (28/3071) | 2.0% (30/1471) |
| ARC Definite+Probable | 0.4% (4/1028) | 0.4% (9/2233) | 0.4% (13/3261) | 1.0% (16/1574) | 0.5% (5/961) | 0.9% (19/2108) | 0.8% (24/3069) | 1.8% (26/1463) |
| ARC Definite | 0.4% (4/1026) | 0.3% (7/2229) | 0.3% (11/3255) | 0.8% (12/1577) | 0.4% (4/961) | 0.7% (14/2108) | 0.6% (18/3069) | 1.2% (18/1463) |
| SPIRIT IV | XIENCE V | | All Subjects | | XIENCE V | | All Subjects | |
| | Females (N = 793) | Males (N = 1665) | XIENCE V (N = 2458) | TAXUS (N = 1229) | Females (N = 792) | Males (N = 1666) | XIENCE V (N = 2458) | TAXUS (N = 1229) |
| TLF | 4.0% (31/777) | 4.0% (66/1639) | 4.0% (97/2416) | 6.8% (81/1195) | 9.3% (69/745) | 9.6% (154/1603) | 9.5% (223/2348) | 11.9% (138/1158) |
| Ischemia-Driven TLR | 2.2% (17/777) | 2.4% (39/1639) | 2.3% (56/2416) | 4.6% (55/1195) | 5.8% (43/745) | 6.6% (105/1603) | 6.3% (148/2348) | 7.9% (92/1158) |
| Ischemia-Driven TVR, Non TL | 2.7% (21/777) | 2.0% (33/1639) | 2.2% (54/2416) | 2.4% (29/1195) | 5.6% (42/745) | 5.6% (90/1603) | 5.6% (132/2348) | 5.4% (63/1158) |

Notes:

- One subject in SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 1-year and 3-year time frames include follow-up window (365 ± 28 days and 1095 ± 28 days, respectively).
- TLF is defined as a hierarchical composite of cardiac death, Target Vessel MI (per protocol definition), and ischemia-driven TLR.

9.7 XIENCE V USA Post-Approval Study

Objective: The objectives of the XIENCE V USA post-approval study were: (1) to evaluate the continued safety and effectiveness of the XIENCE V EECSS during commercial use in real-world settings; (2) to support the Food and Drug Administration's (FDA) dual antiplatelet therapy (DAPT) initiative.

Design: The XIENCE V USA study was a prospective, multicenter, FDA-mandated post-approval study with 3 cohorts: phase I (from index procedure to 1 year), long-term follow-up cohort of phase II (from 1 year to 4 years), and AV-DAPT cohort of phase II (from 1 year to 33 months). Patients were considered as enrolled upon signing the Institutional Review Board (IRB)-approved informed consent form (ICF) and only XIENCE V EECSS was (were) implanted during the index procedure. There were no angiographic inclusion and exclusion criteria for this study. A total of 8,040 patients were consecutively enrolled from 191 sites in U.S. from two enrollment phases (5,042 patients from the first enrollment phase and 2,998 patients from the second enrollment phase). Phase I cohort consisted of all the 8,040 enrolled patients. Clinical follow-up occurred at 14, 30, 180 days, and 1 year. The long-term follow-up cohort of phase II consisted of 4,663 patients from the first enrollment phase who were not transferred to the HCRI- DAPT study (IDE#G080186) and remained in the study beyond 1 year. Clinical follow-up occurred at 2, 3, and 4 years. For phase I and the long-term follow-up cohort, the primary endpoint was the annual rate of ARC-defined stent thrombosis (definite and probable), and the co-primary endpoint was the annual composite rate of cardiac death or any MI. For phase I, the primary hypothesis for the co-primary endpoint of cardiac death or MI from 0-1 year is based on a comparison of the near on-label patients from the second enrollment stage of XIENCE V USA who had cardiac markers drawn between 12 – 24 hours post procedure to the population of SPIRIT III and SPIRIT III-like patients in SPIRIT IV treated with XIENCE V (with a non-inferiority margin of 3%). For the long-term follow-up cohort, the four yearly annual rates of ARC-defined definite and probable stent thrombosis will be simultaneously evaluated against a performance goal of 1.5%. The AV-DAPT cohort of phase II consisted of 868 patients from the second enrollment phase who were eligible and got randomized at 12 months post index procedure to either DAPT or placebo for an additional 18 months thienopyridine treatment (from 12 to 30 months). Clinical follow-up and endpoints for the AV-DAPT cohort are the same as the HCRI-DAPT study (IDE#G080186). All clinical endpoint events were adjudicated by an independent CEC.

Results: Phase I of the study has been completed in the entire population. A total of 8,040 patients with 11,137 lesions were treated with a total of 12,873 XIENCE V stents during the index procedure. There were 39% near on-label patients and 61% non near on-label patients. The non near on-label cohort includes patients with any of the following: baseline lesion length > 28 mm, reference vessel diameter < 2.5 mm or > 4.25 mm, restenosis, chronic total occlusion, graft lesion, bifurcation with side branch \geq 2 mm, ostial, left main, more than 2 lesions stented in the same vessel, more than 2 vessels treated, acute MI, renal insufficiency, ejection fraction < 30%, or staged procedure. Patients who do not meet the above criteria are classified as the "near on-label" cohort. Baseline characteristics (Table 9.7-1) and key endpoint results were summarized below (Table 9.7-2 and Table 9.7-3). The 4-year follow-up rate for the XIENCE V USA clinical trial was 87.7% (4,405/5,020).

The 1-year primary endpoint of ARC definite and probable ST rate was 0.81%. The 1-year co-primary endpoint of the composite cardiac death or MI rate was 7.2%. The primary analysis for the co-primary endpoint was summarized in Table 9.7-2. The difference in cardiac death or

MI rate between XIENCE V USA and SPIRIT study was 0.01% with the 95% upper confidence limit being 1.74%, which was less than the quasi non-inferiority margin of 3% ($P_{NI} = 0.0022$).

Table 9.7-1: XIENCE V USA Baseline Characteristics

| Analysis population: 8040 patients, 11137 lesions, 12873 stents | | | |
|---|----------------------|-------------------------------|---------------------|
| Patient Demographics | | Procedural Characteristics | |
| Male | 69.6% (5599/8040) | Vessels Treated | |
| Age (year) | 64.58 ± 10.82 (8040) | 1 | 86.3% (6564/7609) |
| All Diabetes Mellitus | 35.8% (2856/7969) | 2 | 13.1% (998/7609) |
| Oral Hypoglycemics Treated | 23.6% (1879/7969) | ≥ 3 | 0.6% (47/7609) |
| Insulin Treated | 12.3% (979/7969) | Target Vessels | |
| Multi-vessel Disease | 39.8% (3202/8040) | RCA | 32.8% (3656/11136) |
| Prior MI | 29.7% (2212/7440) | LAD | 37.5% (4173/11136) |
| Prior PCI | 39.1% (3065/7836) | LCX | 23.5% (2617/11136) |
| Prior CABG | 16.4% (1289/7836) | LMCA | 1.6% (182/11136) |
| Unstable Angina | 28.7% (2188/7612) | Graft | 4.6% (508/11136) |
| AMI | 14.7% (1054/7146) | Lesions Treated | |
| Renal Insufficiency | 10.5% (840/8015) | 1 | 70.0% (5627/8040) |
| | | 2 | 23.2% (1868/8040) |
| | | ≥ 3 | 6.8% (545/8040) |
| Reference Vessel Diameter (mm) | 3.02 ± 0.53 (10707) | Stenting | |
| Lesion Length (mm) | 15.8 ± 9.4 (10642) | Direct stenting (per lesion) | 36.8% (4096/11126) |
| Lesion Type | | Stents implanted per patient | 1.6 ± 0.9 (8040) |
| A | 17.7% (1643/9273) | Patients with > 1 stent | 40.8% (3280/8040) |
| B1 | 32.4% (3002/9273) | Stent length per patient (mm) | 29.2 ± 19.1 (8039) |
| B2 | 25.8% (2390/9273) | Stent length per lesion (mm) | 21.2 ± 11.3 (11093) |
| C | 24.1% (2238/9273) | | |
| Restenosis Lesion | 8.7% (972/11134) | | |
| Bifurcation Lesion | 9.7% (1084/11120) | | |
| Ostial Lesion | 11.2% (1176/10456) | | |
| Patient Categorization | | | |
| Near On-label | 39.0% (3132/8040) | | |
| Non Near On-label ¹ | 61.0% (4908/8040) | | |
| Lesion length > 28 mm | 12.5% (613/4908) | > 2 lesions in same vessel | 4.6% (227/4908) |
| Reference vessel diameter < 2.5 mm | 5.3% (258/4908) | > 2 vessels treated | 1.0% (47/4908) |
| Reference vessel diameter > 4.25 mm | 2.0% (97/4908) | AMI | 21.5% (1054/4908) |
| Chronic total occlusion | 3.7% (184/4908) | Renal insufficiency | 17.1% (840/4908) |
| Graft lesion | 8.8% (431/4908) | LVEF < 30% | 4.1% (200/4908) |
| Bifurcation with side branch ≥ 2 mm | 15.2% (746/4908) | With staged procedure | 8.9% (439/4908) |
| Ostial lesion | 22.5% (1103/4908) | | |
| Left main | 3.6% (179/4908) | | |
| Restenosis lesion | 17.3% (847/4908) | | |

Note: numbers presented here are % (n/N) or mean ± SD

¹ a patient can be counted in more than 1 category of the non near on-label criteria

Table 9.7-2: XIENCE V USA Primary Analysis of the 1-Year Co-Primary Endpoint

| | XIENCE V USA (N = 997) | SPIRIT III and IV (N = 2720) | Difference (Upper One-Sided 95% CI) | Non-inferiority p-value |
|-----------------------------|---------------------------|---------------------------------|---|----------------------------|
| 1 Year Cardiac Death and MI | 6.2% (55/881) | 6.2% (166/2663) | 0.01% (1.74%) | 0.0022 |

Notes:

- N is the total number of patients.
- The 1-year window is through 407 days (or randomization date if occurred within 407 days for the second enrollment phase) for XIENCE V USA, and 393 days for SPIRIT III and IV.
- The XIENCE V USA arm includes near on-label patients from the second enrollment phase who had cardiac enzyme collected between 12 and 24 hours post index procedure.
- The SPIRIT study arm includes XIENCE V patients in SPIRIT III and SPIRIT III-like XIENCE V patients in SPIRIT IV.
- One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 3% at 0.05 significance level.

Table 9.7-3: XIENCE V USA Clinical Outcomes at 1 and 4 Years

| | XIENCE V USA Overall Population at 1 Year (N = 8040) | XIENCE V USA Long-Term Follow-up Cohort at 4 Years (N = 5020) |
|---|--|--|
| COMPOSITE EFFICACY & SAFETY | | |
| TLF (WHO MI Definition) | 6.9% (514/7491) | 16.5% (747/4518) |
| TLF (ARC MI Definition) | 9.4% (707/7522) | 19.3% (875/4530) |
| EFFICACY (Non-Hierarchical Subject Counts) | | |
| Clinically indicated TLR | 4.4% (330/7522) | 10.4% (473/4530) |
| Clinically indicated TLR, CABG | 0.8% (57/7522) | 2.0% (91/4530) |
| Clinically indicated TLR, PCI | 4.0% (301/7522) | 8.9% (402/4530) |
| Clinically indicated TVR, nonTLR | 2.1% (161/7522) | 6.1% (277/4530) |
| SAFETY (Non-Hierarchical Subject Counts) | | |
| All Death | 2.6% (194/7522) | 10.9% (494/4530) |
| Cardiac Death | 1.4% (108/7522) | 5.4% (244/4530) |
| Vascular Death | 0.2% (12/7522) | 0.7% (32/4530) |
| Non-Cardiovascular Death | 1.0% (74/7522) | 4.8% (218/4530) |
| Target Vessel MI (WHO) | 1.9% (140/7491) | 3.5% (157/4518) |
| Target Vessel MI (ARC) | 5.5% (415/7522) | 8.7% (396/4530) |
| All MI (WHO) | 2.2% (162/7491) | 4.8% (215/4518) |
| QMI | 0.5% (39/7491) | 1.5% (68/4518) |
| NQMI | 1.7% (126/7491) | 3.4% (152/4518) |
| All MI (ARC) | 6.3% (475/7522) | 11.3% (511/4530) |
| QMI | 0.5% (39/7522) | 1.5% (68/4530) |
| NQMI | 5.9% (442/7522) | 10.1% (457/4530) |
| COMPOSITE SAFETY | | |
| Cardiac Death or Target Vessel MI (WHO) | 3.1% (231/7491) | 8.0% (361/4518) |
| Cardiac Death or Target Vessel MI (ARC) | 6.5% (491/7522) | 12.6% (571/4530) |
| Cardiac Death or MI (WHO) | 3.3% (250/7491) | 9.1% (412/4518) |
| Cardiac Death or MI (ARC) | 7.2% (545/7522) | 14.9% (676/4530) |
| STENT THROMBOSIS (ARC-Defined Definite/Probable) | | |
| Cumulative through 1 year | 0.81% (60/7380) | - |
| Acute/Subacute (0 – 30 days) | 0.40% (32/7951) | - |
| Late (31 – 365 days) | 0.37% (27/7364) | - |
| Very Late (366 – 1502 days) | - | 0.55% (22/4032) |

| | XIENCE V USA Overall Population at 1 Year (N = 8040) | XIENCE V USA Long-Term Follow-up Cohort at 4 Years (N = 5020) |
|--|--|--|
| Cumulative through 4 years | - | 1.56% (64/4093) |
| STENT THROMBOSIS (ARC-Defined Definite) | | |
| Cumulative through 1 year | 0.54% (40/7380) | - |
| Acute/Subacute (0 – 30 days) | 0.23% (18/7951) | - |
| Late (31 – 365 days) | 0.29% (21/7364) | - |
| Very Late (366 – 1502 days) | - | 0.42% (17/4032) |
| Cumulative through 4 years | - | 1.05% (43/4093) |

Notes:

- N is the total number of patients
- The 1-year window is through 407 days (or randomization date if occurred within 407 days for the second enrollment phase of XIENCE V USA).
The 4-year window is through 1502 days.
- TLR is defined as hierarchical composite of cardiac death, target vessel MI (per ARC definition), and clinically indicated TLR.

Study Strengths and Limitations: The XIENCE V USA study was a prospective, open-label, multicenter, post-approval study. All event adjudications were performed by an independent event committee with 100% site-reported adjudicable events being source-verified. With a large sample size and high data quality, the study provides important information on the clinical outcomes in a real-world population beyond those from selected patients in randomized pre-approval studies. However, the study is limited by being observational in nature, and therefore a head-to-head comparison with other DES platforms was not possible. In addition, the monitoring level is less rigorous than a randomized pivotal trial. However, the consistent results between XIENCE V USA near on-label population and the XIENCE V arm in SPIRIT III and IV trials suggests that the quality measures taken in XIENCE V USA study as described above produced high quality data. Therefore, this study affords a reliable benchmark for understanding the safety of XIENCE V EECSS in the context of real-world clinical practice.

9.7.1 Analysis of Patients with 4.0 mm Stent

There were 186 near on-label patients with at least one XIENCE V 4.0 mm stent implanted during the index procedure. A pre-specified descriptive comparison of 1-year TLR is summarized in Table 9.7.1-1.

Table 9.7.1-1: XIENCE V USA Patients with 4.0 mm Stent

| | XIENCE V USA (N = 186) | SPIRIT III and IV (N = 74) |
|------------|---------------------------|-------------------------------|
| 1 Year TLR | 3.4% (6/177) | 2.7% (2/74) |

Notes:

- N is the total number of patients.
- The 1-year window is through 407 days (or randomization date if occurred within 407 days for the second enrollment phase) for XIENCE V USA, and 393 days for SPIRIT III and IV.
- The XIENCE V USA arm includes near on label patients who had at least a 4.0 mm XIENCE V stent implanted during the index procedure.
- The SPIRIT study arm includes XIENCE V patients in SPIRIT III 4.0 mm registry and SPIRIT III-like XIENCE V patients in SPIRIT IV who were treated with at least a 4.0 mm XIENCE V stent.

9.7.2 Analysis of Patients Treated with Direct Stenting

There were two pre-specified hypothesis tests on direct stenting. The results of both tests were summarized in Table 9.7-5. One-year TLF rate of XIENCE V USA patients who had a single lesion treated with direct stenting in real world settings was non-inferior to the event rate of SPIRIT III-like XIENCE V patients in SPIRIT IV who had a single lesion treated with pre-dilatation ($P_{NI} = 0.0119$). In XIENCE V USA, one-year TLF rate in patients who had a single lesion treated with direct stenting was non-inferior to the event rate of those who had a single lesion treated with pre-dilatation ($P_{NI} < 0.0001$).

In these two analyses, there was, as expected, some degree of selection bias with lesions undergoing direct-stenting displaying lower complexity than lesions undergoing pre-dilatation. For hypothesis 1, there were more patients who had prior cardiac intervention and history of MI in XIENCE V USA direct stenting group, but there were more B2/C lesions and more multiple stents implanted in the SPIRIT IV pre-dilatation group. The propensity score approach was utilized to address this selection bias. A logistic regression was fit to obtain the propensity score for direct stenting, which was defined as the probability of having direct stenting given specific values for the following variables: age, sex, current smoker, diabetes treated, hypertension requiring medication, lipid disorder requiring medication, prior CABG, prior PCI, CCS III or IV stable angina, prior MI, prior brachytherapy, multi-vessel disease, LAD, heavy calcification, baseline DS%, TIMI, lesion length ≥ 22 mm, B2/C lesion, and multiple stents per lesion. Then patients were divided into 5 strata with approximately equal size based on the rank of their propensity scores. A stratified non-inferiority test was finally performed. For hypothesis 2, the XIENCE V USA direct stenting group had less B2/C lesion, less bifurcations, and fewer patients with multiple stents implanted than the predilatation group. For hypothesis 2, the propensity analysis method was the same as hypothesis 1, except that some additional variables were added such as AMI, renal insufficiency, LVEF $< 30\%$, left main, graft, restenotic lesion, bifurcation, ostial lesion, and history of stroke, which were not included in the propensity model of hypothesis 1 because these patients were either excluded in SPIRIT IV or data were not collected in SPIRIT IV. The propensity analysis results for both hypothesis 1 and hypothesis 2 indicated that adjustment for baseline differences in lesion characteristics did not change the findings of non-inferiority of direct stenting to pre-dilatation in either analysis (Table 9.7.2-1).

Table 9.7.2-1: XIENCE V USA Direct Stenting Results

| Analysis 1 | XIENCE V USA Direct Stenting (N = 506) | SPIRIT IV Pre-dilatation (N = 1726) | Difference (Upper One-Sided 95% CI) | Non-inferiority p-value |
|---|---|--|-------------------------------------|-------------------------|
| 1 Year TLF | 7.7% (34/440) | 7.4% (124/1687) | 0.38% (3.01%) | 0.0119 |
| 1-Year TLF (Propensity Score Analysis) | 7.7% (34/440) | 7.4% (124/1687) | -0.09% (2.70%) | 0.0079 |
| Hierarchical TLF Components | | | | |
| Cardiac Death | 0.7% (3/440) | 0.4% (6/1687) | NA | NA |
| Target Vessel MI | 4.5% (20/440) | 5.7% (97/1687) | NA | NA |
| Clinically Indicated TLR | 2.5% (11/440) | 1.2% (21/1687) | NA | NA |
| 1-Year Stent Thrombosis (ARC definite/probable) | 0.23% (1/430) | 0.18% (3/1675) | NA | NA |
| 1-Year Stent Thrombosis (ARC definite) | 0.23% (1/430) | 0.18% (3/1675) | NA | NA |
| Analysis 2 | XIENCE V USA Direct Stenting (N = 1947) | XIENCE V USA Pre-dilatation (N = 3405) | Difference (Upper One-Sided 95% CI) | Non-inferiority p-value |
| 1 Year TLF | 6.8% (124/1817) | 7.9% (252/3182) | -1.10% (0.23%) | < 0.0001 |
| 1-Year TLF (Propensity Score Analysis) | 6.8% (124/1817) | 7.9% (252/3182) | -0.60% (0.75%) | 0.0008 |
| Hierarchical TLF Components | | | | |
| Cardiac Death | 1.3% (24/1817) | 1.3% (40/3182) | NA | NA |
| Target Vessel MI | 3.3% (60/1817) | 4.5% (142/3182) | NA | NA |
| Clinically Indicated TLR | 2.2% (40/1817) | 2.2% (70/3182) | NA | NA |
| 1-Year Stent Thrombosis (ARC definite/probable) | 0.56% (10/1786) | 0.51% (16/3118) | NA | NA |
| 1-Year Stent Thrombosis (ARC definite) | 0.28% (5/1786) | 0.35% (11/3118) | NA | NA |

Notes:

- N is the total number of patients.
- The 1-year window is through 407 days (or randomization date if occurred within 407 days for the second enrollment phase) for XIENCE V USA, and 393 days for SPIRIT IV study.
- In Analysis 1, the XIENCE V USA direct stenting arm included patients from the second enrollment phases who had cardiac enzyme collected between 12 and 24 hours post procedure and only 1 lesion treated during index procedure and the lesion was treated with direct stenting. Patients with staged procedure (s) were excluded. The SPIRIT IV pre-dilatation arm included SPIRIT III-like XIENCE V patients in SPIRIT IV who had only 1 lesion treated. All SPIRIT IV patients were considered to have pre-dilatation done for lesions treated during index procedure per protocol requirement. One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 4% at 0.05 significance level.
- In Analysis 2, the XIENCE V USA direct stenting arm included all patients who had only 1 lesion treated and the lesion was treated with direct stenting from both enrollment phases of XIENCE V USA. The XIENCE V USA pre-dilatation arm included all patients who had only 1 lesion treated and the lesion was treated with pre-dilatation from both enrollment phases of XIENCE V USA. Patients with staged procedure (s) were excluded. One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 2% at 0.05 significance level.
- TLF included cardiac death, target vessel MI (per ARC definition) and clinically indicated TLR. In SPIRIT IV, ischemic-driven TLR was used rather than clinically indicated. The two definitions are similar but differ in regards to clinically indicated TLR requiring that there is ≥ 50% diameter stenosis and the presence of clinical symptoms. Ischemic-driven TLR does not always require angiographic evidence of ≥ 50% diameter stenosis; revascularization due to a positive functional ischemia study alone qualifies as ischemic-driven.

9.7.3 Pre-specified XIENCE V USA Subgroup Analysis

Elderly (age \geq 65 years), female, insulin-treated diabetic, acute MI (STEMI and NSTEM combined) patients and patients with multi-vessel disease and two vessels stented are at increased risk for cardiovascular morbidity and mortality. In addition, patients with complex lesion characteristics, such as long lesions (\geq 20 mm), bifurcation lesions, ostial lesions and in-stent restenotic lesion are also associated with worse clinical outcomes. In XIENCE V USA, the above-mentioned subgroups were pre-specified for descriptive analysis to assess the safety and effectiveness of those high-risk patients. There were no pre-specified hypotheses for those subgroups.

The pre-specified XIENCE V USA subgroup 4-year clinical outcomes were summarized in Table 9.7.3-1.

Table 9.7.3-1: XIENCE V USA Subgroup Clinical Outcomes through 4 Years

| | XV USA Overall (N = 5020) | Near on-label (N = 1871) | Age ≥ 65 (N = 2495) | Female (N = 1564) | Insulin-Treated Diabetics (N = 593) | Acute MI (STEMI/NSTEMI) (N = 667) | Multivessel Disease (N = 2050) | Two Vessels Treated (N = 620) | Long Lesions (≥ 20mm) (N = 860) | Bifurcation Lesions (N = 261) | Ostial Lesions (N = 366) | ISR (N = 257) |
|--------------------------------------|---------------------------|--------------------------|---------------------|-------------------|-------------------------------------|-----------------------------------|--------------------------------|-------------------------------|---------------------------------|-------------------------------|--------------------------|----------------|
| COMPOSITE EFFICACY AND SAFETY | | | | | | | | | | | | |
| ARC-Defined Device Oriented Endpoint | 19.7% (893/4530) | 13.4% (228/1704) | 20.3% (475/2339) | 21.7% (305/1406) | 37.3% (198/531) | 22.2% (129/581) | 25.1% (471/1875) | 26.2% (148/565) | 18.3% (142/776) | 12.6% (28/222) | 23.9% (77/322) | 27.6% (64/232) |
| TLF | 19.3% (875/4530) | 13.0% (222/1704) | 20.0% (468/2339) | 21.1% (297/1406) | 37.1% (197/531) | 21.9% (127/581) | 24.7% (463/1875) | 25.3% (143/565) | 18.2% (141/776) | 12.2% (27/222) | 23.9% (77/322) | 27.2% (63/232) |
| SAFETY | | | | | | | | | | | | |
| Cardiac Death or Target Vessel MI | 12.6% (571/4530) | 8.3% (142/1704) | 14.5% (338/2339) | 14.0% (197/1406) | 26.9% (143/531) | 15.8% (92/581) | 15.8% (296/1875) | 16.5% (93/565) | 12.1% (94/776) | 6.8% (15/222) | 14.6% (47/322) | 14.7% (34/232) |
| Cardiac Death or MI | 14.9% (676/4530) | 10.3% (176/1704) | 16.2% (380/2339) | 16.1% (227/1406) | 30.1% (160/531) | 20.1% (117/581) | 18.6% (348/1875) | 18.2% (103/565) | 14.3% (111/776) | 8.1% (18/222) | 18.0% (58/322) | 17.7% (41/232) |
| All Death | 10.9% (494/4530) | 7.8% (133/1704) | 15.0% (352/2339) | 11.7% (164/1406) | 22.0% (117/531) | 14.1% (82/581) | 12.3% (230/1875) | 11.5% (65/565) | 12.0% (93/776) | 6.3% (14/222) | 13.7% (44/322) | 9.9% (23/232) |
| Cardiac Death | 5.4% (244/4530) | 3.3% (57/1704) | 6.7% (157/2339) | 5.4% (76/1406) | 14.1% (75/531) | 6.7% (39/581) | 6.6% (123/1875) | 6.4% (36/565) | 5.0% (39/776) | 1.8% (4/222) | 6.2% (20/322) | 4.7% (11/232) |
| All MI | 11.3% (511/4530) | 8.0% (137/1704) | 11.6% (272/2339) | 12.5% (176/1406) | 20.9% (111/531) | 15.3% (89/581) | 14.3% (268/1875) | 14.3% (81/565) | 10.8% (84/776) | 6.3% (14/222) | 13.0% (42/322) | 15.1% (35/232) |
| QMI | 1.5% (68/4530) | 1.1% (18/1704) | 1.1% (26/2339) | 1.5% (21/1406) | 2.3% (12/531) | 3.6% (21/581) | 1.8% (34/1875) | 2.5% (14/565) | 1.4% (11/776) | 0.5% (1/222) | 0.6% (2/322) | 0.9% (2/232) |
| NQMI | 10.1% (457/4530) | 7.1% (121/1704) | 10.7% (251/2339) | 11.2% (158/1406) | 19.0% (101/531) | 12.7% (74/581) | 12.9% (242/1875) | 12.6% (71/565) | 9.8% (76/776) | 5.9% (13/222) | 12.4% (40/322) | 14.7% (34/232) |
| Target Vessel MI | 8.7% (396/4530) | 5.9% (101/1704) | 9.5% (222/2339) | 10.2% (143/1406) | 17.3% (92/531) | 10.7% (62/581) | 11.3% (212/1875) | 12.4% (70/565) | 8.2% (64/776) | 5.0% (11/222) | 9.6% (31/322) | 11.6% (27/232) |
| Efficacy | | | | | | | | | | | | |
| TLR | 10.9% (495/4530) | 7.1% (121/1704) | 9.5% (222/2339) | 11.9% (167/1406) | 20.0% (106/531) | 11.2% (65/581) | 14.5% (271/1875) | 15.6% (88/565) | 10.1% (78/776) | 7.2% (16/222) | 13.7% (44/322) | 20.3% (47/232) |
| Stent Thrombosis | | | | | | | | | | | | |
| ARC Definite/probable | 1.56% (64/4093) | 0.70% (11/1577) | 1.60% (33/2058) | 1.53% (19/1244) | 3.39% (15/443) | 2.57% (13/506) | 2.27% (38/1674) | 2.34% (12/513) | 1.45% (10/688) | 0.98% (2/205) | 1.04% (3/288) | 2.86% (6/210) |
| ARC Definite | 1.05% (43/4093) | 0.25% (4/1577) | 0.92% (19/2058) | 1.05% (13/1244) | 2.03% (9/443) | 2.17% (11/506) | 1.43% (24/1674) | 1.17% (6/513) | 1.02% (7/688) | 0.98% (2/205) | 0.69% (2/288) | 2.38% (5/210) |

Notes:

- N is the total number of patients
- The 4-year window is through 1502 days
- Per ARC definition was used for MI and MI related endpoints.
- ARC-defined device oriented endpoint is defined as hierarchical composite of cardiac death, target vessel MI (per ARC definition), and TLR.
- TLF included cardiac death, target vessel MI (per ARC definition) and clinically indicated TLR. Near on-label patients are those who are not defined as non near on-label. The non near on-label cohort includes patients with any of the following: baseline lesion length >28 mm, reference vessel diameter < 2.5 mm or > 4.25 mm, restenosis, chronic total occlusion, graft lesion, bifurcation with side branch ≥ 2 mm, ostial, left main, more than 2 lesions stented in the same vessel, more than 2 vessels treated, acute MI, renal insufficiency, ejection fraction < 30%, or staged procedure.
- For long lesion (≥ 20mm), bifurcation, ostial and ISR subgroups, only patients with single-lesion treated during the index procedure and without any staged procedures were included in the analysis

9.8 EXPERT CTO Clinical Trial

The EXPERT CTO clinical trial was designed to demonstrate the safety and effectiveness of the XIENCE family of stent systems in the treatment of chronic total occlusions (CTO). The trial, conducted in the United States, consists of a single arm, and one-year results are presented here.

Primary Objective: The objective of the EXPERT CTO clinical trial is to evaluate the safety and effectiveness of the XIENCE family of stent systems in improving coronary luminal diameter in subjects with symptomatic heart disease due to CTO.

Design: The EXPERT CTO clinical trial is a prospective, nonrandomized, open-label, multicenter single-arm study evaluating stent diameters of 2.25 – 4.0 mm with stent lengths 8 – 38 mm in 222 subjects at 20 sites in the United States. Each subject was to receive treatment of one *de novo* native coronary CTO lesion. However, treatment of non-CTO lesions distal to the target lesion (non-target lesions in the target vessel) which were not identified on the pre-procedural angiogram prior to CTO recanalization but were identified only after successful CTO recanalization, was allowed using XIENCE stents. Treatment of one lesion in a non-target vessel was also allowed during the index procedure.

The primary endpoint is major adverse cardiac events (MACE) at one year, a composite endpoint of death, myocardial infarction (MI), and clinically driven target lesion revascularization (TLR). The primary endpoint rate of MACE at 1 year was compared to a pre-specified performance goal (PG). The PG of 24.4% for the EXPERT CTO trial was developed utilizing historical clinical trial data. First, the average 1-year MACE rate per ARC MI definition was weighted by sample size and adjusted for MI definition if necessary. The adjustment was derived from Abbott Vascular historical trials to account for difference in the primary endpoint between ARC and protocol MI definitions. The weighted average event rate after the above adjustment was 14.4%. The final performance goal was set at 24.4% after adding a delta of 10% to account for variability and uncertainty. Analyses of the primary endpoint were conducted on both the intent-to-treat (ITT) population and per protocol (PP) population.

Demographics: The mean age was 61.65 ± 10.43 years, 81.1% (180/222) were male, 18.9% (42/222) were female and 80.2% (178/222) were white. Regarding medical risk factors, 26.0% (54/208) were tobacco users, 91.9% (203/221) were hypertensive, and 96.8% (215/222) were dyslipidemic. There were 43.4% (96/221) of subjects who had a prior percutaneous cardiac intervention, 29.0% (61/210) who had a prior MI, and 9.9% (22/222) who had prior coronary artery bypass graft surgery. Furthermore, the population consisted of 40.1% (89/222) diabetics, of which 68.5% (61/89) were diabetics requiring oral medication, 30.3% (27/89) were diabetics requiring insulin, and 28.1% (25/89) were diabetics controlled by diet.

Results: The primary endpoint results are presented in Table 9.8-1. These analyses are based on the ITT and PP populations. The ITT population is defined as all enrolled patients for whom recanalization and pre-dilatation of the target lesion are completed and the study stent(s) (XIENCE V and / or XIENCE PRIME) is inserted into the coronary guiding catheter. The PP population is defined as all ITT patients for the

stent-related analysis in whom at least one study stent is implanted with both procedure success and available follow-up data but without major protocol deviations due to inappropriate enrollment.

The observed MACE rate at one year was 18.5% (39/211) in the ITT population and 8.2% (15/183) in the PP population. Both the ITT and PP populations met the primary endpoint with MACE rates significantly lower than the pre-specified PG (24.4%) ($p = 0.0248$ and $p < 0.0001$, respectively).

Secondary endpoints are presented in Table 9.8-2.

Table 9.8-1: EXPERT CTO Primary Endpoint Results

| Primary Endpoint Analysis | MACE | Upper One-Sided 95% CL ⁴ | Performance Goal | p-value ⁴ |
|---|----------------|-------------------------------------|------------------|----------------------|
| ITT Set ¹ (N = 222) Exact Rate ³ | 18.5% (39/211) | 23.4% | 24.4% | 0.0248 |
| PP Set ² (N = 183) Exact Rate ³ | 8.2% (15/183) | 12.3% | 24.4% | < 0.0001 |

¹ ITT subjects include all subjects who met the study entry criteria, signed the written informed consent, were enrolled in the trial, and whose target lesion was successfully crossed and predilated.

² The per-protocol population is defined as all ITT subjects in whom at least one study stent was implanted, met procedure success, had available follow-up data (i.e., a MACE event within 360 days or follow up of at least 330 days), and did not have major protocol deviations due to inappropriate enrollment.

³ The numerator includes subjects who have MACE events before or on day 360, and the denominator includes subjects who had had available follow-up data (i.e., a MACE event within 360 days or follow up of at least 330 days).

⁴ p-value and upper one-sided 95% CI were calculated using exact binomial method.

Table 9.8-2: EXPERT CTO Clinical Results

| | Outcomes at 1 Year ITT (N = 222) |
|--|---|
| Composite Effectiveness and Safety | |
| TLF (per ARC) | 15.8% (33/209) |
| TLF (per protocol) | 9.1% (19/209) |
| Effectiveness | |
| Clinically driven TLR | 6.3% (13/207) |
| Clinically driven TLR, CABG | 0.5% (1/206) |
| Clinically driven TLR, PCI | 5.8% (12/207) |
| Clinically driven TVR | 7.2% (15/207) |
| Safety | |
| All Death | 1.9% (4/210) |
| Cardiac Death | 1.0% (2/208) |
| Non-Cardiac Death | 1.0% (2/208) |
| Target Vessel MI (per ARC) | 12.0% (25/209) |
| Target Vessel QMI (per ARC) | 1.0% (2/208) |
| Target Vessel NQMI (per ARC) | 11.1% (23/207) |
| All MI (per ARC) | 13.9% (29/209) |
| QMI (per ARC) | 1.0% (2/208) |
| NQMI (per ARC) | 13.0% (27/207) |
| Target Vessel MI (per protocol) | 3.4% (7/208) |
| Target Vessel QMI (per protocol) | 1.0% (2/208) |
| Target Vessel NQMI (per protocol) | 2.4% (5/206) |
| All MI (per protocol) | 3.4% (7/208) |
| QMI (per protocol) | 1.0% (2/208) |
| NQMI (per protocol) | 2.4% (5/206) |
| ARC Definite+Probable Stent Thrombosis | |
| Cumulative through 1 year | 1.4% (3/207) |
| Acute (0 – 1 day) | 0.0% (0/222) |
| Subacute (2 – 30 days) | 0.9% (2/218) |
| Late (31 days – 1 year) | 0.5% (1/206) |
| ARC Definite Stent Thrombosis (cumulative) | 1.0% (2/207) |

Notes:

- TLF is defined as a hierarchical composite of cardiac death, Target Vessel MI, and clinically driven TLR.
- ARC: Academic Research Consortium

Study Strengths and Limitations: The EXPERT CTO study was a prospective, open-label, multicenter study. All event adjudications were performed by an independent Clinical Event Committee (CEC) with 100% site-reported adjudicable events being source-verified. This study provides important information on clinical outcomes in patients with chronic total occlusions treated with the XIENCE family of stents. The study is limited by being a small study with no head-to-head comparison with other DES platforms. In addition, due to the small population size, subgroup analysis can at best be considered exploratory.

9.8.1 Gender-Based Analysis of the EXPERT CTO Clinical Trial

Abbott Vascular performed a post hoc evaluation of the EXPERT CTO clinical trial for possible sex-based differences in baseline characteristics and clinical outcomes, as well as for any interaction between treatment and sex/gender. The EXPERT CTO trial was not designed or powered to study safety or effectiveness differences between sexes, so these analyses are considered exploratory without definitive conclusions.

In the EXPERT CTO study, 81.1% (180/222) were male and 18.9% (42/222) were female. In comparison, the prevalence of coronary artery disease (CAD) is estimated at 9.2 million in males and 8.4 million in females for adults age 20 and older the United States (i.e., the CAD population is estimated to be 52.2% males and 47.7% females). The disproportionate enrollment distribution in this trial may be partly attributable to gender differences in symptoms and pathophysiology, which may lead to under-diagnosis and under-referral of female patients with CAD. The gender proportions enrolled in this trial are similar to other CTO drug-eluting stent trials.^{32,33,34}

Table 9.8.1-1 presents the baseline demographics, risk factors, and angiographic characteristics by gender for subjects in the EXPERT CTO trial. As is consistent with previous literature, female patients at baseline were numerically older. More females than males were diabetic.

³²Kandzari DE, Rao SV, Moses JW, et al. Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial. *J Am Coll Cardiol Intv* 2009;2:97-106.

³³Valenti R, Vergara R, Migliorini A, et al. Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. *J Am Coll Cardiol* 2013;61:545-550.

³⁴Wohrle J, Rottbauer W, Imhof A. Everolimus-eluting stents for treatment of chronic total coronary occlusions. *Clin Res in Cardiol* 2011;101:23-28

Table 9.8.1-1: Demographics, Risk Factors, and Baseline Angiographic Characteristics for EXPERT CTO

| Subject / Lesion Characteristics | Male (N = 180) (L = 180) | Female (N = 42) (L = 42) | Difference [95% CI] | p-value |
|--|--------------------------------|--------------------------------|------------------------|---------|
| Baseline Demographics, Mean ± SD (n) | | | | |
| Age (year) | 61.08±10.46 (180) | 64.12±10.09 (42) | -3.04[-6.45,0.37] | 0.089 |
| Baseline Risk Factors, % (No./total) | | | | |
| All Diabetes | 38.3% (69/180) | 47.6% (20/42) | -9.3%[-26.0%,7.4%] | 0.297 |
| Diabetes Treated with Insulin | 29.0% (20/69) | 35.0% (7/20) | -6.0%[-29.5%,17.5%] | 0.593 |
| Current Tobacco Use | 28.9% (48/166) | 14.3% (6/42) | 14.6%[2.0%,27.3%] | 0.222 |
| Hypertension | 91.6% (164/179) | 92.9% (39/42) | -1.2%[-10.0%,7.5%] | 1.000 |
| Dyslipidemia | 96.1% (173/180) | 100.0% (42/42) | -3.9%[-6.7%,-1.1%] | 0.352 |
| Congestive Heart Failure | 13.3% (24/180) | 7.1% (3/42) | 6.2%[-3.0%,15.4%] | 0.430 |
| Prior PCI | 44.1% (79/179) | 40.5% (17/42) | 3.7%[-12.9%,20.2%] | 0.731 |
| Prior MI | 30.0% (51/170) | 25.0% (10/40) | 5.0%[-10.1%,20.1%] | 0.569 |
| Target Vessel, % (No./total) | | | | |
| LAD | 30.6% (55/180) | 33.3% (14/42) | -2.8%[-18.5%,13.0%] | 0.715 |
| Circumflex or Ramus | 17.8% (32/180) | 7.1% (3/42) | 10.6%[1.1%,20.2%] | 0.103 |
| RCA | 51.7% (93/180) | 59.5% (25/42) | -7.9%[-24.4%,8.7%] | 0.394 |
| LMCA | 0.0% (0/180) | 0.0% (0/42) | 0.0%[0.0%,0.0%] | -- |
| Pre-Procedure QCA Analysis, Mean ± SD (m) | | | | |
| Lesion Length (mm) | 35.92±19.20 (180) | 36.68±15.19 (42) | -0.76[-6.14,4.62] | 0.811 |
| Pre-Procedure RVD (mm) | 2.69±0.43 (180) | 2.52±0.43 (42) | 0.17[0.02,0.31] | 0.022 |
| Pre-Procedure MLD (mm) | 0.01±0.06 (180) | 0.00±0.00 (42) | 0.01[0.00,0.02] | 0.026 |
| Pre-Procedure Percent Diameter Stenosis (%DS) | 99.62±2.36 (180) | 100.00±0.00 (42) | -0.38[-0.72,-0.04] | 0.032 |

A post hoc analysis was conducted on the composite primary safety and effectiveness endpoint of MACE, per ARC and per protocol, to assess for heterogeneity of treatment effect across sex / gender (Table 9.8.1-2). Due to the modest sample size (180 males vs. 42 females), these analyses and interpretation are limited.

Table 9.8.1-2: Clinical Results for All Female and All Male Subgroups in the EXPERT CTO Study through 1 Year

| EXPERT CTO | Male (N = 180) | Female (N = 42) | Difference [95% CI] | p-value |
|-------------------------------|-------------------|--------------------|------------------------|---------|
| All Death | 1.2% (2/171) | 5.1% (2/39) | -4.0%[-11.1%,3.1%] | 0.158 |
| Cardiac Death | 0.6% (1/170) | 2.6% (1/38) | -2.0%[-7.3%,3.2%] | 0.333 |
| Non-Cardiac Death | 0.6% (1/170) | 2.6% (1/38) | -2.0%[-7.3%,3.2%] | 0.333 |
| Target Vessel MI per ARC | 11.1% (19/171) | 15.8% (6/38) | -4.7%[-17.2%,7.8%] | 0.413 |
| Target Vessel MI per Protocol | 3.5% (6/171) | 2.7% (1/37) | 0.8%[-5.1%,6.7%] | 1.000 |
| Clinically Driven TLR | 6.5% (11/170) | 5.4% (2/37) | 1.1%[-7.1%,9.2%] | 1.000 |
| Clinically Driven TVR, non TL | 1.2% (2/169) | 0.0% (0/37) | 1.2%[-0.4%,2.8%] | 1.000 |
| Stent Thrombosis | | | | |
| ARC definite + probable | 1.2% (2/170) | 2.7% (1/37) | -1.5%[-7.0%,3.9%] | 0.448 |
| MACE | | | | |
| per ARC MI definition | 16.9% (29/172) | 25.6% (10/39) | -8.8%[-23.6%,6.0%] | 0.252 |
| per Protocol MI definition | 9.3% (16/172) | 12.8% (5/39) | -3.5%[-14.9%,7.8%] | 0.553 |

9.9 Analysis of Diabetic Patients

9.9.1 *Analysis of Diabetic Subjects in SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Trials*

Diabetic subjects with coronary artery disease comprise an important subgroup that is at increased risk for cardiovascular morbidity and mortality. Although diabetic subjects were included in the SPIRIT family of trials, there were no pre-specified hypotheses for the use of the XIENCE V stent in diabetic individuals.

Tables 9.9.1-1 and 9.9.1-2 show the clinical outcomes through 3 years in subjects from a post-hoc analysis of the SPIRIT IV and the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV population. History of diabetes was one of the stratification factors used in randomization to assure a balance between the XIENCE V and TAXUS treatment arms for each individual trial. In XIENCE V patients, there were numerically higher event rates in diabetics compared with non-diabetics. Given the potential for confounding variables, no conclusions can be drawn from these post-hoc analyses.

**Table 9.9.1-1: Clinical Results in Diabetics and Non-Diabetics through 3 Years
(SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT and SPIRIT IV Population)**

| SPIRIT IV | 1 Year | | | | 3 Years | | | |
|--|------------------------|---------------------|------------------------|--------------------|------------------------|---------------------|------------------------|--------------------|
| | Non-Diabetics | | All Diabetics | | Non-Diabetics | | All Diabetics | |
| | XIENCE V (N = 1669) | TAXUS (N = 829) | XIENCE V (N = 786) | TAXUS (N = 399) | XIENCE V (N = 1669) | TAXUS (N = 829) | XIENCE V (N = 786) | TAXUS (N = 399) |
| TLF | 3.1% (52/1652) | 6.7% (55/815) | 5.9% (45/761) | 6.9% (26/379) | 8.2% (132/1610) | 11.4% (90/790) | 12.4% (91/735) | 13.1% (48/367) |
| Ischemia-Driven TLR | 1.8% (29/1652) | 4.5% (37/815) | 3.5% (27/761) | 4.7% (18/379) | 5.7% (91/1610) | 8.1% (64/790) | 7.8% (57/735) | 7.6% (28/367) |
| Ischemia-Driven TVR, Non-TL | 1.5% (24/1652) | 2.2% (18/815) | 3.9% (30/761) | 2.9% (11/379) | 4.8% (77/1610) | 4.9% (39/790) | 7.5% (55/735) | 6.5% (24/367) |
| Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV | Non-Diabetics | | All Diabetics | | Non-Diabetics | | All Diabetics | |
| | XIENCE V (N = 2312) | TAXUS (N = 1125) | XIENCE V (N = 1035) | TAXUS (N = 509) | XIENCE V (N = 2312) | TAXUS (N = 1125) | XIENCE V (N = 1035) | TAXUS (N = 509) |
| | TLF | 3.2% (74/2284) | 8.0% (89/1106) | 6.8% (69/1008) | 6.2% (30/482) | 8.0% (177/2211) | 12.7% (137/1075) | 12.2% (118/970) |
| Ischemia-Driven TLR | 2.0% (45/2284) | 5.3% (59/1106) | 4.3% (43/1008) | 3.9% (19/482) | 5.7% (125/2211) | 8.7% (94/1075) | 7.2% (70/970) | 7.4% (34/462) |
| Ischemia-Driven TVR, Non-TL | 1.9% (43/2284) | 3.5% (39/1106) | 3.8% (38/1008) | 2.9% (14/482) | 5.2% (114/2211) | 5.6% (60/1075) | 6.9% (67/970) | 7.1% (33/462) |
| All Death | 0.8% (19/2284) | 1.7% (19/1106) | 1.7% (17/1008) | 0.6% (3/482) | 2.5% (56/2211) | 5.5% (59/1075) | 5.5% (53/970) | 4.8% (22/462) |
| Cardiac Death | 0.2% (5/2284) | 0.7% (8/1106) | 1.0% (10/1008) | 0.2% (1/482) | 0.8% (18/2211) | 1.7% (18/1075) | 2.8% (27/970) | 2.8% (13/462) |
| Non-Cardiac Death | 0.6% (14/2284) | 1.0% (11/1106) | 0.7% (7/1008) | 0.4% (2/482) | 1.7% (38/2211) | 3.8% (41/1075) | 2.7% (26/970) | 1.9% (9/462) |
| Target Vessel MI | 1.3% (30/2284) | 3.0% (33/1106) | 3.0% (30/1008) | 3.3% (16/482) | 2.1% (47/2211) | 4.1% (44/1075) | 4.5% (44/970) | 5.2% (24/462) |
| Cardiac Death or Target Vessel MI | 1.5% (35/2284) | 3.3% (37/1106) | 3.8% (38/1008) | 3.5% (17/482) | 2.9% (65/2211) | 5.3% (57/1075) | 6.9% (67/970) | 7.1% (33/462) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.1% (3/2265) | 0.7% (8/1091) | 0.7% (7/990) | 1.0% (5/479) | 0.5% (11/2150) | 1.6% (16/1018) | 1.9% (17/918) | 3.1% (14/449) |
| ARC Definite+Probable | 0.1% (3/2265) | 0.9% (10/1091) | 1.0% (10/993) | 1.3% (6/479) | 0.4% (8/2148) | 1.7% (17/1017) | 1.7% (16/918) | 2.0% (9/442) |
| ARC Definite | 0.1% (3/2265) | 0.5% (6/1091) | 0.8% (8/993) | 1.3% (6/479) | 0.3% (7/2148) | 1.1% (11/1017) | 1.2% (11/918) | 1.6% (7/442) |

Notes:

- One subject in SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 1-year and 3-year time frames include follow-up window (365 + 28 days and 1095 + 28 days, respectively).

**Table 9.9.1-2: Clinical Results in Diabetics through 3 Years
(SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and
SPIRIT IV Population – XIENCE V Subjects)**

| SPIRIT IV | 1 Year | | | | 3 Years | | | |
|---|-----------------------------|-----------------------------|--|--|-----------------------------|-----------------------------|--|--|
| | Non-Diabetics (N = 1669) | All Diabetics (N = 786) | Insulin-Dependent Diabetics (N = 209) | Non-Insulin-Dependent Diabetics (N = 577) | Non-Diabetics (N = 1669) | All Diabetics (N = 786) | Insulin-Dependent Diabetics (N = 209) | Non-Insulin-Dependent Diabetics (N = 577) |
| TLF | 3.1% (52/1652) | 5.9% (45/761) | 7.0% (14/199) | 5.5% (31/562) | 8.2% (132/1610) | 12.4% (91/735) | 17.3% (33/191) | 10.7% (58/544) |
| Ischemia-Driven TLR | 1.8% (29/1652) | 3.5% (27/761) | 5.0% (10/199) | 3.0% (17/562) | 5.7% (91/1610) | 7.8% (57/735) | 13.1% (25/191) | 5.9% (32/544) |
| Ischemia-Driven TVR, Non TL | 1.5% (24/1652) | 3.9% (30/761) | 6.5% (13/199) | 3.0% (17/562) | 4.8% (77/1610) | 7.5% (55/735) | 11.0% (21/191) | 6.3% (34/544) |
| Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV | Non-Diabetics (N = 2312) | All Diabetics (N = 1035) | Insulin-Dependent Diabetics (N = 272) | Non-Insulin-Dependent Diabetics (N = 763) | Non-Diabetics (N = 2312) | All Diabetics (N = 1035) | Insulin-Dependent Diabetics (N = 272) | Non-Insulin-Dependent Diabetics (N = 763) |
| TLF | 3.2% (74/2284) | 6.8% (69/1008) | 8.8% (23/262) | 6.2% (46/746) | 8.0% (177/2211) | 12.2% (118/970) | 16.3% (41/252) | 10.7% (77/718) |
| Ischemia-Driven TLR | 2.0% (45/2284) | 4.3% (43/1008) | 6.1% (16/262) | 3.6% (27/746) | 5.7% (125/2211) | 7.2% (70/970) | 11.9% (30/252) | 5.6% (40/718) |
| Ischemia-Driven TVR, Non TL | 1.9% (43/2284) | 3.8% (38/1008) | 5.3% (14/262) | 3.2% (24/746) | 5.2% (114/2211) | 6.9% (67/970) | 8.7% (22/252) | 6.3% (45/718) |
| All Death | 0.8% (19/2284) | 1.7% (17/1008) | 2.3% (6/262) | 1.5% (11/746) | 2.5% (56/2211) | 5.5% (53/970) | 6.0% (15/252) | 5.3% (38/718) |
| Cardiac Death | 0.2% (5/2284) | 1.0% (10/1008) | 1.1% (3/262) | 0.9% (7/746) | 0.8% (18/2211) | 2.8% (27/970) | 3.2% (8/252) | 2.6% (19/718) |
| Non-Cardiac Death | 0.6% (14/2284) | 0.7% (7/1008) | 1.1% (3/262) | 0.5% (4/746) | 1.7% (38/2211) | 2.7% (26/970) | 2.8% (7/252) | 2.6% (19/718) |
| Target Vessel MI | 1.3% (30/2284) | 3.0% (30/1008) | 4.6% (12/262) | 2.4% (18/746) | 2.1% (47/2211) | 4.5% (44/970) | 6.0% (15/252) | 4.0% (29/718) |
| Cardiac Death or Target Vessel MI | 1.5% (35/2284) | 3.8% (38/1008) | 5.0% (13/262) | 3.4% (25/746) | 2.9% (65/2211) | 6.9% (67/970) | 7.9% (20/252) | 6.5% (47/718) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.1% (3/2265) | 0.7% (7/993) | 0.8% (2/256) | 0.7% (5/734) | 0.5% (11/2150) | 1.9% (17/918) | 2.5% (6/238) | 1.6% (11/680) |
| ARC Definite+Probable | 0.1% (3/2265) | 1.0% (10/993) | 1.2% (3/257) | 1.0% (7/736) | 0.4% (8/2148) | 1.7% (16/918) | 2.1% (5/237) | 1.6% (11/681) |
| ARC Definite | 0.1% (3/2265) | 0.8% (8/993) | 0.8% (2/257) | 0.8% (6/736) | 0.3% (7/2148) | 1.2% (11/918) | 1.3% (3/237) | 1.2% (8/681) |

Notes:

- One subject in SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- year and 3-year time frames include follow-up window (365 + 28 days and 1095 ± 28 days, respectively)

9.9.2 Bayesian Analysis of Diabetic Patients treated with XIENCE Stents

A Statistical Analysis Plan (SAP) was developed with a pre-specified hypothesis to evaluate the safety and effectiveness of the XIENCE Family of Everolimus-Eluting Coronary Stent Systems (XIENCE stent, including XIENCE V, XIENCE PRIME, XIENCE Xpedition and XIENCE Alpine stents) to treat *de novo* native coronary artery lesions in diabetic patients with coronary artery disease. This section provides an overview of the SAP and the results supporting the use of the XIENCE stent in patients with diabetes mellitus (DM).

Primary Objective: To evaluate the safety and effectiveness of the XIENCE stent for the treatment of *de novo* lesions in native coronary arteries in diabetic patients.

Population: The analysis population consists of diabetic patients from the following trial/registry databases:

- SPIRIT IV
- SPIRIT PRIME (including Core Size Registry and Long Lesion Registry)
- XIENCE V USA First Enrollment Phase
- XIENCE V USA Second Enrollment Phase
- External databases: Cleveland Clinic and Wake Forest Baptist Medical Center databases

A total of 1239 patients were included in the DM analysis. The contributions of patients from each trial/registry database were: SPIRIT IV (N=451); SPIRIT PRIME (N=121); XIENCE V USA First Enrollment Phase (N=185); XIENCE V USA Second Enrollment Phase (N=192); and the pooled external databases from Cleveland Clinic and Wake Forest (N=290).

Design: A Bayesian hierarchical modeling approach was utilized to analyze the primary endpoint of Target Vessel Failure (TVF) at 12 months, defined as a composite of cardiac death, target-vessel myocardial infarction (TVMI), and ischemia driven target vessel revascularization (ID-TVR), which was tested against a pre-specified performance goal of 14.8% (expected rate 8.6% plus a delta of 6.2%).

Results from the six data sources were used in the analysis. Data from the four historical Abbott Vascular (AV) sponsored trial databases (SPIRIT IV, SPIRIT PRIME, XIENCE V USA first enrollment phase, and XIENCE V USA second enrollment phase) were considered as prior information. The two external XIENCE databases (Cleveland Clinic and Wake Forest) were pooled as current data and served as the basis for statistical inference.

Patients were included in the analysis if they have diabetes mellitus (based on medical history) and had at least one XIENCE stent implanted for the treatment of up to two *de novo* lesions (each located in a different epicardial vessel) < 32 mm in length in native coronary arteries with an RVD between 2.25 and 4.25 mm. The other clinical and lesion criteria of the diabetic analysis population are consistent with the enrollment criteria of the SPIRIT III US Pivotal Clinical Trial.

Demographics and Lesion Characteristics: The mean age of the diabetic population was 63 years from the pooled historical AV trials (SPIRIT IV, SPIRIT

PRIME, XIENCE V USA first enrollment phase and second enrollment phase) and 65 years from the pooled two external databases (Wake Forest and Cleveland Clinic). There were 62.8% males from the pooled AV trials and 64.1% from the pooled external databases. Insulin treated diabetic patients comprised of 25.9% and 35.5% of the overall diabetic analysis population from the pooled AV trials and pooled external databases, respectively. A total of 26.6% of patients presented with unstable angina from the pooled AV trials and 57.6% from the pooled external databases. There were 23.8% and 35.9% patients who had prior MI, 34.2% and 44.8% who had prior PCI, and 10.5% and 24.5% who had prior CABG from the pooled AV trials and pooled external databases, respectively. The mean lesion length was 13.5 mm for the pooled AV trials, and 16.3 mm for the pooled external databases. There were 12.0% type C lesions in the pooled AV trials and 25.5% in the pooled external databases. There were 2.6% (32/1239) patients treated with 33 or 38 mm stents in this pooled dataset (2.5% from the pooled AV trials, and 2.8% from the pooled external databases). Compared to the pooled AV trials, patient and lesion characteristics in the two external databases were generally more complex, likely due to their non-trial real-world settings.

Primary Endpoint Results: The primary endpoint of TVF rate at 1-year was evaluated in diabetic patients from the six trial/registry databases using a Bayesian statistical model. The posterior mean of 1-year TVF rate was 8.04%. The posterior probability of a 1-year TVF rate < 14.8% (performance goal) is > 0.999 (Table 9.9.2-1), which exceeds the pre-specified success criteria (> 0.975). Therefore, the XIENCE stent met the pre-specified success criteria for the primary endpoint of 1-year TVF.

Table 9.9.2-1: The XIENCE Diabetic Bayesian Analysis Primary Endpoint

| Primary Endpoint | TVF Rate [95% Central Posterior Interval] * | Bayesian Posterior Probability (TVF < 14.8%) |
|------------------|---|--|
| 1-year TVF | 8.04% [5.23%, 11.52%] | > 0.999 |

* The posterior mean is the Bayesian posterior average; the 95% central posterior interval is the symmetric 95% Bayesian credible interval, similar to the 95% confidence interval.

Notes:

- The 1-year window is through 393 days (365 + 28 days).
- TVF is defined as hierarchical composite of cardiac death, target vessel MI, and ischemia-driven TVR. For the primary composite endpoint of TVF, an adjustment factor of 0.826 was applied to one of the external databases to calculate the TVF rate based on the composite rate of all death/all MI/all TVR as the specifics of these events were not available from that database.

1-Year Clinical Outcomes: The 1-year clinical outcomes of the XIENCE diabetic population from each of the AV trials (SPIRIT IV, SPIRIT PRIME and XIENCE V USA) and the pooled two external databases are presented in Table 9.9.2-2.

Table 9.9.2-2: One- Year Clinical Outcomes of the XIENCE Diabetic Population

| | SPIRIT IV (N=451) | SPIRIT PRIME (N=121) | XV USA 5K (N=185) | XV USA 3K (N=192) | Pooled External (N=290) |
|--------------------------|------------------------------|---------------------------------|------------------------------|------------------------------|------------------------------------|
| TVF | 7.9% (34/433) | 11.8% (14/119) | 7.3% (13/178) | 3.6% (6/169) | 8.0% (21/261) |
| TLF | 5.5% (24/433) | 5.9% (7/119) | 6.7% (12/178) | 2.4% (4/169) | 2.4% (3/126) |
| Cardiac death or TVMI | 3.0% (13/433) | 2.5% (3/119) | 3.4% (6/178) | 0.6% (1/169) | 0.8% (1/126) |
| ID-TVR | 5.5% (24/433) | 9.2% (11/119) | 5.1% (9/178) | 3.0% (5/169) | 6.3% (8/126) |
| ID-TLR | 3.2% (14/433) | 3.4% (4/119) | 3.9% (7/178) | 1.8% (3/169) | 2.4% (3/126) |
| Death | 1.4% (6/433) | 0.0% (0/119) | 2.2% (4/178) | 1.2% (2/169) | 3.1% (8/261) |
| Cardiac death | 0.9% (4/433) | 0.0% (0/119) | 1.1% (2/178) | 0.6% (1/169) | 0.0% (0/126) |
| TVMI | 2.3% (10/433) | 2.5% (3/119) | 2.2% (4/178) | 0.0% (0/169) | 0.8% (1/126) |
| ST (ARC def/prob) | 0.9% (4/431) | 0.0% (0/119) | 0.0% (0/175) | 0.6% (1/169) | 0.8% (2/261) |

Notes:

- Numbers presented in this table are % (n/N).
- The 1-year window is through 393 days (365 + 28 days).
- XV USA 5K refers to the first enrollment phase of 5,000 patients in the XIENCE V USA study; XV USA 3K refers to the second enrollment phase of 3,000 patients in the XIENCE V USA study; pooled external refers to the pooled analysis of the two external databases (Cleveland Clinic and Wake Forest).
- TVF is defined as hierarchical composite of cardiac death, target vessel MI, and ischemia-driven TVR; TLF is defined as hierarchical composite of cardiac death, target vessel MI, and ischemia-driven TLR. ID-TLR= ischemia driven target lesion revascularization; ID-TVR=ischemia driven target vessel revascularization; TVMI=target vessel myocardial infarction; ST (ARC def/prob) = definite or probable stent thrombosis defined per the ARC definition.
- MI from the historical AV trials was defined per protocol and was categorized as Q-wave (development of new, pathological Q waves on the ECG) or non-Q-wave (elevation of CK levels to greater than two times the upper limit of normal and elevated CK-MB in the absence of new pathological Q waves). For the two external databases, MI was defined based on Universal MI definition per the National Cardiovascular Data Registry (NCDR) requirement.
- For the primary composite endpoint of TVF, an adjustment factor of 0.826 was applied to one of the two external databases in order to calculate the TVF rate based on the composite rate of all death/all MI/all TVR, as the specifics of these events were not available from that database.
- For other endpoints (TLF, cardiac death or TVMI, ID-TLR, ID-TVR, cardiac death and TVMI), only one of the external databases was included in the analysis, as the specific event information was not available in the other external database.

10.0 INDIVIDUALIZATION OF TREATMENT

The risks and benefits should be considered for each patient before using the XIENCE PRIME stent. Patient selection factors to be assessed should include a judgment regarding risk of long-term antiplatelet therapy. Stenting is generally avoided in those patients at heightened risk of bleeding (e.g., patients with recently active gastritis or peptic ulcer disease) in which anticoagulation therapy would be contraindicated.

Antiplatelet drugs should be used in combination with the XIENCE PRIME stent. Physicians should use information from the SPIRIT clinical trials, coupled with current drug eluting stent (DES) literature and the specific needs of individual patients to determine the specific antiplatelet/anticoagulation regimen to be used for their patients in general practice. See also section 5.2 – *Precautions, Pre- and Post-Procedure Antiplatelet Regimen*, section 5.6 – *Precautions, Use in Special Populations*, and section 5.7 – *Precautions, Lesion / Vessel Characteristics*.

Premorbid conditions that increase the risk of poor initial results or the risks of emergency referral for bypass surgery (diabetes mellitus, renal failure, and severe obesity) should be reviewed.

11.0 PATIENT COUNSELING AND PATIENT INFORMATION

Physicians should consider the following in counseling patients about this product:

- Discuss the risks associated with stent placement
- Discuss the risks associated with an everolimus eluting stent
- Discuss the risks of early discontinuation of the antiplatelet therapy
- Discuss the risks of late stent thrombosis with DES use in higher risk patient subgroups
- Discuss the risk/benefit issues for this particular patient
- Discuss alternation to current life style immediately following the procedure and over the long term

The following patient materials are provided for this product:

- A Patient Information Guide, including information on coronary artery disease, the implant procedure and the XIENCE PRIME stent system (provided to physician, on-line at http://www.abbottvascular.com/docs/coronary_intervention/xience/ePG_XIENCE.pdf, or by calling customer service 1-800-227-9902)
- A Stent Implant Card, including both patient information and stent implant information (provided in package).

12.0 HOW SUPPLIED

Sterile – This device is sterilized with ethylene oxide gas, and is non-pyrogenic. It is intended for single use only. Do not resterilize. Do not use if the package is opened or damaged.

Contents – One (1) XIENCE PRIME stent system; one (1) flushing tool; one (1) stent implant card

Storage – Store in a dry, dark, cool place. Protect from light. Do not remove from carton until ready for use. Store at 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F).

13.0 OPERATOR'S INSTRUCTIONS

13.1 Inspection Prior to Use

- Carefully inspect the sterile package before opening and check for damage to the sterile barrier. Do not use if the integrity of the sterile package has been compromised.
- Do not use after the "Use by" date.
- Tear open the foil pouch and remove the inner pouch.
Note: The outside of the inner pouch is NOT sterile. Open the inner pouch and pass or drop the product into the sterile field using an aseptic technique.
- Prior to using the XIENCE PRIME stent system, carefully remove the system from the package and inspect for bends, kinks, and other damage. Verify that the stent does not extend beyond the radiopaque balloon markers. Do not use if any defects are noted. However, **do not manipulate, touch, or handle the stent** with your fingers, which may cause coating damage, contamination, or stent dislodgement from the delivery balloon.

Note: At any time during use of the XIENCE PRIME stent system, if the stainless steel proximal shaft has been bent or kinked, do not continue to use the catheter.

13.2 Materials Required

- Appropriate guiding catheter(s). See Table 1-1: XIENCE PRIME Stent System Product Description
- 2 – 3 syringes (10 – 20 ml)
- 1,000 u/500 ml heparinized normal saline (HepNS)
- 0.014" (0.36 mm) x 175 cm (minimum length) guide wire
- Rotating hemostatic valve with appropriate minimum inner diameter (0.096" [2.44 mm])
- Contrast diluted 1:1 with heparinized normal saline
- Inflation device
- Pre-deployment dilatation catheter
- Three-way stopcock
- Torque device
- Guide wire introducer
- Appropriate arterial sheath
- Appropriate anticoagulation and antiplatelet drugs

13.3 Preparation

13.3.1 Packaging Removal

Note: The foil pouch is not a sterile barrier. The inner header bag (pouch) within the foil pouch is the sterile barrier. Only the contents of the inner pouch should be considered sterile. The outside surface of the inner pouch is NOT sterile.

1. Carefully remove the delivery system from its protective tubing for preparation of the delivery system. When using a Rapid Exchange (RX) system, do not bend or kink the hypotube during removal.
2. Remove the product mandrel and protective stent sheath by grasping the catheter just proximal to the stent (at the proximal balloon bond site), and with the other hand, grasp the stent protector and gently remove distally. If unusual resistance is felt during product mandrel and stent sheath removal, do not use this product and replace with another. Follow product returns procedure for the unused device.

13.3.2 Guide Wire Lumen Flush

1. Rapid Exchange (RX) only: Flush the guide wire lumen with HepNS using the flushing tool supplied with the product. Insert the flushing tool into the tip of the catheter and flush until fluid exits the guide wire exit notch.

Note: Avoid manipulation of the stent while flushing the guide wire lumen, as this may disrupt the placement of the stent on the balloon.

13.3.3 Delivery System Preparation

1. Prepare an inflation device / syringe with diluted contrast medium.
2. Attach an inflation device / syringe to the stopcock; attach it to the inflation port of the product. Do not bend the product hypotube, when connecting to the inflation device / syringe.
3. With the tip down, orient the delivery system vertically.
4. Open the stopcock to delivery system; pull negative for 30 seconds; release to neutral for contrast fill.
5. Close the stopcock to the delivery system; purge the inflation device / syringe of all air.
6. Repeat steps 3 through 5 until all air is expelled. If bubbles persist, do not use the product.
7. If a syringe was used, attach a prepared inflation device to stopcock.
8. Open the stopcock to the delivery system.
9. Leave on neutral

Note: While introducing the delivery system into the vessel, do not induce negative pressure on the delivery system. This may cause dislodgement of the stent from the balloon.

Note: If air is seen in the shaft, repeat *section 13.3.3 – Operator’s Instructions, Delivery System Preparation*, steps 3 through 5, to prevent uneven stent expansion.

13.4 Delivery Procedure

1. Prepare the vascular access site according to standard practice.
2. The decision to pre-dilate the lesion with an appropriate sized balloon should be based on patient and lesion characteristics. **If pre-dilatation is performed**, limit the longitudinal length of pre-dilatation by the PTCA balloon to avoid creating a region of vessel injury that is outside the boundaries of the XIENCE PRIME stent.
3. For long lesions, size the stent to the diameter of the most distal portion of the vessel.

Note: If choosing between two stent diameters for tight lesions choose the smaller diameter stent and inflate. See section 14.0 – *In vitro Compliance Information*

4. Maintain neutral pressure on the inflation device attached to the delivery system. Open the rotating hemostatic valve as wide as possible.
5. Backload the delivery system onto the proximal portion of the guide wire, while maintaining guide wire position across the target lesion.
6. Carefully advance the delivery system into the guiding catheter and over the guide wire to the target lesion. When using a Rapid Exchange (RX) system, be sure to keep the hypotube straight. Ensure guiding catheter stability before advancing the stent system into the coronary artery.

Note: If unusual resistance is felt before the stent exits the guiding catheter, do not force passage. Resistance may indicate a problem and the use of excessive force may result in stent damage or dislodgement. Maintain guide wire placement across the lesion and remove the delivery system and guiding catheter as a single unit.

7. Advance the delivery system over the guide wire to the target lesion under direct fluoroscopic visualization. Utilize the radiopaque balloon markers to position the stent across the lesion. Perform angiography to confirm stent position. If the position of the stent is not optimal, it should be carefully repositioned or removed (see section 5.14 – *Precautions, Stent System Removal*). The balloon markers indicate both the stent edges and the balloon shoulders. Expansion of the stent should not be undertaken if the stent is not properly positioned in the target lesion.

Note: If removal of a stent system is required prior to deployment, ensure that the guiding catheter is coaxially positioned relative to the stent delivery system, and cautiously withdraw the stent delivery system into the guiding catheter. Should unusual resistance be felt at any time when withdrawing the stent towards the guiding catheter, the stent delivery system and the guiding catheter should be removed as a single unit. This should be done under direct visualization with fluoroscopy.

8. Tighten the rotating hemostatic valve. The stent is now ready to be deployed.

13.5 Deployment Procedure

CAUTION: Refer to Table 14-1: XIENCE PRIME Stent Compliance, for *in vitro* stent inner diameter, nominal pressure, and RBP.

1. Prior to deployment, reconfirm the correct position of the stent relative to the target lesion using the radiopaque balloon markers.
2. Deploy the stent slowly by pressurizing the delivery system in 2 atm increments, every 5 seconds, until stent is completely expanded. Fully expand the stent by inflating to nominal pressure at a minimum. Accepted practice generally targets an initial deployment pressure that would achieve a stent inner diameter ratio of about 1.1 times the reference vessel diameter (see Table 14-1: XIENCE PRIME Stent Compliance).
3. For long lesions, size the stent to the diameter of the most distal portion of the vessel and expand stent to nominal pressure at minimum. Maintain pressure for 30 seconds. If necessary, the delivery system can be repressurized or further pressurized to assure complete apposition of the stent to the artery wall.
4. Maintain pressure for 30 seconds for full expansion of the stent. Fluoroscopic visualization during stent expansion should be used in order to properly judge the optimum stent diameter as compared to the proximal and distal native coronary artery diameters (reference vessel diameters). Optimal stent expansion and proper apposition requires that the stent be in full contact with the arterial wall.

Note: See section 13.6 – *Removal Procedure* for instruction on withdrawal of stent delivery system.

5. If necessary, the delivery system can be repressurized or further pressurized to assure complete apposition of the stent to the artery wall.

Note: Do not exceed the labeled rated burst pressure (RBP) of 18 atm (1824 kPa).

6. Fully cover the entire lesion and balloon treated area (including dissections) with the XIENCE PRIME stent, allowing for adequate stent coverage into healthy tissue proximal and distal to the lesion.
7. Deflate the balloon by pulling negative on the inflation device for 30 seconds. Confirm complete balloon deflation before attempting to move the delivery system. If unusual resistance is felt during stent delivery system withdrawal, pay particular attention to guiding catheter position.

Note: See section 13.6 – *Removal Procedure* for instruction on withdrawal of stent delivery system.

8. Confirm stent position and deployment using standard angiographic techniques. For optimal results, the entire stenosed arterial segment should be covered by the stent. Fluoroscopic visualization during stent expansion should be used in order to properly judge the optimum expanded stent diameter as compared to the proximal and distal coronary artery diameter(s). Optimal expansion requires that the stent be in full contact with the artery wall. Stent wall contact should be verified through routine angiography or intravascular ultrasound (IVUS).
9. If the deployed stent size is still inadequate with respect to reference vessel diameter, a larger balloon may be used to further expand the stent. If the initial

angiographic appearance is suboptimal, the stent may be further expanded using a low profile, high pressure, non-compliant balloon dilatation catheter. If this is required, the stented segment should be carefully recrossed with a prolapsed guide wire to avoid disrupting the stent geometry. Deployed stents should not be left underdilated.

CAUTION: Do not dilate the stent beyond the following limits.

| <u>Nominal Stent Diameter</u> | <u>Dilatation Limit</u> |
|-------------------------------|-------------------------|
| 2.25 mm and 2.5 mm | 3.25 mm |
| 2.75 mm and 3.0 mm | 3.75 mm |
| 3.5 mm and 4.0 mm | 4.5 mm |

10. If more than one XIENCE PRIME stent is needed to cover the lesion and balloon treated area, it is suggested that, to avoid the potential for gap restenosis, the stents be adequately overlapped. To ensure that there are no gaps between stents, the balloon marker bands of the second XIENCE PRIME stent should be positioned inside the deployed stent prior to expansion.

11. Reconfirm stent position and angiographic results. Repeat inflations until optimal stent deployment is achieved.

13.6 Removal Procedure

Withdrawal of the stent delivery catheter from the deployed stent:

1. Deflate the balloon by pulling negative on the inflation device. Larger and longer balloons will take more time (up to 30 seconds) to deflate than smaller and shorter balloons. Confirm balloon deflation under fluoroscopy and wait 10-15 seconds longer.
2. Position inflation device on “negative” or “neutral” pressure.
3. Stabilize guiding catheter position just outside coronary ostium and anchor in place. Maintain guide wire placement across stent segment.
4. Gently remove the stent delivery system with slow and steady pressure.
5. Tighten the rotating hemostatic valve.

If during withdrawal of the stent delivery catheter resistance is encountered, use the following steps to improve balloon rewrap:

- Re-inflate the balloon up to nominal pressure.
- Repeat steps 1 through 5 above

Post stent delivery system withdrawal – Stent deployment confirmation

1. Confirm stent position and deployment using standard angiographic techniques. For optimal results, the entire stenosed arterial segment should be covered by the stent. Fluoroscopic visualization during stent expansion should be used in order to properly judge the optimum expanded stent diameter as compared to the proximal and distal coronary artery diameter(s). **Optimal expansion requires**

that the stent be in full contact with the artery wall. Stent wall contact should be verified through routine angiography or intravascular ultrasound (IVUS).

2. If more than one XIENCE PRIME stent is needed to cover the lesion and balloon treated area, it is suggested that, to avoid the potential for gap restenosis, the stents be adequately overlapped.
3. To ensure that there are no gaps between stents, the balloon marker bands of the second XIENCE PRIME stent should be positioned inside the deployed stent prior to expansion.
4. Reconfirm stent position and angiographic results to assess stented area. Repeat inflations until optimal stent deployment is achieved. If post-dilatation is necessary, ensure that the final stent diameter matches the reference vessel diameter. **Assure that the stent wall is in contact with the artery wall.**

13.7 Post-Deployment Dilatation of Stent Segments

1. All efforts should be taken to assure that the stent is not underdilated.
2. If the deployed stent size is still inadequate with respect to the vessel diameter, or if full contact with the vessel wall is not achieved, a larger balloon may be used to expand the stent further. The stent may be further expanded using a low profile, high pressure, and noncompliant balloon catheter. If this is required, the stented segment should be recrossed carefully with a prolapsed guide wire to avoid dislodging the stent. The balloon should be centered within the stent and should not extend outside of the stented region).

CAUTION: Do not dilate the stent beyond the following limits.

| <u>Nominal Stent Diameter</u> | <u>Dilatation Limit</u> |
|-------------------------------|-------------------------|
| 2.25 mm and 2.5 mm | 3.25 mm |
| 2.75 mm and 3.0 mm | 3.75 mm |
| 3.5 mm and 4.0 mm | 4.5 mm |

14.0 IN VITRO COMPLIANCE INFORMATION

**Table 14-1: XIENCE PRIME Stent Compliance
Nominal Pressure for Each Diameter Indicated by Bold Font**

| Pressure | | Stent ID (mm) by System Diameter | | | | | |
|-----------|------|----------------------------------|-------------|-------------|-------------|-------------|-------------|
| atm | kPa | 2.25 mm | 2.5 mm | 2.75 mm | 3.0 mm | 3.5 mm | 4.0 mm |
| 8 | 811 | 2.26 | 2.46 | 2.71 | 2.90 | 3.33 | 3.81 |
| 9 | 912 | 2.33 | 2.53 | 2.77 | 2.97 | 3.41 | 3.90 |
| 10 | 1013 | 2.38 | 2.59 | 2.84 | 3.04 | 3.49 | 3.99 |
| 11 | 1115 | 2.44 | 2.65 | 2.89 | 3.10 | 3.56 | 4.07 |
| 12 | 1216 | 2.48 | 2.70 | 2.94 | 3.15 | 3.63 | 4.14 |
| 13 | 1317 | 2.53 | 2.75 | 2.99 | 3.19 | 3.69 | 4.21 |
| 14 | 1419 | 2.56 | 2.79 | 3.03 | 3.24 | 3.74 | 4.26 |
| 15 | 1520 | 2.60 | 2.83 | 3.06 | 3.27 | 3.78 | 4.32 |
| 16 | 1621 | 2.63 | 2.86 | 3.10 | 3.31 | 3.83 | 4.37 |
| 17 | 1723 | 2.67 | 2.90 | 3.13 | 3.34 | 3.87 | 4.42 |
| 18 (RBP)* | 1824 | 2.70 | 2.93 | 3.16 | 3.37 | 3.90 | 4.47 |
| 19 | 1925 | 2.74 | 2.97 | 3.20 | 3.41 | 3.94 | 4.52 |
| 20 | 2027 | 2.77 | 3.00 | 3.23 | 3.44 | 3.98 | 4.57 |
| 21 | 2128 | 2.81 | 3.04 | 3.26 | 3.47 | 4.02 | 4.62 |
| 22 | 2229 | 2.85 | 3.08 | 3.30 | 3.50 | 4.05 | 4.67 |

Note: These nominal data are based on *in vitro* testing at 37°C and do not take into account lesion resistance. Ensure full deployment of the stent (see section 13.5 – *Operator's Instructions, Deployment Procedure*) and confirm the stent sizing angiographically.

*Do not exceed the rated burst pressure (RBP).

15.0 REUSE PRECAUTION STATEMENT

Do not use if sterile barrier is damaged. If damage is found call your Abbott Vascular representative.

For single patient use only. Do not reuse, reprocess, or resterilize.

16.0 PATENTS AND TRADEMARKS

This product and / or its use may be covered by one or more of the following United States Patents: 6,179,810; 6,384,046; 6,629,994; 6,656,220; 6,746,423; 6,887,219; 6,887,510; 6,890,318; 6,929,657; 6,939,373; 6,957,152; 7,549,975; 7,662,130; 7,828,766; 7,833,193; 7,906,066; 7,947,207; 8,043,553; 8,052,638; 8,075,583; 8,173,062; 8,221,112; 8,221,444; 8,308,711; 8,382,738; 8,388,575; 8,388,602; 8,394,055; 8,444,608; 8,444,802; 8,535,596; 8,540,927; 8,613,722. Other U.S. patents pending. Other patents issued and pending outside of the U.S.

XIENCE PRIME, XIENCE V and XIENCE nano are registered trademarks of the Abbott Group of Companies.

TAXUS, TAXUS Express, and TAXUS Liberté are registered trademarks of Boston Scientific Corporation or its affiliates.

Zortress, Certican, and Afinitor are registered trademarks of Novartis Pharmaceuticals, Inc.













Abbott Vascular

3200 Lakeside Drive
Santa Clara, CA 95054 USA

CUSTOMER SERVICE

TEL: (800) 227-9902
FAX: (800) 601-8874
Outside USA TEL: (951) 914-4669
Outside USA FAX: (951) 914-2531

Graphical Symbols for Medical Device Labeling

| | | |
|---|---|--|
|  Manufacturer | REF Catalogue number | F French size |
|  Do not reuse | STERILE EO Sterilized using ethylene oxide |  Consult instructions for use |
|  Use by | LOT Batch code |  Date of manufacture |
|  Guiding catheter |  Non-pyrogenic |  Contents (numeral represents quantity of units inside) |
|  Inner diameter |  MR Conditional | |

©2011, 2012, 2014 Abbott

**XIENCE Xpedition[®], XIENCE Xpedition SV, and XIENCE Xpedition LL
Everolimus Eluting Coronary Stent Systems
Instructions for Use**



Table of Contents

- 1.0 PRODUCT DESCRIPTION
 - 1.1 Device Component Description
 - 1.2 Drug Component Description
 - 1.2.1 Everolimus
 - 1.2.2 Inactive Ingredients – Non-erodible Polymer
 - 1.2.3 Product Matrix and Everolimus Content
- 2.0 INDICATIONS
- 3.0 CONTRAINDICATIONS
- 4.0 WARNINGS
- 5.0 PRECAUTIONS
 - 5.1 General Precautions
 - 5.2 Pre- and Post-Procedure Antiplatelet Regimen
 - 5.3 Multiple Stent Use
 - 5.4 Brachytherapy
 - 5.5 Use in Conjunction with Other Procedures
 - 5.6 Use in Special Populations
 - 5.6.1 Pregnancy
 - 5.6.2 Lactation
 - 5.6.3 Gender
 - 5.6.4 Ethnicity
 - 5.6.5 Pediatric Use
 - 5.6.6 Geriatric Use
 - 5.7 Lesion / Vessel Characteristics
 - 5.8 Drug Interactions
 - 5.9 Immune Suppression Potential
 - 5.10 Lipid Elevation Potential
 - 5.11 Magnetic Resonance Imaging (MRI)
 - 5.12 Stent Handling
 - 5.13 Stent Placement
 - 5.13.1 Stent Preparation
 - 5.13.2 Stent Implantation
 - 5.14 Stent System Removal
 - 5.15 Post-Procedure

-
- 6.0 DRUG INFORMATION
 - 6.1 Mechanism of Action
 - 6.2 Pharmacokinetics
 - 6.3 Interactions with Drugs or Other Substances
 - 6.4 Carcinogenicity, Genotoxicity, and Reproductive Toxicity
 - 6.5 Pregnancy
 - 6.6 Lactation
 - 7.0 OVERVIEW OF CLINICAL EXPERIENCE
 - 8.0 ADVERSE EVENTS
 - 8.1 Observed Adverse Events
 - 8.2 Stent Thrombosis Definitions
 - 8.3 Potential Adverse Events
 - 9.0 SPIRIT FAMILY OF CLINICAL TRIALS
 - 9.1 SPIRIT PRIME Clinical Trial
 - 9.2 SPIRIT III Pivotal Clinical Trial
 - 9.2.1 SPIRIT III Randomized Clinical Trial (RCT)
 - 9.2.2 Dual Vessel Treatment in SPIRIT III
 - 9.2.3 SPIRIT III US 4.0 mm Arm
 - 9.3 SPIRIT IV Clinical Trial
 - 9.3.1 SPIRIT IV Randomized Clinical Trial
 - 9.3.2 Multiple Vessel Treatment in SPIRIT IV
 - 9.4 SPIRIT Small Vessel Registry
 - 9.5 Pooled Analysis of the SPIRIT II-III-IV Clinical Trials
 - 9.6 Gender-Based Analysis of the SPIRIT Family of Clinical Trials
 - 9.6.1 Background
 - 9.6.2 Gender-Based Analysis of the SPIRIT PRIME Clinical Trial
 - 9.6.3 Gender-Based Analysis in the SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Clinical Trials
 - 9.7 XIENCE V USA Post-Approval Study
 - 9.7.1 Analysis of Patients with 4.0 mm Stent
 - 9.7.2 Analysis of Patients Treated with Direct Stenting
 - 9.7.3 Pre-specified XIENCE V USA Subgroup Analysis
 - 9.8 EXPERT CTO Clinical Trial
 - 9.8.1 Gender-Based Analysis of the EXPERT CTO Clinical Trial
 - 9.9 Analysis of Diabetic Patients
 - 9.9.1 Analysis of Diabetic Subjects in SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Trials
 - 9.9.2 Bayesian Analysis of Diabetic Patients Treated with XIENCE Stents
 - 10.0 INDIVIDUALIZATION OF TREATMENT
 - 11.0 PATIENT COUNSELING AND PATIENT INFORMATION
 - 12.0 HOW SUPPLIED

-
- 13.0 OPERATOR'S INSTRUCTIONS
 - 13.1 Inspection Prior to Use
 - 13.2 Materials Required
 - 13.3 Preparation
 - 13.3.1 Packaging Removal
 - 13.3.2 Guide Wire Lumen Flush
 - 13.3.3 Delivery System Preparation
 - 13.4 Delivery Procedure
 - 13.5 Deployment Procedure
 - 13.6 Removal Procedure
 - 13.7 Post-Deployment Dilatation of Stent Segments
 - 14.0 *IN VITRO* COMPLIANCE INFORMATION
 - 15.0 REUSE PRECAUTION STATEMENT
 - 16.0 PATENTS AND TRADEMARKS

THE COMPONENTS OF THE XIENCE XPEDITION STENT SYSTEM ARE STERILE.

1.0 PRODUCT DESCRIPTION

The XIENCE Xpedition Everolimus Eluting Coronary Stent System is comprised of two main components: the drug-coated stent and the balloon expandable delivery system. The XIENCE Xpedition Stent System uses the identical stent and stent contacting balloon materials, and the identical drug coating formulation and drug dose density (100 ug/cm²) as the XIENCE PRIME[®] Everolimus Eluting Coronary Stent System. The XIENCE Xpedition Stent System is available in two delivery system configurations: Rapid Exchange (RX) and Over-the-Wire (OTW).

The XIENCE Xpedition family of stent systems includes:

| Product | Stent Diameter (mm) | Stent Length (mm) | Reference Vessel Diameter (RVD mm) | Lesion Length (mm) |
|---------------------|--------------------------------|-----------------------|------------------------------------|--------------------|
| XIENCE Xpedition SV | 2.25 | 8, 12, 15, 18, 23, 28 | ≥ 2.25 and ≤ 2.5 | ≤ 22 |
| XIENCE Xpedition | 2.5, 2.75, 3.0, 3.25, 3.5, 4.0 | 8, 12, 15, 18, 23, 28 | ≥ 2.5 and ≤ 4.25 | ≤ 22 |
| XIENCE Xpedition LL | 2.5, 2.75, 3.0, 3.25, 3.5, 4.0 | 33 and 38 | ≥ 2.5 and ≤ 4.25 | > 22 and ≤ 32 |

Hereafter the XIENCE Xpedition family of stent systems is referred to as the XIENCE Xpedition stent or XIENCE Xpedition stent system. The XIENCE Xpedition stent systems are device/drug combination products consisting of a drug-coated stent and a balloon expandable delivery system. The stent is coated with a formulation containing everolimus, the active ingredient, embedded in a non-erodible polymer, which is identical to the FDA approved XIENCE V[®] and XIENCE PRIME Everolimus Eluting Coronary Stent System.

1.1 Device Component Description

The device component consists of a medical grade L-605 cobalt chromium (CoCr) drug-coated stent mounted onto the XIENCE Xpedition stent delivery system. The device component characteristics are summarized in Table 1-1.

Table 1-1: XIENCE Xpedition Stent System Product Description

| | XIENCE Xpedition Stent System | | |
|---|--|---|--------------------------------|
| | XIENCE Xpedition SV | XIENCE Xpedition | XIENCE Xpedition LL |
| Available Stent Lengths (mm) | 8, 12, 15, 18, 23, 28 | 8, 12, 15, 18, 23, 28 | 33, 38 |
| Available Stent Diameters (mm) | 2.25 | 2.5, 2.75, 3.0, 3.25, 3.5, 4.0 | 2.5, 2.75, 3.0, 3.25, 3.5, 4.0 |
| Stent Material | A medical grade L-605 cobalt chromium CoCr alloy identical to the material used in the XIENCE V and XIENCE PRIME stent | | |
| Drug Component | A conformal coating of a non-erodible polymer loaded with 100 µg/cm ² of everolimus with a maximum nominal drug content of 232 µg on the large stent (4.0 x 38 mm) | | |
| Delivery System Working Length | 145 cm | | |
| Delivery System Design | RX: Single access port to inflation lumen; guide wire exit notch is located 25.5 cm from tip; designed for guide wires ≤ 0.014". OTW: Sidearm adaptor provides access to balloon inflation/deflation lumen and guide wire lumen; designed for guide wires ≤ 0.014". | | |
| Stent Delivery System Balloon | A compliant, tapered balloon, with two radiopaque markers located on the catheter shaft to indicate balloon positioning and expanded stent length | | |
| Balloon Inflation Pressure | Rated Burst Pressure (RBP): 18 atm (1824 kPa) | | |
| | Stent Diameter (mm) | <i>In vitro</i> Stent Nominal Pressure (atm) | |
| | 2.25 | 10 | |
| | 2.5 | 10 | |
| | 2.75 | 10 | |
| | 3.0 | 10 | |
| | 3.25 | 10 | |
| | 3.5 | 10 | |
| | 4.0 | 10 | |
| Minimum Guiding Catheter Inner Diameter | 2.25 - 3.5 mm Stent Diameters 5 F (0.056" / 1.42 mm ID) | 4.0 Stent Diameter, 8 – 33 mm lengths 5 F (0.056" / 1.42 mm ID) 4.0 Stent Diameter, 38 mm length 6 F (0.066" / 1.68 mm ID) | |
| Catheter Shaft Outer Diameter | Distal: 0.034" (0.86 mm) Proximal (RX): 0.028" (0.71 mm) Proximal (OTW): 0.045" (1.14 mm) | | |


1.2 Drug Component Description

The XIENCE Xpedition Everolimus Eluting Coronary Stent (XIENCE Xpedition stent) is coated with everolimus (active ingredient), embedded in a non-erodible polymer (inactive ingredient).

1.2.1 Everolimus

Everolimus is the active pharmaceutical ingredient in the XIENCE Xpedition stent. It is a novel semi-synthetic macrolide immunosuppressant, synthesized by chemical modification of rapamycin (sirolimus). The everolimus chemical name is 40-O-(2-hydroxyethyl)-rapamycin and the chemical structure is shown in Figure 1.2.1-1 below.

Figure 1.2.1-1: Everolimus Chemical Structure



1.2.3 Product Matrix and Everolimus Content

Table 1.2.3-1: XIENCE Xpedition Stent System Product Matrix and Everolimus Content

| Model Number (RX) | Model Number (OTW) | Nominal Expanded Stent Diameter (mm) | Nominal Unexpanded Stent Length (mm) | Nominal Everolimus Content (µg) |
|-------------------|--------------------|--------------------------------------|--------------------------------------|---------------------------------|
| 1074225-08 | 1165225-08 | 2.25 | 8 | 40 |
| 1074250-08 | 1165250-08 | 2.5 | | 40 |
| 1074275-08 | 1165275-08 | 2.75 | | 40 |
| 1074300-08 | 1165300-08 | 3.0 | | 40 |
| 1074325-08 | 1165325-08 | 3.25 | | 40 |
| 1074350-08 | 1165350-08 | 3.5 | | 50 |
| 1074400-08 | 1165400-08 | 4.0 | | 50 |
| 1074225-12 | 1165225-12 | 2.25 | 12 | 60 |
| 1074250-12 | 1165250-12 | 2.5 | | 60 |
| 1074275-12 | 1165275-12 | 2.75 | | 60 |
| 1074300-12 | 1165300-12 | 3.0 | | 60 |
| 1074325-12 | 1165325-12 | 3.25 | | 60 |
| 1074350-12 | 1165350-12 | 3.5 | | 75 |
| 1074400-12 | 1165400-12 | 4.0 | | 75 |
| 1074225-15 | 1165225-15 | 2.25 | 15 | 74 |
| 1074250-15 | 1165250-15 | 2.5 | | 74 |
| 1074275-15 | 1165275-15 | 2.75 | | 74 |
| 1074300-15 | 1165300-15 | 3.0 | | 74 |
| 1074325-15 | 1165325-15 | 3.25 | | 74 |
| 1074350-15 | 1165350-15 | 3.5 | | 91 |
| 1074400-15 | 1165400-15 | 4.0 | | 91 |
| 1074225-18 | 1165225-18 | 2.25 | 18 | 88 |
| 1074250-18 | 1165250-18 | 2.5 | | 88 |
| 1074275-18 | 1165275-18 | 2.75 | | 88 |
| 1074300-18 | 1165300-18 | 3.0 | | 88 |
| 1074325-18 | 1165325-18 | 3.25 | | 88 |
| 1074350-18 | 1165350-18 | 3.5 | | 116 |
| 1074400-18 | 1165400-18 | 4.0 | | 116 |
| 1074225-23 | 1165225-23 | 2.25 | 23 | 109 |
| 1074250-23 | 1165250-23 | 2.5 | | 109 |
| 1074275-23 | 1165275-23 | 2.75 | | 109 |
| 1074300-23 | 1165300-23 | 3.0 | | 109 |
| 1074325-23 | 1165325-23 | 3.25 | | 109 |
| 1074350-23 | 1165350-23 | 3.5 | | 141 |
| 1074400-23 | 1165400-23 | 4.0 | | 141 |
| 1074225-28 | 1165225-28 | 2.25 | 28 | 137 |
| 1074250-28 | 1165250-28 | 2.5 | | 137 |
| 1074275-28 | 1165275-28 | 2.75 | | 137 |
| 1074300-28 | 1165300-28 | 3.0 | | 137 |
| 1074325-28 | 1165325-28 | 3.25 | | 137 |
| 1074350-28 | 1165350-28 | 3.5 | | 174 |
| 1074400-28 | 1165400-28 | 4.0 | | 174 |
| 1074250-33 | 1165250-33 | 2.5 | 33 | 157 |
| 1074275-33 | 1165275-33 | 2.75 | | 157 |
| 1074300-33 | 1165300-33 | 3.0 | | 157 |
| 1074325-33 | 1165325-33 | 3.25 | | 157 |
| 1074350-33 | 1165350-33 | 3.5 | | 199 |
| 1074400-33 | 1165400-33 | 4.0 | | |
| 1074250-38 | 1165250-38 | 2.5 | 38 | 185 |
| 1074275-38 | 1165275-38 | 2.75 | | 185 |
| 1074300-38 | 1165300-38 | 3.0 | | 185 |
| 1074325-38 | 1165325-38 | 3.25 | | 185 |
| 1074350-38 | 1165350-38 | 3.5 | | 232 |
| 1074400-38 | 1165400-38 | 4.0 | | |

2.0 INDICATIONS

The XIENCE Xpedition stent system is indicated for improving coronary artery luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease due to *de novo* native coronary artery lesions (length \leq 32 mm) with reference vessel diameters of \geq 2.25 mm to \leq 4.25 mm. In addition, the XIENCE Xpedition stent system is indicated for treating *de novo* chronic total coronary occlusions.

3.0 CONTRAINDICATIONS

The XIENCE Xpedition stent system is contraindicated for use in patients:

- Who cannot receive antiplatelet and / or anticoagulant therapy (see section 5.2 – *Precautions, Pre- and Post-Procedure Antiplatelet Regimen* for more information)
- With lesions that prevent complete angioplasty balloon inflation or proper placement of the stent or stent delivery system
- With hypersensitivity or contraindication to everolimus or structurally-related compounds, cobalt, chromium, nickel, tungsten, acrylic, and fluoropolymers

4.0 WARNINGS

- Ensure that the inner package sterile barrier has not been opened or damaged prior to use.
- Judicious patient selection is necessary, because the use of this device carries the associated risk of stent thrombosis, vascular complications, and / or bleeding events.
- This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy (see section 5.2 for important information regarding antiplatelet therapy).

5.0 PRECAUTIONS

5.1 General Precautions

- Stent implantation should only be performed by physicians who have received appropriate training.
- Stent placement should be performed at hospitals where emergency coronary artery bypass graft surgery is accessible.
- Subsequent restenosis may require repeat dilatation of the arterial segment containing the stent. Long-term outcomes following repeat dilatation of the stent is presently unknown.
- Risks and benefits should be considered in patients with severe contrast agent allergies.
- Care should be taken to control the guiding catheter tip during stent delivery, deployment, and balloon withdrawal. Before withdrawing the stent delivery system, visually confirm complete balloon deflation by fluoroscopy to avoid guiding catheter movement into the vessel and subsequent arterial damage.
- Stent thrombosis is a low-frequency event that is frequently associated with myocardial infarction (MI) or death. Data from the SPIRIT family of clinical trials have been

prospectively evaluated and adjudicated using both the protocol definition of stent thrombosis and the definition developed by the Academic Research Consortium (ARC), and demonstrate specific patterns of stent thrombosis that vary depending on the definition used (see section 8.2 – *Adverse Events, Stent Thrombosis Definitions* and section 9.5 – *Pooled Analysis of the SPIRIT II-III-IV Clinical Trials* for more information).

- When DES are used outside the specified Indications for Use, patient outcomes may differ from the results observed in the SPIRIT family of clinical trials.
- Compared to use within the specified Indications for Use, the use of DES in patients and lesions outside of the labeled indications, including more tortuous anatomy, may have an increased risk of adverse events, including stent thrombosis, stent embolization, MI, or death.
- Orally administered everolimus combined with cyclosporine is associated with increased serum cholesterol and triglyceride levels.

5.2 Pre- and Post-Procedure Antiplatelet Regimen

- In the SPIRIT PRIME clinical trial, clopidogrel bisulfate or ticlopidine hydrochloride was administered pre-procedure and for a minimum of 12 months post-procedure (75 mg per day). Aspirin was administered pre-procedure and continued through 5 years (a minimum of 80 mg per day) to reduce thrombosis risk. At 1 year, dual antiplatelet therapy compliance in the Core Size Registry was 92.8% (360/388) and in the Long Lesion Registry was 89.0% (89/100). Upon subject completion of the study, physicians recommended that the subject remain on the aspirin regimen indefinitely).
- The optimal duration of dual antiplatelet therapy, specifically clopidogrel, is unknown and DES thrombosis may still occur despite continued therapy. Data from several studies on sirolimus-eluting or paclitaxel-eluting stents suggest that a longer duration of clopidogrel than was recommended post-procedurally in DES pivotal trials may be beneficial. Current guidelines recommend that patients receive aspirin indefinitely and P2Y₁₂ inhibitor therapy for at least 12 months, if subjects are not at high risk of bleeding (ref: ACCF/AHA/SCAI PCI Practice Guidelines¹).
- It is very important that the patient comply with the post-procedural antiplatelet therapy recommendations. Early discontinuation of prescribed antiplatelet medication could result in a higher risk of thrombosis, MI, or death. Prior to percutaneous coronary intervention (PCI), if the patient is required to undergo a surgical or dental procedure that might require early discontinuation of antiplatelet therapy, the interventionalist and patient should carefully consider whether a DES and its associated recommended antiplatelet therapy is the appropriate PCI treatment of choice. Following PCI, should a surgical or dental procedure be recommended, requiring suspension of antiplatelet therapy, the risks and benefits of the procedure should be weighed against the possible risks associated with early discontinuation of antiplatelet therapy. Patients who require early discontinuation of antiplatelet therapy (e.g., secondary to active bleeding) should be monitored carefully for cardiac events. At the discretion of the patient's treating physicians, the antiplatelet therapy should be restarted as soon as possible.

¹ Levine et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation*, 2011; 124: e574-651

5.3 Multiple Stent Use

The XIENCE Xpedition Stent System is the newest member to the XIENCE Family of Stents. The XIENCE Xpedition Stent System is based on the predicate XIENCE PRIME and XIENCE V Stent Systems. Therefore, the extensive body of XIENCE PRIME and XIENCE V clinical data is supportive of the performance of the XIENCE Xpedition Stent System.

A patient's exposure to drug and polymer is proportional to the number and total length of implanted stents. In the SPIRIT PRIME study; total stent length per subject was limited to 76 mm with treatment allowed for up to two lesions each in a different epicardial vessel using XIENCE PRIME and XIENCE PRIME LL. Use of more than two XIENCE PRIME stents to treat lesions longer than 32 mm has not been evaluated and may increase patient complication risks. Studies evaluating the effects of higher drug doses have not been conducted.

In the SPIRIT II, SPIRIT III, and SPIRIT IV clinical trials, lesions > 22 mm in length and ≤ 28 mm in length were treated with planned overlapping XIENCE V stents in the XIENCE V arm, or a single 32 mm TAXUS stent or planned overlapping TAXUS stents in the TAXUS arm.

In the SPIRIT IV clinical trial, there were 239 patients in the planned overlapping XIENCE V stent subgroup, 55 patients in the single 32 mm TAXUS stent subgroup, and 99 patients in the planned overlapping TAXUS subgroup (with 6 patients in the TAXUS arm receiving both single 32 mm and overlapping TAXUS stents). At two years, the target lesion failure (TLF) rate was 11.9% in the planned overlapping XIENCE V stent subgroup, 11.3% in the single 32 mm TAXUS stent subgroup, and 12.9% in the planned overlapping TAXUS stent subgroup.

In the pooled SPIRIT II, SPIRIT III, and SPIRIT IV analysis, there were a total of 317 patients in the planned overlapping XIENCE V stent subgroup, 86 patients in the single 32 mm TAXUS stent subgroup, and 113 patients in the planned overlapping TAXUS stent subgroup. At two years, the TLF rate was 11.7% in the planned overlapping XIENCE V stent subgroup, 12.2% in the single 32 mm TAXUS stent subgroup, and 12.1% in the planned overlapping TAXUS stent subgroup. At two years, the all cause mortality rate was 3.2% in the planned overlapping XIENCE V stent subgroup, 4.9% in the single 32 mm TAXUS stent subgroup, and 1.9% in the planned overlapping TAXUS stent subgroup. The cardiac death rate was 1.0% in the planned overlapping XIENCE V stent subgroup, 1.2% in the single 32 mm TAXUS stent subgroup, and 0.9% in the planned overlapping TAXUS stent subgroup. At two years, the rate of target vessel MI was 3.2% in the planned overlapping XIENCE V stent subgroup, 7.3% in the single 32 mm TAXUS stent subgroup, and 3.7% in the planned overlapping TAXUS stent subgroup. The Academic Research Consortium (ARC)-defined definite plus probable stent thrombosis rate at two years was 0.7% in the planned overlapping XIENCE V stent subgroup, 1.3% in the single 32 mm TAXUS stent subgroup, and 1.9% in the planned overlapping TAXUS stent subgroup.

In XIENCE V USA, there was no angiographic restriction for patient enrollment. Stent implantation was done per site's standard care. There were 8040 patients with a total of 11137 lesions treated during the index procedure. The mean lesion length was 15.8 mm, with 29% of those ≥ 20 mm in length based on visual estimation. Approximately 40.8% of patients had 2 or more stents implanted during the index procedure with a total of 12873 XIENCE V stents implanted. The mean stent length was 29.2 mm per patient and 21.2 mm per lesion. Stent overlaps occurred in 14.5% of the lesions treated during the index procedure.

In XIENCE V USA, the clinical results of patients with single lesion treated and lesion length ≥ 20 mm (N = 1388) are summarized in Section 9.7.3. In this pre-specified subgroup of patients

with long lesions, the mean lesion length was 28 mm with a total XIENCE V stent length of 34.3 mm per patient. At 1 year, the composite of cardiac death or target vessel MI rate (defined by ARC) was 6.8%, the ARC definite and probable ST rate was 0.79%, the ARC defined device-oriented endpoint (composite of cardiac death, target vessel MI [per ARC] and all TLR) was 9.3%.

In XIENCE V USA, there were 1301 (16.7%) patients with 1577 lesions (14.5%) where stent overlapping during the index procedure was reported, including situations where an implanted XIENCE V stent overlaps with a previous implanted stent prior to the index procedure. At 1 year, the composite of cardiac death or target vessel MI rate (defined by ARC) was 9.8%, the ARC definite and probable ST rate was 1.40%, TLF (composite of cardiac death, target vessel MI [per ARC] and clinically indicated TLR) was 13.1%.

Effects of multiple stenting using XIENCE Xpedition stents combined with other drug-eluting stents are unknown. When multiple drug-eluting stents are required, use only XIENCE stents with the identical Co-Cr stent material and drug coating (e.g., XIENCE V, XIENCE nano[®], XIENCE PRIME, or XIENCE Xpedition) in order to avoid potential interactions with other drug-eluting or coated stents.

In addition, only stents composed of similar materials should be implanted in consecutive stent-to-stent contact, to avoid corrosion potential between unrelated materials.

5.4 Brachytherapy

XIENCE Xpedition stent safety and effectiveness have not been evaluated in patients with prior target lesion or in-stent restenosis-related brachytherapy.

5.5 Use in Conjunction with Other Procedures

The safety and effectiveness of using mechanical atherectomy devices (directional atherectomy catheters, rotational atherectomy catheters) or laser angioplasty catheters in conjunction with XIENCE Xpedition stent implantation have not been established.

5.6 Use in Special Populations

5.6.1 Pregnancy

Pregnancy Category C, see section 6.5 – *Drug Information, Pregnancy*. The XIENCE Xpedition stent has not been tested in pregnant women or in men intending to father children. Effects on the developing fetus have not been studied. Effective contraception should be initiated before implanting a XIENCE Xpedition stent and continued for one year after implantation. While there is no contraindication, the risks and reproductive effects are unknown at this time.

5.6.2 Lactation

See section 6.6 – *Drug Information, Lactation*. A decision should be made whether to discontinue nursing prior to stent implantation, considering the importance of the stent to the mother.

5.6.3 Gender

A gender analysis was not pre-specified in the SPIRIT PRIME clinical study. However, post-hoc analyses were conducted to evaluate gender-specific outcomes associated with the XIENCE PRIME stents in the SPIRIT PRIME trials, and the XIENCE V stent in the pooled data from the SPIRIT II, SPIRIT III, and SPIRIT IV trials (see Section 9.6). Additional gender specific data associated with the EXPERT CTO trial can be found in Section 9.8.

5.6.4 Ethnicity

Insufficient subject numbers prevent ethnicity-related analyses of the XIENCE family of stents safety and effectiveness. **Table 5.6.4-1** provides an overview of all Non-Caucasians enrolled in the SPIRIT Trials.

Table 5.6.4-1: Non-Caucasians in the SPIRIT and XIENCE V USA Trials

| | Non-Caucasian Population |
|---------------------|---------------------------------|
| SPIRIT III | 8.8% (88/1001) |
| SPIRIT IV | 6.4% (236/3687) |
| SPIRIT Small Vessel | 9.9% (14/142) |
| SPIRIT PRIME CSR | 7.7% (29/375) |
| SPIRIT PRIME LLR | 8.3% (8/96) |
| XIENCE V USA | 12.3% (990/8027) |

5.6.5 Pediatric Use

The safety and effectiveness of the XIENCE Xpedition stent in pediatric subjects have not been established.

5.6.6 Geriatric Use

The XIENCE PRIME clinical trial did not have an upper age limit. Among the 401 patients in the SPIRIT PRIME Core Size Registry, 167 were older than age 65 and 234 were age 65 or younger. Among the 104 patients in the SPIRIT PRIME Long Lesion Registry, 48 patients were older than age 65 and 56 were age 65 or younger. A post hoc analysis showed no clinically significant differences in clinical endpoints between patients older than age 65 compared to those age 65 years or younger.

5.7 Lesion / Vessel Characteristics

Safety and effectiveness of the XIENCE Xpedition stent have not been established for subject populations with the following clinical settings:

- Unresolved vessel thrombus at the lesion site
- Coronary artery reference vessel diameters < 2.25 mm or > 4.25 mm
- Lesion lengths > 32 mm
- Lesions located in saphenous vein grafts

-
- Lesions located in unprotected left main coronary artery, ostial lesions, and lesions located at a bifurcation
 - Previously stented lesions
 - Diffuse disease or poor flow (TIMI < 1) distal to the identified lesions
 - Excessive tortuosity proximal to or within the lesion
 - Recent acute myocardial infarction (AMI) or evidence of thrombus in the target vessel
 - Multivessel disease
 - In-stent restenosis

In the all-inclusive, real-world XIENCE V USA post-approval study, several pre-specified subgroup analyses (including the above-mentioned AMI, multivessel disease and in-stent restenosis) were conducted. Please see section 9.7.3 for the clinical outcomes of XIENCE V in those clinical settings.

5.8 Drug Interactions

See section 6.3 – *Drug Information, Interactions with Drugs or Other Substances*.

Several drugs are known to affect everolimus metabolism, and other drug interactions may also occur. Everolimus is known to be a substrate for both cytochrome P4503A4 (CYP3A4) and P-glycoprotein (PgP). Everolimus absorption and subsequent elimination may be influenced by drugs that affect these pathways. Everolimus has also been shown to reduce the clearance of some prescription medications when administered orally along with cyclosporine (CsA). Formal drug interaction studies have not been performed with the XIENCE Xpedition stent because of limited systemic exposure to everolimus eluted from XIENCE Xpedition (see section 6.2 – *Drug Information, Pharmacokinetics*). Therefore, due consideration should be given to the potential for both systemic and local drug interactions in the vessel wall, when deciding to place the XIENCE Xpedition stent in a patient taking a drug with known interaction with everolimus, or when deciding to initiate therapy with such a drug in a patient who has recently received a XIENCE Xpedition stent.

5.9 Immune Suppression Potential

Everolimus, the XIENCE Xpedition stent active ingredient, is an immunosuppressive agent. Immune suppression was not observed in the SPIRIT family of clinical trials. However, for patients who receive several XIENCE Xpedition stents simultaneously, it may be possible for everolimus systemic concentrations to approach immunosuppressive levels temporarily, especially in patients who also have hepatic insufficiency or who are taking drugs that inhibit CYP3A4 or P-glycoprotein. Therefore, consideration should be given to patients taking other immunosuppressive agents or who are at risk for immune suppression.

5.10 Lipid Elevation Potential

Oral everolimus use in renal transplant and advanced renal cell carcinoma patients was associated with increased serum cholesterol and triglycerides, which in some cases required treatment. The effect was seen with both low and high dose prolonged oral therapy in a dose related manner. When used according to the indications for use, exposure to systemic everolimus concentrations from the XIENCE Xpedition stent is expected to be significantly lower than concentration exposure usually obtained in transplant patients. Increased serum cholesterol and triglycerides were not observed in the SPIRIT family of clinical trials.

5.11 Magnetic Resonance Imaging (MRI)

Nonclinical testing has demonstrated that the XIENCE Xpedition stent, in single and in overlapped configurations up to 71 mm in length, is MR Conditional. It can be scanned safely under the following conditions:

- Static magnetic field of 1.5 or 3 Tesla
- Spatial gradient field of 2500 Gauss/cm or less
- Maximum whole-body-averaged specific absorption rate (SAR) of 2.0 W/kg (normal operating mode) for up to 15 minutes of scanning for each sequence

The XIENCE Xpedition stent should not migrate in this MRI environment. Nonclinical testing at field strengths greater than 3 Tesla has not been performed to evaluate stent migration or heating. MRI at 1.5 or 3 Tesla may be performed immediately following the implantation of the XIENCE Xpedition stent.

Stent heating was derived by using the measured nonclinical, *in vitro* temperature rises in a GE Excite 3 Tesla scanner and in a GE 1.5 Tesla coil in combination with the local specific absorption rates (SARs) in a digitized human heart model. The maximum whole body averaged SAR was determined by validated calculation. At overlapped lengths of up to 71 mm, the XIENCE Xpedition stent produced a nonclinical maximum local temperature rise of 3.3°C at a maximum whole body averaged SAR of 2.0 W/kg (normal operating mode) for 15 minutes. These calculations do not take into consideration the cooling effects of blood flow.

The effects of MRI on overlapped stents greater than 71 mm in length or stents with fractured struts are unknown.

As demonstrated in nonclinical testing, an image artifact can be present when scanning the XIENCE Xpedition stent. MR image quality may be compromised if the area of interest is in the exact same area, or relatively close to, the position of the XIENCE Xpedition stent. Therefore, it may be necessary to optimize the MR imaging parameters for the presence of XIENCE Xpedition stent.

It is suggested that patients register the conditions under which the implant can safely be scanned with the MedicAlert Foundation (www.medicalert.org) or an equivalent organization.

5.12 Stent Handling

- **Each stent is for single use only.** Do not resterilize or reuse this device. Note the “Use by” (expiration) date on the product label.
- **The foil pouch is not a sterile barrier.** The inner header bag (pouch) within the foil pouch is the sterile barrier. **Only the contents of the inner pouch should be considered sterile.** The outside surface of the inner pouch is NOT sterile.
- **Do not remove the stent from the delivery system.** Removal may damage the stent and / or lead to stent embolization. These components are intended to perform together as a system.
- The delivery system should not be used in conjunction with other stents.
- Special care must be taken not to handle or disrupt the stent on the balloon, particularly during delivery system removal from packaging, placement over the guide wire and advancement through the rotating hemostatic valve adapter and guiding catheter hub.

-
- **Do not manipulate, touch, or handle the stent** with your fingers, which may cause coating damage, contamination, or stent dislodgement from the delivery balloon.
 - Use only the appropriate balloon inflation media (see section 13.3.3 – *Operator’s Instructions, Delivery System Preparation*). Do not use air or any gaseous medium to inflate the balloon as this may cause uneven expansion and difficulty in stent deployment.

5.13 Stent Placement

5.13.1 Stent Preparation

- **Do not prepare or pre-inflate the delivery system prior to stent deployment other than as directed.** Use the balloon purging technique described in section 13.3.3 – *Operator’s Instructions, Delivery System Preparation*.
- **While introducing the delivery system into the vessel, do not induce negative pressure on the delivery system.** This may cause dislodgement of the stent from the balloon.
- Use guiding catheters which have lumen sizes that are suitable to accommodate the stent delivery system (see section 1.1 – *Product Description, Device Component Description*).

5.13.2 Stent Implantation

- The decision to pre-dilate the lesion with an appropriate sized balloon should be carefully based on patient and lesion characteristics. The XIENCE V USA Clinical Trial demonstrated that in a real-world setting, direct stenting with XIENCE V stents in single-lesion treated patients who did not have a staged procedure was non-inferior to stenting utilizing pre-dilation. In this analysis there was, as expected, some degree of selection bias with lesions undergoing direct-stenting displaying lower complexity than lesions undergoing pre-dilation. However, adjustment for baseline differences in lesion characteristics did not change the finding of non-inferiority of direct stenting to pre-dilation. Please see Section 9.7.2 for the detailed clinical results from XIENCE V USA post-approval study.
- Do not expand the stent if it is not properly positioned in the vessel (see section 5.14 – *Precautions, Stent System Removal*).
- Implanting a stent may lead to vessel dissection and acute closure require additional intervention (CABG, further dilatation, placement of additional stents, or other).
- Although the safety and effectiveness of treating more than one lesion per coronary artery with XIENCE Xpedition stents have not been established, if this is performed, place the stent in the distal lesion before the proximal lesion in order to minimize dislodgement risk incurred by traversing through deployed stents.
- Stent placement may compromise side branch patency.
- **Do not exceed Rated Burst Pressure (RBP) as indicated on product label.** See Table 14-1: XIENCE Xpedition Stent Compliance. Balloon pressures should be monitored during inflation. Applying pressures higher than specified on the product label may result in a ruptured balloon with possible arterial damage and dissection. The stent inner diameter should approximate 1.1 times the reference diameter of the vessel.

-
- An unexpanded stent may be retracted into the guiding catheter one time only. An unexpanded stent should not be reintroduced into the artery once it has been pulled back into the guiding catheter. Subsequent movement in and out through the distal end of the guiding catheter should not be performed, as the stent may be damaged when retracting the undeployed stent back into the guiding catheter.
 - Should **resistance** be felt **at any time** during coronary stent system withdrawal, please follow the steps provided in section 5.14 – *Precautions, Stent System Removal*.
 - Stent retrieval methods (i.e., using additional wires, snares, and / or forceps) may result in additional trauma to the coronary vasculature and / or the vascular access site. Complications may include bleeding, hematoma, or pseudoaneurysm.
 - Although the stent delivery system balloon is strong enough to expand the stent without rupture, a circumferential balloon tear distal to the stent and prior to complete stent expansion, could cause the balloon to become tethered to the stent, requiring surgical removal. In case of balloon rupture, it should be withdrawn and, if necessary, a new dilatation catheter exchanged over the guide wire to complete the expansion of the stent.
 - Ensure the stented area covers the entire lesion / dissection site and that no gaps exist between stents.
 - Do not torque the catheter more than one (1) full turn.

5.14 Stent System Removal

Stent delivery system removal prior to stent deployment:

If removal of a stent system is required prior to deployment, ensure that the guiding catheter is coaxially positioned relative to the stent delivery system, and cautiously withdraw the stent delivery system into the guiding catheter. Should unusual resistance be felt at any time when withdrawing the stent towards the guiding catheter, the stent delivery system and the guiding catheter should be removed as a single unit. This should be done under direct visualization with fluoroscopy.

Withdrawal of the stent delivery catheter from the deployed stent:

1. Deflate the balloon by pulling negative on the inflation device. Larger and longer balloons will take more time (up to 30 seconds) to deflate than smaller and shorter balloons. Confirm balloon deflation under fluoroscopy and wait 10 – 15 seconds longer.
2. Position the inflation device to “negative” or “neutral” pressure.
3. Stabilize guiding catheter position just outside coronary ostium and anchor in place. Maintain guide wire placement across stent segment.
4. Gently remove the stent delivery system with slow and steady pressure.
5. Tighten the rotating hemostatic valve.

If during withdrawal of the catheter resistance is encountered use the following steps to improve balloon rewrap.

- Re-inflate the balloon up to nominal pressure.

-
- Repeat steps 1 through 5 above.

Failure to follow these steps and / or applying excessive force to the delivery system can potentially result in loss of or damage to the stent and / or delivery system components.

If it is necessary to retain guide wire position for subsequent artery / lesion access, leave the guide wire in place and remove all other system components.

Stent retrieval methods (i.e., additional wires, snares, and / or forceps) may result in additional trauma to the coronary vasculature and / or the vascular access site. Complications may include, but are not limited to, bleeding, hematoma, or pseudoaneurysm.

5.15 Post-Procedure

- When **crossing a newly deployed stent** with an intravascular ultrasound (IVUS) catheter, a coronary guide wire, a balloon catheter or delivery system, exercise care to avoid disrupting the stent placement, apposition, geometry, and / or coating.
- Antiplatelet therapy should be administered post-procedure (see section 5.2 – *Precautions, Pre- and Post-Procedure Antiplatelet Regimen*). Patients who require early discontinuation of antiplatelet therapy (e.g., secondary to active bleeding) should be monitored carefully for cardiac events. At the discretion of the patient's treating physician, the antiplatelet therapy should be restarted as soon as possible.
- If the patient requires imaging, see section 5.11 – *Precautions, Magnetic Resonance Imaging (MRI)*.

6.0 DRUG INFORMATION

6.1 Mechanism of Action

The mechanism by which the XIENCE Xpedition stent inhibits neointimal growth as seen in pre-clinical and clinical studies has not been established. At the cellular level, everolimus inhibits growth factor-stimulated cell proliferation. At the molecular level, everolimus forms a complex with the cytoplasmic protein FKBP-12 (FK 506 Binding Protein). This complex binds to and interferes with FKBP-12 Rapamycin Associated Protein (FRAP), also known as mammalian target of rapamycin (mTOR), leading to inhibition of cell metabolism, growth, and proliferation by arresting the cell cycle at the late G1 stage.

6.2 Pharmacokinetics

Pharmacokinetic studies have not been performed using the XIENCE Xpedition stent, but were conducted on the similar XIENCE V stent. The XIENCE Xpedition stent is similar to XIENCE V with regards to the stent design, identical stent coating technology (dosing and drug to polymer ratio), and similar delivery system materials. Given these similarities, the findings from the XIENCE V pharmacokinetic studies, as described below, are applicable to the XIENCE Xpedition stent. Everolimus pharmacokinetics when eluted from the XIENCE V stent post-implantation has been evaluated in three different substudies in three different geographies. The SPIRIT III clinical trial design includes a pharmacokinetic substudy in the U.S. randomized arm and a pharmacokinetic substudy in the Japanese nonrandomized arm. The third PK substudy was conducted as part of the SPIRIT II clinical trial at sites in Europe, India,

and New Zealand. Whole blood everolimus PK parameters determined from subjects receiving the XIENCE V stent are provided in Table 6.2-1.

Table 6.2-1: Whole Blood Everolimus Pharmacokinetic Parameters in Patients Following XIENCE V Stent Implantation

| SPIRIT III RCT and 4.0 Arm | | | | | | | |
|---------------------------------------|-----------|----------------------|--------------------------|-----------------------------------|---|---|-----------------------|
| | Dose (µg) | t _{max} (h) | C _{max} (ng/mL) | t _{1/2} (h) ^a | AUC _{0-t} ^a (ng.h/mL) | AUC _{0-∞} ^a (ng.h/mL) | CL (L/h) ^a |
| | | median (range) | mean ± SD | mean ± SD | mean ± SD | mean ± SD | mean ± SD |
| 2.5-3.0 x 18 mm (n = 3 ^b) | 88 µg | 0.050 (0.50-1.88) | 0.3867 ± 0.09866 | | 5.31 ± 4.114 | | |
| 3.5-4.0 x 28 mm (n = 6 ^c) | 181 µg | 0.50 (0.07-1.00) | 1.175 ± 0.6817 | 79.08 ± 57.24 | 23.73 ± 13.63 | 44.00 ± 28.67 | 5.130 ± 2.114 |
| SPIRIT III Japanese Arm | | | | | | | |
| | Dose (µg) | t _{max} (h) | C _{max} (ng/mL) | t _{1/2} (h) ^a | AUC _{0-t} (ng.h/mL) | AUC _{0-∞} ^a (ng.h/mL) | CL (L/h) |
| | | median (range) | mean ± SD | mean ± SD | mean ± SD | mean ± SD | mean ± SD |
| 2.5-3.0 x 18 mm (n = 6) | 88 µg | 1.00 (0.50-1.02) | 0.5017 ± 0.1398 | 45.22 ± 35.08 | 5.049 ± 2.138 | 12.98 ± 7.078 | 9.286 ± 6.069 |
| 3.5-4.0 x 18 mm (n = 4 ^b) | 113 µg | 0.51 (0.50-0.53) | 0.6500 ± 0.08756 | 53.57 ± 19.34 | 11.02 ± 4.002 | 19.97 ± 7.890 | 6.471 ± 2.807 |
| SPIRIT II Clinical Trial | | | | | | | |
| | Dose (µg) | t _{max} (h) | C _{max} (ng/mL) | t _{1/2} (h) ^a | AUC _{last} (ng.h/mL) | AUC _{0-∞} ^a (ng.h/mL) | CL (L/h) ^a |
| | | median (range) | mean ± SD | mean ± SD | mean ± SD | mean ± SD | mean ± SD |
| 2.5-3.0 x 18 mm (n = 13) | 88 µg | 0.50 (0.13-2.17) | 0.4369 ± 0.1507 | 54.08 ± 35.78 | 8.255 ± 5.863 | 19.60 ± 15.30 | 8.066 ± 6.443 |
| 3.5-4.0 x 18 mm (n = 4 ^c) | 113 µg | 0.50 (0.50-0.50) | 0.5850 ± 0.2630 | 47.60 ± 62.13 | 42.54 ± 58.83 | 22.79 ± 31.47 | 16.96 ± 13.07 |
| 3.5-4.0 x 28 mm (n = 4) | 181 µg | 0.46 (0.17-1.00) | 0.7925 ± 0.1406 | 103.4 ± 64.17 | 28.07 ± 13.18 | 52.71 ± 27.40 | 5.332 ± 5.048 |

^a Accurate determination not possible due to rapid disappearance of everolimus from the blood

^b n = 5 for t_{1/2} and CL

^c n = 3 for t_{1/2} and CL

t_{max}(h) = time to maximum concentration

C_{max} = maximum observed blood concentration

t_{1/2} (h) = terminal phase half-life

AUC_{0-t} or AUC_{last} = the area beneath the blood concentration versus time curve: time zero to the final quantifiable concentration

AUC_(0-∞) = the area beneath the blood concentration versus time curve: time zero to the extrapolated infinite time

CL = total blood clearance

In all subjects, the maximum time to everolimus disappearance was 168 hours; however, 1 subject in the SPIRIT II clinical trial had detectable levels at 30 days. In all 3 studies, the C_{max} value never reached the minimum therapeutic value of 3.0 ng/mL necessary for effective systemic administration to prevent organ rejection in patients taking Certican[®]. The PK parameters representing elimination, t_{1/2}, AUC_{0-t}, AUC_{last}, AUC_∞, and CL, could also not be determined accurately due to rapid everolimus disappearance from blood. These types of results have been seen with other drug-eluting stents.

Everolimus disappearance from circulation following XIENCE V stent implantation should further limit systemic exposure and adverse events associated with long-term systemic administration at therapeutic levels. Despite limited systemic exposure to everolimus, local arterial delivery has been demonstrated in pre-clinical studies. The same results are expected for XIENCE Xpedition due to the similarities with XIENCE V stated above.

6.3 Interactions with Drugs or Other Substances

Everolimus is extensively metabolized by the cytochrome P4503A4 (CYP3A4) in the liver and to some extent in the intestinal wall, and is a substrate for the countertransporter P-glycoprotein (PgP). Therefore, absorption and subsequent elimination of everolimus may be influenced by drugs that also affect CYP3A4 and PgP pathways. Everolimus has also been shown to reduce the clearance of some prescription medications when it was administered orally along with cyclosporine (CsA). Formal drug interaction studies have not been performed with the XIENCE Xpedition or XIENCE V stents because of limited systemic exposure to everolimus eluted from XIENCE V (see section 6.2 – *Drug Information, Pharmacokinetics*). However, consideration should be given to the potential for both systemic and local drug interactions in the vessel wall when deciding to place the XIENCE Xpedition stent in a subject taking a drug with known interaction with everolimus.

Everolimus, when prescribed as an oral medication, may interact with the drugs / foods² listed below. Medications that are strong inhibitors of CYP3A4 or PgP might reduce everolimus metabolism *in vivo*. Hence, co-administration of strong inhibitors of CYP3A4 or PgP may increase the blood concentrations of everolimus. Medications that are strong inducers of CYP3A4 or PgP might increase everolimus metabolism *in vivo* resulting in decreased blood concentrations of everolimus.

- CYP3A4/PgP inhibitors
 - Antifungal agents (e.g., fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole)
 - Macrolide antibiotics (e.g., erythromycin, clarithromycin, telithromycin)
 - Calcium channel blockers (e.g., verapamil, nifedipine, diltiazem)
 - Protease inhibitors (e.g., ritonavir, atazanavir, saquinavir, darunavir, indinavir, nelfinavir, amprenavir, fosamprenavir)
 - Other (e.g., cyclosporine, nefazodone, cisapride, metoclopramide, bromocriptine, cimetidine, danazol, sildenafil, terfenadine, astemizole, grapefruit / grapefruit juice, digoxin)
- CYP3A4/PgP inducers
 - Antibiotics (e.g., rifampin, rifabutin, ciprofloxacin, ofloxacin)
 - Anticonvulsants (e.g., carbamazepine, phenobarbital, phenytoin)
 - Non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, nevirapine)
 - Glucocorticoids (e.g., dexamethasone, prednisone, prednisolone)
 - HMGCoA reductase inhibitors (simvastatin, lovastatin)
 - Other (e.g., St. John's Wort)

Everolimus is approved in the United States under the name of Zortress[®] for the prophylaxis of organ rejection in adult kidney transplant recipients at low-moderate immunologic risk, at the dose of 1.5 mg/day when taken by mouth. Outside the United States, Zortress is sold under the brand name Certican in more than 70 countries. Everolimus is also approved in the United States under the name of Afinitor[®] for the treatment of patients with advanced renal cell carcinoma (cancer) after failure of treatment with sunitinib or sorafenib, at doses of 5 to 20 mg/day when taken by mouth. The amount of drug that circulates in the bloodstream

² Zortress Prescribing Information from Drugs@FDA, label approved on April 20, 2010.

following implantation of a XIENCE Xpedition stent is several folds lower than that obtained with oral doses (1.5 mg to 20 mg/day).

6.4 Carcinogenicity, Genotoxicity, and Reproductive Toxicity

The carcinogenicity, genotoxicity, and reproductive toxicity of the XIENCE Xpedition stent have not been evaluated; however, long term carcinogenicity and teratology studies were performed with the similar XIENCE V stent. The test results from the XIENCE V stent, as described below, are applicable to the XIENCE Xpedition, due to similar stent design, delivery system materials, and identical stent coating technology.

A 26-week carcinogenicity study was conducted to evaluate the carcinogenic potential of XIENCE V stents following subcutaneous implantation in transgenic mice. During the course of the study, there were no abnormal clinical observations that suggested a carcinogenic effect of the test group (XIENCE V stent). The test group did not demonstrate an increased incidence of neoplastic lesions when compared to the negative control group. However, the positive control and the experimental positive control groups demonstrated notable increases in the incidence of neoplastic lesions compared to either the test or the negative control group. Based on the results of this study, the XIENCE V stent does not appear to be carcinogenic when implanted in transgenic mice for 26 weeks.

Genotoxicity studies were conducted on the XIENCE V stent in mammalian cells and bacteria. These studies included gene mutations in bacteria (Ames Test), gene mutations in mammalian cells (chromosomal aberration), test for clastogenicity in mammalian cells, and mammalian erythrocyte micronucleus test. Based on the results of these studies, the XIENCE V stent is not genotoxic.

In addition, a reproductive toxicity (teratology) study was conducted in female Sprague-Dawley rats. The XIENCE V stent did not affect the fertility or reproductive capability of female Sprague-Dawley rats. There was no statistical difference between the test article (XIENCE V stent) and the control system in terms of any of the evaluated parameters. The test article had no effect on litter size and caused no increase of *in utero* mortality. Additionally, the XIENCE V stent did not cause any reproductive toxicity in the offspring in this study.

6.5 Pregnancy

Pregnancy Category C: There are no adequate everolimus or XIENCE Xpedition stent related studies in pregnant women. Effects of a similar stent, XIENCE V, on prenatal and postnatal rat development were no different than the controls (see section 6.4 – *Drug Information, Carcinogenicity, Genotoxicity, and Reproductive Toxicity*). When administered at oral doses of 0.1 mg/kg or above, everolimus showed effects on prenatal and postnatal rat development limited to slight body weight changes and fetal survival without any specific toxic potential.³ Effective contraception should be initiated before implanting a XIENCE Xpedition stent and continued for one year post-implantation. The XIENCE Xpedition stent should be used in pregnant women only if potential benefits outweigh potential risks.

The safety of the XIENCE Xpedition stent has not been evaluated in males intending to father children.

³ Certican Investigator's Brochure

6.6 Lactation

It is unknown whether everolimus is distributed in human milk. Also, everolimus pharmacokinetic and safety profiles have not been determined in infants. Consequently, mothers should be advised of potential serious adverse reactions to everolimus in nursing infants. Prior to XIENCE Xpedition stent implantation, decisions should be made regarding whether to discontinue nursing or conduct an alternate percutaneous coronary intervention procedure.

7.0 OVERVIEW OF CLINICAL EXPERIENCE

SPIRIT PRIME is a prospective, open-label, multicenter nonrandomized clinical trial using the core size XIENCE PRIME and XIENCE PRIME LL stent system. Approximately 500 subjects at up to 75 sites were to be enrolled in the Core Size Registry or Long Lesion Registry. Each subject was to receive treatment in up to two *de novo* native coronary lesions, each in a different epicardial vessel. The Core Size Registry was to enroll approximately 400 subjects in which all were to be treated with core size XIENCE PRIME (stent diameters 2.25, 2.5, 3.0, 3.5 or 4.0 mm with stent lengths 8, 18, or 28⁴ mm). The Long Lesion Registry was to enroll approximately 100 subjects in which all were to be treated with at least one XIENCE PRIME LL (stent diameters 2.5, 3.0, 3.5 or 4.0 mm with stent lengths 33 or 38 mm). Treatment of a second target lesion with a core size XIENCE PRIME was recommended. The primary endpoint was target lesion failure (TLF) at 1 year. Secondary endpoints included clinical outcomes at 30 and 180 days and annually from 1 to 3 years. Final follow-up through 3 year is presented here. The SPIRIT PRIME clinical trial is Abbott Vascular's pivotal US trial evaluating XIENCE PRIME.

The XIENCE PRIME stent is similar to the FDA approved XIENCE V stent system. XIENCE V EECSS has been studied extensively in four clinical trials, SPIRIT FIRST, SPIRIT II, SPIRIT III, and SPIRIT IV. Initial clinical safety and performance of the XIENCE V EECSS stent was demonstrated in the SPIRIT FIRST clinical trial in which the XIENCE V EECSS was compared to the VISION bare metal stent. The SPIRIT II clinical trial was a continuation in the assessment of the safety and performance of the XIENCE V EECSS versus the TAXUS[®] Express[®] stent. The SPIRIT III clinical trial was a pivotal clinical trial to demonstrate the safety and effectiveness of the XIENCE V EECSS. SPIRIT IV further evaluated the safety and effectiveness of XIENCE V in a large population of complex subjects. The SPIRIT family of trials evaluating the XIENCE V EECSS is ongoing, inclusive of Investigational Device Exemption (IDE) and post-marketing trials. For more information on the XIENCE V EECSS, refer to the XIENCE V EECSS Instructions for Use (IFU).

Principal XIENCE V safety and effectiveness information is derived from the SPIRIT III clinical trial and confirmed by the SPIRIT IV clinical trial. These studies evaluated the performance of XIENCE V in subjects with symptomatic ischemic disease due to *de novo* lesions in native coronary arteries. Major study characteristics for SPIRIT III and SPIRIT IV are summarized below and listed in Table 7-1.

SPIRIT III, a pivotal clinical trial, was designed to demonstrate the non-inferiority of the XIENCE V stent to the TAXUS Express stent (TAXUS stent) and was conducted in the United States (US) and Japan. The SPIRIT III RCT was a prospective, randomized (2:1; XIENCE V:TAXUS), active-controlled, single-blinded, multicenter, clinical trial in the US designed to evaluate the safety and efficacy of the XIENCE V stent in the treatment of up to two *de novo* lesions ≤ 28 mm in length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 3.75 mm.

⁴ The 28 mm length stent was studied in the XIENCE PRIME Core Size Registry. The results of the Core Size Registry are presented in Tables 9.1-2 to 9.1-3.

The RCT study was designed to enroll 1,002 subjects at up to 80 sites in the US. The primary endpoint in the RCT was in-segment late loss at 240 days, and the co-primary endpoint was ischemia-driven target vessel failure (TVF, defined as the composite of cardiac death, MI, or ischemia-driven TVR) at 270 days. Other secondary endpoints included clinical outcomes of all the subjects (30, 180, 270 days and annually from 1 to 5 years), as well as angiographic results and intravascular ultrasound (IVUS) results at 240 days. Five year results are available, completing follow-up for SPIRIT III RCT.

The SPIRIT IV trial was a prospective, randomized, active-controlled, single-blinded, multicenter evaluation of the XIENCE V stent compared to the TAXUS Express Stent⁵ (TAXUS stent) in the treatment of up to three *de novo* lesions ≤ 28 mm in length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 4.25 mm. The SPIRIT IV trial was randomized 2:1 (XIENCE V:TAXUS) and designed to enroll 3,690 subjects at up to 80 sites in the US. Subjects were stratified by diabetes mellitus (diabetic vs. non-diabetic) and lesion characteristics (complex vs. noncomplex). Complex lesion characteristics included triple vessels treatment, or dual lesions per vessel treatment, or lesions involving RCA-aorto-ostial locations, or bifurcation lesions. The primary endpoint was target lesion failure (TLF) at 1 year. The major secondary endpoints were ID-TLR at 1 year and the composite of cardiac death or target vessel MI at 1 year. Formal non-inferiority and superiority testing were planned for the primary and the two major secondary endpoints by following a fixed sequence. Secondary endpoints included clinical outcomes at 30, 180, 270 days and annually from 1 to 3 years. Three-year results are available, completing follow-up for the SPIRIT IV trial.

The SPIRIT Small Vessel (SV) Registry was a prospective, single-arm, open-label, US multicenter registry study using 2.25 mm diameter XIENCE V EECSS. The trial enrolled a total of 150 subjects, of which 69 subjects were included in an angiographic follow-up cohort, at 33 sites. The SPIRIT SV trial allowed for target and non-target lesion treatment. The target lesion was identified as that lesion intended to be treated by the 2.25 mm XIENCE V EECSS and the non-target lesion was identified as that lesion intended to be treated by the commercial XIENCE V EECSS. The SPIRIT SV trial allowed for single target lesion or two lesion treatment (two target lesions or one target and one non-target lesion) in separate epicardial vessels. The primary endpoint was target lesion failure (TLF, defined as the composite of cardiac death, target vessel myocardial infarction and clinically indicated target lesion revascularization) at 1 year. Three-year results are available, completing follow-up for SPIRIT SV.

The XIENCE V USA study was a prospective, multicenter, FDA mandated post-approval study to evaluate the continued safety and effectiveness of the XIENCE V EECSS in “real-world” settings after commercialization in US, and also to support the FDA dual antiplatelet therapy (DAPT) initiative. A total of 8,040 patients were consecutively enrolled from 191 sites in US in two enrollment stages (5,042 patients from the first stage and 2,998 patients from the second stage). There were three cohorts in this study: (1) phase I cohort (from index procedure to 1 year), consisting of all enrolled patients from both enrollment stages; (2) long-term follow-up cohort (from 1 year to 4 years), consisting of patients from the first enrollment stage who were not transferred to HCRI-DAPT study and remained in the study beyond 1 year; (3) AV-DAPT cohort (from 1 year to 33 months), consisting of patients from the second enrollment stage who were eligible and randomized to the AV-DAPT study. Patients were considered enrolled upon signing the Institutional Review Board (IRB)-approved informed consent form (ICF) and upon completion of the index procedure utilizing only XIENCE V EECSS was (were) implanted during the index procedure. There were no angiographic inclusion and exclusion criteria for this study. For the phase I and the long-term follow-up cohorts, the primary endpoint was the annual rate of ARC-defined stent thrombosis (definite and probable), and the co-primary endpoint was the annual composite rate of cardiac death or any MI. The study design of the AV-DAPT cohort

⁵ In the TAXUS stent arm, there was 1 subject who received 1 TAXUS® Liberté® Stent.

follows the HCRI-DAPT study (IDE#G080186). Final clinical follow-up through 4 years is available for all the enrolled patients (long-term follow-up cohort).

Table 7-1 summarizes the clinical trial designs for the SPIRIT family of trials. Table 7-2 summarizes the clinical trial design for the XIENCE V USA post-approval study.

Table 7-1: SPIRIT Family Clinical Trial Designs

| | SPIRIT PRIME Clinical Trial | | SPIRIT III Clinical Trial | | SPIRIT IV Clinical Trial | SPIRIT Small Vessel Registry |
|---|---|---|---|---|---|--|
| | Core Size Registry | Long Lesion Registry | RCT (Pivotal) | 4.0 Arm (Registry) | | |
| Study Type/Design | <ul style="list-style-type: none"> • Multicenter • Single-arm • Open-label | <ul style="list-style-type: none"> • Multicenter • Single-arm • Open-label | <ul style="list-style-type: none"> • Multicenter • Randomized • Single-blinded • Active-Control | <ul style="list-style-type: none"> • Multicenter • Single-arm • Open-label | <ul style="list-style-type: none"> • Multicenter • Randomized • Single-blinded • Active-Control | <ul style="list-style-type: none"> • Multicenter • Non-randomized • Open-label • Non-blinded • Single-arm |
| Number of Subjects Enrolled | Total: 400 | Total: 100 | Total: 1,002 XIENCE V: 668 TAXUS Express Control: 334 | Total: 80 | Total: 3,690 XIENCE V: 2,460 TAXUS Express Control: 1,230 | Total : 150 No Control |
| Treatment | Up to two <i>de novo</i> lesions in different epicardial vessels | Up to two <i>de novo</i> lesions in different epicardial vessels | Up to two <i>de novo</i> lesions in different epicardial vessels | Up to two <i>de novo</i> lesions in different epicardial vessels | Up to three <i>de novo</i> lesions, maximum of two lesions per epicardial vessel | Up to two <i>de novo</i> lesions in different epicardial vessels |
| Lesion Size | RVD: $\geq 2.25 \leq 4.25$ mm Length: ≤ 22 mm | XIENCE PRIME CS: RVD: $\geq 2.25 \leq 4.25$ mm Length: ≤ 22 mm XIENCE PRIME LL: RVD: $\geq 2.5 \leq 4.25$ mm Length: > 22 mm and ≤ 32 mm | RVD: $\geq 2.5 \leq 3.75$ mm Length: ≤ 28 mm | RVD: $> 3.75 \leq 4.25$ mm Length: ≤ 28 mm | RVD: $\geq 2.5 \leq 4.25^{\$}$ mm Length: ≤ 28 mm | RVD: $\geq 2.25 < 2.50$ mm Length: ≤ 28 mm |
| Stent Sizes (XIENCE PRIME/ XIENCE V) | XIENCE PRIME Diameter: 2.25, 2.5, 3.0, 3.5, 4.0 mm Length: 8, 18, 28*** mm | XIENCE PRIME LL Diameter: 2.5, 3.0, 3.5, 4.0 mm Length: 33, 38 mm | XIENCE V Diameter: 2.5, 3.0, 3.5 mm Length: 8, 18, 28 mm | XIENCE V Diameter: 4.0 mm Length: 8, 18, 28 mm | XIENCE V Diameter: 2.5, 3.0, 3.5, 4.0 [§] mm Length: 8, 18, 28 mm | XIENCE V Diameter: 2.25 mm Length: 8, 18, 28 mm |
| Post-Procedure Antiplatelet Therapy | Clopidogrel 12 months minimum (or ticlopidine per site standard), aspirin 3 years | Clopidogrel 12 months minimum (or ticlopidine per site standard), aspirin 3 years | Clopidogrel 6 months minimum (or ticlopidine per site standard), aspirin 5 years | Clopidogrel 6 months minimum (or ticlopidine per site standard), aspirin 5 years | Clopidogrel 12 months minimum (or ticlopidine per site standard), [#] aspirin 3 years | Clopidogrel 12 months minimum (or ticlopidine per site standard), aspirin indefinitely |

| | SPIRIT PRIME Clinical Trial | | SPIRIT III Clinical Trial | | SPIRIT IV Clinical Trial | SPIRIT Small Vessel Registry |
|---|---|---|---|--------------------------------------|---|--|
| | Core Size Registry | Long Lesion Registry | RCT (Pivotal) | 4.0 Arm (Registry) | | |
| Primary Endpoint •Primary Analysis •Major Secondary Analysis 1 •Major Secondary Analysis 2 | TLF (Target lesion failure) at 1 year •TLF (per ARC) at 1 year compared to PG* of 9.2% •TLF (per protocol) at 1 year compared to PG* of 9.2% •TLF (per ARC) at 1 year compared to PG* of 15.3% | TLF (Target Lesion failure) at 1 year •TLF (per ARC) at 1 year compared to PG* of 19.2% •TLF (per protocol) at 1 year compared to PG* of 19.2% •TLF (per ARC) at 1 year compared to PG* of 26% | In-segment late loss at 240 days | In-segment late loss at 240 days | TLF (Target Lesion failure) at 1 year | Clinically indicated target lesion failure at 1 year (composite of cardiac death, target vessel MI and clinically indicated TLR) |
| Co-Primary Endpoint | None | None | TVF (Target vessel Failure) at 270 days | None | None | None |
| Major Secondary Endpoint | None | None | None | None | • Ischemia-driven Target Lesion Revascularization (ID-TLR) at 1 year • Composite endpoint of cardiac death or target vessel MI at 1-year | None |
| Clinical Follow-up | 30, 180 days, 1 to 3 years | 30, 180 days, 1 to 3 years | 30, 180, 240, 270 days, 1 to 5 years | 30, 180, 240, 270 days, 1 to 5 years | 30, 180, 270 days, 1 to 3 years | 30 days, 240 days, 1 to 3 years |
| Status | One, 2, and 3 years reported | One, 2, and 3 years reported | One, 2, 3, 4, and 5 years reported | One, 2, 3, 4, and 5 years reported | One, 2, and 3 years reported | One, 2, and 3 years reported |

* Performance Goal (PG)

** In the TAXUS arm, there was 1 patient who received 1 TAXUS® Liberté® stent.

*** The 28 mm length stent was studied in the Core Size Registry. The results of the Core Size Registry are presented in Tables 9.1-2 to 9.1-3.

§ RVD ≥ 2.5 mm to ≤ 3.75 mm and stent sizes up to 3.5 mm until 4.0 mm TAXUS is commercially available

All subjects receiving a study stent were to be maintained on 75 mg of clopidogrel bisulfate daily for a minimum of 6 months, and per the American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI) guidelines it was strongly recommended that subjects should be treated with clopidogrel bisulfate up to 12 months if they are not at high risk for bleeding.

Table 7-2: XIENCE V USA Post-Approval Study Design

| | XIENCE V USA Phase I Cohort | XIENCE V USA Long-Term Follow-up Cohort | XIENCE V USA AV-DAPT Cohort |
|--|--|--|---|
| Study Type/Design | <ul style="list-style-type: none"> • Multicenter • Prospective | <ul style="list-style-type: none"> • Multicenter • Prospective | <ul style="list-style-type: none"> • Multicenter • Randomized • Double-blinded • Placebo Control |
| Number of Subjects Enrolled | Total: 8040 | Total: 4663 | Total: 868 |
| Treatment | Only XIENCE V EECSS implanted during the index procedure; otherwise per site standard care | Only XIENCE V EECSS implanted during the index procedure; otherwise per site standard care | Only XIENCE V EECSS implanted during the index procedure; otherwise per site standard care. At 1 year, patients were randomized to receive either thienopyridine or placebo treatment for additional 18 months along with aspirin |
| Lesion Size | No angiographic restrictions | No angiographic restrictions | No angiographic restrictions |
| Stent Sizes (XIENCE V) | Diameter: 2.5, 2.75, 3.0, 3.5, 4.0 mm Length: 8, 12, 15, 18, 23, 28 mm | Diameter: 2.5, 2.75, 3.0, 3.5, 4.0 mm Length: 8, 12, 15, 18, 23, 28 mm | Diameter: 2.5, 2.75, 3.0, 3.5, 4.0 mm Length: 8, 12, 15, 18, 23, 28 mm |
| Post-Procedure Antiplatelet Therapy | Per site standard | Per site standard | Patients were randomized to receive either thienopyridine or placebo treatment between 12 and 30 months. Thienopyridine or placebo will be discontinued between 30 and 33 months. Aspirin is required through 33 months. |
| Primary Endpoint | ARC definite and probable stent thrombosis up to 1 year | ARC definite and probable stent thrombosis from year 1 to 4 | MACE (composite of all death, MI and stroke) 12 – 33 months |
| Co-Primary Endpoint | Composite rate of cardiac death or any MI at 1 year | Composite rate of cardiac death or any MI from year 1 to 4 | ARC definite and probable ST 12 – 33 months |
| Major Safety Endpoint | None | None | Major bleeding (GUSTO severe and moderate bleeding combined) 12 – 33 months |
| Major Secondary Endpoint | None | None | None |
| Clinical Follow-up | 14, 30, 180 days, and 1 year | 2, 3, and 4 years | 15, 24, 30, and 33 months |
| Angiographic Follow-up | None | None | None |
| IVUS Follow-up | None | None | None |
| PK Study | None | None | None |
| Status | 1 year reported | Two, 3, and 4 years reported | 15, 24, 30, and 33 months reported |

8.0 ADVERSE EVENTS

8.1 Observed Adverse Events

Principal adverse event information is derived from the SPIRIT PRIME Core Size Registry, SPIRIT IV, SPIRIT III, and SPIRIT SV clinical trials and is shown in Table 8.1-1. Principal adverse events from the XIENCE V USA clinical trial are presented in Table 8.1-2. See also section 8.3 – *Adverse Events, Potential Adverse Events*. See section 9.0 – *SPIRIT Family of Clinical Trials* for more complete study design descriptions and results.

Note: Information on adverse events for subjects in the SPIRIT PRIME Long Lesion Registry is in Table 9.1-4.

**Table 8.1-1: SPIRIT Family:
Principal Adverse Events from Post-Procedure to Latest Follow-up**

| | SPIRIT PRIME | SPIRIT IV | | SPIRIT III (RCT) | | | SPIRIT SV |
|---|---|---------------------|------------------|--------------------|-----------------|------------------------------|----------------------------|
| | Core Size Registry ^s (N = 401) | XIENCE V (N = 2458) | TAXUS (N = 1229) | XIENCE V (N = 669) | TAXUS (N = 333) | XIENCE V 4.0 mm Arm (N = 73) | 2.25 mm XIENCE V (N = 144) |
| In Hospital Adverse Events | | | | | | | |
| TLF | 2.0% (8/401) | 1.4% (35/2451) | 1.9% (23/1224) | 0.9% (6/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| MACE | 2.0% (8/401) | 1.4% (35/2451) | 1.9% (23/1224) | 0.9% (6/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| TVF | NA | 1.5% (36/2451) | 2.0% (24/1224) | 0.9% (6/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| All Death | 0.0% (0/401) | 0.0% (0/2451) | 0.0% (0/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.0% (0/143) |
| Cardiac Death | 0.0% (0/401) | 0.0% (0/2451) | 0.0% (0/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.0% (0/143) |
| Non-Cardiac Death | 0.0% (0/401) | 0.0% (0/2451) | 0.0% (0/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.0% (0/143) |
| MI | 1.7% (7/401) | 1.4% (35/2451) | 1.8% (22/1224) | 0.7% (5/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| QMI | 0.2% (1/401) | 0.1% (3/2451) | 0.2% (2/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.7% (1/143) |
| NQMI | 1.5% (6/401) | 1.3% (32/2451) | 1.6% (20/1224) | 0.7% (5/669) | 1.8% (6/330) | 4.1% (3/73) | 0.7% (1/143) |
| Cardiac Death or MI | 1.7% (7/401) | 1.4% (35/2451) | 1.8% (22/1224) | 0.7% (5/669) | 1.8% (6/330) | 4.1% (3/73) | 1.4% (2/143) |
| Ischemia-Driven Revascularization | 0.5% (2/401) | 0.4% (9/2451) | 0.5% (6/1224) | 0.1% (1/669) | 0.0% (0/330) | 0.0% (0/73) | 0.7% (1/143) |
| Ischemia – Driven TLR | 0.2% (1/401) | 0.3% (8/2451) | 0.4% (5/1224) | 0.1% (1/669) | 0.0% (0/330) | 0.0% (0/73) | 0.0% (0/143) |
| Ischemia – Driven TVR, Non TL | 0.2% (1/401) | 0.1% (3/2451) | 0.2% (2/1224) | 0.0% (0/669) | 0.0% (0/330) | 0.0% (0/73) | 0.7% (1/143) |
| Stent Thrombosis (Per Protocol) | 0.5% (2/401) | 0.1% (3/2451) | 0.4% (5/1224) | 0.1% (1/669) | 0.0% (0/330) | 1.4% (1/73) | 0.0% (0/143) |
| 30-Day TLF | 2.2% (9/401) | 1.6% (38/2451) | 2.7% (33/1222) | 1.2% (8/667) | 2.1% (7/330) | 4.1% (3/73) | 2.1% (3/140) |
| 6-Month TLF ¹ | 3.8% (15/399) | 2.5% (62/2435) | 5.1% (62/1208) | 2.3% (15/663) | 4.3% (14/326) | 6.8% (5/73) | NA |
| 9-Month TLF ² | NA | 3.4% (83/2419) | 6.1% (73/1201) | 4.1% (27/657) | 7.8% (25/321) | 6.8% (5/73) | 7.2% (10/139) |
| 30-Day TVF | NA | 1.9% (46/2451) | 2.9% (36/1222) | 1.5% (10/667) | 2.7% (9/330) | 4.1% (3/73) | 2.9% (4/140) |
| 6-Month TVF | NA | 3.4% (82/2435) | 6.0% (73/1208) | 3.8% (25/663) | 4.9% (16/326) | 6.8% (5/73) | NA |
| 9-Month ⁵ TVF | NA | 4.6% (111/2419) | 7.1% (85/1201) | 7.2% (47/657) | 9.0% (29/321) | 6.8% (5/73) | 9.4% (13/139) |
| 1-Year Subject Counts of Adverse Events | | | | | | | |
| TLF ³ | 4.5% (18/399) | 4.0% (97/2416) | 6.8% (81/1195) | 5.2% (34/653) | 9.7% (31/320) | 6.8% (5/73) | 8.1% (11/136) |

| | SPiRiT PRIME | SPiRiT IV | | SPiRiT III (RCT) | | | SPiRiT SV |
|---|---|---------------------|------------------|--------------------|-----------------|------------------------------|----------------------------|
| | Core Size Registry [§] (N = 401) | XiENCE V (N = 2458) | TAXUS (N = 1229) | XiENCE V (N = 669) | TAXUS (N = 333) | XiENCE V 4.0 mm Arm (N = 73) | 2.25 mm XiENCE V (N = 144) |
| TVF | NA | 5.5% (134/2416) | 7.7% (92/1195) | 8.6% (56/653) | 11.3% (36/320) | 6.8% (5/73) | 11.0% (15/136) |
| All Death | 0.8% (3/399) | 1.0% (25/2416) | 1.3% (15/1195) | 1.2% (8/655) | 1.2% (4/321) | 1.4% (1/73) | 1.5% (2/136) |
| Cardiac Death | 0.3% (1/399) | 0.4% (10/2416) | 0.4% (5/1195) | 0.8% (5/655) | 0.9% (3/321) | 1.4% (1/73) | 1.5% (2/136) |
| Non-Cardiac Death | 0.5% (2/399) | 0.6% (15/2416) | 0.8% (10/1195) | 0.5% (3/655) | 0.3% (1/321) | 0.0% (0/73) | 0.0% (0/136) |
| All MI | 1.8% (7/399) | 1.9% (45/2416) | 3.1% (37/1195) | 2.8% (18/653) | 4.1% (13/320) | 4.1% (3/73) | 1.5% (2/136) |
| QMI | 0.3% (1/399) | 0.1% (3/2416) | 0.4% (5/1195) | 0.3% (2/653) | 0.3% (1/320) | 0.0% (0/73) | 0.7% (1/136) |
| NQMI | 1.5% (6/399) | 1.7% (42/2416) | 2.8% (33/1195) | 2.5% (16/653) | 3.8% (12/320) | 4.1% (3/73) | 0.7% (1/136) |
| Target Vessel MI | 1.8% (7/399) | 1.8% (44/2416) | 2.9% (35/1195) | NA | NA | NA | 1.5% (2/136) |
| Cardiac Death or all MI | 2.0% (8/399) | 2.2% (54/2416) | 3.3% (39/1195) | 3.4% (22/653) | 4.7% (15/320) | 5.5% (4/73) | 2.9% (4/136) |
| ID* TVR | 4.5% (18/399) | 3.9% (94/2416) | 5.9% (70/1195) | 6.1% (40/653) | 7.5% (24/320) | 2.7% (2/73) | 8.8% (12/136) |
| ID* TLR | 2.5% (10/399) | 2.5% (61/2416) | 4.6% (55/1195) | 3.4% (22/653) | 5.6% (18/320) | 2.7% (2/73) | 5.1% (7/136) |
| ID* Non-TLR TVR | 2.8% (11/399) | 2.3% (56/2416) | 3.1% (37/1195) | 3.1% (20/653) | 4.4% (14/320) | 0.0% (0/73) | 5.9% (8/136) |
| Protocol Defined Stent Thrombosis ⁴ | 0.5% (2/399) | 0.17% (4/2389) | 0.85% (10/1181) | 0.8% (5/647) | 0.6% (2/317) | 1.4% (1/72) | 2.2% (3/136) |
| ARC Definite+Probable Stent Thrombosis ⁴ | 0.5% (2/399) | 0.29% (7/2391) | 1.10% (13/1181) | 1.1% (7/652) | 0.6% (2/319) | 0.0% (0/72) | 1.5% (2/136) |
| ARC Definite Stent Thrombosis ⁴ | 0.5% (2/399) | 0.25% (6/2391) | 0.85% (10/1181) | 0.8% (5/652) | 0.0% (0/319) | 0.0% (0/72) | 0.7% (1/138) |
| 2-Year Subject Counts of Adverse Events | | | | | | | |
| TLF ³ | 6.4% (25/392) | 7.0% (167/2388) | 10.0% (119/1190) | 7.1% (45/637) | 12.8% (39/305) | 8.6% (6/70) | 8.3% (11/133) |
| TVF | NA | 9.6% (230/2388) | 11.8% (140/1190) | 11.3% (72/637) | 16.4% (50/305) | 10.0% (7/70) | 12.0% (16/133) |
| All Death | 2.0% (8/392) | 2.1% (51/2388) | 2.7% (32/1190) | 2.0% (13/642) | 2.6% (8/309) | 6.9% (5/72) | 1.5% (2/133) |
| Cardiac Death | 0.5% (2/392) | 0.9% (22/2388) | 1.3% (15/1190) | 1.1% (7/642) | 1.3% (4/309) | 2.8% (2/72) | 1.5% (2/133) |
| Vascular Death | 0.5% (2/392) | NA | NA | NA | NA | NA | NA |
| Non-Cardiac Death | 1.0% (4/392) | 1.2% (29/2388) | 1.4% (17/1190) | 0.9% (6/642) | 1.3% (4/309) | 4.2% (3/72) | 0.0% (0/133) |
| All MI | 2.0% (8/392) | 2.6% (61/2388) | 3.9% (47/1190) | 3.3% (21/637) | 5.9% (18/305) | 4.3% (3/70) | 1.5% (2/133) |
| QMI | 0.5% (2/392) | 0.1% (3/2388) | 0.8% (9/1190) | 0.5% (3/637) | 0.7% (2/305) | 0.0% (0/70) | 0.8% (1/133) |

| | SPiRiT PRIME | SPiRiT IV | | SPiRiT III (RCT) | | | SPiRiT SV |
|---|---|---------------------|------------------|--------------------|-----------------|------------------------------|----------------------------|
| | Core Size Registry [§] (N = 401) | XiENCE V (N = 2458) | TAXUS (N = 1229) | XiENCE V (N = 669) | TAXUS (N = 333) | XiENCE V 4.0 mm Arm (N = 73) | 2.25 mm XiENCE V (N = 144) |
| NQMI | 1.5% (6/392) | 2.4% (58/2388) | 3.4% (40/1190) | 2.8% (18/637) | 5.2% (16/305) | 4.3% (3/70) | 0.8% (1/133) |
| Target Vessel MI | 1.8% (7/392) | 2.3% (56/2388) | 3.5% (42/1190) | NA | NA | NA | 1.5% (2/133) |
| Cardiac Death or all MI | 2.6% (10/392) | 3.4% (82/2388) | 4.6% (55/1190) | 4.1% (26/637) | 6.9% (21/305) | 7.1% (5/70) | 3.0% (4/133) |
| ID* TVR | 6.9% (27/392) | 7.0% (168/2388) | 8.9% (106/1190) | 8.8% (56/637) | 11.1% (34/305) | 4.3% (3/70) | 9.8% (13/133) |
| ID* TLR | 4.1% (16/392) | 4.4% (106/2388) | 6.9% (82/1190) | 4.6% (29/637) | 7.5% (23/305) | 2.9% (2/70) | 5.3% (7/133) |
| ID* Non-TLR TVR | 4.3% (17/392) | 3.9% (94/2388) | 4.3% (51/1190) | 4.9% (31/637) | 6.6% (20/305) | 1.4% (1/70) | 6.8% (9/133) |
| 3-Year Subject Counts of Adverse Events | | | | | | | |
| TLF ³ | 8.5% (33/390) | 9.5% (223/2348) | 11.9% (138/1158) | 8.9% (56/629) | 15.1% (46/305) | 8.8% (6/68) | 12.1% (16/132) |
| TVF | NA | 13.3% (312/2348) | 14.5% (168/1158) | 14.3% (90/629) | 20.0% (61/305) | 11.8% (8/68) | 16.7% (22/132) |
| All Death | 3.1% (12/390) | 3.4% (81/2348) | 5.2% (60/1158) | 2.8% (18/636) | 4.5% (14/312) | 8.5% (6/71) | 3.8% (5/132) |
| Cardiac Death | 0.8% (3/390) | 1.4% (34/2348) | 1.9% (22/1158) | 1.6% (10/636) | 1.9% (6/312) | 2.8% (2/71) | 3.8% (5/132) |
| Vascular Death | 0.5% (2/390) | NA | NA | NA | NA | NA | NA |
| Non-Cardiac Death | 1.8% (7/390) | 2.0% (47/2348) | 3.3% (38/1158) | 1.3% (8/636) | 2.6% (8/312) | 5.6% (4/71) | 0.0% (0/132) |
| All MI | 3.1% (12/390) | 3.1% (73/2348) | 4.7% (55/1158) | 3.8% (24/629) | 6.6% (20/305) | 4.4% (3/68) | 1.5% (2/132) |
| QMI | 1.0% (4/390) | 0.3% (6/2348) | 0.9% (11/1158) | 0.5% (3/629) | 0.7% (2/305) | 0.0% (0/68) | 0.8% (1/132) |
| NQMI | 2.6% (10/390) | 2.9% (67/2348) | 4.0% (46/1158) | 3.3% (21/629) | 5.9% (18/305) | 4.4% (3/68) | 0.8% (1/132) |
| Target Vessel MI | 2.6% (10/390) | 2.8% (65/2348) | 4.1% (48/1158) | NA | NA | NA | 1.5% (2/132) |
| Cardiac Death or all MI | 3.8% (15/390) | 4.5% (105/2348) | 6.0% (70/1158) | 5.1% (32/629) | 8.2% (25/305) | 7.4% (5/68) | 5.3% (7/132) |
| ID* TVR | 9.5% (37/390) | 10.1% (238/2348) | 10.6% (123/1158) | 11.1% (70/629) | 14.8% (45/305) | 5.9% (4/68) | 12.1% (16/132) |
| ID* TLR | 5.4% (21/390) | 6.3% (148/2348) | 7.9% (92/1158) | 5.7% (36/629) | 9.2% (28/305) | 2.9% (2/68) | 6.8% (9/132) |
| ID* Non-TLR TVR | 5.9% (23/390) | 5.6% (132/2348) | 5.4% (63/1158) | 6.7% (42/629) | 8.9% (27/305) | 2.9% (2/68) | 8.3% (11/132) |
| 4-Year Subject Counts of Adverse Events | | | | | | | |
| TLF ³ | NA | NA | NA | 11.9% (73/615) | 17.2% (52/302) | 8.8% (6/68) | NA |
| TVF | NA | NA | NA | 18.5% (114/615) | 22.5% (68/302) | 11.8% (8/68) | NA |

| | SPiRiT PRIME | SPiRiT IV | | SPiRiT III (RCT) | | | SPiRiT SV |
|---|--|------------------------|---------------------|-----------------------|--------------------|---------------------------------|-------------------------------|
| | Core Size Registry [§] (N = 401) | XiENCE V (N = 2458) | TAXUS (N = 1229) | XiENCE V (N = 669) | TAXUS (N = 333) | XiENCE V 4.0 mm Arm (N = 73) | 2.25 mm XiENCE V (N = 144) |
| All Death | NA | NA | NA | 4.9% (31/628) | 6.1% (19/311) | 8.5% (6/71) | NA |
| Cardiac Death | NA | NA | NA | 2.5% (16/628) | 2.6% (8/311) | 2.8% (2/71) | NA |
| Non-Cardiac Death | NA | NA | NA | 2.4% (15/628) | 3.5% (11/311) | 5.6% (4/71) | NA |
| All MI | NA | NA | NA | 4.4% (27/615) | 6.6% (20/302) | 4.4% (3/68) | NA |
| QMI | NA | NA | NA | 1.0% (6/615) | 0.7% (2/302) | 0.0% (0/68) | NA |
| NQMI | NA | NA | NA | 3.4% (21/615) | 6.0% (18/302) | 4.4% (3/68) | NA |
| Target Vessel MI | NA | NA | NA | NA | NA | NA | NA |
| Cardiac Death or all MI | NA | NA | NA | 6.5% (40/615) | 8.9% (27/302) | 7.4% (5/68) | NA |
| ID* TVR | NA | NA | NA | 14.3% (88/615) | 16.6% (50/302) | 5.9% (4/68) | NA |
| ID* TLR | NA | NA | NA | 8.0% (49/615) | 10.6% (32/302) | 4.4% (3/68) | NA |
| ID* Non-TLR TVR | NA | NA | NA | 7.8% (48/615) | 9.6% (29/302) | 2.9% (2/68) | NA |
| 5-Year Subject Counts of Adverse Events | | | | | | | |
| 5-Year TLF ³ | NA | NA | NA | 13.4% (81/605) | 20.6% (59/286) | 10.4% (7/67) | NA |
| TVF | NA | NA | NA | 20.3% (123/605) | 26.6% (76/286) | 11.9% (8/67) | NA |
| All Death | NA | NA | NA | 6.0% (37/621) | 10.3% (31/300) | 8.6% (6/70) | NA |
| Cardiac Death | NA | NA | NA | 2.7% (17/621) | 4.3% (13/300) | 2.9% (2/70) | NA |
| Non-Cardiac Death | NA | NA | NA | 3.2% (20/621) | 6.0% (18/300) | 5.7% (4/70) | NA |
| All MI | NA | NA | NA | 4.6% (28/605) | 7.0% (20/286) | 4.5% (3/67) | NA |
| QMI | NA | NA | NA | 1.0% (6/605) | 0.7% (2/286) | 0.0% (0/67) | NA |
| NQMI | NA | NA | NA | 3.8% (23/605) | 6.3% (18/286) | 4.5% (3/67) | NA |
| Target Vessel MI | NA | NA | NA | NA | NA | NA | NA |
| Cardiac Death or all MI | NA | NA | NA | 7.1% (43/605) | 11.2% (32/286) | 7.5% (5/67) | NA |
| ID* TVR | NA | NA | NA | 15.7% (95/605) | 19.9% (57/286) | 6.0% (4/67) | NA |
| ID* TLR | NA | NA | NA | 8.9% (54/605) | 12.9% (37/286) | 4.5% (3/67) | NA |

| | SPIRIT PRIME | SPIRIT IV | | SPIRIT III (RCT) | | | SPIRIT SV |
|-----------------|--|------------------------|---------------------|-----------------------|--------------------|---------------------------------------|----------------------------------|
| | Core Size Registry [§] (N = 401) | XIENCE V (N = 2458) | TAXUS (N = 1229) | XIENCE V (N = 669) | TAXUS (N = 333) | XIENCE V 4.0 mm Arm (N = 73) | 2.25 mm XIENCE V (N = 144) |
| ID* Non-TLR TVR | NA | NA | NA | 8.8% (53/605) | 11.9% (34/286) | 3.0% (2/67) | NA |

Notes:

- Population for SPIRIT PRIME Core Size Registry consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8-hour post-index procedure and hospital discharge. SPIRIT III and IV based on intent-to-treat population (all subjects randomized, regardless of the treatment they actually received).
- In-hospital is defined as hospitalization less than or equal to 7-day post-index procedure.
- All counts presented in this table are subject counts. Subjects are counted only once for each event for each time period.
- This table includes revascularizations on any target vessel(s) / lesion(s) for subjects with two or more target vessels / lesions treated.
- One subject in the SPIRIT III, TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- TLF includes cardiac death, target vessel MI (per protocol definition) and ischemia-driven TLR. For SPIRIT III 4.0 mm arm, MACE (cardiac death, all MI [per protocol definition] and ischemia-driven TLR) is reported, as TLF was not an endpoint.
- SPIRIT SV based on full analysis set (FAS) population.
- For SPIRIT III, cardiac death is defined as the number of patients experiencing cardiac death through the follow-up time point / (the number of patients experiencing cardiac death through the follow-up time point + the number of patients followed through the follow-up time point without cardiac death + the number of patients terminated prior to the follow-up time point who did not experience cardiac death but experienced non-cardiac death, MI, ID or non-ID TLR, or ID or non-ID TVR).
- Deaths were adjudicated in SPIRIT PRIME as cardiac, vascular, and non-cardiovascular. SPIRIT III, IV, and SV adjudicated deaths as cardiac or non-cardiac.

¹ SPIRIT III and SPIRIT IV include 14-day window. SPIRIT PRIME includes 28-day window.

² SPIRIT III and SPIRIT IV includes 14-day window.

³ SPIRIT III, SPIRIT IV, and SPIRIT PRIME include 28-day window.

⁴ See section 8.2 – *Adverse Events, Stent Thrombosis Definitions*.

⁵ SPIRIT SV 8-month data are presented, as follow-up was not required at 9 months

[§] For Long Lesion Registry data, see Table 9.1-4.

* For SPIRIT PRIME, it is captured as clinically indicated (CI).

**Table 8.1-2: XIENCE V USA Post-Approval Study
Principal Adverse Events from Post-Procedure to 4 Years**

| | XIENCE V USA | | | | |
|--|------------------------|--------------------|--------------------|--------------------|------------------------|
| | XIENCE V (N = 8040) | | | | XIENCE V (N = 5020) |
| | In-Hospital | 30 Days | 6 Months | 1 Year | 4 Years |
| TLF | 2.7% (214/8001) | 3.5% (275/7963) | 6.2% (490/7854) | 9.4% (707/7522) | 19.3% (875/4530) |
| All Death | 0.02% (2/8001) | 0.4% (28/7963) | 1.4% (108/7854) | 2.6% (194/7522) | 10.9% (494/4530) |
| Cardiac Death | 0.01% (1/8001) | 0.3% (25/7963) | 0.9% (69/7854) | 1.4% (108/7522) | 5.4% (244/4530) |
| Vascular Death | 0.0% (0/8001) | 0.01% (1/7963) | 0.1% (6/7854) | 0.2% (12/7522) | 0.7% (32/4530) |
| Non-Cardiovascular Death | 0.01% (1/8001) | 0.03% (2/7963) | 0.4% (33/7854) | 1.0% (74/7522) | 4.8% (218/4530) |
| MI | 2.7% (216/8001) | 3.3% (266/7963) | 4.7% (372/7854) | 6.3% (475/7522) | 11.3% (511/4530) |
| QMI | 0.2% (18/8001) | 0.3% (25/7963) | 0.4% (30/7854) | 0.5% (39/7522) | 1.5% (68/4530) |
| NQMI | 2.5% (198/8001) | 3.0% (241/7963) | 4.4% (346/7854) | 5.9% (442/7522) | 10.1% (457/4530) |
| Cardiac Death or MI | 2.7% (216/8001) | 3.6% (286/7963) | 5.4% (422/7854) | 7.2% (545/7522) | 14.9% (676/4530) |
| Clinically Indicated Revascularization | 0.2% (17/8001) | 1.0% (81/7963) | 4.5% (352/7854) | 8.1% (607/7522) | 19.9% (901/4530) |
| Clinically Indicated TLR | 0.2% (13/8001) | 0.4% (30/7963) | 2.2% (173/7854) | 4.4% (330/7522) | 10.4% (473/4530) |
| Clinically Indicated TVR, Non TL | 0.02% (2/8001) | 0.2% (15/7963) | 1.0% (82/7854) | 2.1% (161/7522) | 6.1% (277/4530) |
| Stent Thrombosis (ARC Definite and Probable) | 0.11% (9/8000) | 0.40% (32/7951) | 0.58% (45/7790) | 0.81% (60/7380) | 1.56% (64/4093) |
| Stent Thrombosis (ARC Definite) | 0.11% (9/8000) | 0.23% (18/7951) | 0.35% (27/7790) | 0.54% (40/7380) | 1.05% (43/4093) |

Notes:

- In-hospital is defined as hospitalization less than or equal to 7 days post-index procedure.
- 30-day window is through 37 days (7-day window).
- 6-month window is through 194 days (14-day window).
- 1-year window is through 407 days (42-day window) or randomization date if occurred within 407 days for the second enrollment phase.
- 4-year window is through 1502 days (42-day window).
- All counts presented in this table are subject counts. Subjects are counted only once for each event for each time period.
- ARC MI definition was used for MI and MI related endpoints.
- TLF includes cardiac death, target vessel MI and clinically indicated TLR.

8.2 Stent Thrombosis Definitions

Protocol defined stent thrombosis (ST) was categorized as acute (< 1 day), subacute (1 – 30 days) and late (> 30 days) and was defined as any of the following⁶:

- Clinical presentation of acute coronary syndrome with angiographic evidence of stent thrombosis (angiographic appearance of thrombus within or adjacent to a previously treated target lesion)
- In the absence of angiography, any unexplained death, or acute MI (ST segment elevation or new Q-wave)⁷ in the distribution of the target lesion within 30 days

All stent thrombosis events were also classified using the ST definitions proposed by the Academic Research Consortium (ARC)⁸. This was performed by an independent event committee blinded to the treatment group of the individual subject. The committee categorized each incident of ST by timing and level of probability (definite, probable, possible), and relation to the original index procedure (primary, secondary after revascularization). These categories are defined as follows:

Timing:

- Early ST: 0 to 30 days post stent implantation
- Late ST: 31 days to 1 year post stent implantation
- Very late ST: > 1 year post stent implantation

Level of probability:

- Definite ST – considered to have occurred by either angiographic or pathologic confirmation
- Probable ST – considered to have occurred after intracoronary stenting in the following cases:
 1. Any unexplained death within the first 30 days
 2. Irrespective of the time after the index procedure, any MI which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause
- Possible ST – considered to have occurred with any unexplained death following 30 days after the intracoronary stenting until the end of trial follow-up⁹

8.3 Potential Adverse Events

Adverse events (in alphabetical order) which may be associated with percutaneous coronary and treatment procedures including coronary stent use in native coronary arteries include, but are not limited to:

- Abrupt closure
- Access site, hematoma, or hemorrhage
- Acute myocardial infarction

⁶ For SPIRIT FIRST Stent Thrombosis is defined as total occlusion by angiography at the stent site with abrupt onset of symptoms, elevated biochemical markers, and ECG changes consistent with MI.

⁷ Non-specific ST/T changes, and cardiac enzyme elevations do not suffice.

⁸ Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. *Circ* 2007;115:2344-51.

⁹ All data within these Instructions for Use are presented as definite+probable only.

-
- Allergic reaction or hypersensitivity to contrast agent or cobalt, chromium, nickel, tungsten, acrylic and fluoropolymers; and drug reactions to antiplatelet drugs or contrast agent
 - Aneurysm
 - Arterial perforation and injury to the coronary artery
 - Arterial rupture
 - Arteriovenous fistula
 - Arrhythmias, atrial and ventricular
 - Bleeding complications, which may require transfusion
 - Cardiac tamponade
 - Coronary artery spasm
 - Coronary or stent embolism
 - Coronary or stent thrombosis
 - Death
 - Dissection of the coronary artery
 - Distal emboli (air, tissue or thrombotic)
 - Emergent or non-emergent surgery
 - Fever
 - Hypotension and / or hypertension
 - Infection and pain at insertion site
 - Injury to the coronary artery
 - Ischemia (myocardial)
 - Myocardial infarction (MI)
 - Nausea and vomiting
 - Palpitations
 - Peripheral ischemia (due to vascular injury)
 - Pseudoaneurysm
 - Renal failure
 - Restenosis of the stented segment of the artery
 - Shock / pulmonary edema
 - Stroke / cerebrovascular accident (CVA)
 - Total occlusion of coronary artery
 - Unstable or stable angina pectoris
 - Vascular complications including at the entry site which may require vessel repair
 - Vessel dissection

Zortress the oral formulation of everolimus developed by Novartis Pharmaceuticals Corporation, has been evaluated in clinical trials and is approved in the United States for the prevention of organ rejection in adult kidney transplant recipients at the dose of 1.5 mg/day.

Outside the U.S., Zortress is sold under the brand name, Certican, in more than 70 countries. Everolimus is also approved in the United States under the name of Afinitor for patients with advanced renal cell carcinoma (cancer), after failure of treatment with sunitinib or sorafenib, at doses of 5 to 20 mg/day when taken by mouth. The following list includes the known risks of everolimus at the oral doses listed above:

- Abdominal pain (including upper abdominal pain)
- Anemia
- Angioedema

-
- Anorexia
 - Asthenia
 - Constipation
 - Cough
 - Delayed wound healing / fluid accumulation
 - Diarrhea
 - Dyslipidemia (including hyperlipidemia and hypercholesterolemia)
 - Dysgeusia
 - Dyspepsia
 - Dyspnea
 - Dysuria
 - Dry skin
 - Edema (peripheral)
 - Epistaxis
 - Fatigue
 - Headache
 - Hematuria
 - Hyperglycemia (may include new onset of diabetes)
 - Hyperkalemia
 - Hyperlipidemia
 - Hypertension
 - Hypokalemia
 - Hypomagnesemia
 - Hypophosphatemia
 - Increased serum creatinine
 - Infections and serious infections: bacterial, viral, fungal, and protozoal infections (may include herpes virus infection, polyoma virus infection which may be associated with BK virus associated nephropathy, and / or other opportunistic infections)
 - Insomnia
 - Interaction with strong inhibitors and inducers of CYP3A4 or PgP
 - Leukopenia
 - Lymphoma and other malignancies (including skin cancer)
 - Male infertility (azospermia and / or oligospermia)
 - Mucosal inflammation (including oral ulceration and oral mucositis)
 - Nausea
 - Neutropenia
 - Non-infectious pneumonitis
 - Pain: extremity, incision site and procedural, back, chest, musculoskeletal
 - Proteinuria
 - Pruritus
 - Pyrexia
 - Rash
 - Stomatitis
 - Thrombocytopenia
 - Thrombotic microangiopathy (TMA) / Thrombotic thrombocytopenic purpura (TTP) / Hemolytic uremic syndrome (HUS)
 - Tremor
 - Upper respiratory tract infection

-
- Urinary tract infection
 - Vomiting

Live vaccines should be avoided and close contact with those that have had live vaccines should be avoided. Fetal harm can occur when administered to a pregnant woman. There may be other potential adverse events that are unforeseen at this time.

9.0 SPIRIT FAMILY OF CLINICAL TRIALS

The SPIRIT PRIME clinical trial was conducted to demonstrate the safety and effectiveness of the XIENCE PRIME family of stent systems. Given the substantial similarities between the XIENCE PRIME and XIENCE V stent systems, clinical trials previously conducted on the XIENCE V stent are also relevant and included below.

9.1 SPIRIT PRIME Clinical Trial

The SPIRIT PRIME clinical trial was designed to demonstrate the safety and effectiveness of the XIENCE PRIME family of stent systems. This global trial consists of two separate arms, the Core Size Registry and the Long Lesion Registry. One-year results are presented here.

Primary Objective: The objective of the SPIRIT PRIME clinical trial is to evaluate the safety and effectiveness of the XIENCE PRIME family of stent systems in improving coronary luminal diameter in subjects with symptomatic heart disease due to a maximum of two *de novo* native coronary artery lesions, each in a different epicardial vessel.

Design: The SPIRIT PRIME clinical trial is a prospective, nonrandomized, open-label, multicenter study consisting of two separate arms, the Core Size Registry (stent diameters 2.25, 2.5, 3.0, 3.5, 4.0 mm with stent lengths 8, 18, and 28¹⁰ mm) and the Long Lesion Registry (stent diameters, 2.5, 3.0, 3.5, 4.0 mm with stent lengths 33 and 38 mm) in approximately 500 subjects at up to 75 global sites. For clinical trial design purposes, the 28 mm length stent is included in the Core Size Registry because the historical data on XIENCE V used to develop the comparative performance goal includes stent lengths up to 28 mm. The Long Lesion Registry only includes subjects with at least one 33 and 38 mm length stents as there were limited data on these stent lengths from which to develop a comparative performance goal.

Each subject was to receive treatment in up to two *de novo* native coronary lesions, each lesion in a different epicardial vessel. Subjects in the Core Size Registry were allowed to have: one target lesion treated with the core size XIENCE PRIME stent systems (stent diameters 2.25 – 4.0 mm with stent lengths 8, 18, 28 mm) or two target lesions in separate epicardial vessels, treated with two core size XIENCE PRIME stent systems (stent diameters 2.25 – 4.0 mm with stent lengths 8, 18, 28 mm).

Subjects in the Long Lesion Registry were allowed to have: one target lesion treated with the XIENCE PRIME stent system (stent diameters 2.5 – 4.0 mm with stent lengths 33 or 38 mm) or two target lesions in separate epicardial vessels, treated with two XIENCE PRIME stent system (stent diameters 2.5 – 4.0 mm with stent lengths 33 or 38 mm) or one XIENCE PRIME stent system (stent diameters 2.5 – 4.0 mm with stent lengths 33 or 38 mm) and one XIENCE PRIME stent system (stent diameters 2.25 – 4.0 mm with stent lengths 8, 18, 28 mm). All subjects in the

¹⁰ The 28 mm length stent was studied in the XIENCE PRIME Core Size Registry. The results of the Core Size Registry are presented in Tables 9.1-2 to 9.1-3.

Long Lesion Registry were required to be treated with at least one XIENCE PRIME stent of 33 or 38 mm in length. For both the Core Size Registry and Long Lesion Registry, planned overlap was not allowed; however, overlap was allowed in case of bailout stenting.

The primary endpoint is target lesion failure (TLF) at one year, a composite endpoint of cardiac death, target vessel myocardial infarction (TV-MI), and clinically indicated target lesion revascularization (CI-TLR). The primary endpoint rates of TLF at 1 year (per protocol and per ARC definitions) were compared to a set of pre-specified performance goals (PGs) for both Core Size Registry and Long Lesion Registry as shown below.

The PG for the Core Size Registry was developed utilizing historical data from the SPIRIT III trial, while the PG for the Long Lesion Registry was developed based on a regression analysis conducted on the historical data from the pooled SPIRIT II and III trials. Although the SPIRIT PRIME trial defined TLF based on the ARC definition of MI, the historical SPIRIT II and III trials used to develop the initial PG were based on the per protocol definition of MI. In order to provide a comparison of outcomes using the same definitions for both the treatment arms and PGs, two subsequent analyses, with PGs developed using the same definitions (per protocol and per ARC), were developed and are presented in rows 2 and 3 of the table below.

Table 9.1-1: Analyses of the Primary Endpoint

| TLF Primary Endpoint | Core Size Registry* Performance Goal | Long Lesion Registry** Performance Goal |
|--|---|--|
| TLF Cardiac Death, <i>ARC-Defined TV-MI,</i> CI-TLR | 9.2% ¹ | 19.2% ¹ |
| TLF Cardiac Death, <i>Protocol-Defined TV-MI,</i> CI-TLR | 9.2% ¹ | 19.2% ¹ |
| TLF Cardiac Death, <i>ARC-Defined TV-MI,</i> CI-TLR | 15.3% ² | 26.0% ² |

¹ Performance goal developed based on per protocol-defined MI.

² Performance goal developed based on per ARC-defined MI.

* The Core Size Registry includes 2.25 – 4.0 mm stent diameters, 8, 18, 28 mm lengths

** The Long Lesion Registry includes 2.5 – 4.0 mm stent diameters, 33 and 38 mm stent lengths

Demographics: In the Core Size Registry, the mean age was 62.70 ± 10.23 years, 70.3% (282/401) were male, 29.7% (119/401) were female and 92.3% (346/375) were white. The average body mass index (BMI) was 30.86 ± 5.83 kg/m² and 50.3% (192/382) of subjects were obese, with a BMI ≥ 30. Regarding medical risk factors in the Core Size Registry, 19.2% (77/401) were tobacco users, 76.6% (307/401) were hypertensive requiring medication, and 80.3% (322/401) were hypercholesterolemic requiring medication. There were 11.1% (44/397) of subjects having had a prior cardiac intervention on the target vessel and 23.0% (91/395) had a prior MI. In addition, there were 45.6% (183/401) of subjects with stable angina and 24.9% (100/401) of subjects with unstable angina. Furthermore, the Core Size Registry consisted of 34.9% (140/401) diabetics, 29.9% (120/401) diabetics requiring medication and 3.5% (14/401) diabetics requiring diet and exercise only.

In the Long Lesion Registry, the mean age was 63.46 ± 9.44 years, 62.5% (65/104) were male, 37.5% (39/104) were female and 91.7% (88/96) were white. The average body mass index (BMI) was 30.67 ± 5.84 kg/m², and 49.5% (50/101) of subjects were obese, with a BMI ≥ 30 . Regarding medical risk factors in the Long Lesion Registry, 26.9% (28/104) were tobacco users, 75.0% (78/104) were hypertensive requiring medication, and 80.8% (84/104) were hypercholesterolemic requiring medication. There were 11.8% (12/102) of subjects having had a prior cardiac intervention on the target vessel and 22.5% (23/102) had a prior MI. In addition, there were 49.0% (51/104) of subjects with stable angina and 23.1% (24/104) of subjects with unstable angina. Furthermore, the Long Lesion Registry consisted of 35.6% (37/104) diabetics, 31.7% (33/104) diabetics requiring medication and 1.9% (2/104) diabetics requiring diet and exercise only.

Results: The results are presented in Table 9.1-2 to Table 9.1-4. These analyses are based on the Full Analysis Set (FAS). The FAS population is defined as subjects who have received at least one of the following: the core size XIENCE PRIME stent system (stent diameters 2.25 – 4.0 mm with stent lengths 8, 18, 28 mm) or the XIENCE PRIME LL stent system (stent diameters 2.5 – 4.0 mm with stent lengths 33 or 38 mm), including bailout. SPIRIT PRIME Core Size and Long Lesion Registries met all pre-specified PGs with statistical significance. The observed TLF rate at one year was 4.5% (18/399) (per protocol-defined MI) and 6.5% (26/399) (per ARC-defined MI) in the Core Size Registry, and 7.7% (8/104) (per protocol-defined MI) and 12.5% (13/104) (per ARC-defined MI) in the Long Lesion Registry. At the three-year follow-up visit, the follow-up rate for the CSR was 377 (94.0%) and 99 (95.2%) for the LLR. At 3 years, the observed TLF rate was 8.5% (33/390) (per protocol-defined MI) and 10.8% (42/390) (per ARC-defined MI) in the Core Size Registry, and 9.6% (10/104) (per protocol-defined MI) and 14.4% (15/104) (per ARC-defined MI) in the Long Lesion Registry.

Table 9.1-2: SPIRIT PRIME Primary Endpoint Results

| Core Size Registry* | XIENCE PRIME (N = 401) | Performance Goal | p-value¹ |
|---|-----------------------------------|-----------------------------|----------------------------|
| 1 Year TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 6.5% (26/399) | 9.2% [§] | 0.0338 |
| 1 Year TLF Cardiac Death, <i>Protocol-Defined TV-MI</i> , CI-TLR | 4.5% (18/399) | 9.2% [§] | 0.0003 |
| 1 Year TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 6.5% (26/399) | 15.3% [#] | < 0.0001 |
| Long Lesion Registry** | XIENCE PRIME (N = 104) | Performance Goal | p-value¹ |
| 1 Year TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 12.5% (13/104) | 19.2% [§] | 0.0484 |
| 1 Year TLF Cardiac Death, <i>Protocol-Defined TV-MI</i> , CI-TLR | 7.7% (8/104) | 19.2% [§] | 0.0009 |
| 1 Year TLF Cardiac Death, <i>ARC-Defined TV-MI</i> , CI-TLR | 12.5% (13/104) | 26.0% [#] | 0.0006 |

Notes:

- N is the total number of subjects.
- Population for SPIRIT PRIME consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8-hour post-index procedure and hospital discharge.
- TLF includes cardiac death, target vessel MI and clinically indicated TLR.
- Time frame includes follow-up window (365 + 28 days).

¹ One-sided p-value against pre-specified performed goals, to be compared at a 0.05 significance level.

[§] Performance Goal developed based on per protocol-defined MI.

[#] Performance Goal developed based on per ARC-defined MI.

* The Core Size Registry includes 2.25 – 4.0 mm stent diameters, 8, 18, 28 mm lengths

** The Long Lesion Registry includes 2.5 – 4.0 mm stent diameters, 33 and 38 mm stent lengths.

Table 9.1-3: SPIRIT PRIME Core Size Registry Clinical Results*

| | Outcomes at 3 Years Core Size Registry* (N = 401) |
|---|--|
| Composite Effectiveness and Safety | |
| TLF (per protocol) | 8.5% (33/390) |
| TLF (per ARC) | 10.8% (42/390) |
| Effectiveness | |
| CI-TLR | 5.4% (21/390) |
| CI-TLR, CABG | 1.0% (4/390) |
| CI-TLR, PCI | 4.6% (18/390) |
| CI-TVR | 9.5% (37/390) |
| Safety | |
| All Death | 3.1% (12/390) |
| Cardiac Death | 0.8% (3/390) |
| Vascular Death | 0.5% (2/390) |
| Non-Cardiac Death | 1.8% (7/390) |
| Target Vessel MI (per protocol) | 2.6% (10/390) |
| Target Vessel QMI (per protocol) | 0.3% (1/390) |
| Target Vessel NQMI (per protocol) | 2.3% (9/390) |
| All MI (per protocol) | 3.1% (12/390) |
| QMI (per protocol) | 1.0% (4/390) |
| NQMI (per protocol) | 2.6% (10/390) |
| Target Vessel MI (per ARC) | 6.2% (24/390) |
| Target Vessel QMI (per ARC) | 0.3% (1/390) |
| Target Vessel NQMI (per ARC) | 5.9% (23/390) |
| All MI (per ARC) | 7.9% (31/390) |
| QMI (per ARC) | 1.0% (4/390) |
| NQMI (per ARC) | 7.4% (29/390) |
| Cardiac Death or All protocol MI | 3.8% (15/390) |
| Cardiac Death or All ARC MI | 8.7% (34/390) |
| ARC Definite+Probable Stent Thrombosis | |
| Cumulative through 3 years | 0.8% (3/380) |
| Acute/Subacute (0 – 30 days) | 0.5% (2/401) |
| Late (31 days – 1 year) | 0.0% (0/399) |
| Very Late (1 – 3 years) | 0.3% (1/379) |

Notes:

- TLF is defined as a hierarchical composite of cardiac death, Target Vessel MI, and clinically indicated TLR.
- Population for SPIRIT PRIME Core Size Registry consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8-hour post-index procedure and hospital discharge.
- ARC: Academic Research Consortium

* The Core Size Registry includes 2.25 – 4.0 mm stent diameters, 8, 18, 28 mm lengths

Table 9.1-4: SPIRIT PRIME Long Lesion Registry Clinical Results

| | Outcomes at 3 Years Long Lesion Registry* (N = 104) |
|---|--|
| Composite Effectiveness and Safety | |
| TLF (per protocol) | 9.6% (10/104) |
| TLF (per ARC) | 14.4% (15/104) |
| Effectiveness | |
| CI-TLR | 4.8% (5/104) |
| CI-TLR, CABG | 1.0% (1/104) |
| CI-TLR, PCI | 4.8% (5/104) |
| CI-TVR | 7.7% (8/104) |
| Safety | |
| All Death | 2.9% (3/104) |
| Cardiac Death | 0.0% (0/104) |
| Vascular Death | 0.0% (0/104) |
| Non-Cardiac Death | 2.9% (3/104) |
| Target Vessel MI (per protocol) | 4.8% (5/104) |
| Target Vessel QMI (per protocol) | 1.9% (2/104) |
| Target Vessel NQMI (per protocol) | 2.9% (3/104) |
| All MI (per protocol) | 5.8% (6/104) |
| QMI (per protocol) | 2.9% (3/104) |
| NQMI (per protocol) | 3.8% (4/104) |
| Target Vessel MI (per ARC) | 10.6% (11/104) |
| Target Vessel QMI (per ARC) | 1.9% (2/104) |
| Target Vessel NQMI (per ARC) | 8.7% (9/104) |
| All MI (per ARC) | 11.5% (12/104) |
| QMI (per ARC) | 2.9% (3/104) |
| NQMI (per ARC) | 9.6% (10/104) |
| Cardiac Death or All protocol MI | 5.8% (6/104) |
| Cardiac Death or All ARC MI | 11.5% (12/104) |
| ARC Definite+Probable Stent Thrombosis | |
| Cumulative through 3 years | 0.0% (0/99) |
| Acute/Subacute (0 – 30 days) | 0.0% (0/104) |
| Late (31 days – 1 year) | 0.0% (0/104) |
| Very Late (1–3 years) | 0.0% (0/99) |

Notes:

- TLF is defined as a hierarchical composite of cardiac death, Target Vessel MI, and clinically indicated TLR.
- Population for SPIRIT PRIME Core Size Registry consists of those subjects who were treated with at least one XIENCE PRIME stent and had cardiac enzyme data between 8-hour post-index procedure and hospital discharge.
- ARC: Academic Research Consortium

* The Long Lesion Registry includes 2.5 – 4.0 mm stent diameters, 33 and 38 mm stent lengths

Study Strengths and Limitations: The SPIRIT PRIME study was a prospective, open-label, multicenter study with two separate arms. All event adjudications were performed by an independent Clinical Event Committee (CEC) with 100% site-reported adjudicable events being source-verified. The study provides important information on the clinical outcomes in patients with long lesions and demonstrates the safety and effectiveness of both the core size and

33 mm and 38 mm XIENCE PRIME stents. The study is limited by being a small study with no head-to-head comparison with other DES platforms. In addition, due to the small population size, subgroup analysis can at best be considered exploratory.

9.2 SPIRIT III Pivotal Clinical Trial

SPIRIT III, a pivotal clinical trial, was designed to demonstrate the non-inferiority of the XIENCE V stent to the TAXUS Express Stent (TAXUS stent) and was conducted in the United States (US) and Japan. The SPIRIT III clinical trial consists of a US randomized clinical trial (RCT), a nonrandomized 4.0 mm diameter stent arm in the US, and a nonrandomized arm in Japan, which included a pharmacokinetic substudy. Enrollment is complete in the RCT, the 4.0 mm diameter stent arm, and the Japan arm.

The SPIRIT III clinical trial included a pharmacokinetic substudy in a subject subset derived from the RCT¹¹ and Japan nonrandomized arm (see section 6.2 – *Drug Information, Pharmacokinetics*). Eleven sites in the US and 9 sites in Japan participated in this substudy and have enrolled 34 subjects (17 subjects in the US and 17 subjects in Japan). Venous blood was drawn at regular intervals for pharmacokinetics analysis of total blood everolimus level at pre-determined sites.

9.2.1 SPIRIT III Randomized Clinical Trial (RCT)

Primary Objective: The objective of the SPIRIT III RCT was to demonstrate the non-inferiority in in-segment late loss at 240 days and target vessel failure at 270 days of the XIENCE V stent compared to the TAXUS stent in the treatment of up to two *de novo* lesions ≤ 28 mm in length in native coronary arteries with a reference vessel diameter (RVD) ≥ 2.5 mm to ≤ 3.75 mm.

Design: The SPIRIT III RCT was a prospective, 2:1 (XIENCE V:TAXUS) randomized, active-controlled, single-blinded, parallel, multicenter non-inferiority evaluation of the XIENCE V stent compared to the TAXUS stent in the treatment of up to two *de novo* lesions ≤ 28 mm in length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 3.75 mm. Given the available XIENCE V stent lengths of 8, 18 and 28 mm for this trial, in the XIENCE V arm, treatment of a target lesion > 22 mm and ≤ 28 mm in length was accomplished by planned overlap of either two 18 mm stents or a 28 mm and an 8 mm stent (see section 5.3 – *Precautions, Multiple Stent Use*). In the TAXUS arm, overlap was only permitted for bailout or to ensure adequate lesion coverage. The RCT was designed to enroll 1,002 subjects at up to 80 sites in the United States.

If non-inferiority of the primary endpoint of in-segment late loss was demonstrated, it was pre-specified that testing for superiority could be conducted.

All subjects had clinical follow-up at 30, 180, and 270 days and annually from 1 to 5 years. A pre-specified subgroup of 564 subjects had angiographic follow-up at 240 days. Of these 564, 240 subjects had IVUS at baseline and 240 days. Subjects that received a bailout stent also had IVUS at baseline and angiographic and IVUS follow-up at 240 days.

Following the index procedure, all subjects were to be maintained on clopidogrel bisulfate daily for a minimum of 6 months and aspirin daily to be taken throughout the length of the trial (5 years).

¹¹ Includes one subject from the 4.0 mm nonrandomized arm.

Demographics: The mean age was 63.2 years for the XIENCE V arm and 62.8 for the TAXUS arm. The XIENCE V arm had 70.1% (469/669) males and the TAXUS arm had 65.7% (218/332) males. The XIENCE V arm had 32.3% (215/666) of subjects with prior cardiac interventions and the TAXUS arm had 29.5% (98/332). The XIENCE V arm had 29.6% (198/669) of subjects with a history of diabetes and the TAXUS arm had 27.9% (92/330). The XIENCE V arm had 15.4% (103/669) of subjects with a lesion treated in two vessels and TAXUS had 15.4% (51/332). The XIENCE V arm had 8.1% (54/669) of subjects with planned stent overlap. The XIENCE V arm had 8.6% (57/666) of subjects with a history of prior CABG while the TAXUS arm had 3.6% (12/332) ($p = 0.0033$). The XIENCE V arm had 18.7% (123/657) of subjects with a history of unstable angina while the TAXUS arm had 25.1% (82/327) ($p = 0.0243$). The remaining subject baseline clinical features were well-matched between the XIENCE V arm and the TAXUS arm.

Results: The results are presented in Table 9.2.1-1: SPIRIT III RCT Primary Endpoint Results, Table 9.2.1-2: SPIRIT III RCT Clinical Results, Table 9.2.1-3: SPIRIT III 8-Month Angiographic and IVUS Results, Figure 9.2.1-1: SPIRIT III: Kaplan Meier Time-to-Event Curve for Target Vessel Failure through 5 Years and Table 9.2.1-4: SPIRIT III RCT ARC-Defined Definite+Probable Stent Thrombosis through 5 Years. These analyses are based on the intent-to-treat population.

The co-primary endpoint of in-segment late loss at 240 days was met with measurements of 0.14 ± 0.41 mm (301) for the XIENCE V arm and 0.28 ± 0.48 mm (134) for the TAXUS arm ($p < 0.0001$ for non-inferiority). In a pre-specified analysis, the XIENCE V stent was shown to be superior to the TAXUS stent with respect to in-segment late loss at 240 days ($p = 0.0037$).

The co-primary endpoint of ischemia-driven TVF through 284 days was met with rates of 7.6% (50/660) for the XIENCE V arm and 9.7% (31/320) for the TAXUS arm ($p < 0.0001$ for non-inferiority).

Table 9.2.1-1: SPIRIT III RCT Primary Endpoint Results

| Measurements | XIENCE V (N = 669) (M = 376) | TAXUS (N = 333) (M = 188) | Difference [95% CI] | Non- Inferiority p-value | Superiority p-value |
|--|------------------------------------|---------------------------------|--|--------------------------------|------------------------|
| 8-Month¹ Late Loss, In-Segment (mm) | 0.14 ± 0.41 (301) | 0.28 ± 0.48 (134) | -0.14 [-0.23, -0.05] ² | < 0.0001 ³ | 0.0037 ⁴ |
| 9-Month⁵ Target Vessel Failure⁶ | 7.2% (47/657) | 9.0% (29/321) | -1.88% [-5.58%, 1.82%] ² | < 0.0001 ⁷ | Not Pre-specified |

Notes:

- N is the total number of subjects; M is the total number of analysis lesions for the angiographic group.
- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- Analysis results include 9-month events identified at the 9-month follow-up.
- ¹ 8-month time frame includes follow-up window (240 + 28 days).
- ² By normal approximation.
- ³ One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 0.195 mm, to be compared at a 0.025 significance level.
- ⁴ Two-sided p-value by superiority test using two-sample T-test, to be compared at a 0.05 significance level.
- ⁵ 9-month time frame includes follow-up window (270 + 14 days).
- ⁶ TVF is defined as hierarchical composite of cardiac death, MI, ischemia-driven TLR and ischemia-driven non-TLR TVR.
- ⁷ One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 5.5%, to be compared at a 0.05 significance level.

Table 9.2.1-2: SPIRIT III RCT Clinical Results

| | Outcomes at 9 Months | | | Outcomes at 5 Years (latest available follow-up) | | |
|--------------------------------------|-----------------------|--------------------|-------------------------------------|---|--------------------|-------------------------------------|
| | XIENCE V (N = 669) | TAXUS (N = 333) | Difference [95% CI] ¹ | XIENCE V (N = 669) | TAXUS (N = 333) | Difference [95% CI] ¹ |
| Composite Efficacy and Safety | | | | | | |
| TVF ² | 7.2% (47/657) | 9.0% (29/321) | -2.11% [-5.93%, 1.71%] | 20.3% (123/605) | 26.6% (76/286) | -6.24% [-12.28%, -0.20%] |
| MACE ³ | 4.6% (30/657) | 8.1% (26/321) | -3.75% [-7.26%, -0.24%] | 14.4% (87/605) | 22.0% (63/286) | -7.65% [-13.21%, -2.09%] |
| Efficacy | | | | | | |
| Ischemia-Driven TLR | 2.6% (17/657) | 5.0% (16/321) | -2.40% [-5.07%, 0.28%] | 8.9% (54/605) | 12.9% (37/286) | -4.01% [-8.52%, 0.49%] |
| TLR, CABG | 0.2% (1/657) | 0.0% (0/321) | 0.15% [Assump. not met] | 1.0% (6/605) | 1.0% (3/286) | -0.06% [Assump. not met] |
| TLR, PCI | 2.4% (16/657) | 5.0% (16/321) | -2.55% [-5.21%, 0.11%] | 8.3% (50/605) | 11.9% (34/286) | -3.62% [-7.97%, 0.72%] |
| Ischemia-Driven TVR, Non TL | 3.0% (20/657) | 4.0% (13/321) | -1.01% [-3.53%, 1.52%] | 8.8% (53/605) | 11.9% (34/286) | -3.13% [-7.50%, 1.25%] |
| Non-TLR TVR, CABG | 0.5% (3/657) | 0.6% (2/321) | -0.17% [Assump. not met] | 1.8% (11/605) | 2.4% (7/286) | -0.63% [-2.71%, 1.45%] |
| Non-TLR TVR, PCI | 2.6% (17/657) | 3.4% (11/321) | -0.84% [-3.17%, 1.49%] | 6.9% (42/605) | 9.8% (28/286) | -2.85% [-6.84%, 1.15%] |
| Safety | | | | | | |
| All Death | 0.9% (6/658) | 0.9% (3/322) | -0.02% [Assump. not met] | 6.0% (37/621) | 10.3% (31/300) | -4.38% [-8.29%, -0.46%] |
| Cardiac Death | 0.5% (3/658) | 0.6% (2/322) | -0.17% [Assump. not met] | 2.7% (17/621) | 4.3% (13/300) | -1.60% [-4.23%, 1.04%] |
| Non-Cardiac Death | 0.5% (3/658) | 0.3% (1/322) | 0.15% [Assump. not met] | 3.2% (20/621) | 6.0% (18/300) | -2.78% [-5.80%, 0.25%] |
| MI | 2.0% (13/657) | 2.5% (8/321) | -0.51% [-2.52%, 1.50%] | 4.6% (28/605) | 7.0% (20/286) | -2.36% [-5.76%, 1.03%] |
| QMI | 0.2% (1/657) | 0.0% (0/321) | 0.15% [Assump. not met] | 1.0% (6/605) | 0.7% (2/286) | 0.29% [Assump. not met] |
| NQMI | 1.8% (12/657) | 2.5% (8/321) | -0.67% [-2.65%, 1.32%] | 3.8% (23/605) | 6.3% (18/286) | -2.49% [-5.69%, 0.71%] |
| Cardiac Death or MI | 2.4% (16/657) | 3.1% (10/321) | -0.68% [-2.92%, 1.56%] | 7.1% (43/605) | 11.2% (32/286) | -4.08% [-8.27%, 0.11%] |
| Stent Thrombosis – Protocol Defined | 0.5% (3/654) | 0.0% (0/320) | 0.46% [Assump. not met] | 1.7% (10/583) | 2.2% (6/269) | -0.52% [-2.57%, 1.54%] |
| Acute (< 1 day) | 0.0% (0/669) | 0.0% (0/330) | 0.00% [Assump. not met] | 0.1% (1/669) | 0.0% (0/330) | 0.15% [Assump. not met] |
| Subacute (1 – 30 days) | 0.3% (2/667) | 0.0% (0/330) | 0.30% [Assump. not met] | 0.3% (2/667) | 0.0% (0/330) | 0.30% [Assump. not met] |
| Late (> 30 days) | 0.2% (1/653) | 0.0% (0/320) | 0.15% [Assump. not met] | 1.2% (7/582) | 2.2% (6/269) | -1.03% [-3.00%, 0.95%] |
| Stent Thrombosis – ARC Definite | 0.8% (5/652) | 0.0% (0/319) | 0.77% [Assump. not met] | 1.2% (7/582) | 0.7% (2/268) | 0.46% [Assump. not met] |

Notes:

- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 9-month and 5-year time frames include follow-up window (270 +14 days and 1825 + 28 days, respectively).
- “Assump. not met” means that the assumption of normal approximation was not met due to small sample size or frequency of events.
- Cardiac death is defined as the number of patients experiencing cardiac death through the follow-up time point / (the number of patients experiencing cardiac death through the follow-up time point + the number of patients followed through the follow-up time point without cardiac death + the number of patients terminated prior to the follow-up time point who did not experience cardiac death but experienced non-cardiac death, MI, ID or non-ID TLR, or ID or non-ID TVR).

¹ Confidence Interval was calculated using the normal approximation, not adjusted for multiplicity, and is meant for descriptive purposes only.

² TVF is defined as a hierarchical composite of cardiac death, MI, ischemic-driven TLR and ischemic-driven non-TLR TVR.

³ MACE is defined as a hierarchical composite of cardiac death, MI, ischemic-driven TLR.

Table 9.2.1-3: SPIRIT III 8-Month Angiographic and IVUS Results


| | XIENCE V (N = 376) (M _{ANGIO} = 427) (M _{IVUS} = 181) | TAXUS (N = 188) (M _{ANGIO} = 220) (M _{IVUS} = 93) | Difference [95% CI] ¹ |
|--------------------------------------|--|--|-------------------------------------|
| Angiographic Results | | | |
| In-Stent MLD | | | |
| Post-Procedure | 2.71 ± 0.43 (425) | 2.74 ± 0.40 (220) | -0.03 [-0.10, 0.04] |
| 8 Months | 2.56 ± 0.53 (343) | 2.45 ± 0.65 (158) | 0.11 [-0.01, 0.23] |
| In-Segment MLD | | | |
| Post-Procedure | 2.35 ± 0.44 (426) | 2.36 ± 0.45 (220) | -0.01 [-0.08, 0.06] |
| 8 Months | 2.22 ± 0.53 (344) | 2.12 ± 0.60 (158) | 0.10 [-0.01, 0.21] |
| In-Stent %DS | | | |
| Post-Procedure | 0.32 ± 8.86 (424) | -0.78 ± 10.65 (220) | 1.10 [-0.55, 2.74] |
| 8 Months | 5.92 ± 16.40 (343) | 10.30 ± 21.43 (158) | -4.38 [-8.16, -0.60] |
| In-Segment %DS | | | |
| Post-Procedure | 13.89 ± 8.04 (425) | 13.92 ± 7.20 (220) | -0.03 [-1.26, 1.19] |
| 8 Months | 18.77 ± 14.43 (344) | 22.82 ± 16.35 (158) | -4.05 [-7.03, -1.06] |
| Late Loss | | | |
| In-Stent | 0.16 ± 0.41 (342) | 0.30 ± 0.53 (158) | -0.15 [-0.24, -0.05] |
| In-Segment | 0.14 ± 0.39 (343) | 0.26 ± 0.46 (158) | -0.13 [-0.21, -0.04] |
| Binary Restenosis | | | |
| In-Stent | 2.3% (8/343) | 5.7% (9/158) | -3.36% [-7.32%, 0.59%] |
| In-Segment | 4.7% (16/344) | 8.9% (14/158) | -4.21% [-9.17%, 0.75%] |
| IVUS Results | | | |
| Neointimal Volume (mm ³) | 10.13 ± 11.46 (101) | 20.87 ± 13.51 (41) | -10.74 [-20.92, -0.56] |
| % Volume Obstruction | 6.91 ± 6.35 (98) | 11.21 ± 9.86 (39) | -4.30 [-7.72, -0.88] |
| Incomplete Apposition | | | |
| Post-Procedure | 34.4% (31/90) | 25.6% (11/43) | 8.86% [-7.46%, 25.19%] |
| 8 Months | 25.6% (23/90) | 16.3% (7/43) | 9.28% [-4.97%, 23.52%] |
| Persistent | 24.4% (22/90) | 14.0% (6/43) | 10.49% [-3.15%, 24.13%] |
| Late Acquired | 1.1% (1/90) | 2.3% (1/43) | -1.21% [Assump. not met] |

Notes:

- N is the total number of subjects; MANGIO is the total number of lesions in the protocol required angiographic cohort and MIVUS is the total number of lesions in the protocol required IVUS cohort.
- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 8-month time frame includes follow-up window (240 + 28 days).
- "Assump. not met" means that the assumption of normal approximation was not met due to small sample size or frequency of events.

¹ Confidence Interval was calculated using the normal approximation, not adjusted for multiplicity, and is meant for descriptive purposes only.

Figure 9.2.1-1: SPIRIT III: Kaplan Meier Time-to-Event Curve for Target Vessel Failure through 5 Years



| TVF | Event Free | Event Rate | p-value [†] |
|----------|------------|------------|----------------------|
| XIENCE V | 80.7% | 19.3% | 0.0549 |
| TAXUS | 75.5% | 24.5% | |

Note:

– Time frame includes follow-up window (1825 + 28 days).

[†]p-value based on log rank and not adjusted for multiple comparisons

Table 9.2.1-4: SPIRIT III RCT ARC-Defined Definite+Probable Stent Thrombosis through 5 Years

| | XIENCE V (N = 669) | TAXUS (N = 333) | Difference [95% CI]¹ |
|---|-------------------------------|----------------------------|--|
| ARC Definite+Probable Stent Thrombosis (0 days – 5 years) | 1.5% (9/582) | 1.9% (5/268) | -0.32% [-2.22%, 1.59%] |
| Acute (< 1 day) | 0.1% (1/669) | 0.0% (0/330) | 0.15% [Assump. not met] |
| Subacute (1 – 30 days) | 0.3% (2/667) | 0.0% (0/330) | 0.30% [Assump. not met] |
| Late (31 days – 1 year) | 0.5% (3/649) | 0.6% (2/317) | -0.17% [Assump. not met] |
| Very Late (> 1 years) | 0.5% (3/580) | 1.1% (3/267) | -0.61% [Assump. not met] |

Notes:

- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- Time frame includes follow-up window (1825 + 28 days).
- "Assump. not met" means that assumption of the normal approximation was not met due to small sample size or frequency of events.

¹ Confidence Interval was calculated using the normal approximation, not adjusted for multiplicity, and is meant for descriptive purposes only.

9.2.2 Dual Vessel Treatment in SPIRIT III

Subjects requiring treatment in more than one vessel comprise a subgroup that is at increased risk for cardiovascular events compared with single vessel disease patients. Subjects requiring both single and dual vessel treatment were included in the SPIRIT III trial; however, there were no pre-specified hypotheses for these patient subgroups.

Table 9.2.2-1 shows the clinical outcomes through 9 months and 5 years in single vessel and dual vessel treated subjects from a post-hoc analysis of SPIRIT III. The number of vessels treated was one of the stratification factors used in the randomization to assure a balance between the XIENCE V and TAXUS treatment arms.

Table 9.2.2-1: Clinical Results in Single and Dual Vessel Treatment through 5 Years (SPIRIT III RCT)

| | 9 Months | | | | 5 Years | | | |
|-----------------------------|----------------------------------|-------------------------------|--------------------------------|----------------------------|----------------------------------|-------------------------------|--------------------------------|----------------------------|
| | Single Vessel XIENCE V (N = 566) | Single Vessel TAXUS (N = 281) | Dual Vessel XIENCE V (N = 103) | Dual Vessel TAXUS (N = 51) | Single Vessel XIENCE V (N = 566) | Single Vessel TAXUS (N = 281) | Dual Vessel XIENCE V (N = 103) | Dual Vessel TAXUS (N = 51) |
| TVF | 6.3% (35/556) | 7.0% (19/271) | 11.9% (12/101) | 20.0% (10/50) | 18.0% (92/510) | 22.9% (55/240) | 32.6% (31/95) | 45.7% (21/46) |
| Ischemia-Driven TLR | 2.3% (13/556) | 4.1% (11/271) | 4.0% (4/101) | 10.0% (5/50) | 8.4% (43/510) | 11.3% (27/240) | 11.6% (11/95) | 21.7% (10/46) |
| Ischemia-Driven TVR, Non TL | 2.7% (15/556) | 2.2% (6/271) | 5.0% (5/101) | 14.0% (7/50) | 6.7% (34/510) | 8.8% (21/240) | 20.0% (19/95) | 28.3% (13/46) |
| All Death | 1.1% (6/557) | 0.4% (1/271) | 0.0% (0/101) | 3.9% (2/51) | 6.1% (32/523) | 9.9% (25/252) | 5.1% (5/98) | 12.5% (6/48) |
| Cardiac Death | 0.5% (3/557) | 0.4% (1/271) | 0.0% (0/101) | 2.0% (1/51) | 2.9% (15/523) | 4.0% (10/252) | 2.0% (2/98) | 6.3% (3/48) |
| Non-Cardiac Death | 0.5% (3/557) | 0.0% (0/271) | 0.0% (0/101) | 2.0% (1/51) | 3.3% (17/523) | 6.0% (15/252) | 3.1% (3/98) | 6.3% (3/48) |
| MI | 1.6% (9/556) | 1.5% (4/271) | 4.0% (4/101) | 8.0% (4/50) | 3.7% (19/510) | 4.6% (11/240) | 9.5% (9/95) | 19.6% (9/46) |
| Cardiac Death or MI | 2.2% (12/556) | 1.8% (5/271) | 4.0% (4/101) | 10.0% (5/50) | 6.5% (33/510) | 8.8% (21/240) | 10.5% (10/95) | 23.9% (11/46) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.4% (2/553) | 0.0% (0/271) | 1.0% (1/101) | 0.0% (0/49) | 1.2% (6/490) | 1.8% (4/226) | 4.3% (4/93) | 4.7% (2/43) |
| ARC Definite+Probable | 0.7% (4/554) | 0.0% (0/271) | 2.0% (2/101) | 0.0% (0/49) | 0.8% (4/488) | 1.3% (3/225) | 5.3% (5/94) | 4.7% (2/43) |
| ARC Definite | 0.4% (2/554) | 0.0% (0/271) | 2.0% (2/101) | 0.0% (0/49) | 0.6% (3/488) | 0.4% (1/225) | 4.3% (4/94) | 2.3% (1/43) |

Note:

- Cardiac death is defined as the number of patients experiencing cardiac death through the follow-up time point / (the number of patients experiencing cardiac death through the follow-up time point + the number of patients followed through the follow-up time point without cardiac death + the number of patients terminated prior to the follow-up time point who did not experience cardiac death but experienced non-cardiac death, MI, ID or non-ID TLR, or ID or non-ID TVR).

9.2.3 SPIRIT III US 4.0 mm Arm

Primary Objective: The objective of the SPIRIT III 4.0 mm arm was to demonstrate the non-inferiority in in-segment late loss at 240 days of the XIENCE V 4.0 mm stent in the treatment of *de novo* lesions with RVD 3.75 to 4.25 mm, compared to the TAXUS arm from the SPIRIT III RCT.

Design: The SPIRIT III 4.0 mm study was a prospective, single-arm, multicenter clinical trial in the United States evaluating the 4.0 mm diameter XIENCE V stent in *de novo* native coronary artery lesions ≤ 28 mm in length with a RVD > 3.75 mm to ≤ 4.25 mm. Seventy-three (73) subjects were enrolled in the SPIRIT III 4.0 mm study arm. For early demonstration of efficacy (in-segment late loss at 240 days), an interim analysis was performed after 69 of the enrolled subjects had completed their scheduled follow-up and after unblinding of the SPIRIT III RCT.

All subjects had clinical follow-up at 30, 180, 240, and 270 days, and annually from 1 to 5 years. In addition, all subjects had angiographic follow-up at 240 days. IVUS was performed for subjects who received a bailout stent at baseline and 240 days.

Following the index procedure, all subjects were to be maintained on clopidogrel bisulfate daily for a minimum of 6 months and aspirin daily to be taken throughout the length of the trial (5 years).

Demographics: The mean age in the SPIRIT III 4.0 arm was 61.9 years with 72.5% (50/69) male, 21.7% (15/69) had prior cardiac interventions, and 30.4% (21/69) had a history of diabetes.

Results: The results are presented in Table 9.2.3-1: SPIRIT III 4.0 mm Primary Endpoint Result, Table 9.2.3-2: SPIRIT III 4.0 mm Clinical Results, Table 9.2.3-3: SPIRIT III 4.0 mm 8-month Angiographic Results, and Table 9.2.3-4: SPIRIT III 4.0 mm ARC-Defined Stent Thrombosis through 5 years. These analyses were performed on the intent-to-treat population. Although SPIRIT III allowed treatment of two separate epicardial vessels, all subjects in the SPIRIT III 4.0 arm had only one vessel treated. The 5-year follow-up rate for the SPIRIT III 4.0 mm arm was 87.7% (64/73).

The primary endpoint of in-segment late loss at 240 days was met with measurements of 0.17 ± 0.38 mm (49 analysis lesions) for the XIENCE V 4.0 mm arm and 0.28 ± 0.48 mm (134 analysis lesions) for the TAXUS arm from the SPIRIT III RCT ($p < 0.0001$ for non-inferiority).

Table 9.2.3-1: SPIRIT III 4.0 mm Primary Endpoint Result

| Measurements | XIENCE V (M = 69) | TAXUS (M = 188) | Difference [95% CI] | Non- Inferiority p-value |
|---|----------------------|-----------------------|---------------------------------------|--------------------------------|
| 8-Month Late Loss, In-Segment (mm) | 0.17 ± 0.38 (49) | 0.28 ± 0.48 (134) | -0.11 [-0.24, 0.03] ¹ | < 0.0001 ² |

Notes:

- M is the total number of analysis lesions.
- One subject in the SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- Time frame includes follow-up window (240 + 28 days).

¹ By normal approximation.

² One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 0.195 mm, to be compared at a 0.038 significance level.

Table 9.2.3-2: SPIRIT III 4.0 mm Clinical Results

| | Outcomes at 9 Months XIENCE V (N = 73) | Outcomes at 5 Years (Final Follow-up) XIENCE V (N = 73) | Outcomes at 5 Years (Final Follow-up) TAXUS RCT (N = 333) |
|--------------------------------------|--|--|--|
| Composite Efficacy and Safety | | | |
| TVF ¹ | 6.8% (5/73) | 11.9% (8/67) | 26.6% (76/286) |
| MACE ² | 6.8% (5/73) | 10.4% (7/67) | 22.0% (63/286) |
| Efficacy | | | |
| Ischemia-Driven TLR | 2.7% (2/73) | 4.5% (3/67) | 12.9% (37/286) |
| TLR, CABG | 0.0% (0/73) | 0.0% (0/67) | 1.0% (3/286) |
| TLR, PCI | 2.7% (2/73) | 4.5% (3/67) | 11.9% (34/286) |
| Ischemia-Driven TVR, Non TL | 0.0% (0/73) | 3.0% (2/67) | 11.9% (34/286) |
| Non-TLR TVR, CABG | 0.0% (0/73) | 0.0% (0/67) | 2.4% (7/286) |
| Non-TLR TVR, PCI | 0.0% (0/73) | 3.0% (2/67) | 9.8% (28/286) |
| Safety | | | |
| All Death | 1.4% (1/73) | 8.6% (6/70) | 10.3% (31/300) |
| Cardiac Death | 1.4% (1/73) | 2.9% (2/70) | 4.3% (13/300) |
| Non-Cardiac Death | 0.0% (0/73) | 5.7% (4/70) | 6.0% (18/300) |
| MI | 4.1% (3/73) | 4.5% (3/67) | 7.0% (20/286) |
| QMI | 0.0% (0/73) | 0.0% (0/67) | 0.7% (2/286) |
| NQMI | 4.1% (3/73) | 4.5% (3/67) | 6.3% (18/286) |
| Cardiac Death or MI | 5.5% (4/73) | 7.5% (5/67) | 11.2% (32/286) |
| Stent Thrombosis – Protocol Defined | 1.4% (1/72) | 3.1% (2/65) | 2.2% (6/269) |
| Acute (≤ 1 day) | 1.4% (1/73) | 1.4% (1/73) | 0.0% (0/330) |
| Subacute (>1 – 30 days) | 0.0% (0/73) | 0.0% (0/73) | 0.0% (0/330) |
| Late (> 30 days) | 0.0% (0/72) | 1.5% (1/65) | 2.2% (6/269) |
| Stent Thrombosis – ARC Definite | 0.0% (0/72) | 0.0% (0/64) | 0.8% (2/268) |

Notes:

- 9-month and 5-year time frames include follow-up window (270 +14 days and 1825 + 28 days, respectively).
- Cardiac death is defined as the number of patients experiencing cardiac death through the follow-up time point / (the number of patients experiencing cardiac death through the follow-up time point + the number of patients followed through the follow-up time point without cardiac death + the number of patients terminated prior to the follow-up time point who did not experience cardiac death but experienced non-cardiac death, MI, ID or non-ID TLR, or ID or non-ID TVR).

¹ TVF is defined as a hierarchical composite of cardiac death, MI, ischemic-driven TLR and ischemic-driven non-TLR TVR.

² MACE is defined as a hierarchical composite of cardiac death, MI, ischemic-driven TLR.

Table 9.2.3-3: SPIRIT III 4.0 mm 8-Month Angiographic Results

| | XIENCE V (N = 69) (M = 69) |
|-----------------------------|---|
| Angiographic Results | |
| In-Stent MLD | |
| Post-Procedure | 3.46 ± 0.38 (69) |
| 8 Months | 3.36 ± 0.46 (49) |
| In-Segment MLD | |
| Post-Procedure | 3.07 ± 0.43 (69) |
| 8 Months | 2.91 ± 0.51 (49) |
| In-Stent %DS | |
| Post-Procedure | 2.12 ± 10.27 (69) |
| 8 Months | 4.78 ± 13.20 (49) |
| In-Segment %DS | |
| Post-Procedure | 13.42 ± 8.08 (69) |
| 8 Months | 17.92 ± 10.83 (49) |
| Late Loss | |
| In-Stent | 0.12 ± 0.34 (49) |
| In-Segment | 0.17 ± 0.38 (49) |
| Binary Restenosis | |
| In-Stent | 0.0% (0/49) |
| In-Segment | 2.0% (1/49) |

Notes:

- N is the total number of subjects; M is the total number of lesions at baseline.
- 8-month time frame includes follow-up window (240 + 28 days).

Table 9.2.3-4: SPIRIT III 4.0 mm ARC-Defined Stent Thrombosis through 5 Years

| | XIENCE V (N = 73) |
|--|------------------------------|
| ARC Definite+Probable Stent Thrombosis (0 days – 5 years) | 0.0% (0/64) |
| Acute (≤ 1 day) | 0.0% (0/73) |
| Subacute (>1 – 30 days) | 0.0% (0/73) |
| Late (31 days – 1 year) | 0.0% (0/72) |
| Very Late (>1 year) | 0.0% (0/64) |
| ARC Definite Stent Thrombosis (0 days – 5 years) | 0.0% (0/64) |

Note:

- Time frame includes follow-up window (1825 + 28 days).

9.3 SPIRIT IV Clinical Trial

The SPIRIT IV clinical study was designed to confirm the safety and efficacy of the XIENCE V stent when compared to the TAXUS Express stent¹² (TAXUS stent). This randomized controlled trial (RCT) was conducted in the United States (US).

9.3.1 SPIRIT IV Randomized Clinical Trial

Primary Objective: The objective of the SPIRIT IV clinical trial was to determine the safety and effectiveness of the XIENCE V stent for the treatment of subjects with up to three *de novo* coronary artery lesions (maximum of two lesions per epicardial vessel).

Design: The SPIRIT IV clinical trial was a prospective, 2:1 randomized (XIENCE V:TAXUS), active-controlled, single-blinded, multicenter evaluation of the XIENCE V stent compared to the TAXUS stent in the treatment of up to three *de novo* lesions ≤ 28 mm in length in native coronary arteries with RVD ≥ 2.5 mm to ≤ 4.25 mm. Subjects were stratified by diabetes mellitus (diabetic vs. non-diabetic) and lesion characteristics (complex vs. non-complex). Complex lesion characteristics included triple vessel treatment, or dual lesions per vessel treatment, or lesions involving RCA-aorto-ostial locations, or bifurcations lesions. The SPIRIT IV clinical trial was designed to enroll 3,690 subjects at up to 80 sites in the US.

The primary endpoint was target lesion failure (TLF) at 1 year. The major secondary endpoints were ischemia-driven TLR at 1 year and the composite of cardiac death or target vessel MI at 1 year. Formal non-inferiority and superiority testing were planned for the primary and the two major secondary endpoints. To control the familywise Type I error rate, all non-inferiority and superiority hypotheses were tested following a fixed sequence.

The XIENCE V stents used in the SPIRIT IV trial included stents 2.5, 3.0, and 3.5 mm in diameter, and 8, 18 and 28 mm in length. In the XIENCE V arm, treatment of target lesions > 22 mm and ≤ 28 mm in length was accomplished by overlapping either two 18 mm stents or a 28 mm and an 8 mm stent (see section 5.3 – *Precautions, Multiple Stent Use*). In the TAXUS arm, the treatment strategy for lesions > 22 mm and ≤ 28 mm was recommended to be in accordance to the TAXUS Directions for Use (DFU) at the time of enrollment; these lesions were treated with single 32 mm TAXUS stent or planned overlapping TAXUS stents.

Subjects were evaluated at 30, 180, and 270 days following the index procedure. Follow-up has been performed through 3 years, completing the trial.

According to the guidelines from the American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI), following the index procedure, all subjects were to be maintained on 75 mg clopidogrel bisulfate daily for 12 months if subjects were not at high risk for bleeding and ≥ 80 mg of aspirin daily throughout the length of the trial (3 years).

Demographics: The mean age was 63.3 years for both the XIENCE V arm and the TAXUS arm. The XIENCE V arm had 67.7% (1665/2458) males and the TAXUS arm had 67.8% (833/1229) males. The XIENCE V arm had 31.5% (772/2450) of subjects with prior cardiac interventions and the TAXUS arm had 30.7% (376/1224). The XIENCE V arm had 32.0%

¹² Of the 1,229 subjects enrolled in the TAXUS arm, 1 subject received one TAXUS Liberté stent.

(786/2455) of subjects with a history of diabetes and the TAXUS arm had 32.5% (399/1228). The XIENCE V arm had 24.8% (609/2458) of subjects with two or more lesions treated and TAXUS had 25.3% (311/1229). The XIENCE V arm had 9.7% (239/2458) of subjects with planned stent overlap. The TAXUS arm had 8.1% (99/1229)¹³ of subjects with planned stent overlap and 4.5% (55/1229) of subjects treated with single 32 mm TAXUS stent only. The XIENCE V arm had 27.7% (669/2416) of subjects with a history of unstable angina while the TAXUS arm had 28.9% (347/1202). The remaining subject baseline clinical features were well-matched between the XIENCE V arm and the TAXUS arm.

Results: The results are presented in Table 9.3.1-1: SPIRIT IV Primary and Major Secondary Endpoint Results, Table 9.3.1-2: SPIRIT IV Clinical Results through 3 Years, Figure 9.3.1-1: SPIRIT IV: Kaplan Meier Time-to-Event Curve for TLF through 3 Years, Figure 9.3.1-2: SPIRIT IV: Kaplan Meier Time-to-Event Curve for ID-TLR through 3 Years, and Figure 9.3.1-3: SPIRIT IV: Kaplan Meier Time-to-Event Curve for Cardiac Death or Target Vessel MI through 3 Years. These analyses are based on the intent-to-treat population. At the three-year visit, the follow-up rate for the XIENCE V arm was 91.8% (2257) and 89.1% (1095) for the TAXUS arm.

Primary Endpoint Analysis (Table 9.3.1-1): The primary endpoint was met with TLF rates at 1 year of 4.0% (97/2416) for the XIENCE V arm and 6.8% (81/1195) for the TAXUS arm ($p < 0.0001$ for non-inferiority). In a pre-specified analysis, the XIENCE V stent was shown to be superior to the TAXUS stent in terms of the primary endpoint of TLF at 1 year ($p_{\text{Sup}} = 0.0004$).

Major Secondary Endpoint Analysis (Table 9.3.1-1): The major secondary endpoint of ID-TLR was shown to be statistically non-inferior for the XIENCE V stent compared to the TAXUS stent. The ID-TLR rate through 1 year was 2.3% (56/2416) for the XIENCE V arm and 4.6% (55/1195) for the TAXUS arm ($p < 0.0001$ for non-inferiority). The XIENCE V arm also showed non-inferiority to the TAXUS arm in terms of the composite endpoint of cardiac death or target vessel MI with rates of 2.2% (53/2416) for the XIENCE V arm and 3.2% (38/1195) for the TAXUS arm ($p < 0.0001$ for non-inferiority).

In a pre-specified analysis, the XIENCE V stent was shown to be superior to the TAXUS stent in terms of ID-TLR at 1 year ($p_{\text{Sup}} = 0.0003$). The rate of composite of cardiac death or target vessel MI was numerically lower in patients treated with the XIENCE V EECSS compared to the TAXUS PECSS ($p_{\text{Sup}} = 0.09$).

¹³ Includes 6 patients who received planned overlapping TAXUS stents as well as single 32 mm TAXUS stent in two different lesions.

Table 9.3.1-1: SPIRIT IV Primary and Major Secondary Endpoint Results

| Primary Endpoint | XIENCE V (N = 2458) | TAXUS (N = 1229) | Difference [Upper 1-Sided 97.5% CL] | Non-Inferiority p-value | Superiority p-value |
|---|------------------------|---------------------|--|----------------------------|------------------------|
| 1 Year TLF | 4.0% (97/2416) | 6.8% (81/1195) | -2.76% [-1.14%] ¹ | < 0.0001 ² | 0.0004 ³ |
| Major Secondary Endpoints | XIENCE V (N = 2458) | TAXUS (N = 1229) | Difference [Upper 1-Sided 95% CL] | Non-Inferiority p-value | Superiority p-value |
| 1 Year ID-TLR | 2.3% (56/2416) | 4.6% (55/1195) | -2.28% [-1.17%] ¹ | < 0.0001 ⁴ | 0.0003 ³ |
| 1 Year Cardiac Death or Target Vessel MI | 2.2% (53/2416) | 3.2% (38/1195) | -0.99% [-0.02%] ¹ | < 0.0001 ⁴ | 0.09 ³ |

Notes:

- N is the total number of subjects.
- TLF includes cardiac death, target vessel MI (per protocol definition) and ischemia-driven TLR.
- Time frame includes follow-up window (365 + 28 days).

¹ By normal approximation.

² One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 3.1%, to be compared at a 0.025 significance level.

³ Two-sided p-value by superiority test using Fisher's exact test, to be compared at a 0.05 significance level.

⁴ One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 2.1%, to be compared at a 0.05 significance level.

Table 9.3.1-2: SPIRIT IV Clinical Results through 3 Years


| | Outcomes at 1 Year | | | Outcomes at 3 Years (final follow-up) | | |
|--|------------------------|---------------------|-------------------------------------|--|---------------------|-------------------------------------|
| | XIENCE V (N = 2458) | TAXUS (N = 1229) | Difference [95% CI] ¹ | XIENCE V (N = 2458) | TAXUS (N = 1229) | Difference [95% CI] ¹ |
| Composite Efficacy and Safety | | | | | | |
| TLF | 4.0% (97/2416) | 6.8% (81/1195) | -2.76% [-4.39%, -1.14%] | 9.5% (223/2348) | 11.9% (138/1158) | -2.42% [-4.63%, -0.21%] |
| TVF | 5.5% (134/2416) | 7.7% (92/1195) | -2.15% [-3.92%, -0.39%] | 13.3% (312/2348) | 14.5% (168/1158) | -1.22% [-3.67%, 1.23%] |
| Efficacy | | | | | | |
| Ischemia-Driven TLR | 2.3% (56/2416) | 4.6% (55/1195) | -2.28% [-3.62%, -0.95%] | 6.3% (148/2348) | 7.9% (92/1158) | -1.64% [-3.48%, 0.20%] |
| TLR, CABG | 0.4% (9/2416) | 0.4% (5/1195) | -0.05% [-0.49%, 0.39%] | 0.8% (18/2348) | 0.9% (10/1158) | -0.10% [-0.74%, 0.54%] |
| TLR, PCI | 2.0% (48/2416) | 4.3% (51/1195) | -2.28% [-3.56%, -1.01%] | 5.7% (134/2348) | 7.5% (87/1158) | -1.81% [-3.59%, -0.02%] |
| Ischemia-Driven TVR | 3.8% (93/2416) | 5.7% (68/1195) | -1.84% [-3.36%, -0.32%] | 10.1% (238/2348) | 10.6% (123/1158) | -0.49% [-2.64%, 1.67%] |
| Safety | | | | | | |
| All Death | 1.0% (25/2416) | 1.3% (15/1195) | -0.22% [-0.97%, 0.53%] | 3.4% (81/2348) | 5.2% (60/1158) | -1.73% [-3.21%, -0.26%] |
| Cardiac Death | 0.4% (10/2416) | 0.4% (5/1195) | -0.00% [-0.45%, 0.44%] | 1.4% (34/2348) | 1.9% (22/1158) | -0.45% [-1.37%, 0.47%] |
| Non-Cardiac Death | 0.6% (15/2416) | 0.8% (10/1195) | -0.22% [-0.82%, 0.39%] | 2.0% (47/2348) | 3.3% (38/1158) | -1.28% [-2.45%, -0.11%] |
| Target Vessel MI | 1.8% (44/2416) | 2.9% (35/1195) | -1.11% [-2.20%, -0.01%] | 2.8% (65/2348) | 4.1% (48/1158) | -1.38% [-2.70%, -0.05%] |
| Cardiac Death or Target Vessel MI | 2.2% (53/2416) | 3.2% (38/1195) | -0.99% [-2.14%, 0.17%] | 4.1% (97/2348) | 5.5% (64/1158) | -1.40% [-2.94%, 0.15%] |
| All MI | 1.9% (45/2416) | 3.1% (37/1195) | -1.23% [-2.35%, -0.11%] | 3.1% (73/2348) | 4.7% (55/1158) | -1.64% [-3.05%, -0.23%] |
| QMI | 0.1% (3/2416) | 0.4% (5/1195) | -0.29% [Assump. not met] | 0.3% (6/2348) | 0.9% (11/1158) | -0.69% [-1.29%, -0.10%] |
| NQMI | 1.7% (42/2416) | 2.8% (33/1195) | -1.02% [-2.09%, 0.04%] | 2.9% (67/2348) | 4.0% (46/1158) | -1.12% [-2.43%, 0.19%] |
| Cardiac Death or MI | 2.2% (54/2416) | 3.3% (39/1195) | -1.03% [-2.20%, 0.14%] | 4.5% (105/2348) | 6.0% (70/1158) | -1.57% [-3.18%, 0.03%] |
| Protocol Defined Stent Thrombosis (Cumulative) | 0.17% (4/2389) | 0.85% (10/1181) | -0.68% [Assump. not met] | 0.79% (18/2266) | 1.99% (22/1104) | -1.20% [-2.10%, -0.30%] |
| Acute/Subacute (0 – 30 days) | 0.12% (3/2451) | 0.57% (7/1221) | -0.45% [Assump. not met] | 0.12% (3/2451) | 0.57% (7/1221) | -0.45% [Assump. not met] |
| Late (> 30 days) | 0.04% (1/2389) | 0.34% (4/1181) | -0.30% [Assump. not met] | 0.62% (14/2265) | 1.45% (16/1103) | -0.83% [-1.61%, -0.06%] |
| ARC Definite+Probable Stent Thrombosis (Cumulative) | 0.29% (7/2391) | 1.10% (13/1181) | -0.81% [-1.44%, -0.17%] | 0.62% (14/2263) | 1.73% (19/1098) | -1.11% [-1.95%, -0.28%] |
| Early (0 – 30 days) | 0.16% (4/2451) | 0.74% (9/1221) | -0.57% [Assump. not met] | 0.16% (4/2451) | 0.74% (9/1221) | -0.57% [Assump. not met] |
| Late (31 days – 1 year) | 0.13% (3/2391) | 0.42% (5/1181) | -0.30% [Assump. not met] | 0.13% (3/2385) | 0.42% (5/1183) | -0.30% [Assump. not met] |
| Very late (> 1 year) | - | - | - | 0.31% (7/2260) | 0.55% (6/1095) | -0.24% [-0.73%, 0.26%] |
| ARC Definite Stent Thrombosis (Cumulative) | 0.25% (6/2391) | 0.85% (10/1181) | -0.60% [-1.16%, -0.04%] | 0.49% (11/2263) | 1.28% (14/1098) | -0.79% [-1.51%, -0.07%] |

Notes:

- 1-year and 3-year time frames include follow-up window (365 + 28 days and 1095 ± 28 days, respectively).
- TLF is defined as a hierarchical composite of cardiac death, target vessel MI (per protocol definition), and ischemic-driven TLR.
- TVF is defined as a hierarchical composite of cardiac death, all MI (per protocol definition), ischemic-driven TLR and ischemic-driven non-TLR TVR.

¹ Confidence Interval was calculated using the normal approximation, not adjusted for multiplicity and is meant for descriptive purposes only.

Figure 9.3.1-1: SPIRIT IV: Kaplan Meier Time-to-Event Curve for TLF through 3 Years




| TLF | Event Free | Event Rate | p-value ¹ |
|----------|------------|------------|----------------------|
| XIENCE V | 90.8% | 9.2% | 0.0221 |
| TAXUS | 88.3% | 11.7% | |

Note:

- Time frame includes follow-up window (1095 + 28 days).

¹p-value based on log rank and not adjusted for multiple comparisons

Figure 9.3.1-2: SPIRIT IV: Kaplan Meier Time-to-Event Curve for ID-TLR through 3 Years




| ID-TLR | Event Free | Event Rate | p-value ¹ |
|----------|------------|------------|----------------------|
| XIENCE V | 93.8% | 6.2% | 0.0577 |
| TAXUS | 92.2% | 7.8% | |

Note:

- Time frame includes follow-up window (1095 + 28 days).

¹p-value based on log rank and not adjusted for multiple comparisons

Figure 9.3.1-3: SPIRIT IV: Kaplan Meier Time-to-Event Curve for Cardiac Death or Target Vessel MI through 3 Years



| Cardiac Death or TV-MI | Event Free | Event Rate | p-value ¹ |
|------------------------|------------|------------|----------------------|
| XIENCE V | 96.0% | 4.0% | 0.0670 |
| TAXUS | 94.6% | 5.4% | |

Note:

– Time frame includes follow-up window (1095 + 28 days).

¹p-value based on log rank and not adjusted for multiple comparisons

9.3.2 Multiple Vessel Treatment in SPIRIT IV

Subjects requiring treatment in more than one vessel comprise a subgroup that is at increased risk for cardiovascular events compared with single vessel disease patients. The SPIRIT IV trial allowed for up to 3 vessels to be treated. In the XIENCE V arm, 389 subjects received dual vessel treatment while 19 subjects received triple vessel treatment. In the TAXUS arm, 218 subjects received dual vessel treatment while 5 subjects received triple vessel treatment. There were no pre-specified hypotheses for patients in the single vessel treatment and multiple vessel treatment subgroups.

Table 9.3.2-1 shows the clinical outcomes through 3 years in single- and multiple-vessel treated subjects from a post-hoc analysis of SPIRIT IV.

Table 9.3.2-1: Clinical Results in Single and Multiple Vessel Treatment through 3 Years (SPIRIT IV)

| | Outcomes at 1 Year | | | | Outcomes at 3 Years (final follow-up) | | | |
|-----------------------------------|---|--------------------------------------|--|---------------------------------------|--|--------------------------------------|--|---------------------------------------|
| | Single Vessel XIENCE V (N = 2050) | Single Vessel TAXUS (N = 1006) | Multiple Vessel XIENCE V (N = 408) | Multiple Vessel TAXUS (N = 223) | Single Vessel XIENCE V (N = 2050) | Single Vessel TAXUS (N = 1006) | Multiple Vessel XIENCE V (N = 408) | Multiple Vessel TAXUS (N = 223) |
| TLF | 3.8% (76/2014) | 6.0% (59/983) | 5.2% (21/402) | 10.4% (22/212) | 8.3% (163/1959) | 11.0% (105/952) | 15.4% (60/389) | 16.0% (33/206) |
| Ischemia-Driven TLR | 2.1% (42/2014) | 4.0% (39/983) | 3.5% (14/402) | 7.5% (16/212) | 5.3% (104/1959) | 7.0% (67/952) | 11.3% (44/389) | 12.1% (25/206) |
| Ischemia-Driven TVR, Non TL | 1.9% (38/2014) | 2.0% (20/983) | 4.0% (16/402) | 4.2% (9/212) | 4.6% (91/1959) | 5.0% (48/952) | 10.5% (41/389) | 7.3% (15/206) |
| All Death | 0.9% (18/2014) | 1.3% (13/983) | 1.7% (7/402) | 0.9% (2/212) | 3.1% (60/1959) | 5.6% (53/952) | 5.4% (21/389) | 3.4% (7/206) |
| Cardiac Death | 0.3% (6/2014) | 0.4% (4/983) | 1.0% (4/402) | 0.5% (1/212) | 1.2% (24/1959) | 2.0% (19/952) | 2.6% (10/389) | 1.5% (3/206) |
| Non-Cardiac Death | 0.6% (12/2014) | 0.9% (9/983) | 0.7% (3/402) | 0.5% (1/212) | 1.8% (36/1959) | 3.6% (34/952) | 2.8% (11/389) | 1.9% (4/206) |
| Target Vessel MI | 1.8% (37/2014) | 2.3% (23/983) | 1.7% (7/402) | 5.7% (12/212) | 2.7% (53/1959) | 3.7% (35/952) | 3.1% (12/389) | 6.3% (13/206) |
| Cardiac Death or Target Vessel MI | 2.1% (43/2014) | 2.6% (26/983) | 2.5% (10/402) | 5.7% (12/212) | 3.9% (77/1959) | 5.3% (50/952) | 5.1% (20/389) | 6.8% (14/206) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.15% (3/1996) | 0.51% (5/971) | 0.25% (1/393) | 2.38% (5/210) | 0.79% (15/1900) | 1.88% (17/903) | 0.82% (3/366) | 2.49% (5/201) |
| ARC Definite+Probable | 0.20% (4/1996) | 0.72% (7/971) | 0.76% (3/395) | 2.86% (6/210) | 0.47% (9/1895) | 1.45% (13/897) | 1.36% (5/368) | 2.99% (6/201) |
| ARC Definite | 0.20% (4/1990) | 0.51% (5/972) | 0.51% (2/395) | 2.37% (5/211) | 0.47% (9/1895) | 1.00% (9/897) | 0.54% (2/368) | 2.49% (5/201) |

Notes:

- 1-year and 3-year time frames include follow-up window (365 ± 28 days and 1095 ± 28 days, respectively)
- Multiple vessel subgroup included subjects having two or more vessels treated.
- There were 24 triple vessel treated subjects in SPIRIT IV; Of those, 19 were XIENCE V subjects and 5 were TAXUS subjects.

Study Strengths and Limitations: The SPIRIT IV trial was a prospective, randomized, active-controlled, single-blinded, multicenter evaluation of the XIENCE V stent compared to the TAXUS Express Stent and was designed to enroll 3,690 subjects in the US. With a large sample size and high data quality, the study provides important safety and effectiveness information on clinical outcomes in a more complex population than those in SPIRIT III. In spite of the large population and less restrictive enrollment criteria however, subgroup analyses from SPIRIT IV are considered exploratory.

9.4 SPIRIT Small Vessel Registry

Objective: The objective of the SPIRIT SV Registry trial was to evaluate the safety and effectiveness of the 2.25 mm XIENCE V EECSS in improving coronary luminal diameter in subjects with ischemic heart disease due to a maximum of two *de novo* native coronary artery lesions in small vessels, each in a different epicardial vessel.

Design: The SPIRIT SV trial enrolled a total of 150 subjects at 33 sites. Additionally, there was an angiographic cohort of 69 subjects who received the 2.25 mm XIENCE V EECSS. Subjects enrolled in the SPIRIT SV trial were allowed to have: 1) one target lesion (treated with one 2.25 mm XIENCE V EECSS), 2) two target lesions (treated with two 2.25 mm XIENCE V EECSS) in separate epicardial vessels, or 3) one target lesion (treated with one 2.25 mm XIENCE V EECSS) and one non-target lesion (treated with commercial sizes of XIENCE V EECSS) in separate epicardial vessels. Planned overlap was allowed for both the target and non-target lesions only with commercial sizes of XIENCE V EECSS. Bailout was allowed with a commercial XIENCE V or 2.25 mm XIENCE V EECSS. The protocol-required RVD for the target lesion was ≥ 2.25 mm to < 2.50 mm and the lesion length was ≤ 28 mm. The 2.25 mm XIENCE V EECSS was available in stent lengths of 8, 18 and 28 mm. The non-target lesion could be treated by the commercial XIENCE V EECSS with a RVD of ≥ 2.5 mm to ≤ 4.25 mm. The commercial XIENCE V EECSS was available in stent diameters of 2.5, 2.75, 3.0, 3.5, 4.0 mm and stent lengths of 8, 12, 15, 18, 23, 28 mm. The primary endpoint was target lesion failure (TLF, defined as the composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularization) at 1 year.

Demographics: For the subjects treated with the 2.25 mm XIENCE V EECSS, the mean age was 63 ± 11 years, and the majority of the population was male (61.8%, 89/144). In subjects treated with the 2.25 mm XIENCE V EECSS, 22.9% (32/140) were tobacco users, 81.9% (118/144) were hypertensive requiring medication, 86.5% (122/141) had hypercholesterolemia requiring medication, and 39.2% (56/143) were diabetic. Additionally, 68.8% (99/144) of the subjects had stable angina and 27.1% (39/144) had unstable angina. In subjects treated with the 2.25 mm XIENCE V EECSS, 72.2% (104/144) underwent single vessel treatment, and 27.8% (40/144) underwent dual vessel treatment.

Results: The results are presented in Table 9.4-1 (Primary Endpoint Results), Table 9.4-2 (Clinical Results), Table 9.4-3 (Stent Thrombosis Results), Table 9.4-4 (Angiographic Results) and Figure 9.4-1 (Time-to-Event Curve for TLF). These analyses are based on the full analysis set (FAS) population (defined as subjects that received the 2.25 mm XIENCE V EECSS). The primary analysis of the primary endpoint was analyzed in the FAS population. The 1-year TLF rate was 8.1% with an upper limit of the one-sided 95% confidence interval of 13.03%, which met the pre-specified performance goal of 20.4% ($p < 0.0001$). The 3-year follow-up rate for the SPIRIT Small Vessel Registry was 88.2% (127/144).

Table 9.4-1: SPIRIT SV Primary Endpoint Result

| Primary Endpoint | 2.25 mm XIENCE V (N = 144) | Upper 1-Sided 95% CL | p-value ¹ |
|------------------|-------------------------------|-------------------------|----------------------|
| 1-year TLF | 8.1% (11/136) | 13.03% | < 0.0001 |

Notes:

- N is the total number of subjects.
- TLF includes cardiac death, target vessel MI (per protocol definition) and clinical-indicated TLR.
- Time frame includes follow-up window (365 ± 28 days).

¹ One-sided p-value by testing against the performance goal of 20.4% using exact test at 0.05 significance level.

Table 9.4-2: SPIRIT SV Clinical Endpoint Results through 3 Years

| 2.25 mm XIENCE V Arm | Per Protocol Definition | |
|--|---------------------------|---|
| Acute Success (post index procedure) | ITT* (N = 149) | |
| Clinical Device Success | 95.21% (139/146) | |
| Clinical Procedure Success | 97.93% (142/145) | |
| Clinical Outcomes | At 1 Year | At 3 Years (final follow-up) |
| Component Endpoints | FAS (N = 144) | FAS (N = 144) |
| All Death | 1.5% (2/136) | 3.8% (5/132) |
| Cardiac Death | 1.5% (2/136) | 3.8% (5/132) |
| Non-Cardiac Death | 0.0% (0/136) | 0.0% (0/132) |
| Target Vessel MI | 1.5% (2/136) | 1.5% (2/132) |
| Non Target Vessel MI | 0.0% (0/136) | 0.0% (0/132) |
| Clinically -Indicated TLR (CI-TLR) | 5.1% (7/136) | 6.8% (9/132) |
| Clinically -Indicated TVR (CI-TVR) | 8.8% (12/136) | 12.1% (16/132) |
| All TLR | 6.6% (9/136) | 8.3% (11/132) |
| All TVR | 10.3% (14/136) | 13.6% (18/132) |
| All Revascularization | 14.7% (20/136) | 23.5% (31/132) |
| Composite Endpoints | | |
| Cardiac Death or MI | 2.9% (4/136) | 5.3% (7/132) |
| Cardiac Death or All MI or CI-TLR | 8.1% (11/136) | 12.1% (16/132) |
| All Death or All MI or All Revascularization | 16.9% (23/136) | 26.5% (35/132) |
| TLF | 8.1% (11/136) | 12.1% (16/132) |

Notes:

- N is the total number of subjects; L is the number of lesions.
- Per protocol MI definition was used for Target Vessel MI, Non Target Vessel MI, and all composite endpoints. MI per protocol definition is: Q-wave MI: Development of new, pathological Q waves on the ECG, and Non Q-wave MI: Elevation of CK levels to ≥ two times the upper limit of normal with elevated CK-MB in the absence of new pathological Q waves.
- 1-year and 3-year time frames include follow-up window (365 ± 28 days and 1095 ± 28 days, respectively).
- Non Target Vessel MI includes MI not attributed to the treated vessel.
- All Revascularization includes TVR and non-TVR, and non-treated vessel revascularization.
- FAS (full analysis set) is defined as subjects that received the 2.25 mm XIENCE V EECSS in the SPIRIT SV trial.
- Clinical Device Success: The successful delivery and deployment of the first study stent intended to be implanted at the intended target lesion (or in an overlapping stent setting, a successful delivery and deployment of the intended first and second investigational stents) and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (or by visual estimation if QCA unavailable). Bailout lesions were included as device success only if the above criteria for clinical device success were met for the bailout stent.
- Clinical Procedure Success: The achievement of a final in-stent diameter stenosis (DS) of < 50% (by QCA) using the assigned device and with any adjunctive devices, without the occurrence of cardiac death, target vessel MI (per protocol definition), or repeat coronary revascularization of the target lesion during the hospital stay (up to 7 days if a subject still is in the hospital). If QCA %DS was not available, procedure success data were considered missing.

* The ITT population provides the most accurate estimate of successful 2.25 mm XIENCE V stent implantation because it includes all subjects, regardless of whether the attempted implantation of 2.25 mm XIENCE V stent was successful.

Table 9.4-3: SPIRIT SV Stent Thrombosis Results through 3 Years

| Stent Thrombosis | FAS (N = 144) | | |
|--|-------------------------|--|-------------------------------|
| | Per Protocol Definition | Per ARC Definition (Definite+Probable) | Per ARC Definition (Definite) |
| Acute (\leq 1 day) | 0.0% (0/144) | 0.0% (0/144) | 0.0% (0/144) |
| Subacute ($>$ 1 – 30 days) | 0.7% (1/142) | 0.7% (1/142) | 0.0% (0/142) |
| Acute/Subacute (0 – 30 days) | 0.7% (1/142) | 0.7% (1/142) | 0.0% (0/142) |
| Late (Protocol: $>$ 30 days; ARC: 31 – 393 days) | 2.3% (3/129) | 0.7% (1/137) | 0.7% (1/137) |
| Very Late (ARC only) (394 – 1123 days) | - | 0.0% (0/128) | 0.0% (0/128) |
| Overall (0 – 1123 days) | 3.1% (4/130) | 1.5% (2/130) | 0.8% (1/130) |

Table 9.4-4: SPIRIT SV 240-Day Angiographic Results (Angiographic Cohort¹)

| XIENCE V 2.25 mm Arm | FAS (N = 69) (L = 69) |
|-------------------------|-----------------------------|
| 240-day Late Loss | |
| In-Stent | 0.20 \pm 0.40 (52) |
| In-Segment | 0.16 \pm 0.41 (52) |
| Proximal | 0.21 \pm 0.35 (34) |
| Distal | 0.00 \pm 0.28 (45) |
| 240-day %DS | |
| In-Stent | 12.86 \pm 19.58 (52) |
| In-Segment | 20.85 \pm 22.53 (52) |
| Proximal | 14.31 \pm 13.16 (37) |
| Distal | 10.40 \pm 8.45 (46) |
| 240-day ABR | |
| In-Stent | 3.8% (2/52) |
| In-Segment | 9.6% (5/52) |
| Proximal | 2.7% (1/37) |
| Distal | 0.0% (0/46) |


Notes:

N is the total number of subjects. L is the total number of lesions.

240-day angiographic data is available for 52 subjects.

¹ Per protocol defined qualifying angiogram with follow-up window extended to 268 days.

Figure 9.4-1: SPIRIT SV: Kaplan Meier Time-to-Event Curve for TLF through 3 Years



| TLF | Event Free | Event Rate |
|----------------------|------------|------------|
| XIENCE V 2.25 mm Arm | 88.4% | 11.6% |

Note:
 – Time frame includes follow-up window (1095 + 28 days).

Study Strengths and Limitations: The SPIRIT SV study was a prospective, open-label, multicenter registry. All event adjudications were performed by an independent Clinical Event Committee (CEC) with 100% site-reported adjudicable events being source-verified. The study provides important information on clinical outcomes and demonstrates the safety and effectiveness of the 2.25 mm XIENCE V stent in patients with small vessels. The study is limited by being a small registry with no head-to-head comparison with other DES platforms. In addition, due to the small population size, subgroup analysis can at best be considered exploratory.

9.5 Pooled Analysis of the SPIRIT II-III-IV Clinical Trials

A subject-level pooled analysis of three randomized, single-blinded, controlled trials was conducted to provide an assessment of safety outcomes with increased precision and to better estimate the incidence of low frequency events in specific subgroups. Definitive proof of the presence or absence of any differences between such subgroups requires prospectively powered assessment in dedicated clinical trials.

Data from the SPIRIT II, SPIRIT III randomized control trial (RCT) arm, and SPIRIT IV clinical trials were pooled to compare the XIENCE V stent to the TAXUS stent in 4989 subjects (with 6233 lesions) through 3 years (1123 days) of follow-up. Although SPIRIT IV permitted the enrollment of somewhat more complex patients, the three studies have subjects with generally similar baseline and angiographic characteristics and share key elements of study design, allowing pooling of the data for the purposes of these safety analyses.

Table 9.5-1: Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Clinical Results through 3 Years

| Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV | 1 Year | | 3 Years | |
|---|---|---|---|---|
| | XIENCE V (N = 3350) [95% CI] ¹ | TAXUS (N = 1639) ² [95% CI] ¹ | XIENCE V (N = 3350) [95% CI] ¹ | TAXUS (N = 1639) ² [95% CI] ¹ |
| TLF | 4.3% (143/3295) [3.67%, 5.09%] | 7.5% (119/1592) [6.23%, 8.88%] | 9.3% (295/3184) [8.28%, 10.33%] | 12.7% (196/1541) [11.10%, 14.49%] |
| Ischemia-Driven TLR | 2.7% (88/3295) [2.15%, 3.28%] | 4.9% (78/1592) [3.89%, 6.08%] | 6.1% (195/3184) [5.32%, 7.01%] | 8.3% (128/1541) [6.98%, 9.80%] |
| TLR, CABG | 0.3% (11/3295) [0.17%, 0.60%] | 0.3% (5/1592) [0.10%, 0.73%] | 0.7% (23/3184) [0.46%, 1.08%] | 0.8% (13/1541) [0.45%, 1.44%] |
| TLR, PCI | 2.4% (78/3295) [1.88%, 2.95%] | 4.6% (74/1592) [3.67%, 5.80%] | 5.6% (178/3184) [4.82%, 6.45%] | 7.8% (120/1541) [6.50%, 9.24%] |
| Ischemia-Driven TVR | 4.3% (143/3295) [3.67%, 5.09%] | 6.3% (100/1592) [5.14%, 7.59%] | 10.2% (326/3184) [9.21%, 11.34%] | 11.5% (177/1541) [9.94%, 13.18%] |
| All Death | 1.1% (36/3295) [0.77%, 1.51%] | 1.4% (22/1592) [0.87%, 2.08%] | 3.4% (109/3184) [2.82%, 4.11%] | 5.3% (81/1541) [4.20%, 6.49%] |
| Cardiac Death | 0.5% (15/3295) [0.26%, 0.75%] | 0.6% (9/1592) [0.26%, 1.07%] | 1.4% (45/3184) [1.03%, 1.89%] | 2.0% (31/1541) [1.37%, 2.84%] |
| Non-Cardiac Death | 0.6% (21/3295) [0.39%, 0.97%] | 0.8% (13/1592) [0.44%, 1.39%] | 2.0% (64/3184) [1.55%, 2.56%] | 3.2% (50/1541) [2.42%, 4.26%] |
| Target Vessel MI | 1.8% (60/3295) [1.39%, 2.34%] | 3.1% (49/1592) [2.29%, 4.05%] | 2.9% (91/3184) [2.31%, 3.50%] | 4.4% (68/1541) [3.44%, 5.56%] |
| Cardiac Death or Target Vessel MI | 2.2% (73/3295) [1.74%, 2.78%] | 3.4% (54/1592) [2.56%, 4.40%] | 4.1% (132/3184) [3.48%, 4.90%] | 5.8% (90/1541) [4.72%, 7.13%] |
| All MI | 2.0% (65/3295) [1.53%, 2.51%] | 3.3% (53/1592) [2.50%, 4.33%] | 3.3% (106/3184) [2.73%, 4.01%] | 5.2% (80/1541) [4.14%, 6.42%] |
| QMI | 0.2% (5/3295) [0.05%, 0.35%] | 0.4% (6/1592) [0.14%, 0.82%] | 0.3% (11/3184) [0.17%, 0.62%] | 0.8% (13/1541) [0.45%, 1.44%] |
| NQMI | 1.8% (60/3295) [1.39%, 2.34%] | 3.0% (48/1592) [2.23%, 3.98%] | 3.0% (95/3184) [2.42%, 3.64%] | 4.5% (69/1541) [3.50%, 5.63%] |
| Cardiac Death or All MI | 2.4% (78/3295) [1.88%, 2.95%] | 3.6% (57/1592) [2.72%, 4.61%] | 4.6% (147/3184) [3.91%, 5.40%] | 6.6% (101/1541) [5.37%, 7.91%] |
| Protocol Defined Stent Thrombosis (Cumulative) | 0.3% (10/3258) [0.15%, 0.56%] | 0.8% (13/1574) [0.44%, 1.41%] | 0.9% (28/3071) [0.61%, 1.32%] | 2.0% (30/1471) [1.38%, 2.90%] |
| Acute/Subacute (0 – 30 days) | 0.2% (6/3341) [0.07%, 0.39%] | 0.4% (7/1628) [0.17%, 0.88%] | 0.2% (7/3341) [0.08%, 0.43%] | 0.4% (7/1628) [0.17%, 0.88%] |
| Late (> 30 days) | 0.1% (4/3257) [0.03%, 0.31%] | 0.4% (7/1574) [0.18%, 0.91%] | 0.7% (21/3069) [0.42%, 1.04%] | 1.6% (24/1470) [1.05%, 2.42%] |
| ARC Definite+Probable Stent Thrombosis (Cumulative) | 0.4% (13/3261) [0.21%, 0.68%] | 1.0% (16/1574) [0.58%, 1.65%] | 0.8% (24/3069) [0.50%, 1.16%] | 1.8% (26/1463) [1.16%, 2.59%] |
| Acute/Subacute (0 – 30 days) | 0.2% (7/3341) [0.08%, 0.43%] | 0.6% (10/1628) [0.29%, 1.13%] | 0.2% (7/3341) [0.08%, 0.43%] | 0.6% (10/1628) [0.29%, 1.13%] |
| Late (31 days – 1 year) | 0.2% (6/3260) [0.07%, 0.40%] | 0.5% (8/1574) [0.22%, 1.00%] | 0.2% (6/3254) [0.07%, 0.40%] | 0.5% (8/1577) [0.22%, 1.00%] |
| Very late (> 1 year) | - | - | 0.4% (11/3064) [0.18%, 0.64%] | 0.7% (10/1458) [0.33%, 1.26%] |
| ARC Definite Stent Thrombosis (Cumulative) | 0.3% (11/3261) [0.17%, 0.60%] | 0.8% (12/1574) [0.39%, 1.33%] | 0.6% (18/3069) [0.35%, 0.93%] | 1.2% (18/1463) [0.73%, 1.94%] |
| Bleeding Complications | 3.1% (102/3261) [2.56%, 3.78%] | 3.3% (52/1573) [2.48%, 4.31%] | 5.8% (180/3086) [5.03%, 6.72%] | 6.6% (97/1474) [5.37%, 7.97%] |


Notes:

- 1-year and 3-year time frames include follow-up window (365 + 28 days and 1095 ± 28 days, respectively)

¹ By Clopper-Pearson Exact Confidence Interval

² In the pooled TAXUS stent arm, there were 18 subjects who received at least one TAXUS Liberté stent.

Figure 9.5-1: Kaplan Meier Time-to-Event Curves through 3 Years (Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV)



Note: p-value based on log rank and not adjusted for multiple comparisons

9.6 Gender-Based Analysis of the SPIRIT Family of Clinical Trials

9.6.1 Background

Cardiovascular disease is the leading cause of death for both women and men in the U.S. and coronary artery disease is a major cause of morbidity and mortality in women. It is estimated that the prevalence of coronary artery disease in the United States is 9.1% (9,200,000) in males and 7.0% (8,400,000) in females for adults at least 20 years old according to the American Heart Association 2010 Update.¹⁴ However, it is estimated that only 36% of annual PCIs are performed in women.¹⁵ In PCI clinical trials, women represent only 25 – 35% of the enrolled populations, and there are relatively little gender-specific data. The disproportionate enrollment distribution in these trials may be partly attributable to gender differences in symptoms and pathophysiology,¹⁶ which may lead to under-diagnosis and under-referral of female patients with CAD. Women tend to have worse clinical outcomes compared to men, most likely due to their higher baseline risk profile and more complex angiographic characteristics.^{17, 18, 19}

9.6.2 Gender-Based Analysis of the SPIRIT PRIME Clinical Trial

Abbott Vascular performed a post hoc evaluation of the SPIRIT PRIME clinical trial for possible sex-based differences in baseline characteristics and clinical outcomes, as well as for any interaction between treatment and sex / gender. The SPIRIT PRIME trial was not designed or powered to study safety or effectiveness differences between sexes, so these analyses are considered exploratory without definitive conclusions.

In the Core Size Registry, 119/401 (29.7%) subjects were female and 282/401 (70.3%) were male. In the Long Lesion Registry, 39/104 (37.5%) subjects were female and 65/104 (62.5%) were male. In comparison, the prevalence of coronary artery disease (CAD) is estimated at 9.2 million in males and 8.4 million in females for adults age 20 and older the United States (i.e., the CAD population is estimated to be 52.2% males and 47.7% females). The disproportionate enrollment distribution in this trial may be partly attributable to gender differences in symptoms and pathophysiology, which may lead to under-diagnosis and under-referral of female patients with CAD. The gender proportions enrolled in this trial are similar to other drug-eluting stent trials.^{20, 21}

¹⁴ Lloyd-Jones D, Adams R, Carnethon M, De Simone G, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. *Circulation* 2010; 121:e46-215.

¹⁵ Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2009; 119(3):e21-181.

¹⁶ Shaw LJ, Bairey Merz CN, Pepine CJ, et al. Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: Gender Differences in Traditional and Novel Risk Factors, Symptom Evaluation, and Gender-Optimized Diagnostic Strategies. *J Am Coll Cardiol* 2006 47: S4-20.

¹⁷ Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. *Jama* 2002; 288(15):1851-8.

¹⁸ Akhter N, Milford-Beland S, Roe MT, Piana RN, Kao J, Shroff A. Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). *Am Heart J* 2009; 157(1):141-8.

¹⁹ Vaina S, Voudris V, Morice M-C, de Bruyne B, Colombo A, Macaya C, Richardt, G, Fajadet, J et al. Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularization in patients with multivessel coronary artery disease: Insights from ARTS I and ARTS II. *EuroInterv*. 2009; 4(4):492-501.

²⁰ Lansky AJ, Costa RA, Mooney M, et al. Gender-Based Outcomes After Paclitaxel-Eluting Stent Implantation in Patients With Coronary Artery Disease. *J Am Coll Cardiol* 2005 45: 1180-5.

²¹ Solinas E, Nikolsky E, Lansky AJ, et al. Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation. *J Am Coll Cardiol* 2007;50:2111-6

Table 9.6.2-1 presents the baseline demographics, risk factors, and angiographic characteristics by gender for subjects in the Core Size Registry. As is consistent with previous literature, female patients at baseline were numerically older and had a higher BMI. Additionally, more females than males had hypertension requiring medication and diabetes mellitus. Table 9.6.2-2 presents the baseline demographics, risk factors, and angiographic characteristics by gender for subjects in the Long Lesion Registry

Table 9.6.2-1: Demographics, Risk Factors, and Baseline Angiographic Characteristics for SPIRIT PRIME Core Size Registry Subjects*

| Subject / Lesion Characteristics | Male (N = 282) (M = 315) | Female (N = 119) (M = 132) | Total (N = 401) (M = 447) | p-value |
|--|--------------------------------|----------------------------------|---------------------------------|---------------------|
| Baseline Demographics, Mean ± SD (n) | | | | |
| Age (year) | 61.63 ± 10.37 (282) | 65.23 ± 9.47 (119) | 62.70 ± 10.23 (401) | 0.0009 ¹ |
| Baseline Risk Factors, % (No./total) | | | | |
| All Diabetes | 31.9% (90/282) | 42.0% (50/119) | 34.9% (140/401) | 0.0663 ² |
| Diabetes Treated with Insulin | 7.4% (21/282) | 14.3% (17/119) | 9.5% (38/401) | 0.0400 ² |
| Current Tobacco Use | 19.1% (54/282) | 19.3% (23/119) | 19.2% (77/401) | 1.0000 ² |
| Hypertension Requiring Medication | 73.4% (207/282) | 84.0% (100/119) | 76.6% (307/401) | 0.0278 ² |
| Hypercholesterolemia Requiring Medication | 80.9% (228/282) | 79.0% (94/119) | 80.3% (322/401) | 0.6815 ² |
| Stable Angina | 44.0% (124/282) | 49.6% (59/119) | 45.6% (183/401) | 0.3244 ² |
| Unstable Angina | 25.2% (71/282) | 24.4% (29/119) | 24.9% (100/401) | 0.9001 ² |
| Prior MI | 25.0% (69/276) | 18.5% (22/119) | 23.0% (91/395) | 0.1927 ² |
| Target Vessel, % (No./total) | | | | |
| LAD | 44.1% (139/315) | 46.2% (61/132) | 44.7% (200/447) | 0.7545 ² |
| Circumflex or Ramus | 23.8% (75/315) | 25.8% (34/132) | 24.4% (109/447) | 0.7174 ² |
| RCA | 31.7% (100/315) | 28.0% (37/132) | 30.6% (137/447) | 0.5001 ² |
| LMCA | 0.0% (0/315) | 0.0% (0/132) | 0.0% (0/447) | NA |
| Pre-Procedure QCA Analysis, Mean ± SD (m) | | | | |
| Lesion Length (mm) | 13.91 ± 5.10 (315) | 13.06 ± 4.75 (132) | 13.66 ± 5.01 (447) | 0.0940 ¹ |
| Pre-Procedure RVD (mm) | 2.76 ± 0.48 (315) | 2.63 ± 0.45 (132) | 2.72 ± 0.48 (447) | 0.0067 ¹ |
| Pre-Procedure MLD (mm) | 0.82 ± 0.40 (315) | 0.81 ± 0.26 (132) | 0.81 ± 0.36 (447) | 0.7352 ¹ |
| Pre-Procedure Percent Diameter Stenosis (%DS) | 70.01 ± 12.87 (315) | 68.58 ± 8.53 (132) | 69.59 ± 11.76 (447) | 0.1676 ¹ |

*Subjects with Cardiac Enzyme Data in Window

¹ From T-test.

² From Fisher's exact test.

Note: All p-values displayed are two-tailed and not from formal hypothesis testing and are displayed for descriptive purposes only.

Note: N is the total number of subjects.

Note: M is the total number of target lesions.

Note: This table contains only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge).

Table 9.6.2-2: Demographics, Risk Factors, and Baseline Angiographic Characteristics for SPIRIT PRIME Long Lesion Registry Subjects*

| Subject / Lesion Characteristics | Male (N = 65) (M = 80) | Female (N = 39) (M = 44) | Total (N = 104) (M = 124) | p-value |
|--|------------------------------|--------------------------------|---------------------------------|---------------------|
| Baseline Demographics, Mean ± SD (n) | | | | |
| Age (year) | 63.64 ± 9.97 (65) | 63.15 ± 8.60 (39) | 63.46 ± 9.44 (104) | 0.7927 ¹ |
| Baseline Risk Factors, % (No./total) | | | | |
| All Diabetes | 32.3% (21/65) | 41.0% (16/39) | 35.6% (37/104) | 0.4027 ² |
| Diabetes Treated with Insulin | 9.2% (6/65) | 10.3% (4/39) | 9.6% (10/104) | 1.0000 ² |
| Current Tobacco Use | 26.2% (17/65) | 28.2% (11/39) | 26.9% (28/104) | 0.8232 ² |
| Hypertension Requiring Medication | 76.9% (50/65) | 71.8% (28/39) | 75.0% (78/104) | 0.6418 ² |
| Hypercholesterolemia Requiring Medication | 81.5% (53/65) | 79.5% (31/39) | 80.8% (84/104) | 0.8023 ² |
| Stable Angina | 43.1% (28/65) | 59.0% (23/39) | 49.0% (51/104) | 0.1563 ² |
| Unstable Angina | 27.7% (18/65) | 15.4% (6/39) | 23.1% (24/104) | 0.2289 ² |
| Prior MI | 25.0% (16/64) | 18.4% (7/38) | 22.5% (23/102) | 0.4753 ² |
| Target Vessel, % (No./total) | | | | |
| LAD | 41.3% (33/80) | 40.9% (18/44) | 41.1% (51/124) | 1.0000 ² |
| Circumflex or Ramus | 27.5% (22/80) | 18.2% (8/44) | 24.2% (30/124) | 0.2803 ² |
| RCA | 31.3% (25/80) | 40.9% (18/44) | 34.7% (43/124) | 0.3261 ² |
| LMCA | 0.0% (0/80) | 0.0% (0/44) | 0.0% (0/124) | NA |
| Pre-Procedure QCA Analysis, Mean ± SD (m) | | | | |
| Lesion Length (mm) | 26.62 ± 7.89 (80) | 25.17 ± 6.83 (44) | 26.10 ± 7.53 (124) | 0.2872 ¹ |
| Pre-Procedure RVD (mm) | 2.80 ± 0.46 (80) | 2.66 ± 0.40 (44) | 2.75 ± 0.44 (124) | 0.0864 ¹ |
| Pre-Procedure MLD (mm) | 0.75 ± 0.28 (80) | 0.79 ± 0.31 (44) | 0.77 ± 0.29 (124) | 0.5067 ¹ |
| Pre-Procedure Percent Diameter Stenosis (%DS) | 72.05 ± 8.74 (80) | 68.76 ± 9.60 (44) | 70.88 ± 9.15 (124) | 0.0632 ¹ |

*Subjects with Cardiac Enzyme Data in Window

¹ From T-test.

² From Fisher's exact test.

Note: All p-values displayed are two-tailed and not from formal hypothesis testing and are displayed for descriptive purposes only.

Note: N is the total number of subjects.

Note: M is the total number of target lesions.

Note: This table contains only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge).

A post hoc analysis was conducted on the composite primary safety and effectiveness endpoint of TLF, per protocol and per ARC, to assess for heterogeneity of treatment effect across sex / gender (using Fisher's Exact Test). Table 9.6.2-3 and Table 9.6.2-4 present the 3-year clinical results for the Core Size Registry and Long Lesion Registry, respectively. Due to the modest sample size (Core Size Registry 282 males vs. 119 females and Long Lesion Registry 65 males vs. 39 females), these analyses and interpretation are limited.

Table 9.6.2-3: Clinical Results for All Female and All Male Subgroups in the SPIRIT PRIME Core Size Registry through 3 Years*

| SPIRIT PRIME | Male (N = 282) | Female (N = 119) | Total (N = 401) | p-value ¹ |
|--|-------------------|---------------------|--------------------|----------------------|
| All Death | 4.0% (11/274) | 0.9% (1/116) | 3.1% (12/390) | 0.1192 |
| Cardiac Death | 1.1% (3/274) | 0.0% (0/116) | 0.8% (3/390) | 0.5578 |
| Non-Cardiac Death | 2.6% (7/274) | 0.0% (0/116) | 1.8% (7/390) | 0.1091 |
| Target Vessel MI per Protocol | 2.9% (8/274) | 1.7% (2/116) | 2.6% (10/390) | 0.7297 |
| Cardiac Death or Target Vessel MI per Protocol | 4.0% (11/274) | 1.7% (2/116) | 3.3% (13/390) | 0.3599 |
| Target Vessel MI per ARC | 5.5% (15/274) | 7.8% (9/116) | 6.2% (24/390) | 0.4891 |
| Cardiac Death or Target Vessel MI per ARC | 6.6% (18/274) | 7.8% (9/116) | 6.9% (27/390) | 0.6666 |
| Major Bleeding Complication | 4.5% (12/265) | 1.7% (2/115) | 3.7% (14/380) | 0.2439 |
| Stent Thrombosis | | | | |
| Protocol defined | 1.5% (4/263) | 0.0% (0/115) | 1.1% (4/378) | 0.3185 |
| ARC definite + probable | 1.1% (3/265) | 0.0% (0/115) | 0.8% (3/380) | 0.5566 |
| TLF | | | | |
| per Protocol | 9.1% (25/274) | 6.9% (8/116) | 8.5% (33/390) | 0.5540 |
| per ARC | 10.2% (28/274) | 12.1% (14/116) | 10.8% (42/390) | 0.5948 |
| Ischemia-Driven TLR | 5.5% (15/274) | 5.2% (6/116) | 5.4% (21/390) | 1.0000 |
| Ischemia-Driven TVR, non TL | 5.8% (16/274) | 6.0% (7/116) | 5.9% (23/390) | 1.0000 |

*Subjects with Cardiac Enzyme Data in Window

¹ From Fisher's exact test.

Note: All p-values displayed are two-tailed and not from formal hypothesis testing and are displayed for descriptive purposes only.

Note: Subjects are only counted once for each type of event in each time period.

Note: N is the total number of subjects.

Note: This table contains only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge).

Table 9.6.2-4: Clinical Results for All Female and All Male Subgroups in the SPIRIT PRIME Long Lesion Registry through 3 Years*

| SPIRIT PRIME | Male (N = 65) | Female (N = 39) | Total (N = 104) | p-value ¹ |
|--|------------------|--------------------|--------------------|----------------------|
| All Death | 3.1% (2/65) | 2.6% (1/39) | 2.9% (3/104) | 1.0000 |
| Cardiac Death | 0.0% (0/65) | 0.0% (0/39) | 0.0% (0/104) | NA |
| Non-Cardiac Death | 3.1% (2/65) | 2.6% (1/39) | 2.9% (3/104) | 1.0000 |
| Target Vessel MI per Protocol | 4.6% (3/65) | 5.1% (2/39) | 4.8% (5/104) | 1.0000 |
| Cardiac Death or Target Vessel MI per Protocol | 4.6% (3/65) | 5.1% (2/39) | 4.8% (5/104) | 1.0000 |
| Target Vessel MI per ARC | 13.8% (9/65) | 5.1% (2/39) | 10.6% (11/104) | 0.2024 |
| Cardiac Death or Target Vessel MI per ARC | 13.8% (9/65) | 5.1% (2/39) | 10.6% (11/104) | 0.2024 |
| Major Bleeding Complication | 3.2% (2/62) | 2.7% (1/37) | 3.0% (3/99) | 1.0000 |
| Stent Thrombosis | | | | |
| Protocol defined | 0.0% (0/62) | 0.0% (0/37) | 0.0% (0/99) | NA |
| ARC definite + probable | 0.0% (0/62) | 0.0% (0/37) | 0.0% (0/99) | NA |
| TLF | | | | |
| per Protocol | 10.8% (7/65) | 7.7% (3/39) | 9.6% (10/104) | 0.7397 |
| per ARC | 18.5% (12/65) | 7.7% (3/39) | 14.4% (15/104) | 0.1585 |
| Ischemia-Driven TLR | 6.2% (4/65) | 2.6% (1/39) | 4.8% (5/104) | 0.6480 |
| Ischemia-Driven TVR, non TL | 7.7% (5/65) | 2.6% (1/39) | 5.8% (6/104) | 0.4063 |

*Subjects with Cardiac Enzyme Data in Window

¹ From Fisher's exact test.

Note: All p-values displayed are two-tailed and not from formal hypothesis testing and are displayed for descriptive purposes only.

Note: Subjects are only counted once for each type of event in each time period.

Note: N is the total number of subjects.

Note: This table contains only subjects with post index procedure cardiac enzyme data in window (between 8 hours post index procedure and hospital discharge).

9.6.3 Gender-Based Analysis in the SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Clinical Trials

To evaluate gender-specific clinical outcomes with the XIENCE V stent, Abbott Vascular conducted a pooled analysis of SPIRIT II, SPIRIT III RCT, and SPIRIT IV. The pooled SPIRIT trial data were assessed for differences between males and females in baseline characteristics and study outcomes, as well as for any interaction between treatment and gender. Results suggest that the general conclusions of safety and effectiveness of the XIENCE V stent can be generalized for males and females.

In the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV intent-to-treat population, 1584 subjects were female (32%) and 3404 subjects were male (68%). The gender proportions enrolled in this trial are similar to other drug-eluting stent trials.^{22, 23}

Of the 1584 female subjects in the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV population, 1058 were XIENCE V subjects and 526 were TAXUS subjects.

Table 9.6.3-1 describes the demographics, risk factors, and baseline angiographic characteristics of all female and all male subgroups of the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV population.

Table 9.6.3-1: Demographics, Risk Factors, and Baseline Angiographic Characteristics for the All-Female and All-Male Subgroups (Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Population)

| Subject Characteristics | All Females (N = 1584; 32%) (M = 1901) | All Males (N = 3404; 68%) (M = 4332) | p-value ¹ |
|--|--|--|----------------------|
| Baseline Demographics, Mean ± SD (n) | | | |
| Age (year) | 65.7 ± 10.5 (1584) | 62.0 ± 10.2 (3404) | < 0.0001 |
| Baseline Risk Factors, % (No./total) | | | |
| All Diabetes | 35.9% (569/1583) | 28.7% (975/3398) | < 0.0001 |
| Diabetes Treated with Insulin | 12.1% (192/1583) | 6.5% (222/3398) | < 0.0001 |
| Current Tobacco Use | 21.7% (337/1550) | 23.2% (772/3321) | 0.2555 |
| Hypertension Requiring Medication | 80.7% (1278/1584) | 73.9% (2511/3398) | < 0.0001 |
| Hypercholesterolemia Requiring Medication | 73.2% (1143/1562) | 75.9% (2537/3341) | 0.0399 |
| Stable Angina | 57.2% (889/1554) | 57.7% (1933/3348) | 0.7327 |
| Unstable Angina | 29.1% (452/1554) | 25.5% (854/3348) | 0.0092 |
| Prior MI | 15.8% (245/1551) | 23.6% (783/3316) | < 0.0001 |
| Target Vessel, % (No./total) | | | |
| LAD | 43.1% (820/1901) | 39.6% (1712/4327) | 0.0085 |
| Circumflex or Ramus | 21.9% (416/1901) | 26.8% (1159/4327) | < 0.0001 |
| RCA | 35.0% (665/1901) | 33.6% (1454/4327) | 0.2959 |
| LMCA | 0.0% (0/1901) | 0.0% (2/4327) | 1.0000 |
| Pre-Procedure QCA Analysis, Mean ± SD (m) | | | |
| Lesion Length (mm) | 14.22 ± 6.25 (1888) | 14.79 ± 6.51 (4293) | 0.0012 |
| Pre-Procedure RVD (mm) | 2.66 ± 0.44 (1894) | 2.79 ± 0.48 (4303) | < 0.0001 |
| Pre-Procedure MLD (mm) | 0.79 ± 0.38 (1899) | 0.78 ± 0.40 (4310) | 0.2207 |
| Pre-Procedure Percent Diameter Stenosis (%DS) | 69.92 ± 12.84 (1899) | 71.58 ± 13.05 (4310) | < 0.0001 |

N is the total number of subjects; M is the total number of lesions analyzed.

¹p-values are displayed for descriptive purposes only.

²² Lansky AJ, Costa RA, Mooney M, et al. Gender-Based Outcomes After Paclitaxel-Eluting Stent Implantation in Patients With Coronary Artery Disease. *J Am Coll Cardiol* 2005 45: 1180-5.

²³ Solinas E, Nikolsky E, Lansky AJ, et al. Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation. *J Am Coll Cardiol* 2007;50:2111-6

Table 9.6.3-1 shows that females in the SPIRIT family of trials were older and had higher rates of diabetes, hypertension, and unstable angina compared with males. The generally higher clinical risk profile in females is consistent with gender differences in baseline demographics reported from other PCI studies.^{24, 25, 26, 27, 28, 29, 30}

Table 9.6.3-2 presents key clinical outcomes through 3 years in female and male subjects from the SPIRIT IV trial and the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV population. In post-hoc analyses of the pooled SPIRIT II, SPIRIT III RCT and SPIRIT IV population, rates of death, target vessel MI and stent thrombosis through 3 years were comparable between females and males. At 3 years, post-hoc analyses of the SPIRIT IV trial suggest that females treated with XIENCE V stents (despite generally increased clinical risk factors at baseline) had numerically similar adverse event rates compared to males treated with XIENCE V stents. Comparisons of study outcomes in patients receiving the XIENCE V stent versus the TAXUS stent were consistent within each gender subgroup. Based on the interaction p-value calculated from Wald Chi-square statistics of logistic regression analysis, no significant treatment-by-gender interaction effect was observed at a 0.15 significance level. These analyses suggest that the conclusions regarding safety and effectiveness of the XIENCE V stent are generalizable to both males and females. However, it should be noted that there were no pre-specified hypotheses for the use of the XIENCE V stent in females.

²⁴ Correa-De-Araujo R. Serious gaps: how lack of sex/gender- based research impairs health. *J Womens Health (Larchmt)* 2006; 15(10):1116-22.

²⁵ Abbott JD, Vlachos HA, Selzer F, Sharaf BL, Holper E, Glaser R et al. Gender-based outcomes in percutaneous coronary intervention with drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry). *Am J Cardiol* 2007; 99(5):626-31.

²⁶ Akhter N, Milford-Beland S, Roe MT, Piana RN, Kao J, Shroff A. Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). *Am Heart J* 2009; 157(1):141-8.

²⁷ Vaina S, Voudris V, Morice M-C, de Bruyne B, Colombo A, Macaya C, Richardt, G, Fajadet, J et al. Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularization in patients with multivessel coronary artery disease: Insights from ARTS I and ARTS II. *EuroInterv.* 2009; 4(4):492-501.

²⁸ Blomkalns AI, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. *J Am Coll Cardiol* 2005; 45(6):832-7.

²⁹ Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, et al. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigations to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation* 2005; 111(13):1611-8.

³⁰ Lansky AJ, Costa RA, Mooney M, Midei MG, Lui HK, Strickland W, et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. *J Am Coll Cardiol* 2005; 45 (8):1180-5.

Table 9.6.3-2: Clinical Results in XIENCE V Females, XIENCE V Males and All Subjects through 3 Years (SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Population)

| Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV | 1 Year | | | | 3 Years | | | |
|---|--------------------|------------------|---------------------|------------------|--------------------|------------------|---------------------|------------------|
| | XIENCE V | | All Subjects | | XIENCE V | | All Subjects | |
| | Females (N = 1058) | Males (N = 2292) | XIENCE V (N = 3350) | TAXUS (N = 1639) | Females (N = 1057) | Males (N = 2293) | XIENCE V (N = 3350) | TAXUS (N = 1639) |
| All Death | 1.2% (12/1038) | 1.1% (24/2257) | 1.1% (36/3295) | 1.4% (22/1592) | 3.0% (30/993) | 3.6% (79/2191) | 3.4% (109/3184) | 5.3% (81/1541) |
| Cardiac Death | 0.5% (5/1038) | 0.4% (10/2257) | 0.5% (15/3295) | 0.6% (9/1592) | 1.2% (12/993) | 1.5% (33/2191) | 1.4% (45/3184) | 2.0% (31/1541) |
| Non-Cardiac Death | 0.7% (7/1038) | 0.6% (14/2257) | 0.6% (21/3295) | 0.8% (13/1592) | 1.8% (18/993) | 2.1% (46/2191) | 2.0% (64/3184) | 3.2% (50/1541) |
| Target Vessel MI | 1.9% (20/1038) | 1.8% (40/2257) | 1.8% (60/3295) | 3.1% (49/1592) | 2.7% (27/993) | 2.9% (64/2191) | 2.9% (91/3184) | 4.4% (68/1541) |
| Cardiac Death or Target Vessel MI | 2.4% (25/1038) | 2.1% (48/2257) | 2.2% (73/3295) | 3.4% (54/1592) | 3.9% (39/993) | 4.2% (93/2191) | 4.1% (132/3184) | 5.8% (90/1541) |
| Bleeding Complication | 4.5% (46/1029) | 2.5% (56/2232) | 3.1% (102/3261) | 3.3% (52/1573) | 8.3% (80/967) | 4.7% (100/2119) | 5.8% (180/3086) | 6.6% (97/1474) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.4% (4/1028) | 0.3% (6/2230) | 0.3% (10/3258) | 0.8% (13/1574) | 0.7% (7/963) | 1.0% (21/2108) | 0.9% (28/3071) | 2.0% (30/1471) |
| ARC Definite+Probable | 0.4% (4/1028) | 0.4% (9/2233) | 0.4% (13/3261) | 1.0% (16/1574) | 0.5% (5/961) | 0.9% (19/2108) | 0.8% (24/3069) | 1.8% (26/1463) |
| ARC Definite | 0.4% (4/1026) | 0.3% (7/2229) | 0.3% (11/3255) | 0.8% (12/1577) | 0.4% (4/961) | 0.7% (14/2108) | 0.6% (18/3069) | 1.2% (18/1463) |
| SPIRIT IV | XIENCE V | | All Subjects | | XIENCE V | | All Subjects | |
| | Females (N = 793) | Males (N = 1665) | XIENCE V (N = 2458) | TAXUS (N = 1229) | Females (N = 792) | Males (N = 1666) | XIENCE V (N = 2458) | TAXUS (N = 1229) |
| | | | | | | | | |
| TLF | 4.0% (31/777) | 4.0% (66/1639) | 4.0% (97/2416) | 6.8% (81/1195) | 9.3% (69/745) | 9.6% (154/1603) | 9.5% (223/2348) | 11.9% (138/1158) |
| Ischemia-Driven TLR | 2.2% (17/777) | 2.4% (39/1639) | 2.3% (56/2416) | 4.6% (55/1195) | 5.8% (43/745) | 6.6% (105/1603) | 6.3% (148/2348) | 7.9% (92/1158) |
| Ischemia-Driven TVR, Non TL | 2.7% (21/777) | 2.0% (33/1639) | 2.2% (54/2416) | 2.4% (29/1195) | 5.6% (42/745) | 5.6% (90/1603) | 5.6% (132/2348) | 5.4% (63/1158) |

Notes:

- One subject in SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 1-year and 3-year time frames include follow-up window (365 ± 28 days and 1095 ± 28 days, respectively).
- TLF is defined as a hierarchical composite of cardiac death, Target Vessel MI (per protocol definition), and ischemia-driven TLR.

9.7 XIENCE V USA Post-Approval Study

Objective: The objectives of the XIENCE V USA post-approval study were: (1) to evaluate the continued safety and effectiveness of the XIENCE V EECSS during commercial use in real-world settings; (2) to support the Food and Drug Administration's (FDA) dual antiplatelet therapy (DAPT) initiative.

Design: The XIENCE V USA study was a prospective, multicenter, FDA-mandated post-approval study with 3 cohorts: phase I (from index procedure to 1 year), long-term follow-up cohort of phase II (from 1 year to 4 years), and AV-DAPT cohort of phase II (from 1 year to 33 months). Patients were considered as enrolled upon signing the Institutional Review Board (IRB)-approved informed consent form (ICF) and only XIENCE V EECSS was (were) implanted during the index procedure. There were no angiographic inclusion and exclusion criteria for this study. A total of 8,040 patients were consecutively enrolled from 191 sites in U.S. from two enrollment phases (5,042 patients from the first enrollment phase and 2,998 patients from the second enrollment phase). Phase I cohort consisted of all the 8,040 enrolled patients. Clinical follow-up occurred at 14, 30, 180 days, and 1 year. The long-term follow-up cohort of phase II consisted of 4,663 patients from the first enrollment phase who were not transferred to the HCRI- DAPT study (IDE#G080186) and remained in the study beyond 1 year. Clinical follow-up occurred at 2, 3, and 4 years. For phase I and the long-term follow-up cohort, the primary endpoint was the annual rate of ARC-defined stent thrombosis (definite and probable), and the co-primary endpoint was the annual composite rate of cardiac death or any MI. For phase I, the primary hypothesis for the co-primary endpoint of cardiac death or MI from 0-1 year is based on a comparison of the near on-label patients from the second enrollment stage of XIENCE V USA who had cardiac markers drawn between 12 – 24 hours post procedure to the population of SPIRIT III and SPIRIT III-like patients in SPIRIT IV treated with XIENCE V (with a non-inferiority margin of 3%). For the long-term follow-up cohort, the four yearly annual rates of ARC-defined definite and probable stent thrombosis will be simultaneously evaluated against a performance goal of 1.5%. The AV-DAPT cohort of phase II consisted of 868 patients from the second enrollment phase who were eligible and got randomized at 12 months post index procedure to either DAPT or placebo for an additional 18 months thienopyridine treatment (from 12 to 30 months). Clinical follow-up and endpoints for the AV-DAPT cohort are the same as the HCRI-DAPT study (IDE#G080186). All clinical endpoint events were adjudicated by an independent CEC.

Results: Phase I of the study has been completed in the entire population. A total of 8,040 patients with 11,137 lesions were treated with a total of 12,873 XIENCE V stents during the index procedure. There were 39% near on-label patients and 61% non near on-label patients. The non near on-label cohort includes patients with any of the following: baseline lesion length > 28 mm, reference vessel diameter < 2.5 mm or > 4.25 mm, restenosis, chronic total occlusion, graft lesion, bifurcation with side branch \geq 2 mm, ostial, left main, more than 2 lesions stented in the same vessel, more than 2 vessels treated, acute MI, renal insufficiency, ejection fraction < 30%, or staged procedure. Patients who do not meet the above criteria are classified as the "near on-label" cohort. Baseline characteristics (Table 9.7-1) and key endpoint results through 4 years were summarized below (Table 9.7-2 and Table 9.7-3). The 4-year follow-up rate for the XIENCE V USA clinical trial was 87.7% (4,405/5,020).

The 1-year primary endpoint of ARC definite and probable ST rate was 0.81%. The 1-year co-primary endpoint of the composite cardiac death or MI rate was 7.2%. The primary analysis for the co-primary endpoint was summarized in Table 9.7-2. The difference in cardiac death or

MI rate between XIENCE V USA and SPIRIT study was 0.01% with the 95% upper confidence limit being 1.74%, which was less than the quasi non-inferiority margin of 3% ($P_{NI} = 0.0022$).

Table 9.7-1: XIENCE V USA Baseline Characteristics

| Analysis population: 8040 patients, 11137 lesions, 12873 stents | | | |
|---|--------------------------|-------------------------------|---------------------|
| Patient Demographics | | Procedural Characteristics | |
| Male | 69.6% (5599/8040) | Vessels Treated | |
| Age (year) | 64.58 ± 10.82 (8040) | 1 | 86.3% (6564/7609) |
| All Diabetes Mellitus | 35.8% (2856/7969) | 2 | 13.1% (998/7609) |
| Oral Hypoglycemics Treated | 23.6% (1879/7969) | ≥ 3 | 0.6% (47/7609) |
| Insulin Treated | 12.3% (979/7969) | Target Vessels | |
| Multi-vessel Disease | 39.8% (3202/8040) | RCA | 32.8% (3656/11136) |
| Prior MI | 29.7% (2212/7440) | LAD | 37.5% (4173/11136) |
| Prior PCI | 39.1% (3065/7836) | LCX | 23.5% (2617/11136) |
| Prior CABG | 16.4% (1289/7836) | LMCA | 1.6% (182/11136) |
| Unstable Angina | 28.7% (2188/7612) | Graft | 4.6% (508/11136) |
| AMI | 14.7% (1054/7146) | Lesions Treated | |
| Renal Insufficiency | 10.5% (840/8015) | 1 | 70.0% (5627/8040) |
| | | 2 | 23.2% (1868/8040) |
| | | ≥ 3 | 6.8% (545/8040) |
| Lesion Characteristics | | | |
| Reference Vessel Diameter (mm) | 3.02 ± 0.53 (10707) | Stenting | |
| Lesion Length (mm) | 15.8 ± 9.4 (10642) | Direct stenting (per lesion) | 36.8% (4096/11126) |
| Lesion Type | | Stents implanted per patient | 1.6 ± 0.9 (8040) |
| A | 17.7% (1643/9273) | Patients with > 1 stent | 40.8% (3280/8040) |
| B1 | 32.4% (3002/9273) | Stent length per patient (mm) | 29.2 ± 19.1 (8039) |
| B2 | 25.8% (2390/9273) | Stent length per lesion (mm) | 21.2 ± 11.3 (11093) |
| C | 24.1% (2238/9273) | | |
| Restenosis Lesion | 8.7% (972/11134) | | |
| Bifurcation Lesion | 9.7% (1084/11120) | | |
| Ostial Lesion | 11.2% (1176/10456) | | |
| Patient Categorization | | | |
| Near On-label | 39.0% (3132/8040) | | |
| Non Near On-label¹ | 61.0% (4908/8040) | | |
| Lesion length > 28 mm | 12.5% (613/4908) | > 2 lesions in same vessel | 4.6% (227/4908) |
| Reference vessel diameter < 2.5 mm | 5.3% (258/4908) | > 2 vessels treated | 1.0% (47/4908) |
| Reference vessel diameter > 4.25 mm | 2.0% (97/4908) | AMI | 21.5% (1054/4908) |
| Chronic total occlusion | 3.7% (184/4908) | Renal insufficiency | 17.1% (840/4908) |
| Graft lesion | 8.8% (431/4908) | LVEF < 30% | 4.1% (200/4908) |
| Bifurcation with side branch ≥ 2 mm | 15.2% (746/4908) | With staged procedure | 8.9% (439/4908) |
| Ostial lesion | 22.5% (1103/4908) | | |
| Left main | 3.6% (179/4908) | | |
| Restenosis lesion | 17.3% (847/4908) | | |

Note: numbers presented here are % (n/N) or mean ± SD

¹ a patient can be counted in more than 1 category of the non near on-label criteria

Table 9.7-2: XIENCE V USA Primary Analysis of the 1-Year Co-Primary Endpoint

| | XIENCE V USA (N = 997) | SPIRIT III and IV (N = 2720) | Difference (Upper One-Sided 95% CI) | Non-inferiority p-value |
|-----------------------------|---------------------------|---------------------------------|---|----------------------------|
| 1 Year Cardiac Death and MI | 6.2% (55/881) | 6.2% (166/2663) | 0.01% (1.74%) | 0.0022 |

Notes:

- N is the total number of patients.
- The 1-year window is through 407 days (or randomization date if occurred within 407 days for the second enrollment phase) for XIENCE V USA, and 393 days for SPIRIT III and IV.
- The XIENCE V USA arm includes near on-label patients from the second enrollment phase who had cardiac enzyme collected between 12 and 24 hours post index procedure.
- The SPIRIT study arm includes XIENCE V patients in SPIRIT III and SPIRIT III-like XIENCE V patients in SPIRIT IV.
- One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 3% at 0.05 significance level.

Table 9.7-3: XIENCE V USA Clinical Outcomes at 1 and 4 Years

| | XIENCE V USA Overall Population at 1 Year (N = 8040) | XIENCE V USA Long-Term Follow-up Cohort at 4 Years (N = 5020) |
|---|--|--|
| COMPOSITE EFFICACY & SAFETY | | |
| TLF (WHO MI Definition) | 6.9% (514/7491) | 16.5% (747/4518) |
| TLF (ARC) | 9.4% (707/7522) | 19.3% (875/4530) |
| EFFICACY (Non-Hierarchical Subject Counts) | | |
| Clinically indicated TLR | 4.4% (330/7522) | 10.4% (473/4530) |
| Clinically indicated TLR, CABG | 0.8% (57/7522) | 2.0% (91/4530) |
| Clinically indicated TLR, PCI | 4.0% (301/7522) | 8.9% (402/4530) |
| Clinically indicated TVR, nonTLR | 2.1% (161/7522) | 6.1% (277/4530) |
| SAFETY (Non-Hierarchical Subject Counts) | | |
| All Death | 2.6% (194/7522) | 10.9% (494/4530) |
| Cardiac Death | 1.4% (108/7522) | 5.4% (244/4530) |
| Vascular Death | 0.2% (12/7522) | 0.7% (32/4530) |
| Non-Cardiovascular Death | 1.0% (74/7522) | 4.8% (218/4530) |
| Target Vessel MI (WHO) | 1.9% (140/7491) | 3.5% (157/4518) |
| Target Vessel MI (ARC) | 5.5% (415/7522) | 8.7% (396/4530) |
| All MI (WHO) | 2.2% (162/7491) | 4.8% (215/4518) |
| QMI | 0.5% (39/7491) | 1.5% (68/4518) |
| NQMI | 1.7% (126/7491) | 3.4% (152/4518) |
| All MI (ARC) | 6.3% (475/7522) | 11.3% (511/4530) |
| QMI | 0.5% (39/7522) | 1.5% (68/4530) |
| NQMI | 5.9% (442/7522) | 10.1% (457/4530) |
| COMPOSITE SAFETY | | |
| Cardiac Death or Target Vessel MI (WHO) | 3.1% (231/7491) | 8.0% (361/4518) |
| Cardiac Death or Target Vessel MI (ARC) | 6.5% (491/7522) | 12.6% (571/4530) |
| Cardiac Death or MI (WHO) | 3.3% (250/7491) | 9.1% (412/4518) |
| Cardiac Death or MI (ARC) | 7.2% (545/7522) | 14.9% (676/4530) |
| STENT THROMBOSIS (ARC-Defined Definite/Probable) | | |
| Cumulative through 1 year | 0.81% (60/7380) | - |
| Acute/Subacute (0 – 30 days) | 0.40% (32/7951) | - |
| Late (31 – 365 days) | 0.37% (27/7364) | - |

| | XIENCE V USA Overall Population at 1 Year (N = 8040) | XIENCE V USA Long-Term Follow-up Cohort at 4 Years (N = 5020) |
|--|--|--|
| Very Late (366 – 1502 days) | - | 0.55% (22/4032) |
| Cumulative through 4 years | - | 1.56% (64/4093) |
| STENT THROMBOSIS (ARC-Defined Definite) | | |
| Cumulative through 1 year | 0.54% (40/7380) | - |
| Acute/Subacute (0 – 30 days) | 0.23% (18/7951) | - |
| Late (31 – 365 days) | 0.29% (21/7364) | - |
| Very Late (366 – 1502 days) | - | 0.42% (17/4032) |
| Cumulative through 4 years | - | 1.05% (43/4093) |

Notes:

- N is the total number of patients
- The 1-year window is through 407 days (or randomization date if occurred within 407 days for the second enrollment phase of XIENCE V USA). The 4-year window is through 1502 days.
- TLF is defined as hierarchical composite of cardiac death, target vessel MI (per ARC definition), and clinically indicated TLR.

Study Strengths and Limitations: The XIENCE V USA study was a prospective, open-label, multicenter, post-approval study. All event adjudications were performed by an independent event committee with 100% site-reported adjudicable events being source-verified. With a large sample size and high data quality, the study provides important information on the clinical outcomes in a real-world population beyond those from selected patients in randomized pre-approval studies. However, the study is limited by being observational in nature, and therefore a head-to-head comparison with other DES platforms was not possible. In addition, the monitoring level is less rigorous than a randomized pivotal trial. However, the consistent results between XIENCE V USA near on-label population and the XIENCE V arm in SPIRIT III and IV trials suggests that the quality measures taken in XIENCE V USA study as described above produced high quality data. Therefore, this study affords a reliable benchmark for understanding the safety of XIENCE V EECSS in the context of real-world clinical practice.

9.7.1 Analysis of Patients with 4.0 mm Stent

There were 186 near on-label patients with at least one XIENCE V 4.0 mm stent implanted during the index procedure. A pre-specified descriptive comparison of 1-year TLR is summarized in Table 9.7.1-1.

Table 9.7.1-1: XIENCE V USA Patients with 4.0 mm Stent

| | XIENCE V USA (N = 186) | SPIRIT III and IV (N = 74) |
|------------|---------------------------|-------------------------------|
| 1 Year TLR | 3.4% (6/177) | 2.7% (2/74) |

Notes:

- N is the total number of patients.
- The 1-year window is through 407 days (or randomization date if occurred within 407 days for the second enrollment phase) for XIENCE V USA, and 393 days for SPIRIT III and IV.
- The XIENCE V USA arm includes near on label patients who had at least a 4.0 mm XIENCE V stent implanted during the index procedure.
- The SPIRIT study arm includes XIENCE V patients in SPIRIT III 4.0 mm registry and SPIRIT III-like XIENCE V patients in SPIRIT IV who were treated with at least a 4.0 mm XIENCE V stent.

9.7.2 Analysis of Patients Treated with Direct Stenting

There were two pre-specified hypothesis tests on direct stenting. The results of both tests were summarized in Table 9.7.2-1. One-year TLF rate of XIENCE V USA patients who had a single lesion treated with direct stenting in real world settings was non-inferior to the event rate of SPIRIT III-like XIENCE V patients in SPIRIT IV who had a single lesion treated with pre-dilatation ($P_{NI} = 0.0119$). In XIENCE V USA, one-year TLF rate in patients who had a single lesion treated with direct stenting was non-inferior to the event rate of those who had a single lesion treated with pre-dilatation ($P_{NI} < 0.0001$).

In these two analyses, there was, as expected, some degree of selection bias with lesions undergoing direct-stenting displaying lower complexity than lesions undergoing pre-dilatation. For hypothesis 1, there were more patients who had prior cardiac intervention and history of MI in XIENCE V USA direct stenting group, but there were more B2/C lesions and more multiple stents implanted in the SPIRIT IV pre-dilatation group. The propensity score approach was utilized to address this selection bias. A logistic regression was fit to obtain the propensity score for direct stenting, which was defined as the probability of having direct stenting given specific values for the following variables: age, sex, current smoker, diabetes treated, hypertension requiring medication, lipid disorder requiring medication, prior CABG, prior PCI, CCS III or IV stable angina, prior MI, prior brachytherapy, multi-vessel disease, LAD, heavy calcification, baseline DS%, TIMI, lesion length ≥ 22 mm, B2/C lesion, and multiple stents per lesion. Then patients were divided into 5 strata with approximately equal size based on the rank of their propensity scores. A stratified non-inferiority test was finally performed. For hypothesis 2, the XIENCE V USA direct stenting group had less B2/C lesion, less bifurcations, and fewer patients with multiple stents implanted than the predilatation group. For hypothesis 2, the propensity analysis method was the same as hypothesis 1, except that some additional variables were added such as AMI, renal insufficiency, LVEF $< 30\%$, left main, graft, restenotic lesion, bifurcation, ostial lesion, and history of stroke, which were not included in the propensity model of hypothesis 1 because these patients were either excluded in SPIRIT IV or data were not collected in SPIRIT IV. The propensity analysis results for both hypothesis 1 and hypothesis 2 indicated that adjustment for baseline differences in lesion characteristics did not change the findings of non-inferiority of direct stenting to pre-dilatation in either analysis (Table 9.7.2-1).

Table 9.7.2-1: XIENCE V USA Direct Stenting Results

| Analysis 1 | XIENCE V USA Direct Stenting (N = 506) | SPIRIT IV Pre-dilatation (N = 1726) | Difference (Upper One-Sided 95% CI) | Non-inferiority p-value |
|---|--|---|--|--------------------------------|
| 1 Year TLF | 7.7% (34/440) | 7.4% (124/1687) | 0.38% (3.01%) | 0.0119 |
| 1-Year TLF (Propensity Score Analysis) | 7.7% (34/440) | 7.4% (124/1687) | -0.09% (2.70%) | 0.0079 |
| Hierarchical TLF Components | | | | |
| Cardiac Death | 0.7% (3/440) | 0.4% (6/1687) | NA | NA |
| Target Vessel MI | 4.5% (20/440) | 5.7% (97/1687) | NA | NA |
| Clinically indicated TLR | 2.5% (11/440) | 1.2% (21/1687) | NA | NA |
| 1-Year Stent Thrombosis (ARC definite/probable) | 0.23% (1/430) | 0.18% (3/1675) | NA | NA |
| 1-Year Stent Thrombosis (ARC definite) | 0.23% (1/430) | 0.18% (3/1675) | NA | NA |
| Analysis 2 | XIENCE V USA Direct Stenting (N = 1947) | XIENCE V USA Pre-dilatation (N = 3405) | Difference (Upper One-Sided 95% CI) | Non-inferiority p-value |
| 1 Year TLF | 6.8% (124/1817) | 7.9% (252/3182) | -1.10% (0.23%) | < 0.0001 |
| 1-Year TLF (Propensity Score Analysis) | 6.8% (124/1817) | 7.9% (252/3182) | -0.60% (0.75%) | 0.0008 |
| Hierarchical TLF Components | | | | |
| Cardiac Death | 1.3% (24/1817) | 1.3% (40/3182) | NA | NA |
| Target Vessel MI | 3.3% (60/1817) | 4.5% (142/3182) | NA | NA |
| Clinically indicated TLR | 2.2% (40/1817) | 2.2% (70/3182) | NA | NA |
| 1-Year Stent Thrombosis (ARC definite/probable) | 0.56% (10/1786) | 0.51% (16/3118) | NA | NA |
| 1-Year Stent Thrombosis (ARC definite) | 0.28% (5/1786) | 0.35% (11/3118) | NA | NA |

Notes:

- N is the total number of patients.
- The 1-year window is through 407 days (or randomization date if occurred within 407 days for the second enrollment phase) for XIENCE V USA, and 393 days for SPIRIT IV study.
- In Analysis 1, the XIENCE V USA direct stenting arm included patients from the second enrollment phases who had cardiac enzyme collected between 12 and 24 hours post procedure and only 1 lesion treated during index procedure and the lesion was treated with direct stenting. Patients with staged procedure (s) were excluded. The SPIRIT IV pre-dilatation arm included SPIRIT III-like XIENCE V patients in SPIRIT IV who had only 1 lesion treated. All SPIRIT IV patients were considered to have pre-dilatation done for lesions treated during index procedure per protocol requirement. One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 4% at 0.05 significance level.
- In Analysis 2, the XIENCE V USA direct stenting arm included all patients who had only 1 lesion treated and the lesion was treated with direct stenting from both enrollment phases of XIENCE V USA. The XIENCE V USA pre-dilatation arm included all patients who had only 1 lesion treated and the lesion was treated with pre-dilatation from both enrollment phases of XIENCE V USA. Patients with staged procedure (s) were excluded. One-sided p-value by non-inferiority test using asymptotic test statistic with non-inferiority margin of 2% at 0.05 significance level.
- TLF included cardiac death, target vessel MI (per ARC definition) and clinically indicated TLR. In SPIRIT IV, ischemic-driven TLR was used rather than clinically indicated. The two definitions are similar but differ in regards to clinically indicated TLR requiring that there is ≥ 50% diameter stenosis and the presence of clinical symptoms. Ischemic-driven TLR does not always require angiographic evidence of ≥ 50% diameter stenosis; revascularization due to a positive functional ischemia study alone qualifies as ischemic-driven.

9.7.3 Pre-specified XIENCE V USA Subgroup Analysis

Elderly (age \geq 65 years), female, insulin-treated diabetic, acute MI (STEMI and NSTEMI combined) patients and patients with multi-vessel disease and two vessels stented are at increased risk for cardiovascular morbidity and mortality. In addition, patients with complex lesion characteristics, such as long lesions (\geq 20 mm), bifurcation lesions, ostial lesions and in-stent restenotic lesion are also associated with worse clinical outcomes. In XIENCE V USA, the above-mentioned subgroups were pre-specified for descriptive analysis to assess the safety and effectiveness of those high-risk patients. There were no pre-specified hypotheses for those subgroups.

The pre-specified XIENCE V USA subgroup 4-year clinical outcomes were summarized in Table 9.7.3-1.

Table 9.7.3-1: XIENCE V USA Subgroup Clinical Outcomes through 4 Years

| | XV USA Overall (N = 5020) | Near on-label (N = 1871) | Age ≥ 65 (N = 2495) | Female (N = 1564) | Insulin-Treated Diabetics (N = 593) | Acute MI (STEMI/NSTEMI) (N = 667) | Multivessel Disease (N = 2050) | Two Vessels Treated (N = 620) | Long Lesions (≥ 20mm) (N = 860) | Bifurcation Lesions (N = 261) | Ostial Lesions (N = 366) | ISR (N = 257) |
|--------------------------------------|---------------------------|--------------------------|---------------------|-------------------|-------------------------------------|-----------------------------------|--------------------------------|-------------------------------|---------------------------------|-------------------------------|--------------------------|----------------|
| COMPOSITE EFFICACY AND SAFETY | | | | | | | | | | | | |
| ARC-Defined Device Oriented Endpoint | 19.7% (893/4530) | 13.4% (228/1704) | 20.3% (475/2339) | 21.7% (305/1406) | 37.3% (198/531) | 22.2% (129/581) | 25.1% (471/1875) | 26.2% (148/565) | 18.3% (142/776) | 12.6% (28/222) | 23.9% (77/322) | 27.6% (64/232) |
| TLF | 19.3% (875/4530) | 13.0% (222/1704) | 20.0% (468/2339) | 21.1% (297/1406) | 37.1% (197/531) | 21.9% (127/581) | 24.7% (463/1875) | 25.3% (143/565) | 18.2% (141/776) | 12.2% (27/222) | 23.9% (77/322) | 27.2% (63/232) |
| SAFETY | | | | | | | | | | | | |
| Cardiac Death or Target Vessel MI | 12.6% (571/4530) | 8.3% (142/1704) | 14.5% (338/2339) | 14.0% (197/1406) | 26.9% (143/531) | 15.8% (92/581) | 15.8% (296/1875) | 16.5% (93/565) | 12.1% (94/776) | 6.8% (15/222) | 14.6% (47/322) | 14.7% (34/232) |
| Cardiac Death or MI | 14.9% (676/4530) | 10.3% (176/1704) | 16.2% (380/2339) | 16.1% (227/1406) | 30.1% (160/531) | 20.1% (117/581) | 18.6% (348/1875) | 18.2% (103/565) | 14.3% (111/776) | 8.1% (18/222) | 18.0% (58/322) | 17.7% (41/232) |
| All Death | 10.9% (494/4530) | 7.8% (133/1704) | 15.0% (352/2339) | 11.7% (164/1406) | 22.0% (117/531) | 14.1% (82/581) | 12.3% (230/1875) | 11.5% (65/565) | 12.0% (93/776) | 6.3% (14/222) | 13.7% (44/322) | 9.9% (23/232) |
| Cardiac Death | 5.4% (244/4530) | 3.3% (57/1704) | 6.7% (157/2339) | 5.4% (76/1406) | 14.1% (75/531) | 6.7% (39/581) | 6.6% (123/1875) | 6.4% (36/565) | 5.0% (39/776) | 1.8% (4/222) | 6.2% (20/322) | 4.7% (11/232) |
| All MI | 11.3% (511/4530) | 8.0% (137/1704) | 11.6% (272/2339) | 12.5% (176/1406) | 20.9% (111/531) | 15.3% (89/581) | 14.3% (268/1875) | 14.3% (81/565) | 10.8% (84/776) | 6.3% (14/222) | 13.0% (42/322) | 15.1% (35/232) |
| QMI | 1.5% (68/4530) | 1.1% (18/1704) | 1.1% (26/2339) | 1.5% (21/1406) | 2.3% (12/531) | 3.6% (21/581) | 1.8% (34/1875) | 2.5% (14/565) | 1.4% (11/776) | 0.5% (1/222) | 0.6% (2/322) | 0.9% (2/232) |
| NQMI | 10.1% (457/4530) | 7.1% (121/1704) | 10.7% (251/2339) | 11.2% (158/1406) | 19.0% (101/531) | 12.7% (74/581) | 12.9% (242/1875) | 12.6% (71/565) | 9.8% (76/776) | 5.9% (13/222) | 12.4% (40/322) | 14.7% (34/232) |
| Target Vessel MI | 8.7% (396/4530) | 5.9% (101/1704) | 9.5% (222/2339) | 10.2% (143/1406) | 17.3% (92/531) | 10.7% (62/581) | 11.3% (212/1875) | 12.4% (70/565) | 8.2% (64/776) | 5.0% (11/222) | 9.6% (31/322) | 11.6% (27/232) |
| Efficacy | | | | | | | | | | | | |
| TLR | 10.9% (495/4530) | 7.1% (121/1704) | 9.5% (222/2339) | 11.9% (167/1406) | 20.0% (106/531) | 11.2% (65/581) | 14.5% (271/1875) | 15.6% (88/565) | 10.1% (78/776) | 7.2% (16/222) | 13.7% (44/322) | 20.3% (47/232) |
| Stent Thrombosis | | | | | | | | | | | | |
| ARC Definite/probable | 1.56% (64/4093) | 0.70% (11/1577) | 1.60% (33/2058) | 1.53% (19/1244) | 3.39% (15/443) | 2.57% (13/506) | 2.27% (38/1674) | 2.34% (12/513) | 1.45% (10/688) | 0.98% (2/205) | 1.04% (3/288) | 2.86% (6/210) |
| ARC Definite | 1.05% (43/4093) | 0.25% (4/1577) | 0.92% (19/2058) | 1.05% (13/1244) | 2.03% (9/443) | 2.17% (11/506) | 1.43% (24/1674) | 1.17% (6/513) | 1.02% (7/688) | 0.98% (2/205) | 0.69% (2/288) | 2.38% (5/210) |

Notes:

- N is the total number of patients
 - The 4-year window is through 1502 days
 - Per ARC definition was used for MI and MI related endpoints.
 - ARC-defined device oriented endpoint is defined as hierarchical composite of cardiac death, target vessel MI (per ARC definition), and TLR.
 - TLF included cardiac death, target vessel MI (per ARC definition) and clinically indicated TLR. Near on-label patients are those who are not defined as non near on-label. The non near on-label cohort includes patients with any of the following: baseline lesion length >28 mm, reference vessel diameter < 2.5 mm or > 4.25 mm, restenosis, chronic total occlusion, graft lesion, bifurcation with side branch ≥ 2 mm, ostial, left main, more than 2 lesions stented in the same vessel, more than 2 vessels treated, acute MI, renal insufficiency, ejection fraction < 30%, or staged procedure.
- For long lesion (≥ 20mm), bifurcation, ostial and ISR subgroups, only patients with single-lesion treated during the index procedure and without any staged procedures were included in the analysis

9.8 EXPERT CTO Clinical Trial

The EXPERT CTO clinical trial was designed to demonstrate the safety and effectiveness of the XIENCE family of stent systems in the treatment of chronic total occlusions (CTO). The trial, conducted in the United States, consists of a single arm, and one-year results are presented here.

Primary Objective: The objective of the EXPERT CTO clinical trial is to evaluate the safety and effectiveness of the XIENCE family of stent systems in improving coronary luminal diameter in subjects with symptomatic heart disease due to CTO.

Design: The EXPERT CTO clinical trial is a prospective, nonrandomized, open-label, multicenter single-arm study evaluating stent diameters of 2.25 – 4.0 mm with stent lengths 8 – 38 mm in 222 subjects at 20 sites in the United States. Each subject was to receive treatment of one *de novo* native coronary CTO lesion. However, treatment of non-CTO lesions distal to the target lesion (non-target lesions in the target vessel) which were not identified on the pre-procedural angiogram prior to CTO recanalization but were identified only after successful CTO recanalization, was allowed using XIENCE stents. Treatment of one lesion in a non-target vessel was also allowed during the index procedure.

The primary endpoint is major adverse cardiac events (MACE) at one year, a composite endpoint of death, myocardial infarction (MI), and clinically driven target lesion revascularization (TLR). The primary endpoint rate of MACE at 1 year was compared to a pre-specified performance goal (PG). The PG of 24.4% for the EXPERT CTO trial was developed utilizing historical clinical trial data. First, the average 1-year MACE rate per ARC MI definition was weighted by sample size and adjusted for MI definition if necessary. The adjustment was derived from Abbott Vascular historical trials to account for difference in the primary endpoint between ARC and protocol MI definitions. The weighted average event rate after the above adjustment was 14.4%. The final performance goal was set at 24.4% after adding a delta of 10% to account for variability and uncertainty. Analyses of the primary endpoint were conducted on both the intent-to-treat (ITT) population and per protocol (PP) population.

Demographics: The mean age was 61.65 ± 10.43 years, 81.1% (180/222) were male, 18.9% (42/222) were female and 80.2% (178/222) were white. Regarding medical risk factors, 26.0% (54/208) were tobacco users, 91.9% (203/221) were hypertensive, and 96.8% (215/222) were dyslipidemic. There were 43.4% (96/221) of subjects who had a prior percutaneous cardiac intervention, 29.0% (61/210) who had a prior MI, and 9.9% (22/222) who had prior coronary artery bypass graft surgery. Furthermore, the population consisted of 40.1% (89/222) diabetics, of which 68.5% (61/89) were diabetics requiring oral medication, 30.3% (27/89) were diabetics requiring insulin, and 28.1% (25/89) were diabetics controlled by diet.

Results: The primary endpoint results are presented in Table 9.8-1. These analyses are based on the ITT and PP populations. The ITT population is defined as all enrolled patients for whom recanalization and pre-dilatation of the target lesion are completed and the study stent(s) (XIENCE V and / or XIENCE PRIME) is inserted into the coronary guiding catheter. The PP population is defined as all ITT patients for the stent-related analysis in whom at least one study stent is implanted with both procedure success and available follow-up data but without major protocol deviations due to inappropriate enrollment.

The observed MACE rate at one year was 18.5% (39/211) in the ITT population and 8.2% (15/183) in the PP population. Both the ITT and PP populations met the primary endpoint with MACE rates significantly lower than the pre-specified PG (24.4%) ($p = 0.0248$ and $p < 0.0001$, respectively).

Secondary endpoints are presented in Table 9.8-2.

Table 9.8-1: EXPERT CTO Primary Endpoint Results

| Primary Endpoint Analysis | MACE | Upper One-Sided 95% CL ⁴ | Performance Goal | p-value ⁴ |
|---|----------------|-------------------------------------|------------------|----------------------|
| ITT Set ¹ (N = 222) Exact Rate ³ | 18.5% (39/211) | 23.4% | 24.4% | 0.0248 |
| PP Set ² (N = 183) Exact Rate ³ | 8.2% (15/183) | 12.3% | 24.4% | < 0.0001 |

¹ ITT subjects include all subjects who met the study entry criteria, signed the written informed consent, were enrolled in the trial, and whose target lesion was successfully crossed and predilated.

² The per-protocol population is defined as all ITT subjects in whom at least one study stent was implanted, met procedure success, had available follow-up data (i.e., a MACE event within 360 days or follow up of at least 330 days), and did not have major protocol deviations due to inappropriate enrollment.

³ The numerator includes subjects who have MACE events before or on day 360, and the denominator includes subjects who had had available follow-up data (i.e., a MACE event within 360 days or follow up of at least 330 days).

⁴ p-value and upper one-sided 95% CI were calculated using exact binomial method.

Table 9.8-2: EXPERT CTO Clinical Results

| | Outcomes at 1 Year ITT (N = 222) |
|--|---|
| Composite Effectiveness and Safety | |
| TLF (per ARC) | 15.8% (33/209) |
| TLF (per protocol) | 9.1% (19/209) |
| Effectiveness | |
| Clinically driven TLR | 6.3% (13/207) |
| Clinically driven TLR, CABG | 0.5% (1/206) |
| Clinically driven TLR, PCI | 5.8% (12/207) |
| Clinically driven TVR | 7.2% (15/207) |
| Safety | |
| All Death | 1.9% (4/210) |
| Cardiac Death | 1.0% (2/208) |
| Non-Cardiac Death | 1.0% (2/208) |
| Target Vessel MI (per ARC) | 12.0% (25/209) |
| Target Vessel QMI (per ARC) | 1.0% (2/208) |
| Target Vessel NQMI (per ARC) | 11.1% (23/207) |
| All MI (per ARC) | 13.9% (29/209) |
| QMI (per ARC) | 1.0% (2/208) |
| NQMI (per ARC) | 13.0% (27/207) |
| Target Vessel MI (per protocol) | 3.4% (7/208) |
| Target Vessel QMI (per protocol) | 1.0% (2/208) |
| Target Vessel NQMI (per protocol) | 2.4% (5/206) |
| All MI (per protocol) | 3.4% (7/208) |
| QMI (per protocol) | 1.0% (2/208) |
| NQMI (per protocol) | 2.4% (5/206) |
| ARC Definite+Probable Stent Thrombosis | |
| Cumulative through 1 year | 1.4% (3/207) |
| Acute (0 – 1 day) | 0.0% (0/222) |
| Subacute (2 – 30 days) | 0.9% (2/218) |
| Late (31 days – 1 year) | 0.5% (1/206) |
| ARC Definite Stent Thrombosis (cumulative) | 1.0% (2/207) |

Notes:

- TLF is defined as a hierarchical composite of cardiac death, Target Vessel MI, and clinically driven TLR.
- ARC: Academic Research Consortium

Study Strengths and Limitations: The EXPERT CTO study was a prospective, open-label, multicenter study. All event adjudications were performed by an independent Clinical Event Committee (CEC) with 100% site-reported adjudicable events being source-verified. This study provides important information on clinical outcomes in patients with chronic total occlusions treated with the XIENCE family of stents. The study is limited by being a small study with no head-to-head comparison with other DES platforms. In addition, due to the small population size, subgroup analysis can at best be considered exploratory.

9.8.1 Gender-Based Analysis of the EXPERT CTO Clinical Trial

Abbott Vascular performed a post hoc evaluation of the EXPERT CTO clinical trial for possible sex-based differences in baseline characteristics and clinical outcomes, as well as for any interaction between treatment and sex/gender. The EXPERT CTO trial was not designed or powered to study safety or effectiveness differences between sexes, so these analyses are considered exploratory without definitive conclusions.

In the EXPERT CTO study, 81.1% (180/222) were male and 18.9% (42/222) were female. In comparison, the prevalence of coronary artery disease (CAD) is estimated at 9.2 million in males and 8.4 million in females for adults age 20 and older the United States (i.e., the CAD population is estimated to be 52.2% males and 47.7% females). The disproportionate enrollment distribution in this trial may be partly attributable to gender differences in symptoms and pathophysiology, which may lead to under-diagnosis and under-referral of female patients with CAD. The gender proportions enrolled in this trial are similar to other CTO drug-eluting stent trials.^{31,32,33}

Table 9.8.1-1 presents the baseline demographics, risk factors, and angiographic characteristics by gender for subjects in the EXPERT CTO trial. As is consistent with previous literature, female patients at baseline were numerically older. More females than males were diabetic.

³¹Kandzari DE, Rao SV, Moses JW, et al. Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial. *J Am Coll Cardiol Intv* 2009;2:97-106.

³²Valenti R, Vergara R, Migliorini A, et al. Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. *J Am Coll Cardiol* 2013;61:545-550.

³³Wohrle J, Rottbauer W, Imhof A. Everolimus-eluting stents for treatment of chronic total coronary occlusions. *Clin Res in Cardiol* 2011;101:23-28

Table 9.8.1-1: Demographics, Risk Factors, and Baseline Angiographic Characteristics for EXPERT CTO

| Subject / Lesion Characteristics | Male (N = 180) (L = 180) | Female (N = 42) (L = 42) | Difference [95% CI] | p-value |
|--|--------------------------------|--------------------------------|------------------------|---------|
| Baseline Demographics, Mean ± SD (n) | | | | |
| Age (year) | 61.08±10.46 (180) | 64.12±10.09 (42) | -3.04[-6.45,0.37] | 0.089 |
| Baseline Risk Factors, % (No./total) | | | | |
| All Diabetes | 38.3% (69/180) | 47.6% (20/42) | -9.3%[-26.0%,7.4%] | 0.297 |
| Diabetes Treated with Insulin | 29.0% (20/69) | 35.0% (7/20) | -6.0%[-29.5%,17.5%] | 0.593 |
| Current Tobacco Use | 28.9% (48/166) | 14.3% (6/42) | 14.6%[2.0%,27.3%] | 0.222 |
| Hypertension | 91.6% (164/179) | 92.9% (39/42) | -1.2%[-10.0%,7.5%] | 1.000 |
| Dyslipidemia | 96.1% (173/180) | 100.0% (42/42) | -3.9%[-6.7%,-1.1%] | 0.352 |
| Congestive Heart Failure | 13.3% (24/180) | 7.1% (3/42) | 6.2%[-3.0%,15.4%] | 0.430 |
| Prior PCI | 44.1% (79/179) | 40.5% (17/42) | 3.7%[-12.9%,20.2%] | 0.731 |
| Prior MI | 30.0% (51/170) | 25.0% (10/40) | 5.0%[-10.1%,20.1%] | 0.569 |
| Target Vessel, % (No./total) | | | | |
| LAD | 30.6% (55/180) | 33.3% (14/42) | -2.8%[-18.5%,13.0%] | 0.715 |
| Circumflex or Ramus | 17.8% (32/180) | 7.1% (3/42) | 10.6%[1.1%,20.2%] | 0.103 |
| RCA | 51.7% (93/180) | 59.5% (25/42) | -7.9%[-24.4%,8.7%] | 0.394 |
| LMCA | 0.0% (0/180) | 0.0% (0/42) | 0.0%[0.0%,0.0%] | -- |
| Pre-Procedure QCA Analysis, Mean ± SD (m) | | | | |
| Lesion Length (mm) | 35.92±19.20 (180) | 36.68±15.19 (42) | -0.76[-6.14,4.62] | 0.811 |
| Pre-Procedure RVD (mm) | 2.69±0.43 (180) | 2.52±0.43 (42) | 0.17[0.02,0.31] | 0.022 |
| Pre-Procedure MLD (mm) | 0.01±0.06 (180) | 0.00±0.00 (42) | 0.01[0.00,0.02] | 0.026 |
| Pre-Procedure Percent Diameter Stenosis (%DS) | 99.62±2.36 (180) | 100.00±0.00 (42) | -0.38[-0.72,-0.04] | 0.032 |

A post hoc analysis was conducted on the composite primary safety and effectiveness endpoint of MACE, per ARC and per protocol, to assess for heterogeneity of treatment effect across sex / gender (Table 9.8.1-2). Due to the modest sample size (180 males vs. 42 females), these analyses and interpretation are limited.

Table 9.8.1-2: Clinical Results for All Female and All Male Subgroups in the EXPERT CTO Study through 1 Year

| EXPERT CTO | Male (N = 180) | Female (N = 42) | Difference [95% CI] | p-value |
|-------------------------------|-------------------|--------------------|------------------------|---------|
| All Death | 1.2% (2/171) | 5.1% (2/39) | -4.0%[-11.1%,3.1%] | 0.158 |
| Cardiac Death | 0.6% (1/170) | 2.6% (1/38) | -2.0%[-7.3%,3.2%] | 0.333 |
| Non-Cardiac Death | 0.6% (1/170) | 2.6% (1/38) | -2.0%[-7.3%,3.2%] | 0.333 |
| Target Vessel MI per ARC | 11.1% (19/171) | 15.8% (6/38) | -4.7%[-17.2%,7.8%] | 0.413 |
| Target Vessel MI per Protocol | 3.5% (6/171) | 2.7% (1/37) | 0.8%[-5.1%,6.7%] | 1.000 |
| Clinically Driven TLR | 6.5% (11/170) | 5.4% (2/37) | 1.1%[-7.1%,9.2%] | 1.000 |
| Clinically Driven TVR, non TL | 1.2% (2/169) | 0.0% (0/37) | 1.2%[-0.4%,2.8%] | 1.000 |
| Stent Thrombosis | | | | |
| ARC definite + probable | 1.2% (2/170) | 2.7% (1/37) | -1.5%[-7.0%,3.9%] | 0.448 |
| MACE | | | | |
| per ARC MI definition | 16.9% (29/172) | 25.6% (10/39) | -8.8%[-23.6%,6.0%] | 0.252 |
| per Protocol MI definition | 9.3% (16/172) | 12.8% (5/39) | -3.5%[-14.9%,7.8%] | 0.553 |

9.9 Analysis of Diabetic Patients

9.9.1 *Analysis of Diabetic Subjects in SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV Trials*

Diabetic subjects comprise an important subject subgroup that is at increased risk for cardiovascular morbidity and mortality. Although diabetic subjects were included in the SPIRIT family of trials, there were no pre-specified hypotheses for the use of the XIENCE V stent in diabetic individuals.

Tables 9.9.1-1 and 9.9.1-2 show the clinical outcomes through 3 years in subjects from a post-hoc analysis of the SPIRIT IV and the pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV population. History of diabetes was one of the stratification factors used in randomization to assure a balance between the XIENCE V and TAXUS treatment arms for each individual trial. In XIENCE V patients, there were numerically higher event rates in diabetics compared with non-diabetics. Given the potential for confounding variables, no conclusions can be drawn from these post-hoc analyses.

**Table 9.9.1-1: Clinical Results in Diabetics and Non-Diabetics through 3 Years
(SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT and SPIRIT IV Population)**

| SPIRIT IV | 1 Year | | | | 3 Years | | | |
|--|------------------------|---------------------|------------------------|--------------------|------------------------|---------------------|------------------------|--------------------|
| | Non-Diabetics | | All Diabetics | | Non-Diabetics | | All Diabetics | |
| | XIENCE V (N = 1669) | TAXUS (N = 829) | XIENCE V (N = 786) | TAXUS (N = 399) | XIENCE V (N = 1669) | TAXUS (N = 829) | XIENCE V (N = 786) | TAXUS (N = 399) |
| TLF | 3.1% (52/1652) | 6.7% (55/815) | 5.9% (45/761) | 6.9% (26/379) | 8.2% (132/1610) | 11.4% (90/790) | 12.4% (91/735) | 13.1% (48/367) |
| Ischemia-Driven TLR | 1.8% (29/1652) | 4.5% (37/815) | 3.5% (27/761) | 4.7% (18/379) | 5.7% (91/1610) | 8.1% (64/790) | 7.8% (57/735) | 7.6% (28/367) |
| Ischemia-Driven TVR, Non-TL | 1.5% (24/1652) | 2.2% (18/815) | 3.9% (30/761) | 2.9% (11/379) | 4.8% (77/1610) | 4.9% (39/790) | 7.5% (55/735) | 6.5% (24/367) |
| Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV | Non-Diabetics | | All Diabetics | | Non-Diabetics | | All Diabetics | |
| | XIENCE V (N = 2312) | TAXUS (N = 1125) | XIENCE V (N = 1035) | TAXUS (N = 509) | XIENCE V (N = 2312) | TAXUS (N = 1125) | XIENCE V (N = 1035) | TAXUS (N = 509) |
| | TLF | 3.2% (74/2284) | 8.0% (89/1106) | 6.8% (69/1008) | 6.2% (30/482) | 8.0% (177/2211) | 12.7% (137/1075) | 12.2% (118/970) |
| Ischemia-Driven TLR | 2.0% (45/2284) | 5.3% (59/1106) | 4.3% (43/1008) | 3.9% (19/482) | 5.7% (125/2211) | 8.7% (94/1075) | 7.2% (70/970) | 7.4% (34/462) |
| Ischemia-Driven TVR, Non-TL | 1.9% (43/2284) | 3.5% (39/1106) | 3.8% (38/1008) | 2.9% (14/482) | 5.2% (114/2211) | 5.6% (60/1075) | 6.9% (67/970) | 7.1% (33/462) |
| All Death | 0.8% (19/2284) | 1.7% (19/1106) | 1.7% (17/1008) | 0.6% (3/482) | 2.5% (56/2211) | 5.5% (59/1075) | 5.5% (53/970) | 4.8% (22/462) |
| Cardiac Death | 0.2% (5/2284) | 0.7% (8/1106) | 1.0% (10/1008) | 0.2% (1/482) | 0.8% (18/2211) | 1.7% (18/1075) | 2.8% (27/970) | 2.8% (13/462) |
| Non-Cardiac Death | 0.6% (14/2284) | 1.0% (11/1106) | 0.7% (7/1008) | 0.4% (2/482) | 1.7% (38/2211) | 3.8% (41/1075) | 2.7% (26/970) | 1.9% (9/462) |
| Target Vessel MI | 1.3% (30/2284) | 3.0% (33/1106) | 3.0% (30/1008) | 3.3% (16/482) | 2.1% (47/2211) | 4.1% (44/1075) | 4.5% (44/970) | 5.2% (24/462) |
| Cardiac Death or Target Vessel MI | 1.5% (35/2284) | 3.3% (37/1106) | 3.8% (38/1008) | 3.5% (17/482) | 2.9% (65/2211) | 5.3% (57/1075) | 6.9% (67/970) | 7.1% (33/462) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.1% (3/2265) | 0.7% (8/1091) | 0.7% (7/990) | 1.0% (5/479) | 0.5% (11/2150) | 1.6% (16/1018) | 1.9% (17/918) | 3.1% (14/449) |
| ARC Definite+Probable | 0.1% (3/2265) | 0.9% (10/1091) | 1.0% (10/993) | 1.3% (6/479) | 0.4% (8/2148) | 1.7% (17/1017) | 1.7% (16/918) | 2.0% (9/442) |
| ARC Definite | 0.1% (3/2265) | 0.5% (6/1091) | 0.8% (8/993) | 1.3% (6/479) | 0.3% (7/2148) | 1.1% (11/1017) | 1.2% (11/918) | 1.6% (7/442) |

Notes:

- One subject in SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 1-year and 3-year time frames include follow-up window (365 + 28 days and 1095 + 28 days, respectively).

**Table 9.9.1-2: Clinical Results in Diabetics through 3 Years
(SPIRIT IV and Pooled SPIRIT II, SPIRIT III RCT, and
SPIRIT IV Population – XIENCE V Subjects)**

| SPIRIT IV | 1 Year | | | | 3 Years | | | |
|--|-------------------------------------|-------------------------------------|--|--|-------------------------------------|-------------------------------------|--|--|
| | Non-Diabetics (N = 1669) | All Diabetics (N = 786) | Insulin-Dependent Diabetics (N = 209) | Non-Insulin-Dependent Diabetics (N = 577) | Non-Diabetics (N = 1669) | All Diabetics (N = 786) | Insulin-Dependent Diabetics (N = 209) | Non-Insulin-Dependent Diabetics (N = 577) |
| TLF | 3.1% (52/1652) | 5.9% (45/761) | 7.0% (14/199) | 5.5% (31/562) | 8.2% (132/1610) | 12.4% (91/735) | 17.3% (33/191) | 10.7% (58/544) |
| Ischemia-Driven TLR | 1.8% (29/1652) | 3.5% (27/761) | 5.0% (10/199) | 3.0% (17/562) | 5.7% (91/1610) | 7.8% (57/735) | 13.1% (25/191) | 5.9% (32/544) |
| Ischemia-Driven TVR, Non TL | 1.5% (24/1652) | 3.9% (30/761) | 6.5% (13/199) | 3.0% (17/562) | 4.8% (77/1610) | 7.5% (55/735) | 11.0% (21/191) | 6.3% (34/544) |
| Pooled SPIRIT II, SPIRIT III RCT, and SPIRIT IV | Non-Diabetics (N = 2312) | All Diabetics (N = 1035) | Insulin-Dependent Diabetics (N = 272) | Non-Insulin-Dependent Diabetics (N = 763) | Non-Diabetics (N = 2312) | All Diabetics (N = 1035) | Insulin-Dependent Diabetics (N = 272) | Non-Insulin-Dependent Diabetics (N = 763) |
| TLF | 3.2% (74/2284) | 6.8% (69/1008) | 8.8% (23/262) | 6.2% (46/746) | 8.0% (177/2211) | 12.2% (118/970) | 16.3% (41/252) | 10.7% (77/718) |
| Ischemia-Driven TLR | 2.0% (45/2284) | 4.3% (43/1008) | 6.1% (16/262) | 3.6% (27/746) | 5.7% (125/2211) | 7.2% (70/970) | 11.9% (30/252) | 5.6% (40/718) |
| Ischemia-Driven TVR, Non TL | 1.9% (43/2284) | 3.8% (38/1008) | 5.3% (14/262) | 3.2% (24/746) | 5.2% (114/2211) | 6.9% (67/970) | 8.7% (22/252) | 6.3% (45/718) |
| All Death | 0.8% (19/2284) | 1.7% (17/1008) | 2.3% (6/262) | 1.5% (11/746) | 2.5% (56/2211) | 5.5% (53/970) | 6.0% (15/252) | 5.3% (38/718) |
| Cardiac Death | 0.2% (5/2284) | 1.0% (10/1008) | 1.1% (3/262) | 0.9% (7/746) | 0.8% (18/2211) | 2.8% (27/970) | 3.2% (8/252) | 2.6% (19/718) |
| Non-Cardiac Death | 0.6% (14/2284) | 0.7% (7/1008) | 1.1% (3/262) | 0.5% (4/746) | 1.7% (38/2211) | 2.7% (26/970) | 2.8% (7/252) | 2.6% (19/718) |
| Target Vessel MI | 1.3% (30/2284) | 3.0% (30/1008) | 4.6% (12/262) | 2.4% (18/746) | 2.1% (47/2211) | 4.5% (44/970) | 6.0% (15/252) | 4.0% (29/718) |
| Cardiac Death or Target Vessel MI | 1.5% (35/2284) | 3.8% (38/1008) | 5.0% (13/262) | 3.4% (25/746) | 2.9% (65/2211) | 6.9% (67/970) | 7.9% (20/252) | 6.5% (47/718) |
| Stent Thrombosis | | | | | | | | |
| Protocol Defined | 0.1% (3/2265) | 0.7% (7/990) | 0.8% (2/256) | 0.7% (5/734) | 0.5% (11/2150) | 1.9% (17/918) | 2.5% (6/238) | 1.6% (11/680) |
| ARC Definite+Probable | 0.1% (3/2265) | 1.0% (10/993) | 1.2% (3/257) | 1.0% (7/736) | 0.4% (8/2148) | 1.7% (16/918) | 2.1% (5/237) | 1.6% (11/681) |
| ARC Definite | 0.1% (3/2265) | 0.8% (8/993) | 0.8% (2/257) | 0.8% (6/736) | 0.3% (7/2148) | 1.2% (11/918) | 1.3% (3/237) | 1.2% (8/681) |

Notes:

- One subject in SPIRIT III TAXUS arm did not provide written informed consent and was inadvertently randomized into the study. Data from this subject are excluded from all data analyses.
- 1-year and 3-year time frames include follow-up window (365 + 28 days and 1095 ± 28 days, respectively)

9.9.2 Bayesian Analysis of Diabetic Patients treated with XIENCE Stents

A Statistical Analysis Plan (SAP) was developed with a pre-specified hypothesis to evaluate the safety and effectiveness of the XIENCE Family of Everolimus-Eluting Coronary Stent Systems (XIENCE stent, including XIENCE V, XIENCE PRIME, XIENCE Xpedition and XIENCE Alpine stents) to treat *de novo* native coronary artery lesions in diabetic patients with coronary artery disease. This section provides an overview of the SAP and the results supporting the use of the XIENCE stent in patients with diabetes mellitus (DM).

Primary Objective: To evaluate the safety and effectiveness of the XIENCE stent for the treatment of *de novo* lesions in native coronary arteries in diabetic patients.

Population: The analysis population consists of diabetic patients from the following trial/registry databases:

- SPIRIT IV
- SPIRIT PRIME (including Core Size Registry and Long Lesion Registry)
- XIENCE V USA First Enrollment Phase
- XIENCE V USA Second Enrollment Phase
- External databases: Cleveland Clinic and Wake Forest Baptist Medical Center databases

A total of 1239 patients were included in the DM analysis. The contributions of patients from each trial/registry database were: SPIRIT IV (N=451); SPIRIT PRIME (N=121); XIENCE V USA First Enrollment Phase (N=185); XIENCE V USA Second Enrollment Phase (N=192); and the pooled external databases from Cleveland Clinic and Wake Forest (N=290).

Design: A Bayesian hierarchical modeling approach was utilized to analyze the primary endpoint of Target Vessel Failure (TVF) at 12 months, defined as a composite of cardiac death, target-vessel myocardial infarction (TVMI), and ischemia driven target vessel revascularization (ID-TVR), which was tested against a pre-specified performance goal of 14.8% (expected rate 8.6% plus a delta of 6.2%).

Results from the six data sources were used in the analysis. Data from the four historical Abbott Vascular (AV) sponsored trial databases (SPIRIT IV, SPIRIT PRIME, XIENCE V USA first enrollment phase, and XIENCE V USA second enrollment phase) were considered as prior information. The two external XIENCE databases (Cleveland Clinic and Wake Forest) were pooled as current data and served as the basis for statistical inference.

Patients were included in the analysis if they have diabetes mellitus (based on medical history) and had at least one XIENCE stent implanted for the treatment of up to two *de novo* lesions (each located in a different epicardial vessel) < 32 mm in length in native coronary arteries with an RVD between 2.25 and 4.25 mm. The other clinical and lesion criteria of the diabetic analysis population are consistent with the enrollment criteria of the SPIRIT III US Pivotal Clinical Trial.

Demographics and Lesion Characteristics: The mean age of the diabetic population was 63 years from the pooled historical AV trials (SPIRIT IV, SPIRIT PRIME, XIENCE V USA first enrollment phase and second enrollment phase) and 65 years from the pooled two external databases (Wake Forest and Cleveland Clinic). There were 62.8% males from the pooled AV trials and 64.1% from the pooled external databases. Insulin treated diabetic patients comprised of 25.9% and 35.5% of the overall diabetic analysis population from the pooled AV trials and

pooled external databases, respectively. A total of 26.6% of patients presented with unstable angina from the pooled AV trials and 57.6% from the pooled external databases. There were 23.8% and 35.9% patients who had prior MI, 34.2% and 44.8% who had prior PCI, and 10.5% and 24.5% who had prior CABG from the pooled AV trials and pooled external databases, respectively. The mean lesion length was 13.5 mm for the pooled AV trials, and 16.3 mm for the pooled external databases. There were 12.0% type C lesions in the pooled AV trials and 25.5% in the pooled external databases. There were 2.6% (32/1239) patients treated with 33 or 38 mm stents in this pooled dataset (2.5% from the pooled AV trials, and 2.8% from the pooled external databases). Compared to the pooled AV trials, patient and lesion characteristics in the two external databases were generally more complex, likely due to their non-trial real-world settings.

Primary Endpoint Results: The primary endpoint of TVF rate at 1-year was evaluated in diabetic patients from the six trial/registry databases using a Bayesian statistical model. The posterior mean of 1-year TVF rate was 8.04%. The posterior probability of a 1-year TVF rate < 14.8% (performance goal) is > 0.999 (Table 9.9.2-1), which exceeds the pre-specified success criteria (> 0.975). Therefore, the XIENCE stent met the pre-specified success criteria for the primary endpoint of 1-year TVF.

Table 9.9.2-1: The XIENCE Diabetic Bayesian Analysis Primary Endpoint

| Primary Endpoint | TVF Rate [95% Central Posterior Interval] * | Bayesian Posterior Probability (TVF < 14.8%) |
|------------------|--|---|
| 1-year TVF | 8.04% [5.23%, 11.52%] | > 0.999 |

* The posterior mean is the Bayesian posterior average; the 95% central posterior interval is the symmetric 95% Bayesian credible interval, similar to the 95% confidence interval.

Notes:

- The 1-year window is through 393 days (365 + 28 days).
- TVF is defined as hierarchical composite of cardiac death, target vessel MI, and ischemia-driven TVR. For the primary composite endpoint of TVF, an adjustment factor of 0.826 was applied to one of the external databases to calculate the TVF rate based on the composite rate of all death/all MI/all TVR as the specifics of these events were not available from that database.

1-Year Clinical Outcomes: The 1-year clinical outcomes of the XIENCE diabetic population from each of the AV trials (SPIRIT IV, SPIRIT PRIME and XIENCE V USA) and the pooled two external databases are presented in Table 9.9.2-2.

Table 9.9.2-2: One- Year Clinical Outcomes of the XIENCE Diabetic Population

| | SPIRIT IV (N=451) | SPIRIT PRIME (N=121) | XV USA 5K (N=185) | XV USA 3K (N=192) | Pooled External (N=290) |
|--------------------------|------------------------------|---------------------------------|------------------------------|------------------------------|------------------------------------|
| TVF | 7.9% (34/433) | 11.8% (14/119) | 7.3% (13/178) | 3.6% (6/169) | 8.0% (21/261) |
| TLF | 5.5% (24/433) | 5.9% (7/119) | 6.7% (12/178) | 2.4% (4/169) | 2.4% (3/126) |
| Cardiac death or TVMI | 3.0% (13/433) | 2.5% (3/119) | 3.4% (6/178) | 0.6% (1/169) | 0.8% (1/126) |
| ID-TVR | 5.5% (24/433) | 9.2% (11/119) | 5.1% (9/178) | 3.0% (5/169) | 6.3% (8/126) |
| ID-TLR | 3.2% (14/433) | 3.4% (4/119) | 3.9% (7/178) | 1.8% (3/169) | 2.4% (3/126) |
| Death | 1.4% (6/433) | 0.0% (0/119) | 2.2% (4/178) | 1.2% (2/169) | 3.1% (8/261) |
| Cardiac death | 0.9% (4/433) | 0.0% (0/119) | 1.1% (2/178) | 0.6% (1/169) | 0.0% (0/126) |
| TVMI | 2.3% (10/433) | 2.5% (3/119) | 2.2% (4/178) | 0.0% (0/169) | 0.8% (1/126) |
| ST (ARC def/prob) | 0.9% (4/431) | 0.0% (0/119) | 0.0% (0/175) | 0.6% (1/169) | 0.8% (2/261) |

Notes:

- Numbers presented in this table are % (n/N).
- The 1-year window is through 393 days (365 + 28 days).
- XV USA 5K refers to the first enrollment phase of 5,000 patients in the XIENCE V USA study; XV USA 3K refers to the second enrollment phase of 3,000 patients in the XIENCE V USA study; pooled external refers to the pooled analysis of the two external databases (Cleveland Clinic and Wake Forest).
- TVF is defined as hierarchical composite of cardiac death, target vessel MI, and ischemia-driven TVR; TLF is defined as hierarchical composite of cardiac death, target vessel MI, and ischemia-driven TLR. ID-TLR= ischemia driven target lesion revascularization; ID-TVR=ischemia driven target vessel revascularization; TVMI=target vessel myocardial infarction; ST (ARC def/prob) = definite or probable stent thrombosis defined per the ARC definition.
- MI from the historical AV trials was defined per protocol and was categorized as Q-wave (development of new, pathological Q waves on the ECG) or non-Q-wave (elevation of CK levels to greater than two times the upper limit of normal and elevated CK-MB in the absence of new pathological Q waves). For the two external databases, MI was defined based on Universal MI definition per the National Cardiovascular Data Registry (NCDR) requirement.
- For the primary composite endpoint of TVF, an adjustment factor of 0.826 was applied to one of the two external databases in order to calculate the TVF rate based on the composite rate of all death/all MI/all TVR, as the specifics of these events were not available from that database.
- For other endpoints (TLF, cardiac death or TVMI, ID-TLR, ID-TVR, cardiac death and TVMI), only one of the external databases was included in the analysis, as the specific event information was not available in the other external database.

10.0 INDIVIDUALIZATION OF TREATMENT

The risks and benefits should be considered for each patient before using the XIENCE Xpedition stent. Patient selection factors to be assessed should include a judgment regarding risk of long-term antiplatelet therapy. Stenting is generally avoided in those patients at heightened risk of bleeding (e.g., patients with recently active gastritis or peptic ulcer disease) in which anticoagulation therapy would be contraindicated.

Antiplatelet drugs should be used in combination with the XIENCE Xpedition stent. Physicians should use information from the SPIRIT clinical trials, coupled with current drug eluting stent (DES) literature and the specific needs of individual patients to determine the specific antiplatelet / anticoagulation regimen to be used for their patients in general practice. See also section 5.2 – *Precautions, Pre- and Post-Procedure Antiplatelet Regimen*, section 5.6 – *Precautions, Use in Special Populations*, and section 5.7 – *Precautions, Lesion / Vessel Characteristics*.

Premorbid conditions that increase the risk of poor initial results or the risks of emergency referral for bypass surgery (diabetes mellitus, renal failure, and severe obesity) should be reviewed.

11.0 PATIENT COUNSELING AND PATIENT INFORMATION

Physicians should consider the following in counseling patients about this product:

- Discuss the risks associated with stent placement
- Discuss the risks associated with an everolimus eluting stent
- Discuss the risks of early discontinuation of the antiplatelet therapy
- Discuss the risks of late stent thrombosis with DES use in higher risk patient subgroups
- Discuss the risk / benefit issues for this particular patient
- Discuss alternation to current life style immediately following the procedure and over the long term

The following patient materials are provided for this product:

- A Patient Information Guide, including information on coronary artery disease, the implant procedure and the XIENCE Xpedition stent system (provided to physician, on-line at http://www.abbottvascular.com/docs/coronary_intervention/xience/ePG_XIENCE.pdf, or by calling customer service 1-800-227-9902)
- A Stent Implant Card, including both patient information and stent implant information (provided in package).

12.0 HOW SUPPLIED

Sterile – This device is sterilized with ethylene oxide gas, and is non-pyrogenic. It is intended for single use only. Do not resterilize. Do not use if the package is opened or damaged.

Contents – One (1) XIENCE Xpedition stent system; one (1) flushing tool (for the XIENCE Xpedition RX stent system); one (1) stent implant card

Storage – Store in a dry, dark, cool place. Protect from light. Do not remove from carton until ready for use. Store at 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F).

13.0 OPERATOR'S INSTRUCTIONS

13.1 Inspection Prior to Use

- Carefully inspect the sterile package before opening and check for damage to the sterile barrier. Do not use if the integrity of the sterile package has been compromised.
- Do not use after the "Use by" date.
- Tear open the foil pouch and remove the inner pouch.
Note: The outside of the inner pouch is NOT sterile. Open the inner pouch and pass or drop the product into the sterile field using an aseptic technique.
- Prior to using the XIENCE Xpedition stent system, carefully remove the system from the package and inspect for bends, kinks, and other damage. Verify that the stent does not extend beyond the radiopaque balloon markers. Do not use if any defects are noted. However, **do not manipulate, touch, or handle the stent** with your fingers, which may cause coating damage, contamination, or stent dislodgement from the delivery balloon.

Note: At any time during use of the XIENCE Xpedition RX stent system, if the stainless steel proximal shaft has been bent or kinked, do not continue to use the catheter.

13.2 Materials Required

- Appropriate guiding catheter(s). See Table 1-1: XIENCE Xpedition Stent System Product Description
- 2 – 3 syringes (10 – 20 ml)
- 1,000 u/500 ml heparinized normal saline (HepNS)
- 0.014" (0.36 mm) x 175 cm (minimum length) guide wire
- Rotating hemostatic valve with appropriate minimum inner diameter (0.096" [2.44 mm])
- Contrast diluted 1:1 with heparinized normal saline
- Inflation device
- Pre-deployment dilatation catheter
- Three-way stopcock
- Torque device
- Guide wire introducer
- Appropriate arterial sheath
- Appropriate anticoagulation and antiplatelet drugs

13.3 Preparation

13.3.1 Packaging Removal

Note: The foil pouch is not a sterile barrier. The inner header bag (pouch) within the foil pouch is the sterile barrier. Only the contents of the inner pouch should be considered sterile. The outside surface of the inner pouch is NOT sterile.

1. Carefully remove the delivery system from its protective tubing for preparation of the delivery system. When using a Rapid Exchange (RX) system, do not bend or kink the hypotube during removal.
2. Remove the product mandrel and protective stent sheath by grasping the catheter just proximal to the stent (at the proximal balloon bond site), and with the other hand, grasp the stent protector and gently remove distally. If unusual resistance is felt during product mandrel and stent sheath removal, do not use this product and replace with another. Follow product returns procedure for the unused device.

13.3.2 Guide Wire Lumen Flush

1. Over the Wire (OTW) only: Flush the guide wire lumen with HepNS until fluid exits the distal end of the delivery system
2. Rapid Exchange (RX) only: Flush the guide wire lumen with HepNS using the flushing tool supplied with the product. Insert the flushing tool into the tip of the catheter and flush until fluid exits the guide wire exit notch.

Note: Avoid manipulation of the stent while flushing the guide wire lumen, as this may disrupt the placement of the stent on the balloon.

13.3.3 Delivery System Preparation

1. Prepare an inflation device / syringe with diluted contrast medium.
2. Attach an inflation device / syringe to the stopcock; attach it to the inflation port of the product. Do not bend the product hypotube, when connecting to the inflation device / syringe.
3. With the tip down, orient the delivery system vertically.
4. Open the stopcock to delivery system; pull negative for 30 seconds; release to neutral for contrast fill.
5. Close the stopcock to the delivery system; purge the inflation device / syringe of all air.
6. Repeat steps 3 through 5 until all air is expelled. If bubbles persist, do not use the product.
7. If a syringe was used, attach a prepared inflation device to stopcock.
8. Open the stopcock to the delivery system.
9. Leave on neutral

Note: While introducing the delivery system into the vessel, do not induce negative pressure on the delivery system. This may cause dislodgement of the stent from the balloon.

Note: If air is seen in the shaft, repeat section 13.3.3 – *Operator's Instructions, Delivery System Preparation*, steps 3 through 5, to prevent uneven stent expansion.

13.4 Delivery Procedure

1. Prepare the vascular access site according to standard practice.
2. The decision to pre-dilate the lesion with an appropriate sized balloon should be based on patient and lesion characteristics. **If pre-dilatation is performed**, limit the longitudinal length of pre-dilatation by the PTCA balloon to avoid creating a region of vessel injury that is outside the boundaries of the XIENCE Xpedition stent.
3. For long lesions, size the stent to the diameter of the most distal portion of the vessel.

Note: If choosing between two stent diameters for tight lesions choose the smaller diameter stent and inflate. See section *14.0 – In vitro Compliance Information*

4. Maintain neutral pressure on the inflation device attached to the delivery system. Open the rotating hemostatic valve as wide as possible.
5. Backload the delivery system onto the proximal portion of the guide wire, while maintaining guide wire position across the target lesion.
6. Carefully advance the delivery system into the guiding catheter and over the guide wire to the target lesion. When using a Rapid Exchange (RX) system, be sure to keep the hypotube straight. Ensure guiding catheter stability before advancing the stent system into the coronary artery.

Note: If unusual resistance is felt before the stent exits the guiding catheter, do not force passage. Resistance may indicate a problem and the use of excessive force may result in stent damage or dislodgement. Maintain guide wire placement across the lesion and remove the delivery system and guiding catheter as a single unit.

7. Advance the delivery system over the guide wire to the target lesion under direct fluoroscopic visualization. Utilize the radiopaque balloon markers to position the stent across the lesion. Perform angiography to confirm stent position. If the position of the stent is not optimal, it should be carefully repositioned or removed (see section *5.14 – Precautions, Stent System Removal*). The balloon markers indicate both the stent edges and the balloon shoulders. Expansion of the stent should not be undertaken if the stent is not properly positioned in the target lesion.

Note: If removal of a stent system is required prior to deployment, ensure that the guiding catheter is coaxially positioned relative to the stent delivery system, and cautiously withdraw the stent delivery system into the guiding catheter. Should unusual resistance be felt at any time when withdrawing the stent towards the guiding catheter, the stent delivery system and the guiding catheter should be removed as a single unit. This should be done under direct visualization with fluoroscopy.

8. Tighten the rotating hemostatic valve. The stent is now ready to be deployed.

13.5 Deployment Procedure

CAUTION: Refer to Table 14-1: XIENCE Xpedition Stent Compliance, for *in vitro* stent inner diameter, nominal pressure, and RBP.

1. Prior to deployment, reconfirm the correct position of the stent relative to the target lesion using the radiopaque balloon markers.
2. Deploy the stent slowly by pressurizing the delivery system in 2 atm increments, every 5 seconds, until stent is completely expanded. Fully expand the stent by inflating to nominal pressure at a minimum. Accepted practice generally targets an initial deployment pressure that would achieve a stent inner diameter ratio of about 1.1 times the reference vessel diameter (see Table 14-1: XIENCE Xpedition Stent Compliance).
3. For long lesions, size the stent to the diameter of the most distal portion of the vessel and expand stent to nominal pressure at minimum. Maintain pressure for 30 seconds. If necessary, the delivery system can be repressurized or further pressurized to assure complete apposition of the stent to the artery wall.
4. Maintain pressure for 30 seconds for full expansion of the stent. Fluoroscopic visualization during stent expansion should be used in order to properly judge the optimum stent diameter as compared to the proximal and distal native coronary artery diameters (reference vessel diameters). Optimal stent expansion and proper apposition requires that the stent be in full contact with the arterial wall.

Note: See section 13.6 – *Removal Procedure* for instruction on withdrawal of stent delivery system.

5. If necessary, the delivery system can be repressurized or further pressurized to assure complete apposition of the stent to the artery wall.

Note: Do not exceed the labeled rated burst pressure (RBP) of 18 atm (1824 kPa).

6. Fully cover the entire lesion and balloon treated area (including dissections) with the XIENCE Xpedition stent, allowing for adequate stent coverage into healthy tissue proximal and distal to the lesion.
7. Deflate the balloon by pulling negative on the inflation device for 30 seconds. Confirm complete balloon deflation before attempting to move the delivery system. If unusual resistance is felt during stent delivery system withdrawal, pay particular attention to guiding catheter position.

Note: See section 13.6 – *Removal Procedure* for instruction on withdrawal of stent delivery system.

8. Confirm stent position and deployment using standard angiographic techniques. For optimal results, the entire stenosed arterial segment should be covered by the stent. Fluoroscopic visualization during stent expansion should be used in order to properly judge the optimum expanded stent diameter as compared to the proximal and distal coronary artery diameter(s). Optimal expansion requires that the stent be in full contact with the artery wall. Stent wall contact should be verified through routine angiography or intravascular ultrasound (IVUS).
9. If the deployed stent size is still inadequate with respect to reference vessel diameter, a larger balloon may be used to further expand the stent. If the initial

angiographic appearance is suboptimal, the stent may be further expanded using a low profile, high pressure, non-compliant balloon dilatation catheter. If this is required, the stented segment should be carefully recrossed with a prolapsed guide wire to avoid disrupting the stent geometry. Deployed stents should not be left underdilated.

CAUTION: Do not dilate the stent beyond the following limits.

| <u>Nominal Stent Diameter</u> | <u>Dilatation Limit</u> |
|-------------------------------|-------------------------|
| 2.25 mm and 2.5 mm | 3.25 mm |
| 2.75 mm, 3.0 mm, and 3.25 mm | 3.75 mm |
| 3.5 mm and 4.0 mm | 4.5 mm |

10. If more than one XIENCE Xpedition stent is needed to cover the lesion and balloon treated area, it is suggested that, to avoid the potential for gap restenosis, the stents be adequately overlapped. To ensure that there are no gaps between stents, the balloon marker bands of the second XIENCE Xpedition stent should be positioned inside the deployed stent prior to expansion.
11. Reconfirm stent position and angiographic results. Repeat inflations until optimal stent deployment is achieved.

13.6 Removal Procedure

Withdrawal of the stent delivery catheter from the deployed stent:

1. Deflate the balloon by pulling negative on the inflation device. Larger and longer balloons will take more time (up to 30 seconds) to deflate than smaller and shorter balloons. Confirm balloon deflation under fluoroscopy and wait 10 – 15 seconds longer.
2. Position inflation device on “negative” or “neutral” pressure.
3. Stabilize guiding catheter position just outside coronary ostium and anchor in place. Maintain guide wire placement across stent segment.
4. Gently remove the stent delivery system with slow and steady pressure.
5. Tighten the rotating hemostatic valve.

If during withdrawal of the stent delivery catheter resistance is encountered, use the following steps to improve balloon rewrap:

- Re-inflate the balloon up to nominal pressure.
- Repeat steps 1 through 5 above

Post stent delivery system withdrawal – Stent deployment confirmation

1. Confirm stent position and deployment using standard angiographic techniques. For optimal results, the entire stenosed arterial segment should be covered by the stent. Fluoroscopic visualization during stent expansion should be used in order to properly judge the optimum expanded stent diameter as compared to the proximal and distal coronary artery diameter(s). **Optimal expansion requires**

that the stent be in full contact with the artery wall. Stent wall contact should be verified through routine angiography or intravascular ultrasound (IVUS).

2. If more than one XIENCE Xpedition stent is needed to cover the lesion and balloon treated area, it is suggested that, to avoid the potential for gap restenosis, the stents be adequately overlapped.
3. To ensure that there are no gaps between stents, the balloon marker bands of the second XIENCE Xpedition stent should be positioned inside the deployed stent prior to expansion.
4. Reconfirm stent position and angiographic results to assess stented area. Repeat inflations until optimal stent deployment is achieved. If post-dilatation is necessary, ensure that the final stent diameter matches the reference vessel diameter. **Assure that the stent wall is in contact with the artery wall.**

13.7 Post-Deployment Dilatation of Stent Segments

1. All efforts should be taken to assure that the stent is not underdilated.
2. If the deployed stent size is still inadequate with respect to the vessel diameter, or if full contact with the vessel wall is not achieved, a larger balloon may be used to expand the stent further. The stent may be further expanded using a low profile, high pressure, and noncompliant balloon catheter. If this is required, the stented segment should be recrossed carefully with a prolapsed guide wire to avoid dislodging the stent. The balloon should be centered within the stent and should not extend outside of the stented region).

CAUTION: Do not dilate the stent beyond the following limits.

| <u>Nominal Stent Diameter</u> | <u>Dilatation Limit</u> |
|-------------------------------|-------------------------|
| 2.25 mm and 2.5 mm | 3.25 mm |
| 2.75 mm, 3.0 mm, and 3.25 mm | 3.75 mm |
| 3.5 mm and 4.0 mm | 4.5 mm |

14.0 IN VITRO COMPLIANCE INFORMATION

**Table 14-1: XIENCE Xpedition Stent Compliance
Nominal Pressure for Each Diameter Indicated by Bold Font**

| Pressure | | Stent ID (mm) by System Diameter | | | | | | |
|-----------|------|----------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|
| atm | kPa | 2.25 mm | 2.5 mm | 2.75 mm | 3.0 mm | 3.25 mm | 3.5 mm | 4.0 mm |
| 8 | 811 | 2.14 | 2.41 | 2.71 | 2.91 | 3.10 | 3.37 | 3.85 |
| 9 | 912 | 2.19 | 2.46 | 2.77 | 2.97 | 3.16 | 3.43 | 3.92 |
| 10 | 1013 | 2.23 | 2.51 | 2.81 | 3.03 | 3.22 | 3.49 | 3.99 |
| 11 | 1115 | 2.27 | 2.55 | 2.87 | 3.08 | 3.28 | 3.55 | 4.05 |
| 12 | 1216 | 2.30 | 2.59 | 2.90 | 3.12 | 3.33 | 3.60 | 4.11 |
| 13 | 1317 | 2.34 | 2.62 | 2.94 | 3.15 | 3.37 | 3.65 | 4.15 |
| 14 | 1419 | 2.37 | 2.66 | 2.97 | 3.19 | 3.41 | 3.69 | 4.20 |
| 15 | 1520 | 2.39 | 2.68 | 3.00 | 3.21 | 3.44 | 3.72 | 4.24 |
| 16 | 1621 | 2.42 | 2.71 | 3.02 | 3.24 | 3.47 | 3.75 | 4.27 |
| 17 | 1723 | 2.44 | 2.73 | 3.04 | 3.26 | 3.50 | 3.78 | 4.30 |
| 18 (RBP)* | 1824 | 2.46 | 2.74 | 3.07 | 3.28 | 3.52 | 3.81 | 4.33 |
| 19 | 1925 | 2.48 | 2.76 | 3.09 | 3.30 | 3.54 | 3.83 | 4.35 |
| 20 | 2027 | 2.49 | 2.77 | 3.11 | 3.32 | 3.56 | 3.85 | 4.38 |

Note: These nominal data are based on *in vitro* testing at 37°C and do not take into account lesion resistance.

Ensure full deployment of the stent (see section 13.5 – *Operator's Instructions, Deployment Procedure*) and confirm the stent sizing angiographically.

*Do not exceed the rated burst pressure (RBP).

15.0 REUSE PRECAUTION STATEMENT

Do not use if sterile barrier is damaged. If damage is found call your Abbott Vascular representative.

For single patient use only. Do not reuse, reprocess, or resterilize.

16.0 PATENTS AND TRADEMARKS

This product and / or its use may be covered by one or more of the following United States Patents: 6,179,810; 6,384,046; 6,629,994; 6,656,220; 6,746,423; 6,887,219; 6,887,510; 6,890,318; 6,929,657; 6,939,373; 6,957,152; 7,549,975; 7,662,130; 7,828,766; 7,833,193; 7,906,066; 7,947,207; 8,043,553; 8,052,638; 8,075,583; 8,173,062; 8,221,112; 8,221,444; 8,308,711; 8,382,738; 8,388,575; 8,388,602; 8,394,055; 8,444,608; 8,444,802; 8,535,596; 8,540,927; 8,613,722. Other U.S. patents pending. Other patents issued and pending outside of the U.S.

XIENCE Xpedition, XIENCE V, XIENCE nano, and XIENCE PRIME are registered trademarks of the Abbott Group of Companies.

TAXUS, TAXUS Express, and TAXUS Liberté are registered trademarks of Boston Scientific Corporation or its affiliates.

Zortress, Certican, and Afinitor are registered trademarks of Novartis Pharmaceuticals, Inc.



















Abbott Vascular

3200 Lakeside Drive
Santa Clara, CA 95054 USA

CUSTOMER SERVICE

TEL: (800) 227-9902
FAX: (800) 601-8874
Outside USA TEL: (951) 914-4669
Outside USA FAX: (951) 914-2531

Graphical Symbols for Medical Device Labeling

| | | | |
|---|---|--|--|
|  Manufacturer |  Catalogue number |  French size |  Date of manufacture |
|  Do not resterilize |  Sterilized using ethylene oxide |  Consult instructions for use |  Inner diameter |
|  Use by |  Batch code |  Do not reuse |  Flushing tool |
|  Non-pyrogenic |  Contents (numeral represents quantity of units inside) |  Guiding catheter |  MR conditional |

©2012, 2014 Abbott